0001193125-13-409536.txt : 20131024 0001193125-13-409536.hdr.sgml : 20131024 20131024131250 ACCESSION NUMBER: 0001193125-13-409536 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20130930 FILED AS OF DATE: 20131024 DATE AS OF CHANGE: 20131024 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BARD C R INC /NJ/ CENTRAL INDEX KEY: 0000009892 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 221454160 STATE OF INCORPORATION: NJ FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-06926 FILM NUMBER: 131167578 BUSINESS ADDRESS: STREET 1: 730 CENTRAL AVE CITY: MURRAY HILL STATE: NJ ZIP: 07974 BUSINESS PHONE: 9082778000 MAIL ADDRESS: STREET 1: 730 CENTRAL AVENUE CITY: MURRAY HILL STATE: NJ ZIP: 07974 10-Q 1 d587637d10q.htm FORM 10-Q Form 10-Q
Table of Contents

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 10-Q

 

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2013

Commission File Number 1-6926

 

 

C. R. BARD, INC.

(Exact name of registrant as specified in its charter)

 

 

 

New Jersey  

730 Central Avenue

Murray Hill, New Jersey 07974

  22-1454160
(State of incorporation)   (Address of principal executive offices)  

(I.R.S. Employer

Identification No.)

Registrant’s telephone number, including area code: (908) 277-8000

 

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  x    No  ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer   x    Accelerated filer   ¨
Non-accelerated filer   ¨  (Do not check if smaller reporting company)    Smaller reporting company   ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ¨    No  x

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

 

Class

  

Outstanding at September 30, 2013

Common Stock - $0.25 par value    77,890,296

 

 

 


Table of Contents

C. R. BARD, INC. AND SUBSIDIARIES

INDEX

 

         Page  

PART I – FINANCIAL INFORMATION

  

Item 1.

 

Financial Statements (unaudited)

  
 

Condensed Consolidated Statements of Income for the Quarter and Nine Months Ended September  30, 2013 and 2012

     3   
 

Condensed Consolidated Statements of Comprehensive Income for the Quarter and Nine Months Ended September  30, 2013 and 2012

     4   
 

Condensed Consolidated Balance Sheets – September 30, 2013 and December 31, 2012

     5   
 

Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2013 and 2012

     6   
 

Notes to Condensed Consolidated Financial Statements

     7   

Item 2.

 

Management’s Discussion and Analysis of Financial Condition and Results of Operations

     19   

Item 3.

 

Quantitative and Qualitative Disclosures About Market Risk

     29   

Item 4.

 

Controls and Procedures

     29   

PART II – OTHER INFORMATION

  

Item 1.

 

Legal Proceedings

     31   

Item 1A.

 

Risk Factors

     34   

Item 2.

 

Unregistered Sales of Equity Securities and Use of Proceeds

     34   

Item 5.

 

Other Information

     34   

Item 6.

 

Exhibits

     34   

Signatures

     35   

 

2


Table of Contents

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements

C. R. BARD, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(dollars in thousands except per share amounts, unaudited)

 

     Quarter
Ended September 30,
     Nine Months
Ended September 30,
 
     2013      2012      2013      2012  

Net sales

   $ 758,000       $ 722,900       $ 2,258,200       $ 2,195,500   

Costs and expenses:

           

Cost of goods sold

     291,900         272,600         883,800         837,700   

Marketing, selling and administrative expense

     223,900         196,600         666,600         604,300   

Research and development expense

     99,400         52,200         224,800         150,500   

Interest expense

     11,200         9,700         33,700         28,900   

Other (income) expense, net

     12,600         13,600         338,600         19,000   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total costs and expenses

     639,000         544,700         2,147,500         1,640,400   
  

 

 

    

 

 

    

 

 

    

 

 

 

Income from operations before income taxes

     119,000         178,200         110,700         555,100   

Income tax provision

     25,800         48,900         88,400         153,200   
  

 

 

    

 

 

    

 

 

    

 

 

 

Net income

   $ 93,200       $ 129,300       $ 22,300       $ 401,900   
  

 

 

    

 

 

    

 

 

    

 

 

 

Basic earnings per share available to common shareholders

   $ 1.17       $ 1.52       $ 0.28       $ 4.70   
  

 

 

    

 

 

    

 

 

    

 

 

 

Diluted earnings per share available to common shareholders

   $ 1.15       $ 1.50       $ 0.27       $ 4.64   
  

 

 

    

 

 

    

 

 

    

 

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

3


Table of Contents

C. R. BARD, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(dollars in thousands, unaudited)

 

     Quarter
Ended September 30,
     Nine Months
Ended September 30,
 
     2013     2012      2013     2012  

Net income

   $ 93,200      $ 129,300       $ 22,300      $ 401,900   

Other comprehensive income (loss):

         

Change in derivative instruments designated as cash flow hedges, net of tax

     (1,200     100         1,600        2,100   

Foreign currency translation adjustments

     8,000        14,900         (700     (24,300

Benefit plan adjustments, net of tax

     2,200        1,800         6,600        5,200   
  

 

 

   

 

 

    

 

 

   

 

 

 

Other comprehensive income (loss)

     9,000        16,800         7,500        (17,000
  

 

 

   

 

 

    

 

 

   

 

 

 

Comprehensive income

   $ 102,200      $ 146,100       $ 29,800      $ 384,900   
  

 

 

   

 

 

    

 

 

   

 

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

4


Table of Contents

C. R. BARD, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(dollars in thousands except share and per share amounts, unaudited)

 

     September 30,
2013
    December 31,
2012
 

ASSETS

    

Current assets

    

Cash and cash equivalents

   $ 781,700      $ 896,300   

Restricted cash

     19,000        25,000   

Accounts receivable, less allowances of $13,500 and $12,400, respectively

     456,500        480,900   

Inventories

     332,100        328,500   

Short-term deferred tax assets

     33,800        42,600   

Other current assets

     103,800        73,900   

Assets held for sale

     24,400        —     
  

 

 

   

 

 

 

Total current assets

     1,751,300        1,847,200   
  

 

 

   

 

 

 

Property, plant and equipment, at cost

     655,600        631,900   

Less accumulated depreciation and amortization

     295,100        272,600   
  

 

 

   

 

 

 

Net property, plant and equipment

     360,500        359,300   

Goodwill

     971,000        961,600   

Core technologies, net

     482,400        506,500   

Other intangible assets, net

     358,600        368,100   

Deferred tax assets

     10,100        10,000   

Other assets

     231,100        98,600   
  

 

 

   

 

 

 

Total assets

   $ 4,165,000      $ 4,151,300   
  

 

 

   

 

 

 

LIABILITIES AND SHAREHOLDERS’ INVESTMENT

    

Current liabilities

    

Short-term borrowings

   $ 97,500      $ —     

Accounts payable

     72,800        56,200   

Accrued expenses

     208,200        242,900   

Accrued compensation and benefits

     114,500        137,800   

Income taxes payable

     8,800        10,700   

Liabilities held for sale

     2,600        —     
  

 

 

   

 

 

 

Total current liabilities

     504,400        447,600   
  

 

 

   

 

 

 

Long-term debt

     1,406,500        1,409,600   

Other long-term liabilities

     731,700        342,400   

Deferred income taxes

     18,300        26,000   

Commitments and contingencies

    

Shareholders’ investment:

    

Preferred stock, $1 par value, authorized 5,000,000 shares; none issued

     —          —     

Common stock, $0.25 par value, authorized 600,000,000 shares; issued and outstanding 77,890,296 shares at September 30, 2013 and 81,697,409 shares at December 31, 2012

     19,500        20,400   

Capital in excess of par value

     1,648,000        1,513,300   

Accumulated deficit / retained earnings

     (89,700     473,200   

Accumulated other comprehensive loss

     (73,700     (81,200
  

 

 

   

 

 

 

Total shareholders’ investment

     1,504,100        1,925,700   
  

 

 

   

 

 

 

Total liabilities and shareholders’ investment

   $ 4,165,000      $ 4,151,300   
  

 

 

   

 

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

5


Table of Contents

C. R. BARD, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(dollars in thousands, unaudited)

 

     Nine Months
Ended September 30,
 
     2013     2012  

Cash flows from operating activities:

    

Net income

   $ 22,300      $ 401,900   

Adjustments to reconcile net income to net cash provided by operating activities, net of acquired business:

    

Depreciation and amortization

     106,000        101,400   

Litigation charges, net

     318,200        —     

Acquired in-process research and development

     30,000        2,000   

Asset impairments

     12,300        22,200   

Restructuring

     (1,400     (1,600

Deferred income taxes

     (16,800     12,600   

Share-based compensation

     44,700        39,000   

Inventory reserves and provision for doubtful accounts

     17,100        15,000   

Other items

     1,600        (5,800

Changes in assets and liabilities:

    

Accounts receivable

     10,200        31,600   

Inventories

     (34,400     (34,000

Current liabilities

     (96,700     (153,900

Taxes

     6,000        (2,500

Other, net

     (2,100     (700
  

 

 

   

 

 

 

Net cash provided by operating activities

     417,000        427,200   
  

 

 

   

 

 

 

Cash flows from investing activities:

    

Capital expenditures

     (47,300     (55,500

Change in restricted cash

     6,000        119,600   

Payments made for purchases of businesses, net of cash acquired

     (35,000     —     

Payments made for intangibles

     (33,500     (14,100

Proceeds from sale of financial instruments

     —          10,000   

Other

     1,900        —     
  

 

 

   

 

 

 

Net cash (used in) provided by investing activities

     (107,900     60,000   
  

 

 

   

 

 

 

Cash flows from financing activities:

    

Change in short-term borrowings, net

     97,500        77,000   

Proceeds from exercises under share-based compensation plans, net

     74,400        70,200   

Excess tax benefit relating to share-based compensation plans

     9,500        10,300   

Purchases of common stock

     (546,900     (372,500

Dividends paid

     (49,800     (49,900

Other

     (500     (4,900
  

 

 

   

 

 

 

Net cash used in financing activities

     (415,800     (269,800
  

 

 

   

 

 

 

Effect of exchange rate changes on cash and cash equivalents

     (7,900     (4,700
  

 

 

   

 

 

 

(Decrease) increase in cash and cash equivalents during the period

     (114,600     212,700   
  

 

 

   

 

 

 

Balance at January 1

     896,300        596,400   
  

 

 

   

 

 

 

Balance at September 30

   $ 781,700      $ 809,100   
  

 

 

   

 

 

 

Supplemental cash flow information

    

Cash paid for:

    

Interest

   $ 36,200      $ 31,600   

Income taxes

     89,700        132,800   

Non-cash transactions:

    

Purchase of common stock not settled

     6,500        9,100   

Purchase of business and related costs

     8,200        —     

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

6


Table of Contents

C. R. BARD, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

1. Basis of Presentation

The accompanying unaudited condensed consolidated financial statements of C. R. Bard, Inc. and its subsidiaries (the “company” or “Bard”) should be read in conjunction with the audited consolidated financial statements and notes thereto included in Bard’s 2012 Annual Report on Form 10-K. These financial statements have been prepared on a basis that is substantially consistent with the accounting principles applied in the financial statements in Bard’s 2012 Annual Report on Form 10-K. The preparation of these financial statements requires the company to make estimates and judgments that affect reported amounts of assets, liabilities, revenues and expenses and the related disclosure of contingent assets and liabilities at the date of the financial statements. These financial statements include all normal and recurring adjustments necessary for a fair presentation. The accounts of most foreign subsidiaries are consolidated as of and for the quarter and nine months ended August 31, 2013 and August 31, 2012 and as of November 30, 2012. No events occurred related to these foreign subsidiaries during the months of September 2013, September 2012 or December 2012 that materially affected the financial position or results of operations of the company. The results for the interim periods presented are not necessarily indicative of the results expected for the year.

2. Acquisitions and Divestiture

On October 1, 2013, the company acquired all of the outstanding shares of Medafor, Inc. (“Medafor”), a privately-held developer and supplier of plant-based hemostatic agents. The purchase consideration included an up-front cash payment of $203.7 million and future contingent payments of up to an additional $80 million based on specific revenue-based milestones through June 30, 2015. The company has not yet completed the initial purchase accounting due to the timing of this acquisition.

On September 4, 2013, the company entered into a definitive agreement to acquire Rochester Medical, Inc. (“Rochester Medical”), a publicly-held developer and supplier of silicone urinary incontinence and urine drainage products, for a purchase price of $20 per share, or approximately $262 million in the aggregate to be paid at closing. The transaction is expected to close in 2013, and is subject to customary closing conditions, including approval by the shareholders of Rochester Medical as well as regulatory approvals.

On August 29, 2013, the company acquired early stage technology from 3DT Holdings LLC (“3DT”), providing the company with rights to develop and commercialize a novel technology related to peripherally inserted central catheters (“PICCs”). 3DT received an up-front cash payment of $29.5 million and is eligible for milestone payments of up to $5 million based upon regulatory product approval. The company recorded the up-front payment as a research and development expense.

On July 29, 2013, the company acquired all of the outstanding shares of Loma Vista Medical, Inc., a privately-held company specializing in the development and commercialization of aortic valvuloplasty products, which use noncompliant fiber-based balloon technology. The total purchase consideration of $39.4 million included an up-front cash payment of $32.5 million and the fair value of contingent consideration of up to $8.0 million. The fair value of the assets acquired resulted in the recognition of core technologies of $20.6 million, deferred tax liabilities of $14.7 million, primarily consisting of intangible assets, goodwill of $8.6 million, and other net assets of $4.9 million. The goodwill is not deductible for tax purposes. An in process research and development (“IPR&D”) asset of $20.0 million was recorded for the development of a next generation valvuloplasty product. The fair value of the IPR&D asset was determined based upon the present value of expected future cash flows adjusted for the probability of technological and commercial risk, utilizing a risk-adjusted discount rate of 25%. The company has not yet finalized the purchase accounting, which may be adjusted as further information about conditions existing at the acquisition date become available.

On June 27, 2013, the company reached a definitive agreement to sell certain assets and liabilities of its electrophysiology division (“BEP”) to Boston Scientific Corporation (“Boston Scientific”) for $275 million in cash. The transaction is expected to be completed in 2013, subject to certain regulatory and customary closing conditions. The company expects to record a gain on the sale when the transaction is completed, which will include, among other things, assets and liabilities held for sale, and the de-recognition of a portion of goodwill.

Assets and liabilities held for sale associated with BEP include the following:

 

(dollars in millions)    September 30,
2013
 

Inventories

   $ 14.4   

Other current assets

     0.4   

Net property, plant and equipment

     2.6   

 

7


Table of Contents

C. R. BARD, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

 

(dollars in millions)    September 30,
2013
 

Other intangible assets, net

     7.0   
  

 

 

 
   $ 24.4   
  

 

 

 

Accrued expenses

   $ 1.8   

Accrued compensation and benefits

     0.8   
  

 

 

 
   $ 2.6   
  

 

 

 
   $ 21.8   
  

 

 

 

The company has agreed to provide contract manufacturing and other transition services to Boston Scientific for up to five years following the closing date. Due to the company’s continuing involvement in the operations of BEP, the criteria for reporting the results of BEP as a discontinued operation were not met.

3. Restructuring

During the fourth quarter of 2012, the company committed to a plan (the “2012 Restructuring Plan”) to improve its overall cost structure and enhance operational effectiveness. At September 30, 2013, the remaining liability related to the 2012 Restructuring Plan was $2.3 million. Cash payments of $14.1 million and a reversal of $1.4 million of previously accrued restructuring costs were made during the nine months ended September 30, 2013. The company expects activities under this plan to be substantially complete by the end of 2013.

4. Earnings per Common Share

Earnings per share (“EPS”) is computed under the two-class method using the following common share information:

 

     Quarter Ended
September 30,
     Nine Months
Ended September 30,
 
     2013      2012      2013      2012  
(dollars and shares in millions)                            

EPS Numerator:

           

Net income

   $ 93.2       $ 129.3       $ 22.3       $ 401.9   

Less: Income allocated to participating securities

     1.6         2.4         0.3         7.7   
  

 

 

    

 

 

    

 

 

    

 

 

 

Net income available to common shareholders

   $ 91.6       $ 126.9       $ 22.0       $ 394.2   
  

 

 

    

 

 

    

 

 

    

 

 

 

EPS Denominator:

           

Weighted average common shares outstanding

     78.5         83.4         79.9         83.8   

Dilutive common share equivalents from share-based compensation plans

     1.5         1.2         1.3         1.1   
  

 

 

    

 

 

    

 

 

    

 

 

 

Weighted average common and common equivalent shares outstanding, assuming dilution

     80.0         84.6         81.2         84.9   
  

 

 

    

 

 

    

 

 

    

 

 

 

5. Income Taxes

The effective tax rate for the quarter ended September 30, 2013 was approximately 22%, compared to approximately 27% for the prior year quarter. The effective tax rate for the quarter and nine months ended September 30, 2013 reflected the discrete tax effects of an IPR&D charge related to the acquisition of 3DT, which was incurred in a high tax jurisdiction, and a benefit associated with the remeasurement of an uncertain tax position as a result of the settlement of the Brachytherapy Matter. In addition, the effective tax rate for the nine months ended September 30, 2013 reflected the discrete tax effects of litigation charges, primarily related to product liability claims, which were substantially incurred in a low tax jurisdiction, and the write-down of an insurance receivable, which also was incurred in low tax jurisdiction. See Note 8 of the notes to condensed consolidated financial statements. The effective tax rate was also impacted by the American Taxpayer Relief Act of 2012, which was signed into law on January 2, 2013 and retroactively reinstated the research tax credit. Although the reinstatement of this tax credit is retroactive to January 1, 2012, the enactment of this legislation in 2013 precluded the company from recording the benefit in 2012. As a result, the company’s income tax provision was reduced by approximately $3.7 million during the nine months ended September 30, 2013 to recognize the 2012 benefit of this tax credit that would

 

8


Table of Contents

C. R. BARD, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

 

have been recorded in 2012. At September 30, 2013, the total amount of liability for unrecognized tax benefits related to federal, state and foreign taxes was $48.5 million (of which $40.4 million would impact the effective tax rate, if recognized) plus $6.3 million of accrued interest. At December 31, 2012, the liability for unrecognized tax benefits was $43.4 million plus $4.8 million of accrued interest. Depending upon the result of open tax examinations and/or the expiration of applicable statutes of limitation, the company believes it is reasonably possible that the total amount of unrecognized tax benefits may decrease by up to $18.4 million within the next 12 months.

6. Financial Instruments

Foreign Exchange Derivative Instruments

The company enters into readily marketable forward and option contracts with financial institutions to help reduce its exposure to foreign currency exchange rate fluctuations. These contracts limit volatility because gains and losses associated with foreign currency exchange rate movements are generally offset by movements in the underlying hedged item. The notional value of the company’s forward currency and option currency contracts was $150.0 million and $128.1 million at September 30, 2013 and December 31, 2012, respectively. For further discussion regarding the company’s use of derivative instruments, see Note 1 of the notes to consolidated financial statements in Bard’s 2012 Annual Report on Form 10-K.

Interest Rate Derivative Instrument

The company’s outstanding interest rate swap contract effectively converts its 2.875% fixed-rate notes due 2016 to a floating-rate instrument. The notional value of the company’s interest rate swap contract is $250.0 million.

The location and fair value of derivative instruments that are designated as hedging instruments recognized in the condensed consolidated balance sheets are as follows:

 

    

Balance Sheet

Location

   Fair Value
of Derivatives
 

Derivatives Designated as Hedging Instruments

      September 30,
2013
     December 31,
2012
 
(dollars in millions)                   

Forward currency contracts

  

Other current assets

   $ 1.7       $ 1.4   

Option currency contracts

  

Other current assets

     1.4         0.6   

Forward currency contracts

  

Other assets

     0.2         —     

Interest rate swap contract

  

Other assets

     9.8         13.3   
     

 

 

    

 

 

 
      $ 13.1       $ 15.3   
     

 

 

    

 

 

 

Forward currency contracts

  

Accrued expenses

   $ 0.3       $ 0.4   

Forward currency contracts

  

Other long-term liabilities

     0.1         —     
     

 

 

    

 

 

 
      $ 0.4       $ 0.4   
     

 

 

    

 

 

 

The location and amounts of gains and losses on derivative instruments designated as cash flow hedges and the impact on shareholders’ investment are as follows:

 

     Gain/(Loss)
Recognized in Other
Comprehensive
Income (Loss)
    Location of
Gain/(Loss) Reclassified
from Accumulated
Other Comprehensive Loss to
Income
   Gain/(Loss) Reclassified
from Accumulated
Other Comprehensive Loss
into Income
 
     Quarter Ended
September 30,
       Quarter Ended
September 30,
 
     2013     2012        2013     2012  
(dollars in millions)                              

Forward currency contracts

   $ (0.5   $ 1.5      Cost of goods sold    $ 1.7      $ (0.4

Option currency contracts

     0.9        (0.6   Cost of goods sold      (0.6     0.6   
  

 

 

   

 

 

      

 

 

   

 

 

 
   $ 0.4      $ 0.9         $ 1.1      $ 0.2   
  

 

 

   

 

 

      

 

 

   

 

 

 

 

9


Table of Contents

C. R. BARD, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

 

     Gain/(Loss)
Recognized in Other
Comprehensive
Income (Loss)
     Location of
Gain/(Loss) Reclassified
from Accumulated
Other Comprehensive Loss to
Income
   Gain/(Loss) Reclassified
from Accumulated
Other Comprehensive Loss
into Income
 
     Nine Months Ended
September 30,
        Nine Months Ended
September 30,
 
     2013      2012         2013     2012  
(dollars in millions)                                

Forward currency contracts

   $ 4.1       $ 4.0       Cost of goods sold    $ 1.7      $ (0.4

Option currency contracts

     1.0         1.0       Cost of goods sold      (1.1     1.5   
  

 

 

    

 

 

       

 

 

   

 

 

 
   $ 5.1       $ 5.0          $ 0.6      $ 1.1   
  

 

 

    

 

 

       

 

 

   

 

 

 

The location and amounts of gains and losses on the derivative instrument designated as a fair value hedge are as follows:

 

     Income Statement
Location
     (Loss)/Gain Recognized on Swap      Gain/(Loss) Recognized on Long-Term Debt  
        Quarter Ended
September 30,
     Nine Months Ended
September 30,
     Quarter Ended
September 30,
    Nine Months Ended
September 30,
 
        2013     2012      2013     2012      2013      2012     2013      2012  
(dollars in millions)                                                            

Interest rate swap contract

     Interest expense       $ (0.3   $ 1.0       $ (3.5   $ 2.5       $ 0.3       $ (1.0   $ 3.5       $ (2.5
     

 

 

   

 

 

    

 

 

   

 

 

    

 

 

    

 

 

   

 

 

    

 

 

 

The location and amounts of gains on derivative instruments not designated as hedging instruments are as follows:

 

    

Income Statement

Location

   Gain Recognized in Earnings  
        Quarter Ended
September 30,
     Nine Months Ended
September 30,
 
        2013      2012      2013      2012  
(dollars in millions)                                 

Forward currency contracts(A)

  

Other (income) expense, net

   $ —         $ —         $ —         $ 3.0   
     

 

 

    

 

 

    

 

 

    

 

 

 

 

(A)  These derivative contracts mitigate changes in the value of remeasured foreign currency denominated intercompany loans attributable to changes in foreign currency exchange rates.

Financial Instruments Measured at Fair Value on a Recurring Basis

Fair value is defined as the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement that is determined using assumptions that market participants would use in pricing an asset or liability. The fair value guidance establishes a three-level hierarchy which maximizes the use of observable inputs and minimizes the use of unobservable inputs used in measuring fair value. The levels within the hierarchy range from Level 1 having observable inputs to Level 3 having unobservable inputs.

The following table summarizes certain financial instrument assets measured at fair value on a recurring basis:

 

     September 30,
2013
     December 31,
2012
 
(dollars in millions)              

Forward currency contracts

   $ 1.5       $ 1.0   

Option currency contracts

     1.4         0.6   

Interest rate swap contract

     9.8         13.3   

The fair values were measured using significant other observable inputs and valued by reference to similar financial instruments, adjusted for restrictions and other terms specific to each instrument. These financial instruments are categorized as Level 2 under the fair value hierarchy.

The fair value of the liability for contingent consideration related to acquisitions was $86.8 million and $77.1 million at September 30, 2013 and December 31, 2012, respectively. The fair value was measured using significant unobservable inputs and is categorized as Level 3 under the fair value hierarchy.

 

10


Table of Contents

C. R. BARD, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

 

Financial Instruments not Measured at Fair Value

The fair value of commercial paper borrowings of $97.5 million at September 30, 2013 approximated the carrying value. There were no commercial paper borrowings outstanding at December 31, 2012. On September 26, 2013, the company amended its $600 million five-year committed syndicated bank credit facility that was scheduled to expire in October 2016. The amendment includes an increase of the aggregate principal amount of credit available under the syndicated bank credit facility to $750 million and extends the commitment termination date until September 26, 2018. The amended credit facility supports the company’s commercial paper program and can be used for general corporate purposes. The facility includes pricing based on the company’s long-term credit rating and includes a financial covenant that limits the amount of total debt to total capitalization. At September 30, 2013, the company was in compliance with this covenant.

The estimated fair value of long-term debt including the effect of the related interest rate swap contract was approximately $1,454.2 million and $1,532.2 million at September 30, 2013 and December 31, 2012, respectively. The fair value was estimated using dealer quotes for similarly-rated debt instruments over the remaining contractual term of the company’s obligation. Long-term debt is categorized as Level 2 under the fair value hierarchy.

Concentration Risk

Accounts receivable balances include sales to government-supported healthcare systems outside the United States. The company continues to monitor sovereign debt issues and economic conditions in Europe and evaluates accounts receivable in certain countries for potential collection risks. Economic conditions and other factors in certain countries in Europe have resulted in, and may continue to result in, an increase in the average length of time that it takes to collect these accounts receivable and may require the company to re-evaluate the collectability of these receivables in future periods. The company has experienced significant delays in the collection of accounts receivable associated with the national healthcare systems in Spain, Italy, Greece and Portugal. At September 30, 2013, the company’s accounts receivable, net of allowances, from the national healthcare systems in these countries and amounts past due greater than 365 days are as follows:

 

     Accounts
receivable, net
     Greater than
365 days past due
 
(dollars in millions)              

Spain

   $ 23.0       $ 4.8   

Italy

     23.1         2.4   

Greece

     10.5         3.2   

Portugal

     4.0         1.7   
  

 

 

    

 

 

 
   $ 60.6       $ 12.1   
  

 

 

    

 

 

 

7. Inventories

Inventories consisted of:

 

     September 30,
2013
     December 31,
2012
 
(dollars in millions)              

Finished goods

   $ 199.4       $ 194.6   

Work in process

     23.0         19.1   

Raw materials

     109.7         114.8   
  

 

 

    

 

 

 
   $ 332.1       $ 328.5   
  

 

 

    

 

 

 

8. Contingencies

General

In the ordinary course of business, the company is subject to various legal proceedings, investigations and claims, including, for example, environmental matters, employment disputes, disputes on agreements and other commercial disputes. In addition, the company operates in an industry susceptible to significant product liability and patent legal claims. The company accounts for estimated losses with respect to legal proceedings and claims when such losses are probable and reasonably estimable. Legal costs associated with these matters are expensed as incurred. At any given time, in the ordinary course of business, the company is involved as either a plaintiff or defendant in a number of patent infringement actions. If a

 

11


Table of Contents

C. R. BARD, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

 

third party’s patent infringement claim were to be determined against the company, the company might be required to make significant royalty or other payments or might be subject to an injunction or other limitation on its ability to manufacture or distribute one or more products. If a patent owned by or licensed to the company is found to be invalid or unenforceable, the company might be required to reduce the value of certain intangible assets on the company’s balance sheet and to record a corresponding charge, which could be significant in amount. Many of the company’s legal proceedings and claims could have a material adverse effect on its business, results of operations, financial condition and/or liquidity.

Product Liability Matters

As of October 17, 2013, approximately 745 federal and 720 state lawsuits involving individual claims by approximately 1,575 plaintiffs, as well as two putative class actions in the United States are currently pending against the company with respect to its Composix® Kugel® and certain other hernia repair implant products (collectively, the “Hernia Product Claims”). The company voluntarily recalled certain sizes and lots of the Composix® Kugel® products beginning in December 2005. One of the U.S. class action lawsuits consolidated ten previously-filed U.S. class action lawsuits. The putative class actions, none of which has been certified, seek: (i) medical monitoring; (ii) compensatory damages; (iii) punitive damages; (iv) a judicial finding of defect and causation; and/or (v) attorneys’ fees. A settlement has been reached with respect to the three pending putative Canadian class actions within amounts previously recorded by the company. Approximately 685 of the state lawsuits, involving individual claims by approximately 785 plaintiffs, are pending in the Superior Court of the State of Rhode Island, with the remainder in various other jurisdictions. The Hernia Product Claims also generally seek damages for personal injury resulting from use of the products.

In June 2007, the Composix® Kugel® lawsuits and, subsequently, other hernia repair product lawsuits, pending in federal courts nationwide were transferred into one Multidistrict Litigation (“MDL”) for coordinated pre-trial proceedings in the United States District Court for the District of Rhode Island.

On June 30, 2011, the company announced that it had reached agreements in principle with various plaintiffs’ law firms to settle the majority of its existing Hernia Product Claims. Each agreement is subject to certain conditions, including requirements for participation in the proposed settlements by a certain minimum number of plaintiffs. In addition, the company continues to engage in discussions with other plaintiffs’ law firms regarding potential resolution of unsettled Hernia Product Claims, and intends to vigorously defend Hernia Product Claims that do not settle, including through litigation. The company cannot give any assurances that the resolution of the Hernia Product Claims that have not settled, including asserted and unasserted claims and the putative class action lawsuits, will not have a material adverse effect on the company’s business, results of operations, financial condition and/or liquidity.

As of October 17, 2013, product liability lawsuits involving individual claims by approximately 9,635 plaintiffs have been filed or asserted against the company in various federal and state jurisdictions alleging personal injuries associated with the use of certain of the company’s surgical continence products for women, including its Avaulta® line of products. In addition, five putative class actions in the United States and three putative class actions in Canada have been filed against the company (all lawsuits, collectively, the “Women’s Health Product Claims”). The Women’s Health Product Claims generally seek damages for personal injury resulting from use of the products. The putative class actions, none of which has been certified, seek: (i) medical monitoring; (ii) compensatory damages; (iii) punitive damages; (iv) a judicial finding of defect and causation; and/or (v) attorneys’ fees. With respect to certain of these claims, the company believes that one of its suppliers has an obligation to defend and indemnify the company. In October 2010, the Women’s Health Product Claims involving solely Avaulta® products pending in federal courts nationwide were transferred into an MDL in the United States District Court for the Southern District of West Virginia, the scope of which was later expanded to include lawsuits involving all women’s surgical continence products that are manufactured or distributed by the company. The company expects additional Women’s Health Product Claims pending in federal courts to be transferred to the MDL in West Virginia, with the remainder of the Women’s Health Product Claims in other jurisdictions. The first trial in the MDL commenced in July 2013 and resulted in a judgment against the company of approximately $2 million. The company intends to appeal the judgment. The next MDL trial is scheduled to occur in December 2013, with additional trials scheduled in 2014. The first trial in a state court was completed in July 2012 and resulted in a judgment against the company of approximately $3.6 million. The company has appealed this decision. During the third quarter, the company settled one MDL case and one New Jersey state case. The amounts of the settlements are subject to confidentiality requirements. In addition, during the third quarter, an MDL case was voluntarily dismissed with prejudice, and the company is currently seeking to recover attorneys’ fees for this case. The company does not believe that any verdicts or settlements entered to date are representative of potential outcomes of all Women’s Health Product Claims. The case numbers set forth above do not include generic complaints involving women’s health products where the company cannot, based on the allegations in such complaints, determine whether any of

 

12


Table of Contents

C. R. BARD, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

 

such cases involve the company’s women’s health products. While the company intends to vigorously defend the Women’s Health Product Claims, it cannot give any assurances that the resolution of these claims will not have a material adverse effect on the company’s business, results of operations, financial condition and/or liquidity.

As of October 17, 2013, product liability lawsuits involving individual claims by 40 plaintiffs are currently pending against the company in various federal and state jurisdictions alleging personal injuries associated with the use of the company’s vena cava filter products. In addition, three putative class actions were filed against the company in various state courts on behalf of plaintiffs who are alleged to have no present injury (all lawsuits, collectively, the “Filter Product Claims”). Two of these putative class actions were dismissed during the second quarter, and class certification was denied for the third putative class action in July 2013. The first Filter Product Claim trial was completed in June 2012 and resulted in a judgment for the company. The company expects additional trials of Filter Product Claims to take place over the next 12 months. During the second quarter of 2013, the company finalized settlement agreements with respect to more than 30 Filter Product Claims, and made payments with respect to such claims within the amounts previously recorded. While the company intends to vigorously defend the remaining unsettled Filter Product Claims, it cannot give any assurances that the resolution of these claims will not have a material adverse effect on the company’s business, results of operations, financial condition and/or liquidity.

In most product liability litigations of this nature, plaintiffs allege a wide variety of claims, ranging from allegations of serious injury caused by the products to efforts to obtain compensation notwithstanding the absence of any injury. In many of these cases, the company has not yet received and reviewed complete information regarding the plaintiffs and their medical conditions, and consequently, is unable to fully evaluate the claims. The company expects that it will receive and review additional information regarding any remaining unsettled product liability matters.

The company believes that some settlements and judgments, as well as legal defense costs, relating to product liability matters are or may be covered in whole or in part under its product liability insurance policies with a limited number of insurance carriers. In certain circumstances, insurance carriers reserve their rights with respect to coverage, or contest or deny coverage, as has occurred with respect to certain claims. When this occurs, the company intends to vigorously contest disputes with respect to its insurance coverage and to enforce its rights under the terms of its insurance policies, and accordingly, will record receivables with respect to amounts due under these policies, when recovery is probable. Amounts recovered under the company’s product liability insurance policies may be less than the stated coverage limits and may not be adequate to cover damages and/or costs relating to claims. In addition, there is no guarantee that insurers will pay claims or that coverage will otherwise be available.

The company’s insurance coverage with respect to the Hernia Product Claims has been exhausted. In the first quarter of 2013 the company recorded a non-cash charge of $25.0 million ($24.5 million after tax) to other (income) expense, net, for the write-down of an insurance receivable related to a dispute with one of its excess insurance carriers in connection with these claims.

In connection with the Women’s Health Product Claims, the company was in dispute with one of its excess insurance carriers relating to an aggregate of $50 million of insurance coverage. In June 2013, the company settled this dispute with no change to the amount of the insurance coverage or the related receivable.

Other Legal Matters

During the first half of 2013, the company received subpoenas or Civil Investigative Demands from a number of State Attorneys General seeking information related to the sales and marketing of certain of the company’s products that are the subject of the Hernia Product Claims and the Women’s Health Product Claims. The company is cooperating with these requests. Since it is not feasible to predict the outcome of these proceedings, the company cannot give any assurances that the resolution of these proceedings will not have a material adverse effect on the company’s business, results of operations, financial condition and/or liquidity.

In November 2006, the company received a subpoena issued by the U.S. Department of Health and Human Services, Office of Inspector General (“OIG”), under the authority of the federal healthcare fraud and false claims statutes, seeking documents related to the company’s brachytherapy business (the “Brachytherapy Matter”). In January 2012, the company reached a preliminary agreement with the civil and criminal divisions of the United States Attorney’s Office for the Northern District of Georgia to resolve claims with respect to the Brachytherapy Matter and recorded a charge of approximately $51.0 million ($40.8 million after tax) in the fourth quarter of 2011. On May 2, 2013, the company settled this matter. The resolution includes agreements with the government that required the company to pay approximately the amount that was previously recorded.

 

13


Table of Contents

C. R. BARD, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

 

In December 2007, a U.S. District Court jury in Arizona found that certain of W.L. Gore & Associates Inc.’s (“Gore”) ePTFE vascular grafts and stent-grafts infringe the company’s patent number 6,436,135 (the “135 patent”). The jury upheld the validity of the patent and awarded the company $185 million in past damages. The jury also found that Gore willfully infringed the patent. In a second phase of the trial, the District Court ruled that Gore failed to prove that the patent is unenforceable due to inequitable conduct. In March 2009, the District Court doubled the jury award to approximately $371 million for damages through June 2007. The District Court also awarded the company attorneys’ fees of $19 million and prejudgment interest of approximately $20 million. In addition, the District Court denied Gore’s remaining motions, including its motions for a new trial and to set aside the jury’s verdict. In July 2010, the District Court awarded the company approximately $109 million in additional damages for the period from July 2007 through March 2009. Gore has deposited or secured the foregoing amounts with the District Court. The District Court also assessed a royalty rate of between 12.5% and 20%, depending on the product, that will be used to calculate damages for Gore’s infringing sales from April 2009 through the expiration of the patent. Gore has made additional deposits with the District Court of approximately $542 million, representing Gore’s calculation of royalties for its infringing sales through July 2013. Gore appealed this matter to the Court of Appeals for the Federal Circuit (the “Court of Appeals”), which on February 10, 2012 affirmed the decision of the District Court. Gore filed a petition with the Court of Appeals for a rehearing of its appeal. On June 14, 2012, the Court of Appeals reaffirmed its February 10, 2012 decision, including the ongoing royalty rates as set by the District Court, with the exception of the issue of willfulness with respect to Gore’s infringement of the 135 patent, which was remanded to the District Court. On October 12, 2012, Gore filed a petition for a writ of certiorari to the U.S. Supreme Court requesting a review of the portion of the decision that the Court of Appeals reaffirmed. The U.S. Supreme Court denied Gore’s petition on January 14, 2013. The District Court heard oral argument on June 5, 2013 as to three pending motions before it, including the company’s motion to execute on the judgment with respect to all amounts other than enhanced damages due to willfulness. In October 2013, the District Court granted Bard’s motion to execute on the judgment, denied Gore’s motion requesting a determination that Gore’s infringement was not willful and denied Gore’s motion for a new trial. The District Court’s rulings on the motions are subject to appeal. On January 28, 2013, Gore filed with the U.S. District Court a Request for Judicial Notice that the U.S. Patent and Trademark Office (“USPTO”) granted Gore’s previously filed request for a re-examination of the 135 patent. On April 1, 2013, the USPTO issued a First Office Action initially rejecting all of the claims of the 135 patent that are the subject of the re-examination. On July 10, 2013, the USPTO issued a Notice of Intent to Issue an Ex Parte Reexamination Certificate upholding the patentability of all re-examined claims of the 135 patent. This action terminated the re-examination proceeding and upheld the claims involved in the re-examination. The timing of final resolution of this litigation remains uncertain. Since the company considers these matters a gain contingency, no amounts have been recorded. Even if the company is ultimately successful in this lawsuit, it cannot give any assurances that royalties for Gore’s future infringing sales will remain at or near historic levels.

The company is subject to numerous federal, state, local and foreign environmental protection laws governing, among other things, the generation, storage, use and transportation of hazardous materials and emissions or discharges into the ground, air or water. The company is or may become a party to proceedings brought under various federal laws including the Comprehensive Environmental Response, Compensation and Liability Act (CERCLA), commonly known as Superfund, the Resource Conservation and Recovery Act, the Clean Water Act, the Clean Air Act and similar state or foreign laws. These proceedings seek to require the owners or operators of contaminated sites, transporters of hazardous materials to the sites and generators of hazardous materials disposed of at the sites to clean up the sites or to reimburse the government for cleanup costs. In most cases, there are other potentially responsible parties that may be liable for remediation costs. In these cases, the government alleges that the defendants are jointly and severally liable for the cleanup costs; however, these proceedings are frequently resolved so that the allocation of cleanup costs among the parties more closely reflects the relative contributions of the parties to the site contamination. The company’s potential liability varies greatly from site to site. For some sites, the potential liability is de minimis and for others the costs of cleanup have not yet been determined. Accruals for estimated losses from environmental remediation obligations generally are recognized no later than completion of the remedial feasibility study and are adjusted as further information develops or circumstances change. Costs of future expenditures for environmental remediation obligations are not discounted to their present value. Recoveries of environmental remediation costs from other parties are recorded as assets when their receipt is deemed probable. The company believes that the proceedings and claims described above will likely be resolved over an extended period of time. While it is not feasible to predict the outcome of these proceedings, based upon the company’s experience, current information and applicable law, the company does not expect these proceedings to have a material adverse effect on its financial condition and/or liquidity. However, one or more of the proceedings could be material to the company’s business and/or results of operations.

 

14


Table of Contents

C. R. BARD, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

 

Litigation Reserves

The company regularly monitors and evaluates the status of product liability and other legal matters, and may, from time-to-time, engage in settlement and mediation discussions taking into consideration developments in the matters and the risks and uncertainties surrounding litigation. These discussions could result in settlements of one or more of these claims at any time.

The company evaluated the product liability matters discussed above under the heading “Product Liability Matters” based on information currently available, including: the allegations and documentation supporting or refuting such allegations; publicly available information regarding similar medical device mass tort settlements; historical information regarding other product liability settlements involving the company; and the procedural posture and stage of litigation. Based on these, and other factors, the company recorded a charge, net of estimated recoveries to other (income) expense, net, of approximately $293.0 million ($276.0 million after tax) in the second quarter of 2013, which recognized the estimated costs for certain of these product liability matters, including (with respect to such matters) asserted and unasserted claims, and costs to administer the settlements related to such matters. The charge excludes any costs associated with all but one putative class action lawsuit. The company cannot give any assurances that the actual costs incurred with respect to these product liability matters will not exceed the related amounts accrued. With respect to product liability claims that are not resolved through settlement, the company intends to vigorously defend against such claims, including through litigation. The company cannot give any assurances that the resolution of any of its product liability matters, including asserted and unasserted claims and the putative class action lawsuits, will not have a material adverse effect on the company’s business, results of operations, financial condition and/or liquidity.

Accruals for product liability and other legal matters amounted to $520.3 million and $158.1 million at September 30, 2013 and December 31, 2012, respectively. The company made total payments of $177.1 million to qualified settlement funds (“QSFs”), of which $19.5 million were made during the nine months ended September 30, 2013 subject to certain settlement conditions, for certain Hernia Product Claims. Payments to QSFs were recorded as a component of restricted cash. Total payments of $158.2 million from these QSFs have been made to qualified claimants, of which $25.6 million were made during the nine months ended September 30, 2013. In addition, other payments of $26.2 million have been made to qualified claimants, of which $15.6 million were made during the nine months ended September 30, 2013.

The company recorded receivables related to product liability matters amounting to $186.2 million and $45.6 million at September 30, 2013 and December 31, 2012, respectively. A substantial amount of the receivable at September 30, 2013 is the subject of a dispute with a supplier who has contested at least, in part, its obligation to defend and indemnify the company, which the company refutes. After considering the following factors (as appropriate): the nature of the claims, relevant contracts, relevant legal issues, the advice and judgment of outside legal counsel, and other pertinent factors, the company believes that it should collect these receivables.

The company is unable to estimate the reasonably possible losses or range of losses, if any, arising from certain existing product liability matters and other legal matters. Under U.S. generally accepted accounting principles, an event is “reasonably possible” if “the chance of the future event or events occurring is more than remote but less than likely” and an event is “remote” if “the chance of the future event or events occurring is slight”. With respect to all putative class action lawsuits relating to product liability matters, the company is unable to estimate a range of reasonably possible losses for the following reasons: (i) all or certain of the proceedings are in early stages; (ii) the company has not received and reviewed complete information regarding all or certain of the plaintiffs and their medical conditions; and/or (iii) there are significant factual issues to be resolved. In addition, there is uncertainty as to the likelihood of a class being certified or the ultimate size of the class.

9. Share-Based Compensation Plans

The company may grant a variety of share-based payments under the 2012 Long Term Incentive Plan of C. R. Bard, Inc., as amended and restated (the “LTIP”) and the 2005 Directors’ Stock Award Plan of C. R. Bard, Inc., as amended and restated (the “Directors’ Plan”) to certain directors, officers and employees. At the company’s Annual Meeting of Shareholders on April 17, 2013, the shareholders authorized an additional 2,000,000 shares for issuance under the LTIP. The total number of remaining shares at September 30, 2013 that may be issued under the LTIP was 5,710,855 and under the Directors’ Plan was 39,843. Awards under the LTIP may be in the form of stock options, stock appreciation rights, limited stock appreciation rights, restricted stock, unrestricted stock and other stock-based awards. Awards under the Directors’ Plan may be in the form of stock awards, stock options or stock appreciation rights. The company also has two employee stock purchase programs.

 

15


Table of Contents

C. R. BARD, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

 

Amounts recognized for share-based compensation are as follows:

 

     Quarter Ended
September 30,
    Nine Months Ended
September 30,
 
     2013     2012     2013     2012  
(dollars in millions)                         

Total cost of share-based compensation plans

   $ 16.0      $ 11.5      $ 44.6      $ 39.0   

Amounts capitalized in inventory and fixed assets

     (0.3     (0.4     (1.4     (1.2

Amounts recognized in income for amounts previously capitalized in inventory and fixed assets

     0.5        0.4        1.5        1.2   
  

 

 

   

 

 

   

 

 

   

 

 

 

Amounts charged against income

   $ 16.2      $ 11.5      $ 44.7      $ 39.0   
  

 

 

   

 

 

   

 

 

   

 

 

 

In the first quarter of each of 2013 and 2012, the company granted performance restricted stock units to certain officers. These units have requisite service periods of three years and have no dividend rights. The actual payout of these units varies based on the company’s performance over the three-year period based on pre-established targets over the period and a market condition modifier based on total shareholder return (“TSR”) compared to an industry peer group. The actual payout under these awards may exceed an officer’s target payout; however, compensation cost initially recognized assumes that the target payout level will be achieved and may be adjusted for subsequent changes in the expected outcome of the performance-related condition. The fair values of these units are based on the market price of the company’s stock on the date of the grant and use a Monte Carlo simulation model for the TSR component. The fair values of the TSR components of the 2013 and 2012 grants were estimated based on the following assumptions: risk-free interest rate of 0.42% and 0.41%, respectively; dividend yield of 0.81% and 0.85%, respectively; and expected life of 2.88 and 2.83 years, respectively.

Anticipated purchases under the Management Stock Purchase Program (the “MSPP”) are approximately 0.2 million shares for the 2013 grant. Purchases under the MSPP were approximately 0.2 million shares for the 2012 grant. The fair value of the 2013 annual MSPP purchases was $37.20 per share and was estimated in July 2013. The fair value of the 2012 MSPP purchases was $38.33 per share. These fair value calculations used the Black-Scholes model based on the following assumptions: risk free interest rate of 0.10% and 0.16%, respectively; expected volatility of 15% and 20%, respectively; dividend yield of 0.8% and 0.9%, respectively; and expected life of 0.6 years for both valuations.

As of September 30, 2013, there were $79.3 million of unrecognized compensation expenses related to share-based payment arrangements. These costs are expected to be recognized over a weighted-average period of approximately two years. The company has sufficient shares to satisfy expected share-based payment arrangements in 2013.

10. Pension and Other Postretirement Benefit Plans

Defined Benefit Pension Plans - The company has both tax-qualified and nonqualified, noncontributory defined benefit pension plans, that together cover certain domestic and foreign employees. These plans provide benefits based upon a participant’s compensation and years of service.

The components of net periodic pension cost are as follows:

 

     Quarter Ended
September 30,
    Nine Months Ended
September 30,
 
     2013     2012     2013     2012  
(dollars in millions)                         

Service cost, net of employee contributions

   $ 7.5      $ 7.0      $ 22.6      $ 20.8   

Interest cost

     4.6        4.9        13.7        14.6   

Expected return on plan assets

     (6.5     (6.2     (19.5     (17.9

Amortization

     3.4        2.8        10.2        7.8   
  

 

 

   

 

 

   

 

 

   

 

 

 

Net periodic pension cost

   $ 9.0      $ 8.5      $ 27.0      $ 25.3   
  

 

 

   

 

 

   

 

 

   

 

 

 

Other Postretirement Benefit Plan - The company does not provide subsidized postretirement healthcare benefits and life insurance coverage except for a limited number of former employees. As this plan is unfunded, contributions are made as benefits are incurred. The net periodic benefit cost was $0.1 million and $0.2 million for the quarters ended September 30, 2013 and 2012, respectively. The net periodic benefit cost was $0.4 million and $0.5 million for the nine month periods ended September 30, 2013 and 2012, respectively.

 

16


Table of Contents

C. R. BARD, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

 

11. Shareholders’ Investment

The company repurchased approximately 5.2 million shares of common stock for $533.4 million in the nine months ended September 30, 2013 under its previously announced share repurchase authorizations.

Other Comprehensive Income (Loss)

During the first quarter of 2013, the company adopted new Financial Accounting Standards Board guidance that requires the company to present information about reclassification adjustments from accumulated other comprehensive loss. Under this guidance, the company presents the effect of amounts reclassified from each component of accumulated other comprehensive loss based on its source.

The changes in accumulated other comprehensive income (loss) by component are as follows:

 

    Derivative
Instruments
Designated as
Cash Flow Hedges
    Foreign Currency
Translation
    Benefit
Plans
    Total  
(dollars in millions)                        

Balance at December 31, 2011

  $ (1.4   $ 41.1      $ (106.3   $ (66.6

Other comprehensive income (loss) before reclassifications

    5.2        (24.3     —          (19.1

Tax (provision) benefit related to other comprehensive income (loss) before reclassifications(a)

    (2.2     —          —          (2.2
 

 

 

   

 

 

   

 

 

   

 

 

 

Other comprehensive income (loss) before reclassifications, net of taxes

    3.0        (24.3     —          (21.3
 

 

 

   

 

 

   

 

 

   

 

 

 

Amounts reclassified from accumulated other comprehensive income (loss)

    (1.1 )(b)      —          8.0 (c)      6.9   

Tax provision (benefit) related to amounts reclassified from accumulated other comprehensive income (loss)

    0.2        —          (2.8     (2.6
 

 

 

   

 

 

   

 

 

   

 

 

 

Reclassifications, net of tax

    (0.9     —          5.2        4.3   
 

 

 

   

 

 

   

 

 

   

 

 

 

Other comprehensive income (loss)

    2.1        (24.3     5.2        (17.0
 

 

 

   

 

 

   

 

 

   

 

 

 

Balance at September 30, 2012

  $ 0.7      $ 16.8      $ (101.1   $ (83.6
 

 

 

   

 

 

   

 

 

   

 

 

 

Balance at December 31, 2012

  $ (0.7   $ 32.6      $ (113.1   $ (81.2

Other comprehensive income (loss) before reclassifications

    2.3        (0.7     —          1.6   

Tax (provision) benefit related to other comprehensive income (loss) before reclassifications(a)

    (0.4     —          —          (0.4
 

 

 

   

 

 

   

 

 

   

 

 

 

Other comprehensive income (loss) before reclassifications, net of taxes

    1.9        (0.7     —          1.2   
 

 

 

   

 

 

   

 

 

   

 

 

 

Amounts reclassified from accumulated other comprehensive income (loss)

    (0.6 )(b)      —          10.3 (c)      9.7   

Tax provision (benefit) related to amounts reclassified from accumulated other comprehensive income (loss)

    0.3        —          (3.7     (3.4
 

 

 

   

 

 

   

 

 

   

 

 

 

Reclassifications, net of tax

    (0.3     —          6.6        6.3   
 

 

 

   

 

 

   

 

 

   

 

 

 

Other comprehensive income (loss)

    1.6        (0.7     6.6        7.5   
 

 

 

   

 

 

   

 

 

   

 

 

 

Balance at September 30, 2013

  $ 0.9      $ 31.9      $ (106.5   $ (73.7
 

 

 

   

 

 

   

 

 

   

 

 

 

 

(a) Income taxes are not provided for foreign currency translation adjustment.
(b) See Note 6 of the notes to condensed consolidated financial statements.
(c) These components are included in the computation of net periodic pension cost. See Note 10 of the notes to condensed consolidated financial statements.

 

17


Table of Contents

C. R. BARD, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

 

12. Segment Information

The company’s management considers its business to be a single segment entity—the manufacture and sale of medical devices. The company’s products generally share similar distribution channels and customers. The company designs, develops, manufactures, packages, distributes and sells medical, surgical, diagnostic and patient care devices. The company sells a broad range of products to hospitals, individual healthcare professionals, extended care health facilities and alternate site facilities on a global basis. In general, the company’s products are intended to be used once and then discarded or either temporarily or permanently implanted. The company’s chief operating decision makers evaluate their various global product portfolios on a net sales basis and generally evaluate profitability and associated investment on an enterprise-wide basis due to shared geographic infrastructures.

Net sales based on the location of external customers by geographic region are:

 

     Quarter Ended
September 30,
     Nine Months Ended
September 30,
 
     2013      2012      2013      2012  
(dollars in millions)                            

United States

   $ 500.3       $ 483.4       $ 1,496.4       $ 1,469.6   

Europe(a)

     116.7         108.9         356.5         349.4   

Japan

     43.4         41.6         123.4         122.2   

Other(a)

     97.6         89.0         281.9         254.3   
  

 

 

    

 

 

    

 

 

    

 

 

 
   $ 758.0       $ 722.9       $ 2,258.2       $ 2,195.5   
  

 

 

    

 

 

    

 

 

    

 

 

 

 

(a) Beginning in 2013, certain emerging markets in Europe are included in the “other” geographic region. Prior year amounts have been reclassified to conform to the current year presentation.

Total net sales by product group category are:

 

     Quarter Ended
September 30,
     Nine Months Ended
September 30,
 
     2013      2012      2013      2012  
(dollars in millions)                            

Vascular

   $ 209.9       $ 202.5       $ 625.3       $ 633.0   

Urology

     193.7         188.1         574.2         562.0   

Oncology

     215.5         203.9         636.7         601.9   

Surgical Specialties

     118.1         107.7         358.4         333.8   

Other

     20.8         20.7         63.6         64.8   
  

 

 

    

 

 

    

 

 

    

 

 

 
   $ 758.0       $ 722.9       $ 2,258.2       $ 2,195.5   
  

 

 

    

 

 

    

 

 

    

 

 

 

 

18


Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

This management’s discussion and analysis provides a review of the results of operations, financial condition and the liquidity and capital resources of C. R. Bard, Inc. and its subsidiaries (the “company” or “Bard”). The following discussion should be read in conjunction with Bard’s 2012 Annual Report on Form 10-K, and the condensed consolidated financial statements and notes thereto included elsewhere in this Form 10-Q. Certain statements contained herein may contain forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995; see “Risks and Uncertainties; Cautionary Statement Regarding Forward-Looking Information” below.

Overview

The company designs, develops, manufactures, packages, distributes and sells medical, surgical, diagnostic and patient care devices. The company sells a broad range of products to hospitals, individual healthcare professionals, extended care health facilities and alternate site facilities on a global basis. Outside the United States, Europe and Japan are the company’s largest markets, while certain emerging markets in Asia, Latin America, and Europe are the company’s fastest-growing markets. In general, the company’s products are intended to be used once and then discarded or either temporarily or permanently implanted. The company reports sales in four major product group categories: vascular; urology; oncology; and surgical specialties. The company also has a product group category of other products.

The company’s earnings are driven by its ability to continue to generate sales of its products and improve operating efficiency. Bard’s ability to increase sales over time depends upon its success in developing, acquiring and marketing differentiated products that meet the needs of clinicians and their patients. For the nine months ended September 30, 2013, the company’s research and development (“R&D”) expense as a percentage of net sales was 10.0%. The company also makes selective acquisitions of businesses, products and technologies, generally focusing on small-to-medium sized transactions to provide ongoing growth opportunities. In addition, the company may from time-to-time consider acquisitions of larger, established companies. The company may also periodically divest lines of business in which it is not able to reasonably attain or maintain a leadership position in the market or for other strategic reasons.

Recent Developments

On October 1, 2013, the company acquired all of the outstanding shares of Medafor, Inc. (“Medafor”), a privately-held developer and supplier of plant-based hemostatic agents. The purchase consideration included an up-front cash payment of $203.7 million and future contingent payments of up to an additional $80 million based on specific revenue-based milestones through June 30, 2015.

On September 4, 2013, the company entered into a definitive agreement to acquire Rochester Medical, Inc. (“Rochester Medical”), a publicly-held developer and supplier of silicone urinary incontinence and urine drainage products, for a purchase price of $20 per share, or approximately $262 million in the aggregate to be paid at closing. The transaction is expected to close in 2013, and is subject to customary closing conditions, including approval by the shareholders of Rochester Medical as well as regulatory approvals.

On August 29, 2013, the company acquired early stage technology from 3DT Holdings LLC (“3DT”), providing the company with the rights to develop and commercialize a novel technology related to peripherally inserted central catheters (“PICCs”). 3DT received an up-front cash payment of $29.5 million and is eligible for milestone payments of up to $5 million based upon regulatory product approval. The company recorded the up-front payment as a research and development expense.

On July 29, 2013, the company acquired all of the outstanding shares of Loma Vista Medical, Inc., a privately-held company specializing in the development and commercialization of aortic valvuloplasty products, which use noncompliant fiber-based balloon technology. The total purchase consideration of $39.4 million included an up-front cash payment of $32.5 million and the fair value of contingent consideration of up to $8.0 million.

The purchases of these acquisitions were funded or are expected to be funded through a mixture of available cash and short-term debt. See Note 2 of the notes to condensed consolidated financial statements.

On June 27, 2013, the company reached a definitive agreement to sell certain assets and liabilities of its electrophysiology division (“BEP”) to Boston Scientific Corporation for $275 million in cash. The transaction is expected to be completed in 2013, subject to certain regulatory and customary closing conditions. The company expects to record a gain on the sale when the transaction is completed. See Note 2 of the notes to condensed consolidated financial statements.

During the second quarter of 2013, the company evaluated certain product liability matters based on information currently available, including: the allegations and documentation supporting or refuting such allegations; publicly available

 

19


Table of Contents

information regarding similar medical device mass tort settlements; historical information regarding other product liability settlements involving the company; and the procedural posture and stage of litigation. Based on these, and other factors, the company determined to record a charge, net of estimated recoveries to other (income) expense, net of approximately $293.0 million ($276.0 million after tax) in the second quarter of 2013, which recognized the estimated costs for certain product liability matters, including (with respect to such matters) asserted and unasserted claims, as well as costs to administer the settlements related to such matters. The charge excludes any costs associated with all but one putative class action lawsuit against the company. See Note 8 of the notes to condensed consolidated financial statements.

Healthcare Reform

Significant reforms to the U.S. healthcare system were adopted in the form of the Patient Protection and Affordable Care Act of 2010 (the “PPACA”). The PPACA requires, among other things, the company to pay a 2.3% excise tax on most U.S. medical device sales beginning in 2013. During the quarter and nine months ended September 30, 2013, the company recorded to marketing, selling and administrative expense an excise tax of $7.0 million and $22.1 million, respectively.

Results of Operations

Net Sales

Bard’s consolidated net sales for the quarter ended September 30, 2013 increased 5% on a reported basis (4% on a constant currency basis) compared to the same period in the prior year. Bard’s consolidated net sales for the nine months ended September 30, 2013 increased 3% on both a reported basis and constant currency basis compared to the same period in the prior year. Net sales “on a constant currency basis” is a non-GAAP measure and should not be viewed as a replacement of GAAP results. See “Management’s Use of Non-GAAP Measures” below. Price changes had the effect of decreasing consolidated net sales for the quarter and nine months ended September 30, 2013 by approximately 80 basis points and 110 basis points, respectively, as compared to the same periods in the prior year. Exchange rate fluctuations had the effect of increasing consolidated net sales for the quarter ended September 30, 2013 by approximately 1 percentage point as compared to the same period in the prior year. Exchange rate fluctuations had a nominal impact on consolidated net sales for the nine months ended September 30, 2013 as compared to the same period in the prior year. The primary exchange rate movement that impacts net sales is the movement of the Euro compared to the U.S. dollar. The impact of exchange rate movements on net sales is not indicative of the impact on net earnings due to the offsetting impact of exchange rate movements on operating costs and expenses, costs incurred in other currencies and the company’s hedging activities.

Bard’s United States net sales of $500.3 million for the quarter ended September 30, 2013 increased 3% compared to $483.4 million in the prior year quarter. Net sales in the United States have moderated in recent quarters, a trend that may continue. International net sales of $257.7 million for the quarter ended September 30, 2013 increased 8% on a reported basis (6% on a constant currency basis) compared to $239.5 million in the prior year quarter. Bard’s United States net sales of $1,496.4 million for the nine months ended September 30, 2013 increased 2% compared to $1,469.6 million in the prior year. International net sales of $761.8 million for the nine months ended September 30, 2013 increased 5% on a reported basis (4% on a constant currency basis) compared to $725.9 million in the prior year period.

A summary of net sales by product group category is as follows:

Product Group Summary of Net Sales

 

     Quarter Ended September 30,     Nine Months Ended September 30,  
     2013      2012      Change     Constant
Currency
    2013      2012      Change     Constant
Currency
 
(dollars in millions)                                                     

Vascular

   $ 209.9       $ 202.5         4     2   $ 625.3       $ 633.0         (1 )%      (2 )% 

Urology

     193.7         188.1         3     3     574.2         562.0         2     2

Oncology

     215.5         203.9         6     6     636.7         601.9         6     6

Surgical Specialties

     118.1         107.7         10     9     358.4         333.8         7     7

Other

     20.8         20.7         —          1     63.6         64.8         (2 )%      (2 )% 
  

 

 

    

 

 

        

 

 

    

 

 

      

Total net sales

   $ 758.0       $ 722.9         5     4   $ 2,258.2       $ 2,195.5         3     3
  

 

 

    

 

 

        

 

 

    

 

 

      

Vascular Products - Bard markets a wide range of products for the peripheral vascular market, including endovascular products, electrophysiology products and vascular graft products. Consolidated net sales of vascular products for the quarter ended September 30, 2013 increased 4% on a reported basis (2% on a constant currency basis) compared to the prior year quarter primarily due to an increase in sales of endovascular products. Consolidated net sales of vascular

 

20


Table of Contents

products for the nine months ended September 30, 2013 decreased 1% on a reported basis (2% on a constant currency basis) compared to the prior year period primarily due to a decline in sales of endovascular products and vascular graft products. United States net sales of vascular products for the quarter ended September 30, 2013 were flat compared to the prior year quarter. International net sales of vascular products for the quarter ended September 30, 2013 increased 8% on a reported basis (6% on a constant currency basis) compared to the prior year quarter. United States net sales of vascular products for the nine months ended September 30, 2013 decreased 3% compared to the prior year period. International net sales of vascular products for the nine months ended September 30, 2013 increased 1% on a reported basis (flat on a constant currency basis) compared to the prior year period.

Consolidated net sales of endovascular products for the quarter ended September 30, 2013 increased 3% on a reported basis (2% on a constant currency basis) compared to the prior year quarter. Net sales in the product line were favorably impacted by growth in sales of biopsy products and percutaneous transluminal angioplasty (“PTA”) balloon catheters. This growth was partially offset by a decline in sales of stents. Consolidated net sales of endovascular products for the nine months ended September 30, 2013 decreased 1% on a reported basis (2% on a constant currency basis) compared to the prior year period. Declining sales of stents was the primary contributor to this decrease. This decline was partially offset by growth in sales of PTA balloon catheters and biopsy products. Net sales of stents for the quarter and nine months ended September 30, 2012 benefited from an issue with the availability of a competitor’s products.

Consolidated net sales of electrophysiology products for the quarter ended September 30, 2013 increased 9% on a reported basis (7% on a constant currency basis) compared to the prior year quarter. Net sales of electrophysiology systems were the primary contributor to the increase in sales of electrophysiology products for the quarter ended September 30, 2013. Consolidated net sales of electrophysiology products for the nine months ended September 30, 2013 increased 2% on a reported basis (1% on a constant currency basis) compared to the prior year period.

Consolidated net sales of vascular graft products for the quarter ended September 30, 2013 decreased 3% on a reported basis (4% on a constant currency basis) compared to the prior year quarter. Consolidated net sales of vascular graft products for the nine months ended September 30, 2013 decreased 6% on both a reported basis and constant currency basis compared to the prior year period. Declining sales of peripheral vascular grafts and dialysis access grafts were the primary contributors to the decrease in sales for vascular graft products for the nine months ended September 30, 2013.

Urology Products - Bard markets a wide range of products for the urology market, including basic drainage products, continence products and urological specialty products. Bard also markets StatLock® catheter stabilization products, which are used to secure many types of catheters sold by Bard and other companies. Bard also markets Targeted Temperature Management products for therapeutic hypothermia. Consolidated net sales of urology products for the quarter ended September 30, 2013 increased 3% on both a reported basis and constant currency basis compared to the prior year quarter. Consolidated net sales of urology products for the nine months ended September 30, 2013 increased 2% on both a reported basis and constant currency basis compared to the prior year period. These increases included sales growth of Targeted Temperature Management products, basic drainage products and urological specialty products. For the quarter and nine months ended September 30, 2013, this growth was partially offset by a decline in sales of continence products, a trend that may continue. In addition, the growth for the nine months ended September 30, 2013 was partially offset by a decline in sales of StatLock® catheter stabilization products, a trend that may continue. United States net sales of urology products for the quarter ended September 30, 2013 increased 2% compared to the prior year quarter. International net sales of urology products for the quarter ended September 30, 2013 increased 6% on both a reported basis and constant currency basis compared to the prior year quarter. United States net sales of urology products for the nine months ended September 30, 2013 were flat compared to the prior year period. International net sales of urology products for the nine months ended September 30, 2013 increased 7% on both a reported basis and constant currency basis compared to the prior year period.

Consolidated net sales of basic drainage products for the quarter and nine months ended September 30, 2013 increased 3% on both a reported basis and constant currency basis compared to the prior year periods. Consolidated net sales of infection control Foley catheter products for the quarter ended September 30, 2013 increased 1% on both a reported basis and constant currency basis compared to the prior year quarter. Consolidated net sales of infection control Foley catheter products for the nine months ended September 30, 2013 were flat on both a reported basis and constant currency basis compared to the prior year period.

Consolidated net sales of urological specialty products, which include brachytherapy products, for the quarter and nine months ended September 30, 2013 increased 1% on both a reported basis and constant currency basis compared to the prior year periods. Consolidated net sales of brachytherapy products for the quarter ended September 30, 2013 were flat on both a reported basis and constant currency basis compared to the prior year quarter. Consolidated net sales of brachytherapy products for the nine months ended September 30, 2013 decreased 2% on a reported basis (1% on a constant currency basis) compared to the prior year period. The brachytherapy market has been losing procedural share to alternative therapies, a trend that may continue.

 

21


Table of Contents

Consolidated net sales of continence products for the quarter ended September 30, 2013 decreased 8% on a reported basis (9% on a constant currency basis) compared to the prior year quarter. Consolidated net sales of continence products for the nine months ended September 30, 2013 decreased 10% on both a reported basis and constant currency basis compared to the prior year period. The decrease was primarily due to a decline in sales of surgical continence products, a trend that may continue.

Consolidated net sales of the StatLock® catheter stabilization product line for the quarter ended September 30, 2013 were flat on a reported basis (increased 1% on a constant currency basis) compared to the prior year quarter. Consolidated net sales of the StatLock® catheter stabilization product line for the nine months ended September 30, 2013 decreased 3% on both a reported basis and constant currency basis compared to the prior year period.

Oncology Products - Bard’s oncology business includes specialty vascular access products and enteral feeding devices. Specialty vascular access products include PICCs used for intermediate to long-term central venous access, specialty access ports and accessories (“Ports”) used most commonly for chemotherapy, dialysis access catheters and vascular access ultrasound devices, which help facilitate the placement of PICCs. Consolidated net sales of oncology products for the quarter and nine months ended September 30, 2013 increased 6% on both a reported basis and constant currency basis compared to the prior year periods. These increases are due to growth in sales of PICCs, Ports and dialysis access catheters. United States net sales of oncology products for the quarter and nine months ended September 30, 2013 increased 4% compared to the prior year periods. International net sales of oncology products for the quarter ended September 30, 2013 increased 11% on both a reported basis and constant currency basis compared to the prior year quarter. International net sales of oncology products for the nine months ended September 30, 2013 increased 10% on both a reported basis and constant currency basis compared to the prior year period.

Consolidated net sales of PICCs for the quarter and nine months ended September 30, 2013 increased 7% on both a reported basis and constant currency basis compared to the prior year periods. Consolidated net sales of Ports for the quarter ended September 30, 2013 increased 5% on a reported basis (4% on a constant currency basis) compared to the prior year quarter. Consolidated net sales of Ports for the nine months ended September 30, 2013 increased 3% on both a reported basis and constant currency basis compared to the prior year period.

Consolidated net sales of dialysis access catheters for the quarter ended September 30, 2013 increased 10% on both a reported basis and constant currency basis compared to the prior year quarter. Consolidated net sales of dialysis access catheters for the nine months ended September 30, 2013 increased 8% on both a reported basis and constant currency basis compared to the prior year period. Consolidated net sales of vascular access ultrasound devices for the quarter ended September 30, 2013 increased 3% on both a reported basis and constant currency basis compared to the prior year quarter. Consolidated net sales of vascular access ultrasound devices for the nine months ended September 30, 2013 increased 7% on a reported basis (6% on a constant currency basis) compared to the prior year period.

Surgical Specialty Products - Surgical specialty products include soft tissue repair products, performance irrigation devices and sealant products. Consolidated net sales of surgical specialty products for the quarter ended September 30, 2013 increased 10% on a reported basis (9% on a constant currency basis) compared to the prior year quarter. This increase includes 7 percentage points of growth on a reported basis (6 percentage points on a constant currency basis) from the addition of surgical sealant products through the acquisition of Neomend, Inc. Consolidated net sales of surgical specialty products for the nine months ended September 30, 2013 increased 7% on both a reported basis and constant currency basis compared to the prior year period, which includes 5 percentage points of growth on a reported basis (6 percentage points on a constant currency basis) from the addition of the surgical sealant products. United States net sales of surgical specialty products for the quarter ended September 30, 2013 increased 12% compared to the prior year quarter. International net sales of surgical specialty products for the quarter ended September 30, 2013 increased 4% on a reported basis (3% on a constant currency basis) compared to the prior year quarter. United States net sales of surgical specialty products for the nine months ended September 30, 2013 increased 8% compared to the prior year period. International net sales of surgical specialty products for the nine months ended September 30, 2013 increased 6% on both a reported basis and constant currency basis compared to the prior year period.

The soft tissue repair product line includes synthetic and natural-tissue hernia repair implants, natural-tissue breast reconstruction implants and hernia fixation products. Consolidated net sales of soft tissue repair products for the quarter ended September 30, 2013 increased 5% on both a reported basis and constant currency basis compared to the prior year quarter. Consolidated net sales of soft tissue repair products for the nine months ended September 30, 2013 increased 4% on both a reported basis and constant currency basis compared to the prior year period. Net sales in this product line for the

 

22


Table of Contents

quarter and nine months ended September 30, 2013 were favorably impacted by growth in sales of synthetic hernia repair products and natural-tissue hernia repair. This growth was partially offset by declines in hernia fixation products, a trend that may continue.

Other Products - The other product group includes irrigation, wound drainage and certain original equipment manufacturers’ products.

Costs and Expenses

A summary of costs and expenses as a percentage of net sales is as follows:

 

     Quarter Ended
September 30,
    Nine Months Ended
September 30,
 
     2013     2012     2013     2012(A)  

Cost of goods sold

     38.5     37.7     39.1     38.2

Marketing, selling and administrative expense

     29.5     27.2     29.5     27.5

Research and development expense

     13.1     7.2     10.0     6.9

Interest expense

     1.5     1.3     1.5     1.3

Other (income) expense, net

     1.7     1.9     15.0     0.9
  

 

 

   

 

 

   

 

 

   

 

 

 

Total costs and expenses

     84.3     75.3     95.1     74.7
  

 

 

   

 

 

   

 

 

   

 

 

 

 

(A) Amounts do not add due to rounding.

Cost of goods sold - Cost of goods sold consists principally of the manufacturing and distribution costs of the company’s products. The category also includes royalties, amortization of intangible assets and the impact of certain hedging activities. Cost of goods sold as a percentage of net sales for the quarter and nine months ended September 30, 2013 increased 80 basis points and 90 basis points, respectively, compared to the prior year periods. These costs as a percentage of net sales increased primarily due to decreases in selling prices and targeted investments. Incremental amortization of intangible assets acquired in 2013 and 2012 increased cost of goods sold as a percentage of net sales by approximately 20 basis points over both the prior year quarter and nine month period.

Marketing, selling and administrative expense - Marketing, selling and administrative expense consists principally of the costs associated with the company’s sales and administrative organizations. These costs as a percentage of net sales for the quarter and nine months ended September 30, 2013 increased 230 basis points and 200 basis points, respectively, compared to the prior year periods. These costs as a percentage of net sales increased primarily due to the new excise tax on the U.S. sales of medical devices, targeted investments in this area including in emerging markets, and related costs from operations acquired in 2012.

Research and development expense - Research and development expense consists principally of costs related to internal research and development activities, milestone payments for third-party research and development activities, and acquired in-process R&D (“IPR&D”) costs arising from the company’s business development activities. IPR&D payments may impact the comparability of the company’s results of operations between periods. Research and development expense for the quarter ended September 30, 2013 was $99.4 million, an increase of approximately 90% compared to the prior year quarter. Research and development expense for the nine months ended September 30, 2013 was $224.8 million, an increase of approximately 49% compared to the prior year period. These increases in research and development expense reflect targeted investments in this area and costs from operations acquired in 2012. Included in research and development expense for the quarter and nine months ended September 30, 2013 were IPR&D charges of $29.5 million related to the acquisition of early stage technology and $3.4 million for an impairment charge related to an IPR&D project.

Interest expense - Interest expense was $11.2 million and $9.7 million for the quarters ended September 30, 2013 and 2012, respectively. Interest expense was $33.7 million and $28.9 million for the nine months ended September 30, 2013 and 2012, respectively. The increase in interest expense was partially due to the issuance of $500 million of senior unsecured notes in October 2012.

 

23


Table of Contents

Other (income) expense, net - The components of other (income) expense, net, are as follows:

 

     Quarter Ended
September 30,
    Nine Months Ended
September 30,
 
     2013     2012     2013     2012  
(dollars in millions)                         

Interest income

   $ (0.3   $ (1.0   $ (0.9   $ (4.6

Foreign exchange losses (gains)

     1.7        (1.0     4.5        (0.6

Litigation charges, net

     —          —          318.2        —     

Asset impairments

     —          13.2        6.4        22.2   

Restructuring

     —          —          (1.4     (1.6

Divestiture-related charges

     9.7        —          9.7        —     

Other, net

     1.5        2.4        2.1        3.6   
  

 

 

   

 

 

   

 

 

   

 

 

 

Total other (income) expense, net

   $ 12.6      $ 13.6      $ 338.6      $ 19.0   
  

 

 

   

 

 

   

 

 

   

 

 

 

Litigation charges, net - For the nine months ended September 30, 2013, the amount reflects the estimated costs for product liability matters, net of recoveries, and a write-down of an insurance receivable. See Note 8 of the notes to condensed consolidated financial statements.

Asset impairments - For the nine months ended September 30, 2013, the amount reflects charges for the write-down of certain core technologies. For the quarter and nine months ended September 30, 2012, the amounts reflect a charge for the write-down of certain core technologies. In addition, the amount for the nine months ended September 30, 2012 reflects impairments of assets not related to operations.

Restructuring - For the nine months ended September 30, 2013, the amount reflects the reversal of certain restructuring costs recognized during the fourth quarter of 2012. For the nine months ended September 30, 2012, the amount reflects the reversal of certain restructuring costs recognized in the second half of 2011.

Divestiture-related charges - For the quarter and nine months ended September 30, 2013, the amounts reflect charges incurred in connection with the divestiture of the BEP business including transaction costs, primarily consisting of legal costs, and other separation costs, including employee termination and consulting costs.

Income Tax Provision

The effective tax rate for the quarter ended September 30, 2013 was approximately 22%, compared to approximately 27% for the prior year quarter. The effective tax rate for the quarter and nine months ended September 30, 2013 reflected the discrete tax effects of an IPR&D charge related to the acquisition of 3DT, which was incurred in a high tax jurisdiction, and a benefit associated with the remeasurement of an uncertain tax position as a result of the settlement of the Brachytherapy Matter. In addition, the effective tax rate for the nine months ended September 30, 2013 reflected the discrete tax effects of litigation charges, primarily related to product liability claims, which were substantially incurred in a low tax jurisdiction, and the write-down of an insurance receivable, which also was incurred in a low tax jurisdiction. See Note 8 of the notes to condensed consolidated financial statements. The effective tax rate was also impacted by the American Taxpayer Relief Act of 2012, which was signed into law on January 2, 2013 and retroactively reinstated the research tax credit. Although the reinstatement of this tax credit is retroactive to January 1, 2012, the enactment of this legislation in 2013 precluded the company from recording the benefit in 2012. As a result, the company’s income tax provision was reduced by approximately $3.7 million during the nine months ended September 30, 2013 to recognize the 2012 benefit of this tax credit that would have been recorded in 2012.

Net Income and Earnings Per Share Available to Common Shareholders

The company reported net income and diluted earnings per share available to common shareholders for the quarter ended September 30, 2013 of $93.2 million and $1.15, respectively. Net income and diluted earnings per share available to common shareholders for the prior year quarter were $129.3 million and $1.50, respectively. The current year quarter reflects acquisition-related items (primarily consisting of an IPR&D charge, transaction costs, purchase accounting adjustments and integration costs) of $22.9 million, or $0.28 per diluted share, divestiture-related charges of $6.2 million, or $0.08 per diluted share, and an asset impairment of $2.2 million, or $0.03 per diluted share. The current year quarter also reflects a $2.2 million, or $0.03 per diluted share, benefit to the income tax provision associated with the remeasurement of an uncertain tax position as a result of the settlement of the Brachytherapy Matter. The prior year quarter reflects asset impairments of $8.0 million, or $0.09 per diluted share, and acquisition-related items (primarily consisting of an IPR&D charge and transaction costs) of $4.1 million, or $0.05 per diluted share.

 

24


Table of Contents

The company reported net income and diluted earnings per share available to common shareholders for the nine months ended September 30, 2013 of $22.3 million and $0.27, respectively. Net income and diluted earnings per share available to common shareholders for the nine months ended September 30, 2012 was $401.9 million and $4.64, respectively. The current nine month period reflects net litigation charges of $300.1 million, or $3.63 per diluted share, acquisition-related items (primarily consisting of IPR&D charges, transaction costs, purchase accounting adjustments and integration costs) of $25.3 million, or $0.31 per diluted share, asset impairments of $9.5 million, or $0.12 per diluted share, divestiture-related charges of $6.2 million, or $0.08 per diluted share, and a reversal of certain restructuring costs of $1.0 million, or $0.01 per diluted share. The current nine month period also reflects a $2.2 million, or $0.03 per diluted share, benefit to the income tax provision associated with the remeasurement of an uncertain tax position as a result of the settlement of the Brachytherapy Matter. The prior nine month period reflects asset impairments of $13.8 million, or $0.16 per diluted share, acquisition-related items (primarily consisting of an IPR&D charge, transaction costs, purchase accounting adjustments and integration costs) of $5.7 million, or $0.07 per diluted share, and a reversal of certain restructuring costs of $1.1 million, or $0.01 per diluted share. The prior nine month period also reflects an increase to the income tax provision of $1.1 million, or $0.01 per diluted share, due to the write-down of a tax receivable in a foreign jurisdiction.

Liquidity and Capital Resources

The company assesses its liquidity in terms of its ability to generate cash to fund its operating, investing and financing activities. Significant factors affecting the management of liquidity are cash flows generated from operating activities, capital expenditures, acquisitions of businesses and technologies, cash dividends and common stock repurchases. Cash provided from operations continues to be a primary source of funds. The company believes that it could borrow adequate funds at competitive terms should it be necessary. The company also believes that its overall financial strength gives it sufficient financial flexibility. A summary of certain liquidity measures for Bard as of September 30 is as follows:

 

     2013      2012  
(dollars in millions)              

Working capital

   $ 1,246.9       $ 1,000.7   
  

 

 

    

 

 

 

Current ratio

     3.47/1         2.28/1   
  

 

 

    

 

 

 

Cash and cash equivalents held by the company’s foreign subsidiaries were $767.3 million and $786.1 million at September 30, 2013 and December 31, 2012, respectively. It is the company’s intention to permanently reinvest the majority of these funds outside the United States to finance foreign operations, and the company’s plans do not demonstrate a need to repatriate these funds. If these funds are needed for U.S. operations for currently unforeseen circumstances or can no longer be permanently reinvested outside the United States, the company would be required to accrue and pay U.S. taxes on the earnings associated with these funds. In the United States, ongoing operating cash flows and available borrowings under the company’s committed syndicated bank credit facility provide it with sufficient liquidity.

For the nine months ended September 30, 2013 and 2012, net cash provided by operating activities was $417.0 million and $427.2 million, respectively. The decrease in net cash provided by operating activities reflects a settlement payment for the Brachytherapy Matter previously recorded in 2012, partially offset by lower payments to claimants for Hernia Product Claims previously recorded in 2011.

For the nine months ended September 30, 2013, net cash used by investing activities was $107.9 million compared to the $60.0 million net cash provided by investing activities in the prior year period. Capital expenditures were approximately $47.3 million and $55.5 million for the nine month periods ended September 30, 2013 and 2012, respectively. The company spent $68.5 million and $14.1 million for the acquisition of businesses, products and technology to augment existing product lines for the nine months ended September 30, 2013 and 2012, respectively. Net cash used by investing activities in the prior year reflected $119.6 million related to the release of restricted cash from qualified settlement funds to claimants pursuant to the settlement of certain Hernia Product Claims.

For the nine months ended September 30, 2013, the company used $415.8 million in cash for financing activities, compared to the $269.8 million used in the prior year period. Total debt was $1.5 billion and $1.4 billion at September 30, 2013 and December 31, 2012, respectively. Total debt to total capitalization was 50.0% and 42.3% at September 30, 2013 and December 31, 2012, respectively. Net cash used in financing activities reflects $546.9 million used to repurchase 5,110,235 shares of common stock in the nine months ended September 30, 2013 compared to approximately $372.5 million to repurchase 3,876,516 shares of common stock in the prior year period. The company paid cash dividends of $0.61 per share and $0.58 per share for the nine month periods ended September 30, 2013 and 2012, respectively.

 

25


Table of Contents

On September 26, 2013, the company amended its $600 million five-year committed syndicated bank credit facility that was scheduled to expire in October 2016. The amendment includes an increase of the aggregate principal amount of credit available under the syndicated bank credit facility to $750 million and extends the commitment termination date until September 26, 2018. The amended credit facility supports the company’s commercial paper program and can be used for general corporate purposes. The facility includes pricing based on the company’s long-term credit rating and includes a financial covenant that limits the amount of total debt to total capitalization. At September 30, 2013, the company was in compliance with this covenant. The company had commercial paper borrowings outstanding of $97.5 million at September 30, 2013. There were no commercial paper borrowings outstanding at December 31, 2012.

Contingencies

In the ordinary course of business, the company is subject to various legal proceedings and claims, including product liability matters, environmental matters, employment disputes, contractual disputes on agreements and other commercial disputes. In addition, the company operates in an industry susceptible to significant patent legal claims. At any given time in the ordinary course of business, the company is involved as either a plaintiff or defendant in a number of patent infringement actions. See Note 8 of the notes to condensed consolidated financial statements.

Management’s Use of Non-GAAP Measures

Net sales “on a constant currency basis” is a non-GAAP measure. The company analyzes net sales on a constant currency basis to better measure the comparability of results between periods. Because changes in foreign currency exchange rates have a non-operating impact on net sales, the company believes that evaluating growth in net sales on a constant currency basis provides an additional and meaningful assessment of net sales to both management and the company’s investors. Constant currency growth rates are calculated by translating the prior year’s local currency sales by the current period’s exchange rate. Constant currency growth rates are not indicative of changes in corresponding cash flows. The limitation of these non-GAAP measures is that they do not reflect results on a standardized reporting basis. Non-GAAP measures are intended to supplement the applicable GAAP disclosures and should not be viewed as replacements of GAAP results.

Critical Accounting Policies

The preparation of financial statements requires the company’s management to make estimates and assumptions that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Critical accounting policies are those that require application of management’s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain and may change in subsequent periods. Such policies are summarized in the Management’s Discussion and Analysis of Financial Condition and Results of Operations section in Bard’s 2012 Annual Report on Form 10-K. There have been no significant changes to the company’s critical accounting policies since December 31, 2012.

Risks and Uncertainties; Cautionary Statement Regarding Forward-Looking Information

Certain statements contained herein or in other company documents and certain statements that may be made by management of the company orally may contain forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. You can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “forecast,” “plan,” “believe” and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. In particular, these include statements relating to product approvals, future performance of current and anticipated products, sales efforts, expenses, the outcome of contingencies, such as legal proceedings, and financial results. The company’s forward-looking statements speak only as of the date of this report or as of the date they are made, and the company undertakes no obligation to update its forward-looking statements.

In addition, there are substantial risks inherent in the medical device business. The company’s business involves the design, development, manufacture, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. These devices are often used on, or permanently or temporarily implanted in, patients in clinically demanding circumstances, such as operating rooms, emergency units, intensive care and critical care settings, among others. These circumstances, among other factors, can cause the products to become associated with adverse clinical events, including patient mortality and injury, and could lead to product liability claims (including lawsuits seeking class action status or seeking to establish multi-district litigation proceedings) and other litigation, product withdrawals, warning letters, recalls, field corrections or

 

26


Table of Contents

regulatory enforcement actions relating to one or more of the company’s products, any of which could have a material adverse effect on our business, results of operations, financial condition and/or liquidity. For further discussion of risks applicable to our business, see “Risk Factors” in Bard’s 2012 Annual Report on Form 10-K.

Because actual results are affected by these and other risks and uncertainties, the company cautions investors that actual results may differ materially from those expressed or implied. It is not possible to predict or identify all risks and uncertainties. In addition to the risks addressed above and those described in the “Risk Factors” in Bard’s 2012 Annual Report on Form 10-K, certain other risks could adversely affect our business or cause the actual results to differ materially from those expressed or implied including, but not limited to:

Effective management of and reaction to risks involved in our business, including:

 

    the ability to achieve manufacturing or administrative efficiencies, including gross margin benefits from our manufacturing processes and supply chain programs or in connection with the integration of acquired businesses;

 

    the effects of negative publicity concerning our products, which could result in product withdrawals or decreased product demand and which could reduce market or governmental acceptance of our products;

 

    the ability to identify appropriate companies, businesses and technologies as potential acquisition candidates, to consummate and successfully integrate such transactions or to obtain agreements for such transactions on favorable terms;

 

    the reduction in the number of procedures using our devices caused by customers’ cost-containment pressures or preferences for alternate therapies;

 

    the ability to implement, and realize the benefits of, our plans to invest in our business, including our plan to increase research and development expenditures with a focus on new market categories, increase growth in emerging and/or faster growing markets outside the United States and acquire growth platforms designed to change the mix of our portfolio towards faster, sustainable long-term growth;

 

    the uncertainty of whether increased research and development expenditures and sales force expansion will result in increased sales;

 

    the ability to reduce exposure and uncertainty related to tax audits, appeals and litigation;

 

    internal factors, such as retention of key employees, including sales force employees;

 

    the ability to achieve earnings forecasts, which are generated based, among other things, on projected volumes and sales of many product types, some of which are more profitable than others;

 

    changes in factors and assumptions or actual results that differ from our assumptions on stock valuation and employee stock option exercise patterns, which could cause compensation expense recorded in future periods to differ significantly from the compensation expense recorded in the current period;

 

    changes in factors and assumptions could cause pension cost recorded in future periods to differ from the pension cost recorded in the current period;

 

    the effect of market fluctuations on the value of assets in the company’s pension plans and the possibility that the company may need to make additional contributions to the plans as a result of any decline in the fair value of such assets;

 

    damage to a facility where our products are manufactured or from which they are distributed, which could render the company unable to manufacture or distribute one or more products and may require the company to reduce the output of products at the damaged facility thereby making it difficult to meet product shipping targets;

 

    the potential impairment of goodwill and intangible assets of the company resulting from insufficient cash flow generated from such assets specifically, or our business more broadly, so as to not allow the company to justify the carrying value of the assets;

 

    the ability to obtain appropriate levels of product liability insurance on reasonable terms;

 

    the ability to recover for claims made to our insurance companies;

 

    the ability to maintain or protect our information technology systems and data integrity effectively or fail to anticipate, plan for or manage significant disruptions to these systems; and

 

    the ability to realize the anticipated benefits of our restructuring activities, including our 2012 Restructuring Plan, to improve the company’s overall cost structure and improve efficiency.

 

27


Table of Contents

Competitive factors, including:

 

    the trend of consolidation in the medical device industry as well as among our customers, resulting in potentially greater pricing pressures and more significant and complex contracts than in the past, both in the United States and abroad;

 

    development of new products or technologies by competitors having superior performance compared to our current products or products under development which could negatively impact sales of our products or render one or more of our products obsolete;

 

    technological advances, patents and registrations obtained by competitors that would have the effect of excluding the company from new market segments or preventing the company from selling a product or including key features in the company’s products;

 

    attempts by competitors to gain market share through aggressive marketing programs; and

 

    reprocessing by third-party reprocessors of our products designed and labeled for single use.

Difficulties and delays inherent in the development, manufacturing, marketing and sale of medical products, including:

 

    the ability to complete planned and/or ongoing clinical trials successfully, to develop and obtain regulatory approval for products on a timely basis and to launch products on a timely basis within cost estimates;

 

    lengthy and costly regulatory approval processes, which may result in lost market opportunities and/or delayed product launches;

 

    delays or denials of, or grants of low or reduced levels of reimbursement for, procedures using newly developed products;

 

    the suspension or revocation of authority to manufacture, market or distribute existing products;

 

    the imposition of additional or different regulatory requirements, such as those affecting manufacturing and labeling;

 

    performance, efficacy, quality or safety concerns for existing products, whether scientifically justified or not, that may lead to product discontinuations, product withdrawals, recalls, field corrections, regulatory enforcement actions, litigation or declining sales, including adverse events and/or concerns relating to the company’s vena cava filters, pelvic floor repair products and hernia repair products;

 

    FDA inspections resulting in Form-483 notices and/or warning letters identifying deficiencies in the company’s manufacturing practices and/or quality systems; warning letters identifying violations of FDA regulations that could result in product holds, recalls, restrictions on future clearances by the FDA and/or civil penalties;

 

    the failure to obtain, limitations on the use of, or the loss of, patent and other intellectual property rights, and the failure of efforts to protect our intellectual property rights against infringement and legal challenges that can increase our costs;

 

    difficulties obtaining necessary components or raw materials used in the company’s products and/or price increases from the company’s suppliers of critical components or raw materials, including oil-based resins, or other interruptions of the supply chain; and

 

    customers that may limit the number of manufacturers or vendors from which they will purchase products, which can result in the company’s inability to sell products to or contract with large hospital systems, integrated delivery networks or group purchasing organizations.

Governmental action, including:

 

    the impact of continued healthcare cost containment;

 

    new laws and judicial decisions related to healthcare availability, healthcare reform, payment for healthcare products and services or the marketing and distribution of products, including legislative or administrative reforms to the United States Medicare and Medicaid systems or other United States or international reimbursement systems in a manner that would significantly reduce or eliminate reimbursements for procedures that use the company’s products;

 

    changes in the FDA and/or foreign regulatory approval processes that may delay or prevent the approval of new products and result in lost market opportunity;

 

28


Table of Contents
    the impact of more vigorous compliance and enforcement activities affecting the healthcare industry in general or the company in particular;

 

    changes in the tax laws affecting our business, such as the excise tax in Puerto Rico;

 

    changes in the environmental laws or standards affecting our business;

 

    changes in laws that could require facility upgrades or process changes and could affect production rates and output; and

 

    compliance costs and potential penalties and remediation obligations in connection with environmental laws, including regulations regarding air emissions, waste water discharges and solid waste.

Legal disputes, including:

 

    disputes over legal proceedings, including our patent infringement suit against W.L. Gore & Associates Inc. (“Gore”), the outcome of the Gore matters and the timing of final resolution of the Gore matters;

 

    product liability claims, which may involve lawsuits seeking class action status or seeking to establish multi-district litigation proceedings, including the Hernia Product Claims, the Women’s Health Product Claims and the Filter Product Claims;

 

    claims asserting securities law violations;

 

    claims asserting, and/or subpoenas seeking information regarding, violations of law in connection with federal and/or state healthcare programs such as Medicare or Medicaid;

 

    derivative shareholder actions;

 

    claims and subpoenas asserting antitrust violations;

 

    environmental claims, including risks relating to accidental contamination or injury from the use of hazardous materials in the company’s manufacturing, sterilization and research activities and the potential for the company to be held liable for any resulting damages; and

 

    commercial disputes, including disputes over distribution agreements, license agreements, manufacturing/supply agreements, development/research agreements, acquisition or sale agreements, and insurance policies.

General economic conditions, including:

 

    international and domestic business conditions;

 

    political or economic instability in foreign countries;

 

    interest rates;

 

    foreign currency exchange rates;

 

    changes in the rate of inflation; and

 

    instability of global financial markets and economies including Greece, Italy, Spain, Portugal and other countries in Europe.

Other factors beyond our control, including catastrophes, both natural and man-made, earthquakes, floods, fires, explosions, acts of terrorism or war.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

The quantitative and qualitative disclosures about market risk are discussed in “Part II, Item 7A. Quantitative and Qualitative Disclosures About Market Risk” in Bard’s 2012 Annual Report on Form 10-K. There have been no material changes in the information reported since the year ended December 31, 2012.

Item 4. Controls and Procedures

The company maintains disclosure controls and procedures that are designed to ensure that information required to be disclosed in the company’s reports under the Securities Exchange Act of 1934 (the “Exchange Act”) is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to the company’s management, including its Chief Executive Officer and Chief Financial Officer, as appropriate, to allow for timely decisions regarding required disclosures. Any controls and procedures, no matter how well defined and operated, can provide only reasonable assurance of achieving the desired control objectives.

 

29


Table of Contents

The company’s management, with the participation of the company’s Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the design and operation of the company’s disclosure controls and procedures as of September 30, 2013. Based upon that evaluation, the company’s Chief Executive Officer and Chief Financial Officer have concluded that, as of September 30, 2013, the design and operation of the company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) were effective to accomplish their objectives at the reasonable assurance level. There have been no changes in internal control over financial reporting for the quarter ended September 30, 2013 that have materially affected, or are likely to materially affect, the company’s internal control over financial reporting.

 

30


Table of Contents

PART II – OTHER INFORMATION

Item 1. Legal Proceedings

General

In the ordinary course of business, the company is subject to various legal proceedings, investigations and claims, including, for example, environmental matters, employment disputes, disputes on agreements and other commercial disputes. In addition, the company operates in an industry susceptible to significant product liability and patent legal claims. At any given time, in the ordinary course of business, the company is involved as either a plaintiff or defendant in a number of patent infringement actions. If a third party’s patent infringement claim were to be determined against the company, the company might be required to make significant royalty or other payments or might be subject to an injunction or other limitation on its ability to manufacture or distribute one or more products. If a patent owned by or licensed to the company is found to be invalid or unenforceable, the company might be required to reduce the value of certain intangible assets on the company’s balance sheet and to record a corresponding charge, which could be significant in amount. Many of the company’s legal proceedings and claims could have a material adverse effect on its business, results of operations, financial condition and/or liquidity.

Product Liability Matters

As of October 17, 2013, approximately 745 federal and 720 state lawsuits involving individual claims by approximately 1,575 plaintiffs, as well as two putative class actions in the United States are currently pending against the company with respect to its Composix® Kugel® and certain other hernia repair implant products (collectively, the “Hernia Product Claims”). The company voluntarily recalled certain sizes and lots of the Composix® Kugel® products beginning in December 2005. One of the U.S. class action lawsuits consolidated ten previously-filed U.S. class action lawsuits. The putative class actions, none of which has been certified, seek: (i) medical monitoring; (ii) compensatory damages; (iii) punitive damages; (iv) a judicial finding of defect and causation; and/or (v) attorneys’ fees. A settlement has been reached with respect to the three pending putative Canadian class actions within amounts previously recorded by the company. Approximately 685 of the state lawsuits, involving individual claims by approximately 785 plaintiffs, are pending in the Superior Court of the State of Rhode Island, with the remainder in various other jurisdictions. The Hernia Product Claims also generally seek damages for personal injury resulting from use of the products.

In June 2007, the Composix® Kugel® lawsuits and, subsequently, other hernia repair product lawsuits, pending in federal courts nationwide were transferred into one Multidistrict Litigation (“MDL”) for coordinated pre-trial proceedings in the United States District Court for the District of Rhode Island.

On June 30, 2011, the company announced that it had reached agreements in principle with various plaintiffs’ law firms to settle the majority of its existing Hernia Product Claims. Each agreement is subject to certain conditions, including requirements for participation in the proposed settlements by a certain minimum number of plaintiffs. In addition, the company continues to engage in discussions with other plaintiffs’ law firms regarding potential resolution of unsettled Hernia Product Claims, and intends to vigorously defend Hernia Product Claims that do not settle, including through litigation. The company cannot give any assurances that the resolution of the Hernia Product Claims that have not settled, including asserted and unasserted claims and the putative class action lawsuits, will not have a material adverse effect on the company’s business, results of operations, financial condition and/or liquidity.

As of October 17, 2013, product liability lawsuits involving individual claims by approximately 9,635 plaintiffs have been filed or asserted against the company in various federal and state jurisdictions alleging personal injuries associated with the use of certain of the company’s surgical continence products for women, including its Avaulta® line of products. In addition, five putative class actions in the United States and three putative class actions in Canada have been filed against the company (all lawsuits, collectively, the “Women’s Health Product Claims”). The Women’s Health Product Claims generally seek damages for personal injury resulting from use of the products. The putative class actions, none of which has been certified, seek: (i) medical monitoring; (ii) compensatory damages; (iii) punitive damages; (iv) a judicial finding of defect and causation; and/or (v) attorneys’ fees. With respect to certain of these claims, the company believes that one of its suppliers has an obligation to defend and indemnify the company. In October 2010, the Women’s Health Product Claims involving solely Avaulta® products pending in federal courts nationwide were transferred into an MDL in the United States District Court for the Southern District of West Virginia, the scope of which was later expanded to include lawsuits involving all women’s surgical continence products that are manufactured or distributed by the company. The company expects additional Women’s Health Product Claims pending in federal courts to be transferred to the MDL in West Virginia, with the remainder of the Women’s Health Product Claims in other jurisdictions. The first trial in the MDL commenced in July 2013 and resulted in a judgment against the company of approximately $2 million. The company intends to appeal the judgment. The next MDL trial is scheduled to occur in December 2013, with additional trials scheduled in 2014. The first trial in a state

 

31


Table of Contents

court was completed in July 2012 and resulted in a judgment against the company of approximately $3.6 million. The company has appealed this decision. During the third quarter, the company settled one MDL case and one New Jersey state case. The amounts of the settlements are subject to confidentiality requirements. In addition, during the third quarter, an MDL case was voluntarily dismissed with prejudice, and the company is currently seeking to recover attorneys’ fees for this case. The company does not believe that any verdicts or settlements entered to date are representative of potential outcomes of all Women’s Health Product Claims. The case numbers set forth above do not include generic complaints involving women’s health products where the company cannot, based on the allegations in such complaints, determine whether any of such cases involve the company’s women’s health products. While the company intends to vigorously defend the Women’s Health Product Claims, it cannot give any assurances that the resolution of these claims will not have a material adverse effect on the company’s business, results of operations, financial condition and/or liquidity.

As of October 17, 2013, product liability lawsuits involving individual claims by 40 plaintiffs are currently pending against the company in various federal and state jurisdictions alleging personal injuries associated with the use of the company’s vena cava filter products. In addition, three putative class actions were filed against the company in various state courts on behalf of plaintiffs who are alleged to have no present injury (all lawsuits, collectively, the “Filter Product Claims”). Two of these putative class actions were dismissed during the second quarter, and class certification was denied for the third putative class action in July 2013. The first Filter Product Claim trial was completed in June 2012 and resulted in a judgment for the company. The company expects additional trials of Filter Product Claims to take place over the next 12 months. During the second quarter of 2013, the company finalized settlement agreements with respect to more than 30 Filter Product Claims, and made payments with respect to such claims within the amounts previously recorded. While the company intends to vigorously defend the remaining unsettled Filter Product Claims, it cannot give any assurances that the resolution of these claims will not have a material adverse effect on the company’s business, results of operations, financial condition and/or liquidity.

In most product liability litigations of this nature, plaintiffs allege a wide variety of claims, ranging from allegations of serious injury caused by the products to efforts to obtain compensation notwithstanding the absence of any injury. In many of these cases, the company has not yet received and reviewed complete information regarding the plaintiffs and their medical conditions, and consequently, is unable to fully evaluate the claims. The company expects that it will receive and review additional information regarding any remaining unsettled product liability matters.

The company believes that some settlements and judgments, as well as legal defense costs, relating to product liability matters are or may be covered in whole or in part under its product liability insurance policies with a limited number of insurance carriers. In certain circumstances, insurance carriers reserve their rights with respect to coverage, or contest or deny coverage, as has occurred with respect to certain claims. When this occurs, the company intends to vigorously contest disputes with respect to its insurance coverage and to enforce its rights under the terms of its insurance policies, and accordingly, will record receivables with respect to amounts due under these policies, when recovery is probable. Amounts recovered under the company’s product liability insurance policies may be less than the stated coverage limits and may not be adequate to cover damages and/or costs relating to claims. In addition, there is no guarantee that insurers will pay claims or that coverage will otherwise be available.

The company’s insurance coverage with respect to the Hernia Product Claims has been exhausted. In the first quarter of 2013 the company recorded a non-cash charge of $25.0 million ($24.5 million after tax) to other (income) expense, net, for the write-down of an insurance receivable related to a dispute with one of its excess insurance carriers in connection with these claims.

In connection with the Women’s Health Product Claims, the company was in dispute with one of its excess insurance carriers relating to an aggregate of $50 million of insurance coverage. In June 2013, the company settled this dispute with no change to the amount of the insurance coverage or the related receivable.

Other Legal Matters

During the first half of 2013, the company received subpoenas or Civil Investigative Demands from a number of State Attorneys General seeking information related to the sales and marketing of certain of the company’s products that are the subject of the Hernia Product Claims and the Women’s Health Product Claims. The company is cooperating with these requests. Since it is not feasible to predict the outcome of these proceedings, the company cannot give any assurances that the resolution of these proceedings will not have a material adverse effect on the company’s business, results of operations, financial condition and/or liquidity.

In November 2006, the company received a subpoena issued by the U.S. Department of Health and Human Services, Office of Inspector General (“OIG”), under the authority of the federal healthcare fraud and false claims statutes, seeking documents related to the company’s brachytherapy business (the “Brachytherapy Matter”). In January 2012, the company

 

32


Table of Contents

reached a preliminary agreement with the civil and criminal divisions of the United States Attorney’s Office for the Northern District of Georgia to resolve claims with respect to the Brachytherapy Matter and recorded a charge of approximately $51.0 million ($40.8 million after tax) in the fourth quarter of 2011. On May 2, 2013, the company settled this matter. The resolution includes agreements with the government that required the company to pay approximately the amount that was previously recorded.

In December 2007, a U.S. District Court jury in Arizona found that certain of W.L. Gore & Associates Inc.’s (“Gore”) ePTFE vascular grafts and stent-grafts infringe the company’s patent number 6,436,135 (the “135 patent”). The jury upheld the validity of the patent and awarded the company $185 million in past damages. The jury also found that Gore willfully infringed the patent. In a second phase of the trial, the District Court ruled that Gore failed to prove that the patent is unenforceable due to inequitable conduct. In March 2009, the District Court doubled the jury award to approximately $371 million for damages through June 2007. The District Court also awarded the company attorneys’ fees of $19 million and prejudgment interest of approximately $20 million. In addition, the District Court denied Gore’s remaining motions, including its motions for a new trial and to set aside the jury’s verdict. In July 2010, the District Court awarded the company approximately $109 million in additional damages for the period from July 2007 through March 2009. Gore has deposited or secured the foregoing amounts with the District Court. The District Court also assessed a royalty rate of between 12.5% and 20%, depending on the product, that will be used to calculate damages for Gore’s infringing sales from April 2009 through the expiration of the patent. Gore has made additional deposits with the District Court of approximately $542 million, representing Gore’s calculation of royalties for its infringing sales through July 2013. Gore appealed this matter to the Court of Appeals for the Federal Circuit (the “Court of Appeals”), which on February 10, 2012 affirmed the decision of the District Court. Gore filed a petition with the Court of Appeals for a rehearing of its appeal. On June 14, 2012, the Court of Appeals reaffirmed its February 10, 2012 decision, including the ongoing royalty rates as set by the District Court, with the exception of the issue of willfulness with respect to Gore’s infringement of the 135 patent, which was remanded to the District Court. On October 12, 2012, Gore filed a petition for a writ of certiorari to the U.S. Supreme Court requesting a review of the portion of the decision that the Court of Appeals reaffirmed. The U.S. Supreme Court denied Gore’s petition on January 14, 2013. The District Court heard oral argument on June 5, 2013 as to three pending motions before it, including the company’s motion to execute on the judgment with respect to all amounts other than enhanced damages due to willfulness. In October 2013, the District Court granted Bard’s motion to execute on the judgment, denied Gore’s motion requesting a determination that Gore’s infringement was not willful and denied Gore’s motion for a new trial. The District Court’s rulings on the motions are subject to appeal. On January 28, 2013, Gore filed with the U.S. District Court a Request for Judicial Notice that the U.S. Patent and Trademark Office (“USPTO”) granted Gore’s previously filed request for a re-examination of the 135 patent. On April 1, 2013, the USPTO issued a First Office Action initially rejecting all of the claims of the 135 patent that are the subject of the re-examination. On July 10, 2013, the USPTO issued a Notice of Intent to Issue an Ex Parte Reexamination Certificate upholding the patentability of all re-examined claims of the 135 patent. This action terminated the re-examination proceeding and upheld the claims involved in the re-examination. The timing of final resolution of this litigation remains uncertain. Since the company considers these matters a gain contingency, no amounts have been recorded. Even if the company is ultimately successful in this lawsuit, it cannot give any assurances that royalties for Gore’s future infringing sales will remain at or near historic levels.

The company is subject to numerous federal, state, local and foreign environmental protection laws governing, among other things, the generation, storage, use and transportation of hazardous materials and emissions or discharges into the ground, air or water. The company is or may become a party to proceedings brought under various federal laws including the Comprehensive Environmental Response, Compensation and Liability Act (CERCLA), commonly known as Superfund, the Resource Conservation and Recovery Act, the Clean Water Act, the Clean Air Act and similar state or foreign laws. These proceedings seek to require the owners or operators of contaminated sites, transporters of hazardous materials to the sites and generators of hazardous materials disposed of at the sites to clean up the sites or to reimburse the government for cleanup costs. In most cases, there are other potentially responsible parties that may be liable for remediation costs. In these cases, the government alleges that the defendants are jointly and severally liable for the cleanup costs; however, these proceedings are frequently resolved so that the allocation of cleanup costs among the parties more closely reflects the relative contributions of the parties to the site contamination. The company’s potential liability varies greatly from site to site. For some sites, the potential liability is de minimis and for others the costs of cleanup have not yet been determined. Accruals for estimated losses from environmental remediation obligations generally are recognized no later than completion of the remedial feasibility study and are adjusted as further information develops or circumstances change. Costs of future expenditures for environmental remediation obligations are not discounted to their present value. Recoveries of environmental remediation costs from other parties are recorded as assets when their receipt is deemed probable. The company believes that the proceedings and claims described above will likely be resolved over an extended period of time. While it is not feasible to predict the outcome of these proceedings, based upon the company’s experience, current information and applicable law, the company does not expect these proceedings to have a material adverse effect on its financial condition and/or liquidity. However, one or more of the proceedings could be material to the company’s business and/or results of operations.

 

33


Table of Contents

The company regularly monitors and evaluates the status of product liability and other legal matters, and may, from time-to-time, engage in settlement and mediation discussions taking into consideration developments in the matters and the risks and uncertainties surrounding litigation. These discussions could result in settlements of one or more of these claims at any time.

Item 1A. Risk Factors

There have been no material changes to the risk factors disclosed in Part I, Item 1A. in Bard’s 2012 Annual Report on Form 10-K.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

The following table provides information with respect to the shares of the company’s common stock repurchased during the quarter ended September 30, 2013:

 

     Issuer Purchases of Equity Securities  

Period

   Total
Number
of Shares
Purchased(1)
     Average
Price
Paid
Per Share
     Total Number
of Shares
Purchased as
Part of Publicly
Announced
Programs(2)
     Maximum
Approximate
Dollar Value of
Shares
that May Yet
Be Purchased
Under Plans or
Programs(2)
 

July 1 – July 31, 2013

     781,221       $ 111.11         776,420       $ 377,129,352   

August 1 – August 31, 2013

     843,942         115.06         805,500         284,505,631   

September 1 – September 30, 2013

     382,010         118.00         381,408         239,498,031   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total

     2,007,173       $ 114.08         1,963,328       $ 239,498,031   
  

 

 

    

 

 

    

 

 

    

 

 

 

 

(1) The company repurchased 43,845 shares during the three-month period ended September 30, 2013 that were not part of publicly-announced share repurchase authorizations. These shares were purchased from employees to satisfy tax withholding requirements on the vesting of restricted shares from equity-based awards.
(2) On June 12, 2013, the Board of Directors approved the repurchase of up to $500 million of common stock of the company.

Item 5. Other Information

The company’s policy governing transactions in its securities by the company’s directors, executive officers and other specified employees permits such persons to adopt trading plans pursuant to Rule 10b5-1 of the Exchange Act. From time-to-time, the company’s executive officers have established trading plans relating to the company’s common stock under Rule 10b5-1, and the company anticipates additional trading plans may be established in the future. The company currently discloses details regarding individual trading plans on its website.

Item 6. Exhibits

 

Number

  

Description

  10.34    2005 Directors’ Stock Award Plan of C. R. Bard, Inc. (as Amended and Restated)*
  10.35    Amendment No. 1, dated as of September 26, 2013, to Credit Agreement dated as of October 12, 2011, among C. R. Bard, Inc., J.P. Morgan Securities LLC and Merrill Lynch, Pierce, Fenner & Smith Incorporated (as Joint Lead Arrangers and Joint Bookrunners), JPMorgan Chase Bank, N.A. (as Administrative Agent), Bank of America, N.A. (as Syndication Agent) and Barclays Bank PLC, Goldman Sachs Bank USA, Wells Fargo Bank, National Association and Royal Bank of Canada (each as Documentation Agents)*
  12.1    Computation of Ratio of Earnings to Fixed Charges*
  31.1    Rule 13a-14(a) / 15d-14(a) Certification of Chief Executive Officer*
  31.2    Rule 13a-14(a) / 15d-14(a) Certification of Chief Financial Officer*
  32.1    Section 1350 Certification of Chief Executive Officer (furnished herewith)
  32.2    Section 1350 Certification of Chief Financial Officer (furnished herewith)
101.INS    XBRL Instance Document*
101.SCH    XBRL Taxonomy Extension Schema Document*
101.CAL    XBRL Taxonomy Extension Calculation Linkbase Document*
101.DEF    XBRL Taxonomy Extension Definition Linkbase Document*
101.LAB    XBRL Taxonomy Extension Label Linkbase Document*
101.PRE    XBRL Taxonomy Extension Presentation Linkbase Document*

 

* Filed herewith.

 

34


Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

    C. R. BARD, INC.
        (Registrant)
Date: October 24, 2013      
     

/s/    CHRISTOPHER S. HOLLAND        

     

Christopher S. Holland

Senior Vice President and

Chief Financial Officer

     

/s/    FRANK LUPISELLA JR.        

     

Frank Lupisella Jr.

Vice President and Controller

 

35


Table of Contents

INDEX TO EXHIBITS

 

Number

  

Description

  10.34    2005 Directors’ Stock Award Plan of C. R. Bard, Inc. (as Amended and Restated)
  10.35    Amendment No. 1, dated as of September 26, 2013, to Credit Agreement dated as of October 12, 2011, among C. R. Bard, Inc., J.P. Morgan Securities LLC and Merrill Lynch, Pierce, Fenner & Smith Incorporated (as Joint Lead Arrangers and Joint Bookrunners), JPMorgan Chase Bank, N.A. (as Administrative Agent), Bank of America, N.A. (as Syndication Agent) and Barclays Bank PLC, Goldman Sachs Bank USA, Wells Fargo Bank, National Association and Royal Bank of Canada (each as Documentation Agents)
  12.1    Computation of Ratio of Earnings to Fixed Charges
  31.1    Rule 13a-14(a) / 15d-14(a) Certification of Chief Executive Officer
  31.2    Rule 13a-14(a) / 15d-14(a) Certification of Chief Financial Officer
  32.1    Section 1350 Certification of Chief Executive Officer (furnished herewith)
  32.2    Section 1350 Certification of Chief Financial Officer (furnished herewith)
101.INS    XBRL Instance Document
101.SCH    XBRL Taxonomy Extension Schema Document
101.CAL    XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF    XBRL Taxonomy Extension Definition Linkbase Document
101.LAB    XBRL Taxonomy Extension Label Linkbase Document
101.PRE    XBRL Taxonomy Extension Presentation Linkbase Document

 

36

EX-10.34 2 d587637dex1034.htm EX-10.34 EX-10.34

Exhibit 10.34

2005 DIRECTORS’ STOCK AWARD PLAN

OF

C. R. BARD, INC.

(AS AMENDED AND RESTATED)

Effective as of October 9, 2013, the 2005 Directors’ Stock Award Plan of C. R. Bard, Inc. (the “Plan”) is hereby amended and restated by C. R. Bard, Inc., a New Jersey corporation (the “Corporation”), as set forth herein.

The Corporation’s objectives in maintaining the Plan are (a) to attract and retain highly qualified individuals to serve on the Board of Directors of the Corporation, (b) to relate non-employee directors’ compensation more closely to the Corporation’s performance and its shareholders’ interests, and (c) to increase non-employee directors’ stock ownership in the Corporation.

SECTION 1. DEFINITIONS.

For purposes of the Plan, the following terms shall have the indicated meanings:

1.01 “Award” shall mean an Option, Stock Award, SAR or other stock-based award granted pursuant to the Plan.

1.02 “Board” shall mean the Board of Directors of the Corporation.

1.03 “Code” shall mean the Internal Revenue Code of 1986, as amended (or any successor statute thereto).

1.04 “Committee” shall mean the Governance Committee of the Board or such other committee as may be designated by the Board.

1.05 “Common Stock” shall mean the Common Stock of the Corporation, par value $0.25 per share.

1.06 “Corporation” shall mean C. R. Bard, Inc., a New Jersey corporation.

1.07 “Director” shall mean a member of the Board.

1.08 “Exchange Act” shall mean the Securities Exchange Act of 1934, as amended.

1.09 “Fair Market Value” shall mean on any given date: (a) the mean between the high and low sale price of the Common Stock on that day as reported on the New York Stock Exchange-Composite Transactions Tape or, if no sale of Common Stock shall have occurred on the New York Stock Exchange on that day, on the next preceding day on which there was a sale; or (b) in the case of a simultaneous exercise and sale, the actual price Optionee receives in the open market on the date of the exercise. If the Common Stock is not traded on the New York Stock Exchange, the Fair Market Value shall be the amount that is reasonably determined by the Committee.

1.10 “Option” shall mean a stock option granted pursuant to Section 5 of the Plan.

1.11 “Option Price” shall mean the purchase price per share of an Option, as determined pursuant to Section 5.04 of the Plan.

1.12 “Option Period” shall mean the period from the date of the grant of an Option to the date of its expiration as provided in Section 5.

1.13 “Optionee” shall mean a Participant who has been granted an Option under the Plan.

1.14 “Participant” shall mean any non-employee Director who receives an Award.

1.15 “Permanent Disability” shall mean any disability which prevents a Director from performing all duties as a Director.

1.16 “Plan” shall mean the C. R. Bard, Inc. 2005 Directors’ Stock Award Plan (as amended and restated).

1.17 “Retirement” shall mean the voluntary cessation of service as a director by a director who is 55 years of age or older and who has served on the Board for at least five years.

1.18 “SAR” shall mean stock appreciation right granted pursuant to Section 6 of the Plan.

1.19 “Stock Award” shall mean Common Stock awards granted pursuant to Section 4 of the Plan.

1.20 “Term” shall mean the number of years that the Participant is appointed or elected to serve as a Director.


1.21 “Transfer Restriction Period” shall mean the period of time during which a Stock Award will remain subject to the transfer restrictions set forth in Section 4.05 of the Plan.

1.22 “Unrestricted Stock” shall mean Common Stock awarded to a Participant which Common Stock is not subject to a vesting period or installment delivery specified by the Committee.

1.23 “Vesting Restriction Period” shall mean the period of time during which a Stock Award will remain subject to vesting restrictions as described in Section 4.01(b) of the Plan.

SECTION 2. SHARES SUBJECT TO THE PLAN.

Subject to adjustment as provided in Section 11, the total number of shares of Common Stock which may be issued under the Plan is 350,000. The shares may consist, in whole or in part, of unissued shares or treasury shares. The issuance of shares or the payment of cash upon the exercise of an Award or in consideration of the cancellation or termination of an Award shall reduce the total number of shares available under the Plan, as applicable. Shares subject to Awards which are forfeited, terminate or otherwise lapse will be added back to the aggregate number of shares available under the Plan.

SECTION 3. ADMINISTRATION.

3.01 Determination of Awards. Subject to the provisions of the Plan, the Committee shall have exclusive power to select the Participants and to determine the amount of, or method of determining, the Awards to be made to Participants. All Awards granted to Participants under the Plan shall be evidenced by an Award agreement which specifies the type of Award granted pursuant to the Plan, the number of shares of Common Stock underlying the Award and all terms governing the Award, including, without limitation, terms regarding vesting, exercisability and expiration of the Award.

3.02 Interpretation of Plan. The Committee is authorized to interpret the Plan, to establish, amend or rescind any rules and regulations relating to the Plan and to make any other determinations that it deems necessary or desirable for the administration of the Plan. The Committee may correct any defect or supply any omission or reconcile any inconsistency in the Plan in the manner and to the extent the Committee deems necessary or desirable. Any decision of the Committee in the interpretation and administration of the Plan, as described herein, shall lie within its sole and absolute discretion and shall be final, conclusive and binding on all parties concerned (including, but not limited to, Participants and their beneficiaries or successors). The Committee shall have the full power and authority, consistent with the provisions of the Plan, to establish the terms and conditions of any Award and to waive any such terms or conditions at any time (including, without limitation, accelerating or waiving any vesting conditions).

3.03 Tax Withholding. The Committee shall require payment of any amount it may determine to be necessary to withhold for federal, state, local or other taxes as a result of the exercise, grant or vesting of an Award as a condition to such exercise, grant or vesting. Unless the Committee specifies otherwise, the Participant may elect to pay a portion or all of such withholding taxes by (a) delivery in shares of Common Stock or (b) having shares of Common Stock withheld by the Corporation from any shares of Common Stock that would have otherwise been received by the Participant.

SECTION 4. STOCK AWARDS.

4.01 Formula Grant of Stock Award. For Directors elected prior to April 18, 2012, the following shall apply:

(a) Grant. On the first business day in October following the appointment or election of an individual as a Director (the “Formula Grant Date”), each nonemployee Director shall receive a Stock Award of 400 shares of Common Stock for each year or partial year remaining in his or her Term (other than a partial year resulting from the appointment or election of a Director subsequent to the October 1st immediately preceding the annual meeting at which the term of office of such Director will expire).

(b) Formula Grant Vesting Restriction Period. Unless otherwise determined by the Committee, each Stock Award granted pursuant to Section 4.01 shall vest with respect to the first 400 shares of Common Stock on the Formula Grant Date and, with respect to the remaining shares of Common Stock included in such Stock Award, on each October 1 following the date on which the Stock Award was granted. If for any reason, the Participant ceases to serve as a Director prior to the date on which he or she is fully vested in the Stock Award granted under this Section 4.01, he or she shall forfeit all of the unvested shares underlying such Stock Award.

 

- 2 -


(c) Formula Grant Transfer Restriction Period. The transfer restrictions set forth in Section 4.05 of this Plan shall apply to shares of Common Stock underlying grants of Stock Awards made pursuant to this Section 4.01 until the second anniversary of the end of the Vesting Restriction Period applicable to such shares. Notwithstanding the foregoing sentence, however, the Transfer Restriction Period shall end upon the death or Permanent Disability of the Participant.

4.02 Value-Based Stock Awards.

(a) Grant. Subject to Section 7 below, on or about the date on which the annual management stock grants are made pursuant to the 2012 Long Term Incentive Plan of C. R. Bard, Inc. (as amended and restated) or a similar plan then in effect (the “Value-Based Grant Date”), each nonemployee Director shall receive a Stock Award based on the target equity value established by the Board that year prior to the Value-Based Grant Date (the “Target Equity Value”). To determine the appropriate number of shares granted for a value-based Stock Award, the Board shall (i) first subtract from the Target Equity Value the value of any formula Stock Award (or portion thereof) granted pursuant to Section 4.01 of the Plan with respect to the same year of such Director’s term for which a value-based Stock Award is being granted (the “Applicable Formula Award”) and (ii) then divide the remaining Target Equity Value by the average price of Common Stock during the month of October in the year in which the value-based Stock Award is made. The value of the Applicable Formula Award shall be calculated by multiplying the Applicable Formula Award times such average price of Common Stock.

(b) Value-Based Grant. Except as otherwise provided by the Committee, Stock Awards granted pursuant to this Section 4.02 shall not vest earlier than the third anniversary of the date on which they are granted.

4.03 Additional Stock Awards. Subject to Section 7 below, the Committee may grant Stock Awards in addition to those provided in Sections 4.01 and 4.02 of the Plan in such form, and dependent on such conditions and restrictions (or without conditions and restrictions), as the Committee, in its sole discretion, shall determine and as set forth in the Stock Award agreement, including, without limitation, the right to receive, or vest with respect to the Stock Award upon the completion of a specified period of service as a Director, the occurrence of an event and/or the attainment of performance objectives, and all other terms and conditions of such Stock Award. Except as otherwise provided by the Committee, Stock Awards granted pursuant to this Section 4.03 shall not vest earlier than the third anniversary of the date on which they are granted. Restrictions on Stock Awards shall lapse over a period of time or according to such other criteria as set forth in the Stock Award agreement. Notwithstanding anything else to the contrary, a Stock Award that is not subject to vesting shall be made only in lieu of the payment of a cash retainer to the Director.

4.04 Termination of Director, Death, Permanent Disability, or Retirement.

(a) With respect to formula based Stock Awards (granted pursuant to Section 4.01) of the Plan, if for any reason, the Participant ceases to serve as a Director prior to the end of the Vesting Restriction Period applicable to such shares, he or she shall forfeit all unvested shares underlying such Stock Award.

(b) With respect to value-based and additional Stock Awards (granted pursuant to Sections 4.02 and 4.03 of the Plan), except as otherwise provided herein, in the event that a Participant ceases during the Vesting Restriction Period to be a Director for any reason other than death or Retirement, the Participant shall forfeit the Stock Award as to all shares of Common Stock covered by the Award with respect to which such Vesting Restriction Period has not ended, and those shares of Common Stock must be immediately returned to the Corporation. The Committee may, however, provide for complete or partial exceptions to this requirement as it deems appropriate.

(c) With respect to value-based and additional Stock Awards (granted pursuant to Sections 4.02 and 4.03 of the Plan), in the event the Participant ceases to be a Director during the Vesting Restriction Period due to death or Retirement, the Vesting Restriction Period shall terminate and all of the shares of Common Stock covered by the Award shall be free of all restrictions.

 

- 3 -


4.05 Restrictions on Transfer and Legend on Stock Certificate.

(a) During the Transfer Restriction Period set forth in Section 4.01(c) or in the applicable grant Agreement governing a Stock Award granted pursuant to Sections 4.02 or 4.03 of the Plan, a Participant may not sell, assign, transfer, pledge, or otherwise dispose of the shares of Common Stock of the Stock Award except as provided under Section 8. Shares of Common Stock related to a Stock Award shall be held at the Corporation’s transfer agent in book entry form and shall contain a legend giving appropriate notice of the restrictions in the Stock Award agreement. The Participant shall be entitled to have the legend removed from the book entry covering the shares of Common Stock subject to restrictions when all restrictions on such shares of Common Stock have lapsed.

(b) Each share of Common Stock representing a Stock Award subject to restrictions shall be registered in the name of the Participant to whom the Stock Award was granted and bear the following, or a substantially similar, legend:

“The transferability of this Certificate and the Common Stock represented hereby is subject to the terms and conditions, including forfeiture, contained in Section 4 of the C. R. Bard, Inc. 2005 Directors’ Stock Award Plan, as amended from time to time, and an agreement entered into between the registered owner and C. R. Bard, Inc. Copies of the Plan and Stock Award agreement are on file in the executive office of C. R. Bard, Inc., 730 Central Avenue, Murray Hill, New Jersey 07974.”

4.06 Right to Vote and to Receive Dividends. During the Vesting Restriction Period and Transfer Restriction Period, the Participant shall have the right to vote shares of Common Stock subject to Stock Awards and to receive any dividends or other distributions paid on such shares of Common Stock.

4.07 Delivery of Certificates. When each of the Vesting Restriction Period and Transfer Restriction Period have lapsed with regard to shares of Common Stock related to a Stock Award, the Corporation shall direct the transfer agent to remove the restrictions relating to the Award or, at the Participant’s request, (or at the request of the Participant’s legal representative, beneficiary or heir) shall deliver within 60 days after such vesting to the Participant, or to the Participant’s legal representative, beneficiary or heir, a certificate or certificates without the legend referred to in Section 4.05 above, for such shares of Common Stock.

SECTION 5. OPTIONS.

5.01 Grant of Options. Subject to Section 7 below, the Committee, in its sole discretion, may grant Options to any Director under the Plan.

5.02 Term of Option. The term of any Option shall not exceed ten years from the date of grant.

5.03 Conditions of Option. Except to the extent otherwise provided in the Plan, Options shall be in such form, and dependent on such conditions, as the Committee shall determine and as set forth in the Option agreement, including, without limitation, the right to receive, or vest with respect to the Option upon the completion of a specified period of service as a Director, the occurrence of an event and/or the attainment of performance objectives, and all other terms and conditions of such Option.

5.04 Option Price. The Option Price per share of Common Stock shall not be less than 100% of the Fair Market Value of a share of Common Stock on the date the Option is granted. Notwithstanding any provision in this Plan to the contrary other than the last sentence of this paragraph, no Option may be amended to reduce the per share Option Price of any outstanding Option below the Option Price determined as of the date the Option is granted without the approval of the Corporation’s shareholders, nor may an Option or other Award be granted in exchange for, or in connection with, the cancellation or surrender of an Option or other Award having a higher Option Price or exercise price without the approval of the Corporation’s shareholders. The restrictions set forth in this Section 5.04 shall not apply to the assumption of, substitution for, or adjustment of outstanding Options that are assumed, substituted, or adjusted in connection with a transaction described in Section 11, provided that the aggregate Option Price times the number of shares underlying the Option immediately before the transaction equals or exceeds the aggregate Option Price times the number of shares underlying the Option (or substituted Option) immediately following the transaction.

5.05 Exercisability. Except as determined by the Committee and set forth in the Option agreement, an Option shall become exercisable with regard to twenty-five percent of the Option on the date of the four successive anniversary dates of the grant date. Further, all Options shall become immediately exercisable upon the death of a Participant if as of the date of the Participant’s death, the Participant had not otherwise ceased to be a Director. In no event shall an Option be exercisable at any time after the expiration of the term of the Option.

 

- 4 -


5.06 Exercise of Options. Except as otherwise provided in the Plan or in an Option agreement, an Option may be exercised for all, or from time to time any part, of the shares of Common Stock for which it is then vested and exercisable.

(a) The exercise date of an Option shall be the later of the date a notice of exercise is received by the Corporation and, if applicable, the date payment is received by the Corporation pursuant to (b) below.

(b) The purchase price for the shares of Common Stock as to which an Option is exercised shall be paid to the Corporation in full at the time of exercise at the election of the Participant (i) in cash or its equivalent (e.g., by check), (ii) to the extent permitted by the Committee, in shares of Common Stock having a Fair Market Value equal to the aggregate Option Price for the shares of Common Stock being purchased and satisfying such other requirements as may be imposed by the Committee; provided, that such shares of Common Stock have been held by the Participant for no less than six months (or such other period as established from time to time by the Committee in order to avoid adverse accounting treatment applying generally accepted accounting principles), (iii) partly in cash and, to the extent permitted by the Committee, partly in such shares of Common Stock or (iv) subject to rules and limitations established by the Committee, through the delivery of irrevocable instructions to a broker to sell shares of Common Stock obtained upon the exercise of the Option and to deliver promptly to the Corporation an amount out of the proceeds of such sale equal to the aggregate Option Price for the shares of Common Stock being purchased.

(c) No Participant shall have any rights to dividends or other rights of a stockholder with respect to shares of Common Stock subject to an Option until the Participant has given written notice of exercise of the Option, paid in full for such shares of Common Stock, received such shares of Common Stock from the Corporation and, if applicable, has satisfied any other conditions imposed by the Committee pursuant to the Plan.

(d) If a Participant pays the exercise price of an Option or taxes relating to the exercise of an Option by delivering shares of Common Stock, the Participant may, subject to procedures established by the Committee, satisfy such delivery requirement by presenting proof that he or she is the beneficial owner (as such term is defined in Rule 13d-3 under the Act (or any successor rule thereto)) of such shares of Common Stock, in which case the Corporation shall treat the Option as exercised without further payment and shall withhold such number of shares of Common Stock from the shares of Common Stock acquired by the exercise of the Option.

5.07 Cessation of Service as a Director.

(a) Except as provided below, an Option may be exercised at anytime during the term of the Option.

(b) Except as provided in Sections (c), (d) and (e) below, any of the Participant’s Options that are not otherwise exercisable as of the date on which the Participant ceases to be a Director for any reason shall terminate as of such date.

(c) Any of the Participant’s Options that are exercisable as of the date on which the Participant ceases to be a Director for any reason other than death or Retirement shall terminate sixty (60) days from the date the Participant ceases to be a Director; but in no event beyond the term of the Option.

(d) If a Participant ceases to be a Director by reason of his or her death, his or her personal representative shall be permitted to exercise his or her outstanding vested and unvested Option for a period of one (1) year from the date of the Director’s death, but in no event beyond the term of the Option.

(e) If a Participant ceases to be a Director by reason of his or her Retirement, his or her outstanding vested Option shall remain exercisable for the remaining term of the Option and the portion of his or her Option that was not vested on the date of his or her Retirement shall be forfeited. Notwithstanding the foregoing, if a Participant ceases to be a Director by reason of his or her Retirement, any of his or her outstanding vested Option issued on or prior to April 18, 2001 shall remain exercisable only for a period of three years from the last day of the month in which he or she retired and the portion of his or her Option that was not vested on the date of his or her Retirement shall be forfeited.

 

- 5 -


SECTION 6. STOCK APPRECIATION RIGHTS.

Subject to Section 7 below, the Committee, in its sole discretion, may grant SARs in connection with an Option, or a portion thereof. An SAR represents a right to receive appreciation on the Corporation’s Common Stock in cash or stock as the Committee shall determine. An SAR may be granted at the time the related Option is granted or at any time prior to the exercise or cancellation of the related Option, shall cover the same number of shares of Common Stock covered by an Option (or such lesser number of shares of Common Stock as the Committee may determine), and shall be subject to the same terms and conditions as such Option except for such additional limitations as are contemplated by this Section 6 (or such additional limitations as may be included in an Award agreement). Notwithstanding any provision in this Plan to the contrary other than the last sentence of this Section 6, no Stock Appreciation Right may be amended to reduce the exercise price per share of the shares subject to such Stock Appreciation Right below the exercise price determined as of the date the Stock Appreciation Right is granted, nor may a Stock Appreciation Right be granted in exchange for, or in connection with, the cancellation or surrender of a Stock Appreciation Right or other Award having a higher exercise price. The restrictions set forth in this Section 6 shall not apply to the assumption of, substitution for, or adjustment of outstanding Stock Appreciation Rights that are assumed, substituted, or adjusted in connection with a transaction described in Section 11, provided that the aggregate exercise price times the number of shares underlying the Stock Appreciation Right immediately before the transaction equals or exceeds the aggregate exercise price times the number of shares underlying the Stock Appreciation Right (or substituted Stock Appreciation Right) immediately following the transaction.

SECTION 7. LIMITATIONS ON AWARDS.

Notwithstanding any provision of this Plan to the contrary, the maximum aggregate grant date Fair Market Value of Awards granted to a Director during a calendar year shall not exceed $150,000; provided that Stock Awards that are granted in lieu of the payment of a cash retainer to a Director shall not be included in these limitations.

SECTION 8. TRANSFERABILITY OF AWARDS.

8.01 Limits on Transferability. Except as otherwise provided, Stock Awards (prior to the end of their Transfer Restriction Period), Options or SARs may not be assigned, alienated, attached, sold or transferred, pledged or otherwise disposed or encumbered by the Participant, other than by will or by the laws of descent and distribution. Any attempt to assign, transfer, pledge or otherwise dispose of an Award contrary to the provisions hereof, and the levy of any execution, attachment or similar process upon the Award, shall be null, void and without effect; provided, however, that the designation of a beneficiary shall not constitute an assignment, alienation, pledge, attachment, sale, transfer or encumbrance. A Participant may designate a beneficiary, on a form supplied by the Committee, who may possess all rights with respect to an Award in the event of Employee’s death. No such permitted transfer of an Award to heirs or legatees of a Participant shall be effective to bind the Corporation unless the Committee shall have been furnished with written notice thereof and a copy of such evidence as the Committee may deem necessary to establish the validity of the transfer and the acceptance by the transferee or transferees of the terms and conditions hereof.

8.02 Transferability of Certain Awards. Notwithstanding the foregoing, an Award agreement may provide that a Participant may transfer certain Awards to family members, or one or more trusts or other entities for the benefit of or owned by family members, consistent with applicable securities laws, provided that the Participant receives no consideration for the transfer of the Award and the transferred Award shall continue to be subject to the same terms and conditions as were applicable to the Award immediately before the transfer.

SECTION 9. NO LIMITATION ON RIGHTS OF THE CORPORATION.

The granting of any Awards under this Plan shall not in any way affect the right or power of the Corporation to make adjustments, reclassification or changes in its capital or business structure, or to merge, consolidate, dissolve, liquidate, sell or transfer all or any part of its business or assets.

SECTION 10. SHARE OF COMMON STOCK ISSUANCE AND DELIVERY IN COMPLIANCE WITH SECURITIES LAWS.

If in the opinion of counsel for the Corporation (who may be an employee of the Corporation or independent counsel employed by the Corporation), any issuance or delivery of shares of Common Stock to a Participant will violate the requirements of any applicable federal or state laws, rules or regulations (including, without limitation, the provisions of the Securities Act of 1933, as amended, or the Act), such issuance or delivery may be postponed until the Corporation is satisfied that the distribution will not violate such laws, rules or regulations. The transfer agent’s book entry relating to a Stock Award (and, if requested in accordance with Section 4.07 above, certificates delivered to Participants pursuant to the Plan) may bear such legends as the Corporation may deem advisable.

 

- 6 -


SECTION 11. ADJUSTMENT UPON CERTAIN EVENTS.

In the event after the Effective Date there is any share of Common Stock dividend or split, reorganization, recapitalization, merger, consolidation, spin-off, combination, combination or transaction or exchange of shares of Common Stock or other corporate exchange, or any distribution to shareholders of shares of Common Stock or other property or securities (other than regular cash dividends) or any transaction similar to the foregoing or other transaction that results in a change to the Corporation’s equity capitalization, the Committee in its sole discretion and without liability to any person may make such substitution or adjustment, if any, as it deems to be equitable or appropriate, as to (i) the number or kind of shares of Common Stock or other securities issued or reserved for issuance pursuant to the Plan or pursuant to outstanding Awards, (ii) the maximum number of shares of Common Stock for which Stock Awards, Options and Stock Appreciation Rights may be granted (ii) the Option Price, exercise price of any Stock Appreciation Right or purchase price of any Award and/or (iii) any other affected terms of an Award or the Plan.

SECTION 12. AMENDMENTS OR TERMINATION.

The Board may amend the Plan at any time, provided that no amendment shall be made without the approval of the shareholders of the Corporation that would (a) increase the maximum number of shares of Common Stock which may be acquired under the Plan, (b) extend the term during which Options may be granted under the Plan, (c) permit the Option Price or exercise price per share of Common Stock to be less than 100% of the Fair Market Value of the shares of Common Stock on the date an Option or Stock Appreciation Right is granted (other than as specifically provided in Sections 5.04 and 6), (d) terminate restrictions applicable to Awards (except in connection with a Participant’s death, Disability or termination of employment or in connection with a Change of Control) or (e) provide for Awards not permitted pursuant to the terms of the Plan. The Board shall also have the right to terminate the Plan at any time. Without the consent of a Participant (except as otherwise provided for in Section 11), no amendment shall materially diminish any of the rights of such Participant under any Award theretofore granted to such Participant under the Plan; provided, however, that the Committee may amend the Plan in such manner as it deems necessary to permit the granting of Awards meeting the requirements of the Code or other applicable laws.

SECTION 13. NO RIGHTS TO CONTINUED DIRECTORSHIP.

Nothing in this Agreement shall confer upon a Director any right to continue to service as a member of the Board of Directors or any committee of the Board of Directors, to be retained by the Corporation as a consultant or to be employed by the Corporation as an employee and shall not interfere in any way with the right of the Corporation to terminate the Director’s service as a member of the Board of Directors or any committee of the Board of Directors as set forth in the by-laws of the Corporation or the Director’s consulting or employment relationship with the Corporation, if any, at any time.

SECTION 14. CHOICE OF LAW.

The Plan shall be governed by and construed in accordance with the laws of the State of New Jersey without regard to conflicts of laws.

SECTION 15. EFFECTIVE DATE.

The Plan was originally effective as of July 13, 1988, was subsequently amended from time-to-time, and was amended and restated as of December 12, 2012. The Plan was initially approved by the shareholders of the Corporation on April 19, 1989. The effective date of the Plan as amended and restated herein is October 9, 2013, provided, however that the version of the Plan that was last approved by the Corporation’s shareholders was effective as of April 19, 2006.

 

- 7 -

EX-10.35 3 d587637dex1035.htm EX-10.35 EX-10.35

Exhibit 10.35

EXECUTION COPY

AMENDMENT NO. 1

Dated as of September 26, 2013

to

CREDIT AGREEMENT

Dated as of October 12, 2011

THIS AMENDMENT NO. 1 (this “Amendment”) is made as of September 26, 2013 by and among C. R. Bard, Inc., a New Jersey corporation (the “Borrower”), the financial institutions listed on the signature pages hereof and JPMorgan Chase Bank, N.A., as Administrative Agent (the “Administrative Agent’), under that certain Credit Agreement dated as of October 12, 2011 by and among the Borrower, the Lenders from time to time party thereto and the Administrative Agent (as amended, restated, supplemented or otherwise modified from time to time, the “Credit Agreement”). Capitalized terms used herein and not otherwise defined herein shall have the respective meanings given to them in the Credit Agreement.

WHEREAS, the Borrower has requested that the requisite Lenders and the Administrative Agent agree to provide additional commitments under and make certain amendments to the Credit Agreement;

WHEREAS, the Borrower, the Lenders party hereto and the Administrative Agent have so agreed on the terms and conditions set forth herein;

NOW, THEREFORE, in consideration of the premises set forth above, the terms and conditions contained herein, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Borrower, the Lenders party hereto and the Administrative Agent hereby agree to enter into this Amendment.

1. Amendments to the Credit Agreement. Effective as of the Amendment No. 1 Effective Date (as defined below), the parties hereto agree that the Credit Agreement shall be amended as follows:

(a) The definition of “Commitment” appearing in Section 1.01 of the Credit Agreement is amended to restate the final two sentences thereof in their entirety to read as follows:

The amount of each Lender’s Commitment as of the Amendment No. 1 Effective Date is set forth on Schedule 1.01, or in the Assignment and Assumption or other agreement pursuant to which such Lender shall have assumed its Commitment, as applicable. As of the Amendment No. 1 Effective Date, the aggregate amount of the Commitments is $750,000,000.

(b) The definition of “Commitment Termination Date” appearing in Section 1.01 of the Credit Agreement is amended to delete the reference to “October 12, 2016” appearing therein and to replace such reference with “September 26, 2018”.


(c) The definition of “Swingline Sublimit” appearing in Section 1.01 of the Credit Agreement is amended to delete the reference to “$25,000,000” appearing therein and to replace such reference with “$50,000,000”.

(d) Section 1.01 of the Credit Agreement is amended to add the following definitions thereto in proper alphabetical order and, where applicable, replace the corresponding previously existing definitions:

Amendment No. 1 Effective Date” means September 26, 2013.

Interpolated Rate” means, at any time, the rate per annum determined by the Administrative Agent (which determination shall be conclusive and binding absent manifest error) to be equal to the rate that results from interpolating on a linear basis between: (a) the LIBOR Screen Rate for the longest period (for which the LIBOR Screen Rate is available) that is shorter than the Impacted Interest Period and (b) the LIBOR Screen Rate for the shortest period (for which the LIBOR Screen Rate is available) that exceeds the Impacted Interest Period, in each case, at such time.

LIBO Rate” means, with respect to any Eurodollar Borrowing for any applicable Interest Period, the London interbank offered rate administered by the British Bankers Association (or any other Person that takes over the administration of such rate) for Dollars for a period equal in length to such Interest Period as displayed on pages LIBOR01 or LIBOR02 of the Reuters screen or, in the event such rate does not appear on either of such Reuters pages, on any successor or substitute page on such screen that displays such rate, or on the appropriate page of such other information service that publishes such rate as shall be selected by the Administrative Agent, with written notice to the Borrower, from time to time in its reasonable discretion; in each case the “LIBOR Screen Rate”) at approximately 11:00 a.m., London time, two (2) Business Days prior to the commencement of such Interest Period; provided that, if the LIBOR Screen Rate shall be less than zero, such rate shall be deemed to be zero for purposes of this Agreement; provided, further, that if a LIBOR Screen Rate shall not be available at such time for such Interest Period (the “Impacted Interest Period”), then the LIBO Rate for such Interest Period shall be the Interpolated Rate; provided, that, if any Interpolated Rate shall be less than zero, such rate shall be deemed to be zero for purposes of this Agreement. It is understood and agreed that all of the terms and conditions of this definition of “LIBO Rate” shall be subject to Section 2.11.

LIBOR Screen Rate” has the meaning assigned to such term in the definition of “LIBO Rate”.

(e) Section 2.06(c) of the Credit Agreement is amended to delete the reference to “$850,000,000” appearing in subclause (ii) thereof and to replace such reference with “$1,000,000,000”.

(f) Section 6.04 of the Credit Agreement is amended to delete the reference to “0.60 to 1.00” appearing therein and to replace such reference with “0.65 to 1.00”.

(g) Schedule 1.01 to the Credit Agreement is amended and restated in its entirety in the form of Schedule 1.01 attached hereto.

 

2


2. Departing Lenders. The parties hereto hereby acknowledge and agree that:

(a) Each of PNC Bank National Association, The Royal Bank of Scotland plc, SunTrust Bank and Banca Monte dei Paschi di Siena S.p.A. (each a “Departing Lender” and collectively the “Departing Lenders”) is entering into this Amendment solely to evidence its exit from the Credit Agreement and shall have absolutely no obligation hereunder. Upon the effectiveness hereof and the payment described in Section 2(b)(ii), each Departing Lender shall no longer (i) constitute a “Lender” for all purposes under the Loan Documents, (ii) be a party to the Credit Agreement and (iii) have any obligations under any of the Loan Documents, in each case, without further action required on the part of any Person; and

(b) Upon the effectiveness hereof: (i) each Departing Lender’s “Commitment” under the Credit Agreement shall be terminated, (ii) each Departing Lender shall have received payment in full in immediately available funds of all of its Loans, all interest thereon and all other amounts payable to it under the Credit Agreement, (iii) each Departing Lender shall not be a Lender hereunder as evidenced by its execution and delivery of its signature page hereto and (iv) the defined term “Lenders” in the Credit Agreement shall exclude the Departing Lenders.

3. Conditions of Effectiveness. The effectiveness of this Amendment (the “Amendment No. 1 Effective Date”) is subject to the satisfaction of the following conditions precedent:

(a) The Administrative Agent shall have received counterparts of this Amendment duly executed by the Borrower, the Lenders (including the Departing Lenders), the Issuing Bank and the Administrative Agent.

(b) The Administrative Agent shall have received favorable written opinions (addressed to the Administrative Agent and the Lenders and dated the Amendment No. 1 Effective Date) of (i) Drinker Biddle & Reath LLP, special New Jersey counsel for the Borrower and (ii) Weil, Gotshal & Manges LLP, special New York counsel for the Borrower, each covering such matters relating to the Borrower, this Amendment or the Credit Agreement as amended hereby as the Administrative Agent shall reasonably request (and the Borrower hereby instructs such counsels to deliver such opinions to the Lenders and the Administrative Agent).

(c) The Administrative Agent shall have received such documents and certificates as the Administrative Agent or its counsel may reasonably request relating to the organization, existence and good standing of the Borrower, the authorization of this Amendment and the Credit Agreement as amended hereby, and any other matters relevant hereto, all in form and substance reasonably satisfactory to the Administrative Agent and its counsel.

(d) The Administrative Agent shall have received a certificate, dated the Amendment No. 1 Effective Date and signed by the President, a Vice President or a Financial Officer of the Borrower, confirming compliance with the conditions set forth in clauses (a) and (b) of the first sentence of Section 4.02 of the Credit Agreement (excluding, however, the first parenthetical clause in such clause (a)).

(e) The Administrative Agent shall have received, for the account of each Lender (excluding any Departing Lender) party hereto that delivers its executed signature page to this Amendment by no later than the date and time specified by the Administrative Agent, an upfront fee in an amount equal to the amount previously disclosed to the Lenders.

(f) The Administrative Agent shall have received payment of the Administrative Agent’s and its affiliates’ fees and reasonable out-of-pocket expenses (including the reasonable fees and expenses of Sidley Austin LLP, counsel to the Administrative Agent, that are due and payable on or prior to the Amendment No. 1 Effective Date and for which an invoice has been presented to the Borrower at least one Business Day prior to the Amendment No. 1 Effective Date) in connection with this Amendment.

 

3


4. Representations and Warranties of the Borrower. The Borrower hereby represents and warrants as follows:

(a) This Amendment and the Credit Agreement as modified hereby constitute legal, valid and binding obligations of the Borrower, enforceable in accordance with their terms, except as such enforceability may be limited by (a) bankruptcy, insolvency, reorganization, moratorium or similar laws of general applicability affecting the enforcement of creditors’ rights and (b) the application of general principles of equity (regardless of whether such enforceability is considered in a proceeding in equity or at law).

(b) As of the date hereof and after giving effect to the terms of this Amendment, (i) no Default has occurred and is continuing and (ii) the representations and warranties of the Borrower set forth in the Credit Agreement are true and correct in all material respects (or, in the case of any such representations and warranties qualified as to materiality, in all respects) on and as of the date hereof (or, if any such representation or warranty is expressly stated to have been made as of a specific date, as of such specific date).

5. Reference to and Effect on the Credit Agreement.

(a) Upon the effectiveness hereof, each reference to the Credit Agreement in the Credit Agreement or any other Loan Document shall mean and be a reference to the Credit Agreement as amended hereby.

(b) The Credit Agreement and all other documents, instruments and agreements executed and/or delivered in connection therewith shall remain in full force and effect and are hereby ratified and confirmed.

(c) Except as expressly set forth herein, the execution, delivery and effectiveness of this Amendment shall not operate as a waiver of any right, power or remedy of the Administrative Agent or the Lenders, nor constitute a waiver of any provision of the Credit Agreement or any other documents, instruments and agreements executed and/or delivered in connection therewith.

(d) On the Amendment No. 1 Effective Date, the Administrative Agent shall make such reallocations of each Lender’s Applicable Percentage of the Revolving Credit Exposure under the Credit Agreement as are necessary in order that the Revolving Credit Exposure with respect to such Lender reflects such Lender’s Applicable Percentage of the Revolving Credit Exposure under the Credit Agreement as amended hereby. Each Departing Lender and each Lender hereby waives any compensation by the Borrower of any and all losses, costs and expenses incurred by such Departing Lender or Lender solely in connection with the sale and assignment of any Eurodollar Loans and the reallocation described in this clause (d) and occurring on the Amendment No. 1 Effective Date that would otherwise be due to such Departing Lender or Lender pursuant to Section 2.13 of the Credit Agreement.

(e) This Amendment is a “Loan Document” under (and as defined in) the Credit Agreement.

6. Governing Law. This Amendment shall be construed in accordance with and governed by the law of the State of New York.

 

4


7. Submission to Jurisdiction. The Borrower hereby irrevocably and unconditionally submits, for itself and its property, to the exclusive jurisdiction of the Supreme Court of the State of New York sitting in New York County and of the United States District Court of the Southern District of New York, and any appellate court from any thereof, in any action or proceeding arising out of or relating to this Amendment, or for recognition or enforcement of any judgment, and each of the parties hereto hereby irrevocably and unconditionally agrees that all claims in respect of any such action or proceeding may be heard and determined in such New York State court or, to the extent permitted by law, in such Federal court. Each of the parties hereto agrees that a final judgment in any such action or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by law. Nothing in this Amendment shall affect any right that the Administrative Agent, any Issuing Bank or any Lender may otherwise have to bring any action or proceeding relating to this Amendment against the Borrower or its properties in the courts of any jurisdiction.

8. Headings. Section headings used in this Amendment are for convenience of reference only, are not part of this Amendment and shall not affect the construction of, or be taken into consideration in interpreting, this Amendment.

9. Counterparts. This Amendment may be executed by one or more of the parties hereto on any number of separate counterparts, and all of said counterparts taken together shall be deemed to constitute one and the same instrument. Delivery of an executed counterpart of a signature page to this Agreement by fax or other electronic transmission (including, without limitation, PDF) shall be effective as delivery of a manually executed counterpart of this Agreement.

[Signature Pages Follow]

 

5


IN WITNESS WHEREOF, this Amendment has been duly executed as of the day and year first above written.

 

C.R. BARD, INC.,

as the Borrower

By:   /s/ Christopher S. Holland
Name: Christopher S. Holland

Title: Senior Vice President and Chief Financial

Officer

By:   /s/ Scott T. Lowry
Name: Scott T. Lowry
Title: Vice President and Treasurer

 

Signature Page to Amendment No. 1 to

Credit Agreement dated as of October 12, 2011

C. R. Bard, Inc.


JPMORGAN CHASE BANK, N.A.,

individually as a Lender, as the Issuing Bank and as

Administrative Agent

By:   /s/ James A. Knight
Name: James A. Knight
Title: Vice President

 

Signature Page to Amendment No. 1 to

Credit Agreement dated as of October 12, 2011

C. R. Bard, Inc.


BANK OF AMERICA, N.A.,

individually as a Lender and as Syndication Agent

By:   /s/ David J. Bardwil
Name: David J. Bardwil
Title: SVP

 

Signature Page to Amendment No. 1 to

Credit Agreement dated as of October 12, 2011

C. R. Bard, Inc.


WELLS FARGO BANK, NATIONAL ASSOCIATION, as a Lender
By:   /s/ Monique Gasque
Name: Monique Gasque
Title: Vice President

 

Signature Page to Amendment No. 1 to

Credit Agreement dated as of October 12, 2011

C. R. Bard, Inc.


GOLDMAN SACHS BANK USA,

as a Lender

By:   /s/ Mark Walton
Name: Mark Walton
Title: Authorized Signatory

 

Signature Page to Amendment No. 1 to

Credit Agreement dated as of October 12, 2011

C. R. Bard, Inc.


BARCLAYS BANK PLC,

as a Lender

By:   /s/ Christopher R. Lee
Name: Christopher R. Lee
Title: Assistant Vice President

 

Signature Page to Amendment No. 1 to

Credit Agreement dated as of October 12, 2011

C. R. Bard, Inc.


ROYAL BANK OF CANADA,

as a Lender

By:   /s/ Scott MacVicar
Name: Scott MacVicar
Title: Authorized Signatory

 

Signature Page to Amendment No. 1 to

Credit Agreement dated as of October 12, 2011

C. R. Bard, Inc.


TD BANK, N.A.,

as a Lender

By:   /s/ Todd Antico
Name: Todd Antico
Title: Senior Vice President

 

Signature Page to Amendment No. 1 to

Credit Agreement dated as of October 12, 2011

C. R. Bard, Inc.


THE BANK OF TOKYO-MITSUBISHI UFJ, LTD.,

as a Lender

By:   /s/ B. McNany
Name:   B. McNany
Title:   Vice President

 

Signature Page to Amendment No. 1 to

Credit Agreement dated as of October 12, 2011

C. R. Bard, Inc.


U.S. BANK NATIONAL ASSOCIATION,

as a Lender

By:   /s/ Jennifer Hwang
Name:   Jennifer Hwang
Title:   Vice President

 

Signature Page to Amendment No. 1 to

Credit Agreement dated as of October 12, 2011

C. R. Bard, Inc.


SOVEREIGN BANK, N.A.

as a Lender

By:   /s/ William R. Rogers
Name:   William R. Rogers
Title:   Senior Vice President

 

Signature Page to Amendment No. 1 to

Credit Agreement dated as of October 12, 2011

C. R. Bard, Inc.


HSBC BANK USA, NATIONAL ASSOCIATION,

as a Lender

By:   /s/ Robert Moravec
Name:   Robert Moravec
Title:   Sr. Relationship Manager

 

Signature Page to Amendment No. 1 to

Credit Agreement dated as of October 12, 2011

C. R. Bard, Inc.


The undersigned Departing Lender hereby acknowledges and agrees that, form and after the Amendment No. 1 Effective Date, it is no longer a party to the Credit Agreement

PNC BANK, NATIONAL ASSOCIATION,

as a Departing Lender

By:   /s/ Edward M. Tessalone
Name:   Edward M. Tessalone
Title:   Senior Vice President PNC Bank, N.A.

 

Signature Page to Amendment No. 1 to

Credit Agreement dated as of October 12, 2011

C. R. Bard, Inc.


The undersigned Departing Lender hereby acknowledges and agrees that, from and after the Amendment No. 1 Effective Date, it is no longer a party to the Credit Agreement

THE ROYAL BANK OF SCOTLAND PLC,

as a Departing Lender

By:   /s/ William McGinty
Name:   William McGinty
Title:   Director

 

Signature Page to Amendment No. 1 to

Credit Agreement dated as of October 12, 2011

C. R. Bard, Inc.


The undersigned Departing Lender hereby acknowledges and agrees that, form and after the Amendment No. 1 Effective Date, it is no longer a party to the Credit Agreement

SUNTRUST BANK,

as a Departing Lender

By:   /s/ John Cappellari
Name:   John Cappellari
Title:   Director

 

Signature Page to Amendment No. 1 to

Credit Agreement dated as of October 12, 2011

C. R. Bard, Inc.


The undersigned Departing Lender hereby acknowledges and agrees that, from and after the Amendment No. 1 Effective Date, it is no longer a party to the Credit Agreement

BANCA MONTE DEI PASCHI DI SIENA S.P.A.,

as a Departing Lender

By:   /s/ Enrico Vignoli
Name:   Enrico Vignoli
Title:   Senior Vice President & General Manager
By:   /s/ Victor DiIorio
Name:   Victor DiIorio
Title:   VP & Credit Manager

 

Signature Page to Amendment No. 1 to

Credit Agreement dated as of October 12, 2011

C. R. Bard, Inc.


SCHEDULE 1.01

Commitments

 

Name of Lender

   Commitment ($)  

JPMorgan Chase Bank, N.A.

   $ 116,250,000   

Bank of America, N.A.

   $ 116,250,000   

Wells Fargo Bank, National Association

   $ 62,500,000   

Goldman Sachs Bank USA

   $ 62,500,000   

Barclays Bank PLC

   $ 62,500,000   

Royal Bank of Canada

   $ 62,500,000   

TD Bank, N.A.

   $ 62,500,000   

The Bank of Tokyo-Mitsubishi UFJ, Ltd.

   $ 62,500,000   

U.S. Bank National Association

   $ 62,500,000   

Sovereign Bank, N.A.

   $ 40,000,000   

HSBC Bank USA, National Association

   $ 40,000,000   

Total:

   $ 750,000,000   
EX-12.1 4 d587637dex121.htm EX-12.1 EX-12.1

EXHIBIT 12.1

C. R. BARD, INC. AND SUBSIDIARIES

Exhibit 12.1 - Computation of Ratio of Earnings to Fixed Charges

 

     Nine Months
Ended
September 30,
2013
    Years Ended December 31,  
       2012     2011     2010     2009     2008  
(dollars in millions)                                     

Earnings from operations before taxes

   $ 110.7      $ 732.4      $ 510.8      $ 717.7      $ 671.5      $ 552.7   

Add (Deduct):

            

Fixed charges

     38.6        46.1        42.7        18.4        17.5        17.4   

Undistributed earnings of equity investments

     (1.5     (9.6     (3.8     (3.6     (2.3     (1.9
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Earnings available for fixed charges

   $ 147.8      $ 768.9      $ 549.7      $ 732.5      $ 686.7      $ 568.2   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Fixed charges:

            

Interest, including amounts capitalized(1)

   $ 33.7      $ 39.6      $ 36.4      $ 12.7      $ 11.8      $ 12.1   

Proportion of rent expense deemed to represent interest factor

     4.9        6.5        6.3        5.7        5.7        5.3   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Fixed charges

   $ 38.6      $ 46.1      $ 42.7      $ 18.4      $ 17.5      $ 17.4   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Ratio of earnings to fixed charges

     3.83        16.68        12.87        39.81        39.24        32.66   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

 

(1)  Interest related to unrecognized tax benefits is included as income tax expense and not included in fixed charges.
EX-31.1 5 d587637dex311.htm EX-31.1 EX-31.1

EXHIBIT 31.1

Certification of Chief Executive Officer

I, Timothy M. Ring, certify that:

 

  1. I have reviewed this quarterly report on Form 10-Q of C. R. Bard, Inc.;

 

  2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

  3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

  4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

  5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: October 24, 2013

/s/ Timothy M. Ring

Timothy M. Ring
Chief Executive Officer
EX-31.2 6 d587637dex312.htm EX-31.2 EX-31.2

EXHIBIT 31.2

Certification of Chief Financial Officer

I, Christopher S. Holland, certify that:

 

  1. I have reviewed this quarterly report on Form 10-Q of C. R. Bard, Inc.;

 

  2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

  3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

  4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

  5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: October 24, 2013

/s/ Christopher S. Holland

Christopher S. Holland
Senior Vice President and Chief Financial Officer
EX-32.1 7 d587637dex321.htm EX-32.1 EX-32.1

EXHIBIT 32.1

SECTION 1350 CERTIFICATIONS

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE

SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of C. R. Bard, Inc. on Form 10-Q for the period ended September 30, 2013, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Timothy M. Ring, Chairman and Chief Executive Officer of C. R. Bard, Inc., certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

  1. the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

  2. the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of C. R. Bard, Inc.

 

/s/ Timothy M. Ring

Name: Timothy M. Ring
Date: October 24, 2013
EX-32.2 8 d587637dex322.htm EX-32.2 EX-32.2

EXHIBIT 32.2

SECTION 1350 CERTIFICATIONS

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE

SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of C. R. Bard, Inc. on Form 10-Q for the period ended September 30, 2013, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Christopher S. Holland, Senior Vice President and Chief Financial Officer of C. R. Bard, Inc., certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

  1. the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

  2. the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of C. R. Bard, Inc.

 

/s/ Christopher S. Holland

Name: Christopher S. Holland
Date: October 24, 2013
EX-101.INS 9 bcr-20130930.xml XBRL INSTANCE DOCUMENT 0.125 0.20 109000000 542000000 5000000 19000000 20000000 371000000 8000000 14700000 4900000 0.25 20000000 20600000 -83600000 809100000 700000 -101100000 16800000 20 600000000 2016-10 77890296 77890296 1 600000000 0.25 5000000 77890296 40400000 504400000 -73700000 48500000 114500000 1504100000 1406500000 295100000 800000 97500000 1648000000 72800000 731700000 2600000 -89700000 0 208200000 13500000 6300000 19500000 4165000000 520300000 18300000 8800000 1800000 231100000 971000000 7000000 456500000 332100000 199400000 655600000 33800000 109700000 2600000 360500000 358600000 24400000 19000000 10100000 400000 4165000000 781700000 18400000 103800000 60600000 23000000 79300000 14400000 1751300000 21800000 12100000 482400000 900000 -106500000 31900000 2300000 9800000 1500000 1400000 86800000 400000 13100000 9800000 200000 300000 1700000 100000 1400000 5710855 39843 750000000 186200000 250000000 0.02875 150000000 1454200000 4000000 1700000 23100000 2400000 23000000 4800000 10500000 3200000 80000000 1 10 685 720 745 185000000 -66600000 596400000 -1400000 -106300000 41100000 81697409 1 600000000 0.25 5000000 81697409 447600000 -81200000 43400000 137800000 1925700000 1409600000 272600000 0 1513300000 56200000 342400000 0 473200000 0 242900000 12400000 4800000 20400000 4151300000 158100000 26000000 10700000 98600000 961600000 480900000 328500000 194600000 631900000 42600000 114800000 359300000 368100000 0 25000000 10000000 4151300000 896300000 73900000 19100000 1847200000 506500000 -700000 -113100000 32600000 13300000 1000000 600000 77100000 400000 15300000 13300000 0 400000 1400000 0 600000 45600000 128100000 1532200000 5 2 3 3 30 785 9635 2013-12 1575 40 P12M 3 203700000 BCR BARD C R INC /NJ/ false Large Accelerated Filer 2013 10-Q 2013-09-30 0000009892 --12-31 Q3 <div> <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> Earnings per share (&#x201C;EPS&#x201D;) is computed under the two-class method using the following common share information:</p> <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"> <tr> <td width="74%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Quarter Ended<br /> September 30,</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Nine Months</b><br /> <b>Ended&#xA0;September&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom">(dollars and shares in millions)</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> EPS Numerator:</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Net income</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">93.2</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">129.3</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">22.3</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">401.9</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Less: Income allocated to participating securities</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1.6</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2.4</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.3</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">7.7</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Net income available to common shareholders</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">91.6</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">126.9</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">22.0</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">394.2</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> EPS Denominator:</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Weighted average common shares outstanding</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">78.5</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">83.4</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">79.9</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">83.8</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Dilutive common share equivalents from share-based compensation plans</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1.5</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1.2</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1.3</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1.1</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Weighted average common and common equivalent shares outstanding, assuming dilution</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">80.0</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">84.6</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">81.2</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">84.9</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> <div> <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> The components of net periodic pension cost are as follows:</p> <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"> <tr> <td width="74%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Quarter Ended<br /> September 30,</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Nine&#xA0;Months&#xA0;Ended<br /> September 30,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom">(dollars in millions)</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Service cost, net of employee contributions</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">7.5</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">7.0</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">22.6</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">20.8</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Interest cost</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">4.6</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">4.9</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">13.7</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">14.6</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Expected return on plan assets</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(6.5</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(6.2</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(19.5</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(17.9</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Amortization</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3.4</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2.8</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">10.2</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">7.8</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Net periodic pension cost</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">9.0</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">8.5</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">27.0</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">25.3</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> 0.28 <div> <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> The location and amounts of gains on derivative instruments not designated as hedging instruments are as follows:</p> <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr> <td width="61%"></td> <td valign="bottom" width="2%"></td> <td width="21%"></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" rowspan="3" align="center"> <p style="MARGIN-TOP: 0pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt" align="center"><b>Income&#xA0;Statement</b></p> <p style="MARGIN-TOP: 0pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 1pt; FONT-SIZE: 8pt" align="center"><b>Location</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"><b>Gain&#xA0;Recognized in Earnings</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Quarter&#xA0;Ended</b><br /> <b>September&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Nine&#xA0;Months&#xA0;Ended</b><br /> <b>September&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom">(dollars in millions)</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Forward currency contracts<sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">(A)</sup></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-TOP: 0pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 1pt; FONT-SIZE: 10pt"> Other&#xA0;(income)&#xA0;expense,&#xA0;net</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">3.0</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="BORDER-BOTTOM: #000000 1px solid; LINE-HEIGHT: 8pt; MARGIN-TOP: 0pt; WIDTH: 10%; MARGIN-BOTTOM: 2pt"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td valign="top" width="4%" align="left"><sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">(A)</sup>&#xA0;</td> <td valign="top" align="left">These derivative contracts mitigate changes in the value of remeasured foreign currency denominated intercompany loans attributable to changes in foreign currency exchange rates.</td> </tr> </table> </div> <div> <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> Net sales based on the location of external customers by geographic region are:</p> <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"> <tr> <td width="68%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Quarter Ended<br /> September 30,</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Nine&#xA0;Months&#xA0;Ended<br /> September 30,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom">(dollars in millions)</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> United States</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">500.3</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">483.4</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,496.4</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,469.6</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Europe<sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">(a)</sup></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">116.7</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">108.9</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">356.5</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">349.4</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Japan</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">43.4</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">41.6</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">123.4</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">122.2</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Other<sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">(a)</sup></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">97.6</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">89.0</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">281.9</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">254.3</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">758.0</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">722.9</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,258.2</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,195.5</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="BORDER-BOTTOM: #000000 1px solid; LINE-HEIGHT: 8pt; MARGIN-TOP: 0pt; WIDTH: 10%; MARGIN-BOTTOM: 2pt"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td valign="top" width="4%" align="left">(a)</td> <td valign="top" align="left">Beginning in 2013, certain emerging markets in Europe are included in the &#x201C;other&#x201D; geographic region. Prior year amounts have been reclassified to conform to the current year presentation.</td> </tr> </table> </div> 0.27 <div> <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> The changes in accumulated other comprehensive income (loss) by component are as follows:</p> <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"> <tr> <td width="63%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Derivative<br /> Instruments<br /> Designated&#xA0;as<br /> Cash&#xA0;Flow&#xA0;Hedges</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Foreign&#xA0;Currency<br /> Translation</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Benefit<br /> Plans</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Total</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom">(dollars in millions)</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Balance at December&#xA0;31, 2011</p> </td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(1.4</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">41.1</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(106.3</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(66.6</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"> Other comprehensive income (loss) before reclassifications</p> </td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5.2</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(24.3</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(19.1</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"> Tax (provision) benefit related to other comprehensive income (loss) before reclassifications<sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">(a)</sup></p> </td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(2.2</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(2.2</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Other comprehensive income (loss) before reclassifications, net of taxes</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3.0</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(24.3</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(21.3</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"> Amounts reclassified from accumulated other comprehensive income (loss)</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(1.1</td> <td valign="bottom" nowrap="nowrap">)<sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">(b)</sup>&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">8.0</td> <td valign="bottom" nowrap="nowrap"><sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">(c)</sup>&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">6.9</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"> Tax provision (benefit) related to amounts reclassified from accumulated other comprehensive income (loss)</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.2</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(2.8</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(2.6</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Reclassifications, net of tax</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(0.9</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5.2</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">4.3</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Other comprehensive income (loss)</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2.1</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(24.3</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5.2</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(17.0</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Balance at September&#xA0;30, 2012</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.7</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">16.8</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">(101.1</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">(83.6</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Balance at December&#xA0;31, 2012</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.7</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">32.6</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">(113.1</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">(81.2</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"> Other comprehensive income (loss) before reclassifications</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2.3</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(0.7</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1.6</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"> Tax (provision) benefit related to other comprehensive income (loss) before reclassifications<sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">(a)</sup></p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(0.4</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(0.4</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Other comprehensive income (loss) before reclassifications, net of taxes</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1.9</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(0.7</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1.2</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"> Amounts reclassified from accumulated other comprehensive income (loss)</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(0.6</td> <td valign="bottom" nowrap="nowrap">)<sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">(b)</sup>&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">10.3</td> <td valign="bottom" nowrap="nowrap"><sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">(c)</sup>&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">9.7</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"> Tax provision (benefit) related to amounts reclassified from accumulated other comprehensive income (loss)</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.3</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(3.7</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(3.4</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Reclassifications, net of tax</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(0.3</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">6.6</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">6.3</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Other comprehensive income (loss)</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1.6</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(0.7</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">6.6</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">7.5</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Balance at September&#xA0;30, 2013</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.9</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">31.9</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">(106.5</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">(73.7</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="BORDER-BOTTOM: #000000 1px solid; LINE-HEIGHT: 8pt; MARGIN-TOP: 0pt; WIDTH: 10%; MARGIN-BOTTOM: 2pt"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td valign="top" width="4%" align="left">(a)</td> <td valign="top" align="left">Income taxes are not provided for foreign currency translation adjustment.</td> </tr> </table> <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td valign="top" width="4%" align="left">(b)</td> <td valign="top" align="left">See Note 6 of the notes to condensed consolidated financial statements.</td> </tr> </table> <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td valign="top" width="4%" align="left">(c)</td> <td valign="top" align="left">These components are included in the computation of net periodic pension cost. See Note 10 of the notes to condensed consolidated financial statements.</td> </tr> </table> </div> 81200000 <div> <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> Total net sales by product group category are:</p> <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"> <tr> <td width="68%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Quarter Ended<br /> September 30,</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Nine&#xA0;Months&#xA0;Ended<br /> September 30,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom">(dollars in millions)</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Vascular</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">209.9</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">202.5</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">625.3</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">633.0</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Urology</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">193.7</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">188.1</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">574.2</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">562.0</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Oncology</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">215.5</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">203.9</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">636.7</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">601.9</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Surgical Specialties</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">118.1</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">107.7</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">358.4</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">333.8</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Other</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">20.8</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">20.7</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">63.6</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">64.8</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"></td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">758.0</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">722.9</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,258.2</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,195.5</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> <div> <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> The following table summarizes certain financial instrument assets measured at fair value on a recurring basis:</p> <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"> <tr> <td width="72%"></td> <td valign="bottom" width="12%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="12%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>September&#xA0;30,<br /> 2013</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>December&#xA0;31,<br /> 2012</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom">(dollars in millions)</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Forward currency contracts</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.5</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.0</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Option currency contracts</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1.4</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.6</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Interest rate swap contract</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">9.8</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">13.3</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> </table> </div> 1300000 <div> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> Inventories consisted of:</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> &#xA0;</p> <table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="72%"></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> </tr> <tr style="font-family:Times New Roman; font-size:8pt"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>September&#xA0;30,<br /> 2013</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>December&#xA0;31,<br /> 2012</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="font-family:Times New Roman; font-size:8pt"> <td valign="bottom">(dollars in millions)</td> <td valign="bottom">&#xA0;&#xA0;</td> <td colspan="2" valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td colspan="2" valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> Finished goods</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">199.4</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">194.6</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> Work in process</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">23.0</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">19.1</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> Raw materials</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">109.7</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">114.8</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"></td> <td valign="bottom"><font style="font-size:8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">332.1</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"><font style="font-size:8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">328.5</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> <div> <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> <b>6. Financial Instruments</b></p> <p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> <i>Foreign Exchange Derivative Instruments</i></p> <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> The company enters into readily marketable forward and option contracts with financial institutions to help reduce its exposure to foreign currency exchange rate fluctuations. These contracts limit volatility because gains and losses associated with foreign currency exchange rate movements are generally offset by movements in the underlying hedged item. The notional value of the company&#x2019;s forward currency and option currency contracts was $150.0 million and $128.1 million at September&#xA0;30, 2013 and December&#xA0;31, 2012, respectively. For further discussion regarding the company&#x2019;s use of derivative instruments, see Note&#xA0;1 of the notes to consolidated financial statements in Bard&#x2019;s 2012 Annual Report on Form 10-K.</p> <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> <i>Interest Rate Derivative Instrument</i></p> <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> The company&#x2019;s outstanding interest rate swap contract effectively converts its 2.875% fixed-rate notes due 2016 to a floating-rate instrument. The notional value of the company&#x2019;s interest rate swap contract is $250.0 million.</p> <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> The location and fair value of derivative instruments that are designated as hedging instruments recognized in the condensed consolidated balance sheets are as follows:</p> <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="84%" align="center"> <tr> <td width="51%"></td> <td valign="bottom" width="7%"></td> <td width="22%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" rowspan="2" align="center"> <p style="MARGIN-TOP: 0pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt" align="center"><b>Balance Sheet</b></p> <p style="MARGIN-TOP: 0pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 1pt; FONT-SIZE: 8pt" align="center"><b>Location</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Fair Value<br /> of&#xA0;Derivatives</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom" nowrap="nowrap"> <p style="BORDER-BOTTOM: #000000 1pt solid; WIDTH: 162pt; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <b>Derivatives Designated as Hedging Instruments</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>September&#xA0;30,<br /> 2013</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>December&#xA0;31,<br /> 2012</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom">(dollars in millions)</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Forward currency contracts</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Other&#xA0;current&#xA0;assets</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.7</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.4</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Option currency contracts</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Other current assets</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1.4</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.6</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Forward currency contracts</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Other assets</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.2</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Interest rate swap contract</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Other&#xA0;assets</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">9.8</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">13.3</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">13.1</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">15.3</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Forward currency contracts</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Accrued&#xA0;expenses</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.3</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.4</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Forward currency contracts</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> <font style="WHITE-SPACE: nowrap">Other&#xA0;long-term&#xA0;liabilities</font></p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.1</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"></td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.4</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.4</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> The location and amounts of gains and losses on derivative instruments designated as cash flow hedges and the impact on shareholders&#x2019; investment are as follows:</p> <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr> <td width="54%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Gain/(Loss)<br /> Recognized&#xA0;in&#xA0;Other<br /> Comprehensive<br /> Income (Loss)</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" rowspan="3" align="center"><b>Location of</b><br /> <b>Gain/(Loss)&#xA0;Reclassified</b><br /> <b>from&#xA0;Accumulated</b><br /> <b>Other&#xA0;Comprehensive&#xA0;Loss&#xA0;to<br /> Income</b></td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Gain/(Loss)&#xA0;Reclassified<br /> from&#xA0;Accumulated<br /> Other&#xA0;Comprehensive&#xA0;Loss<br /> into Income</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Quarter Ended<br /> September 30,</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Quarter Ended<br /> September 30,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom">(dollars in millions)</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Forward currency contracts</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.5</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.5</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="center"> Cost&#xA0;of&#xA0;goods&#xA0;sold</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.7</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.4</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Option currency contracts</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.9</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(0.6</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="center">Cost of goods sold</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(0.6</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.6</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.4</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.9</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.1</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.2</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr> <td width="54%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Gain/(Loss)<br /> Recognized&#xA0;in&#xA0;Other<br /> Comprehensive<br /> Income (Loss)</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" rowspan="3" align="center"><b>Location of</b><br /> <b>Gain/(Loss)&#xA0;Reclassified</b><br /> <b>from&#xA0;Accumulated</b><br /> <b>Other&#xA0;Comprehensive&#xA0;Loss&#xA0;to<br /> Income</b></td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Gain/(Loss)&#xA0;Reclassified<br /> from&#xA0;Accumulated<br /> Other&#xA0;Comprehensive&#xA0;Loss<br /> into Income</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Nine Months Ended<br /> September 30,</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Nine Months Ended<br /> September 30,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom">(dollars in millions)</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Forward currency contracts</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">4.1</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">4.0</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" align="center"> Cost&#xA0;of&#xA0;goods&#xA0;sold</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.7</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.4</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Option currency contracts</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1.0</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1.0</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" align="center">Cost of goods sold</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(1.1</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1.5</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">5.1</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">5.0</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.6</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.1</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> The location and amounts of gains and losses on the derivative instrument designated as a fair value hedge are as follows:</p> <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr> <td width="45%"></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" rowspan="3" colspan="2" align="center"> <b>Income&#xA0;Statement<br /> Location</b></td> <td valign="bottom" rowspan="3">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"> <b>(Loss)/Gain&#xA0;Recognized&#xA0;on&#xA0;Swap</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" nowrap="nowrap" align="center"><b><font style="WHITE-SPACE: nowrap">Gain/(Loss)&#xA0;Recognized&#xA0;on&#xA0;Long-Term&#xA0;Debt</font></b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Quarter&#xA0;Ended</b><br /> <b>September&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Nine&#xA0;Months&#xA0;Ended</b><br /> <b>September&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Quarter&#xA0;Ended</b><br /> <b>September&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Nine&#xA0;Months&#xA0;Ended</b><br /> <b>September&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom">(dollars in millions)</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Interest&#xA0;rate&#xA0;swap&#xA0;contract</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">Interest&#xA0;expense</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.3</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.0</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(3.5</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">2.5</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.3</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(1.0</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">3.5</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(2.5</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> The location and amounts of gains on derivative instruments not designated as hedging instruments are as follows:</p> <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr> <td width="61%"></td> <td valign="bottom" width="2%"></td> <td width="21%"></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" rowspan="3" align="center"> <p style="MARGIN-TOP: 0pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt" align="center"><b>Income&#xA0;Statement</b></p> <p style="MARGIN-TOP: 0pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 1pt; FONT-SIZE: 8pt" align="center"><b>Location</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"><b>Gain&#xA0;Recognized in Earnings</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Quarter&#xA0;Ended</b><br /> <b>September&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Nine&#xA0;Months&#xA0;Ended</b><br /> <b>September&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom">(dollars in millions)</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Forward currency contracts<sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">(A)</sup></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-TOP: 0pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 1pt; FONT-SIZE: 10pt"> Other&#xA0;(income)&#xA0;expense,&#xA0;net</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">3.0</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="BORDER-BOTTOM: #000000 1px solid; LINE-HEIGHT: 8pt; MARGIN-TOP: 0pt; WIDTH: 10%; MARGIN-BOTTOM: 2pt"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td valign="top" width="4%" align="left"><sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">(A)</sup>&#xA0;</td> <td valign="top" align="left">These derivative contracts mitigate changes in the value of remeasured foreign currency denominated intercompany loans attributable to changes in foreign currency exchange rates.</td> </tr> </table> <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> <i>Financial Instruments Measured at Fair Value on a Recurring Basis</i></p> <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> Fair value is defined as the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement that is determined using assumptions that market participants would use in pricing an asset or liability. The fair value guidance establishes a three-level hierarchy which maximizes the use of observable inputs and minimizes the use of unobservable inputs used in measuring fair value. The levels within the hierarchy range from Level 1 having observable inputs to Level 3 having unobservable inputs.</p> <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> The following table summarizes certain financial instrument assets measured at fair value on a recurring basis:</p> <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"> <tr> <td width="72%"></td> <td valign="bottom" width="12%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="12%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>September&#xA0;30,<br /> 2013</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>December&#xA0;31,<br /> 2012</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom">(dollars in millions)</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Forward currency contracts</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.5</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.0</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Option currency contracts</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1.4</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.6</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Interest rate swap contract</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">9.8</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">13.3</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> </table> <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> The fair values were measured using significant other observable inputs and valued by reference to similar financial instruments, adjusted for restrictions and other terms specific to each instrument. These financial instruments are categorized as Level 2 under the fair value hierarchy.</p> <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> The fair value of the liability for contingent consideration related to acquisitions was $86.8 million and $77.1 million at September&#xA0;30, 2013 and December&#xA0;31, 2012, respectively. The fair value was measured using significant unobservable inputs and is categorized as Level 3 under the fair value hierarchy.</p> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px"> &#xA0;</p> <p style="MARGIN-TOP: 0pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> <i>Financial Instruments not Measured at Fair Value</i></p> <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> The fair value of commercial paper borrowings of $97.5 million at September&#xA0;30, 2013 approximated the carrying value. There were no commercial paper borrowings outstanding at December&#xA0;31, 2012. On September&#xA0;26, 2013, the company amended its $600 million five-year committed syndicated bank credit facility that was scheduled to expire in October 2016. The amendment includes an increase of the aggregate principal amount of credit available under the syndicated bank credit facility to $750 million and extends the commitment termination date until September&#xA0;26, 2018. The amended credit facility supports the company&#x2019;s commercial paper program and can be used for general corporate purposes. The facility includes pricing based on the company&#x2019;s long-term credit rating and includes a financial covenant that limits the amount of total debt to total capitalization. At September&#xA0;30, 2013, the company was in compliance with this covenant.</p> <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> The estimated fair value of long-term debt including the effect of the related interest rate swap contract was approximately $1,454.2&#xA0;million and $1,532.2 million at September&#xA0;30, 2013 and December&#xA0;31, 2012, respectively. The fair value was estimated using dealer quotes for similarly-rated debt instruments over the remaining contractual term of the company&#x2019;s obligation. Long-term debt is categorized as Level 2 under the fair value hierarchy.</p> <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> <i>Concentration Risk</i></p> <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> Accounts receivable balances include sales to government-supported healthcare systems outside the United States. The company continues to monitor sovereign debt issues and economic conditions in Europe and evaluates accounts receivable in certain countries for potential collection risks. Economic conditions and other factors in certain countries in Europe have resulted in, and may continue to result in, an increase in the average length of time that it takes to collect these accounts receivable and may require the company to re-evaluate the collectability of these receivables in future periods. The company has experienced significant delays in the collection of accounts receivable associated with the national healthcare systems in Spain, Italy, Greece and Portugal. At September&#xA0;30, 2013, the company&#x2019;s accounts receivable, net of allowances, from the national healthcare systems in these countries and amounts past due greater than 365 days are as follows:</p> <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"> <tr> <td width="68%"></td> <td valign="bottom" width="13%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="13%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Accounts<br /> receivable,&#xA0;net</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Greater&#xA0;than<br /> 365&#xA0;days&#xA0;past&#xA0;due</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom">(dollars in millions)</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Spain</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">23.0</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">4.8</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Italy</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">23.1</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2.4</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Greece</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">10.5</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3.2</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Portugal</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">4.0</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1.7</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">60.6</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">12.1</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> 5200000 <div> <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> The location and amounts of gains and losses on derivative instruments designated as cash flow hedges and the impact on shareholders&#x2019; investment are as follows:</p> <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr> <td width="54%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Gain/(Loss)<br /> Recognized&#xA0;in&#xA0;Other<br /> Comprehensive<br /> Income (Loss)</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" rowspan="3" align="center"><b>Location of</b><br /> <b>Gain/(Loss)&#xA0;Reclassified</b><br /> <b>from&#xA0;Accumulated</b><br /> <b>Other&#xA0;Comprehensive&#xA0;Loss&#xA0;to<br /> Income</b></td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Gain/(Loss)&#xA0;Reclassified<br /> from&#xA0;Accumulated<br /> Other&#xA0;Comprehensive&#xA0;Loss<br /> into Income</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Quarter Ended<br /> September 30,</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Quarter Ended<br /> September 30,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom">(dollars in millions)</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Forward currency contracts</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.5</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.5</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="center"> Cost&#xA0;of&#xA0;goods&#xA0;sold</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.7</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.4</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Option currency contracts</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.9</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(0.6</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="center">Cost of goods sold</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(0.6</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.6</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.4</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.9</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.1</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.2</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr> <td width="54%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Gain/(Loss)<br /> Recognized&#xA0;in&#xA0;Other<br /> Comprehensive<br /> Income (Loss)</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" rowspan="3" align="center"><b>Location of</b><br /> <b>Gain/(Loss)&#xA0;Reclassified</b><br /> <b>from&#xA0;Accumulated</b><br /> <b>Other&#xA0;Comprehensive&#xA0;Loss&#xA0;to<br /> Income</b></td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Gain/(Loss)&#xA0;Reclassified<br /> from&#xA0;Accumulated<br /> Other&#xA0;Comprehensive&#xA0;Loss<br /> into Income</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Nine Months Ended<br /> September 30,</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Nine Months Ended<br /> September 30,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom">(dollars in millions)</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Forward currency contracts</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">4.1</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">4.0</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" align="center"> Cost&#xA0;of&#xA0;goods&#xA0;sold</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.7</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.4</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Option currency contracts</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1.0</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1.0</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" align="center">Cost of goods sold</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(1.1</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1.5</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">5.1</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">5.0</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.6</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.1</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> <div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <b>7. Inventories</b></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> Inventories consisted of:</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> &#xA0;</p> <table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="72%"></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> </tr> <tr style="font-family:Times New Roman; font-size:8pt"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>September&#xA0;30,<br /> 2013</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>December&#xA0;31,<br /> 2012</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="font-family:Times New Roman; font-size:8pt"> <td valign="bottom">(dollars in millions)</td> <td valign="bottom">&#xA0;&#xA0;</td> <td colspan="2" valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td colspan="2" valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> Finished goods</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">199.4</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">194.6</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> Work in process</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">23.0</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">19.1</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> Raw materials</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">109.7</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">114.8</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"></td> <td valign="bottom"><font style="font-size:8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">332.1</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"><font style="font-size:8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">328.5</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> <div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <b>3. Restructuring</b></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> During the fourth quarter of 2012, the company committed to a plan (the &#x201C;2012 Restructuring Plan&#x201D;) to improve its overall cost structure and enhance operational effectiveness. At September&#xA0;30, 2013, the remaining liability related to the 2012 Restructuring Plan was $2.3 million. Cash payments of $14.1 million and a reversal of $1.4 million of previously accrued restructuring costs were made during the nine months ended September&#xA0;30, 2013. The company expects activities under this plan to be substantially complete by the end of 2013.</p> </div> <div> <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> The location and amounts of gains and losses on the derivative instrument designated as a fair value hedge are as follows:</p> <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr> <td width="45%"></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" rowspan="3" colspan="2" align="center"> <b>Income&#xA0;Statement<br /> Location</b></td> <td valign="bottom" rowspan="3">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"> <b>(Loss)/Gain&#xA0;Recognized&#xA0;on&#xA0;Swap</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" nowrap="nowrap" align="center"><b><font style="WHITE-SPACE: nowrap">Gain/(Loss)&#xA0;Recognized&#xA0;on&#xA0;Long-Term&#xA0;Debt</font></b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Quarter&#xA0;Ended</b><br /> <b>September&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Nine&#xA0;Months&#xA0;Ended</b><br /> <b>September&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Quarter&#xA0;Ended</b><br /> <b>September&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Nine&#xA0;Months&#xA0;Ended</b><br /> <b>September&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom">(dollars in millions)</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Interest&#xA0;rate&#xA0;swap&#xA0;contract</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">Interest&#xA0;expense</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.3</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.0</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(3.5</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">2.5</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.3</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(1.0</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">3.5</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(2.5</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> 417000000 <div> <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> <b>10. Pension and Other Postretirement Benefit Plans</b></p> <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> <i>Defined Benefit Pension Plans</i> - The company has both tax-qualified and nonqualified, noncontributory defined benefit pension plans, that together cover certain domestic and foreign employees. These plans provide benefits based upon a participant&#x2019;s compensation and years of service.</p> <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> The components of net periodic pension cost are as follows:</p> <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"> <tr> <td width="74%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Quarter Ended<br /> September 30,</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Nine&#xA0;Months&#xA0;Ended<br /> September 30,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom">(dollars in millions)</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Service cost, net of employee contributions</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">7.5</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">7.0</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">22.6</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">20.8</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Interest cost</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">4.6</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">4.9</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">13.7</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">14.6</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Expected return on plan assets</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(6.5</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(6.2</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(19.5</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(17.9</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Amortization</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3.4</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2.8</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">10.2</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">7.8</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Net periodic pension cost</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">9.0</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">8.5</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">27.0</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">25.3</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> <i>Other Postretirement Benefit Plan</i> - The company does not provide subsidized postretirement healthcare benefits and life insurance coverage except for a limited number of former employees. As this plan is unfunded, contributions are made as benefits are incurred. The net periodic benefit cost was $0.1 million and $0.2 million for the quarters ended September&#xA0;30, 2013 and 2012, respectively. The net periodic benefit cost was $0.4 million and $0.5 million for the nine month periods ended September&#xA0;30, 2013 and 2012, respectively.</p> </div> <div> <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> <b>4. Earnings per Common Share</b></p> <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> Earnings per share (&#x201C;EPS&#x201D;) is computed under the two-class method using the following common share information:</p> <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"> <tr> <td width="74%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Quarter Ended<br /> September 30,</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Nine Months</b><br /> <b>Ended&#xA0;September&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom">(dollars and shares in millions)</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> EPS Numerator:</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Net income</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">93.2</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">129.3</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">22.3</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">401.9</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Less: Income allocated to participating securities</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1.6</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2.4</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.3</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">7.7</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Net income available to common shareholders</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">91.6</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">126.9</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">22.0</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">394.2</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> EPS Denominator:</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Weighted average common shares outstanding</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">78.5</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">83.4</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">79.9</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">83.8</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Dilutive common share equivalents from share-based compensation plans</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1.5</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1.2</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1.3</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1.1</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Weighted average common and common equivalent shares outstanding, assuming dilution</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">80.0</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">84.6</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">81.2</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">84.9</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> <div> <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> Assets and liabilities held for sale associated with BEP include the following:</p> <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="68%" align="center"> <tr> <td width="84%"></td> <td valign="bottom" width="12%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom">(dollars in millions)</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>September&#xA0;30,</b><br /> <b>2013</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Inventories</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">14.4</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Other current assets</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.4</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Net property, plant and equipment</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2.6</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Other intangible assets, net</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">7.0</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"></td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">24.4</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Accrued expenses</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.8</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Accrued compensation and benefits</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.8</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">2.6</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"></td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">21.8</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> <div> <p style="MARGIN-TOP: 0pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> <b>11. Shareholders&#x2019; Investment</b></p> <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> The company repurchased approximately 5.2&#xA0;million shares of common stock for $533.4 million in the nine months ended September&#xA0;30, 2013 under its previously announced share repurchase authorizations.</p> <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> <i>Other Comprehensive Income (Loss)</i></p> <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> During the first quarter of 2013, the company adopted new Financial Accounting Standards Board guidance that requires the company to present information about reclassification adjustments from accumulated other comprehensive loss. Under this guidance, the company presents the effect of amounts reclassified from each component of accumulated other comprehensive loss based on its source.</p> <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> The changes in accumulated other comprehensive income (loss) by component are as follows:</p> <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"> <tr> <td width="63%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Derivative<br /> Instruments<br /> Designated&#xA0;as<br /> Cash&#xA0;Flow&#xA0;Hedges</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Foreign&#xA0;Currency<br /> Translation</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Benefit<br /> Plans</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Total</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom">(dollars in millions)</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Balance at December&#xA0;31, 2011</p> </td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(1.4</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">41.1</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(106.3</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(66.6</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"> Other comprehensive income (loss) before reclassifications</p> </td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5.2</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(24.3</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(19.1</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"> Tax (provision) benefit related to other comprehensive income (loss) before reclassifications<sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">(a)</sup></p> </td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(2.2</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(2.2</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Other comprehensive income (loss) before reclassifications, net of taxes</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3.0</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(24.3</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(21.3</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"> Amounts reclassified from accumulated other comprehensive income (loss)</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(1.1</td> <td valign="bottom" nowrap="nowrap">)<sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">(b)</sup>&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">8.0</td> <td valign="bottom" nowrap="nowrap"><sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">(c)</sup>&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">6.9</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"> Tax provision (benefit) related to amounts reclassified from accumulated other comprehensive income (loss)</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.2</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(2.8</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(2.6</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Reclassifications, net of tax</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(0.9</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5.2</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">4.3</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Other comprehensive income (loss)</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2.1</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(24.3</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5.2</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(17.0</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Balance at September&#xA0;30, 2012</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.7</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">16.8</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">(101.1</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">(83.6</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Balance at December&#xA0;31, 2012</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.7</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">32.6</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">(113.1</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">(81.2</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"> Other comprehensive income (loss) before reclassifications</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2.3</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(0.7</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1.6</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"> Tax (provision) benefit related to other comprehensive income (loss) before reclassifications<sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">(a)</sup></p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(0.4</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(0.4</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Other comprehensive income (loss) before reclassifications, net of taxes</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1.9</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(0.7</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1.2</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"> Amounts reclassified from accumulated other comprehensive income (loss)</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(0.6</td> <td valign="bottom" nowrap="nowrap">)<sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">(b)</sup>&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">10.3</td> <td valign="bottom" nowrap="nowrap"><sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">(c)</sup>&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">9.7</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"> Tax provision (benefit) related to amounts reclassified from accumulated other comprehensive income (loss)</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.3</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(3.7</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(3.4</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Reclassifications, net of tax</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(0.3</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">6.6</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">6.3</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Other comprehensive income (loss)</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1.6</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(0.7</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">6.6</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">7.5</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Balance at September&#xA0;30, 2013</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.9</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">31.9</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">(106.5</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">(73.7</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="BORDER-BOTTOM: #000000 1px solid; LINE-HEIGHT: 8pt; MARGIN-TOP: 0pt; WIDTH: 10%; MARGIN-BOTTOM: 2pt"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td valign="top" width="4%" align="left">(a)</td> <td valign="top" align="left">Income taxes are not provided for foreign currency translation adjustment.</td> </tr> </table> <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td valign="top" width="4%" align="left">(b)</td> <td valign="top" align="left">See Note 6 of the notes to condensed consolidated financial statements.</td> </tr> </table> <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td valign="top" width="4%" align="left">(c)</td> <td valign="top" align="left">These components are included in the computation of net periodic pension cost. See Note 10 of the notes to condensed consolidated financial statements.</td> </tr> </table> </div> <div> <p style="MARGIN-TOP: 0pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> Amounts recognized for share-based compensation are as follows:</p> <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"> <tr> <td width="76%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Quarter Ended<br /> September 30,</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Nine&#xA0;Months&#xA0;Ended<br /> September 30,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom">(dollars in millions)</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Total cost of share-based compensation plans</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">16.0</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">11.5</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">44.6</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">39.0</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Amounts capitalized in inventory and fixed assets</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(0.3</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(0.4</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(1.4</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(1.2</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Amounts recognized in income for amounts previously capitalized in inventory and fixed assets</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.5</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.4</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1.5</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1.2</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Amounts charged against income</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">16.2</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">11.5</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">44.7</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">39.0</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> <div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <b>1. Basis of Presentation</b></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> The accompanying unaudited condensed consolidated financial statements of C. R. Bard, Inc. and its subsidiaries (the &#x201C;company&#x201D; or &#x201C;Bard&#x201D;) should be read in conjunction with the audited consolidated financial statements and notes thereto included in Bard&#x2019;s 2012 Annual Report on Form 10-K. These financial statements have been prepared on a basis that is substantially consistent with the accounting principles applied in the financial statements in Bard&#x2019;s 2012 Annual Report on Form 10-K. The preparation of these financial statements requires the company to make estimates and judgments that affect reported amounts of assets, liabilities, revenues and expenses and the related disclosure of contingent assets and liabilities at the date of the financial statements. These financial statements include all normal and recurring adjustments necessary for a fair presentation. The accounts of most foreign subsidiaries are consolidated as of and for the quarter and nine months ended August&#xA0;31, 2013 and August&#xA0;31, 2012 and as of November&#xA0;30, 2012. No events occurred related to these foreign subsidiaries during the months of September 2013,&#xA0;September 2012 or December&#xA0;2012 that materially affected the financial position or results of operations of the company. The results for the interim periods presented are not necessarily indicative of the results expected for the year.</p> </div> 79900000 <div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <b>5. Income Taxes</b></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> The effective tax rate for the quarter ended September&#xA0;30, 2013 was approximately 22%, compared to approximately 27% for the prior year quarter. The effective tax rate for the quarter and nine months ended September&#xA0;30, 2013 reflected the discrete tax effects of an IPR&amp;D charge related to the acquisition of 3DT, which was incurred in a high tax jurisdiction, and a benefit associated with the remeasurement of an uncertain tax position as a result of the settlement of the Brachytherapy Matter. In addition, the effective tax rate for the nine months ended September&#xA0;30, 2013 reflected the discrete tax effects of litigation charges, primarily related to product liability claims, which were substantially incurred in a low tax jurisdiction, and the write-down of an insurance receivable, which also was incurred in low tax jurisdiction. See Note 8 of the notes to condensed consolidated financial statements. The effective tax rate was also impacted by the American Taxpayer Relief Act of 2012, which was signed into law on January&#xA0;2, 2013 and retroactively reinstated the research tax credit.&#xA0;Although the reinstatement of this tax credit is retroactive to January&#xA0;1, 2012, the enactment of this legislation in 2013 precluded the company from recording the benefit in 2012.&#xA0;As a result, the company&#x2019;s income tax provision was reduced by approximately $3.7 million during the nine months ended September&#xA0;30, 2013 to recognize the 2012 benefit of this tax credit that would have been recorded in 2012.&#xA0;At September&#xA0;30, 2013, the total amount of liability for unrecognized tax benefits related to federal, state and foreign taxes was $48.5 million (of which $40.4 million would impact the effective tax rate, if recognized) plus $6.3 million of accrued interest. At December&#xA0;31, 2012, the liability for unrecognized tax benefits was $43.4&#xA0;million plus $4.8&#xA0;million of accrued interest. Depending upon the result of open tax examinations and/or the expiration of applicable statutes of limitation, the company believes it is reasonably possible that the total amount of unrecognized tax benefits may decrease by up to $18.4&#xA0;million within the next 12&#xA0;months.</p> </div> <div> <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> <b>9. Share-Based Compensation Plans</b></p> <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> The company may grant a variety of share-based payments under the 2012 Long Term Incentive Plan of C.&#xA0;R.&#xA0;Bard, Inc., as amended and restated (the &#x201C;LTIP&#x201D;) and the 2005 Directors&#x2019; Stock Award Plan of C.&#xA0;R.&#xA0;Bard, Inc., as amended and restated (the &#x201C;Directors&#x2019; Plan&#x201D;) to certain directors, officers and employees. At the company&#x2019;s Annual Meeting of Shareholders on April&#xA0;17, 2013, the shareholders authorized an additional 2,000,000 shares for issuance under the LTIP. The total number of remaining shares at September&#xA0;30, 2013 that may be issued under the LTIP was 5,710,855 and under the Directors&#x2019; Plan was 39,843. Awards under the LTIP may be in the form of stock options, stock appreciation rights, limited stock appreciation rights, restricted stock, unrestricted stock and other stock-based awards. Awards under the Directors&#x2019; Plan may be in the form of stock awards, stock options or stock appreciation rights. The company also has two employee stock purchase programs.</p> <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px"> &#xA0;</p> <p style="MARGIN-TOP: 0pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> Amounts recognized for share-based compensation are as follows:</p> <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"> <tr> <td width="76%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Quarter Ended<br /> September 30,</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Nine&#xA0;Months&#xA0;Ended<br /> September 30,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom">(dollars in millions)</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Total cost of share-based compensation plans</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">16.0</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">11.5</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">44.6</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">39.0</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Amounts capitalized in inventory and fixed assets</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(0.3</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(0.4</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(1.4</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(1.2</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Amounts recognized in income for amounts previously capitalized in inventory and fixed assets</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.5</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.4</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1.5</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1.2</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Amounts charged against income</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">16.2</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">11.5</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">44.7</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">39.0</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> In the first quarter of each of 2013 and 2012, the company granted performance restricted stock units to certain officers. These units have requisite service periods of three years and have no dividend rights. The actual payout of these units varies based on the company&#x2019;s performance over the three-year period based on pre-established targets over the period and a market condition modifier based on total shareholder return (&#x201C;TSR&#x201D;) compared to an industry peer group. The actual payout under these awards may exceed an officer&#x2019;s target payout; however, compensation cost initially recognized assumes that the target payout level will be achieved and may be adjusted for subsequent changes in the expected outcome of the performance-related condition. The fair values of these units are based on the market price of the company&#x2019;s stock on the date of the grant and use a Monte Carlo simulation model for the TSR component. The fair values of the TSR components of the 2013 and 2012 grants were estimated based on the following assumptions: risk-free interest rate of 0.42% and 0.41%, respectively; dividend yield of 0.81% and 0.85%, respectively; and expected life of 2.88 and 2.83 years, respectively.</p> <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> Anticipated purchases under the Management Stock Purchase Program (the &#x201C;MSPP&#x201D;) are approximately 0.2&#xA0;million shares for the 2013 grant. Purchases under the MSPP were approximately 0.2&#xA0;million shares for the 2012 grant. The fair value of the 2013 annual MSPP purchases was $37.20 per share and was estimated in July 2013. The fair value of the 2012 MSPP purchases was $38.33 per share. These fair value calculations used the Black-Scholes model based on the following assumptions: risk free interest rate of 0.10% and 0.16%, respectively; expected volatility of 15% and 20%, respectively; dividend yield of 0.8% and 0.9%, respectively; and expected life of 0.6 years for both valuations.</p> <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> As of September&#xA0;30, 2013, there were $79.3&#xA0;million of unrecognized compensation expenses related to share-based payment arrangements. These costs are expected to be recognized over a weighted-average period of approximately two years. The company has sufficient shares to satisfy expected share-based payment arrangements in 2013.</p> </div> <div> <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> <b>2. Acquisitions and Divestiture</b></p> <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> On October&#xA0;1, 2013, the company acquired all of the outstanding shares of Medafor, Inc. (&#x201C;Medafor&#x201D;), a privately-held developer and supplier of plant-based hemostatic agents. The purchase consideration included an up-front cash payment of $203.7 million and future contingent payments of up to an additional $80 million based on specific revenue-based milestones through June&#xA0;30, 2015. The company has not yet completed the initial purchase accounting due to the timing of this acquisition.</p> <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> On September&#xA0;4, 2013, the company entered into a definitive agreement to acquire Rochester Medical, Inc. (&#x201C;Rochester Medical&#x201D;), a publicly-held developer and supplier of silicone urinary incontinence and urine drainage products, for a purchase price of $20 per share, or approximately $262 million in the aggregate to be paid at closing. The transaction is expected to close in 2013, and is subject to customary closing conditions, including approval by the shareholders of Rochester Medical as well as regulatory approvals.</p> <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> On August&#xA0;29, 2013, the company acquired early stage technology from 3DT Holdings LLC (&#x201C;3DT&#x201D;), providing the company with rights to develop and commercialize a novel technology related to peripherally inserted central catheters (&#x201C;PICCs&#x201D;). 3DT received an up-front cash payment of $29.5 million and is eligible for milestone payments of up to $5 million based upon regulatory product approval. The company recorded the up-front payment as a research and development expense.</p> <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> On July&#xA0;29, 2013, the company acquired all of the outstanding shares of Loma Vista Medical, Inc., a privately-held company specializing in the development and commercialization of aortic valvuloplasty products, which use noncompliant fiber-based balloon technology. The total purchase consideration of $39.4 million included an up-front cash payment of $32.5 million and the fair value of contingent consideration of up to $8.0 million. The fair value of the assets acquired resulted in the recognition of core technologies of $20.6 million, deferred tax liabilities of $14.7 million, primarily consisting of intangible assets, goodwill of $8.6 million, and other net assets of $4.9 million. The goodwill is not deductible for tax purposes. An in process research and development (&#x201C;IPR&amp;D&#x201D;) asset of $20.0 million was recorded for the development of a next generation valvuloplasty product. The fair value of the IPR&amp;D asset was determined based upon the present value of expected future cash flows adjusted for the probability of technological and commercial risk, utilizing a risk-adjusted discount rate of 25%. The company has not yet finalized the purchase accounting, which may be adjusted as further information about conditions existing at the acquisition date become available.</p> <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> On June&#xA0;27, 2013, the company reached a definitive agreement to sell certain assets and liabilities of its electrophysiology division (&#x201C;BEP&#x201D;) to Boston Scientific Corporation (&#x201C;Boston Scientific&#x201D;) for $275 million in cash. The transaction is expected to be completed in 2013, subject to certain regulatory and customary closing conditions. The company expects to record a gain on the sale when the transaction is completed, which will include, among other things, assets and liabilities held for sale, and the de-recognition of a portion of goodwill.</p> <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> Assets and liabilities held for sale associated with BEP include the following:</p> <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="68%" align="center"> <tr> <td width="84%"></td> <td valign="bottom" width="12%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom">(dollars in millions)</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>September&#xA0;30,</b><br /> <b>2013</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Inventories</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">14.4</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Other current assets</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.4</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Net property, plant and equipment</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2.6</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Other intangible assets, net</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">7.0</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"></td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">24.4</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Accrued expenses</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.8</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Accrued compensation and benefits</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.8</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">2.6</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"></td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">21.8</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> The company has agreed to provide contract manufacturing and other transition services to Boston Scientific for up to five years following the closing date. Due to the company&#x2019;s continuing involvement in the operations of BEP, the criteria for reporting the results of BEP as a discontinued operation were not met.</p> </div> <div> <p style="MARGIN-TOP: 0pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> <b>12. Segment Information</b></p> <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> The company&#x2019;s management considers its business to be a single segment entity&#x2014;the manufacture and sale of medical devices. The company&#x2019;s products generally share similar distribution channels and customers. The company designs, develops, manufactures, packages, distributes and sells medical, surgical, diagnostic and patient care devices. The company sells a broad range of products to hospitals, individual healthcare professionals, extended care health facilities and alternate site facilities on a global basis. In general, the company&#x2019;s products are intended to be used once and then discarded or either temporarily or permanently implanted. The company&#x2019;s chief operating decision makers evaluate their various global product portfolios on a net sales basis and generally evaluate profitability and associated investment on an enterprise-wide basis due to shared geographic infrastructures.</p> <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> Net sales based on the location of external customers by geographic region are:</p> <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"> <tr> <td width="68%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Quarter Ended<br /> September 30,</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Nine&#xA0;Months&#xA0;Ended<br /> September 30,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom">(dollars in millions)</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> United States</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">500.3</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">483.4</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,496.4</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,469.6</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Europe<sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">(a)</sup></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">116.7</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">108.9</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">356.5</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">349.4</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Japan</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">43.4</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">41.6</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">123.4</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">122.2</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Other<sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">(a)</sup></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">97.6</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">89.0</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">281.9</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">254.3</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">758.0</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">722.9</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,258.2</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,195.5</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="BORDER-BOTTOM: #000000 1px solid; LINE-HEIGHT: 8pt; MARGIN-TOP: 0pt; WIDTH: 10%; MARGIN-BOTTOM: 2pt"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td valign="top" width="4%" align="left">(a)</td> <td valign="top" align="left">Beginning in 2013, certain emerging markets in Europe are included in the &#x201C;other&#x201D; geographic region. Prior year amounts have been reclassified to conform to the current year presentation.</td> </tr> </table> <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> Total net sales by product group category are:</p> <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"> <tr> <td width="68%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Quarter Ended<br /> September 30,</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Nine&#xA0;Months&#xA0;Ended<br /> September 30,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom">(dollars in millions)</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Vascular</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">209.9</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">202.5</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">625.3</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">633.0</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Urology</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">193.7</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">188.1</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">574.2</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">562.0</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Oncology</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">215.5</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">203.9</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">636.7</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">601.9</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Surgical Specialties</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">118.1</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">107.7</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">358.4</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">333.8</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Other</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">20.8</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">20.7</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">63.6</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">64.8</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"></td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">758.0</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">722.9</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,258.2</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,195.5</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> <div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <b>8. Contingencies</b></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <i>General</i></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> In the ordinary course of business, the company is subject to various legal proceedings, investigations and claims, including, for example, environmental matters, employment disputes, disputes on agreements and other commercial disputes. In addition, the company operates in an industry susceptible to significant product liability and patent legal claims. The company accounts for estimated losses with respect to legal proceedings and claims when such losses are probable and reasonably estimable. Legal costs associated with these matters are expensed as incurred. At any given time, in the ordinary course of business, the company is involved as either a plaintiff or defendant in a number of patent infringement actions. If a third party&#x2019;s patent infringement claim were to be determined against the company, the company might be required to make significant royalty or other payments or might be subject to an injunction or other limitation on its ability to manufacture or distribute one or more products. If a patent owned by or licensed to the company is found to be invalid or unenforceable, the company might be required to reduce the value of certain intangible assets on the company&#x2019;s balance sheet and to record a corresponding charge, which could be significant in amount. Many of the company&#x2019;s legal proceedings and claims could have a material adverse effect on its business, results of operations, financial condition and/or liquidity.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <i>Product Liability Matters</i></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> As of October&#xA0;17, 2013, approximately 745 federal and 720 state lawsuits involving individual claims by approximately 1,575 plaintiffs, as well as two putative class actions in the United States are currently pending against the company with respect to its Composix<sup style="font-size:85%; vertical-align:top">&#xAE;</sup> Kugel<sup style="font-size:85%; vertical-align:top">&#xAE;</sup> and certain other hernia repair implant products (collectively, the &#x201C;Hernia Product Claims&#x201D;). The company voluntarily recalled certain sizes and lots of the Composix<sup style="font-size:85%; vertical-align:top">&#xAE;</sup> Kugel<sup style="font-size:85%; vertical-align:top">&#xAE;</sup> products beginning in December 2005. One of the U.S. class action lawsuits consolidated ten previously-filed U.S. class action lawsuits. The&#xA0;putative class actions, none of which has been certified, seek: (i)&#xA0;medical monitoring; (ii)&#xA0;compensatory damages; (iii)&#xA0;punitive damages; (iv)&#xA0;a judicial finding of defect and causation; and/or (v)&#xA0;attorneys&#x2019; fees. A settlement has been reached with respect to the three pending putative Canadian class actions within amounts previously recorded by the company. Approximately 685 of the state lawsuits, involving individual claims by approximately 785 plaintiffs, are pending in the Superior Court of the State of Rhode Island, with the remainder in various other jurisdictions. The Hernia Product Claims also generally seek damages for personal injury resulting from use of the products.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> In June&#xA0;2007, the Composix<sup style="font-size:85%; vertical-align:top">&#xAE;</sup> Kugel<sup style="font-size:85%; vertical-align:top">&#xAE;</sup> lawsuits and, subsequently, other hernia repair product lawsuits, pending in federal courts nationwide were transferred into one Multidistrict Litigation (&#x201C;MDL&#x201D;) for coordinated pre-trial proceedings in the United States District Court for the District of Rhode Island.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> On June&#xA0;30, 2011, the company announced that it had reached agreements in principle with various plaintiffs&#x2019; law firms to settle the majority of its existing Hernia Product Claims. Each agreement is subject to certain conditions, including requirements for participation in the proposed settlements by a certain minimum number of plaintiffs. In addition, the company continues to engage in discussions with other plaintiffs&#x2019; law firms regarding potential resolution of unsettled Hernia Product Claims, and intends to vigorously defend Hernia Product Claims that do not settle, including through litigation. The company cannot give any assurances that the resolution of the Hernia Product Claims that have not settled, including asserted and unasserted claims and the putative class action lawsuits, will not have a material adverse effect on the company&#x2019;s business, results of operations, financial condition and/or liquidity.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> As of October&#xA0;17, 2013, product liability lawsuits involving individual claims by approximately 9,635 plaintiffs have been filed or asserted against the company in various federal and state jurisdictions alleging personal injuries associated with the use of certain of the company&#x2019;s surgical continence products for women, including its Avaulta<sup style="font-size:85%; vertical-align:top">&#xAE;</sup> line of products. In addition, five putative class actions in the United States and three putative class actions in Canada have been filed against the company (all lawsuits, collectively, the &#x201C;Women&#x2019;s Health Product Claims&#x201D;). The Women&#x2019;s Health Product Claims generally seek damages for personal injury resulting from use of the products. The putative class actions, none of which has been certified, seek: (i)&#xA0;medical monitoring; (ii)&#xA0;compensatory damages; (iii)&#xA0;punitive damages; (iv)&#xA0;a judicial finding of defect and causation; and/or (v)&#xA0;attorneys&#x2019; fees. With respect to certain of these claims, the company believes that one of its suppliers has an obligation to defend and indemnify the company. In October 2010, the Women&#x2019;s Health Product Claims involving solely Avaulta<sup style="font-size:85%; vertical-align:top">&#xAE;</sup> products pending in federal courts nationwide were transferred into an MDL in the United States District Court for the Southern District of West Virginia, the scope of which was later expanded to include lawsuits involving all women&#x2019;s surgical continence products that are manufactured or distributed by the company. The company expects additional Women&#x2019;s Health Product Claims pending in federal courts to be transferred to the MDL in West Virginia, with the remainder of the Women&#x2019;s Health Product Claims in other jurisdictions. The first trial in the MDL commenced in July 2013 and resulted in a judgment against the company of approximately $2 million. The company intends to appeal the judgment. The next MDL trial is scheduled to occur in December 2013, with additional trials scheduled in 2014. The first trial in a state court was completed in July 2012 and resulted in a judgment against the company of approximately $3.6 million. The company has appealed this decision. During the third quarter, the company settled one MDL case and one New Jersey state case. The amounts of the settlements are subject to confidentiality requirements. In addition, during the third quarter, an MDL case was voluntarily dismissed with prejudice, and the company is currently seeking to recover attorneys&#x2019; fees for this case. The company does not believe that any verdicts or settlements entered to date are representative of potential outcomes of all Women&#x2019;s Health Product Claims. The case numbers set forth above do not include generic complaints involving women&#x2019;s health products where the company cannot, based on the allegations in such complaints, determine whether any of such cases involve the company&#x2019;s women&#x2019;s health products. While the company intends to vigorously defend the Women&#x2019;s Health Product Claims, it cannot give any assurances that the resolution of these claims will not have a material adverse effect on the company&#x2019;s business, results of operations, financial condition and/or liquidity.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> As of October&#xA0;17, 2013, product liability lawsuits involving individual claims by 40 plaintiffs are currently pending against the company in various federal and state jurisdictions alleging personal injuries associated with the use of the company&#x2019;s vena cava filter products. In addition, three putative class actions were filed against the company in various state courts on behalf of plaintiffs who are alleged to have no present injury (all lawsuits, collectively, the &#x201C;Filter Product Claims&#x201D;). Two of these putative class actions were dismissed during the second quarter, and class certification was denied for the third putative class action in July 2013. The first Filter Product Claim trial was completed in June 2012 and resulted in a judgment for the company. The company expects additional trials of Filter Product Claims to take place over the next 12 months. During the second quarter of 2013, the company finalized settlement agreements with respect to more than 30 Filter Product Claims, and made payments with respect to such claims within the amounts previously recorded. While the company intends to vigorously defend the remaining unsettled Filter Product Claims, it cannot give any assurances that the resolution of these claims will not have a material adverse effect on the company&#x2019;s business, results of operations, financial condition and/or liquidity.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> In most product liability litigations of this nature, plaintiffs allege a wide variety of claims, ranging from allegations of serious injury caused by the products to efforts to obtain compensation notwithstanding the absence of any injury. In many of these cases, the company has not yet received and reviewed complete information regarding the plaintiffs and their medical conditions, and consequently, is unable to fully evaluate the claims. The company expects that it will receive and review additional information regarding any remaining unsettled product liability matters.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> The company believes that some settlements and judgments, as well as legal defense costs, relating to product liability matters are or may be covered in whole or in part under its product liability insurance policies with a limited number of insurance carriers. In certain circumstances, insurance carriers reserve their rights with respect to coverage, or contest or deny coverage, as has occurred with respect to certain claims. When this occurs, the company intends to vigorously contest disputes with respect to its insurance coverage and to enforce its rights under the terms of its insurance policies, and accordingly, will record receivables with respect to amounts due under these policies, when recovery is probable. Amounts recovered under the company&#x2019;s product liability insurance policies may be less than the stated coverage limits and may not be adequate to cover damages and/or costs relating to claims. In addition, there is no guarantee that insurers will pay claims or that coverage will otherwise be available.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> The company&#x2019;s insurance coverage with respect to the Hernia Product Claims has been exhausted. In the first quarter of 2013 the company recorded a non-cash charge of $25.0 million ($24.5 million after tax) to other (income) expense, net, for the write-down of an insurance receivable related to a dispute with one of its excess insurance carriers in connection with these claims.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> In connection with the Women&#x2019;s Health Product Claims, the company was in dispute with one of its excess insurance carriers relating to an aggregate of $50 million of insurance coverage. In June 2013, the company settled this dispute with no change to the amount of the insurance coverage or the related receivable.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <i>Other Legal Matters</i></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> During the first half of 2013, the company received subpoenas or Civil Investigative Demands from a number of State Attorneys General seeking information related to the sales and marketing of certain of the company&#x2019;s products that are the subject of the Hernia Product Claims and the Women&#x2019;s Health Product Claims. The company is cooperating with these requests. Since it is not feasible to predict the outcome of these proceedings, the company cannot give any assurances that the resolution of these proceedings will not have a material adverse effect on the company&#x2019;s business, results of operations, financial condition and/or liquidity.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> In November 2006, the company received a subpoena issued by the U.S. Department of Health and Human Services, Office of Inspector General (&#x201C;OIG&#x201D;), under the authority of the federal healthcare fraud and false claims statutes, seeking documents related to the company&#x2019;s brachytherapy business (the &#x201C;Brachytherapy Matter&#x201D;). In January 2012, the company reached a preliminary agreement with the civil and criminal divisions of the United States Attorney&#x2019;s Office for the Northern District of Georgia to resolve claims with respect to the Brachytherapy Matter and recorded a charge of approximately $51.0 million ($40.8 million after tax) in the fourth quarter of 2011. On May&#xA0;2, 2013, the company settled this matter. The resolution includes agreements with the government that required the company to pay approximately the amount that was previously recorded.</p> <p style="font-size:1px;margin-top:12px;margin-bottom:0px"> &#xA0;</p> <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> In December 2007, a U.S. District Court jury in Arizona found that certain of W.L. Gore&#xA0;&amp; Associates Inc.&#x2019;s (&#x201C;Gore&#x201D;) ePTFE vascular grafts and stent-grafts infringe the company&#x2019;s patent number 6,436,135 (the &#x201C;135 patent&#x201D;). The jury upheld the validity of the patent and awarded the company $185 million in past damages. The jury also found that Gore willfully infringed the patent. In a second phase of the trial, the District Court ruled that Gore failed to prove that the patent is unenforceable due to inequitable conduct. In March 2009, the District Court doubled the jury award to approximately $371 million for damages through June 2007. The District Court also awarded the company attorneys&#x2019; fees of $19 million and prejudgment interest of approximately $20 million. In addition, the District Court denied Gore&#x2019;s remaining motions, including its motions for a new trial and to set aside the jury&#x2019;s verdict. In July 2010, the District Court awarded the company approximately $109 million in additional damages for the period from July 2007 through March 2009. Gore has deposited or secured the foregoing amounts with the District Court. The District Court also assessed a royalty rate of between 12.5% and 20%, depending on the product, that will be used to calculate damages for Gore&#x2019;s infringing sales from April 2009 through the expiration of the patent. Gore has made additional deposits with the District Court of approximately $542&#xA0;million, representing Gore&#x2019;s calculation of royalties for its infringing sales through July 2013. Gore appealed this matter to the Court of Appeals for the Federal Circuit (the &#x201C;Court of Appeals&#x201D;), which on February&#xA0;10, 2012 affirmed the decision of the District Court. Gore filed a petition with the Court of Appeals for a rehearing of its appeal. On June&#xA0;14, 2012, the Court of Appeals reaffirmed its February&#xA0;10, 2012 decision, including the ongoing royalty rates as set by the District Court, with the exception of the issue of willfulness with respect to Gore&#x2019;s infringement of the 135 patent, which was remanded to the District Court. On October&#xA0;12, 2012, Gore filed a petition for a writ of certiorari to the U.S. Supreme Court requesting a review of the portion of the decision that the Court of Appeals reaffirmed. The U.S. Supreme Court denied Gore&#x2019;s petition on January&#xA0;14, 2013. The District Court heard oral argument on June&#xA0;5, 2013 as to three pending motions before it, including the company&#x2019;s motion to execute on the judgment with respect to all amounts other than enhanced damages due to willfulness. In October 2013, the District Court granted Bard&#x2019;s motion to execute on the judgment, denied Gore&#x2019;s motion requesting a determination that Gore&#x2019;s infringement was not willful and denied Gore&#x2019;s motion for a new trial. The District Court&#x2019;s rulings on the motions are subject to appeal. On January&#xA0;28, 2013, Gore filed with the U.S. District Court a Request for Judicial Notice that the U.S. Patent and Trademark Office (&#x201C;USPTO&#x201D;) granted Gore&#x2019;s previously filed request for a re-examination of the 135 patent. On April&#xA0;1, 2013, the USPTO issued a First Office Action initially rejecting all of the claims of the 135 patent that are the subject of the re-examination. On July&#xA0;10, 2013, the USPTO issued a Notice of Intent to Issue an <i>Ex Parte</i> Reexamination Certificate upholding the patentability of all re-examined claims of the 135 patent. This action terminated the re-examination proceeding and upheld the claims involved in the re-examination. The timing of final resolution of this litigation remains uncertain. Since the company considers these matters a gain contingency, no amounts have been recorded. Even if the company is ultimately successful in this lawsuit, it cannot give any assurances that royalties for Gore&#x2019;s future infringing sales will remain at or near historic levels.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> The company is subject to numerous federal, state, local and foreign environmental protection laws governing, among other things, the generation, storage, use and transportation of hazardous materials and emissions or discharges into the ground, air or water. The company is or may become a party to proceedings brought under various federal laws including the Comprehensive Environmental Response, Compensation and Liability Act (CERCLA), commonly known as Superfund, the Resource Conservation and Recovery Act, the Clean Water Act, the Clean Air Act and similar state or foreign laws. These proceedings seek to require the owners or operators of contaminated sites, transporters of hazardous materials to the sites and generators of hazardous materials disposed of at the sites to clean up the sites or to reimburse the government for cleanup costs. In most cases, there are other potentially responsible parties that may be liable for remediation costs. In these cases, the government alleges that the defendants are jointly and severally liable for the cleanup costs; however, these proceedings are frequently resolved so that the allocation of cleanup costs among the parties more closely reflects the relative contributions of the parties to the site contamination. The company&#x2019;s potential liability varies greatly from site to site. For some sites, the potential liability is de minimis and for others the costs of cleanup have not yet been determined. Accruals for estimated losses from environmental remediation obligations generally are recognized no later than completion of the remedial feasibility study and are adjusted as further information develops or circumstances change. Costs of future expenditures for environmental remediation obligations are not discounted to their present value. Recoveries of environmental remediation costs from other parties are recorded as assets when their receipt is deemed probable. The company believes that the proceedings and claims described above will likely be resolved over an extended period of time. While it is not feasible to predict the outcome of these proceedings, based upon the company&#x2019;s experience, current information and applicable law, the company does not expect these proceedings to have a material adverse effect on its financial condition and/or liquidity. However, one or more of the proceedings could be material to the company&#x2019;s business and/or results of operations.</p> <p style="font-size:1px;margin-top:18px;margin-bottom:0px"> &#xA0;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <i>Litigation Reserves</i></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> The company regularly monitors and evaluates the status of product liability and other legal matters, and may, from time-to-time, engage in settlement and mediation discussions taking into consideration developments in the matters and the risks and uncertainties surrounding litigation. These discussions could result in settlements of one or more of these claims at any time.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> The company evaluated the product liability matters discussed above under the heading &#x201C;Product Liability Matters&#x201D; based on information currently available, including: the allegations and documentation supporting or refuting such allegations; publicly available information regarding similar medical device mass tort settlements; historical information regarding other product liability settlements involving the company; and the procedural posture and stage of litigation. Based on these, and other factors, the company recorded a charge, net of estimated recoveries to other (income) expense, net, of approximately $293.0 million ($276.0 million after tax) in the second quarter of 2013, which recognized the estimated costs for certain of these product liability matters, including (with respect to such matters) asserted and unasserted claims, and costs to administer the settlements related to such matters. The charge excludes any costs associated with all but one putative class action lawsuit. The company cannot give any assurances that the actual costs incurred with respect to these product liability matters will not exceed the related amounts accrued. With respect to product liability claims that are not resolved through settlement, the company intends to vigorously defend against such claims, including through litigation. The company cannot give any assurances that the resolution of any of its product liability matters, including asserted and unasserted claims and the putative class action lawsuits, will not have a material adverse effect on the company&#x2019;s business, results of operations, financial condition and/or liquidity.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> Accruals for product liability and other legal matters amounted to $520.3 million and $158.1 million at September&#xA0;30, 2013 and December&#xA0;31, 2012, respectively. The company made total payments of $177.1&#xA0;million to qualified settlement funds (&#x201C;QSFs&#x201D;), of which $19.5 million were made during the nine months ended September&#xA0;30, 2013 subject to certain settlement conditions, for certain Hernia Product Claims. Payments to QSFs were recorded as a component of restricted cash. Total payments of $158.2&#xA0;million from these QSFs have been made to qualified claimants, of which $25.6 million were made during the nine months ended September&#xA0;30, 2013. In addition, other payments of $26.2 million have been made to qualified claimants, of which $15.6 million were made during the nine months ended September&#xA0;30, 2013.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> The company recorded receivables related to product liability matters amounting to $186.2 million and $45.6&#xA0;million at September&#xA0;30, 2013 and December&#xA0;31, 2012, respectively. A substantial amount of the receivable at September&#xA0;30, 2013 is the subject of a dispute with a supplier who has contested at least, in part, its obligation to defend and indemnify the company, which the company refutes. After considering the following factors (as appropriate): the nature of the claims, relevant contracts, relevant legal issues, the advice and judgment of outside legal counsel, and other pertinent factors, the company believes that it should collect these receivables.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> The company is unable to estimate the reasonably possible losses or range of losses, if any, arising from certain existing product liability matters and other legal matters. Under U.S. generally accepted accounting principles, an event is &#x201C;reasonably possible&#x201D; if &#x201C;the chance of the future event or events occurring is more than remote but less than likely&#x201D; and an event is &#x201C;remote&#x201D; if &#x201C;the chance of the future event or events occurring is slight&#x201D;. With respect to all putative class action lawsuits relating to product liability matters, the company is unable to estimate a range of reasonably possible losses for the following reasons: (i)&#xA0;all or certain of the proceedings are in early stages; (ii)&#xA0;the company has not received and reviewed complete information regarding all or certain of the plaintiffs and their medical conditions; and/or (iii)&#xA0;there are significant factual issues to be resolved. In addition, there is uncertainty as to the likelihood of a class being certified or the ultimate size of the class.</p> </div> <div> <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> The location and fair value of derivative instruments that are designated as hedging instruments recognized in the condensed consolidated balance sheets are as follows:</p> <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="84%" align="center"> <tr> <td width="51%"></td> <td valign="bottom" width="7%"></td> <td width="22%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" rowspan="2" align="center"> <p style="MARGIN-TOP: 0pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt" align="center"><b>Balance Sheet</b></p> <p style="MARGIN-TOP: 0pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 1pt; FONT-SIZE: 8pt" align="center"><b>Location</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Fair Value<br /> of&#xA0;Derivatives</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom" nowrap="nowrap"> <p style="BORDER-BOTTOM: #000000 1pt solid; WIDTH: 162pt; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <b>Derivatives Designated as Hedging Instruments</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>September&#xA0;30,<br /> 2013</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>December&#xA0;31,<br /> 2012</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom">(dollars in millions)</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Forward currency contracts</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Other&#xA0;current&#xA0;assets</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.7</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.4</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Option currency contracts</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Other current assets</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1.4</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.6</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Forward currency contracts</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Other assets</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.2</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Interest rate swap contract</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Other&#xA0;assets</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">9.8</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">13.3</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">13.1</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">15.3</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Forward currency contracts</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Accrued&#xA0;expenses</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.3</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.4</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Forward currency contracts</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> <font style="WHITE-SPACE: nowrap">Other&#xA0;long-term&#xA0;liabilities</font></p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.1</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"></td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.4</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.4</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> 1600000 2258200000 47300000 49800000 8200000 22300000 -1900000 89700000 22000000 35000000 -338600000 36200000 110700000 -700000 -10200000 2100000 29800000 -1600000 33500000 -6000000 1200000 546900000 1600000 3700000 34400000 7500000 -6300000 883800000 -16800000 2147500000 -500000 -415800000 44700000 106000000 97500000 -114600000 318200000 -1400000 666600000 88400000 -7900000 533400000 33700000 6000000 1400000 74400000 12300000 300000 0 30000000 9500000 44600000 -96700000 -107900000 -6600000 224800000 -9700000 400000 -3400000 P12M 17100000 6500000 <div> <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> At September&#xA0;30, 2013, the company&#x2019;s accounts receivable, net of allowances, from the national healthcare systems in these countries and amounts past due greater than 365 days are as follows:</p> <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"> <tr> <td width="68%"></td> <td valign="bottom" width="13%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="13%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Accounts<br /> receivable,&#xA0;net</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Greater&#xA0;than<br /> 365&#xA0;days&#xA0;past&#xA0;due</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom">(dollars in millions)</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Spain</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">23.0</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">4.8</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Italy</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">23.1</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2.4</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Greece</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">10.5</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3.2</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Portugal</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">4.0</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1.7</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">60.6</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">12.1</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> 1500000 636700000 625300000 574200000 358400000 63600000 2300000 1900000 1600000 300000 600000 400000 300000 0 0 6600000 -6600000 -10300000 0 -3700000 -700000 -700000 -700000 0 0 0 0 P5Y 19500000 -10200000 22600000 27000000 13700000 400000 14100000 1400000 1700000 -1100000 -3500000 3500000 0 600000 5100000 4100000 1000000 2018-09-26 1 50000000 15600000 19500000 25600000 2016 1496400000 123400000 356500000 281900000 4.70 4.64 84900000 1100000 427200000 83800000 -19100000 2195500000 55500000 49900000 0 401900000 0 132800000 394200000 0 -19000000 31600000 555100000 -24300000 -31600000 700000 384900000 5800000 14100000 -119600000 -21300000 372500000 2100000 34000000 -17000000 -4300000 837700000 12600000 1640400000 -4900000 -269800000 39000000 101400000 77000000 212700000 0 -1600000 604300000 153200000 -4700000 28900000 -2500000 1200000 70200000 22200000 7700000 10000000 2000000 10300000 39000000 -153900000 60000000 -5200000 150500000 -6900000 2200000 -2600000 15000000 9100000 1200000 601900000 633000000 562000000 333800000 64800000 5200000 3000000 2100000 900000 1100000 2200000 200000 0 0 5200000 -5200000 -8000000 0 -2800000 -24300000 -24300000 -24300000 0 0 0 0 17900000 -7800000 20800000 25300000 14600000 500000 -400000 1500000 2500000 -2500000 3000000 1100000 5000000 4000000 1000000 1469600000 122200000 349400000 254300000 1 24500000 25000000 P5Y 32500000 39400000 8600000 1 200000 0.0016 0.20 P7M6D 0.009 38.33 3600000 2000000 200000 0.0010 0.15 P7M6D 0.008 37.20 1 29500000 2000000 275000000 262000000 26200000 177100000 158200000 0.0042 P3Y P2Y10M17D 0.0081 0.0041 P2Y9M29D 0.0085 293000000 276000000 2 1.52 1.50 84600000 1200000 0.27 83400000 722900000 129300000 126900000 -13600000 178200000 14900000 146100000 100000 16800000 272600000 544700000 11500000 196600000 48900000 9700000 400000 2400000 11500000 -1800000 52200000 400000 203900000 202500000 188100000 107700000 20700000 6200000 -2800000 7000000 8500000 4900000 200000 -400000 600000 1000000 -1000000 0 200000 900000 1500000 -600000 483400000 41600000 108900000 89000000 1.17 1.15 80000000 1500000 0.22 P2Y 78500000 758000000 93200000 91600000 -12600000 119000000 8000000 102200000 -1200000 9000000 291900000 639000000 16200000 223900000 25800000 11200000 300000 1600000 16000000 -2200000 99400000 2 500000 215500000 209900000 193700000 118100000 20800000 6500000 -3400000 7500000 9000000 4600000 100000 1700000 -600000 -300000 300000 0 1 1 1 1100000 400000 -500000 900000 500300000 43400000 116700000 97600000 40800000 51000000 0000009892 bcr:BrachytherapyMatterMember 2011-10-01 2011-12-31 0000009892 bcr:OtherLocationMember 2013-07-01 2013-09-30 0000009892 us-gaap:EuropeMember 2013-07-01 2013-09-30 0000009892 country:JP 2013-07-01 2013-09-30 0000009892 country:US 2013-07-01 2013-09-30 0000009892 us-gaap:OptionMemberus-gaap:CashFlowHedgingMember 2013-07-01 2013-09-30 0000009892 us-gaap:ForwardContractsMemberus-gaap:CashFlowHedgingMember 2013-07-01 2013-09-30 0000009892 us-gaap:CashFlowHedgingMember 2013-07-01 2013-09-30 0000009892 bcr:MultiDistrictLitigationMemberbcr:WomenSHealthProductClaimsMember 2013-07-01 2013-09-30 0000009892 stpr:NJbcr:WomenSHealthProductClaimsMember 2013-07-01 2013-09-30 0000009892 us-gaap:ForwardContractsMemberbcr:OtherIncomeExpenseNetMember 2013-07-01 2013-09-30 0000009892 us-gaap:InterestRateSwapMemberus-gaap:InterestExpenseMember 2013-07-01 2013-09-30 0000009892 us-gaap:OptionMemberus-gaap:CashFlowHedgingMemberus-gaap:CostOfSalesMember 2013-07-01 2013-09-30 0000009892 us-gaap:ForwardContractsMemberus-gaap:CashFlowHedgingMemberus-gaap:CostOfSalesMember 2013-07-01 2013-09-30 0000009892 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2013-07-01 2013-09-30 0000009892 us-gaap:PensionPlansDefinedBenefitMember 2013-07-01 2013-09-30 0000009892 bcr:OtherProductGroupMember 2013-07-01 2013-09-30 0000009892 bcr:SurgicalSpecialtiesMember 2013-07-01 2013-09-30 0000009892 bcr:UrologyMember 2013-07-01 2013-09-30 0000009892 bcr:VascularMember 2013-07-01 2013-09-30 0000009892 bcr:OncologyMember 2013-07-01 2013-09-30 0000009892 2013-07-01 2013-09-30 0000009892 bcr:OtherLocationMember 2012-07-01 2012-09-30 0000009892 us-gaap:EuropeMember 2012-07-01 2012-09-30 0000009892 country:JP 2012-07-01 2012-09-30 0000009892 country:US 2012-07-01 2012-09-30 0000009892 us-gaap:OptionMemberus-gaap:CashFlowHedgingMember 2012-07-01 2012-09-30 0000009892 us-gaap:ForwardContractsMemberus-gaap:CashFlowHedgingMember 2012-07-01 2012-09-30 0000009892 us-gaap:CashFlowHedgingMember 2012-07-01 2012-09-30 0000009892 us-gaap:ForwardContractsMemberbcr:OtherIncomeExpenseNetMember 2012-07-01 2012-09-30 0000009892 us-gaap:InterestRateSwapMemberus-gaap:InterestExpenseMember 2012-07-01 2012-09-30 0000009892 us-gaap:OptionMemberus-gaap:CashFlowHedgingMemberus-gaap:CostOfSalesMember 2012-07-01 2012-09-30 0000009892 us-gaap:ForwardContractsMemberus-gaap:CashFlowHedgingMemberus-gaap:CostOfSalesMember 2012-07-01 2012-09-30 0000009892 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2012-07-01 2012-09-30 0000009892 us-gaap:PensionPlansDefinedBenefitMember 2012-07-01 2012-09-30 0000009892 bcr:OtherProductGroupMember 2012-07-01 2012-09-30 0000009892 bcr:SurgicalSpecialtiesMember 2012-07-01 2012-09-30 0000009892 bcr:UrologyMember 2012-07-01 2012-09-30 0000009892 bcr:VascularMember 2012-07-01 2012-09-30 0000009892 bcr:OncologyMember 2012-07-01 2012-09-30 0000009892 2012-07-01 2012-09-30 0000009892 bcr:StateLawClaimsMemberbcr:FilterProductClaimsMember 2013-04-01 2013-06-30 0000009892 2013-04-01 2013-06-30 0000009892 bcr:PerformanceRestrictedStockUnitsMember 2012-01-01 2012-03-31 0000009892 bcr:PerformanceRestrictedStockUnitsMember 2013-01-01 2013-03-31 0000009892 bcr:HerniaProductClaimsMember 2012-01-01 2013-09-30 0000009892 bcr:RochesterMedicalIncMember 2013-08-01 2013-09-04 0000009892 2013-05-28 2013-06-27 0000009892 bcr:TwoThousandTwelveLongTermIncentivePlanMember 2013-03-18 2013-04-17 0000009892 us-gaap:TechnologyBasedIntangibleAssetsMember 2013-07-30 2013-08-29 0000009892 bcr:StateLawClaimsMemberbcr:FilterProductClaimsMember 2013-07-01 2013-07-31 0000009892 bcr:ManagementStockPurchaseProgramMember 2013-07-01 2013-07-31 0000009892 bcr:MultiDistrictLitigationMemberbcr:WomenSHealthProductClaimsMember 2013-07-01 2013-07-31 0000009892 bcr:WomenSHealthProductClaimsMember 2012-07-01 2012-07-31 0000009892 bcr:ManagementStockPurchaseProgramMember 2012-07-01 2012-07-31 0000009892 bcr:HerniaProductClaimsMember 2007-06-01 2007-06-30 0000009892 bcr:LomaVistaMedicalIncMember 2013-07-01 2013-07-29 0000009892 bcr:FiveYearCreditFacilityExpiringInOctoberTwoThousandSixteenMember 2013-08-30 2013-09-26 0000009892 bcr:ArbitrationProceedingsMemberbcr:HerniaProductClaimsMember 2013-02-28 2013-03-27 0000009892 bcr:OtherLocationMember 2012-01-01 2012-09-30 0000009892 us-gaap:EuropeMember 2012-01-01 2012-09-30 0000009892 country:JP 2012-01-01 2012-09-30 0000009892 country:US 2012-01-01 2012-09-30 0000009892 us-gaap:OptionMemberus-gaap:CashFlowHedgingMember 2012-01-01 2012-09-30 0000009892 us-gaap:ForwardContractsMemberus-gaap:CashFlowHedgingMember 2012-01-01 2012-09-30 0000009892 us-gaap:CashFlowHedgingMember 2012-01-01 2012-09-30 0000009892 us-gaap:ForwardContractsMemberbcr:OtherIncomeExpenseNetMember 2012-01-01 2012-09-30 0000009892 us-gaap:InterestRateSwapMemberus-gaap:InterestExpenseMember 2012-01-01 2012-09-30 0000009892 us-gaap:OptionMemberus-gaap:CashFlowHedgingMemberus-gaap:CostOfSalesMember 2012-01-01 2012-09-30 0000009892 us-gaap:ForwardContractsMemberus-gaap:CashFlowHedgingMemberus-gaap:CostOfSalesMember 2012-01-01 2012-09-30 0000009892 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2012-01-01 2012-09-30 0000009892 us-gaap:PensionPlansDefinedBenefitMember 2012-01-01 2012-09-30 0000009892 us-gaap:AccumulatedTranslationAdjustmentMember 2012-01-01 2012-09-30 0000009892 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2012-01-01 2012-09-30 0000009892 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2012-01-01 2012-09-30 0000009892 bcr:OtherProductGroupMember 2012-01-01 2012-09-30 0000009892 bcr:SurgicalSpecialtiesMember 2012-01-01 2012-09-30 0000009892 bcr:UrologyMember 2012-01-01 2012-09-30 0000009892 bcr:VascularMember 2012-01-01 2012-09-30 0000009892 bcr:OncologyMember 2012-01-01 2012-09-30 0000009892 2012-01-01 2012-09-30 0000009892 bcr:OtherLocationMember 2013-01-01 2013-09-30 0000009892 us-gaap:EuropeMember 2013-01-01 2013-09-30 0000009892 country:JP 2013-01-01 2013-09-30 0000009892 country:US 2013-01-01 2013-09-30 0000009892 us-gaap:InterestRateSwapMember 2013-01-01 2013-09-30 0000009892 bcr:HerniaProductClaimsMember 2013-01-01 2013-09-30 0000009892 bcr:WomenSHealthProductClaimsMember 2013-01-01 2013-09-30 0000009892 bcr:FiveYearCreditFacilityExpiringInSeptemberTwoThousandEighteenMember 2013-01-01 2013-09-30 0000009892 us-gaap:OptionMemberus-gaap:CashFlowHedgingMember 2013-01-01 2013-09-30 0000009892 us-gaap:ForwardContractsMemberus-gaap:CashFlowHedgingMember 2013-01-01 2013-09-30 0000009892 us-gaap:CashFlowHedgingMember 2013-01-01 2013-09-30 0000009892 us-gaap:ForwardContractsMemberbcr:OtherIncomeExpenseNetMember 2013-01-01 2013-09-30 0000009892 us-gaap:InterestRateSwapMemberus-gaap:InterestExpenseMember 2013-01-01 2013-09-30 0000009892 us-gaap:OptionMemberus-gaap:CashFlowHedgingMemberus-gaap:CostOfSalesMember 2013-01-01 2013-09-30 0000009892 us-gaap:ForwardContractsMemberus-gaap:CashFlowHedgingMemberus-gaap:CostOfSalesMember 2013-01-01 2013-09-30 0000009892 bcr:TwoThousandTwelveRestructuringPlanMember 2013-01-01 2013-09-30 0000009892 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2013-01-01 2013-09-30 0000009892 us-gaap:PensionPlansDefinedBenefitMember 2013-01-01 2013-09-30 0000009892 us-gaap:MaximumMember 2013-01-01 2013-09-30 0000009892 us-gaap:AccumulatedTranslationAdjustmentMember 2013-01-01 2013-09-30 0000009892 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2013-01-01 2013-09-30 0000009892 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2013-01-01 2013-09-30 0000009892 bcr:OtherProductGroupMember 2013-01-01 2013-09-30 0000009892 bcr:SurgicalSpecialtiesMember 2013-01-01 2013-09-30 0000009892 bcr:UrologyMember 2013-01-01 2013-09-30 0000009892 bcr:VascularMember 2013-01-01 2013-09-30 0000009892 bcr:OncologyMember 2013-01-01 2013-09-30 0000009892 2013-01-01 2013-09-30 0000009892 bcr:MedaforIncMemberbcr:UpFrontPaymentMemberus-gaap:SubsequentEventMember 2013-09-05 2013-10-01 0000009892 bcr:StateLawClaimsMemberbcr:FilterProductClaimsMemberus-gaap:SubsequentEventMember 2013-09-27 2013-10-17 0000009892 bcr:FilterProductClaimsMemberus-gaap:SubsequentEventMember 2013-09-27 2013-10-17 0000009892 bcr:HerniaProductClaimsMemberus-gaap:SubsequentEventMember 2013-09-27 2013-10-17 0000009892 bcr:WomenSHealthProductClaimsMemberus-gaap:SubsequentEventMember 2013-09-27 2013-10-17 0000009892 bcr:SuperiorCourtOfStateOfRhodeIslandMemberbcr:HerniaProductClaimsMemberus-gaap:SubsequentEventMember 2013-09-27 2013-10-17 0000009892 bcr:StateLawClaimsMemberbcr:FilterProductClaimsMemberus-gaap:MinimumMemberus-gaap:SubsequentEventMember 2013-09-27 2013-10-17 0000009892 bcr:HerniaProductClaimsMembercountry:CAus-gaap:SubsequentEventMember 2013-09-27 2013-10-17 0000009892 bcr:WomenSHealthProductClaimsMembercountry:CAus-gaap:SubsequentEventMember 2013-09-27 2013-10-17 0000009892 bcr:HerniaProductClaimsMembercountry:USus-gaap:SubsequentEventMember 2013-09-27 2013-10-17 0000009892 bcr:WomenSHealthProductClaimsMembercountry:USus-gaap:SubsequentEventMember 2013-09-27 2013-10-17 0000009892 us-gaap:FairValueInputsLevel2Member 2012-12-31 0000009892 us-gaap:ForeignExchangeOptionMember 2012-12-31 0000009892 bcr:TotalReceivablesRelatedToProductLiabilityMattersMember 2012-12-31 0000009892 us-gaap:OtherCurrentAssetsMemberus-gaap:OptionMemberus-gaap:DesignatedAsHedgingInstrumentMember 2012-12-31 0000009892 us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:ForwardContractsMemberus-gaap:DesignatedAsHedgingInstrumentMember 2012-12-31 0000009892 us-gaap:OtherCurrentAssetsMemberus-gaap:ForwardContractsMemberus-gaap:DesignatedAsHedgingInstrumentMember 2012-12-31 0000009892 us-gaap:AccruedLiabilitiesMemberus-gaap:ForwardContractsMemberus-gaap:DesignatedAsHedgingInstrumentMember 2012-12-31 0000009892 us-gaap:OtherAssetsMemberus-gaap:ForwardContractsMemberus-gaap:DesignatedAsHedgingInstrumentMember 2012-12-31 0000009892 us-gaap:OtherAssetsMemberus-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember 2012-12-31 0000009892 us-gaap:DesignatedAsHedgingInstrumentMember 2012-12-31 0000009892 us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember 2012-12-31 0000009892 us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OptionMember 2012-12-31 0000009892 us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForwardContractsMember 2012-12-31 0000009892 us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:InterestRateSwapMember 2012-12-31 0000009892 us-gaap:AccumulatedTranslationAdjustmentMember 2012-12-31 0000009892 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2012-12-31 0000009892 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2012-12-31 0000009892 2012-12-31 0000009892 us-gaap:AccumulatedTranslationAdjustmentMember 2011-12-31 0000009892 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2011-12-31 0000009892 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2011-12-31 0000009892 2011-12-31 0000009892 bcr:WLGoreMember 2007-12-31 0000009892 bcr:FederalLawClaimsMemberbcr:HerniaProductClaimsMemberus-gaap:SubsequentEventMember 2013-10-17 0000009892 bcr:StateLawClaimsMemberbcr:HerniaProductClaimsMemberus-gaap:SubsequentEventMember 2013-10-17 0000009892 bcr:StateLawClaimsMemberbcr:SuperiorCourtOfStateOfRhodeIslandMemberbcr:HerniaProductClaimsMemberus-gaap:SubsequentEventMember 2013-10-17 0000009892 bcr:HerniaProductClaimsMembercountry:USus-gaap:SubsequentEventMember 2013-10-17 0000009892 bcr:MedaforIncMemberus-gaap:SubsequentEventMember 2013-10-01 0000009892 country:GR 2013-09-30 0000009892 country:ES 2013-09-30 0000009892 country:IT 2013-09-30 0000009892 country:PT 2013-09-30 0000009892 us-gaap:FairValueInputsLevel2Member 2013-09-30 0000009892 us-gaap:ForeignExchangeOptionMember 2013-09-30 0000009892 us-gaap:InterestRateSwapMember 2013-09-30 0000009892 bcr:TotalReceivablesRelatedToProductLiabilityMattersMember 2013-09-30 0000009892 bcr:FiveYearCreditFacilityExpiringInSeptemberTwoThousandEighteenMember 2013-09-30 0000009892 bcr:DirectorsPlanMember 2013-09-30 0000009892 bcr:TwoThousandTwelveLongTermIncentivePlanMember 2013-09-30 0000009892 us-gaap:OtherCurrentAssetsMemberus-gaap:OptionMemberus-gaap:DesignatedAsHedgingInstrumentMember 2013-09-30 0000009892 us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:ForwardContractsMemberus-gaap:DesignatedAsHedgingInstrumentMember 2013-09-30 0000009892 us-gaap:OtherCurrentAssetsMemberus-gaap:ForwardContractsMemberus-gaap:DesignatedAsHedgingInstrumentMember 2013-09-30 0000009892 us-gaap:AccruedLiabilitiesMemberus-gaap:ForwardContractsMemberus-gaap:DesignatedAsHedgingInstrumentMember 2013-09-30 0000009892 us-gaap:OtherAssetsMemberus-gaap:ForwardContractsMemberus-gaap:DesignatedAsHedgingInstrumentMember 2013-09-30 0000009892 us-gaap:OtherAssetsMemberus-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember 2013-09-30 0000009892 us-gaap:DesignatedAsHedgingInstrumentMember 2013-09-30 0000009892 us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember 2013-09-30 0000009892 us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OptionMember 2013-09-30 0000009892 us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForwardContractsMember 2013-09-30 0000009892 us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:InterestRateSwapMember 2013-09-30 0000009892 bcr:TwoThousandTwelveRestructuringPlanMember 2013-09-30 0000009892 us-gaap:AccumulatedTranslationAdjustmentMember 2013-09-30 0000009892 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2013-09-30 0000009892 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2013-09-30 0000009892 2013-09-30 0000009892 bcr:FiveYearCreditFacilityExpiringInOctoberTwoThousandSixteenMember 2013-09-26 0000009892 bcr:RochesterMedicalIncMember 2013-09-04 0000009892 us-gaap:AccumulatedTranslationAdjustmentMember 2012-09-30 0000009892 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2012-09-30 0000009892 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2012-09-30 0000009892 2012-09-30 0000009892 bcr:LomaVistaMedicalIncMemberbcr:CoreTechnologiesMember 2013-07-29 0000009892 bcr:LomaVistaMedicalIncMemberus-gaap:InProcessResearchAndDevelopmentMember 2013-07-29 0000009892 bcr:LomaVistaMedicalIncMember 2013-07-29 0000009892 bcr:WLGoreMember 2009-03-31 0000009892 bcr:PrejudgmentInterestMemberbcr:WLGoreMember 2009-03-31 0000009892 bcr:AttorneyFeesMemberbcr:WLGoreMember 2009-03-31 0000009892 us-gaap:TechnologyBasedIntangibleAssetsMember 2013-08-29 0000009892 bcr:WLGoreMember 2013-07-31 0000009892 bcr:WLGoreMember 2010-07-31 0000009892 bcr:WLGoreMemberus-gaap:MaximumMember 2010-07-31 0000009892 bcr:WLGoreMemberus-gaap:MinimumMember 2010-07-31 pure iso4217:USD iso4217:USD shares shares bcr:LegalMatter bcr:Plaintiff bcr:Carriers bcr:CompensationPlan bcr:Claim Income taxes are not provided for foreign currency translation adjustment. Beginning in 2013, certain emerging markets in Europe are included in the "other" geographic region. Prior year amounts have been reclassified to conform to the current year presentation. These derivative contracts mitigate changes in the value of remeasured foreign currency denominated intercompany loans attributable to changes in foreign currency exchange rates. See Note 6 of the notes to condensed consolidated financial statements. These components are included in the computation of net periodic pension cost. See Note 10 of the notes to condensed consolidated financial statements. EX-101.SCH 10 bcr-20130930.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 103 - Statement - Condensed Consolidated Statements Of Income link:calculationLink link:presentationLink link:definitionLink 104 - Statement - Condensed Consolidated Statements of Comprehensive Income link:calculationLink link:presentationLink link:definitionLink 105 - Statement - Condensed Consolidated Balance Sheets link:calculationLink link:presentationLink link:definitionLink 106 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 107 - Statement - Condensed Consolidated Statements Of Cash Flows link:calculationLink link:presentationLink link:definitionLink 108 - Disclosure - Basis of Presentation link:calculationLink link:presentationLink link:definitionLink 109 - Disclosure - Acquisitions and Divestiture link:calculationLink link:presentationLink link:definitionLink 110 - Disclosure - Restructuring link:calculationLink link:presentationLink link:definitionLink 111 - Disclosure - Earnings per Common Share link:calculationLink link:presentationLink link:definitionLink 112 - Disclosure - Income Taxes link:calculationLink link:presentationLink link:definitionLink 113 - Disclosure - Financial Instruments link:calculationLink link:presentationLink link:definitionLink 114 - Disclosure - Inventories link:calculationLink link:presentationLink link:definitionLink 115 - Disclosure - Contingencies link:calculationLink link:presentationLink link:definitionLink 116 - Disclosure - Share-Based Compensation Plans link:calculationLink link:presentationLink link:definitionLink 117 - Disclosure - Pension and Other Postretirement Benefit Plans link:calculationLink link:presentationLink link:definitionLink 118 - Disclosure - Shareholders' Investment link:calculationLink link:presentationLink link:definitionLink 119 - Disclosure - Segment Information link:calculationLink link:presentationLink link:definitionLink 120 - Disclosure - Acquisitions and Divestiture (Tables) link:calculationLink link:presentationLink link:definitionLink 121 - Disclosure - Earnings per Common Share (Tables) link:calculationLink link:presentationLink link:definitionLink 122 - Disclosure - Financial Instruments (Tables) link:calculationLink link:presentationLink link:definitionLink 123 - Disclosure - Inventories (Tables) link:calculationLink link:presentationLink link:definitionLink 124 - Disclosure - Share-Based Compensation Plans (Tables) link:calculationLink link:presentationLink link:definitionLink 125 - Disclosure - Pension and Other Postretirement Benefit Plans (Tables) link:calculationLink link:presentationLink link:definitionLink 126 - Disclosure - Shareholders' Investment (Tables) link:calculationLink link:presentationLink link:definitionLink 127 - Disclosure - Segment Information (Tables) link:calculationLink link:presentationLink link:definitionLink 128 - Disclosure - Acquisitions and Divestiture - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 129 - Disclosure - Assets and Liabilities Held for Sale Associated with Electrophysiology Division (Detail) link:calculationLink link:presentationLink link:definitionLink 130 - Disclosure - Restructuring - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 131 - Disclosure - Earnings Per Share Computation (Detail) link:calculationLink link:presentationLink link:definitionLink 132 - Disclosure - Income Taxes - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 133 - Disclosure - Financial Instruments - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 134 - Disclosure - Location and Fair Value of Derivative Instruments Designated as Hedging Instruments (Detail) link:calculationLink link:presentationLink link:definitionLink 135 - Disclosure - Location and Amounts of Gains and Losses on Derivative Instruments Designated as Cash Flow Hedges (Detail) link:calculationLink link:presentationLink link:definitionLink 136 - Disclosure - Location and Amounts of Gains and Losses on Derivative Instrument Designated as Fair Value Hedge (Detail) link:calculationLink link:presentationLink link:definitionLink 137 - Disclosure - Location and Amounts of Gains on Derivative Instruments Not Designated as Hedging Instruments (Detail) link:calculationLink link:presentationLink link:definitionLink 138 - Disclosure - Financial Instrument Assets and (Liabilities) Measured at Fair Value on Recurring Basis (Detail) link:calculationLink link:presentationLink link:definitionLink 139 - Disclosure - Accounts Receivable, Net of Allowances (Detail) link:calculationLink link:presentationLink link:definitionLink 140 - Disclosure - Inventories (Detail) link:calculationLink link:presentationLink link:definitionLink 141 - Disclosure - Contingencies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 142 - Disclosure - Share-Based Compensation Plans - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 143 - Disclosure - Amounts Recognized for Share-Based Compensation (Detail) link:calculationLink link:presentationLink link:definitionLink 144 - Disclosure - Components of Net Periodic Pension Cost (Detail) link:calculationLink link:presentationLink link:definitionLink 145 - Disclosure - Pension and Other Postretirement Benefit Plans - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 146 - Disclosure - Shareholders' Investment - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 147 - Disclosure - Changes in Accumulated Other Comprehensive Income (Loss) By Component (Detail) link:calculationLink link:presentationLink link:definitionLink 148 - Disclosure - Net Sales Based On Location of External Customers by Geographic Region (Detail) link:calculationLink link:presentationLink link:definitionLink 149 - Disclosure - Total Net Sales by Product Group Category (Detail) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 11 bcr-20130930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 12 bcr-20130930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 13 bcr-20130930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE EX-101.PRE 14 bcr-20130930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 15 R17.htm IDEA: XBRL DOCUMENT v2.4.0.8
Shareholders' Investment
9 Months Ended
Sep. 30, 2013
Shareholders' Investment

11. Shareholders’ Investment

The company repurchased approximately 5.2 million shares of common stock for $533.4 million in the nine months ended September 30, 2013 under its previously announced share repurchase authorizations.

Other Comprehensive Income (Loss)

During the first quarter of 2013, the company adopted new Financial Accounting Standards Board guidance that requires the company to present information about reclassification adjustments from accumulated other comprehensive loss. Under this guidance, the company presents the effect of amounts reclassified from each component of accumulated other comprehensive loss based on its source.

The changes in accumulated other comprehensive income (loss) by component are as follows:

 

    Derivative
Instruments
Designated as
Cash Flow Hedges
    Foreign Currency
Translation
    Benefit
Plans
    Total  
(dollars in millions)                        

Balance at December 31, 2011

  $ (1.4   $ 41.1      $ (106.3   $ (66.6

Other comprehensive income (loss) before reclassifications

    5.2        (24.3     —          (19.1

Tax (provision) benefit related to other comprehensive income (loss) before reclassifications(a)

    (2.2     —          —          (2.2
 

 

 

   

 

 

   

 

 

   

 

 

 

Other comprehensive income (loss) before reclassifications, net of taxes

    3.0        (24.3     —          (21.3
 

 

 

   

 

 

   

 

 

   

 

 

 

Amounts reclassified from accumulated other comprehensive income (loss)

    (1.1 )(b)      —          8.0 (c)      6.9   

Tax provision (benefit) related to amounts reclassified from accumulated other comprehensive income (loss)

    0.2        —          (2.8     (2.6
 

 

 

   

 

 

   

 

 

   

 

 

 

Reclassifications, net of tax

    (0.9     —          5.2        4.3   
 

 

 

   

 

 

   

 

 

   

 

 

 

Other comprehensive income (loss)

    2.1        (24.3     5.2        (17.0
 

 

 

   

 

 

   

 

 

   

 

 

 

Balance at September 30, 2012

  $ 0.7      $ 16.8      $ (101.1   $ (83.6
 

 

 

   

 

 

   

 

 

   

 

 

 

Balance at December 31, 2012

  $ (0.7   $ 32.6      $ (113.1   $ (81.2

Other comprehensive income (loss) before reclassifications

    2.3        (0.7     —          1.6   

Tax (provision) benefit related to other comprehensive income (loss) before reclassifications(a)

    (0.4     —          —          (0.4
 

 

 

   

 

 

   

 

 

   

 

 

 

Other comprehensive income (loss) before reclassifications, net of taxes

    1.9        (0.7     —          1.2   
 

 

 

   

 

 

   

 

 

   

 

 

 

Amounts reclassified from accumulated other comprehensive income (loss)

    (0.6 )(b)      —          10.3 (c)      9.7   

Tax provision (benefit) related to amounts reclassified from accumulated other comprehensive income (loss)

    0.3        —          (3.7     (3.4
 

 

 

   

 

 

   

 

 

   

 

 

 

Reclassifications, net of tax

    (0.3     —          6.6        6.3   
 

 

 

   

 

 

   

 

 

   

 

 

 

Other comprehensive income (loss)

    1.6        (0.7     6.6        7.5   
 

 

 

   

 

 

   

 

 

   

 

 

 

Balance at September 30, 2013

  $ 0.9      $ 31.9      $ (106.5   $ (73.7
 

 

 

   

 

 

   

 

 

   

 

 

 

 

(a) Income taxes are not provided for foreign currency translation adjustment.
(b) See Note 6 of the notes to condensed consolidated financial statements.
(c) These components are included in the computation of net periodic pension cost. See Note 10 of the notes to condensed consolidated financial statements.
EXCEL 16 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0`!@`(````(0#A_+]<%@(``"\>```3``@"6T-O;G1E;G1?5'EP97-= M+GAM;""B!`(HH``"```````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````#,F4]OTS`8QN](?(?(5]2X M_L,8J.T.`XXPB?$!3/*VB9K8ENV-]MOCI%LU3:55126>2Z,F]OO\XL/OD&=V ML^F[XI%";)V=,U%.64&V/MF=K_U M%(N\V\8Y:U+RGSB/54.]B:7S9/.3I0N]2?EO6'%OJK59$9?3Z16OG$UDTR0- M,]AB]IF6YJ%+Q9=-OKTC"=1%5MSN%@Y9.: MV+0^OLL8C!],&)[\/>!IW_=\-*&MJ;@S(7TS?<;@FX[_=F']R[EU>7S(`4JW M7+85U:YZZ/,)E-$',G5LB%+?E>.U[$UKG[F/Y(^+(Q\OXL(@P_N-@\_DD"`< M"H1#@W"\!^&X`N'X`,)Q#<+Q$81#3%%`4(PJ4)0J4)PJ4*0J4*PJ4+0J4+PJ M4,0J4,PJ4P3')7I MJMLF-V@7/H3]W&/YN=:["\['7'`&.A_@N<$<=D]\'D0AM;3O,`]U@?O$7(Z> M'_BJC*2A?JVI/I#-Q[IW\0<``/__`P!02P,$%``&``@````A`+55,"/U```` M3`(```L`"`)?]=J>*V?5@^@8B)G:13'&HX<85?=WFQ? M>*24FV+7^ZBRBXL:NI3\(V(T'4\4"_'L)MI<3_3_MCAQ(DN)T$C@\SS?BG-`Z^N!+I]HJ?B]SCSB MIX3A363X8<'%#U1?````__\#`%!+`P04``8`"````"$`S4_#WD4"``!T'0`` M&@`(`7AL+U]R96QS+W=O=^5WP/ M0]SV765D-C=%Z.J^V7:;RGQ]^71S9XJ8?-?X7=^%RAQ#-(^K]^\>/H>=3_E+ ML=T>8I%7Z6)EVI0.'\HRUFW8^SCK#Z'+3];]L/?#UJ]^$4N?S93E< MKF%6;]8LGIO*#,^-6%.\'`]YZ_\OWJ_7VSI\[.MO^]"EO^Q1_NB'U]B&D/*B M?MB$5)EQ*I:G)V)G6;,I_R$GGP=7SAV2HTNR'%TB.?:>+,?>(SDJ9#DJ2(YU M9#G6(3E.R7*<0CFW;#FW2,XBDW"Z0H_IN,OD'*'S>XSV9Y\&/`RV4Z!1A,T\ M@X5]M$(M(M.:I+FT;:!MA$U`@ M`85-0($$5#9R%"+'TJT#O6/916YAE3OV7`54P-; M#13#-L[HF_+-?Z6K7P```/__`P!02P,$%``&``@````A`)M"SHJ`!```T@X` M``\```!X;"]W;W)K8F]O:RYX;6R4EUMSVCH4A=_/3/\#X_<6?`&:3$B'W-K, M=%JFX:2/&L466%-;XEAR2/KKS[(=S+9%&?H$PFAY[Z5O;TD7GU[R;/`L"B.U MFGG^AY$W$"K6B53KF??O\N[]1V]@+%<)S[02,^]5&._3Y;M_+K:Z^/6D]:\! M!)29>:FUF_/AT,2IR+GYH#="XK62L;C1<9D+91N10F3<(GR3RHWQ+B]6,A./348#OME\XSGB?LF\ M0<:-O4VD%E9.`J]X66;Y*(8)&+%R\PND=Y.'7X% M41!,JG]65CQ*L37[2=5P\/)3JD1OJ[_"VM=V%"*`;?WHITQLBN>CT:C][8N0 MZ]3N?H3\D.C7#N(]]>=`U>GM'&%8*7:KK+2O[%XU[DN-):Q)7P5.5:ZU2H0R(F'X9G0F$PZSV(/%1RZ(2D!4@K]300!M,"&1J?T^(9@K MGG$5TV"B,R(3G1C-FPR-9HP%:KT9GZCSY@T,:;.:$)F:#9K5%3?2,+UBBT(8 M(%R32R:/Z0)-^T',X_]*:61->[W4-_(9#$M;%M21,5V?CWV1'YA1E#'FH,CI MJ^ERG/5GW?)"X?^&;40!//)<*_:0\NY[(Y*Z/^I+W*.QY((M^0N:R-ZO,;!O M??<=*.^DPH)+G@'H*O"J\#O3J=^^0^.]>L8$74-M_![4&LJPFDDZ!;[SFGE/D.9L=894NJ M0[GS3PB&#@H'L6#T4PH MG8%#YW$^:$N;4%Z#P[RZ@!Q(C`(;.,`>X,35F%)8FTV3-L:CN,R).5/*;.`P M.S=&6%/7SE?)GV2&;BD,^R*RA*WH3AATO''P[71)-D]P;D!-UET(VRJ))^AX M\V=\%ZCCFH"J>VY*I_.'U!\,>OC2YNF$DY-X0NH/!CV=PV6PRX_H3&EYAP[, M7W7<-+?JQ'''9<$>>5:*:FN[$=2?*2WOT(&YHS//=8GN7HE\QM'0T*((:7EC MT,OKN`XMBNKHU39Q#/Y*"*:T#2>DY8Y!3^B0TZS%D^A,.YFY1,=QX\H/$0OY MC*8GV#=A*Y/F&6V`TTYB#M&T==T(RR6=&U**,>CE@O/@?D-T\*.Y4$\BA^+C M+9"NTI3VP,C!>$<*/-%K)7]CRT59-@5VQ4E`$<48`R>Q?(.+S1MTE:VH4XG[ M3XPO=+>+*,88]'2.]V1*3417&X.>T!\V[3?/:6)TM2,'X^N4XP!CF%1L'N.Z M5.*2!).:\\0UU>FLF$-Q9(( MK!.<0]GG@O;EB/9E#.#/L"XY7'EBGL6XBU4?]64F&D^:+7JXNXY>_@\``/__ M`P!02P,$%``&``@````A`!ZWJRE5!@``C1L``!@```!X;"]W;W)K2W$ ML@Q)FTW^OD/.K,T9VE[K)5E+1\/#F>$YE/CP\7N[][[5_=!TAZ6O9H'OU8>J MVS2'YZ7_S]]?/N2^-XSE85/NNT.]]'_4@__Q\>>?'EZ[_NNPJ^O1@PB'8>GO MQO&XF,^':E>WY3#KCO4![FR[OBU'^-D_SX=C7Y<;\U"[GX=!D,[;LCGX&&'1 MWQ.CVVZ;JO[<52]M?1@Q2%_ORQ'X#[OF.+Q%:ZM[PK5E__7E^*'JVB.$>&KV MS?C#!/6]MEK\]GSH^O)I#_/^KN*R>HMM?CCAVZ;JNZ';CC,(-T>B[IR+>3&' M2(\/FP9FH-/N]?5VZ7]2BW4<^//'!Y.@?YOZ=;#^]H9=]_I+WVQ^;PXU9!OJ MI"OPU'5?-?2WC;X$#\^=I[^8"OS9>YMZ6[[LQ[^ZUU_KYGDW0KD3F)&>V&+S MXW,]5)!1"#,+$QVIZO9``/[UVD:W!F2D_&[^?VTVXV[I1^DLR8)(`=Q[JH?Q M2Z-#^E[U,HQ=^Q^"%(7"("$%B8`]W0]G89ZH)'T_RAP9F0E^+L?R\:'O7CWH M&AAS.):Z!]4"(NN919"?RS.#*>EG/NF'S*.`'J`W]&-%@0*_BX*X2DAI@J`FM84ZJU?3],[/N,5LIIW=?-^B%.+Q%I M62$$Z<5)"@0X_S4#Y`',X`1@!&%!W)\W#1;$U"DLMC!"D%@4A2LCY[3(:M*#E MZ#C*-&4L2Y0M"42,0?(X@]W):7*LFDH+[-U=9M""WMDAS-@KPB"]-$GL1B)V M*.J$B+2X7"&G1=@B=Y]X*)1N6W43*?>$H=(6B;M*.2*[OA[4)$D;.=H4B5W0"< MG/"&=Y:&:PJI&'JEN.B'%Y:LC4@"YAN'IF:RA3^,PZO6J=\_;>M\)V^N M\*=2^$W$I8_DE(HOU-,6?A5E=FIYYB8)?^@*?R86V8HP2"ZW!Z:\V;*O`OLM MBS.;I/JAJ_J95'W"4$U=S:?[MQ?!)+D/7;G/I-P3!EDEP86]+4/$<68SYRF; M)/BA*_B9%'S"4*?%W*2IGK;BJS@HKM+3GT[N7P@&S04DDYI/&*2711=>V1DB MBMDVA.4NFJ3X!BW(2<4G#.4NMS>&F#D&T+O:\U+BU";Y0>3Z02;]@#"@8"?# MRH0XKV]C.,%)SA#A2X'MEIF47\)8;FE?X8,+[==O)C'(WVV9C5P/R*3,$D;J M`14/`\B;G)I0?DTM>Y\::K=M3_FY,\SHJP@QU%N%:P`,$`;V[IM3G*3_D:O_ MN519PA"U-`8'$.S7'`+;,'MM<'K"!.Y[[8Q<,\BE[!(&:7[("]N'J,(8!1%Q M%ME;`$Y2>,*=)%UOR*7\1H@ADEET@21#Y.HZR4G>$+G>D#OBRX0?G,M]&Z`P MU`M%"%_US[W`<@@'%,P;[LNA>8K+<"YEF##X6??R>X&`7'HOP-,//!QHZ_ZY M7M?[_>!5W8L^V0CAL]/I*IZZK-1B%>IOV.+Z&DYCS/7YZ08CQ.`5_C-W1?+-_ZD8X!C%_[N#8JX:/\\$,P-NN&]]^Z`.; MTT':X_\```#__P,`4$L#!!0`!@`(````(0`^!&\;+`,``'D)```9````>&PO M=V]R:W-H965T?OZT/C'^*"I"I`<,K=CX ME93=*@Q%7I$&BX!UI(65DO$&2WCEAU!TG.!".S5U&$?1(FPP;7W#L.(?X6!E M27-RQ_)C0UII2#BIL03]HJ*=.+,U^4?H&LP?C]U5SIH.*/:TIO)%D_I>DZ\> M#BWC>%]#W,\HP?F96[]>-_K M"OS@7D%*?*SE3W;Z2NBADE#N.42D`EL5+W=$Y)!1H`GBN6+*60T"X-MKJ&H- MR`A^UK\G6LAJX\\6P7P9S1#`O3T1\IXJ2M_+CT*RYJ\!Z8@&DK@GF8'Z?CT. MXG2.YHMIEM`HT@'>88FW:\Y.'G0-["DZK'H0K8!91;9\,S((2?G<*"?M"F@! MY7C:)FFV#I\@A7F/N368I>\-F-A%["X1R6*`A*!O$`FAVR)?3_M9G`*/Q,7I MP*L#N#68I2Z5BFAG&9R=(24?WUF!-SY0#2&C=#[:V6"2_SM;!F?GQ-U9%2:9 M+(QR@N:R%"19-%)@,)8"R^`H@-WLV)6"&1R=][.OG-P<)!D:*3"83#<."D89 MVIG5U*P.GHZRA:OL?44*["I"Z7+@-?U@,%9.+(.S,_3S."?355%.4U4Q&$N! M97`4J)DR.K#355%.;@XNJV(P25^5Q,W0SEZ-@C?.:>9J>[\N"NQJ0A>7B,%8 M6;$,3E80-.8X+=.%T5Y3E>E!E@C;XJIXY3:=+@Y,KG$F+JO3@\RAR8(T;4]'!9@\'7X0+YC?J"M\&I2`F44J*G"S>@T+Y)U^IK>,PDC3S]6\!>' MP'4&PO=V]R:W-H965TB`E)FBBD:E=UF[1)T[2/9P=,L`H8V4[3_OM=VWP$2!.RER2$XW-\[_4] M7-9WKWGFO%`A&2]"A-T)T@+N)%SD1,&EV'FR%)3$9E&>>?YD M,O=RP@ID&59B#`=/$A;11Q[M>DL/ MF#;KF$$$.NV.H$F([O'JPI!'OQV9\L-GP>)OK*"0;:B3KL"6 M\V<-_1KKOV"Q-UC]9"KP0S@Q3<@^4S_YX0MENU1!N6<0D0YL%;\]4AE!1H'& M]6>:*>(9;``^G9SIHP$9(:_F^\!BE89H.G=GB\D4`]S94JF>F*9$3K27BN=_ M+BR&8M^,&!4P.:LB3Z#.(5,.O( MII"?TY%!2'K-O5YDE@):0CE>-L'27WLOD,*HPCQ8S`(Y#:9%>"#>[`!4CW=P M7EF#>\K^;4_98A:FHL="TZ[0N%#U(DC)41C!$VY'RPF,+)PYG!SNR,[OT96 M@[NR?M"/UF*&:84S=1S?N#KJ19?J:#%#06WC1SUROHX:W(UL6$>+L0GUV]/4 M2>?R&E$-[HOVJV@Q5C1PVZ;IJ&+H_?&Q&G17UP_ZNA5HF%;\?]YCC>5\1QKJ M$)W0O,IML+62\TU9@>IJOM<>6+O$Z%-DT-W,!LM!9FOCT0[LNVW_=$MZE0WA MH0_Y06LTUA`JT(GT]KQG7&_J1^G%YJQ`)S2O,AX\=)YA?U:@RO$F;IOX;F9[ M3G3>&+"UE^YA:IFKS-8>I$LZ==]Y9.*K',F@NV?)#Q:-B5?"M2?I.>CXJ8E[ M1C2RI-9M+G1I;4E]3?\J%S+H;GS#DE:@ROZ:X#NA^CU#.E]/@^[+]NM9@>PC M&[MMUJVPG3CM0)93L:.?:)9))^)[/4UB>.(V_]I)]T%/NF;0:&[`H%F2'?U. MQ(X5TLEH`DLG[@*:2MA1U5XH7IK):/NJD2!TGAH<"\&6J-GJM#UZN.'Y4'(!]51J@-0&%2-.JW' M110ITE&.52A&.L"=5DB.-2SE+E*CI+BQFW@?I7%<1!RS`3F%A;Q$0[0M(_16 MD#VG@W8BDO98@W_5L5&]J'%RB1S'\F$_7A'!1Y#8LI[I9RN*`DX6][M!2+SM M(>^G),/D1=LNSN0Y(U(HT>H0Y")G]#SG*JHB4%HM&P89F+('DK8UNDD6FP)% MJZ6MSR]&#^KD.E"=.'R2K/G"!@K%AC:9!FR%>##H?6/^@LW1V>X[VX!O,FAH MB_>]_BX.GRG;=1JZG4-")J]%\WQ+%8&"@DR8YD:)B!X,P'?`F9D,*`A^LK\' MUNBN1FD>EGF>%>4<9+94Z3MF-%%`]DH+_MM1R5'+J:1'E1G8/]Y/PWP>SQ(( M^A^1R#FR"=YBC5=+*0X!#`V$5",V(Y@L0/CMC"`5P]X8V&X!KPJZ\+C*JF(9 M/4+IR)%9GS.I3VS.B>RO2`2^7LU!QI>;,W"-((<3;C,QN?R0J?\?QE[_%GX*F_Q(^]=DQA M_:4S&WEJ[Q1)JN0?[F`<+Z^>@:?N)B.S=HQSE\35W(]MAW/C,4E6^HQ7O>(] M_@SL^\NJD9?Z6/W<"N0=TQ#OZ%+N:T MD.[\B4.ST&*T#^16:#@V[&4'KPD*LQV'<+\50K\LS`GW^N)9_0$``/__`P!0 M2P,$%``&``@````A`(ZS,OSQ%0``GXD``!D```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`59U0E4\8W1^&M`V_L9'+J25T8DU-.N+XF M+JCLI=$U9^(:2\O!Q$66W8M-QX67V2VNO`Q)2B\]5[Q\7(UO7D035VA6A(:2 MHDU?C$>-0C9Q)8='?2Z=0M(SR/#D]0SY\R'7`5BUZ@#*'_PZK46:[&6M7BA; MZ]2H/B*@XO+*?Z$&#Z9ZH9IIYFE4/%MYFJK_6NT\C3J>3IY&M=,MH.GE:=0Q M]PMH!M2HJS.D0E_D$275DG)S3(UZH^4?,"FD4!S;*` M9E5`LRZ@V130;',TY8I_[L90I(PP<3JS70Q"8^)X9D6ZG3B?;TGR\EE2=IF\ M@$*4EU"(\B*J^R:3FU%];KDA535O\E**8\J+*40Y.:UF1%YO+3-4K[>V\[B* MO%-YN]>V>]E>VPW.M0BD0UA=@T"#AFLC'7:J%ZK^F@4TK0*:=@%-IX"F6T#3 M*Z#I%]`,\LJ6HI#^+8H#N;;HKRPXN7RT@I17EPARLMK6;TM M-'F!K:B`F+S$0I0768CR,@M17F@S(J_GE7?U7L_[=H]KU5Z/&X%,CZM!H$%# MM]'4H*5!6X..`]E>6PW!W3R-FM/W\C3*X3XUE1LU11XXC1N)AAJ,',@<<4F- M,V.G<:U,-)@ZD&U%3<5GU%SJ]RGS`II%`B*8 MEQ^(<@+$4\E)$$5)A/)/Q>NSY%[B$7V657M]5@0R?98&@08-W493@Y8&;0TZ M&G0UZ&G0UV"@P5"#D09C#28:3!U(KWRUI"(RR].HSG1.3>5*5=6"FFI)=;C+ M'$U9C:BK/(UZK76>1DTY-P4T6Z=).Q60&DC=DGM#P:O[MFTU6_>E4UGZ2 M]?EJ18.V*=<5,^Q<-M<1[UTP(JO+]4MD96W5;]%6[NMKK&-`[:QJP^JL:W;ZN3& M@,!M4X<&?AL8;N"X@>4&GAN8;N"Z@>T&OINL\5XZ[#-Z1\0CE.M\J+=EM5B4 M"0A(`-(`:8*T0-H@'9`N2`^D#S(`&8*,0,8@$Y`IR"PF5^%C8*7JM:K3.?98 M@"Q!5B#KA(39TG'8))M='K8@\IR1K9A/IZF[\EP14)V(ELM30]&.T7G?7%74 M>1N6@&$-&!:!817(`T$XRK0.[/6X5/=[#(M"'OW)-.('26ZH'!,D*]=!4NMA M-?O@JW>IZR`!2`.D"=(":8-T0+H@/9`^R`!D"#("&8-,0*8@,Y!Y0JS%:B1? M)!M=P2]!5B!KD`W(%D2"H]V4X`#187G:#BIZ+%%Q*GNB.DBIX7:KZK`E0&Y? M=QTD0$"TW]!_"8W;,>^5O&+P\V.?M]&/U?[_QS%*T6,Z_H1-G7TM%J5=5ATD M`&F`-$%:(&V0#D@7I`?2!QF`#$%&(&.0"<@49`8R3XBU53^-L4BVN@):@JQ` MUB`;D"V(!"GR/+53@@1$BR5(4-%D"1)4M%DB`Q6-EC$'*EHMD8'*,]O/B7U& MXATYB1ZMD!?*O+%1=_UK]@,2:KS1)("F`=($:8&T03H@79`>2!]D`#($&8&, M028@4Y`9R!QDD9"<#G&9;'3!68&L038@6Q")B?9.8@)4)Z+%,E'#CC19IF90 MT6896:"BT3*R0$6K93J64?DQL2OGV9B\_;;??B((TS&UAEZ+16F_4P<)0!H@ M39`62!ND`](%Z8'T008@0Y!10L+.WG\R=IQL="4[`9F"S$#F(`N0)<@*9`VR M`=F"2#PBRU,W)1Y`=%A&$:CHL8PB4-%E&46@HL\RBD!%IV44@JC5K)K]7)P:/30)H&F`-$%:(&V0#D@7I`?2!QF`#$%&(&.0"<@4 M9`8R!UF`+$%6(&N0#<@61#*A#9-,`-6)Z*L,&6['[(PC72V//@1'LV44<3NZ M_D5B`D2_)290T7&)"52>YWY,[#IJ-B;%%DQ*T?*K%Q=]=Z$6B]+^IPX2@#1` MFB`MD#9(!Z0+T@/I@PQ`AB`CD#'(!&0*,@.9@RQ`EB`KD#7(!F0;DYOP'EWE M3,V=)3N1Z:F?DIT(?0AW4?<>Y(-VV(%^2XR@HN.2&:CHNF!]$$&($.0$<@89`(R!9F!S$$6($N0%<@:9`.R!9'$ M:,,D,4#U!.5E@A;+P((V:+(,+%#19AE8H*+1,K!`1:ME8,FH_)C8===WQ"1: MKO5CHNZ`U^R7:*B8:!)`TP!I@K1`VB`=D"Y(#Z0/,@`9@HQ`QB`3D"G(#&0. ML@!9@JQ`UB`;D"V(Q$0;)C$!JA/15\D&=J2SD@VHZ*UD`ZK479M5U6-+3+`# MK9:89%1>3,IVA?+XF(2[J07)2[T@&8LR\R^0`*0!T@1I@;1!.B!=D!Y('V0` M,@09@8Q!)B!3D!G('&0!L@19@:Q!-B!;$/E8>V8!.WH/7B.J$]%70V/E(^AH MGM8:>BL?)G<[YHU?-%H^,^YV2.9TM-IX7OLQLVX2_T%)1*7S(Y^ M7*3BWQ,7NYL>5=2MDUHY$F5'%4T":!H@39`62!ND`](%Z8'T008@0Y`1R!AD M`C(%F8',018@2Y`5R!ID`[(%D;AHPR0N0'4B^BIQP8YT5N("%;V5404JNBMQ M@8K^2C:D!]('&8`,048@8Y`)R#0AX;1:#2F2CXS*SX==DSPB']$2II\/O2)?UNN<=9``I`'2!&F!M$$Z(%V0'D@? M9``R!!F!C$$F(%.0&<@<9`&R!%F!K$$V(%L0R8>V4#(!1%OE?0A4-%;>AT!% M:^5]B%.%(555)OEPFY.0TFG)!U3T6O*14?GYL"N/1^0C6JCT\Z%67'R3%Z`:+V\ MAX?*,]_/BUV"/"(OT8JEGQ>]$%_.+&O&>=$D@*8!TDQ(."?.?$M3V&C+VURY M5OU-V]MH)2IQ-$>R52 M:-XSV(N4_<#C$9$*Y6IYI:H7[6-1YLT^2`#2`&F"M$#:(!V0+D@O)E>E\$%9 M^;D8_468?:U0P^P`;0Y!1B!CD`G(%&0&,@=9@"Q!5B!KD`W(%D2^-1DKX36B M.A%=-[3=T'=#XPV=EV\IQG'1>^/,3\O3.+T:]$"YW^ M8*1NA-9B47H<=9``I)&0<"I[J4JUF6QVG48+I`W2`>F"]$#Z(`.0(<@(9`PR M`9F"S$#F(`N0)<@*9`VR`=F"2%`RJ]OQB@L1/38T68*"MNBL!`4J>BM!@8KN M2E"@HK_RNW\9E1\4J?7W!,7NIH<8O8)?B427T0<=;M2DKIYL=B4?@#1`FB`M MD#9(!Z0+T@/I@PQ`AB`CD#'(!&0*,@.9@RQ`EB`KD#7(!F0+(D%Q?CK#3(V( MMDI0L".-E1$%*EHK(PI4-%>^Y1XJVBLC"E2>P7Y0[)KE.T:4:*E37BA=PJ^J M-V8U^[-XX>UD.S:4KU6.ZLEF=]T#D`9($Z0%T@;I@'1!>B!]D`'($&0$,@:9 M@$Q!9B!SD`7($F0%L@;9@&Q!)"C.3V>8!`6(MDI0H**Q$A2H:*T$!2J:*T&! MBO9*4*#R#/:#8IP[>__.BONR0DG%;9WQ'-W@%14[?`4Y>J M'\[46_Q&(G#.-4%:(&V0#D@7I`?2!QF`#$%&(&.0"<@49`8R!UF`+$%6(&N0 M#<@61&*DW988`=6)4IN=BS(QPXYT5B9F4-%;F9A!17=E8@85_96)64;EQ\BN M9V9C]/8"O_U54TS(U#VH6BS*OG/)K)J&<]\`F@9($Z0%T@;I@'1!>B!]D`'( M$&0$,DY(>.M/?N_5__Z*B;_]^EIW#=-$X(IJ!C('68`L058@:Y`-R!9$`J/= ME,``U8EHN@0&.])V"0Q4-%X"`Q6ME\!`1?,E,!F5'QB[P)D-3,&W_-&ZJ#?N M7.GU_DIF\32Z_PP2@#1`FB`MD#9(!Z0+T@/I@PQ`AB`CD'%"PLEI57_$?>)M M#\?4[`BLNJ!IHDY3I*_M')H%R!)D!;(&V8!L021%^H`D14!U(E:`I`@[L@8D M15"Q"B1%4+$.)$50L1(D11F5GR*[#/J.%$6KIWZ*U.2J5LDLL<8ITB2`I@'2 M!&F!M$$Z(%V0'D@?9``R!!F!C!,2#C\Y*7)7(DS9U9FZ/SA-]D]SX_9P9`[- M`F0)L@)9@VQ`MB"2&WU`DAN@.A$]E]Q@1[HNN8&*ODMNH*+SDANHZ+WD)J/R M;A=`Y=P/WWI$P3D__-CM7H.[U[O/'Y]V+]]W]=WC MX^'D?O_K66Z5R3<)R=Q^/SQY]WWW>#NY?O#\^'D'[W9^&_WC=?_3 M_B#-R9?]Z^O^*?SKC]W=U]V+%8CXVW[_ZOYA7^#W_N6/\.I__I\`````__\# M`%!+`P04``8`"````"$`^@F`]\,#```)#0``&0```'AL+W=O';`2:P% MC&QGL_OO.\:8!?LV-ZGZ$H?#F>.9\7ALEE_?R\)YPXP36JW.5^8.Y^7?_\T_)&V2N_8"P<4*CXRKT(44>^S[,+ M+A'W:(TK>'.BK$0"'MG9YS7#*&^,RL(/1Z.97R)2N4HA8H]HT-.)9#BFV;7$ ME5`B#!=(@/_\0FJNUS!!F=9N'BSYDF2,E]3(G$(%,N\/P:>5^"Z+#W/77 MRR8_?Q%\X[W_#K_0VYZ1_!=284@V+)-<@".EKY)ZR"4$QKYEG30+\!MS+@-6>0D`RKBC_B#'/(*$@XX53J931`AR`7ZB]&6\D M%Y>5.YYYT_EH'`#=.6(N$B(E72>[N)@&TQ]93EI+&)^:$?QIPH7QR1EGK26,3\TX;^U@?')&V*&- MKS`^->-+:P?C8S/ZJB::$HN10.LEHS<'MBVL.J^1;`)!!&JZMM2*=M7V;\4& M529%ODF51@OJB,,&>5M/%M.E_P95G;6)`CCI.&`XI6TV1-2QU8Q/8F4"B M@4_58"BZUPPMFIK`H0?XD)8N-U#K_T-NI(J1FW`Q]'&C.(/<#!E;S=!1Q!KX M##P<#VUVFJ)M$@WT;(8F>\W0)JD&>B;&-`=-`9M!^F#+F^D;0_/[?MO2E22- M5BY(=E4R6 MN=//&ME8R-9"8@O964AB(7L+22WDT$<&44%OZT?U'\\9J6*6DE$)&\4)^N42 MAB]&374DW>AB"]E92&(A>PM)+02NAM)I<*AKD.JJI\[A$K,SWN*BX$Y&K_(: M)W=!A[8WS%D$J05[`]_,VYNGB0<1')4V/X&;ZO?P31C!"6/SXS""4\3&DS"" MH\+&TS""XP!POW,(;J(U.N-?$3N3BCL%/D&((V\.6X*INZQZ$+1N3LDC%7`' M;?Y>X),#0W\?>4`^42KT@YR@^XA9_P,``/__`P!02P,$%``&``@````A`(U^ MY<#J`@``)0@``!D```!X;"]W;W)K&ULG%7;;MLP M#'T?L'\0]![?$HL\ M/.8A:6IY_U*5Z)D*R7B]PJ$78$3KE&>L/JSPC^^/HP5&4I$Z(R6OZ0J_4HGO MU^_?+4]LY0F/#U6M%:61-"2*,A?%JR1+5N5WD)7$?%T;$8I MKQJ@V+.2J5=#BE&5QI\.-1=D7X+NEW!"TI;;'`;T%4L%ESQ7'M#Y-M&AYCO_ MS@>F]3)CH$"7'0F:K_!#&.]FV%\O37U^,GJ2G60`/RBBNG)@(*0%_-_8IDJ5G@\\Z;S8!P"'.VI5(],4V*4'J7BU2\+ M"L]4EB0ZDT#$F22,O&@Q#:>S?[/X-B,C,"&*K)>"GQ`,#;Q3-D2/8!@#IH%&3/&@6PP4J)+3G>3U9A$O_&6J:GC$;BYEC=,%$D0O9MA!=0:V&6+ZV5]!C%V2Y`K$1>RN M(-Y('(5C5Z'NW!@F^^]*==`*PTLN39@L>CHV%C,QPZ>[L.T;DKYAUS$X.4[^ M)T<=!%JZ.6O?"N'O3G#BA8V_JJMYUW5''Z^B9N7INFPL=U-JVL M45]7-W0HJ^L=#779M6RW5D7%@6YI64J4\J->N1$4\F*UM\$FC&&5P$;HV1.X M)8S=OSA@2S?D0+\0<6"U1"7-@3+PYE!I8?>\/2C>F`6QYPKVLWDLX#JF\'D$ M'H!SSE5[T*OH&ULG%A;;Z-*#'Y?Z?P'Q'N! M(>2J)*L-0\]9:5=:'9W+,R&3!!68B"%-^^_79D(R'KI)NWUH$_NS\6=[;*;S MSR]EX3R+6N6R6KC,"UQ'5)G*C4PMTWS6'F^RK;BS)5GCR("C1;69=I`U_KG:\.M4@WK5%9 M^&$0C/PRS2M7>YC5[_$AM]L\$UQFQU)4C792BR)M('ZUSP^J\U9F[W%7IO73 M\?"0R?(`+M9YD3>OK5/7*;/9UUTEZW1=`.\7%J59Y[O]TG-?YEDME=PV'KCS M=:!]SE-_ZH.GY7R3`P-,NU.+[<+]PF8)&[O^?JSSC?? M\DI`MJ%.6(&UE$\(_;I!$1C[/>O'M@(_:FMD1]7(\G\-8F=7VDEX=@(69R"(3KZ@E]87L%!0G^=E-![._6?(:7;&K#1F M[#H73!A22-Q!,(/HEW>"JPVC)DF'P/(!I0LOR);)Z^U*=>$CV`H_G-`'K?H8 M._HW$`/JA+\!H8CD#<35"6$XH`RQ<@/H[-M,T0AP1A&B\8B&L-*8J&T^K$)L M"[@M2`P!B3'ZG1C1:.%"(BZ-$HW'5HP:,VU;+?`BJHVI=DJUW-0.O6!*?JQD M)!H\:1]T[6A"$HZ-V6I8B`ADMPN!1C9)N^4T)FJ?S3P6D!_K(,0F&,:0Q9EJ M;9*F]L:#".L197V;+8(I6S:Y9K,]ZRN-,=K.%G!;D!@"$AL,&;LB]X\&&MT[ M&AICQ&@+N"U(#`&)$=\-K,%[/T8THGGL'PV-T5WS$'A6FF-3S6PM-[71O;-! MP)>&(RRGO\,2C6R6UB%>:8Q1"5O`;4%B"$B,#*;FQTO16MWKES/("+,GX3U) M8DIHI+CMK*:Y/VJ8WI%TH-JSY@SJAHTU;V.BAJZR)BXG>N99Y@E1$W/*#[>? MP>_V4&%Z5YJ\V,1Z\NH,,BN@S:X2WL,DIH1&B)O.B/!]6Y?I_0B_C95F#>'5 M&72-*^Y)>$^2F!(:*6ZNCT>J]YV9T_Z$81JD>R7PK*,9$S44VR+*B=Y:8\DO ME)0:[JN/4]-;CE";!)>QI9<0OM7#[#&+8$MX#Y.8$AHI;JB/1ZKWVIUV,99? M&WO,;`GO21)30B/%/65%^H[1HK<;R>FX-UHT2+^L]?LAAIL;YKQ[F>NUBZE^ MN/%ZTF8![X%7;^:"TW3U'4]?@4I1[T0LBD(YF3SB_2V$=ZV+5-\M5VP&]Q*X M7EARCG=.E/L7!5SY#NE.?$_K75XIIQ!;MLI6RZ+_B`R[\+EC\!``#__P,`4$L#!!0`!@`(````(0#6 M_U9&.`0``.,/```9````>&PO=V]R:W-H965T M@%P?WZ]CG]B+K^]EX;SQ6N:B6KK,"UR'5ZG(\FJW=/_[]^7+D^O()JFRI!`5 M7[H?7+I?5[__MCB)^E7N.6\<\%#)I;MOFL/<]V6ZYV4B/7'@%8QL15TF#3S6 M.U\>:IYD:E)9^&$03/TRR2N7/,SK(3[$=ING_%FDQY)7#3FI>9$TD+_2O3(>[*I'X]'KZDHCR`BTU>Y,V'+MR7 M>5H+*;:-!^Y\2O2RYID_\\'3:I'E4`&VW:GY=NE^8_-U.'+]U4(UZ&?.3U+[ M[\B]./U1Y]E?><6AV\`3,K`1XA6AWS,TP63_8O:+8N#OVLGX-CD6S3_B]"?/ M=_L&Z)Y`15C8//MXYC*%CH(;+YR@IU04D`!\.V6.2P,ZDKRKWU.>-?NE.YIZ MDR@8,8`[&RZ;EQQ=NDYZE(TH?Q&(M:[(2=@Z&4'V[7CHA4\3-IG>]^)31JK` MYZ1)5HM:G!Q8-1!3'A)<@VP.GK&RZ-/*H"2<\PTGJ:F`ED#'VVH\G2S\-VAA MVF)BPD2NTV-"$[&^1(RG/<2'_/HDH70]R>MM[Y)#L)5<^-3[507$A(E4?[&B MM68P(D-+AD=&,%"KE3R>GBNBR(09GR-K!B/R^)'("%ZZ4$3?[/$TLFHFS$S1 MQ48>,X?7QO#$&_7#1E:P-(;W`\%V5C83A!FKK`)OW$=5W5I_-FKD-#5SPB4\ M@BU^>Y7@)#NWF1D])HS&E68P,H!5/KPK"+ZW2@BC1=8,1F1\PVC;]W;-"+9K MME<)88@/YEFC:W/TS):1T\S,:1@?.,G*+0HL/@BC=44S&!DPH']X6Q3Z'B,M M2`NN6\SHEJ;>)H61#-[>NRVHVR872DH^VN&^:V96*'':4AE&"R-A-+*++.F( M6Y#>&YJF+&86*'=:%G=Z0^((WYJNV8K*-`4EU=`M9O2'1)5=4U5;OUI0Q\Q9 M-MM4R$X8;$\`XW MFF*V#=$L9O2'1)21(!KK:>$()+MYXK8_;N\82V(',7%':R%H:,>O$ M%,^+ZA"B6\S>6))ZAQF2Q3O,:-K91M^\9P MX)UWO)F7I;/#N`FOZ&UTWI>J%W$+TG:-;C&S0*D;K&@A">-M;EJ0'OTS/85; MSR/1$7V7&P+107'F/07&QSX1J`26;G^L/*]RZA+=J>C*4?)ZQ]>\**23BB/> MET(X]_56NLO%;!Z'>#RV[&N\XZ'=[P?@BG5(=OQ'4N_R2CH%WX++P,/[2TV7 M-'IHQ$%="#:B@K[Z'P``__\#`%!+`P04 M``8`"````"$`Z1/4Y&`%``#A%@``&0```'AL+W=O=O M[VFF*G63GG?IJ3R3E?I!:O7'^O??EM>R>JV/A#0*1#C7*_78-)>%IM79D11I M/2HOY`R_[,NJ2!NXK`Y:?:E(NFL;%2?-&(]MK4CSL\HB+*I[8I3[?9X1I\S> M"G)N6)"*G-(&[K\^YI>ZCU9D]X0KTNKU[?*4E<4%0KSDI[SY:(.J2I$MPL.Y MK-*7$XS[IVZF61^[O9#"%WE6E76Y;T803F,W*H]YKLTUB+1>[G(8`;5=J2%UX^4TI*ID;W53%O\QD=Z%8D&, M+L@$[K[[W1@9,TNW[`>BF%T4Z+>+8@"Z\Q;LKO%T:/P+XX"'HC5C_AG$?-@, M'7+(+*7)9'8\X((^9`1<[9M_ZX/&TMK.$B=MTO6R*J\*/'H0K;ZD]$'6%SI$ MO#TO8$)0\3-5KU3P$%)>PV1^7YOF=*F]PP3,.LU&UABB8BLK3%N4.$P"?X>. M4!!75N`@W@V).1<[\F4-ZBCX5A'*"GPKD2Q!W<3?*A)9P76C03Z'I$(>A:32 MAWX"L^WKY-)6-+ET$:#9WF"PQ$=FDC6Z#,T<^);&O0L)%]KA)S!VBCD[.M<4;60*PRV&#@,L(69IM?% MP,/`QR#H`9=O:R+F(+Q#$_6:?JK%&"0<$&R"E>X!FZ@:ICX_/RU3O-\-T[1; M<#OMMQ@X&+@8>!CX&`08A!A$&,08)!P0/($-\0%/J'JEPLS\?&8M"WG"-)PG M&#@8N!AX&/@8!!B$&$0,S-J=QK#&["/>:\QK]-N:1-`8,[T--,01S(1"X0$S MJ1J;B?:R#=-P9F+@8.!BX&'@8Q!@$&(0,6#KS,W1;#H7/NX36BEC'"'A@.`9 M%`0/>$;5V#.T<&Z8AO,,`P<#%P,/`Q^#`(,0@Z@'M-0QQCI*;=S_W*]C"0<$ MA^CKU/UE%E5CA]"VNF$:SB$,'`Q<##P,?`P"!NQVRLSLF?C/JA&G M_ZW/O(N!AX&/08!!B$&$08Q!P@'!./J6\0O.M@C8K532?B M;63-/HDC:5R)>`/A=G0#567^(.HG;""14"*11&*))#P1/:/5[P.>L6)9*$QL MM"5MZ"LJ&/OIT%8BCD1MB1_P MBY70HE_XA0".X_`M0XC(T9R4X.V9E00:H#V9+3J5:R\HV>"DX@M0,=3BR?)_20`/&-OMC< MXEM]`2^CH->&!G#`>$D/Y(^T.N3G6CF1/70U'DVA3*_8$26[:,I+>T+U4C9P MM-A^/<)1,H&WU_$(Q/NR;/H+VL%P.+W^'P``__\#`%!+`P04``8`"````"$` MLS+5_9T#``"+"P``&0```'AL+W=OHI#5>NF^8 MN_>KSY\6)\J>^0%CX0!#S9?N08AF[OL\/^`*<8\VN(:5'645$O#(]CYO&$:% MVE25?A0$8[]"I'8UPYQ=PT%W.Y+CE.;'"M="DS!<(@'Z^8$TO&6K\FOH*L2> MC\U=3JL&*+:D).)-D;I.E<^?]C5E:%N"[]5T)SR@\[70 MH>>9/_.!:;4H"#B0:7<8WBW=AW">A8'KKQ8J07\(/O'>=XY'58$?S"GP#AU+\9.>OF*R/P@H]P@<26/SXBW% M/(>,`HT7C2133DL0`/^=BLC6@(R@5_5Y(H4X+-UX[(TF01P"W-EB+AZ)I'2= M_,@%K?YJ4'BFTB31F20&]>?UR(NFHW`TOH$E.;/`9\LR\I)H-)G>H@54*T/P MV;)\@8I,D?0=B(K(A(AEW$,,A].3U#B48)J"7 M_"2V'6I,H@9`9G]C!U([D/4"AC;H].NU2?#2!>-=8R3QK/.L&F&M,>-0]19, MO)U[>]UJOE2O7[QEO8"A'&;@>N42;"E/`DNYQES>O+$#J0[,E+78LY1G/;@A M=&P*E8,;PR'[<:/+3;9@:Z+6&I/H*9YZ(]//IEWN9K0-J*D?X#-C.?:2CLYP M`\="/^W7N9&;;#=68ZPUYNPFZ+U>]=6F7>[>M;II5SO9;4#*'L"S_FKB7>;>*,'L%@L2;%NXE%;/K,;H MO@ZG7CPS_KH^T(70X,N8I+?LSGJ[#4]P03'J;W!9G1WG?D6=@%]5WL74XA]]. MV9/=`ER%&K3'WQ';DYH[)=[!UL";P''"]&5*/PC:J%^^+15P"5)?#W#IQ7#^ M!QZ`=Y2*]D&^H+M&K_X!``#__P,`4$L#!!0`!@`(````(0!?%KX_E@4``,(6 M```9````>&PO=V]R:W-H965T=JOU+__BE\\56F[_+3-C_6)K-0OTJH_UK_^ MLKS4S5M[(*13P,.I7:F'KCLO=+TM#J3*6ZT^DQ/\LJN;*N_@:[/7VW-#\FUO M5!WUF6$X>I67)Y5Y6#3/^*AWN[(@85V\5^34,2<-.>8=K+\]E.=V]%85S[BK M\N;M_?Q2U-497+R6Q[+[ZIVJ2E4LLOVI;O+7(\3]:<[S8O3=?Y'<5V71U&V] MZS1PI[.%RC'[NJ^#I_5R6T($5':E(;N5^M-<9*:CZNME+]`_);FTW-]*>Z@O M25-N?RM/!-2&/-$,O-;U&Z5F6PJ!L2Y9QWT&_FB4+=GE[\?NS_J2DG)_Z"#= M-D1$`UMLOT+2%J`HN-%F-O54U$=8`+PK54E+`Q3)/_O/2[GM#BO5M+8&HSGD_',T\RYX7QC M`;#4/@KX'!=@:?.9[7K?"<,9O+B3%\O^[DH@[GXE_M7'3/-L>^YX[D-!=9:< M/M=AWN7K95-?%-A`('][SNEV-!?@>4PR2\F4]O_+.J2;.OE)O?2^(*$ME.K' MVG:LI?X!Y54,G$#FS&8B92-3+'\N&:B"]P7$-<;W9+<[U68+RL,%YY>\K3LE4\3'EP0A<4VX[ MMKB8S2V.*W+")SC1+8XG^HEO<7R1DSS!26]P7%/TD]WG""+#Z+G2$S)L,/IFGQ9O M(%22"9T.K^O]4NK92%`/'8+!0.(4E9!00B()B0=D4-73Q)",&1]3WP0FV$(0 MS?<%%8:VD8:_4J_/$$TW:9^K8)-UK<)-Y:%N(!A( MO.+,[(J$$B>2D'A"N`WJ77NW0>31]1U2>M,3VA793=+U%A;5HVTEI]Z#.F5- MJ*@:NJ("DY&N&FTD))202$+B`>'[`O&R2!XR4LEKQB.B$K3WXY1XLHY8QR@J M@B\\DY%X13`22IQ(0N(!\?OCT'*UH5D:=@HJ@T1D>YJ%"*GT@(Q'1'%H=_A] M<5A/*8J#KTB3:SS[G;"1D%!"(@F)!V0X<@S-1'698`+:@*GD,N,140[:.R(Y M'C?_=$J$KTT/W=/!0&(Y=GT-)6TS_'ZMI5!"(@F))221D%1",AX1XZ<](XK? M>?B_/4SEY/AQVS"0H"BN_T+XZ"K<3*2I39202$)B"4DD))40.DNDJ^X%9R*P MT2`;%U6DV9,-.1Y;I:C?Z=C/@MTYH6PD&9H+&,?`6A$>FPN8N,AX2D>8%-8%9,8)9C M:$#>U74W?J$/F*;/Z_\```#__P,`4$L#!!0`!@`(````(0#>BCUR-`,``'X) M```9````>&PO=V]R:W-H965TTT[=OOV`X4$WK(11.L,EZPF,7HF`MUN/G]:GQE_ M$`4AT@&'6L2HD+)9>9Y("U)AX;*&U/!-SGB%)3SRHR<:3G"F-U6E%TPF,Z_" MM$;&8<4_XL'RG*8D8>FI(K4T)IR46$+\HJ"-:-VJ]"-V%>8/I^8F954#%@=: M4OFL39%3I:MOQYIQ?"B!^\F/<-IZZX$R)22"C8N,%4.:6L MA`#@KU-1U1F0$/RDW\\TDT6,PID[G4]"'^3.@0AY3Y4EQ]%\]$I`$3+/%FS=G9@::!,T6#50OZ*W!NR4P<'>MK MJ,"H3.Z42XSFR`$*`>5YW$R7_MI[A)RF%\WV6A,$MF372E0&E6_2+KSX#ESW MK4*5#Y`Z+LA6GVN\4FWX2JS";\_=F@7P[GB&H8XH0ILF&9'8BOV(XL7$P@EM M'%6FZ-4&;+'4)FBU'L5T.>#8&DW4H>^&"\EP8=];L&*,KF,,X5_M[=2K33&" M1+QD>C&,T6@6NJ_\V42_[$SN+(D_'9$D?4D4&1O;9=^7A,O!018KY+[?7JH> M[[.J34/6EWKKCM\:S4RSWH0C'#M+$8TH$DOACTGVM@2F";RZ9%BDLVO2]SM/ M;1J2SCI_0VHTAG2L8+N^8`PBZ0M&:[ZW%&]1PM75K^?;/:O$0[KY@,YHVIX= M'*T3L+,DH_$G?4D4S>TR:1<8>RH8<]`K/6OFFKGV*\*/9$?*4C@I.ZF9%4*O M=:O=.+T+U)4P6-_Z*[BCK]<3&+]ZW>LVP/AK\)'\P/Q(:^&4)(>C)NX<&H^; M`6H>)&OT$#HP"8-/?RS@=PZ!VW_B@CAG3+8/ZH[O?CEM_@,``/__`P!02P,$ M%``&``@````A`(BIGU"#`P``S@H``!D```!X;"]W;W)K&ULE%;;;N(P$'U?:?\ARGN="P0(`JJ&T-U*N])JM9=GDQAB-8DCVY3V M[W=L:/N^ZF8$T'%&M:4_FB27VO*:8/VY9QO*Y!]W,TQ,616S]< MT#>TX$RPC41`%YA`+S6G01H`TV)64E"@TNYQLIG[=]%TE?K!8J;S\X>2O>C] M]T3%]E\X+;_1ED"RH4RJ`&O&'A7TH51+X!Q<>-_K`OS@7DDV>%?+GVS_E=!M M):':"0A2NJ;E2TY$`0D%&A0GBJE@-00`WUY#56=`0O"S_MW34E9S?S!"R3@< M1`#WUD3(>ZHH?:_8"))$R>C_+(&)2`O,L<2+ M&6=[#YH&]A0=5BT838'YJ,S$<=+ZFE30J$CN%(OF`A4"RO.T2-+!+'B"G!8' M3&8P8]\[8>+8ABR/$)5!Q9L?%\X^D>VR.B)4^4#221=DJZ_K>J6.X2NP'?XP MGM@;99<8-_HK""<'^16(O:590[1N4,M72-;U]LY M5V!7C[-M9C!#'?$0):GU<.BR]<*/TZ_BV M7@5V]3K;9@9C]-[`/6U'M73,SBV06^8H==U7MGV,)E8ZT]-FED8U1_1NZ;LYC#-Z/3@98)SH\)9\QWQ+6^'5 M9`.4(1K#G<#-0&(>).OTFVS-)`P2^F\%&00U'2S7>OOJ=]<:+8#8.9 M/KCLZYH3+,.5&SS-]#\_6!<378L3.UC97A@X,_W-B?7O;G_YBYLX>?.1;R?P,7KJQ9O(L50'T= MF/8RE\T^[(GWW644QN$ZN01QO7"]=I?./LII;]H#2;Q/_I'VQ/3@R0'C+T`LC+0$O@WWL2&#[3OJ+A>VYCY&+/UO;ONN]I8<- M/,`"(_N=[X*;\&`OU7!>/8^()K=I@C`XFX9XA-KD@TDV'JRWR?[G`9LX7:-F M7:?PQ^EB5M3;)4W7?ESL<7B*KL)71$_T]#C3+0MRR*#?1UJIPSI2-EWT0=_9 ME%V-SF;9T!I:8ZF6<;&X[S=4.+1D4MF@T'H_OCL;G?*555F7I>%S]0#L<')9 M=*'KUO3OL86O<\3)F0>T;CS&I'))GW6],C<^N+X3:Y^U8KN-UY]CIY7!_UG,J MY\*LG!8T4!5U0= M0Q/GY7#D]@8*H,2)`@L^:-G[A[<-S,H#J-408B_]7<.OGR+[;6`P+XDUB$// M72&*IP6K!;*YV.+JWEK<,[T$F2B*"J&6M1AW(/1^/EW(1[J83F4+-2QX21;Z M?H0OR4(M^&\AC=-L-#9E@2SD:8F+M7O_#J\ED,C6'`]-D)#]F$>T& M*^?5P7)>&DW["$:`8#J<3*\,`-(W)TS561$,`@6Q. M1[IJKQ($BKQ*$"CR*BL?>Q(R?]938"5-<5\E"!1YE2!0Y-6QY`P\5NY5@D"1 M5PD"15YEA8K$O@H+R(K[*D&@R*L$@2*O2IM\9AEXJMRK!($BKQ($Y_9J7E8M M[N\MM@2V/S.KGA^S2@YJQ\/?)-S` MOX]ADL#)L-N;E6L_A8'MP=M>WB+_6],23A?"F<&9GCR[RQ=0QA7&*=Y415<: MBDQDX@S?')O]L3DRKM(B2I)JWUFY6W_?ND+WP5@!&I';9L,)AT&A)`N'5JP`<1$'A*"+6386)X=$+61M!"SD300M)&T$+41NLZASI4S MN0JW<*9ZU\&6->GW6276.EX."R3`#T1,8YM]/AN;'&"TL8THISEYD%_V^L;< MP!>;L1ZPM*'%OIT-#0Y8V=!"U$8^;@Y:7"PG8'H^@&2';^[GQ\$`16G#',]. M$LSR$YX@2D\1"8?O87,;Q1.K04*[X2JW88>F?1MD*&EC20ZLL4V=$[/Q&H;_ MI>-YGW%`_NNZF`/`4M?MS>N:;#"!73^X`P/WK^!;6$_.WJ;C??H!.*YJ9%0V MTNS-QGO[M/4?G%&J'X)+6+_,>,!-65E0 M@PMH4-?AD8D`2OX<`3A!!0(H3W,$$)XJ$$`IE2.``"T1`)R:J#BE'PQ(-H,8 M*%6"_JY40H[)K>14=FAE5?H%_3566ESZ/8EFDF\AT$N:X4,-@)-45J5852F& MN!UZ6DD!?*BAP()15\Z0-ZC*^5)*<"SI+`/6,S"7. M0TA08"I2#0'@*(%`'#%0-/X.*`9%(S"-!D5#,(7`C<%G[!/4$]P(J0@#X%'2 M*\IYPH`;,3^!$4F M7KZWA`-.I./EGHF[I$>^1O;FP7F%4C0][_2ZKE[K!23Y^L9N,/((*S&5^F%Q M7=?:*)?.SPE83B>BT7)6U#RY MJFF"05(Y!NHJ&##%86"/)>W<2F:]QMPJYK+-3';-]+RVG8 MJ2ZN23C4="EYF]K:5;Q(!WJ$4PR`!CD93<1@?O?/VJ36#0?,=U9"7CDE&S:Z6.KLHJL0T558&R M7S@(CSRG>J?K$8#B2Z=^E+`C:P,NC.##48[K!%D7@^@^4/&*JOU`5E,75`J3 MUI.IJ$R*X-4O+(;ZN&[46 MUK`F2^UI+*^;3*5=2'J(GHS.D'UVCHY&3=3\+.<.>_U4RDQ%*<]J0["8D[`; M:"I=KVS5L5O@INGLJ!G+;G;#275^R(%6G1A;L*T/5)3P1S M90^D_A1%R2Z@4'U6$SC)_6N032#U5/&.K"3E4`9FNS]@OP>Y>HZ_=J[8':+A MC17A1M#]7VL7VOLESH&*Y4Y#.G>4VALN_Y^G!;*]%G:QB M@1#7$*DL")ZVLHJ"'"FDLJ#'M)4%ZM.B9PC6$EEP86%K63`=R63A7KN2+Q/& MVK:XH$DFB^=^),B]>"49Y**?W%Q[G:6+]H"KG@O!/']`8=1$4'WKQO/#NPDC-XTW!99B..=/A(4]_LP+#CB M)6"A(P+H#_#8#'@BAP:\I`SQ,8Q;XMJ(*?H"3P]>(]5&#+1.T?#QAP54&S'0 M.A7#)U6(B(]N\.*L^,CA&<;B6T32)V>;1'81?WR7 M,@2)^83W22AD\"DBO5%S?E.';/[Y"6Z+D).(6T9)W\$)O`CP/VT30B.V(D+P M)(J(D`@0MZ,52VD&X^QG!7)_BK;2-WIO_[?CZ>WMU;QL6D/Y]\N1N9B?G=G3?M&?_$?H`R?PG,-CW$YX2DW[&D\L/5[8%[''CP+)\J,S&UL[)W;;AS9E:;O M!^AW"`CTM`J@*!YTM*O48%&E*I55DBS)71@,YB*8&4EF53(CG9$IBK[R0\R- M@1F`3S`/P4?QD_3WK[5WQ(Y#DI1=A@?N!KI=8F;D/JS#OXY[QY?_]NELEGTL MEM6TG']U9V]G]TY6S$?E>#H_^>K.[S^\N/?D3E:M\ODXGY7SXJL[%T5UY]^> M_O;E?3WJCS_-?BCG MJ].*1\?%N/OM^V*QDQWL;F?[NWL'W2_KF9+AL__Y:CHOLI>KXJSZ7QM_\.%B M472_W-N]][ON9X=L9&R;>3'+3[K?UO._+9;34IL=9\_S56_D^KD7TVJ4S[+_ M4>3+[`5DJC:.&)X,`P\^^[L>/3XLT M7BXE&"D9-M$L+.W%=%8LLR.(>E(N>P.^RI5VLLBIGHNX71V7%3J2KQ2>P MH"JJ7P\]DI63[*0LQU4&)7IJ^D.^_+E80B)#9W:EQYHOXU'8V M+U;=H3Z4*P1VU"-!][G`Y%=FJ9/TFV/;- M*=S!0'0'>CZ=K:4?O\!0-ZL%HH*N845.D2VUP/K/Y9*;`BKNS MLJJ^Z`OR:3X',*;S#!I-/\)%%C>=@WUFL2H^KJ8G76:36;E>79: MC$\*-!@1DB+`S2Z!7R`(_#0;&<:-+C+A:34S04$/?EI7*\.,[N^^+N;%9+K* M%K-\GCYWW5PW;KP[29L;PZ*V@:U?YRQL5`!8N`/5)IQ[7HPPTWMFIGO0$V$_ MKRJ&Z*U-1!98&+6+/ZSARTSHVGT0F%@MIR-)L1[M?HT5D"]29ZN3;FUM[_]8!?O`C@!3G_R'+*Y;2O MW.]/R^7J'FATAN1,"JS;6+*1#>\TL"T8P>%G#HU&R-MLG($M!MG=G0;0NG:< MMTO!U.IBVP3+?3'1UH!U.\M7!GK=D5_)#N4C_+JJ&)W.RUEY`MT'L=O).9WC[YY, MA81.T<%GG]^6.\-<<8H/?Q>E>S;-CZ>SZ>IZ,3DNE\OR7&#>)48MOXO\0L([ M\/UR+00/5GK3]\)#8+=AV;$C3&_"`,IFM;(-D[YJ-O4Y,GD-+5Z5\Y.H,<<] M>^P\)7@)SUPS4,W2`/FVCRY1`+ZSJ0.O8PRA!L0G:!I@T]7EU65W`/,2@TW] M5TS%1T!(.-XS+6^74<0J]R^W]B#J,@/,U@!1OEZ!%=,_PL"'V[M`#O_OIKSZ M338G6,NF505[N_-K`_BL<=EX^=FCQ]O/WFZN[W_ M]%%8@O"`2`NW]A@/(X9;]KLG>]N/GCX&)9\FSP+WX=%-D)\OIO*LL+1R>N7= M3IIU=S>)Z">(,YF.L(?WP>153BC7^"S7_:PTGT^RWW@=\@&ZOW%-3CVEE*O# M3R=":"2Y[:]O:5'?XL\1`.,^$QM^LEN80-[V^'AD;R;%_@?&UTG>T). M9I6EX84B*#DD9E!Z:'/8.)0*`&!D":1A`^6@1D`L[2]SJRST&*-+QQRS5``.7 M;#`J[/U6'E,V/5ODT^6@AVU^XWJT6B]!_NZO38/N'>>*\H4>T7)VGXM.X`6T MKHHE9L"@P.BJD,Z9WW_S:_,.9G9_FX,&8LUJ04X*LL3Q3F6LQMEU'6N[OIC]4XF3V^O96X M%J1%3'F58=&$D^F<@&-J%K".+KOS&".Z']8\N+N63$[G7WC>("CO$&6[0W2Y M$19S`S?JT+AJ@IK&6QV4E_;>BT_%XDN3YRQ6JUG?ETY_$Q'!4-9DS`P` MJ=#N>I2",Q%Z*^0GVM2"N@_M[62W>NX#/)%QP%K-+R35ZWF^!OML\IAMQI8W MV>8&24A3Q[PSFS[:R=YITN5X6^FU'=O(E/1'M3ZNIN-IKGQ%=E="\)<__9\P MXU_^]'\SD@I\H!_RUQ?H5+DFUW!%+2>UL+?QB<)_WSY7J.?O9X1SIFV7OB@59!2D%6;2SC$+,;W?( MFT/NJ&P\E&S_-"=M=UP44-NP' MFTAX+8.#Q&1P#EFB,HE+Q32XN22]S*U(_-\YP6A5"<24,,NS"8Z@Z%TKJTU5 M^V3:Q1D)?SUM&=N6PB!,)BIUM837Y4<+I?F%5SGW=[+792;6B'5$QI95C-Q` M$%B#9&=H]0GRAT6Q]@:^54/=OKIL?;`O0(CQ_-6EJ:5)D\1LZ;KC@L7FVLQ< ME!7N/9K'")![/7-92^HCS*Z?!"EV/L0G(SGQK9CG+)@J;+!S3O(++P3GD<%3 MU'@Z'Q,F6]X^#!['DP!;9V>A[BKA)`&`B=*'(!JL[*P2,DDGJDK(,S>Y#S"9T&:^MK*;' M@%M]PLI7I]@48Z&+3T^TX'^M65>7#[QEH2T!4`V3*-,B(JAF8,O`FN4GR\** MRD8>%Y3L74F3!C9K*8%0=B@1B-YWM6BLCV?3TLXJ>@9NMVVW_ M3W+`]0!P7)YI@V%(B:;+'EMQ*3>3HJ62K56*1)RW8"-D?K6Y'L$Q@-DYQ6[] MERVH8D*+@F^9<:HA`8F&8/_ID'C4``%R02YT%;+7=1#LF\K/!\\_9-]1Y&7- M5?;JU5$F>.!#Y[_V@/>'R&H/40W,C5M.3TY!:$@2X,*(Q2-GBMOR&+KSH.;_[0S0 MP7Y'9,0^P2-&=W=:,3=[S`P-Y&1 M_)S(J+!QFQ0C6!-`L9@VN+^[\RAN<+M=,TY]:#VZ]Z`QK%1Q<9$(Z9I`1ESE ML28S%1:X;5TZJJK:A$_2^<1R+Y0H31PVI+D>[#R-J_+MJ]/'QD`!Y8*A%T"_ M55G-O5(WRWJ)`UC@1!S.)5](R+5Y6T.%EV_?_??\;/&;YT(&7T&D2\V`[-P` M-6AC].92T67)`%7Q:97!U"@_@_*ZB9GU.L(:-.58X(6UAZ4)?HCU"W=)O9:G M]=8&:!*<'>5R/(?OK1Z,$1<.78Z],DSJ'3>B+FMCSSL(G"VG%9UIZQ6FV=06 MR.&3>_68BL44TV663&*T_8>_\BU&K4\='D6N0G6'M%KM&D7?'>*M2H6`](0.()$$,,5_B'7G\=XQ.T!Q7-RL-`Z3< MM_W'0P:1E`0>$$9#JC+H*JG;#`NT5*DP2K3$O*--2HS0(SA:T9YP>D'"GKZ" MBVQ,XL^2]S*A7W_SUH02^_@U;C):_)XB,4XL]4C:F1#VX!C;P]TG[*=B^=;^ MX\8.L29YS,ZB:YP8B&](:MXI/W)?AL"T=F+"#A-K9OA]C6_3E@N76+/^;NB@ MZ8EH)IA&Q"UQ?4Z_EOW566J]MB@P#@V>UL$$$6L"1B8O>,GX)7PVG!QH];7P M%)S2[./B7@<^"7%DAAQ+(QKUQ.?P%K-H*:5:6)`C\X-@-&)M*2F;?%*J/XAE M]Y*,=\=\E>/00*<0XE2]%L_$YR>"[\:06]T//K#=5%G-\8<*I0!4>6@I&/3' M>3TC-SOA'_+#O9\RT%B=96YH5(K"^3:^]J56\N@&;J)&-P7$:';LM0KJ#^6,C(6,*501\]KQ/M0-,<^2M"8)!`-" MSTEI`/TBANP`F)AAOI5!FT)&];C40^)@8T9E@5(VO!3G;K9UL/6E!IGM`W;]^;\.!@2=76$CNOFXF-J_/RW@C/NY+SNI2:\^GZZ7[Y6!N`'U/^T5Q>QP9)D MH@EK]_%_,2#W%P<3^23#[5[KJO/R#C-?!9RZQYM-%GCBEVE!6"UA+:X*'A63NYM+__ MJVU3)?35$7P!)M>YI_W'OTI<\BF64>8P&@2'FENL2.2[%7@!G1,YG%H+FY5Y MHQB&9A,Z^3P6$6)BFEAD9"TR74A/O6J0BVQ*[89A.9%FKQ!@C?/L%!FT*7Y" M`2IRAN*;^UF4Q[P1M.<0:7V8%DK,)&YC9I>%400,;J<676?[S5R[";>`AE][ MP37^5.-]C0=S>L&_EOGB(OLAQZPN)1)UWM'J&0^MI#S-F;0/39@">Y`;ZBRKG\HGNC1(W.OP.ILR*W+RAN50-&QK49=5B;2 M(4=Z"%*3EYYG8`"N!/'B.])UQ82ZB94'W,<*I&,0':Y`(2S]/SK"3*@>X-(=?-"*) MG6V>5UXQF4,6H%Y'Z&@-\CEG%:U!9CHK-_.`&)63'R%/*%2X-3DHOJ"Z[Z#M MP5:TW5$#_8?[6G;(*U(\:SFCYG?#>%DJTSX%!Q:K>G8$*860L*$-@EMI->9S M_2V1(81AI(*U%?,FXZ+!'G.U$C):H?#<&@B:FKQOV=AL`VB7USBU*TL*>JU: MTMNXMA:^S.L5`:0P/*Q&_(,+0M*W5MSE)T1'HMG6@R=) MIO`N,[E<;CW83?Q:WXS+N9&@CU`4#28-G<;T9\W6#/^H<:ZUC>@26WD3M]@\ M^^>A;QI#UA*SV^[9]W&P\^#J,I;/F0R=[;G_+_`K_.6O9?-@;"NR_-HAQ.FMWCN11`_&MJ\ M^^LY0!G.FUTS_`?6&>&#"%NU%,-*M>8H]TL*F&.61G@$_)P>'A/V]P4.Z%%9N7L6<T$=H)G7)"`C0\`#V%QE%4>Y2@5*-9E`96K*1Q2Z29D;ICU3EP04X8=$ MDY[U55=/.9FH^Q?V-T\$?J^Q>U31)/%V>@^S0_N4K5D)!6A!6%O7"!)Y->B- MY*W)(,J#Z4A=ZAB MS,K*FURC.MA/%4^7IM?=+8CN*"M4B)(GHQA..NJ:3F2TR\E7"MK94/?S M%^K:^G<=ENI^4TZN+ALAZ>4ADJ^0I?3X[G=ARXU8#?S8#S*90>Y.C,89Q-88 M4.M[]TGKY+ZZ]`=I_@+=!DZZO@DPW8./[G!_^=/_'CJ+5NM-7]"[(X0%#:_C MT+-U5YDP/O6 M*J\NM=VKRU79?=K7V_UT\QC=)X&X,J1ZNE_=W=UYV/WLB_X12UU`<74I+;?[ M):XNP9U>EI*Q'G3'XK-'W<^2A.7PA3)W]W9ZO>Z?*\(2Q$$Q[F!NZ$5U)\.< MD)M$T[E!5E7AKAR>[OYO^H"M7K1_88=P/5+V% ML/W3N"%O?'5IN=[NR"+UU:4GAS<\$A'KZE*0!6=9(#`9"ES=`9NG`S!U'X#A M![W/#OI"!H]W>\_1)]+][&:^;\:KN75%I.9FR,+*#M^`1"D;989CO:"]V*5N M5KK)(/&0_N\M_U/]4;[M5W>>[AP\O'/_V9/EF^@`W^T(?I M&:[/Z^*<)C>*COIV0AR(SV1CV./W;=C5L[N'`329)+G%*0!&O'2EMBVT&]-K M,K"7=)SNHO=V?]$E1\AIKQCFXR`G:AS%DIJ+IPN);"QX4Q!F_K$K,LYRG2VU M-H_VO1_X3UXC,*]J16]=R`?A2RH&6G&,[7CM01S0F4Q!S-$>JA5Z]?L)!R-1 M^L,LCTMDR$5+M5.E5%N>85=P/N0&?JVC$FVV(%]ZW#>)=VHM%VP"^17@T>RA MZQW4ZIFD?:BWX462N?1,C+5CD`\TQT,-H-;.R3:MHV"B!N4FP4-,TYHP#_%M M;/5-$M(VHZT)@GJ/CE?$F&A]9GZ55LF6/41FWE`04LSH21W%0S!26Q`%TE5& M]^;"'?M)LZR3-;<^*3]+@$'6+R;ZE5N]'!NJ$A2@6CZ`7I9%7J:+KNG4*)T0CB;*^].)]]/HDN.7"_ MW&ND"%/M3_#-IFDSRKDEE"IJSGJTGCW:>M%H(MAX__J42(&TFVWRU MS/19/""U%D,#(H-$//A<(@ZCK]R"803N@FUG.S`!0Q%:L8$O.D2RYOBM,C1; M3Q\G"6R@;J@NFI0#O/`XRI=+2X*97)N$(4>AK>;Z*9N*M6Q)/T.UD[VA22Y> M&T(%Y]%0#U^.&ZLJKK(N6UQ24HN'>I+N61%6&_?&F^K"S_?P_'$^_SF4=]!M M+C=0/M$M#Y*FZRO':PYYFAHI.VW@'@[@6`K'<=&FMPH.U10=0Y1&HG/A(&V0 M_>84`N9!!P')#38E"2\R-6V,B:C+/,STPM5\3#F M9FB$82''BH1XYZ.=$PH-ORZZ@24U6:-A]>99_`U`5@)6SU_G$^*2"0K<$LNV M1>8DZ#^5LM^2R[ZIAC=<+Q@0O$@3_:^07"X1;JJYOJ0KK"W566RXX M*(-O.70K>,5E#.(H4&_'6[K9N6:SMCC?GW8KJGA1*:9=(Z(22F],9`I=$]W& M-=_:VW[P\,&."AK)Z2L^?4A+?'/,9A-.((=]C6Y?A.9BEE@4+:+9KV/NN.#* M`_516/I4DA,L)2>0%/3I#C&8TQ@Y;Y`S,C3];-'WUFE@Z4$D32H^)>Z7%_%W M,@M<[4$??0.H?[9E/.)(`R9/@HD`OZ/YN@O;)%ZZU\P!598>59S@;:7JID52 M2WKQ23G/I=[W@EI"D%-(MCH%F&F1"E MU(VRCNPR-G6L*5U2W,?)'!8X!%IPCY2['22S%(N,$.NZ9UL1YEJ7M)G6%[(* M<(GG!_;%L]%SLTW;D7*Q>`&S`2>815RI+A>K1$`MUOO-P*16/&%ON$_4TTOO MJ.T/W:S-JLG>8P(IIJ&%126_2`)1P!\(7XOX]>4(HF/LP^(RP1/*84)ZXES' M$D*9%>>IC8YA"Z(]OM<0';1\S1V.9AN7(DML&?$_8!LU?HE:HQOQRH]V MZ"^R$PU>7P@6R/$U]H;5QMV/QJJ)@I/&W/<\ M_SCEV+3@G]$@`V)2\3'?EGZ$FD*N6G_Y,/[+`E[D-Y:[$6^/'@&<&!W$9P<: MZB(L>8>Y`PTZP+'Y-5$F9TK7U0B/W9LN%-4V07&_]TVZ14LMRP\$\0VW;5*M MX#(,C7<0ZOSF18'3*F0+LGN$=>?3FNS(G]"&4JV)B6.7`":297%^2M=[LAH! M?.@=\:GX`F_`N!5N<>ZC'>P/M#<(",EE2VS!.57CQH9G:MHZ42.^&0J=#39` M^AQ10DAT/,+&+FC"`(/L(`&NW71"G\U26367@'M7'HDU-M^0FH#D(*98."S(HML/F$($.Z(8A$J4R^:NOE*E_UK0+ M2>85'D:+RJX0^J#E@2L@"6?+S\C%.)HH4(Q=G6`.I[HI9&UA]N`54 M:S)9F!@_-J@=JJULQNLC.*F^NNB%56]#$^ZKJ$TX]_2KDXI>9(D=(:;GXGMBSIH`5<5ULTQO0 M5H])$S35NH^(L+DJ(5Q(KE+*W[L$=/7_W,H/S/7+5F[TRI)?5XM\1,UJP;9U M[^*=9]EOUR=%L/L#2_C%*U[_Z.W*[D5`<<#%K,PY6*>[KRC8T!)!^*G:C-_/ MD=V-,8%N,W<$XWSK=_ZCJ%Q'9G)U!*EMSK%?:U#+CIH#0KCH@&>-[++;FM_OO-]I M`5^#LIB!JKY;"\\2J8VG".]-N-MGG&W^L0DJ<=0@M!)4FF<0V[H501_KBCC) MKC726,OCS[_FQ2`TH9SYA3HQB<*6?L,7^D:>D=T"J\MQ45?$9&#RS%1#"_EZN+VFP+3!6LS]FVC_[MKO5@1G\^*" MFU+^C(&RVQ32TS3U+G!\E?'N60"9=BM&UG:C)L]1/J=K&.>K;8)"2W0=,]?T M#SX'D^`Z)2X#OO$"":A/4CUZ\C`RNFU"Y3'+_;VE#7W,."T+*H<.WSB(EU;P M?FW9D25&CN.[<5;+C.F/=YR,++*7%?#'+8@A86MGF;#+8WQO?*$8T3ERIL>B M\!H_,,<@+OIQEZ;/F&;9GZ,P6'F,=2D0F3$%8]JMP/32:^F6R""-'E<;E2>X M.5BLNFV"?Z^>O>0,##XGY9/=7;P7;?N_`/6?'%!KI],$5^?).(M)F"US/63B M@PS5,,I],(VBA-,OENG`*'MJ[US99*ORQOBKC#10?8\H#*%G/;KT&'&O\Y!ME_:YQ6L,[8JKU(`$N_ZX MH[P#NK%Z]B8J1K@8D1,S&D/XK+@FG\\)X)0WG@PBATZ&D\"H MYU>DF<3"T9.JPR%"ASI]Q.KMAD`EC!2?JGVF/M>L&-F#1ZBO0AQ98;OGUI\& MLPD6PWE-ZRM9GZ79A3I4(9E`A!ANWVN3E$4!8:&\0-9HU)Q(6=9D`YQV_TLH$4'%-1&XW]`Z#KY]715:1<6/&QRD]#W[3@*=/ MAG_G@C#FVGN*\#Y#2MQX7V!S&+3M^5(!U0^5`4*X(">M178VDS6HLTC"U]Z' M/AD4`O^!Q=#-6C!1#:?5(.67M.),P(!=Q*(I M;H[7$]WQM(/J=QRHMYH?S,M%T$WT,KGY8+@EL'7?5Y,T;I71@0.=C_J M(;+>)3LR=:*K',$Q*9NU%P7"N,J?<^23VDLC*L*GF% MH'E0D30=U++[;`:58X-!18HW,3U!A(QG3H&_Y\.`Z+N_RW.+MSZX?DK>3&B^:V-K)F:T;M7]@P]%95LV+.DGM]V%_;I*_S1$&VZ)& ME,85?"+R!DIW:#40EP>[>-,2X-K&L!U/'8YX.!*XJ^G9,*BKJ(`/=?>J6@$/ MS)\"#["A_HWE:^SN?#SU7E5,3&W7#[;JAJJVSY@XJ?P`F#*ZU MA<5VFA?MBG>M-LFG<4V[1RK13]?`BKS2W_(3]L955&)TAQQY<&8HYI`W4=^6 M),%OOTX(L_^W$^:@N6"T31K#2J.)-$&79X]YDZ3.+.N>.3N$()GQHF:X\,<5 M*PIM#!(L8!5OY6D[)YD"CGZUE<04UM!RM(HR7JNDFL5R_F$ M0-E:F13AI?%7Q^-(+M/H+#E`C*U.E$XSZ.CG&:\9@P*F!8ME87E"*GCND#0: M"GVL%*TD@-EY.9WHE0J!E-XRF@?:F4*+#XVNS$;KV1!SB:@`R.9C%FD*@#9#:H< M1$,,](HW@LRY?4)<#'5^S`ZSL<=M[O>&,_[6NJ;R!GJ65N@:V/3^)24DK!"L M%@)6+L&*M/"P;COT9:N+@&0?I2K!V\@+($"#?I_3>1:>T&()@S\QP>1 M:6;TFL)N8'5SC&C(M@Z6"-Q,0&]VB9UP(L+7@$$&UJ*9<_4Z"I.CG!694DD;>$R')6_N-JQ99#; M%!0KY$&U+;/:.OQFZ<:&-"G/D"5DA['KRYIUL$$T8^X.+]0Y9=>$UNU$9C*3 M41Q[$4D29/H.$=9>HKE'#.-]I-X]H[:NOP)QFZ[T)D\Y2-Q_(NRMIAP9YO^M M'&5O1QJ`V?H2/;/ZYGI0;%@O\682H'"`(!EM)0@!9^&Y\QASZS1B72A+#3&B M1E+4^B\#E-CE075D$U%0;A%]2'[&!;`XMLN_I3%6MU4O.M9,$@*R>3W1Y(0J M"Y&!>2P8(X-L^7%7U^*/T^(<$#'G`:>! M85D8;5-:19,)U_PIC0``/J)Y(]:ATWJ`!N;OI":$9]2EUPHI,08WCM(LZ03O0E)'19AFI.(U,?V'T`M.B1 MAIQZI?OM&@Q1=B5YK1F@@*:'5ZQXTYHE6\0D+HV`279T)GC*&]=C=@M_-UQS M;_XT+`,^,&K0E*_X]X)2"U0>@Y!*^O1'HW(NFR3[#XHS?4F=ON33*A\TZ*Z0X]P`/!:9JJ)@-.MJC=:,"RJ1.2V^, M3E4EW]A^DYW`G8+]AO&4XE?"#G_KHDCO)@+EXQI"K[VP[@#$C;02+DM`0+*0CBA;E&3;% MWEZH8Y$8B^>\'T`E%4_!J@9!"RL+9&2QO\;.L9]OP^_X"6?PH MH\RRWZRAQV%#NZ(2%2G%NV#A%3.*O+$'@M_JSV$EUC3Z]H:D1]O1`;'H4J$^ M"Q%8G$$&@R#J2N=A$K&][TDK@6W$J.[(33A'$L_`+,A[D1*SB4-:*T@!0P#> ML=.E[1+^M3F79$!'4Z'X_Q_5>W/^X_M(4:9=SO.+&]%UJP61['(01>C):=/: M0[?>36Z:Q9525XK(&&J?XNQW:\0S>Q]>6;*=O9EP'8?YXR_G%BHBUE$RU8?T MYN6W*I+R0B3SRK24G-),W8RC#V+]/CG'.%GRLF)S+"8DS"/@64)7:"OJ[I/1V3KW)D]MQ MR33JK%K3-!2%.!N9FHMZ(]X`IK`;>/6;H,TETG+;5:VHY;;Z0.*857BM?&NW MM/5M45+6XGB1':C5\:5HW8>L[]"&0SA1V]#&=':J*`^YF*N^_^&N;EY.;@MI M#"DVQ'@[],X6WK3]AII>?E'?&-ZF;`OQ/2!QN,`7C2U((<>,)]4WM:7]@JV[##VKU28D=&. MR8O43L]8_U_Q]L.+;TA]TOVEFV^X*F*"KD@6<:\XT1X^B"?64JQP0X#1`01" M5/1H^\'!H^T].G?B.W7T;S^RU?1"V%[6"WM/E.AIQ[)"\YW^#D>\M(AQ.UB8!/89?8)F;1E0V./K>..?&R?TKP,@,_S MBPO<34,N36XY.)?"#F>6?D.)Q,BFX"Z%<&4)9L"BN]!7%K:%=6H=/XMOHJ40 M06.@7ZN$EZ92AZWG!]T[):1^.CC]N.1=L(%"OF^[SQ3A;0ONUL'CYL4_PHK0 MW0YIFU?L:IK'3L/.+HV:0]SHUZPP"%M[];L&39;0D%@OQ0_!F;8@ME^`K8'# M.=%J8.PL*"1V79#_+'B/[TTZLXN?+>3630WF^R#3X6-+!>O-@KS#P4^]28\X M)4O:!W]A[)Z,*&GR350FQR'XGUYJ#LT=G04-$F>!#-1-]5M[NPU9$-P8E@GO M77SK/+6UQ).VUH'Y4.'>?5RSJA$)UW8+_<>\$IXWAB$*,-?>CA.D`F9SGY3( M$$/A&@?;6[B&\90WK<+)@:1P,E3W?LCV'Q>KY#:026ED..B6_TRXD>_23-F6TT8XZ/7S0W,JB'!4BK@*)EE@O M.^Y*>4)&<-(IIR3]\T2''01N]M4H8^AJ"(MF6^J0*"YX8".+Z%"M2RHQ:RUQW]J"0NFR7/#+D8UC1QK=LGH"?G=A[8%=/ M!2^K-PQ=X7&5^OG`+N+"E8R+R*`-\&9#4X]4M)G?R]>AXZ8M#\E!%$7G=C=A M)(=YR_I#,HZM4?^M[S[)E-4B$LU0=*6UGL9F,H^]B5=>A@`N=AP-D?U-W8`& MX_Q%*_RO)E*%$=XES)#\D;RGXUT+E0/!RY*@?A0I\_$YF,.<.JFB_I(09XE! M]LHXI96#`"SP.(.(:V&1S*[I^N0:7CGF#,S7Q?=:D)"EYCTN+A('@\@E>1(8 M`J\`2X; M)G;3#;=K5UA:KE%`R9 MOH]G_E[C5A#)VKXEU/;3M^[^RE7]L"1)J_Q)C'GE9__^_=L/;\S1CERI289R MQ:C!]3,0N\;#>\F+6J*J-=!@P&@6$'6/6[1U:/8Q_-5/ZWCS@WE*PWP+9>BQZ,2)!5(TBSND!4 M)GZ)S!)((/`OE6Y`:#*/H9).^"F7%L=+CW_94^C/OOF4O26C$5Y,D,SY]YEO M.!A$\!(:9D=U-P..TD+7X(M1XK&'$O$J#:@G[M4<0/X=!$,;WI*AV=%.CC'J&K(IA]!V7?LN.]2Z_7;)#`*JQN[LMHN M7ZW[X5JPGEMK;K$3(<-+QDK/,6+<\LJ[JKELEIMU..X?+XEN]U)]2"C$(F,J M%GTB-B]TLBKFT<(KM+;MO2.8(K!+=HY;@K!!'Y/+C!"`5:@M:,_AHCO829*" MIA*X"MU4'.*CRDV1GZ:5-Z!9L+TJ7.+DVRS632QGP>4+_I_F?\1&:VTBMS>_ M:CV%&BH9Q++@8XZFV94H*CRP'S'KA`WI/+#N1H!*Y_JU"UR4$FC`%UYRXS-6 M@-9PJXX0II%LZDD6_<:J<+<'S/;=]A:/Z$&HWPS!^P=2BKVS6UQ4#-)3=:>" MMM1<=`((9W>/OGEW].J0O"=K@Y9(VL]SO3(0TVD'HB>V/6V5,7'`L#Q':A?@ M?FGSM33DNUBR9$0G_]&L`#=_%#7T>K[TPT,HI9GUPWC/L=4>1:;(?VW7R`C' M4B+9F10()Q.E6UBU+MW`0[607WM>7C?^P5*IG[]?#&!0/"K)P"/A>AO@U9\9 M8GM@K/W"%AE$*0P[]!,$P\](,FW(L?C/&6MDE-#[PEBJ?\I*;0O3L^.UKKDQ M.5)]R2[O,K-KO^)'5DTU;\OZ9)IN$?8N^^>"7W?*FB'5_3U>;Y"<*PY3Z36MOO\E.RW,]:2+2X;:&G)@W8J,:9'\4-Z5[@=#,$%[R M8TP7M2/=`CAHSD@)ZPW3:\@%J>&EJ0;?_#&#$DI'(S=V^Y.KO6-R_'TB'(F` M\61+YSTA69]'U?[]1F%K4`*_"!%%)DL>2"8D#_JOOWBKLCZ5(+%:_,!(H,H8 MBV-7ND-[=$D<-7'P_7@=7GH02!(:*+VOR(K7T8^V&\GTFAZU_&L8DF+AFMEP M-9HMM(W)J?`T1Y386X$V&MO%/5DX?VF(+"`4-I@&&D`;G1"`Z'X=]AZ"T8W;5*+46`ABP#^F]]B]@!L6S"4'$B2R6L8&K!1:@@S-M/0 M^66$#DH=E#>2T5L&E`X@0T@@[WTS:NN"R,5T8>7&L:[RT^%YO\:N)96=;BA3 MB]JSQ!15SFL>951QV? MHS3!7Z#` M7O22GB?<0*S\MK7HCP@B]%"Z^[I`R#;5>P-C^F>K>PT#R04,[]@MC5^=N\Y6 MSSXT$S'HB2HRL#[<`>RB$EL"'6UDP-?_P=RY[<259&GX55(MMQI+0)%@L%TM M6<)@=[GE`P-4MT:EN<"0V$QA0"14-:V^F(>8F[GSL_A1YDGF^]>*TX[8.Q.P M2S72'%S)CO.*=?C7(8S"680\!L;T_0[K#)RD/:HNJ,GH3/P!J42LBI5CA6*6 MKLZ71#FJ9AD+`KB/S6`I:Y!$EB[?==#."#N6=F]J&=M?O"`0>(*[7H-]$&9@ M$]">\GKUS[ZJI.^;W"0.R=0[=9V-`[M44$DYOA^7[[_T\SQIVY3VL"5B3SW[ M7JH0VJ`NC!N:O4%+*0;33:1VF^.BPK32Y45_,Z8[4?E=,]R``W;"*65E\(V' MC@`1Y.25\B:%VP49I!BK`HWZWF@3MD]Q3#%UW\WH\W850YFM`NBDKXM6L3WT M;PNT+EK^F3A\4EX/RY$Z=SH'ND;U,<:UJ%ES*@L+J.56A+K5758E41K"QMP*L4`O$RI)7.L;>++I?'/BPY@,C+%T"JT^7>LX MS%HZ#1`VM8"O.&;X>U_N3+3BNZ+Z-@$_!WH;]Q2!H''9'ZLM MVP#\K&O6SAHV&B2@0!;;A[CVB%@0[GI)X`WRO$IU;[E08&JFGDD+T:F4 M+U27Q&'?Z!&ZNZ,V/RVFSMII^#`%`V+>9C]W;MA^(<9NLZ,VT50X)L3I2[:W MZ^PA3"EFPY27A,U,*L!&-65+*LE\M4,TVZX"[ M1%&\2K*^RFMZ*59"31Z,U[_9:\7E.9M'U9_F2+D]\+H'8[T-E)^O8%+$Z)Y: MK;Y"3&!6B`"%F/_;WDL*Y2DBC.;.TX@F*()Q_=TGL'8")U*&,?4*$4"8D!^I MW60ZGD_W*04,S5F)#9`PS['>QFW8W M!0F4.T=4\T8Z__OOG$$AT5]._]P`U:T*&Z!S7MTHWB.Y\S3'WVB:LQ2Y=#+\ M@^0>3Q:(+)$!>/'0]5Q/1(N[$6411XA1Q!73 M0@CD#"E#_IOS1G/)M<@.8L[\T>C'/.+QP(/3 MQ'M@L?8/R)-7DOV]2W8M)Z&"(8'?F1*8$VX<3-$@.O]F.FKQM3.84C;HXQ6] MM&J;E-+9:@@$EK)A;CY0U^QC#!2X7A:/:6%])]^.6SG:"#1L9HI%SY!1"O8?\].5'B MT%')H<3*@5E@Q\,EE;>NSA@-3"Z:I/`"QX*8#7\52A.J^_(=T(]TY+*@ONZT MM'KG%.+S!>!623_OP:YHN$EXE6!8--*2C<9./IX[((<.8,7AWT]TJOK>=9^P M\='3R&3^F0`I:]&`$GL8/Y,EMUZWV+#D7=JA-&X#)3W%`7$1Y'<.[4.'19,PA_%+9AQ$F?V:-=H7Z][O<*'R_D`[6N"NL1;R[R#S/\^ MQ^?'PT/$(\,2.#W4**&83A*"M/B/&*OV>O_5#I<)`]//6.%^ZT3G04A`#592 M>>_J_/#GT::%O7[-4)U.U9&-RZE&?GD41Y6&I;0&O%F:EK_UXH6=KXP&2NM@ M\XQ(E%,>C`1VAP38!SN8\*J]@(@8Q4'P=\X,LLV.'X64"!X!9\`R;G1U<65E M1?^+O($\'$P7$=OS=OELM(UNZKJ.GK-8X9/<(\TL]#"@6I3.++LE92JDNK<* M1.N+CXGW>+*^;AN3QV_VUKY>>[KXY-$:2H_.3FPLDI+U%SQG`?80FM`C202C!+".D7*B=6(;3*6BXN>)WK-H!$R8B=5L(M.+Q=]#"M.)3WL MR,EQ]`!_F'@J1@1LQ7#VU5QY'0ZPM.UCDLMH3PM"^N(/M@UL. MDC;:6"$F,;P,-54WQ:Y_0\G7Q'V9G(H<+;(QHRGT4__`S#=S]9N3=.K)7,'+ M9,`ZJ`_QDGK7U3F@M<#3J+0E(OT0[5*"N!V2*D&T(C%0LD48S#N-%5RS+E0< ME(UKVG1-KP_*QM<7ZD]A[:$PHQUY^^9\GS6S;(4\42Z7(I&=]IVWYS\"&F@L4PEXCOY1!C&\U1E7!QFMA@PDN\:"E< MZO*3)S8&_UCSJ]\=J%%8-]'^],JRB":*HE+(O^'MBO`&VIX)]9THKW;"F\51 M"7RSMQ.40,D?9'W.J5DIX3*[I:X#B1:-71IC!*T+?7.VMVISU4_Q9H. M(H4%)NU*GT;(:U=@-'E8RSQ,Q7UP,6M[JC]DZM/92>+U?*M3%_(;?`G0_/*1[U\]+>(4P.-N'T?UNZ5+10+UV.5R*9C3<: M,DNLXI?S4VX=/CHKT#,NTX@080D<&Z#D.,+39H!>.EX!$'7!I=O]'L7.0D;L MVOZ`VL\&A1L-4'SSF0:H,`'+#I$8FWMMAT5HUV%(G'[G4MX)AA85J M!KQ!S/$0W>DL"3HZ7X0FZ0>\RM2^S2&VT_G-*B/B&5 ML=]O>3E6:0F M9I+B?QCT.3%-QT!ILL4:`W>\PJ7^BAZ4DOMLF_[UCF`:*718C/A[A8(OF>Y4 M'H?1*I[@I>Q!T=91S"3]H(!G-,L026>/&X45O@][*>+3IIL.+B+&W+LZ1T72 M_GMEF:@<'J&AXN(^M`/BLGB$,/%CYS=FZ^Z[BU.'(TA(FA^HB1T98;4FTBQX MR`-O312<`8S]C]>I91XN:K4&OY#09M`U`ZWT1SB;%+9[>4;.IM,ULXPK,QUH MCJ&R%U1:?9O]^6%I4@=S*&*KHP?IJ[;U'U]$J1ETQ+#10Q;+QO)ZW<,"SH7F M-_F_VA\?+S^M?\3<`&#ZIVUL_;>W0YO5_=#NQ=SKZ&W^?]R-%$P6B5`>%!Z^ M$5JB:)""HQ05)!*EBOY,R6FKSBC2`$#;],"^"F#2:+DVT>P6&B`-&VA0UPLP M$3D@S^8$N*M#5(8_>A*J*AJ%.R.BC0$%SHT[!!ZOL!&XJ1(KRSFE6\MX@#:4 M/%-1>0UVY"R_J-JZ25G*VUM.X5$:,4QA/?T0IY"]L^&ZWF,RB>+2RUI7S_8D ME0)&]B<`1=7)D>3H4O35LS$%)B1$`F+R&\BF>0MIA@KI_C] M;Y49O]5;F$DY?P$45KC'PFN<20_K?=O.#O8&DY!([SHB#HZ`K[ASRN9[F:(R M"6-0J*X`QCU5:C2D[_DY_X\"9"='!E28%`JY!;I`>?]1.)BL!?:6P6/$QP(E MH&()6\\%7]U&-97)7>=$T%R;3<>TT/1,Q)6KEYLL^K+LWL8I=5<6IN!3BZ_C MHDAE]"S,@V$\9EO/0TEV)^?_;6:2[4`=^=2R/AJMR:@3OQ@O%DJSFM>O`TVC M!:WTH9X/R+.:(R.W"6A3LLDO/3`53!4T@5B#AF(F\JK(Y/OR^:#YZQ9A#U\^ MO\39^^7S#Y,CEE"W?^EJQI?/6_CTE,)5?T"6Y=GTM%?`/7<^6K5>?BF<8U03?; MLT!9NG9,U(-J>B;$]P_^,5HPF2B-C\,/*F"$7[A;?7?B+C/K40"^^=.\"P>! M+S%8P?L75EM%Z?X;G91`].N6*A=6Q^VV1V@W'UJ\_7>ZDUUBL8/+Z]7^[O!_ M8A+JM]_<]\.#?>,,VR^??:GE,=IR%PY_USD0=L]%2?=DM!#NR4/D"XR&0^6B M#+/ZKSCLJV<0\9,N`=AO#0?9K20=CB^IAN@;T&O3P4IK&"R,'R^OU!\6_*Y% M.'JLD)5QS6>8[1,>!YG1<<-(VWY7EA_7'2R,P0LJGJ:QQNV=7UCK:8[&57@5!DO,57_C-"'8)TX@(YF:.:TA_0Y5J` MVB5?&^F_$.]K'FP/Z.VM0ETV(@+):$+Z<5SCU\#.AH3Y%\E#J%NBYYPR8\YV M$^3M2/%6YI%0/4`2DP*!Z\<-%HHLT6O0;/5G"[A&"X8^.Q9,::*CD<>)CU>^ MZ#H%>FD] M/!3D#Z#DB"LW`6)"!CDH";@PQ\P9V>(V!AD[5^CY*E%=]$HNH]0UN$E,X5LL M9\?O%X#"+%E?Q+XA+9LU);O!B4D+HLH1_NOPY*$^//APAMD=@"/P?T,0J9&M MO%4%WU63(-!.LU0FMAYWC6%+:;7LZT)9%:6AA9PH%`BBXE

=:AP8T2,.3A1E,(%!8\X9`I\RL@@*@OSKV%. M;\LY:B?=JBY3DD4"'"^)&I'T9?T48Y"`9.CSY>3[FCUTBFUV_V@:RXMK7N<- M9A$_Z']^6RTMBAA&*E3@OQY<')SU3,_48/_]=YS=<[VI:H%%2`9'"R*R#+RO M1_8^!#>N&;*^I[TBA6A0,U1PM;<'B!<`LKXT"#FI:3D`O:.=NTA$]GZ*P7HN M?Y6<39F-8.:;<=F0G`?K%Y?C1A+=\J;,P8];[8HR>PI4Z:&HOX4"F]W3NGKV MX^7YZ?F'F_KG=Z`R?;_OQ8=E]_"*4<%'S*QNNWE(C098&L3MC&X;$QYVK)LT M6MBWN/>@<&?1ONG9S>*+,3=1?/('.8R%8NU)1O%1O."6#/;BE"`\;L+'&QBO MIDMMK>?TXN!2E``N"K/;DV;#E5. M]5W($%GD#4*SLS:5HB!TJ&W5FXK1J@D8B@)"Y?C-O8N?0!9$.(?>8U:V,&)C M1$BP0L^9WA"#PT,9KFR;-DZ?EGEJ.DU`)"^L)"XD;24OI&"HPMS:QCK%Y6[8 M,VF>PV%\`M(54R'IR%A@A>Q'?'=L)P&2HHH'G$$;9ZO'NVYAYWP_`X&:>%MA(2 M[3/7)#(>&$Q&Q^%'SV]L&VR.]1[TV"V#$Q#QBG5/1?"N)R5&`=F]B#K25JDC M42L\ZF&[IB/5,W!1F/M&K]H)HO`OBG4CG,I%8=UPIFA:&FV&>K^0?&&[C1:V M)SS^=/IPM/#CWO;H02.[QB,%<9'X]T*>MGI,RCTNCU9#:'7]QS<'%.>]_E3_ MO'G]@39//1R[_N/^Y/#C6:]TIC+C\F@E%..KF[V9'!U`ZA[W7O]Q+\?3O=#= MJ__^X\7HY26+C$F']=^!;QCY4?^$=\\/,=S1AN&,P5J#VAH%AY"CX46_/O]T MP-/(X`6S.WEUM@0IP"7%1**N$%:UPN\]2`?R*91@O:].ZAFJ3?ZLSK2[NT>B_EG0,S M,L-F\:9N=_-[6XR:;U?K11PO>D9YO;LPXH"DZ/1N(685"B+V7;22$W5QU"]_ MP<;><#=E;RI_QK(MC3[L=3#%;UK*6SVM@5'JS[KSD%IFQ\//*J$TN51M MZBD*/C*:>WR?(VDGH)LQ/3GD96W32!7:LJ58AY),]XD@M1]1#7BYYVCFF82K MA\N-RW0+6APBN4-%K=#+S,%>'!][9CT;8@W$0?OXX>Y$0(ZD&SM7?`O"TP]H M_%C&]ZK7X#3LA/4>>_U])7?!:(QL$=_F]Z%)*[R'.[4`F5\MH1P\6-S5HU"4 M73FT)BP.58]A.:A^D'I]L?#,*=E7(6?=<.5R.76CM]"O@<.G@3AOI8J.FK&Q"?!4N6%1F;URB+SFJ^3TD-ZQFT7B& MR]4$D,-\=XLPZP!L-!-/Z%:]``XHLA":H(2Q27%XU?/=+`I5_23?%O] M^M%@,X+PXU,G?1L#$6TLC1N_?W?EIU1R7M+X'.3[ADLDN$!:7R9`G7M!,`42 M.A_=*P19[F(ZO]V0_E%TLEA.<185=[?@*%.PV2G-D0]^GA2+^J1?GE]:0KKN MI>+8\M48_2M`5UOV)VQ:`S+OT<$]&D:AH$!U9:'<8]37B5X*7;WNYYVEK87: MH/=8_:M.CMOTUP/59/;R+FG_^I??(=@(-T*MWPQY+\C70/EC@?(?+9IQ/H4B M)I)7@<=9#KCQ`?*;1:WZ[KOP':P^(J6T$.OFD093 MJ.K>9U*]Z>XZ"8SYZ6B/YPSJYK.H9G[KKS[YB@45W,Y<(,7!SR!/R=DK4[BD M&^B2#5%%^L[$8DWCZ:^AEWJOG!R^,Q(J:`(5=H_;4G]MQVZGU_W6+O.^F/_V M/.;?W"6&RJR752?"5CA2M9<]3IYB.X?)A@=$+4!BX+7E?NM@N+O$.WK[Z]LT MJ5;%?8L64OWI3^,&<^Q39:/I+F':-=]O[;0JMZU0[@;TP5(@UAH@M<<&]J_H MUYFLV2X%N\\^-HB`'0I>-2WK[;E,H_"#N=EFFFAYEW",!L^MPV?!M1OHQ,O>[]#:AYCQ_*'6V9Q.142?!5=+G% M:WG#@[E7T$ZCTYD'S#=RI9GZ#P1)\2YP[`PN_-S+5I0^ZU MS@HOH"ON9VXN9/&P^X[D`D3_#!'!_7,]HB2//HH/[U M97@+\?7!KP*K>A9I:/!HQM^O,0L5:;1E[^&AR'@+_K$+ZC7AW2I`TD:G*2FU M`1WL#?0_*:*$6)Z/-7O>JVVOOK'MV1E_95-GEB9 M-NQP@/[&DBZH?-R$7_>]"EV/\O)$495S%H+GF\I,!ET8-^WRDUF*<(:?3OT1 MIH94\Q=%H"@1E$XK,S[O+5,>WX%K&:-A8>E#8:6P_.%]0I,^4S8C$Q"NX6A"#!9@X8L MWK85&Z`GHEA(?[N\7_WGJG!F[Z`><6Y+"WWSPU8\8\X^)-3^I#VY'8LL\13B M'-_0>T_\I)J#S#,*6X;=5Y0M3N^;-RLY/UN2-T^1X+@V[+E/!;G)%Y&D"%H7 M9?,5H)PUDV_6$>_&FC+3YJCD->4)$*O=*P:P+,(4K3X!2"$8(A4L<;_SBC7. M.![=;"Z,B:QRFP[E<5DD(`H3ME[@T,BI(K(8)1AVYP1N[8ITD=*,$ MF?#2T,4&//&0%?8I+A[>"H-"7/8T'CQ=M-W\JM%%\["#-&AW('NUW5!GN=Z" MG5A?&K@A5;@HCU2I];=K9!>'*'IBWO3FR6!O#66X]9D<@)V9W+O34J$KKF*[ M40,;8XZ^X=B[K_"J%5[#4/H@.Q7OXMM5;%N,X4-1JX+4J6U_@=8XI-DA@H;K MB-;GG:HM6I68^J\$+L2$G?X24VV#9`.T7B!8^7&LK;>E3/0D$]A M4K0RU8_QO07FE1LVVLRE?R2GR^_"G0C53F>I2D7\PE3!1:@FUWAG+U46HUYU MYL9--5#S/,8"EGJ8=4;C6`=CJ/QD/>RFE_TXG'KSE>]U8B\./>2[?+Z!%&*U2#0),VJ:0RTVE0]"I3(DS3W:=PXE[4^N^56OON,% MQVN?&(F5G+IKZ:RZ][\/U\5"`3*D3R*VX]:^TR3*CX<]>N&(Z]E%C!4)$4%' M.$[@`!["V^$4\T)C7\221GNAX%')2\J>""KJ/.A83"`HL,+?9P=$,XM$8&"457C&H(G9[>JMS1^+:7#I7E_R#@.R!3F-1,BNVV' M7K;L-C$NLZ;EO=QZ;^[15;UAU2F$9-]DF^&ST_5:'F62)*).+L M!Q*)U2FDI]=3,JKM"[R_MZI3]CAZ0<(4M0=G3C7%O00.""_DIBL>BL1:UAE# M;!M.FF)^1:Y`<;<&,>T[I"',VI&:K`S(>D'[1$7]QN5'E;EZ-,W7AWAO\AA&!#2K=,W9A+$#&;9'>B/&#M89EZ,8L`RB38?!"9+-`M M!"9A-X*2@+]1)NU.69]_.)?G[P^_=\9G/@=4\6A/=]-I;;)NO6F#SWM>_)QC&R]NGIK:>R1<4-8N M?30.?8^T):MHNU_Z/W_2(/%F'6DA.3[0'2TPY__C MP78[6I*"E<>&M%*;<%)C"?,7!]J)LUM3_H]=@_G#L1N5K.G`8DMK*I][4]]K MROG]OF4<;VO@?D()+L_>_K15^?7Y2"R)**"C8C*.)+!MXI.JR6()J#\YE,S^/"^C=48%0F MM\JE]P(*`>UY7,731?`()2U?)+F63'WO(HDB6[(^2U0!E6UQ'GC-07;*YJQ0 MW0.B"Q84R\6*H>W7&W:F4$D.Q,'5^;<11EL2LH3$$4#>(;,YZ$*#,,++#D M/6!*#)O*!,OLB>=:DO1;2BVNM3M0N`,;8\":&NP3=W$E,/9V[5627?O$J6VN M)6E?^Q$:UE['DSZ.C+KIS6)FH]0-;\QP9&9;:.D0[=_[1B4Y:,X^S;5$H\U" M=W)K,XP2U&4;I MD,F,3R=N^L8,CQ`T\M7?HLK>0Z7$#I5[JFF)/M50>*55EB!)S?VA5Z`IB+(! M.-P^U"3T&^*9M80UF;YK$E="Z]D1W5QB&!37T;UG29'<_@BPH?- M&2_@KM./!Y<`W#4ZO"=?,=_35G@UV8%E.)["GN?ZMJ(?).OZ[]N62;AE]#\/ M<*DD&PO=V]R:W-H965T&ULE%A1;Z,X$'X_ MZ?X#XGT!&T@@2K+:`+U;:4\ZG6[WGBEQ$E3`$="F_??W[;\N3;)^Z@Q"]!0Q-M[(/?7]V[W; M'5N1;X=)=>5RSYNY=5XVMF98M/=PR-VN+$0JB^=:-+TF:465]V!_=RB/W9FM M+NZAJ_/VZ?GXJ9#U$2@>RZKLWP92VZJ+Q==](]O\L0+=KRS(BS/W\#*AK\NB ME9W<]0[0N=K0J>;8C5U@6B^W)2A0VVZU8K>RO[!%QD+;72^'#?I1BE.'_K:Z M@SS]T9;;;V4C8+?!3\H#CU(^*>C7K?H$D]W)[(?!`W^WUE;L\N>J_T>>_A3E M_M"#NT-0I(0MMF^IZ`K84:!Q^&!&(2LP`'Y:=:E"`W8D?QU^G\IM?UC9_LP) MYY[/`&X]BJY_*!6E;17/72_K_S2(*:,N)'PD@1DC">,.CT(6SG[-XFJ+!H%I MWN?K92M/%D0-K-D=TGV! M+2U&R$9#YK9UA7`*20]`:$(K(;B"L)$>I3H>\+5."5#>17'P1TY8V&1(,/ MYV'D>88?$P+@/#8!*09P'D9P5M$U,H)@<1@B!!$7?$2<`D-B87$A77BC(<&0 M5BK`$O-#:G[(T`=B&N0*#K#W]UV!C7V?&:9IR$SG3LPFVYH0P)S/T)[I9,&` M*/+!=72)C`#\^1P!B+09E::.A%_GCIID2)S3]3<:,DKD_E0B!K!X-I6(`3-X MD()A#S("\`(?`8A$.(;N]YX"&](B0YJ&:&EQ'*!E![L2/![R24:D>)SS8.H[ M#&"A]].,43<.=)R_'Y8*;`B+#6$:HH4Q-C$\P>,QCB@=DWC8]R?C&1[G$8X( MXJ[X(ZH4F*KRC4S8:,BH:II*"1GW)V&6XG'?CR:`#`-4+E\-(+H8E*3[W36@ M#65F?1HQ6MI,Y=AU:1V*!!$&P<0I*4%P%LQQM.D\(Q`V"SP<\E2BJM`H(N\[ M39BNZ[A2^<9M83-BSK%Y2ZIF&1'S:25*#0YOLAD9081AR-"&4J&J9B.A[Z<> MTQ6>"+Q6^&&3-R-&FP^%%*T\NE*3:$!`TF<`I(0ABK"31C]B!A;Z.,&I.E6S M[U>G*SQ19UXT&+X%Q&3E41T&,![CPWR4AQ&<3P`962/P2%6E\E291_+NC%)] M.2`RS2L'TYAX*.S,84913(SQT(CRE(Q#>Z%N9.@Q8B8C\,"YKD;EJJO`Q^7J M"P21:UYC5%<$I^]%;A"3AU:7Q$`;>Y>28=!^53-&+UXL<."XP\\5K;7K[DXW M/[5H]R(15=59A7Q6G1L'!UV^ZJYRPQ;0DD!G87Q/5;_)6W M^[+IK$KL@-)SYF!@J]M%_=++X]!@/,H>VKSASP.T]0+NHIX#X)V4_?E%M327 M?Q2L_P<``/__`P!02P,$%``&``@````A`/MBI6V4!@``IQL``!,```!X;"]T M:&5M92]T:&5M93$N>&UL[%E/;]LV%+\/V'<@=&]M)[8;!W6*V+&;K4T;Q&Z' M'FF9EEA3HD#227T;VN.``<.Z89UC1"SF67"72(6=L#/F-^-"0/E(<8E@HFVE[5_+S*UM4*WDP7 M,;5B;6%=W_S2=>F"\73-\!3!*&=:Z]=;5W9R^@;`U#*NU^MU>[66\/7.=K?;=/`&9/'-)7S_2JM9=_$&%#(:3Y?0VJ']?DH]ATPX MVRV%;P!\HYK"%RB(ACRZ-(L)C]6J6(OP?2[Z`-!`AA6-D9HG9()]B.(NCD:" M8LT`;Q)__/QY.1`R M:"'1BR^?_/;LR8NO/OW]N\*1R5D1SBB!4-?A.KL$S(P5SX M15Q/*O!T0!A'O3&1LFS-;0'Z%IQ^`T.]*G7['IM'+E(H.BVC>1-S7D3N\&DW MQ%%2AAW0."QB/Y!3"%&,]KDJ@^]Q-T/T._@!QRO=?9<2Q]VG%X([-'!$6@2( MGIF)$E]>)]R)W\&<33`Q509*NE.I(QK_7=EF%.JVY?"N;+>];=C$RI)G]T2Q M7H7[#Y;H'3R+]PEDQ?(6]:Y"OZO0WEM?H5?E\L77Y44IABJM&Q+;:YO..UK9 M>$\H8P,U9^2F-+VWA`UHW(=!O-29#`P<7""P68,$5Q]1%0Y" MG$#?7O,TD4"FI`.)$B[AO&B&2VEK//3^RIXV&_H<8BN'Q&J/C^WPNA[.CALY M&2-58,ZT&:-U3>"LS-:OI$1!M]=A5M-"G9E;S8AFBJ+#+5=9F]B(K5"MQ:FNP;<#N+DXKLZBO89=Y[$R]E$;SP$E`[F8XL+B8G MB]%1VVLUUAH>\G'2]B9P5(;'*`&O2]U,8A;`?9.OA`W[4Y/99/G"FZU,,3<) M:G#[8>V^I+!3!Q(AU0Z6H0T-,Y6&`(LU)RO_6@/,>E$*E%2CLTFQO@'!\*]) M`79T74LF$^*KHK,+(]IV]C4MI7RFB!B$XR,T8C-Q@,'].E1!GS&5<.-A*H)^ M@>LY;6TSY1;G-.F*EV(&9\F_W4`BA;JI)6@8,[F3\N>]I!HT"W>04\\VI M9/G>:W/@G^Y\;#*#4FX=-@U-9O]2!=(.SB"QLD.VF#2I*QIT]9)6RW;K"^XT\WYGC"V MENPL_CZGL?/FS&7GY.)%&CNUL&-K.[;2U.#9DRD*0Y/L(&,<8[Z4%3]F\=%] M$5LE`[2A<9SY]UM-HU8U M7B7[,C,>3Y=UJ@Y5]BR^?I2%\RYJEF.T\=:Y%NVT-EX06^'WMEFE>NB3"OA\20NUV>"2ZS4RFJQ@2I19$V MD+\ZY$=UB59F0\*5:?UV.G[)9'F$$)N\R)O/-JCKE-G\^[Z2=;HI0/<'&Z?9 M)7;[HA>^S+-:*KEK1A#.,XGV-<^\F0>15HMM#@ITV9U:[);N-S9/V,SU5HNV M0/_DXJS0WXXZR/,O=;[]+:\$5!OZI#NPD?)-4[]O-02'O=[IU[8#?]3.5NS2 M4]'\*<^_BGQ_:*#=$2C2PN;;3RY4!A6%,*,@TI$R64`"\-,I!1-_)`!W=D(U;SF.J3K9"?5R/)?0V)=*!,DZ(+`B2X("T;!-&)1 M_#R*9S)J!?*T25>+6IX=<`U\ICJFVH-L#I$ORDP>5ZT_D@H:=9!O.DH;"U0H MZ,_[*F;3A?<.-HC-!6T:?8(NXP0IHTOT.AC.0.XQ:$"`W_CU!]"$R(>A&S MB*;P8CCCUH.Z&6L;X#:0((#D.*8Y/FZ")B]=*,#-)V,K-4.9MD:;1%/?]REA M30A!,+,)'!."()K"0*4A$L)@LRA"#"(.GAKLM,?B-)F*"^,)_>07PT&%MP%N M`PD"2&XQS4T_W<^?`GWHF3D,!^5H`]P&$@20'&$B#*^?)M/Z!;8Y#"5NS1'X MLU[OUY00X,::J8,),%M#U/F6D!!""._?S$.DZ?V/ANMC:V@RE1;&]O0Q'%1V M&^`VD""`Y#:CN0VSAC[TS!J&@W*T`6X#"0)(C@PF]O`"MFQ:P9XY.HYQ!YN% M$]2ZMK=KRIA.F`]),$(SU'L(93C0+&9[/3$+6G%=[6V$ZZ_D,)YN:A*,T$SU M-D*9/C&+V5VXEOW)8CC=9&']N;%FA.%/>E;@A!%&TW'?+#A&&(;PW>?:4BI0 M[ZCA`LU&PP)CUILLAG0K[YK9".\A"49HAGHSH0P'FL7LLR=F04NO,XN-<&8C M"49HIGH_H4R?F,5L,US+OED,QWR##7S_%6A2%_I_4^KY13B!V$]$<3>$!KZ`^X_N-D]1\```#__P,`4$L#!!0`!@`(````(0!?8\S`V`4``'`8```9 M````>&PO=V]R:W-H965TB#],FD.YY13Y2J[J'GX_EX> MK5=>-T5U6MML-+8M?LJK;7':K^U__HZ^+6RK:;/3-CM6)[ZV/WAC?W_\_;>' MMZI^;@Z2GUIII.;'K(7W;P[%N5'6RGR(N3*K MGU_.W_*J/(.)I^)8M!^=4=LJ\U6Z/U5U]G0$O]_9-,N5[>X#,5\6>5TUU:X= M@3E'OBCU>>DL';#T^+`MP`,1=JOFN[7]@ZU2MK"=QX M,*!;3[QIHT*8M*W\I6FK\C])8KTI:<3MCO6XSF M;+R:CUOB'_S7@?/+ZT'Q=F])SR_M-ZR MU\%SR'J.S(4NM8*LS1X?ZNK-@GJ%W6[.F:A^M@);*J?D3EZR[%=)!MDEC/P0 M5CI;D#\-5,;KH\>F#\XK9'/>'J?V`H7'>)%2%61+K"=6<+N+C-16(L20P)6\YF6))J$B-` M<.(.#Y`@FP&:>*B`-Y)S#8"/@0`#(08B#,082#"0:H#A']P,NG_BQ+Q_*@C1 MO427',U/#`08"#$082#&0(*!5`,,/^%\TOV\G>B";.ZCBQ-=4KPNT2&;)CBA M?$FX^A_HBNEB,L6*$"LB7<&F2X](8BQ)3(FW]/`JJ28Q`B3Z:NWJO!T@038# MY#'/+,*-Y%P#X&,@P$"(@0@#,082#*0:8/@'[8#NW[!$%Z)[B2XYFI\8"#`0 M8B#"0(R!!`.I!AA^,KC3L:-L+GKH.U=])S0WE61]SY%ISY@WQ^GE*X9^2TP7 MJ&<(%*LK'S9>T%-?,6[:B12KLS.9>>1O296*B29#&)9U6JFO,,(F&:GB89/NEAXDQ=&ALF-:C M=6'P"1(0)"1(1)"8(`E!4ATQ/16ME>;IP!*0#1GLXZ69IC\6Q#P$ZN2:\#Y! M`H*$!(D($A,D(4BJ(Z;'HLE"'@^[8F1WIF\SK0;)D3\AEG.2VCZ3!$^W\LD- MHYL1]POZC1`.,A/U+/DV[H*1BRH>9"!KI3@WNUG_RE+CA8!"(84B"L442B@DAJ_]>UV&$W*8*B=>):_WW.?'8V/E MU8L8E(HDO:!JB#N'*>Y<3!O0-^"VFN^2;U8PF***2`R$/\$W[@HF/)0?N"N8 MXE`\>LSW_(ZOWQ:FQCGP';HY'8LA:RXFQ_-!6 MYVY(]52U,.GM_CS`9)_#?&4\`O*NJEKU02QP^;^"Q_\!``#__P,`4$L#!!0` M!@`(````(0#]--=-Y0D``((R```9````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`5^>:JW(^MWLIK.W]^ M/&33]&[RPX[Y.G"6G!/'F)*W%#?"KJYJ@;YNA"6Z9;020X$"`!-KNG-NQYLZ M=W/N0N>NBG/>GG_I`7O2KA74IK:"HR2)1EF2`J@`AYM/,3>FQ7 MZVFO3H2])C&9&DO/`5XIH#R0-5XCZ:(UE1@HN8H6D>04B)!3NR52IZGEGG;J M1-AI-KW!X['T'."4`LH#WNE5*ERT#@PX?=+Y')_(H#*Q-#>*@3JH(79SI0T9 M7J1.A!N2Q.0ZEYX#&D(!Y8$P])(1324&2J[B*!&Z6``1_N'?F\8\\,HLH"WVN6@=1?:LX0Q1#-$,.0`B+8 MC"PT[Z=T>*ZI"*#19&T>Q>!TTP(;-1E#F#TS$GHDPHTS#-DY$EP M$E)$!8XW'$N[JV9E#!+-I`!20!'VZU(&\3N<)B*?3:!?GB0#"?H%D29\@/5( M&&!IJ'0HD\&3\339LOQG#3E.MIS/*N'&N%A"&C,<*",?9N`9>*(,)-@8D(%" M8SSB&Q-)N4FS,B8@7N0G#[L?@3-AORZ<$+]G3`0?:9!?EBLCD'O"2J>("IPP M$:2;DFXI\&191`R:EN4G0B1^J&HYGU5"C8E).',[PG!C&A6^82<)32^!!"8" M0U1`X)CBFYMF&H,TXGX`-=CM11$MYA$M2>A&'TC0I9?UB`J<,/SBOL?*&"R2 MUD@!1=BG'7LXW4_?T&+'QJ.9LL'TG-Y4'E0]H@+B;&:21JA90@[M`LMA`%WR\PIL# M^5YU&;,,QA#%$,T0PY`"(MB%2SIDAQZ^([EO^.W4/9TH`ZGO=LX0Q1#-$,.0 M`B+8#0E:`V/"`Q;_0C*F<2IGB`I(V$[%C^F:J0Q2I?)-!:JP4R%BG3%N/&+Q M2!G30)4S1`4D;*W2PM%,9+`HEC_G0QEV[$(&F:EGW#)]-$'KCGT]&8/\XK,$ M0U2'N` MO*Q'5,<1+E9W!WMO;0&!7D`Z]G91+DIX+F+Q+W!Z(SE#5$!.+48F,ECTR6*$ M,FSTHNB3"-&'?U%]ASA#%$,T0PY`"(M@%B4[G?4>5^'1T.@@&$G1#0Y5B M',T0PY`"(M@-B4<#8\)C$0^""8M%#%$!"6LQBA+I@Y5F.D-T4_&Y20%UV*T0 MC=Q=9L`UCT8\#"8L&C%$=8BP6^KN8+^YMB4%>@'IV*-+!N#&<>;-T><)M-I8 M_$M`Z/#QCR&J0X2+UN'@0/P[5:(8*H%ZD0IA:'B\&Q4)0RS^!1)8JPQ1'2+U MHCO8C7>'"/2B.VCIV..7PE`JA2&2UI>!!#VV6::]:!4X?B5'4_'+HY:#9E=$ MHI=I6EQ90A1U?E*M2GJMX9@RDWE?.$!40[U1\94@SD4$B^;$)%&&?%\6J ME,\9_7[N:]NA2VD.U9I4'-(<,APJ$(1]"TGL*[Z%:$9OGDO[ M`KQ;_<0W>1B4]ZS>=R=L("GSO[`W]@[UK^[;:6K?W6_>3V9'YO;(W$U"=F31ON]/CM@_!/C63%N"+Z/; MO'F;GN#*_N&`B,>W]@UF?F83W]JWE#G^+C;?EL6S"]=N_<'_S?$/A?CM5;\Y[[8W6T[_XW_WRU?^M1VA?,I]>6_%Q5 MQ_87=X+NKT<>_@8``/__`P!02P,$%``&``@````A`)G0!<50`@``@P4``!D` M``!X;"]W;W)K&ULE%1=C]HP$'ROU/]@^?WBA`0. M$.%T"-&>U$JGJA_/QG&(11Q'MB'P[[NV(4"I*OI"8C([LS.[R>SE(&NTY]H( MU>0XB6*,>,-4(9I-CG]\7SV-,3*6-@6M5<-S?.0&O\P_?IAU2F]-Q;E%P-"8 M'%?6ME-"#*NXI"92+6_@2:FTI!:.>D-,JSDM?)&LR2".1T12T>#`,-6/<*BR M%(PO%=M)WMA`HGE-+?1O*M&:,YMDC]!)JK>[]HDIV0+%6M3"'CTI1I)-WS:- MTG1=@^]#DE%VYO:'.WHIF%9&E38".A(:O?<\(1,"3/-9(<"!BQUI7N;X-9DN MAIC,9SZ?GX)WYNH>F4IUG[0HOHB&0]@P)C>`M5);!WTKW%]03.ZJ5WX`[QH5 MO*2[VGY3W6>+XZ"N+6:W0H^%[(IR#&:N!"]&@F#`9'X$P^CR],8FK-CC`3OP MGZII'U]0#9A)4$W3*.N?!]WP'H4U:^F&?Z5Z(QJ#:EZ"ESAZ!@(=WJ)PL*KU M0UTK"]OO;ROXV''8M3@"<*F4/1_<>]I_/N>_`0``__\#`%!+`P04``8`"``` M`"$`F$*7_,@"``!-!P``&0```'AL+W=OP8$ZP"1K;3M/]^U[C0F*1; M7Q)\?>[AG'NOS?+FN:[0$Y.*BR;%H1=@Q!HJKSY^61R$?5)[RM:LIHH3[2L@9U"R)IH6,J]KUK) M2-XEU94?!<',KPEOL&5(Y$^`L?F%;+G(,#4W8D69'BVS#9QMA?+;OZ_.;LJ$Z>D2K%\8OD^0-O&!0; MVF0:L!/BT4#O)EAF['8,CX2O*7C"D* M!04:+^ID4%&!`/A%-3>3`04AS]W_D>>Z3/%DYL7S8!("'.V8TG?<4&)$#TJ+ M^H\%A4;40!*]DD#&*TD8>=%U',:S_[/X5E%G,".:K)92'!$,#;Q3M<2,8)@` M<^_,ZAB\OF<5Y!F26\/2<8$+!>UY6L6+V=)_@IK25\S:8N88#9@H8]H&EP1=4Z]37Y4[U\@W8E3^-KMT7K<\Q8_47$!.7)+L` M<1';"X@W$L?AQ'5H.C>!R?ZW4Y.48GC)T(1X,7U) MP-$X/=#%T3CNAL6<:!P'LG%@>Q)P-(*>CT^*`8_KMQC5SV(6 MW3$(O-'`;MS=T0QE[N[4988KSKR]9XZ'7>O'7E_V=-=,[MF&595"5!S,U12! MGB%J;\UUF,"1@Y,SBF=PFW9Q?]B`VZPE>_:-R#UO%*I8`92!-P=%TMZ'=J%% MVQVDG=!PCW6/)7RV&(Q1X`&X$$+W"W-DAP_AZB\```#__P,`4$L#!!0`!@`( M````(0"Z<6'?2@,``"H*```8````>&PO=V]R:W-H965T&UL ME)9=;YLP%(;O)^T_(-\G8/)5HI"J7=5MTB9-^[QVP`2K@)GM-.V_WS&'0$Q; MC=R0`*_?Q^<<^YC-]5-9>(]<:2&KF-!I0#Q>)3(5U3XFOW[>3ZZ(IPVK4E;( MBL?DF6MRO7W_;G.4ZD'GG!L/'"H=D]R8>NW[.LEYR?14UKR"-YE4)3-PJ_:^ MKA5G:3.H+/PP")9^R41%T&&MQGC(+!,)OY/)H>2501/%"V9@_CH7M3ZYE/RJ1 M?A$5AVQ#G0S;_>`%3PQ/H7+$LQ792?E@AWZ&1P%`=".P$/WWA+D)+<7O,.?_ M3\C[IFS?E)?RC!T*\UT>/W&QSPV0%I`&FXUU^GS'=0)E`-8T7%C71!9@`5>O M%'8]01K9$\Y.I":/R6PY7:R"&06YM^/:W`MK2;SDH(TL_Z"(ME9H$K8F\'O$ M]R$=:^+CA)I8[YAAVXV21P]6&B!US>RZI6LP?CT@B,1J;ZPX)BM(>4PT9/5Q M&VS\1\A;TBIN40'73D$[A0_(C@NL\5PKMER;6#N16WQPC@E?Q\PNP5@Q5.9L M\K/.%;FH:%:G$\W\$HP5QP1"Z'(T'V!0`==.L>@4#A<6S_@L6K'+77:N&!XJ MD+L;U-?A+B_A6K'+70VXJ%@TQ#E=S/OW#A46WOAHK=BE7@VHJ)@WU#"@?:T= MJ.W[HS>(%;O0:`!%Q7EI:;^'''!T"=B*73#M-QX6%R4.^8U-0Z&ICH^Y40_8 M?2Z1W6H<>+_HG;"I;2&C$]ZH!_!^K[1P;$I8Z.@J>BOJBUH2Q19TOHOI<#NU M&@O.MI,)#2;`G*X6AW=/N4Z$]P[L7<.C6;,^_,K47E?8*GL'08+J"SJ;PV,8;(^OF[-M) M`\=M\S>';S(.ATLP!7$FI3G=V(^$[BMO^P\``/__`P!02P,$%``&``@````A M`#Q,63V[`P``%@P``!D```!X;"]W;W)K&ULG%91 MCYLX$'X_Z?X#XKT0`R$A2E(U(=M6ZDFGT[5]=L!)K`6,;&>S^^]O;`>"'=K= MO3S$8'_S,=_,V)[EQ^>Z\IX(%Y0U*Q\%$]\C3<%*VAQ7_O=_'S[,?4](W)2X M8@U9^2]$^!_7?_ZQO##^*$Z$2`\8&K'R3U*VBS`4Q8G46`2L)0VL'!BOL817 M?@Q%RPDNM5%=A=%DDH8UIHUO&!;\+1SL<*`%R5EQKDDC#0DG%9;@OSC15G1L M=?$6NAKSQW/[H6!U"Q1[6E'YHDE]KRX67X\-XWA?@>YGE."BX]8O=_0U+3@3 M["`#H`N-H_>:LS`+@6F]+"DH4&'W.#FL_$]HL7':3"=36($<&]/ MA'R@BM+WBK.0K/YI0.A*94BB*PF,5Q(4!=%\BJ;I.UCB*PN,-Y;WNI)<26"\ MD;S;%9"NHP+CC>6-KH0FPCIA.99XO>3LXL$F@!B*%JLMA19`W&7*Q+7/W:]2 M!SE3))\4B^:"K`@HMZ=U$B?+\`EJI+AB-@8S\[T>$T4V9-M!5$4HWKR;N-D@ MVV37(50Y@J1>%V3=U15#'8]78"=#&;DRIO8'-_<85\4((K9)\A&(C=B-(&XD MEE*H3%=I`IG\O5)E!+MJD(PD3FT7-@:3Z$VELK%U)W)W8C>8L'R$PA_Z^'O? M%'CE0P#Z0KFK)0.9ZTK+8CC+SEE9(M%Z2W1>A=L#";5:E%J>Z`1VR$B2D80^1`Q*G0(F,UL"DMF M^G]D*B-7IGM`&,PUJ>,ZAQ`4I4XVS)DQQ$2F-)S:V`TA<98X]6.IA?/J_4E5 M1JY:=W<93**3.IL'SC&S'2[/X\")53Y*I53U M7LY-\'KY*B-7Z:SG-^5K,$8INA-JKSIG:6ZO.AMC9Z^B3K\9;S>%)3.[E_GZ M<:F,7)FW,!J9!F-DSIV*VUJ+2>!D*+>64>!$`5HU]?DK=1)D?8"-,M.'F6N] M)OQ(MJ2JA%>PL^JQ(BBQ?M:T?QNT@+L6KDQG/H>V4,^'_0*T92T^DK\P/])& M>!4Y`.4DF,%QP4UC9UXD:_7-N6<2&C+]>(+^F\"],0D`?&!,=B_JKNX[^O5_ M````__\#`%!+`P04``8`"````"$`Z?$>J``#``!2"0``&0```'AL+W=O+']+TZ&UO!O853Z50(MN,$\\J/X M_RX>$MD`'ZBFZY44!P>Z!O94#34]Z"_!V406_C,R",FLN3.+[%)0*RC'\SH, MPI7W#"E,6\W]4!-T%9NA(HQ/$@_X3I`0>A\RAB*.I_\(:19!HHES!AF=_&T@ M]Z@);?>Y3$6,8Q$!0,0:!-+L^)$?=`YCT0E"!($(^1H&)($E]#8L1= MDKA?'90@R@8E2#(*@H(AB`_SX_*<6'47 M9=9OFE;3UFJT?UO)N[6"&ULE)39CILP%(;O*_4=+-\/ MAJP-2C)*&J4=J2-559=KQQS`"L;(=K:W[S$0DDXB37H#V/S^_K/!]/FH"K(' M8Z4N9S0*0DJ@%#J193:COWZNGSY18ATO$U[H$F;T!)8^SS]^F!ZTV=HJF#$K82A MTU0*6&FQ4U"Z!F*@X`[CM[FL[)FFQ",XQ%^Z,-7D%GNL-M#3,CG%2>G%5B!!45,T!MZDM`%!H!7HJ2?#"P(/];W M@TQ"]9?1'P7`<]J/W(:R) MITYOQ1V?3XT^$!P9M+05]P,8Q0B^GP\FXK4++Y[1,248J\4>[.?1:#)E>RR< M:#7+1H/7BZ93,#3MG-'M<6^=GL8ZS6?1\5=_N]^-%_3FQ[@6.<\4S>.4FDZ4E!:2(#(,Q#K!I M/HAFX715C]5&.YSD^C''_Q9@U\(`Q:G6[KQ`8];]">=_`0``__\#`%!+`P04 M``8`"````"$`G3*,VV$P``!;&`$`&0```'AL+W=OHXDX6:V%IO7/;ZK9C;,LA MJ:=G_OU)%)%,`&^2*GEF+MJ:!XD$D`M(`BCRE__]U[>O;_YY__CTY>'[KV\G M!X=OW]Q___CPZ[E-_^?L[9NGYP_?/WWX^O#]_M>W_[Y_>ON_O_W_ M__?+WP^/_WCZ?'___(8T?'_Z]>WGY^G@XG[[Y]^/+];:=A]KB/CH<__OCR\3Y^ M^/C7M_OOSYV2Q_NO'YZI_T^?O_QX8FW?/NZC[MN'QW_\]>-_/CY\^T$J?O_R M]&/YP-2 M]Z[K*([Y_-WY.]+TVR^?OM`(C-G?/-[_\>O;:#*+ZLGD\.V[WW[9F>CJR_W? M3\[?;YX^/_R=/7[Y5'_Y?D_V)D\9'_S^\/`/(UI\,H@JOX/:Z7]X-'F%DF.KA)I5E(RT?FHKTK^VXF1R<#P] M>7^V:WZDYGM;D_ZU-:>G^]6D#-K9C?[E-@\/SDY.CD_/WM,`1MH\MS7IWU>V M27%DG67"Q/IASY%.>D?3'Z]ME]T[H3]L7=>_(X.=4$1T\47>Y2[O:2@3QEU= MB8CIU`G.L78Y)B:O#XH)1X7Y@TVU;[L<%Q,G,/9U$4?&Q`F-/=N=[8[Y=`P?_!X)P>3X\/=%#!BY2D'QO3UWC43P\Z[YH_7MWNJ>-C]C&YH]7VOB(;6S^L'7W3*$C-K+Y@YO=<[A'G'[F#Q[N7JX]XMGX MR$F@?5OE!#IZ?0(=<0*9/WBTXX'\KKND[:Z0\8?G#[_]\OCP]QNZ\2!3/_WX M8&YC)C.CCJ^-743W5\NABR5=)8V6R*CY]2T-A2Z#3W2-_^=OD_?37][]DZ[* M'ZW,A2+C2\Q9PER"C=HX!$D(TA!D(!^R+P7P0.C,"#$;@P`A]&X,3(]:(7\'2A\P)>?Q#B MN=U(T^6!3#(RN7="YA+J"!T%\WLOQ$:,@21`4B`9D!Q(`:0$4@&I@2R`-$"6 M0%9`UD`V0%H@6R"70*Z`7`.Y`7(+Y`Y(%"&Z0#1'A'Z-T+$1>C9"UT;HVPB= M&Z%W(W1OY/G72PFZE7M%2ACI74IP(%]TY(1,X<3_<1#_O1!7BX$D0%(@&9`< M2`&D!%(!J8$L@#1`ED!60-9`-D!:(%L@ET"N@%P#N0%R"^0.2!0A$D>S#Z,Y M2J%?(W1LA)Z-T+41^C9"YT;HW0C=&WG^]>*?'C!?$?]&VH__CI@G(B?^3X+X M[X78=C&0!$@*)`.2`RF`E$`J(#60!9`&R!+("L@:R`9("V0+Y!+(%9!K(#=` M;H'<`8DB1!>(YHC0KQ$Z-D+/1NC:"'T;H7,C]&Z$[HT\_WKQ3T_PKXA_(^W' M?T>"^?\TB/]>J(]_(`F0%$@&)`=2`"F!5$!J(`L@#9`ED!60-9`-D!;(%L@E MD"L@UT!N@-P"N0,218@N$,T1Q8C0L1%Z-D+71NC;")T;H7+?UJZ M>47\&VD__CL2S/_O@_COA?KX!Y(`28%D0'(@!9`22`6D!K(`T@!9`ED!60/9 M`&F!;(%<`KD"<@WD!L@MD#L@483H`M$<48P('1NA9R-T;82^C="Y$7HW0O=& MGG^]^*>ESU?$OY'VX[\C0?R?!?'?"_7Q#R0!D@+)@.1`"B`ED`I(#60!I`&R M!+("L@:R`=("V0*Y!'(%Y!K(#9!;('=`H@C1!:(YHA@1.C9"ST;HV@A]&Z%S M(_1NA.Z-//]Z\4];/5[\=_L`!V:?=GQUR%3T4Z$C1]U.NEG&GP.)@21`4B`9 MD!Q(`:0$4@&I@2R`-$"60%9`UD`V0%H@6R"70*Z`7`.Y`7(+Y`Y(%"&Z0(1N MC="O$3HV0L]&Z-H(?1NAG%OS@MX@3\>[3MQ/]P9=:<]=O&. M*$:4($H198AR1`6B$E&%J/:0;QFS7>)N#;Y@F6YWA9:)^>)V8!]<)L86R%S+,%93#CW+Z;)/JI2%J*>B*JSB:\J$RGN:(ZH0%0BJA#1 MX2;'#KZ-S3Z#:V-GVGW^_.7C/RX>J-M47;']$6VSVLW7;K?",WV'/-,#BLV: MOIF\/4.?'?K62:R4HRME1/4=LP:[6YE(B5EM)R1*"I0J$56(:D;=X2]W0\^< MJ/',JIB/CE3T]NL6L$D?]_-BI^'7M\?>>NY9N)]AI$D<',F`MQ8SDC4%(A* M1KWF($,J$6#--2/%F&:=S37F"U'=+E:BJ0E2+*M+NS\=FW>85)NZ6>3P3 M6T0/`&+BLW`AW,RXQL1T4]5+A8.)K="Q.[M,SH(UQ60?5:DF-#D))OK,2M'Q MN-T!GH/@NIQSN7LQ#7M=:$V%0J4F!/VIN#WN3S`5U5P^T!_?LV9%XA6>[18P M/,]VR)SGZWTV.0ML-#?G(8UG!_IDCS5U0L>NT$DPZR3[:$I%B!,ELVAJ[@_H M&-9!8+6 MRRQZ(1FMU'@R=D)>,IZ"R_;0E)I3KUWNL]4RBVSBT=ER_PXLY_(Q;Q2B5^(3 M70:-5ZSE MLHCG@Z.#(&IKKC/0NN=:RD)R^YTARAE)KPI!P]I+%A+M%:*:T4Z[;T_RIF?/GTJ5J=$2F+E#=(2; MS36W4N9$>'\!"R>(F%5)O62?>JG4$^5P1<]8E;VB'QT$3^(Y"XP%><%"8P,I M]^I0Q:ILATX@.5A@H$.^,\W#[=B\MWWX05Y2G^:=QU$SO87>[)"7-#T2@Z,W M>R&.@L1J)U7#]5(66,W*3I&QS67G(]T5XAJADI24,SE6?G%R8A(QYD M1X=,$WTJ3.`NG:;,7<4Q4\56*+B0!'&=[*,J92$WUI0@?<[]Y&-YOUJQEH#]^!E%_/,_^W'1HM`0.M\B= M,A2'=U(OS)"=T+$7.^?!+5MB\HOZ,*HJM4)T`>;TS+A>-R$=X@1I];H^0>_N MT7B)C5?2N(3.Y"R\%62I@2[X#C7+!.Z4^$*JVE4%]WZA0]0HVVA.<^7.MC3* MP0B/18CK)8*&ZZ4L)%?T#%'.2'I5"!K67K*0:*\0U8R4J2]*ZSAAWHCY\:9A'`38W0E7O>+=@%!S=E.N2E3(^&@S.>]D(<`XF@X7HI M"\GU/$.4,W)3IF]P6'O)]41[A:AFI*2,>>1U[?S"%&3$@XM'A_S#'>?!8]3< M3/54D:38>C&B!%&**$.4(RH0E8@J1#6B!:(&T1+1"M$:T091BVB+Z!+1%:)K M1#>(;A'=(:+?_H`CHPN%*0ZG7P!A7<7E]"L@E%.<3K\$0CG%[?1K()13'$^_ M"'+E_.G(+%FX:>),1R]DC%UO<6>@#KEG0,R/B4UZR)4O1I0@2A%EB')$!:(2 M486H1K1`U"!:(EHA6B/:(&H1;1%=(KI"=(WH!M$MHCM$E![@2$H/9'.%*1ZG MG\AA7<7G]#,YE%.\3C^50SG%[_1S.93S/>^EA]GC]=)C/"=VXOY5A)%<'^:( M8D0)HA11ABA'5"`J$56(:D0+1`VB):(5HC6B#:(6T=9#OL?H5NXU'C/B@<;`/DX@4:T\198AR1`6BDI%TOD)4 M6V1VTIRN!D]\"ZDH4N&H&Q;R1QTLSB]%BD>]0K1&M$'4(MHRPMUS\V:(UX1# MMY#EKESO-/C'F1#%C'PS!!O`B4BQ&5)$&:(<48&H9.0ZOQN0$\RUE0J<'WAL M@;H:1NX8Z:U6_J[54J1XC"M$:T0;1"VB+2/%U?3XU;O:K+V_,%<;\2#S.^08 M:VY^VMQE/H\F9N2:87(>;'DF(L454T09HAQ1@:ADY+H:NEI;*<_5X+$%ZFH8 MN6.<'@;//DN1XC&N$*T1;1"UB+:,%%>;E2Z^:S6N=NY:]S]`9Y[LP@CHD!(QKA"M$6T0M8BVC)0(<%<8]TAV7&&D1Y(@L^>"Q*_A!2^V0L=D:W'^ M"3B_TTY2;)A4*C+*$.6("D2E14Z<5HAJBP+G!VO6"ZDH`PI'W5BA\5$O18J' MN$*T1K1!U"+:6M2-VK_K,RMP__F$8-?QG$=:\XXG?_Z?(XH9NJQV0W#PZ2)"+"I4E',*$.4 M2T6K.4C?0@1838EJ*D0U(UEA73`:&VMCA0;'NA0![M%*%#-:(]I(17VLK0BP MFJVGQI\3S**7&R0OW`]V:V1>-%CDF@,/SIKWI[T<()T0]99[GMAZ#DI%%4ME MB'*L6"`JL6*%J$:T$#1V/8#Q+&T]9SPK4<7C62/:8,46T=:KZ#O:+.F\PM'= M"I#G:(MH4')-AX,!1U:*_NFE<"90A&"'*[&JS(U+KVIZ&#PNIBSEWX4'3QJ9 M=(N-G`L2]=")@M7S0=N@^9++W>;#\5;2%+=>6W1,MT#.X(([I(54%*E0>Z,) MP4"65HJL:>:-27B"><7E8P-92U,\D(T@Z2*TWK)VWY?!Q7_+4FX?IH?B2R^B MS7E3+Z)_ZOEFI\5_PK4H.`$3N&;.%=V^AJZ)18CME;!VWK<-UA12KD(/JGU@ MA'HS%I*MY1Q1(4V)JNEAT&#)%=T&7:/O=HHKEI(6:XN.Z?ZI[^E4G+6KMY!Z M(A0.IQ$A-M/2(G-"1I2'?5]Q15\JZ,.:I:3O&T2MM&@2!,YG;[F*VY8S$C\V M*2J\V!R_K)H34L%#MD7N1K4@,8G3@9V]8Q:2O:0$4-_;LY0D939E.SC'YUM5;D76YA[$U;%YZ:"]8F4R\=FLHR%SOHNYA:9 M,])]%Z'U@BMRZS#]V(&.M5ZQ$FF]EM;99@N1D@Z%-FNDG@A!KY>LBJ^6$^^0 M^F&P-K1B\;%!K%E(!K'9JS,M5V03!D\W6RX?:-V/89J^1F-XOZ,UYM>?81!W MR)NQ>B2V#AT26U5T2H4=F2!*&4F&9XAR1J*K0%0R$ET5HAK10M#P>!H6DCXL M$:T821_6B#:,1%>+:,M(F;'HJ3$T623_G9GW+2`F*$26(4D09 MHAQ1@:A$5"&J$2T0-8B6B%:(UH@VB%I$6P_Y^6G61/=_3C//#Z''.N0L>\ZM M%*'AN(U9R)U%<&M6I#A;4T09HAQ1@:ADY*S/"1KN?&V%O%7&R!NAI&[AAQLU:D>(PK1&M$&T0MHBTCQ=5FJ="=]G_NT:); M!`"*CRVB>W&YE3\/ECP2D6+KI(@R1#FB`E')R(T`Z&IMI8(("&[(%ZBK8>2. M$3=K18K'N$*T1K1!U"+:,E(BP*R)<@28==P7DMTNH3K;<,<=\ES=(_$KWH!W M0N:>I'?^=!(<64FL=I)BPZ2(,D0YH@)1:9'3^4J0]"OL?&V%@G`(GI`6^ZAJ MK-"X'98BQ798(5HCVB!J$6TMZNS@W1F>N.N=)D!^:HK8:?%O\2UR3#]'%#-R MTP>W;T6*K9,BRA#EB`I$)2-GBD!46T0QP9U8H%3#:'1`2Y%B72M$:T0;1"VB M+2.<#T[H2N7-!S_G;J,E<+=%DLCS75N[)[KA3(NMT."69B(";*I4%#/*!`VW ME8LJ?9.S$`%67(IB1I6@X;9J%I)G[`4C=T8,9Y[&"@W:8RD"W*&5*&:T1K21 MBOKH6Q%@-5M/C3]O4(![@31^83DQXD'$6.2:`[=XN:(K%1HMMD+._F>"*!55 M/+Y,T+`K)LL+9>'P2WZ8A]5C28$`UM:J<$-8RX?&]I:FN*HW@B2@4#K+6MWEZRFA\&"SI:E MW#ZX>Y=^[-/,Y$V$/W=%-5J"^;%#+VP8G]B*;E]#+\=%*N M0*G4AT6H-6.AL:9S$>*FB]&F2ZXPUG3%0F--UU;(K(3T@X"=Y'TT-2+$@UA: MY.\D3P([KKBB.Q@WDG:[JVN6TS8 MN!Y\TB%W7T:0V-OI0+>3S$*R6YH@2AG)W60F:%A[SD*BO4!4,A+ME:!A[;4( M<1@L!`W7:UA(>K5$M&(DO5HCVC`272VB+:.=+M_S[D+OSS_OX?KO28?N%R;;5WU\.3%R_75GQL?LCVZ5YNA5[8CF95MGO^[W)*+AWK3<5" M8\:JI3<2@7:H8_4:J2=A"E?')7>!=X2#FZ`5EX^-8\U"SG[T7JVW7+%KG;X' M/+HYOF7Q@<[X06^6?-U5L/`:O=_V]$FWR5H6'LM0A*$>XRYX7K2JR6B%2/IU1K1AI'H M:A%M&2G3(*6+%Q$O/+X:\>#VK$/F=S)R=S$)E@CG)[T4VRI&E"!*$66(@&T2VB.T3T839P9'2A,,7A MD>)Q^C@;ZE-\3I]G0SG%Z_2!-I13_$Z?:$,YW_/^Q&D6\0([A!1>H`C*3V0*0ZG]$`YQ>7T\4*44YQ.GR]$.<7M]`%#E%,<3Y\P M=.6\]#@--T_&(KA'=(+I%=(>(OF5HHH/<+;Z-+A2F.#Q2/!XI+J4D6P+9OLTF',]=PMP.@G6<`N1X@9+1!6B&M$" M48-HB6B%:(UH@ZA%M$5TB>C*(B/*\?1XS(.'Y=QM+B,8\-E'!PNX^AP&8='9V`_ M,U^W97>*6W86N7OZ@L0OH?-B%G)3<`*?/1(I]DK*R$W!KEO4A^$&'3M!PYU>B2H2FDV!/9BU2W/D-HA;1%M$EHBN+ M'%=?"Y)^A:Z^$54B-)T$EK\5*>[\'2+*T\[7SND@RE-D?D>&+E'(_0 M%;37YW8XL#9])K@7XQ[31169$E-T444Y):KHHMK)=3;W4Y<6]?\+%U6C);BH M=LAQ\_P44,Q(-B@21"DC-UE!5\Y2--9^(I^$7]DJ1(K-72*J$-6(%H@:1M+5 M):(5H]&NKD6*N[I!U"+:(KI$=,5(NGJ-Z(;1:%=O18J[>H>(TLYZ34X!4MHA MZR/%D>M#1;I+-ZX0!91VO;Z1,*"TZ\6XQY1VR)1XH;1#.25B*.VLW*[+?MJ9 MS=6!Y8]7W,L:+4':6>3>R_9(#!+.KO%I)T2O/V)S)(A21N*#S"*Z*QC6GG.] MH5=I%"+`S9>BF%&%J):*^MFCA0BPF@;5+`4-CV(EJFQ;P:W^6@2XK8TH9M0B MVDI%?127(L!JKE#-M:#A4=R(*GT4MR+`;=V)8D:4RWN$%66WC:O>\\$Z=C07 MB5XW1Z-S+T^YWK?7R_7QV&L//$)IWK??U^)H=+5S`(Z&,25^KTWW4\0A2J?L M^O8X1KOV_&G@=;OEI[A;SH@ZYEST@G,G"AGNZ0E5K1!M1Q3UM$6VQXB6B*ZQX+6BX MIS>HZA;1G:CBGE+RVDARPR9T&24O1`2E*[)8M/4M<.BX2<:QXX03)2CJXUAQ MZW*PO)2@J(T#R&V5(TA+2;/K_9]?F;N]KM]K]_A*+A4K?QT"1+K:%0:*4)06_6W)YODN!X MUX:EW%Z!25IID4VR%31BDDM6WYED>A"L=EUQN=M\.-YKK:E0Z$83`J/< MH@>5GDE5[`BGHSW7>A3ZBIY:;$_=+H1^B#@5O>-&(,6IZ$EAGS@7`^,$7J/G M'Z5GKG'\>R%STF-LXMWO*,UI=V#$FWG[,R1L_+F5&C]*(T)<+T&4(LH$B6=# M6^?G"5G1W#,3+O_YDB-AV M.@VVK>:GO11G6XPH090BRA#EB`I$):(*48UH@:A!M$2T0K1&M$'4(MHBND1T MA>@:T0VB6T1WB"B5P)&4.,@4A]/N-,HI+J?$03G%Z71M1#G%[?1@CW**X^F* MYLKY:6+.J"HSGQ$[<7]EF)-?`.:(848(H M190ARA$5B$I$%:(:T0)1@VB):(5HC6B#J$6T]9#O,7J>\#SF3&C[;U&\-UH" M1UKD.K)'*N11:Q(\="0L-79;E%HA[V,/TVGP%)R)%-^1Y(@* M1"6B"E&-:(&H0;1$M$*T1K1!U"+:6J2LC;TWV\BO2&(C'OB^0^ZN\$[I2]]A MLD+>:S/PG,<^JE(K-'Z"(Q,I\7W7=^?,0(%2):(*46V1LR:Y$"3A'>9`(ZI$ M"$YP+$6*.[]"M$:T0=0BVEJDG"9X;S8\W0#YN3FCVS9U;XAVBOUW@"&*+9K( M.?`$I5)&Y,Y^'H%S`IE(L0US1`6B$E&%J&8D.ZD+1`VCT:XN18J[ND*T1K1! MU"+:,L)=[/XEHD?BM3`]XEV'*$R_U+D6`%:]$,:.UH.&V M-J)*'UN%_L]GV\*<,BBALGS*%(95+\0] M3_:IEUHA9Y;/$.6BBK47@J3O8:]*5%4AJD45:U\(&M;>H*HEHI6H8NUK0K7X6H9B3:%X*&M3@&T2VB.T11I+`+A2D.CQ2/1XK+(\7GD>+T M2/%ZI+@]4OP>*8Z/?,_[.6%6,-V<,#<6IT<'YE;DA?3HUCZ]].B0>6EB/V%/ MI\$%>?[>2KG3^G0J1W>\_IV];AUU)^X_6UED7D4EG3H*SN3,18HS.T:4($H1 M98AR1`6B$E&%J$:T0-0@6B):(5HCVB!J$6T172*Z0G2-Z`;1+:([1%&DL`N% M*0Z/%(]'BLLCQ>>1XO1(\7JDN#U2_!XICH]\S_MI8A:4W30>S]TSN_XLI]\O M+/+?PG$4G-.:BY2D2:>+*C)*4"I%E"'*$16(2D05HAK1`E&#:(EHA6B-:(.H M1;1%=(GH"M$UHAM$MXCN$%&:@-+*^6EBEK1?D2;="KA[B3OK4)`FP3&YN4BQ)6-$":(4488H1U0@ M*A%5B&I$"T0-HB6B%:(UH@VB%M$6T26B*T37B&X0W2*Z0T1ITKN;'4EI@DQQ M.*4)RBDNIS1!.<7IE"8HI[B=T@3E%,=3FKAR?IJ,;&N\<&'!K8RS#KDOJT$4 M(TH0I8@R1#FB`E&)J$)4(UH@:A`M$:T0K1%M$+6(MH@N$5TAND9T@^@6T1TB M2@_P+:4'LKG"%(_3S1;657Q.-ULHIWB=;K903O$[W6RAG.]Y/SW,ULPKKB)V M)\>]V;)(?@8\/P,4(TH0I8@R1#FB`E'I(7_,9DO@%6.V.PCNF#OD;H6?]4@> MS9P%OFX=C87HHMX_O\'V92)2/%&GC&3+,1,DNL(&40'%MB(=_]"WQ1(1X,&DC%SK@>:@5$7YNQ`/#=RAX<`[Z-+<5 MG<6D&%&"*$64(@*T36B&T2W MB.X019'"+A2F.#Q2/!XI+H\4GT>*TR/%ZY'B]DCQ>Z0X/O(][Z>)>:3>_T)P MWCV!NQ<"BX(T"2;LN4AQNL>($D0IH@Q1CJA`5"*J$-6(%H@:1$M$*T1K1!M$ M+:(MHDM$5XBN$=T@ND5TAXC2Q%V#V5U[H@N%*0ZG-,&ZBLLI35!.<3JE"VG2(?HZ`R?`_!Q0C"A!E"+*$.6("D0E MH@I1C6B!J$&T1+1"M$:T0=0BVB*Z1'2%Z!K1#:);1'>(*"?`D903R!2'4TZ@ MG.)RR@F44YQ..8%RBMLI)U!.<3SEA"OGYX19_WE%3MCE(F>!Y;Q#P49W\"./ MN4AQYL2($D0IH@Q1CJA`5"*J$-6(%H@:1$M$*T1K1!M$+:(MHDM$5XBN$=T@ MND5TAXC2I'97IR0'ACW\]/3]\R^^__+D['/O2^97S;O'1NZK8]4AJO7_LFQX%K]R< MVXK>,TI?D7V1H%2**$.4(RH0E8@J1#6B!:(&T1+1"M$:T091BVB+Z!+1%:)K M1#>(;A'=(:(,`J]1!B%3'$X9A'**RRF#4$YQ.F40RBENIPQ".<7QE$&NG)]! MX5KT^"+K>;?HZZ6)70?VTR18W)C;BEZ:]!4E30"E6#%#E",J$)6(*D0UH@6B M!M$2T0K1&M$&48MHB^@2T16B:T0WB&X1W2&B-`$749H@4QQ.:8)RB<(4G].C M/-95O$Z/\BBG^)T>Y5'.][R?)J_;BSC'O0B+@ONQ<"]"I#@G8D0)HA11ABA' M5"`J$56(:D0+1`VB):(5HC6B#:(6T1;1):(K1->(;A#=(KI#1&G210"YFQU) M:8)LKC#%X[3BA745GU.:H)SB=4H3E%/\3FF"7DSU.X)_;G3YW#:!#[F$K*^6@&%&"*$64(@*T36B&T2WB.X047J`;RD]D,T5IGBN4'BBG^)W2`^5\SWOI01\O#?)C_'FED_?W'GOFG+=26*RP1&&IPC*% MY0HK%%;Z+!C^ZW9>)X>X]GX(`@;RH9?B(9/1.\9G%`_AD&(O,>90"OY>]ZC1>RGN M`1G=Z\'107#9(Z-;@8$.!$8W#_.NT9V'B]=<]+HU`=\7'0L2(%P%GAS:J@/= M[NH-TSI&_QCCEOE)A/#GLV'&@TOU@I.2Y!Y@5&-NVUL1THE'LVW`)9 M$+21!8&1T7IMU$)@(O-[SP+=>QJ;PGBRQG&75HIR32\@I`WQCOE M^V<2/HB%_MGO%2N3G9[@-LG#&XB8M4WEI2")PM*>R<^4,X<-MY#W M4M)"H;"R9\Z+1]X]?;Z_?XX_/'_X[9=O]X]_WL_OOWY]>O/QX:_O%$T3VI%P M^)O'^S]^?4MKQC/:OMLUUE?AHC-3=&86F*'HW!3MXAN*)J9H]^@+15-3M%L_ M@J(C4[1;S(:B8U.T&R84G9BBW30#1:>F:/>=J+#HU'2>WJ6KC.N]&3*]AD,I M.CND(OIIOU9DADP_`]:*S)#IIX]:D1DR_11,*=I95RN8FOY-U?Y-3:5NR@D' M?&)JG:BU3DPM^E"ZTHE34XO>R(U%$8U7'9*Q@VH&8P6M1D0V,)&,;5P8ZZC& M,>&@1H,)!C463"BHD6!B7PU],W1MY#1E3F;T'VTL-%%.9C0-:@:@LJDIT^K1 MO#B9T7^T,KHB',UHOM<,03J/C$ZU[.QD9GXSAG:EWU!1B68-^D'9S/Q:"NO0 MCY-FYM=(6$(_+")M6LF%&17]1QL570TG,_J/5D8CGI@1:U:DLJDIT^K1)6\R MH_]H91LGES+S'$DOHE90S\]9)+*$72,[,.R*QA-ZC2.UH M(Z5W(%([6@F]OY#:T4KHW8/4CE9"KX6F$LVO%V2#"]4&7J8;QS. M=I\Q1'WTG;>9^:X;EM`7VV;F"VU80E]:FYF/\V$)?6=O9CZLAR7TU;R9^4P> MEM`7[V;F$W=80N_0I]G5?)U.*:,/S\UV7YI3RNB3@V:\`_7HLF`^J*S4H^_, MFC+5AO2]93.A:V7T\4FRE!;E])E(LI160A\>)4MI)?3A4+*45D*?^21+:25D M*?*P^>RF.BHJ,Q_-Q#+ZSFE"[OYM/U6$0?]YZ9+PUC"?5NIG>#OLP],Y\) MQCKT?6YRE38J^H0PE6AUZ*/M,_-U:-2VI!+SD6@LH0^VDWNU=N@+TE2BU8G) M"(EJ`V-5\Z%R;(=,326ZMF,JT<(AI7;,]U=16TXEEVH/ML?GLRV]#0WKQ"?4 MZQ/-J#>94,E=+8BHICK5[X/CDD'JM6;2D.J5:4E%)I98LJ&2AEC14 MTJH]:*@'K5JG)!N4J@TJ*JG4D@65+-22ADK:8VV:;HY/J42[J6F.WU.)=O/7 M')]1B>X?NA532^;4@[E:$E-)H?8MIKX5:M]BZENA]BVFOA5J.]LCBJKNT\+! M$U1\1#?`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`$)N]84AR?]Q?)2:Z6;SX]]@/XJBX]V]+?6GNJ/ MJ"GWOY:7`J(-ZT16X+6NWP@UV1,(!IMH=-BOP.^-MB\.V?NY^Z/^B(OR>.I@ MN5?@$7',V__PBS:'B(*,8?=FY/49#(#?6E62U("(9-_[YT>Y[T[PEV58R\4# ML+77HNW"DBCJ6O[>=G7U-^,0FX2&S33@R37N'^RPP?#D@XWU:K5\6+OWBRR9 M"#R9B#T2F3$=INC=AR<;N#:6]LI=6\3_F8$/;*`K!EJC&>\,'!1A/SL\A=FN MM=@XQ/69R3=L'#RYU;-\"]**KC+)+[:$=YMKTI3I,]#/NNSYL:D_-"AKR(KV MFI%-PO+(%#SWJ.4B&V\E(V0047DA,D\Z!!(2K84*^O:\LA[-;Y#T.:-L,45A M[#B#Y"51]54@4(%0!2(5B%4@48%T!)@0%1$:*(7_(S1$AH2&>[7EP!`K6P[5 MCC/X$%\%`A4(52!2@5@%$A5(1X`4""AK*1#3^Q)/!<*&;`*QV[E`.0X\!,=> MKI4H")((`T("A(0(B1`2(R1!2#I&I&C`_O2):!!V'PWNQ)8B#CQ&OF\4WP6) M#_,1$B`D1$B$D!@A"4+2,2+Y#EN:Y#O=+0RRU=Y1PE;=I0AEM@`=@CQ$1(@)$1(A)`8(0E" MTC$B.0J[]R<<)6S948HX?:_3[]\[@0RI[KIRION,`YNP*`=KJ91#($B\'$(A MS9%(((.0.EDL=`:.M5[*%B6"Q*53(0V(%#+2@>/3LZ^'[E3F;]L:G`+7)G+& M@5.2GIU$1(XD1<:11(C/$+L_;.V%Y!.)[[D6(-"*$Q&(4.<)!53F9$O$] M5TW'&E)LH+&18C,1`^C/>!`(6PX"0V`O&B6&>D9,D-1%]RG'&4[@`"&AT.%^ M10(9IE>58Z23("05.FKND&[K$P'JZ7*$.`1+($)DKQ9R(NPX"PP1+-43?XID MJ5(!8]F+/NFLS<90:B?DC'$YJY-%4Y.II'B*A"Q*^'S.!Q.LAD>>V-H:U&/\HO7S*%6[8(H>=-)[_>1LE':>Z&@R2"T39 MTW9\X'R!,*F-.,8#-HY7PV)C*&=;R!ESL8[NF3X>2,."4(OX]-;24#;']%^F ME]>`]+OC-9C?KBW:'L,,W)XM@^RE@'8#=#LA?4X:.L$`0R&'!O5H@&ZKQYPT MJ"<82CG4J\MQ(;WP."ZCEO?^(]ZB';44+@K9#Z-P,18\;M:OSZ7&.87VQ8"Q MV$[A.+:A%&C(=6X4:+\'19PT9U',2;,6)8I%]MI8J3LU<_^&1?*RD'9];EF^ MUE?88"<[KU'706[9U#V#0E(:"VAN71AIU&8P=7N`0@Z-T_@.]9B/&Z02#)%+ M2N(.M9W&BUXZTBN?JFB.Q:XXGULMK]_)A:*UAI-$P/2V<[OTX`40REK%5QZ\ M)&$\=CUHF2?PM0?M(L93UX.F$>/^QH/&#./QQH.V"N-P*_O2;S^JG>2V=H*_ MM3VXX9C0<;P7"!S^8NMX<`LP@;O>=LJ!G>OMIG#?]>`%!NOX:P^Z=(R'K@>] M.L8CUX..'7!3>`RWP-?L6/R6-/X'``#__P,`4$L#!!0`!@`(````(0`W M]^.8#P0``#T0```9````>&PO=V]R:W-H965TU+ M$B8SYWC&XX-G??M:%LX+:T3.JXU+O,!U6)7R+*_V&_?']\>;A>L(F5194O"* M;=PW)MS;[9<_UB?>/(L#8](!A$ILW(.4]>'HL624U2,.*1,+ZQ2&OQ1FM M3*?`E4GS?*QO4E[6`/&4%[E\4Z"N4Z:KK_N*-\E3`7F_DEF2GK'50P^^S-.& M"[Z3'L#Y>J']G)?^T@>D[3K+(0,LN].PW<:](ZM[NG#][5H5Z&?.3N+BMR,. M_/17DV?_Y!6#:L,^X0X\'IA(H:(`X]$(D5)>P`+@TRES;`VH2/*JOD]Y)@_P*_1B$BS# M&%">F)"/.4*Z3GH4DI>_6J<62H/0%@2^6Y!P[D5Q$!+@O`+BZP6I_!X2F6S7 M#3\YT#1`*>H$6Y"L`'@X(<@$?>_0>>/&K@-K%;`++UL:A6O_!2J7MC[WV@<^ M.Q_2>?A`VC$#VW1F=$9F+"TNY5X;+FGH,$WX$1ITADH`>+?Z?H:M$S31A=-L MF'WV$79T5NQ=EMH2@HQ<4$7#5-`#E_7$%IT%2V]^;5,QSF1M+49QH_DP*\!? MLK[?/^AL4FF+E6`\3`5]=TF%"8:+$`_T25B"9/J:A)Y5YM:!5HIM[IEICRB4OC6[!5[TG%2 MD18S@O52'E$J\B&I4MX6VY!8S4?$B@RH%0UF4[:V+U<*K)?GB%Z1`<&B\\6$ MK>T+EL+J$8\H%K$DZWUU5-Y6@;50153=Q8R[PF=5B6*@R7(V&>T:C\@A!2^[ M72?)H0JTB!'++F8\(H?4$J7WBZF\+38M1$/%M%3G"G1?::@VF6_M>$1=Z6>5 M1@5:.0TI33PBKG@O^-S6M:JBVK"];0X)33RBK=02&M16&D43CKZ*M%+6HF.^ MR>(1<:6?%AT5:3$/79+B$7&%X:M7['#2FTQ%6LQ#]Z38%EH]K.EAIF3-GOW) MBD(X*3_B($9A/.FLW9!XI_;4MH>K.ST\^MT_,+S5R9Y]2YI]7@FG8#O`#-06 M-GK\TP^2U[!VF+ZXA+%-_3S`F,Y@1`E0<7>&ULK)M;<^(Z$L??MVJ_`\7[`0P!@BO)J>%B?+_5V=UGAC@)-8!3 MP$QFOOVV;+5E=6,/.;OGX63R<^O?;;74EF3GX<^?AWWG1W8Z[_+C8]?H#;J= M[+C-GW?'U\?NO_ZR_KCO=LZ7S?%YL\^/V6/W5W;N_OGTSW\\?.2G;^>W++MT M0.%X?NR^72[O9K]_WKYEA\VYE[]G1[CRDI\.FPO\>GKMG]]/V>:Y:'38]X># MP:1_V.R.W5+!/-VBD;^\[+;9,M]^/V3'2RERRO:;"\1_?MN]GU'ML+U%[K`Y M??O^_LMZ;P>\]/FZQ[N^Z=QM]FB=O$+DS_LMJ?\ MG+]<>B#7+P/E]SSKS_J@]/3PO(,[$-W>.64OC]TOAID.A]W^TT/10?_>91_G MVK\[Y[?\8WW:/?N[8P:]#7D2&?B:Y]^$J?,L$#3NL]96D8'XU'G.7C;?]YO;!=(]ACL2-V8^_UIFYRWT*,CTAF.AM,WW$`#\OW/8B:$!/;+Y6?S\ MV#U?WAZ[PTEO>#\VQA.P[WS-SA=K)S2[G>WW\R4__*>T,J16J3*4*O!3JHPF MO?%T,#(^(3*2(G>5R+!GW`V*.%I\0Y3%'>S"3<#P/^C]@-FVES?R*C6ZQ0`LQ=83LDH(5!18%:PIL"AP* M7`H\"GP*`@I""B(*8@H2"M(:Z$-ZJAS!,/Y_Y$C(B!QA[\X1J*0-24+0`ILL M*5A18%&PIL"FP*'`I<"CP*<@H""D(*(@IB"A(*T!+2%0'K2$7'\`X-P0UC"] M0*QEU51`5$@_8K'65CC&?ZG065$08=,A(Q$C.2,))*4FX-Z\LR6"UK*2R7 MSD7]NKSMMM_F.70R=/65.36")7*YF9+4L\L(TM)]"7%O=XEJ\H(N\1B M9,V(S8C#B"M)+8^,^%6K6M8F`SW$H#+"$$-&(D9B1A)&4DEXUF`S^;]G38CH M69/DKEI=+RJB.H`.[65I,YH4.Z;AP!CI_;.JKF/_6)4JDG5%FOW8E8[8F8$? MLLYWJNNHZE:J2+R*-/OQ*QWIA]Q/4%U'U;!211)5I-E/7.E92"4>IDF)I%IOK^D'' M;])<[L5ATX9AS@V)H++4TDQFT@*M8+Q55C012V6$ZBN.+([6"C6KV\H(U1V. M7(X\A9K5?66$Z@%'(4>10LWJL3)"]82C5$/Z;!9;]D^DN=SA:VDN$9PCJS!' MY"AK(3;SX@$`0Z(ERU>,C#%Y!*ZDU%`L"7X\S48],J(L]`7;W49?:S1J"\B^ M9L0"D#&(RT`5P<7L!K`MC"W;ZJ%`?89(&"2"]? MI/,6:-5>OJ3ZK"J.*]EN."A&L=$C1R(67F_K[_4MSFUEA!7"0?'2^;!'9JN+ MU]N<>TJW>9KYR@B=!RA>.A_PX5AVUK#->:1TFYW'R@B=)[KS:8]LY5*\WN!< M'WGBH.83I;,\UX&QC=',Q6L0&'7#VB)8H>8;6Z*1.KY9<60A4NIKA9K5;312 MZ@Y'+B*E[BG4K.ZCD5(/.`H1*?5(H6;U&(V4>L)1BJA0UW,J#G[J.?U[U:0\ M/M)272+M*6E,R,1;B)>CH@S55\9\,22-ZF.45=F5E,+'Y)4*(V5@NK4\)F\( MR,:H6P-R](`,>)-+RKZ+.FT1>6C4UD4^&K5&%.@1#+MNWA>U:UX>9)2 M]<4.0Y:4,I35^A9UF[=S.'(Y\FY1]WF[@*.0H^@6]9BW2SA*-:1/:>AW+?=0N,V[CT;*>Z![G\YZL]IF$+X_TX^Y0E1H MBR5"H[988C12L21Z+-`3Y,@[Q38-WO7A)XX$ZU7F[ZV-Y,%B_8$B$62E6HD8 M$[(T7T"IN*'X2"E55E;8#G=:;"A*W?K#F1:U-8K40Z1&MC2"'[C"=[`=.B=K M#!>OMSGWT*C-N2^-X`2R-X`T63`@ MIR(IFC?$H@U$V#3K`[&]^A7F>O63J+Z$44@-0IKA)1JI[<6*(PN16@:L%6I6 MM]%(J3L+[CAX@N=BFS;N'1FW>?312W@/BW:`[E1#;M'F/T*C->XQ&RGM" MO-_1C62*;1J\Z\5$'#K3I]KG]TEBB)$EED1:D2FM`#5/I26V4[N!%4<6(C51 MUPHUJ]MHI-0=CEQ$2MU3J%G=1R.E'G`4(E+JD4+-ZC$:*?6$(_%%>S'I:T6F M_$*]_([WD)U>LT6VWY\[V_R[^/H+7'K\!;.E.\EN-7X-/\+\42B?B?PR?[Q52@?`B?\E_3 M&8'.M0OSD9F.KC28WYEIT7/$@3\UDZ+?*;\WD_LK.NG4A&\*^(TM9R:\I>?< MGIGP5IUS?V;"6W#.XYF97./SJ3F_YGP?M5!\&?,KQO7K-@EQ#I>9[S2 M--8>4A6+PW#"%)-9BJZ!V'<1`Q1WF;TO9V!--B5MPBIO- MMKD36C6(6,M*NF,+I42)]*6HM>'K"GT?HC$7)W:[N,(K*8RV.G$O;UX)K;4^X]&9I]E#5AL;)-O MP%KKC0]]R?P6'F97IU=M`[X:DD'.MY7[IO>?0!:EPVXG:,C[2K/C,UB!!45, M$">>)'2%">"5*.DG`PO"#^U]+S-7XE,<3)-D/)G>(V8-UJVD9U(BMM9I]:N/ MZED=)>XI>.\IHTF0W(>C"$7?@+`NH];@,W=\,3-Z3W!H4-(VW(]@E"+X=4=H MQ<_]4;IL/R@V MO,"!;G@!7[@I9&U)!3DBP\`/L.D^B6[A=-..U5H[G.3VL<0_%V#70F\\U]J= M%BC,AG_AXC<```#__P,`4$L#!!0`!@`(````(0!PS$WA\P8``%T=```8```` M>&PO=V]R:W-H965T&ULK%EM;^,V#/X^8/_!\/>+8SLOK9'D MT"36=L`&#,-M^^PZ3F(TC@/;;>_^_4B+4O16-U?NNR1!T.;'HLK:47TISC"RKYLJZ^#/YA"TEZ;(=OVD MZA1$X_$LJ++R[',-27.+CGJ_+_-B6^?/57'NN)*F.&4=V-\>RTLKM%7Y+>JJ MK'EZOGS*Z^H"*A[+4]E][Y7Z7I4G7P[GNLD>3\#[6SC)6^7_7GNL M7W]KRMT?Y;D`;T.<,`*/=?V$HE]V",'DP)K-^@C\U7B[8I\]G[J_Z]??B_)P M["#<4V"$Q)+=]VW1YN!14#.*IJ@IKT]@`/SK526F!G@D^];_OI:[[KCTH]EH M$DWG=R'(>X]%V[$2=?I>_MQV=?4?EPI)%]<2D1;X)2WQ;#2=C^->R<#$F"9. MY,1P/`HGXQDN/C`/1GNSX5>8/5','I@YHYGP2S,'5PRXOWKW;[,N6RV:^M6# MG`:'M)<,=TB8@"[A=[ZRC,1;@8`(H)('U++TY[X'+FXA>UY60'X1O$#$(SHQ=$_44_&2"JN( M%=>]WIZ/@#8VM!50U#=BT3@T:DAZ%1!JF(`<7+`4*EP<-D.3*XWFA5,SFB`X M&*1_IV;3$9(0;$4I9$?*(11.C3XS)571F/K0D5%SF!!0`ZZLI25F-;:8T!3))+OXF4RRJ MMS/E)5AC2I`69VM'DM!PG*70E2F'**C1R*A5+*3Q-SRHQQ0KKL+T8[N3EVW- M`02I#IA9B4Y"PPZ00E<'<(@<8)QA+*31F^ACA5;HO[.A4=JH9!R*)O)@VH02 M-ZS3BN$?BQLJ,?AP*)HI?$@*#AS7QB$^)*0Z MW7$6MPJ(]F@U9V8T-!LQ;S#%A="U M&TP)DC7'<@!?'!L*Z<8W'8`MCK*CWXD^2AM,.:2EK82AZ[J1`"+7# M-A%G+A.0(VVQ$U$,_UCDJ)U1&CP@TAMQ+XW8"&@X=TG5.[E+VGGNVD54+'53 M[F)K,>"!&T\B:E!4%W!("ZF$AD)*0NI)9$$,[V,QRHZ08@D!K+;M99^'F$7,>""&V-*S8L: M4VI/>J_W]#:1A)QVD0](2(VI!;&K*MBY.B'L.`Q"\1V^(/SHC1"6#O/LX9!^ M(V%]V-!$D!+'RM:&4AO"UQ9 M7+K6\"C65T:3"2ARR3_$H,=)/4[@`AV,#:0F>-RZ9(?BSZPYE.?6.Q5["/&X MOT)H^/,8_Z.CCN^Q[N!5"[(`WG#@&;.`^Z7Q"/)\7]>=^`,7D`^CJ_\!``#_ M_P,`4$L#!!0`!@`(````(0#R3?_?50(``%`%```8````>&PO=V]R:W-H965T M&ULE)39CILP%(;O*_4=+-\/ANQ!249)H[0CM5)5=;EVS`&L M8(QL9WO['@-ATDFD26\`F]_??S:8/9]400Y@K-3EG$9!2`F40B>RS.;TU\_- MTX02ZWB9\$*7,*=GL/1Y\?'#[*C-SN8`CB"AM'.:.U?%C%F1@^(VT!64^";5 M1G&'2Y,Q6QG@27U(%:P7AB.FN"QI0XC-(PR=IE+`6HN]@M(U$`,%=QB_S65E M+S0E'L$I;G;[ZDEH52%B*POISC64$B7BEZS4AF\+S/L4#;BXL.O%#5Y)8;35 MJ0L0QYI`;W.>LBE#TF*62,S`EYT82.=T&<6K`66+65V?WQ*.]NJ9V%P?/QN9 M?)4E8+&Q3;X!6ZUW7OJ2^"T\S&Y.;^H&?#)R?)H&D^%P,)J,$;,%ZS;2 M,RD1>^NT^M.J6E9#Z;44O+>4_B@8CL-^A*;O0%@349W@FCN^F!E])#@T:&DK M[D68D7]279%<\&A[. M#,^AEL\?OA_VWK>\JHOR./?5./"]_+@JU\5Q._?__NOS:.9[=9,=U]F^/.9S M_T=>^Q]>?O[I^;VLOM:[/&\\B'"LY_ZN:4Y/DTF]VN6'K!Z7I_P((YNR.F0- M_%IM)_6IRK.U?>FPG^@@B">'K#CZ&.&I>B1&N=D4J_Q3N7H[Y,<&@U3Y/FN` M?[TK3O4YVF'U2+A#5GU].XU6Y>$$(5Z+?='\L$%][[!Z^K(]EE7VNH=U?U=1 MMCK'MK]TPA^*5576Y:890[@)$NVN.9VD$XCT\KPN8`4F[5Z5;^;^1_6TC!)_ M\O)L$_1/D;_7Y&>OWI7OOU3%^K?BF$.VH4ZF`J]E^=5`OZS-(WAYTGG[LZW` M'Y6WSC?9V[[YLWS_-2^VNP;*/845F84]K7]\RNL59!3"C/741%J5>R``_WJ' MPK0&9"3[;O]_+];-;NZ'\7B:!*$"N/>:U\WGPH3TO=5;W92'?Q&D7"@,HEV0 M$-B[<3W6LZF:QO>C3)"17>"GK,E>GJORW8.N@3GK4V9Z4#U!Y//*D$>[UFM+ MA36:(!]-%!L+5E%#?;Z]I/'SY!ND=.4@"X0DOM="%$$D>L(FC(1,;\-R'5;4U"",Q,4)FMH9:AT'`QY=T/`I42@",%_0U38CI MJ^CJCCD7S;PD$B.+AA"2&/*`$8@Y@=L5,6">F#3E"U\@)+:)44$)BKR`&F85J!M[`J2\1$%GJES%&RCB5D('[>\R\ M),F)3;U`C",'2;O,CUFCX\#\,LSHI9S>[9P9L*0E=O8",:Z:/6U.Q[6F*66\ M%.@0S=MM8A8MF5T$!:OI0$AMQ-H(,R8`T(EMN3DW(>UWN*'Z4FU(IFU@1PTQ M9VKQC$SMN%&$TM>Y&64E_7:'&^HPY:8"*5P*04@NBI(N-PH(0;BNY%F MI.O^7E`HT)QC)X$(!-$-SU((=342?/N&S#Y)]U=5]%4C'<2"7F(!J@ND$&H/H<0/JY`V'NH&:7F5WFJ`6,-.S%?FIZD`58M+`` M=8ELIUXXD"NK[LJ$`Z"CCVAB6=:T<(#'E,R^)2G*SG,@I!@IH"`6L>0(G=!] MPUD:77Y8,#2J.`AI>X952KJ[`Q'!H$_X[$+M;_>][E%Y)1W<@5SYHJ1[B.:( MZ?1Z=VC\TKZI`-=[7LVKE1Z5<[,1R>MVX/=A5K.?%))Z;"AY[[+8,A\ M$'>G0]P\T^I!7F#1LNVE23K0F9AAUJJ"(T;-`(YO=//RQA-N\&#ZNJZ@E/1+ MC2"9'$>0.@*P(RO@_`89@NX:@E+221T(L\<^'1TU#")YN*TJ%LV_>Y6^1+93+QR(:!I]PF<7NG]G M=CRSLQVII=Z']&"?)MV^9X"$^0'G)M3^L?J%J/J(.6WA`B"#FF/6FDXRJ@UL$I#C*&L,<8M#0&!W+:-HWB;OMS2)A< M/Q6%PASNM&"/*6AI"C9D:PI12K]`<'=*!%T`S]X@9PA1TEGS=;3-@=R1K*>P MS!>BZ]2$+=Q)7(\=:&E:(57\4:38MYO+'(/HF"67IT[8PH-[H\<>M+2M$$&N M`7O4EP/8)S[G^+\\(NSQ""TMS($<1Z4B>CQRN:0>H96^>CR/!IF$18OSB986 MYD!(;Y;&5#^0'4-,TYA^,K(D1H-,Q*(%NU!:F`,ANV1FOAK$Z8DA9D%Z]?04 M"1NYO4TL6AAL*"W.@8C!TB<\-\(@[LS>8PRA-*^("G\8TZ\E5S@&N/Y7AFB0 M,UBTK)LT+0<)G M'R3[48_LA]*4'`A7'G=EGXW?:.=!J@]7G9V_<(=2]1T(;W)Z+@78^&4?8L+P M)A0O"@]YMZORS=QR*KA):)_B#>P";F#M=>6D'8`+T%.VS7_/JFUQ MK+U]OH%7@W$"U:GP"A5_:WG^\A\```#__P,`4$L#!!0`!@`(````(0!_HRFC%P,``'$)```8````>&PO M=V]R:W-H965T&ULE%9=;]HP%'V?M/\0^;WY`O*!@*I)U:W2 M)DW3/IY-XA"K21S9IK3_?M_Q\;GGVKXLKI_ZSGLD7%`V+%'D MA\@C0\5J.FR6Z/>ONZL,>4+BH<8=&\@2/1.!KE>?/RUVC#^(EA#I`<,@EJB5 MN'6+R?T/:TX$ZR1/M`%1NAISGF0!\"T6M04,E"V>YPT2W03 MS31J\[>1/MOM*Z*:54.X99*02F]?/MT14X"C0^/%,,56L`P'P[?54;0UP M!#_IWQVM9;M$D\2?I>$D`KBW)D+>446)O&HK).O_&E"TIS(D\9YD`NKW\=B/ MLUDT2_[/$AA%.L%;+/%JP=G.@UT#:XH1JST8S8%9938!?][.#%)2TAA("GR#I#81I2GB.DK20#R#AHA\\LUJDF.QM164!A( MJEU6>95'`Y8`,.98P'ES%'B)@.J0>98Y"QM(IIV+)K,PM..E%8^G1W%+UO02 M60KLR,KM90L#VF5QY`L2O)T&KX>($LD M)%TGO(IM5?>*8&ULG%7);MLP%+P7Z#\0O$?4YA66@P1!V@`M$!1=SC1%641$ M42#I[>_[2-KRU@9N?;!$:][,FWD4/;O?R@:MN39"M05.HA@CWC)5BG99X!_? MG^_&&!E+VY(VJN4%WG&#[^+`,-6W<*BJ$HP_*;:2O+6!1/.&6NC? MU*(S!S;);J&35+^MNCNF9`<4"]$(N_.D&$DV?5FV2M-%`[ZW24[9@=LOKNBE M8%H95=D(Z$AH]-KSA$P(,,UGI0`'+G:D>57@AV3Z.,)D/O/Y_!1\8T[ND:G5 MYI,6Y1?1<@@;QN0&L%#JS4%?2O<3%).KZF<_@%>-2E[156._J8I$<0$.\[ M`-73#OZ=+S!N6`R?U>.K68 MGPNYD#/8A.];=46`.Q7,X@O!@+D6A`F>9GJ;H"NZ<)@=9Q8J$LO/K^MH:3GL.+ M%D<`KI2RAX4[I/K_COEO````__\#`%!+`P04``8`"````"$`4*.7@]()```S M+P``&0```'AL+W=O8G)3ZUN M2=UJ7>R[O[\?]KUOV>F\RX_W?6,PZO>RXS9_W!V?[_O_^AZ>7T_9YK&H=-@/S='H>GC8[([]4H-U>H^._.EIM\T6^?;K M(3M>2B6G;+^Y4/O/+[O7,VL[;-^C[K`Y??GZ^M[RHU#:[QVV MEO=\S$^;SWOJ]W?C:K-EW<4_H/ZPVY[R<_YT&9"Z8=E0[/-T.!V2IH>[QQWU M0`Q[[Y0]W?<_&59J&OWAPUTQ0/_=96_GQN_>^25_+[M'B\O]_VQ,3"N1MCL?$!)>-*R56M9#JXG4RNKF]OJ"4= MUJFTZ`$]*^OF6%KOJ'A=5:1G5=$8O:OB3561GBW][;!(DZYH*CVKBN_LX[2J M2,^/]=&@@"K]*R*KFG4H4$_/M9/@R-"_/A83PV.`_'C@WVET"G[*F/H MG1X5,Z:L*J-HW(CA#I\:'$;BQP?[RH%DR$@RIH,;8S0=_R+H#0XE\:.RVMW7 M83GQBSRRV%PV#W>G_*U'R9F\>W[=B%1O6$(;9Y"RSW5.^5E*H5PBM'P2:N[[ MU!%*%V?*@]\>S)O;N^$WREW;2F:&,H8J,6<)D:B$VH4.ECJP=>#HP-6!IX.5 M#GP=!#H(=1#I8*V#6`>)#M(&&))[:A_1-/I_^$BH$3[BT9TQ:#A-#E0Y\'00Z"'40Z6"M@U@'B0[2!E`<0LE)<4C[,!G)1G30_KI=J3YJ1;B:@L@2R`V M$`>("\0#L@+B`PF`A$`B(&L@,9`$2-HDBI_('XJ?NJ>1D%9]49))N;$5Z\4< MR`+($H@-Q`'B`O&`K(#X0`(@(9`(R!I(#"0!DC:),O"T5_G`P`MI=>!+HDT" M?3&OA>I)`&0)Q`;B`'&!>$!60'P@`9`02`1D#20&D@!)FT3Q!>V9%%^4&["! MV`%VSP=1475+2<:-^0!D`60)Q`;B`'&!>$!60'P@`9`02`1D#20&D@!)FT3Q M`>U[%1]T#[R05@>^(N6YN$A$0!9`ED!L(`X0%X@'9`7$!Q(`"8%$0-9`8B`) MD+1)E(&G$^T'!EY(JP-?DG%Q25*<&.8UD>OSS8VZ/"\J&=INUVNX,=&$EK40 MIR\;B`/$!>(!655$-MH'$M2U9!--0VMB6`MQ$R,@:R`QD`1(6I'R\JEY%!$W M"HK'&NGJ\K+;?IGE-*8TLBU3:$SGPNJT*+2HGBP4TS9-CLHG$->F9X5H+R]SYI4V\>:%G<+W4@H=7:H:RXN(956O M@6RIBOOG('*QHH=HA15]1`%6#!%%6'&-*,:*":)4J:@Z3)QM]=EI3@:_W!2* M>U/==16B1;AVG7FKS8$Y5Z3,7TNAZRI532%CHIU^EY4J M^*DE1S:'W>]*).N!<8^U5\:-P40UOV*!+O.^M,7F`XDZS(>LO31_=370>A^Q M0)?YM;3%YF.).LPGK+TT/];NCU(N_HEQ-03%L?VW0K`\[U-P<^-GM!B(J#1I MYM5?0.M(XZW41>:RJG+RC@>;=%9=WF?)1;X`H9%55EM1[%7%YEZDUZHT1 M):R*36D+3\KE/S&E!I"X16D&T"_V,>6EBQ(L)3*;N],:R?2!D5$)R;N5I7CC M)Y*:1#8CJ=U!Y#*2%3U$*T92EX\H8"1UA8@B1E+7&E',2.I*$*6,"EVJ=\3] M2M,[OW52%L^M-/P7+Q&%3.<%HAZ&4`_5D+-:(--Q+)298H3Z[<' MXWJ@!:W-MIII3[?EL)`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```/__`P!02P,$%``&``@````A`*X7-,-: M$P``@&(``!D```!X;"]W;W)K&ULK)U;<]M(DH7? M)V+^@T+O0XD$*[__UD`768574@2NK8 M?FC:'[).%I!U39#E#__^\^[VY(_=P^/-_O[CZ71R?GJRN[_>?[FY__;Q]'_^ M$__K\O3D\>GJ_LO5[?Y^]_'TK]WCZ;\__?,?'W[N'WY[_+[;/9V(POWCQ]/O M3T\_EF=GC]??=W=7CY/]C]V]7/FZ?[B[>I*_/GP[>_SQL+OZTA>ZNSV;G9]? MG-U=W=R?#@K+A]=H[+]^O;G>K??7O]_M[I\&D8?=[=63U/_Q^\V/1ZC=7;]& M[N[JX;???_SK>G_W0R1^O;F]>?JK%ST]N;M>9M_N]P]7O][*??\YG5]=0[O_ M"\G?W5P_[!_W7Y\F(G;AY,ONZ]7OMT_=_F>ZN_GV_4G"O9`[,C>V_/+7>O=X+4]49":SA5&Z MWM]*!>3_)W?/EZ?O'T]E\,KM<3!<78G_RZ^[Q*;XQFJ(S*V(?%J1^>3=]/Q]]$XJ M)0[OVKRKVSY>03MSY[54'I.[U#^3Q4=#Y;O+OL[_9(3=_;@O)I M"TZGD^G\O'_41\I-I5D,43+M8WC`\\GE8C&_N'SAX4P/`98_O.TVIXBJ^+=C#5AG#YJJ>$AF#:_QMO5=K.4%]M1//)ZVX5 MS6BJ[>B5444[FKH-Z5A4SX;.VX\%ZZNGJT\?'O8_3V2`E=@^_K@RP_5T:=0P M"@R/^3`N/#'L#QE_KJW-9[:9^A8K M6)C!QLBN0[`)01R")`1I"+(0;$.0AZ`(01F"*@1U")H0M"'H''`FX3G$2#K1 M_T>,C(R)$9[N9P`-VBP(""Q09!V"30CB$"0A2$.0A6`;@CP$10C*$%0AJ$/0 MA*`-0><`+R`R-'D!&9\RT3>,M70O$3O2.0:C2#XC0SR(;(C$1!(B M*9&,R)9(3J0@4A*IB-1$&B(MD(QU'QX\U,\#B>3#B<6[(!8' M(Q1;$]D0B8DD1%(B&9$MD9Q(0:0D4A&IB31$6B*=2[Q8R(3ZAE@8:S\6`UE( MK)U87`:Q.!@=8D%D0R0FDA!)B61$MD1R(@61DDA%I";2$&F)="[Q8B$K%"\6 M9JZ?+29B_\;9W@CY81I(T&7>!V$Z&!W"1&1#)":2$$F)9$2V1'(B!9&22$6D M)M(0:8ET+O'")*LH+TS'9Q=C[<=B('XLIN=!+`Y&AU@0V1")B21$4B(9D2V1 MG$A!I"12$:F)-$1:(IU+O%C(BMB+Q;`\GIBMT_&PF()^6`82#5MIL[I=$5D3 MV1")B21$4B(9D2V1G$A!I"12$:F)-$1:(IU+O!C(GM>+P?$';ZS]!V_)D'?H M'SR1-9$-D9A(0B0EDA'9$LF)%$1*(A61FDA#I"72N<1[\"9Y\(8GWYO[C]ZB MJ,]$]5NZ%:,UD.Q_=)*?!IO#C5IAR(J!5#YAE`+Y\L'N-%,KR&^!5#YG5`#Y M\L%RL50KR%=`*E\S:H!\^6!J;=4*\AU0+^_'5;3>$E=C'L1U0%Y<":U-!DD* M1O+AQ#788V[4"E6/@?3))(Q2(%\^V#-E:@7Y+9#*YXP*(%\^6'J6:@7Y"DCE M:T8-D`Y++:,.:"2(9G/J9FZ.#XMF^QD&<4!>$`FM;<$@B)&_G-BH%1Y##*2/ M(6&4`NECR!AM@50K9U0`J5;)J`)2K9I1`Z1:+:,.:"0\9G?JAL=9.3Q]O[G^ M[?->^H2TK9&P19)`LVFU88\K;O!8/YL$J>E46OT5HS60Q-/I>O,P:E9+Y6,4 M5/F$40JD!3-&6R#5RAD50*I5,JJ`5*MFU`"I5LNH`^JU_)'1[&/=J(U$1]Y+ M',(S;'N]\%@D'X<'/YT'H\;*)*A-;YP?XKJV*-+\W(91S`431BD7S!AMN6#. MJ.""):.*"]:,&B[8,NJ\@GYXS-;V#>$9=L)>>"R2Q>8A/-$LW!R9UP`F//W; M-YN)/B`M.%T$!3>VX$P63@?YV670[6)8N3/+[#R8N!*N1*I(Y:D2&>3/^SS\ M7-X3^=U^"P/7_[M@P9*K+PP]A:(C[DNHN\\@F@5UJ&#EUH&>0:T>48E&T9%* MM)#W*Q$L/3I8/5<)O_&9#;O;^#1]\L(H,>STO68XH(5\'-I)-`LFU=74%M0Y M:,UH8]',S!I_?%I,@IN,443&^H.O,-H)C-15RBA35RH5S8+FO45!UR&%-H>5 M>BP8E6,>IY?!<%JAH.LQO,4:1NJP8=2..8QFP6:A0T'7H7N+?L,QV86PX42R MZWK#.F!(4'A-:$`+^3B$-9H%@\C*O%H,1S)"&VOE#5O1+!@18E@]UUOZ@3)A MCRFC#%IN_Z2X;F'E>@SCFK-ZP:B$U%&'%:R..:Q9O6'40LIU2,^T@Y7K\/F& M9%(D;D-Z8=P9,BI>HQG03-<=*_/25UJ(@]9`FJK:,(J!5"MAE`*I5L9H"Z1: M.:,"2+5*1A60:M6,&B#5:AEU0+V6WZE-UL2-13\;7)BORKRE7]OREK)4@D3XQI(Q[<-M(:I(9A>8A1P![&P=R4P4D@V]GX`R2&O'@L@]5B.>:0!I$)!UV-XBS6,U&$#I`[;,8?1+,C# M="CH.G1OT6M#9KSUVM#Q_MR;^WD8BYS.NV*T!M*VOF$4`^EC2!BE0*J5,=H" MJ5;.J`!2K9)1!:1:-:,&2+5:1AU0K^7'0D9@+Q:O7=W-3,$@*@/RI^8HV"NL M;,'9I79A:.F^8P,K=QJ9A;G1&%;N-!)%P9H[@95Z3-EC!BO7(_6L+:Q&/;6P&CQ=3,+>B^O/W)3? M8$RJ+)P`WK:JFPW9-G>"MLC?&$3!R+U"0>T2:R`=L386V8V!?(O3WP;&*.*. M56$($QBIJQ1(767J2H,TTF;L_1YSF$-='19`ZK`<$WIA_#?FP4@S(&_\)[26%M`O*71LW#"* M@?0Q)(Q2(-7*&&V!5"MG5`"I5LFH`E*MFE$#I%HMHPZHU_)C83)R87>>+OHW MO:_?ITD@*$06^>-7N$^S!;W)P!9T)X,!F5G,&0O#?1JTW%&,6GT"*QTQ4]1> M/6:P;!*, MLAVN/^/*;SXF/>@VGQ>ZLLTF.NM^LW'P]V$K1FL@;>8;1C&0=IF$40JD6AFC M+9!JY8P*(-4J&55`JE4S:H!4JV74`8UT99,V2_4XFI&L4,3U%=Y<#2-UU0"IJU9=.3<7!6O(#@5=A^[- M^5W9Y,?=#$C&#VS.5S-":R!MYAM&,9!J)8Q2(-7*&&V!5"MG M5`"I5LFH`E*MFE$#I%HMHPZHU_)C89)3;BS^7E<>4ES>.MLB?U8.]@,KF8[[ M,5GGD;5%9I]_Z)CT"F:#@L/4,Q0)7[$@7=-4,T#[:_%:S<.KA]TJ[-*0+-JRK10MZO1+`C[F#U M7"7\QFC25\<:XW_V/V1Y/OI*7V8KO#2>V2R8.V`,R!LP"*UM0>DM&%8VC&(@ M[9@)HQ1(M3)&6R#5RAD50*I5,JJ`5*MFU`"I5LNH`^(!0[X6X#7C#:,8D8)HY11QFC+*&=4,"H958QJ1@VCEE'G(:^_F*\, M>?WEA5@8\R`6`_(67-$\R&.L>C]2T`V/U9*/(Z.T+6@VA0>K*%S0Q9!WK6B@ M2F"EE4B!CE8BTTKTOYJ;38*MX18RKO]PM93#2-T70$?=E^K>?09A(@5:;AWH M&=2PTDHT0$UELKF5)T ME+!:NJ'>P&J8FV>3V7OOOV"FCF'N/K\P^`F,U'-JD2Q34)D,5OZ,&&Q?MK!R M'5*D8N&U\8?VS:SUD>FI_R!*DA1FL@W6MM&,5`^A@21BF0:F6, MMD"JE3,J@%2K9%0!J5;-J`%2K991!]1K^;$(TW3]6[ZWOK67W_!0O[;(VT_2 M6WM;T)LB;$$=J#>PPB@6[$IC7']F%!LVCS#2`3.UR)L3!N]^0CE<`6VAY3IT MFWOO,8>5>BS88PFK%^8$6R_78SB$U)!2APT[;&&%IQFL'CMR.FN`U%GK.WL_N?#6R^^#]6L'!??!.K?I-R&37')GYK^QQ!OR M4VYJ,1J0OUN@5_C6RIL*K)8[%0Q(QF?SI.E!QU!Y9O"R4X$5T7$RM>6\J>#@ M2F,VTHJLU3&'.6JE#@MV6,+*G0FB>;#[K6#E.J2YIX:5>FS88PLKWV.0F^U@ M]9Q'OPF9-)W;A%X8>X:LGM=<*-&W,KL,?[VW!M+1E3!*@50K8[0% M4JV<40&D6B6C"DBU:D8-D&JUC#J@7LN+Q5SBZL7"=.E;T"Q%8J<<42#UF8QZY8Z.@Z]$9-X[ M\MR8!^UD0&X:WUHY:`VDS7S#*`;2^T\8I4"JE3':`JE6SJ@`4JV2406D6C6C M!DBU6D8=4*_EQV(L>_?VKLRIO+E%,HT=LB'A?F=EC=RY&>6([AS=4045<-NVIA-;AZ-PG3OKC^C"N_W4A'?TL?-N9!'QZ0TV%7KYV8%9'PR@XW1?V%'P[1Z^ M[5:[V]O'D^O][^:0;UF+?_IPP,,)Y)\7RZZ?_4-^L>PNS(OED+];=GWG#_GE MLNO7@"&?BY"T05:2K]PLS;=G^(I\@69IO@O#5^3K,$OSS1:^(E]N69KOJ?`5 M.6/]E[ZEAC63L]?[;6;(9\MNS/Z7:/F+1($=?([$\QB?RYV/<#D4:FG..F$E M.1MJ:8X\X2MR1-32''/"5SJY8DX[X2MRW,C2G"_"5U*Y8DX+X2MR%,C2G/W! M5^1@#ZG!V!4Y0VMISH'A,G*4UM(0< M';DRYN>S^#%'_7`-Y`"UI3GQAZ_(.6H2T[&ZR4E<C]GAUX@Y___N/JV*Z\>OMWQC0W8M6?/-2%.0@W@%&8F M,__^M"RW9>DEWF3WS,68/.X/2=UJ2[)O?_]YV+=^I*=\EQWOVE:GUVZEQVWV MM#N^W+7_\X?[V[#=RL^;X]-FGQW3N_:O-&__?O_O?]V^9Z=O^6N:GEMDX9C? MM5_/YS>GV\VWK^EADW>RM_1(=YZSTV%SIC]/+]W\[91NG@JEP[YK]WK7W<-F M=VQ+"\[I,S:RY^?=-IUFV^^']'B61D[I?G.F]N>ON[>O*AF*?1]U1ERS=WS[MJ`=BV%NG]/FN_6`YB35J=^]OBP'Z^Y[7?K?PU M>Y^?=D_A[IC2:%.<1`0>L^R;$/6?!"+E+FB[1036I]93^KSYOC\GV;N7[EY> MSQ3N`?5(=,QY^C5-\RV-*)GIV`-A:9OMJ0'T?^NP$ZE!([+Y65S?=T_GU[MV M_[HSN.GU+1)O/:;YV=T)D^W6]GM^S@[_E4)6:4H:L4LC=+U@I$&Q7RI>58H6 MC4"#`K6I:"Y=2T]VL\)UJ4#74L'JJ?XU>+HI%>GZM3[1S"J:2-?*8V.?1J4" M73_7)S%&,F@B7*H8T;3Y?\1(F!$QXM$=,Z@%30_9A"58 M96J"F0E<$\Q-X)G`-T%@@H4)0A-$)EB:8&6"M0EB$R0UH`6$BI(6D,O/3)X; M0IJF%QEKF!Q2J$^7FI!MA*,2JN(!9`;$!3('X@'Q@01`%D!"(!&0)9`5D#60 M&$A2)UIXJ/!_(3Q"N@@/#^I8D@'9K\6B;\2B$F*U*9`9$!?('(@'Q`<2`%D` M"8%$0)9`5D#60&(@29UHL:`GZ1=B(:3U6$C2)_NU6%P9L:B$JE@`F0%Q@$!\(`&0!9`02`1D"60%9`TD!I+4B18+6IIHL9#/^HY84#57,*&HAT62OMP8 MB$?U!,@4R`R("V0.Q`/B`PF`+("$0"(@2R`K(&L@,9"D3K08T!))BT'SP`MI M?>!+(K=1Q<`#F0*9`7&!S(%X0'P@`9`%D!!(!&0)9`5D#20&DM2)-O"TMOW" MP`MI?>`EZ1>;ZF)Q.JF(*DTW-WIEFI8RM+*KRI@$DK+14$VW+:&)4"7$3ET!60-9`8B!)2>1A17W52[M:+6"U:G5^W6V_ MC3,:4AK8"S.H3SL0N2\11O0X2E*/(Y!I2>HK-FLPU$,[JX1X2%P@$!]( M4)):U("$E9:*&C0QJH2XB4L@*R!K(#&0I"08-7'$\,_#5EC1X\;HJMJ_3!12 M@P`SL!3J7\M=:<\R%G(S)<"CY"K#C.:(/*58['=[EK%<]Y4`FPG0S`)1J!1+ MRT:;(R7`EI=H9H5HK10OMSE6`FPYT,+&CK1_W_$7`Y`:8MJX\6&.QC145ED8KER^3]'_T-5N-%C<1),B6=3TE1QMD?&D$Q**3$#*BE,O-*Z6D3/ MV+I8.?RXO^H,1MH_PXW+;LC0AV[F+*3<>(A\T_.HI_TSMKH!6VCRO&`AY3E$ M%.F>K7['6/0M6:?)UXJ%E*\UHMCP=67FA&P5*/'!9H/$45LJ^ZQWS.*]Y*E&CVNT/P:42 M."JI)]+?VF.(UT9F?DFD%:M^SU@?3EBQWE;,K]*ZFE^S4L^6Q:K?,6J$RW8_ MF$O%SFC.0LJNA\C77=GF,R!@E297"Q92KD)$D>Z*7K9:6@DVDGG)%IH\KUA( M>5XCBG7/-V8G$U;YP)6>4N+DIYY2?['"D@=%VH-.(KN^T:F0*BB8**60.I.; MB9>1XIFID,M(69\C\A@I11]1P$C96B`*&2E;$:(E(V5KA6C-2-F*$26,"EMZ M=,3Q4#TZ?V_"EX=,]=5)B>H/E'[/V+9-Q)M>$8^Z%,:Q-%5_ZL#"=,:FY.K, MF!PNWVVJ+',6&E:++*]$VA,/?/NL*'T/S25YP/>;O"]82'D//^4]8L5R76H\ MM)=\N\GYBH64\_6GG,>L6#H?=(P0)RSP@7L]&RD/&K/QC^R-EA\7C[CJVVIA MQEC?2*35D`HUU9!2J+Z'!N2*S9](8S57YX@\1LJ6CRA@I&PM$(6,E*T(T9*1 MLK5"M&:D;,6($D87:@A-3(B:/>C0<_JK'TT(2T;@)-+>/?9[Q@-^(N8G*9(4 M+PJGB&:(7$1S1!XB'U&`:($H1!0A6B):(5HCBA&)C^;4X,CY)C^"D]^]'-+3 M2SI)]_N\MH3&U+$<< M1*$.G3(YXE@)[]"9D2,.B?`.G0`YXL@'[SQ8SD/Q0#+\C\5WA!?DQ[9#WS=< ML--W'F@(\<:X[]`K]PO\RJ'7O\C#H1,7]=5H4#ARXDOVDZ%#Q\IH9VKU:`"+ MDV;#$IW`T@!>ND,GJ#2`E^[0"2@-X*4[XZ$SON1_,G0FE_ATZ-`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`ZNI6JRW=BZJ?X'M"Z-/;JY]"XR71^OM1W MYH"?OH1.2/]B/&='MW*J3'MO]0MT)Q>+Q7QY\>[XE$Q50OLPDMF%E90C,SM% M:O4OIC7!9':QF"ZZVW!L&.1M*HF;_L9%O<-%J5],:^9O[JU3=`3]R['Y.>O' M33<,P^OGZX_O'_>_3E1M4R/CZ<>UKI33E0Z(`=AWD&%(OC0BU2C243[I,!]. MU66IP?:DRLB?'X.+B_=G?ZJA?V-LKMAFZEJL8:$'IPX;^F#C@\@'L0\2'Z0^ MV/H@\T'N@\('I0\J']0^:'S06N!,I6?(D1I)_Q\YTF%TCG!WKP`D:3,O(;"` M2^B#C0\B'\0^2'R0^F#K@\P'N0\*'Y0^J'Q0^Z#Q06L!)R&J)CD)&9^M,#:T MM1I>*I@U."[=.WW5&P6J3(G1]-PU6@]&0SZ(;(A$1&(B"9&4R)9(1B0G4A`I MB51$:B(-D=8F3GK43732T]>TB9Y^#F=*.W:9POV]ZDG0+SUT25H3"8ELB$1$ M8B()D93(EDA&)"=2$"F)5$1J(@V1UB9.#M2]=G)P^,9K:_?&&](OU+H;3R0D MLB$2$8F))$12(ELB&9&<2$&D)%(1J8DT1%J;.#=>K5#><..UM7OC>Q)TR_9N M$EX3"0U1\Y55K+S)?#,883!%%"@FD@Q>=NB%6P?3P0BAMQ0H(Y(/7G;H=V[H M8C!"Z)("543JPD$1M[2:Q)W82B82&N$GT%@"; MP0AMCBA03"09O.S;L73O=#H8(?26`F5$\L'+#NVM-(O!"*%+"E01JF)GC$AHB)NQP+VMF\$(UQY1H)A(0EXID2UY941R\BJ( ME.15$:G)JR'2VEY.+M2.U\F%-?\_?[^]^>-JK\J6NHLC=.ZE:#`:4D2!8B()>:5$MN25$SDI MTF<+3HY&AP8%LA':,(K8,6:4L&/* M:,N.&:.<'0M&)3M6C&IV;!BUCJ.;'C4ZWI(>;>ZEQR`U2(?T!#-_0S,U5I?# MIC04)([3A>>X,58SU8V&\+,+;Z!%L%(J8G7N342Q***/)(+$D1J1(OQY=^`Q MGTZ\)=`6!K;^.V_%D8D6Y'-!!^0+1+?O03#SVE#"RF[#S+\'E2BB$;6@`XUH M$-YMA+>,:&'U4B/WW?Z9U&PQ44O>5ZI$OU]7.VU=:N>N5`KK:$' M!#-OSEP;*]5*.(:,-@;-]!SQY\?%Q+O(""YJ7SIH^=F.8212":-4I"14,/.Z M]Q:.MB"E-H.5*.:,BC'%J7^$5\+15O0OL8*1"-:,FC'!8.:M]%LXVH+V);H= M1UE1QPG4''3\K*_/G?U*UJ.%6OH-:0UF7A%9P]&N9":6H(VQ8/J1[/Y@-:,0B`Y7MHPBH`D5LPH M`9)8*:,MD,3*&.5`$JM@5`))K(I1#22Q&D8M4!?+'=3ZI,/.A5[-SY;Z<>!; MQK4Y+[%3U*.9LU:?T0+2.,I%AOKYI*X14M\V!IFIP9M>(CBH>C!4$']TQ3`2 MH01(A%(1DE`C$X-IH2UH=_:N@&0(+XHYD"@68XI40$HXVHK^)58P$L$:2`2; M,<%@YAVFM'"T!>U+=/N0/FBQ^]`KX[D_EW'&IBN;G01RAV+KKQ?,SJ MKC][<;+2(W=J#KR]PGK:6\TNAEH<&C2UIV9C94\CLZFWFHX0RYY&@L"SBF$E MB@DKIK"R%6ED;6%E*_HC*X.1".8L6,"JWZ]XE:XTGRZ<'5O@+7(KQ!"EFI4: M6/5*RPF-7G.S7[@HM\/H[5ODIC&$D4@F02*4B)?5_I,^89A\2S!!=!',@$2S& M!(/`VXF4<+0%[6K<33@5K$2Q!A+%9ER1-@8CEV@KNEU(GT/97>B5^M\?6SG= MI4=._2<4JGI"]9]0!"NY#3&C!$CJ;,IH"R2Q,D8YD,0J&)5`$JMB5`-)K(91 M"]3%S*`HS49P,HNS4'@[]-@ M95.5NSN==KUO"3:PR!9#;9&&3FYIE_1!O!Q9ZY_!$5PTBD$B"12D7* M*D!T:`='6Y"*1@8K4_N!M;%R M9F7CJ-9/PW1.CV`V<.RGEO,)3=%]%%W#ABC^"(@11&:Q!,T^J)["L5>?+B?> M>-C"X)!\!B.1SX^2+^!HKQF"N;?]+6%EM\$>D_W:'%;2B/JH1C1P=!OA[8A; M6+W4"+[GN=\9_[7^H0O#:XR!]0N@7C!ZIUN"D=FVL+!0"64^(&45` M$BMFE`!)K)31%DAB98QR((E5,"J!)%;%J`:26`VC%JB+Y>9('W79.7IE'=:? MC-E;JIE!,LFL#5+?@D5Z0D8;1A&CF%'"*&6T990QRAD5C$I&%:.:4<.H=9"; M"WV:\H9<](8QS%C[WSC'6,^-HI\<@>UR/5&D37LW-0Q4._`5=A/"V M%16J&%;2B`3H8"-28Z7FP.[/$V83;VNX11A;WY\K,AB)?`YT4+X0>?L>^`Y!!2MI1`UTL!'->"/\LQ7$>JD1;N?3!S%VYSOV/%=-]E2>>^2>Y]+3 M>N/H+!9,+'L+WR.UM]3IGDUFE\Y_WDP=(:A]__SDQS"223(Q2)UWH&2EL')G M1&_[LH65+4B9SF`EBCDK%K"R%>GPH(25K>A?8@4C$:Q9L(&56?CX0ZG%YR]( MN1U(GY#Y'>AMY[NS_I#-J6@]%!,@44S'%"FA6SC:BGY",QB)8`XD@L51@B4<#PE6,!+!&D@$FS%! MNJY`X'4E],]/M2(>7))VYNY\TR%H+KAF%0++7VC"*@.0VQ(P2((F5 M,MH"2:R,40XDL0I&)9#$JAC50!*K8=0"=;'<7*B13X/ZS4_M`QW%2Y%!JKH/ M8S&@I_;&494A5.40L:10;V"%*N;M2B-\_D(5ZX]W8212"4NEL+(K-*V`MK"R M!>WNWBEFL!+%G!4+6-F*5$)*6-F*?@FI8"2"-0LVL,+=]%:/+3Y_0SC*=85`,H-L#/)F91K# MIA'JA]0+>F"/\**8`(EB.J9(0VH+1UO1'U(9C$0P!Q+!0@3U&G9Z[C\Y*8W! M7"T]K*OS1EZ%R")6`XE8XXI=3I;.>OG26[^VB/#"9;I=2)_"_6=+//V7L7YG MZI&[6Z!'^,;1F0I,+'LJZ)'9+="-CA#EA>)EI@(31.ID@F:+5(I0!POS%E:' M!#,8B6#.@@6L;,%@[BU,2UC9@C3W5+`2Q9H5&UBYBM[9;`NKEQ3=+N2?";XR M(_#9G_HC7MV#G,4=H1!64BTWC"(@&5$QHP1(8J6,MD`2*V.4`TFL@E$))+$J M1C60Q&H8M4!=+#<7_MF??SY[U!]8!7PD:)!^BF25,Z^GKN$H%QD"23G;()9= MGV;^'Z!$<'2L_+^.B&$EB@F0**9CBB/3@[EL6Y&G!V,D@CD+%B*HIX>EOPLO MX7)(JH*12-5`&K5?7(4@(E6S5`.K7NK= MQ#_VQ>,(J`9*S$C!(@ MB94RV@))K(Q1#B2Q"D8ED,2J&-5`$JMAU`+Q&)ZKWNKDXK?&V<)2+#('LGL1/A1"^?R!S[G]).$*40]-7#"-13X`.JJ>N>C#UY;<(B-D!XM[$$?++ROXJR-HVMY#FYVSS_5$`W3PL<7HZH-YK2 MO>N1USAOB;0VCIZ5+$C[QO5O.^U?LWB_>_RV6^_N[IY.;O8_]9M,U6+\X_L! M]Z]9O9K/U'M6NWOE?:*^$[/27V]1SS&\3]0W7%;ZRRK\B?J^RDI_]80_4=\^ M6>DODO`GZD6OG\;TK]0+8+M]H*=^I1H\9O\I6'WJ7QCK.P2K-A@1OIJK*Q_A MI;J&;A/@Q:F6*_4R$KZ`>KEJQGBKKGB,J_>`K/2+/SB2>JO'2K_&@S]1[^A8 MZ9=R\"?JC1LK_8H-_F2KLC2FGRU7ZN4L;)\O5^HE5"/\W4J]UVB$7ZS4.W9& M^.5*O=B%>:3ZTQB/EROUTAFV3Y8K];ZM$?YNI5[A-,(O5NK=02/\6,/\ M:KFZ&N/KY6H]QL/E:C/6GO#=:C/6GO!BI=Z)Q+KAY6K3Q3\;.IAZL?"/ZV^[ MXOKQV^W#T\G=[JL:KNH[I:HT//:O)N[_\6R^?OAY_ZQ>*:QJL'IMJGJ%]$Z] M'O!/U]9@>'VU>]D>[O_^LO M[X_9]=7IO'FYWSP=7G8?K__>G:[__/3/?WSX>3A^.SWN=NGZZ&0V'TYOGS?[E MNG)PCI=X'!X>]MN=>]A^?]Z]G"N3X^YI'+]]?_UC M>WA^!8LO^Z?]^>_2]/KJ>>N$7U\.Q\V7)[CN7]9XLT7O\A_"_GF_/1Y.AX?S M`.QNJD3E-<]OYC?@].G#_1ZN0#7[U7'W\/'ZL^44MGU]\^E#V4#_WN]^GAI_ MOSH]'G[ZQ_U]O'_906M#G50%OAP.WY0TO%<(3KX19WME!;+CU?WN8?/]Z5P< M?@:[_=?',Y1[`E>D+LRY_]O=G;;0HF`S&$V4T_;P!`G`_Z^>]ZIK0(ML?I5_ M_MS?GQ\_7MO3P>1V:%L@O_JR.YV]O;*\OMI^/YT/S_^I1):VJDQ&V@3^U";6 M[6`TFUB3Z1M<;.T"?[X_E;$V@3\QE<%L,AE/9[>77P\HRT:!/[7)Y.V7,]4F M,-+>G\EWBH4%4G_1V=Q>W$W)P'%J,Y^3U5NJK%3#D5W<]Y\^G`\_+R"^0U&Q^EUHV9+R['`&0=A-63J M8=DU*F$X*I?/RN;C-5P7#+@33"4_/MGSX8>;'S#\MUIS)S66J5B@0HUU9>MR ML.3`X\#G(.`@Y&#%0<1!S$'"P9J#E(.,@YR#H@%NH#QUC:#K_S]JI&Q4C;!U M[Q!0T4:L(*C`4UP.EAQX'/@/]24 MM!#$%60IB">(+T@@2"C(2I!(D%B01)"U(*D@F2"Y($63`MC9JT-_P2FTV MO";5PUK9\(*X@BP%\03Q!0D$"059"1()$@N2"+(6)!4D$R07I&@2H^'A$>4- M#:_49L-7Q"X?W(+T@@2"C( M2A-*.JH))<23CFL?THPLEG12BS#IM2"I()D@N2"%)M5+4O-^#X]11@D;\]?Y M<;_]=G>`1H:F;AE3-CQ[54]DRL2L;$6:E17$U:1YK[(F,[/8RUJ$3>()X@L2 M"!(*LM*D44=!XOHLJII(,:E%F.):D%203)!/[?JZ9,S*II,JX? MVQ8UH0;@7=NM-/:T?!0?#2V;E;`^CNWCU:Y(_)ITQPEJ'_7(#W'8`V18'T?7 M5>V*)*I)=YRX]M%QV/4D]7%T7=>N2-*:=,?):I_VZ\GKX^A:U*Y`C(D8WGN- M_M`R6F&%`8>K4IN%UP3NL#2ECME07+2(1%^H-#8]^"\%\6H?O"Z_)A2>.P?" M)Q1D5?N@MI$UGD]Y2NM+4DK; MHO&4LC:12"GG*4WG@ZG92L5O4C(F(PN:\BT=5\E9QZW0J/EH8$_9?+\HX\") M?95S280C=ZG12#V__/AD6=,!>P[S\"1XZ^L<$CZ*^L('),+P(0L_G`WF9F.O M\*2^\!&*^L+'),+PB1G>GL`RMAE^C2?UA4]1U!<^(Q&&SUGX\9SW_@)/Z@AO M=C6U:M)<4NR_\:EU$=[5-#+G2#9M+?#$_CE26\WKQZ>E/D]/B&,Q^W@HZ&M& M_Y+H`8FPK4,TUY.?Q4?U"@5]T2,R[AX,,8DP>H+F571K)"Y^C8J^\"DY=X?/ M2(3A2>2+1&1.XIH6[W#$7DGDM4("K=S9JJ);9F3=\WO>B%NF:I*S2B>])" M;7NKZC?O>/S!T=4BJWG#$P^.2[2JYMA;OGCCX?&^`>.CJ"^?X*)\0K32^8Q& M\M%*7WQ?1A':]&447Y11HE7Z:7\TFLP&5M\T=$%ZZ27I91>EE[/TK/F$/PT6 M&*VCQ&!O74ULK$^HK6]^FZR0,675J'M@NMIJU%B0D,A# M1,/>)]3M'J"(W$.)5HC(/2+4[1ZCB-P3B=:(R#TEU.V>H8C<U5JF<1NJT(0R7ZB/+4#E&\B5:"F1)Y$O42!1*-%*HDBB6*)$HK5$ MJ4291+E$A8',<0!"JVC3E3CBI,/FU1*E$ MF42Y1`4BN;,*2R7F"&M,?)=OB)TIVS55]Z:5MDGE[6)A+IY1A/IV>S+<4" MCW?D8TY4;UMK@=4N,5%52#WW-'HPVP59X(D=.57;3"3"8;S4"&[&JKM:4/3RI8X.C=/91U!<^(!&&#UGX&:RQFN%7>%)?^`A%?>%C$F'XQ`P_N1T/ MX,M]])_HB+HZ?;FD%(;J)3NB=J(7MYSEPC\S4:!O1W"SUZDEGC?<'JL5H>8* MG]IC4'=,<]YD^X`+5/7/F]J*-C*6^CR<)"VQ=NVAHJ^B_B7A`Q)AV4,TQQG1 MYG/T"A5]X2-R[JYT3"(,GZ`YSB_P*1;J<\.AZ'55^ZG7V7H"X!TJI3#=HHQ$ MF$O.!XA#Q&Y^X2Z MW0,4D54HT0H1N4>$NMUC%)%[(M$:$;FGA+K=,Q21>RY1@:AT-VNJUG2;-Z_W MS2C*A96Z0O#:0*76JOY2:Q%4O.X/XFUE:6OWZ@E>?I)#'U>?4ZI=^..#CZ*^ M?`(4]>83LGQ:/LF!/GT912CJRRA&46]&B59-]:SWNT]RH&E?>BF*^M++4-2; M7L[2:_LD!QIUI&1V8Q#U=N/+/LD!/^DA^G&%C"FK1MV=R]56\`*#_7\ID8>( MAKU/J-L]0!&YAQ*M$)%[1*C;/481N2<2K1&1>TJHVSU#$;GG$JE?5U&EJ-J] MJG7U:RG53S0\[XY?=XO=T]/I:GOXKGX)93R&M_D:5S_3]829[-G;R-W\$5WK5>X0*.J'TTZ>7" M$;5OV7;$AB-MY\"FIJ-VO^0Y$1Q1FV#R2#QU\O*>S"MYZ^1M`Z68.D4;=V?. MLJT'!3,'OMG8$G?FP#<1)<]F#GQS4/*[J7/7%G/>.O!E M6LE74P>^4BMY-'6BDM_4#00_K/2Z^;I+-L>O^Y?3U=/N`::;8?EII6/UTTS5 M/\[ZTX)?#F?X225X'(*?C(&?T-K!3R,,![!=\G`XG/$?$/BF_E&N3_\%``#_ M_P,`4$L#!!0`!@`(````(0!,-ZG\UP8``&8?```9````>&PO=V]R:W-H965T M[=I&YY-AF^;,.&?%1><1 M5M60&.5^7VQSM]R^GO-+PX-4^2EKH/_UL;C67;3S=DBXSG!?7^W)MFVB]U^(>'/Q;8JZW+?C""_7^A=KE=JF;CP_M0;]6^1OM?2W5A_+MZ`J=FEQR<%M M&"?;\6N.:[U\6PTG9MC"^3:2UXW M?L%"ZMKVM6[*\W]<9(E0/(@M@L"G"&)-1Q-[.E\\$F4LHL!UNRCVR%Y,K>GL M@;[,1!3X[*+\0E_F(@I,DR[*_/&^+$44^!11;+!HH*D6Y`(?&I84W';;'LTM M#Q\;ZS;"\(<(,P9SAO:B&UOK/KC#>V'P;&N3U\V:[/FI*M\T6!&@+_4U M8^N+M6*1N[3E279+Y)_E,20PB_*%A5GK,%B0HC5,OF_/X^7XR?@&$V8K-`[7 MP&]),U$U&QK'4A5NIV`SB%W:P\#G`'[__#I!I^FBA%V4=QI%G:9K%&.08)!* MP`#';[:#TXKM_:M$YRY3,W>["SL=D'L[58W:4(VM*MP>!1HSCTO@+FY>HB`^ M58R7<_5"09]FJ6K"`9J(:B8FZG'Y.8=!@D$J`<43 M>'PKGK"GYQBJA/>7<]8*=-*B.C'12VY&\P<#'P,/`Q"#`(,8@PB#%( M,$@EH'@#Q8#BS?N>,/5:AT7W]J"96&@E&ZR'W5-C!3-#'9:5!/+FO$2UE7X4<,D^-JI!!0OV2815VD?YQEKA3U%2XW# M-9*G&+@8>!CX&`0(+P@?#&X8\CD@C4)"(D)B M0A)"4IFHCK'J6W9LV(.5;6#)E$5UJ"-$LG.\V9VX1.,1XA,2$!(2$A$2"R*F M@]V7M`EIE4LVA+B$>(3XA`2$A(1$A,2"<*,F2W4JBJ3#74[E,*ISK%K^!>=XD:TZA[=? MEE2)"^(2C4>(3TA`2$A(1$@LR,QJMR'LU$6M'Q/2))6)ZA>KF!_P MBQ?8JE]XYV5QD2CBY[VUUT:([H\$EQ"/$)^0@)"0D(B0F)"$D%0FBF=PV*9Z M-JR&:YNIFXJ)C;==0G2W94.(2XAW(])+!AL5UOY-U+T>"@@)"8D(B0E)"&'G MD;='&_>.'R_R$YIS7AWR37XZU=JV?&5'AW-(Y1N]'6M^:8\3$=]8*S@9@7M` M/+16<&Q!>0+'HWW]5(V<+[9_GF$\^P<7J.:(Q#OR[+IOK`+W$[( MG_\'``#__P,`4$L#!!0`!@`(````(0#!6WQ]"0@```(D```9````>&PO=V]R M:W-H965TGFZ;?W^W_AHV&TGJ7P[^*;H$M\V?0=+\=O?G'S=O4?R< M'(,@;8#");EM'M/T:K;;R?X8G/VD%5V#"UQYC.*SG\*_\5,[N<:!?\@:G4]M MO=/IM\]^>&GF"F;\$8WH\3'?\1N;,? M/[]<_]I'YRM(/(2G,/V9B38;Y[WI/%VBV'\XP;A_:%U_C]K9/T3^'.[C*(D> MTQ;(M?..TC&/VJ,V*-W='$(8`9OV1AP\WC;O-7.G]9KMNYML@OX)@[>D]+V1 M'*.W>1P>W/`2P&Q#G%@$'J+HF9DZ!X:@<9NTMK((>''C$#SZ+Z=T%[W90?AT M3"'>M15"_,!(-H\J^_,98("GRWHCL^'A,-`PH^_+UJ&@#[`1\ M*62,UD#KC(Q/9*B&&<*^?#0L[7S!9>MWZJ?^W4T;KC*_E]Y8R+#^FWWLYOPA!-1F@8#N7Q-"QNX@_'RI?44HQDW MPN5E$3(GQ";$(611$-'I)2$N;R6ZJ&M*%U?<"+NX)F1#B$?(EI!=0?+GJ/+= M'39-4L!*U2H]AOOG<013"A-;L8(,V&GE^R\F(L4V1C_;>.L=S5!"R*_C_%A<%&:6(ENQ M[N!0`A<>LY9#6!"X,XI2V%46U:3"B$0UMS'$AGU&B,5U<%QS0FS2RB%D05HM M"7%)JQ4A:])J0XA'6FT)V95;2=%A9Q%2>%BYU'LMN!_6!RIK*$<*$:0"#Y4^ M5-)\@E;0)6Y%8E5EI/4ZRCHLK/1.ME"UOGS9PLOENZCJ:2X\8>0#7NMZB> MNS=&\M3O\/([SN44!*.OI2!KJ*1@CO3R+5@?*C5QHA4-X:,F!;D13LVL:*?# MDQ)OI^M*5EJH+EEUE/#,T4KLR&V*G$J/':7Z+;!AK<#LMY61Q@=?K7"VI MKDO1"J6**JF.:HW7ZUQMJ*Y'T1:ET)5RX]GA]7==2'UBA>>'+9`6N%;&6HZ4VX?R4#LI MK-@'OPW0.!;JY6PCFX@9.F1/GJ]W6K^E)*V%OB!UWO4U1R,QZS:B6O>.XKYB M#U.,HL[]$GT)]RZB6OQ@PO3`V3#CAK^!=$TZ=*7?[)IRZ5?"! M">')IQX4'MW:,*9!>7>T(13!\K'?7-(A2^.U%5A:.\%N;`%Z'P+:OV7B,HA3_`<=M_NN=N_\` M``#__P,`4$L#!!0`!@`(````(0"?/.RF@`@``(HF```9````>&PO=V]R:W-H M965T M'J,H:X#");UO'K/LQ6FWT_TQ.N_25O(27>#*4W(][S+X>7UNIR_7:'?("YU/ M;NWS+KXT"P7G^A&-Y.DIWD>39/]ZCBY9(7*-3KL,ZI\>XY<4U<[[C\B= M=]?OKR]_[)/S"T@\QJ,)VOW3[.SVJ)W_8/+G>']- MTN0I:X%81"*Z-0_2T>SUE8?+F M1?'S,8-P=Z%%HF'.X=HS1S8R'9;.Q?TRPY_UT8F5*J$+&D"'PJ$;-C]#ZA84N- M3JEAM@;=;JX?/F79 M+S1B*$7@\\N-,&$@%7$5(ZJ(V<>;86)`Q9>O-\3$F(HO4J;SZ<%EPH@HFJ*& MQB>:@N&$28AU^$),S#Y6`KY\O2DX/DPU0/YG4]K%C,T3P&27[1[NKLE;`[(J MS,GT92=RM.D(09SZQ40MD\%[N0"2@%#Y)F3NF]`LF.8I)+`?#_:@=]?^`4EG M+VU&W,;4+<9H(3*,D)U0,*7`I6!&@4?!G((%!4L*?`I6%*PIV%`04+"E(*R` M-H2GC!%$]]^(D9`1,<+>'2%00;-(0-`"BTPHF%+@4C"CP*-@3L&"@B4%/@4K M"M84;"@(*-A2$%:`%A#(1%I`;J^3.#>$-4PO$*M,CK[>TZ/"R(;L5!I9PXYN M-"Z-RG@P,F7$963&B,?(G)$%(TM&?$96C*P9V3`2,+)E)*P2+3S0B5IXBIS6 M$LMW?:1$P3Q2V+^C@MC%ID>DI#$C$T:FC+B,S!CQ&)DSLF!DR8C/R(J1-2,; M1@)&MHR$5:+%`/I:BT%]QPMKO>,E*;:(><4R,F/$8V3.R$(25>DE(WY92E71,DD55Z415G'-R(:1@)$M M(Z$DQ8U8=76'39,6L$JVRH[Q_OLH@2Z%CKTQ@VS8:17[+R&BQ[$@U3@R,I&D MNC*9W8&^Z$Q+(^P2EY$9(QXC5,GF<%Y>1XT%TU@RXI>EI"JIZZJ\CJIKIK%A)"A+W:[KMKR.JF%5 M0TN@<,>L1?;&O(,3"9QXPEH/H22P,JI4V"&3:GS#B$6UL+'5AGW*B%OJ8+MF MC'BLU)R1!2NU9,1GI5:,K%FI#2,!*[5E)*R6TJ(CSB0^$9[<7(\/(A@`98"L M85>?,F.T@HJ45BQ"MXS,KJ%+3:659>33L]\BKER\7ET\J:N9 MYZ@NO>MU6^#5.M]+Y0A]^PK5^%ZA>N';LEKD2&"-!G7N-\H7N@\4JG&_177I MWFB161BBP3ON]8$'1I\9>,*<#+P"6=7EUAJ2+AF;LB!\U`R\T@B[9"K+66)/ M\.,!3LB&VA]QXZ(;N(EZU\T,C=0NW.-H3CT/#>V/W,0N4*'.\Q*-E&>?HY7N MV;1;9#NWQC)UOC9HI'P%'&V)KPX=RR&6><>7/IC$R4+UV*U^D1%G!W0P2:1G M,=+^,1:LSV)2:EAN.J:R'*0L-3JL(9D^+EI5AZIED)$V4W7`L>IQ-$.0 MIJNBJE:MQR67]SE:W?)H&R1YK]&JUN.&RP<<;5&KVD;;((>@(5J]YU$?2##: MM('TI;L'<;1.QU>!M&1E&V0+.,:"U;K2I6NBC'``3"62R` MHZWNN4\;&6*1=USI0TJ5:>G3$ MP4\U.E^;\/+XJ!HTB:H+BFV0N[.Q>"HL0ENUXG&44M55AVU,IRA5[,[(Y'#Q M:EUFF:'1H!Q[GD1FK>\Y%BQ\#^B6?('7Z[POT4AY]S_D?84%Y;Z4+-IKO%SG M?(-&RGGP(>=;+"B==ULDQ"$:O.->'XWB5*MN-/Z5O,`F^.;A5>4F6CQ6I>M/ M@;0<4J*Z'"*-*G?-4MU2R$6DYNJ,(P^1*CCG:(%(:2TY\A$IK15':T1*:\-1 M@$AI;3D2+XRH+%Q$K7@!I'C^>XZNS]$X.IW2QCYY%2]WY*MQB8LW3R9#!TX= M(+,3[@T=.$7@W!\Z<"K`>3!TX"Z?A(C^2+SQ`X>$G$\&SC2?FZ1AWL"! M@S-N[P\<./KB/!@X<'C%^:CGC&[Y'?><\2T^Z3EP;LYU)GT'3F8Y7_0<.)_E M?-ESECEOEPV#-X%>=L_1:G=]CB]IXQ0]P6`R\L=MU^)=HN)')G/!8Y+!.T!Y M6CC".U\1/%4S6K!D/"5)AC_`<;M\B^SA'P```/__`P!02P,$%``&``@````A M`&H&\=\D*@``MNL``!D```!X;"]W;W)K&ULK)U9 M<]PXLK;OOXCO/SA\?V15::]H]PFJN)/%6K7>J6UU6]&VY9#4TS/__B2*2":0 M+TB5W#,78_6#1"*!3`#$0M8O__OO;U_?_>O^Z?GA\?O']Z.]_??O[K]_>OS\ M\/V/C^\O-NG_G+Y_]_QR]_WSW=?'[_7'Y,/'YX_?;G_=O>\]_CC_CNE_/[X].WNA?[SZ8\/SS^> M[N\^;S-]^_IAO+]__.';W6=NW3[NH^W;W].=?/_[GT^.W'Z3BMX>O#R__V2I]_^[;ITGQ MQ_?'I[O?OE*]_STZO/O$NK?_`>J_/7QZ>GQ^_/UEC]1]:`W%.I]]./M`FG[] MY?,#U<`T^[NG^]\_OH]&DZ@^.W[_X==?MBUT^7#_][/S][OG+X]_9T\/G^N' M[_?4W.0HXX+?'A__-*+%9X,H\P?(G6Y=L'AZ]_G^][N_OKZL'O_.[Q_^^/)" M_CZB*IF:33[_)[Y__D1-2FKVQD=&TZ?'KV0`_?^[;P\F-JA)[O[]\?T!%?SP M^>4+_76\=W2R?S`B\7>_W3^_I`]&Y?MWG_YZ?GG\=M4*C:RJ5LFA54+_6B7C M\9N54'%;2^A?JV1T\&8EQU8)_.3M?>B`O6/^>+-W#KA=S1\VMUN5@0YPP)W7_-&UY2YCU@'WUP/I M.KL6REWG0+K.@3-B#-G+?>=`O$:5'AYC/K3SXG::C>]>[G[]Y>GQ[W?T\$+! M_/SCSCP*C29&(4^PK0'=E-LWX])4:[1$1LW']U07FDR?Z3GA7[_2@/_+AW_1 MU/[)RIRCS,B7F+*$F<>-VEB#1(-4@TR#7(-"@U*#2H-:@YD&C09S#18:+#58 M:;#68*/!A0:7&EQI<*W!C0:W&D2=>]DQ4>?,CH#S(O!>!.Z+P'\1.#`"#T;@ MP@A\&($3(]>+'RC\NSY`O>>_T0>,&M,'N$G.&4BG&*N`9PG.$FN0:)!JD&F0 M:U!H4&I0:5!K,-.@T6"NP4*#I08K#=8:;#2XT.!2@RL-KC6XT>!6@R@"TCF3 M715-00:\%X'[(O!?!`Z,P(,1N#`"'T;@Q,CUHA?P--%Y`1]>3?'8;J1I>J#J M.H/[L1_)YZV0F1$[H=')J2\T[82X$6,@"9`42`8D!U(`*8%40&H@,R`-D#F0 M!9`ED!60-9`-D`L@ET"N@%P#N0%R"R2*$(FCV8<1NC5"OT;HV`@]&Z%K(_1M MA,Z-T+L1NC?R_.MU"0IC9"UT;HVPB=&Z%W(W1OY/G7BWN*;R_NAX/=2/O!;DF[ M8;8-=B`QD`1("B0#D@,I@)1`*B"U2[S&H&7<&QK#2/N-T1):P/)8,.V(3(LG M)_ZL&%L]](\S=9[Y0LD.BE(K0X_OHNA4K;&R3HAMS($40$H@%9#:DG9#UWV^ MIF6AUZS.V/KRY>'3G^>/9"]9'8B]`UI+MBM,H\1O[9:XK0TDMKG(-*=)]E7; M0K;4$O>19W2J'MZS3JAK22`%D!)(!:2V!%N2%NA>2P9:C':$N,F,M-]D+3FD M:=UIC@._.::MD-F&Z80@9JUJF>.2'7*EMG@:73O-HT,5Z5DGU#6K52TKJZ(C MHDB;6'9Z1&9T>NC7M>J$N+#:JL:VI\TMK^U_*HJ-$M\E+2&7L`73ECAQ'5MR MULDD()-:,MYNOHSW1\JK69?.Y>2@HP!2=KG,E@YI57V@ZM)9:^WJ\`97L['O M->!P\&[%_:9BY,>/7F2$I'1PQ"+$AB>")&!TOM0*T:X=Y\L0Y:**I0I!_=I+ M5%4AJD45:?>;V.S1-68I\W4GI MIHJMT*$[CHQ.U;HQV455&A(:':EA/+-2M+MO@G6TI^;9G-.IBKU6%Z&B=-7* MD!#84W%Y;(\:>VI.[['']ZS9;'B#9]N]"<^S+3('$%WM1Z>JC:9FE6_\WV.3 MW95MA0Y=H2,UWB2[:$I%B",PLVAL9G[C1=5J.6=QYS#MH(*%7`NU4"E"7'CE M%[Z_IZ*UYBP]A?LN,XOG-[C,B*OQSJ)7.J.5&NZ,K9#7&8_!93MH2LU9I[%3 M)J/,(MOQZ"3>GV1S3A_R1B%Z)3[195!XQOZ94VT7;%5Y77!TID;$9!=5J0AQ-\@LLGWP;.]TW_N? M&C1RUD#.Z886[;J"A8:J58H0VU+YMM"="16U->?I*=UWK5GZN:Y]98*T*T5W M@FP1'=^RA5-SY$Z>)M1?_5B$.%\BJ#]?RD+RI)TARAF)586@?NTE"XGV"E'- M:*O=;T^SYG/;\^>Z2KMRI,&5V^;<7$8P;2JCS)21.QKJ*(NMD#,Z);OD2R6? MM!;,Z!FKLC/ZP9Y:7.[(0X,!*K?;"SI2SD/J5;58)REG([ M35=@OU4EYQ-5%:*:4:#3D..]=GYE$#+BZL&@16HB@:=TFW%X7&J%U$2BXCHQ MZP%CPY"JE(7<6`OT(6M[^WRWKR,V9RT]P_EV^BM8:,B>DH4&[:FLE)WK]O7S M9LU:>NSQ>Y!9_`[UH)UVNLS%)NUPBZCMNAEVA,NR5LK.N!, M/;(EUH9!52D;*H-TQOG:`6D?!TAKHNL3;6+!2H;J46+A%>=[Y5%PV`3/H>:F MF.?0X:ZZ%?>[JD7NT"=HP$TBU`U]@OKSI2PD,WJ&*&?D#'V"^K67+"3:*T0U M(QSZQN1WKSU_ZGEAJT4ULU%,SPO;J\C;,6+*4D-C1,Q"NSQNX;9!!@:ZW9[6C!SF!KL M+/*Z3"LU..O'F"\1U!_4*0O)?)XARAFY768'JTK.)]HK1#6C0)@:T0VB6T1TFZES-SLRX^69.II)1(JGE!11ABA' M5"`J&8GQ%:+:(K,SUBV"1V?J/&`F&45*U[IA(;_6:K]^+E)GYID>=J0+'9[S&/-&XSC,[4*6@B4MP,*:(,48ZH0%0R&R&NAI&;AW'^VKM,Q\IUM?/4NOMM.?,JGHZ` M%GD1`"BV&;(4. MZ3E2G'^DG2]2W#`IH@Q1CJA`5%I$_[#Z"E%MD7*^VL:>24:ID*YU8X6&:ST7 M*39K@6B):(5HC6AC$?U#ZKVG/C,8__,!8:M%18E1[,_^5JJUHKUIP,CM+*,C M]3R5B!2W3HHH0Y0C*A"5C-R8`.MK*T4QP4;,,&/#:+!"B55EHK)3-=Y7R\64 MI?RG<+72R,0L;N1AU5%+3A]J")+*8HKLA(D)D+I:];N^U*-$AN6-]56#)&=T"W4;?/KU5+"4EUA8=NAMD M8W'6-M],\HD-NCJ-"'$SS2TR!S5=,X#M"\[H2RD;EBPEMJ\0K:7$UC%*RX:S MN&4Y-?%CTVR/OF&T;7=3O6FU1;03STTR-1^'H:'5;,YW3>(88)^RK9"<)26< M3U#*2+1GB')&DK%`5#(2716B&M%,4']]&A82&^:(%HS$AB6B%2/1M4:T8;35 MY7O5W2?]^1$'MT_-MWN,9^7^TY21.]NBLZTJ=[*%L3=A57R52NU/I)P^-))E M+'3:Q6-ND3?50^D%9^328?BQ=1\JO6(E4GHMI7,'F8G44$#MTF9S5L6SY4[L>PV0!U1R8]:^YVV\9\ MX4D_'[;(&[$ZU.^0V*JB/6MV9((H920]/$.4,Q)=!:*2D>BJ$-6(9H+ZZ].P MD-@P1[1@)#8L$:T8B:XUH@VCP(AE-CM=;[^RO&OW1KUYR"*Q;NX>%B[BZJ&A?QV M4-/67*2X'1:(EHA6B-:(-HQP6\]Z*&H[^Y2'$=%XB6B%:(UH@V MC`*N-KNJNX_>YB:^=G6+/%<#BFU&LY7<-0,>UHH4-T.**$.4(RH0E8Q<5X.I MM97R7`T>FZ&NAI%;1SRL%2FNXP+1$M$*T1K1AE'`U;2J]%RM'\MV>N'#?(]# M1T"+O`@`%-N,9I_8B0"U192(%+=.BBA#E",J$)6,W`@`4VLKI2)`/9#/4%?# MR*TC'M:*%-=Q@6B):(5HC6C#*!`!9D_T#9W=;J$ZKSJ:-; MD>+621%EB')$!:*2D3M$@/6UE:*88"-FF+%A-%BAN4BQK@6B):(5HC6B#:/` M>&`V\MSQX.=FA'8[T%W1F?U:$P'.BDZ01#X.$VT^VAZS!X_Z^-9J(0%NJE04 M,\H$]9>5BRI;ENK0A0BPXE(4,ZH$]9=5LY"LL6>,W)%`MT=CA7K;8RX";-!" M%#-:(EI)QG#MUR+`:C:>&G_<,!M>;B`-[P$($I%%4ME@OI=F:.J`E$IJEA[):A?>RU"G&\FJ#]?8X6<.L\1+405 M:U\B6F'&-:*-E]$/!KW]]THPX#;?H47T3S=+XAO$+$5;19T4!H-5Y0K!!G)B M5=F#R\.]_3/O?^J8)F5Q]T%?EYSM8EX>$@+S"BZOW9Q5>^LEIPY94X4*TB;7 M5LA,&%V+CO?5(_IL%U5-2`@J-K=2O0?&G#Y4M:44Q5&]$B05@=+7K'WXP)BE M7!ON7`^-!F=&W57HY%B-LKL<@>&*N% M3LH9:*'4A876FK'04-&Y"''1Q6#1)6<8*KIBH:&B:RMDYK"N$G"2O(NF1H2X M$G.+_)/DD6K'!6=T*^-&TO9T=T!ZY M^\$F:(<'[*VXO]UGD7LN(TC:VS&@/4EF(3DM31"EC.1I,A/4KSUG(=%>("H9 MB?9*4+_V6H0X#&:"^O,U+"16S1$M&(E52T0K1J)KC6C#:*O+]SQUF7\^7!T9 M+2H@6N2>-ELI\S)!UP$Q(*PJ&L<3ZR: M(UHP$JN6B%:,1-<:T8918!BD6=*+B% M'TLINKV>XZQW7NE$)J<:/EM$ER"YN:9'@&)$":(4488H1U0@*A%5B&I$,T0- MHCFB!:(EHA6B-:(-H@M$EXBN$%TCND%TBXBZ!S@R.@^P@,.I>V#>@,NI>Z!< MP.G4/5`NX';J'B@7<#QU#U?.[Q[FX,#=#GBE3[3G#.Y.^I%%,@%.$<6($D0I MH@Q1CJA`5"*J$-6(9H@:1'-$"T1+1"M$:T0;1!>(+A%=(;I&=(/H%A'U"?`M M]0ED`8=3GT"Y@,NI3Z!P;#I^]6R+N:,M8_29%8[23%DU/*2$X*,[&AO\"< M\]%C*2V=0N1X@)+1!6B&M$,48-HCFB!:(EHA6B-:(/H`M&E1<[1X94@ M:2_MQ6LK9(XEG$95VV(W(L6->HN(>F8;$J2,Q:AG(IL&6!Q@'#RN/HX>EW'X MN(RCQ64<&R[CX'`91X?+.#S:!O9[IGN*QYO7YC.+;_Q]W2,\WK/(.>R?"A*' M::_&+.2NZT>G^MZ(2+&[4D9NWVS-(AOZ"\QM/G-%P@DCM?=1B!076"*J$-6( M9H@:B]S3/$%BEVZMA:@2H?%(G=\L18J-7R%:(]H@ND!T:9'CZBM!8INBSFG\R])D]EU.V0=9'BR'6A(N;2)@A$ M`76[3I]T.P@#ZG:=&%M,#[G(`O%"W0[E`A%#W<[*;4WVNYTYB/WG#[GV.%>: MZ?S((AG8IH*D0?3H&ELANGW+S9$@2AF)#[)=M.>5B$"7'PIBAE5B&K) M&+ZG-!,!5M.@FKF@_C9:B"I;EKI]MA0!+FLEBAFM$6TD8[@6%R+`:BY1S96@ M_EI9U<%X]]<47='+5S-+K:.0")#=2&8[*_-ARBS@5$&@93:C??B0E(P!%@AYQDF092**G9#)JB_[7)452`J115KKQ#5F'&&J,&,@2,UX)ZK?T&E7=(+H556QI%`GK5Q^=H[)H&F"Q M:.M*X-!Q.QG'CA-A$0>/RSA6W+P<+*]TT(!U'$!N"1Q!;0E^EZ2EY#^?F8^- M%M53+:)G`F?EJ#X_,N6,-&1T4MA3K2IY5S^Q^56.U/"]9RK4*[CU54B('62U(J@-&S%B]O2K@7[=H.-4M M7#?)/%20%EJ$A,":)9?G-XFZ"K9B*=J6TX?LH4&-DDVG&^H[-*@%I,`B&N=: M,;]#C?732\QBKF7@J(B[)YG&GHJX,WKFHB'<'>T=V`/MJXB[HMF(Z^W4$7=% MKS3MK8B[HB>%-G%?5(VCO!9Q__0L;8J%$C;XO<:S=6 MBE!_F\4BQ$Y+$*6(,D']VG,6DFVD`E')2-9S%:*:D>B:(6H8B:ZYH'Y+%RPD MVI>(5HQ$^QK1AI'HND!TR4AT70GJM_2:A43[#:);1J*=QHXN1OK5T]AAI40_ M#13(`I%#0T!7`D<3#0&8MPL>IXPN5AR+NV`9"F'JT%A"%T!."5T$;4OP^^7; M+C\=!R\_J0>1(+A%=(;I&=(/H%A'UKNZN&SN2^A*R@,.C@,>I+V'>@,]I M<8%R`:_3Y(AR`;]'`QR:DFL1:YEY^LE(-B1`FB M%%&&*$=4("H158AJ1#-$#:(YH@6B):(5HC6B#:(+1)>(KA!=([I!=(N(N@?X MEKH'LFF`!3Q.W0/S!GQ.W0/E`EZG[H%R`;]3]T`YW_-^]S!70-P]\%?ZA+TQ M(CO4Y\?N)9+M&R-31#&B!%&**$.4(RH0E8@J1#6B&:(&T1S1`M$2T0K1&M'& M0[['S!4'UV,_=37GN+THX=YB8R3/-U-!_0]D,0N1QF[I@U=S6(JBLY/22Y_4 M"GF?'QF/U?V03*1X(LL1%8A*1!6B&M$,48-HCFB!:(EHA6B-:&-1:+O,G"R[ M(?%*)VX/HCW?NV?3MA-WJ-]A\;%5Y?H>KWY8J<%+':D5&K[4D8F4^+ZUP;D> M4*!4B:A"5%OD;%/.!/6W0R.J1`@N=+&/5RU<0,HWA9/3U)R9SRQR+F9D#*BQ5(W0L"9<292W(8YH@)1 MB:A"5#.2P]49HH;1H*ESD6)3%XB6B%:(UH@VC/!@^]B<=?US=]L3,W>NM\B= M(CHD7M/C>KPUB+Y()#MOB46#1PDIY^L[6LQ$@)LX%\6,"D']-I:B*GS\6XD` M*ZY%,:.9H/ZR&E$5/OZ=BP`K7HAB1DM!_66M1%6X7FL18,4;44S(>_HX>=MA MZ5;<7T,Q2*HOTE2*^2,\AFB7%2Q]D)0O_82556(:E'% MVF>"^K4WJ&J.:"&J6/M24+_V%:I:(]J(*M+NAX?9L/_'(\])N^WO3C2,:'+I M)H>Q_C3`E*5H3.JD,&JL=E=H/%97`I-=5*56R-M;AYWZS$J9;U1T5HU.U:%C M'M*E;2]VL:H,:0*KJIVLJD.ZM%6S7:QJ0IK`JOE.5BU"NK15RUVL6H6$P*HU ME]<>C:DCE@VG]IS]^!W$;`4/=9#=#EA.VAUEKX>TR#U@L5+#!RPBQ$-%(D@" M5C=ORD*R@9TARAG)$T,AJ%][R4*BO4)4,Q+M,T']VAL6$NUS1`M&HGTIJ%_[ MBH5$^QK1AM%6NQ\C9C/3C9'AY=Q)N_?IQ4*+Z)TW]NG42CDH1I0@2A%EB')$ M!:(2486H1C1#U"":(UH@6B):(5HCVB"Z0'2)Z`K1-:(;1+>(HBC`S@,LX/`H MX/$HX/(HX/,HX/0HX/4HX/8HX/ M[7ZHUSU:9#ZYTDW(X[&:D*YF1T9."'0LX'#JV9@WX'+JV2@7<#KU;)0+N)UZ M-LH%'$\]VY7S>\[`?O8K/1OWL$]:Y)S&31'%B!)$*:(,48ZH0%0BJA#5B&:( M&D1S1`M$2T0K1&M$&T07B"X172&Z1G2#Z!81=0_P+74/9`&'4_=`N8#+J7N@ M7,#IU#U0+N!VZAXH%W`\=0]7SN\>9G?;G?A>Z1-V0][9M#NQ2%[OFB**$26( M4D09HAQ1@:CTD%]GLX7\ACJW.\[>#-\B9WMY>M(AF7+UHB9F(7?.ASWH1*1X M4$X9R;YQ)JB_P)R%O`)/U1V<0J2XP)(1[OZ>F!U9M_5^:K-_JT7MW+5;O5ZC M`HIM1CK#"^]M)B+`E4D9N:T'FG.6ZC2K)Z%"!%ASR0B;Z?1M.YE;<;\]&-%S M8O<8B3N9(2F(.ROD[$@FB%)1Q?7+!(D-6GN.J@I$I:@B[5Y_/*7H]")J>`S: MBJNF,AH(41^4IH+?C.6,Y/I.2ER%7?CT9LKI;K_3166AHK10 M'A(">PHN+WC_O>34'FM\9^@=I%><@3M%IW:GB/[IFAE_U]1*C7IL:K\-*D(< MD0EK;W_7=+2GQK*4L]`615>Z;M2,A88*ST6("R_\PO?WU)OI)6?I*=QO:+.) MXHZCKS1TN^?BSD*G%OE1+RO(]L"4I8:CWJIR3M!L/AOB9WNG_D\3J@WME,6' MFC3;Q99&EX`Z.%4O M6OK@5,T@4Y'BJL6($D0IH@Q1CJA`5"*J$-6(9H@:1'-$"T1+1"M$:T0;1!>( M+A%=(;I&=(/H%E$4!9@3`NS<*.#P*.#Q*.#R*.#S*.#T*.#U*.#V*.#W*.#X MR/>\WW/,*MOM.NHXF(7C?ASU4CS:)2'&-4D9N$X+ZG*7<)Z?QH7IT*T2*U9>,`@UFENUN@[W2Q=I5 MOMD/@GAEQY8T6>;_^,CY4E]>GG+''IG99 M+4(T696[+?U3L]=9N[9WQVB+5*BK'8'UIC/S?/[/H[)]RO>BLD7N M[]ELR_KX?OCW;*S0\/<6$E;53C;'L+>8LL!0S&4LY`Y=./O9NKDC5V#VL]6U M6\IC/2.47%:/07ZPZJ61'BIVNY=XADLFB[P@;J6&[R5R/KE%ER!*&;E!O(/V MG/.)]@)1R<@)X@_/7^[O7^*[E[M??_EV__3'_?3^Z]?G=Y\>__I.TRYMH].Q M5\??/=W__O$];49-(E)%_5JET);49+N?$THZ,DG;3J9RT9O+OI5 MAO.Q,2U02$3%T_P8*-W8%33+6!7R3W9Z,LEHR86Z:,D[,0O:4,HII83RT&IW M8A9PF"<^/9LDM%[!E)Q2S.(FD')"Y=!9="B%\M#Q*Z;0V?7$',QB2GRZ3Q9L M5Y6JG>D,DRP(I9Q3?;`^=.E@,@VFT$V#B;E'@-KH`)U20JU#EPPFYJ@<\]!=@TD63*&7`B?F33', M0R]73'R8+0H'-.;7`>;(,II4R#*0FEF)<40^6< M4.N$8H?>8*244!YZKW1B7BU$;?1ZZ<2\88@I]$XIU2=4#KU^2"FA//15W+,) M_3Q0R`_T@4"J4:CEZ%-_$_-I/[2!/M%'UH52Z`.-$_-%1LQ#GUN>B'*2;FARA0FVE5\X7[4`I-)3W::"H)A@/]L,7$?+@7M=%/69!M(0LVAX>3 M#?WL-.:)#\EJ^M%>3,DII0BF-)0R#Z;0S]Y/S"_;HS;ZU7@J)]0&](OO5$XH MA7YUG&(4D*/ULWAF%)"C]#-X0&EA/VS3_X)I4S)@FDP)::4(FA;3+85 M0=MBLJT(VA:3;46PG,T!157[TT0Z#@[&DZ3]ZKM*R2FE"*8TE#(/IJPH91U, MB0\.J)Q0Z^244@13&DJ9!U-6E+(.IFS&QY--NPVCZG-.;7`>;(,II4R#*3&E M%.U!F=(6'Y!_@GE*RE,&4RI*J8(I,TJ9!5,:2ED'+6C(@G4P3TEM4`;;H**4 M*I@RHY19,*6AE/4X-"8V8QK%VA^E5:W3C.DQD7:^@+*$9JZ2G[E`M2UK%A.3KTTD= MXNF(%BJCT!A54DH53#FGE5](UY36?2&>T%0=XBFMWT)U2&F-%I+/3R=YB)^3 M^T(SVI2<%^()3=PAGE*(AJ(MI;5/2+X^GM1;_J$+PN=??_EQ]\?][.[ICX?O MS^^^WO].^V/[VQ?VGA[^,-N+[7^\//Z@?;/W[WY[?'EY_+;]\\O]W>?[)R-` M6YR_/SZ^\']0*'_X^_'IS^T>W*__)P````#__P,`4$L#!!0`!@`(````(0"< M&``670\``-M.```9````>&PO=V]R:W-H965T><9X)Q3,4V+B#)[K??'FE:K9G6R#A[ M]F&)?_I/=VMZ9C07Q(??_WQ^NOJQ.Y[VAY>/U]9H?'VU>]D>[O_^3A^.SWN=N#Z_ MKFYN3MO'W?/F-#J\[E[@RL/A^+PYPY_'KS>GU^-NGZZF8S'\YOGS?[E MNK&P.EYBX_#PL-_NG,/V^_/NY=P8.>Z>-F>(__2X?SVAM>?M)>:>-\=OWU]_ MVQZ>7\'$E_W3_OQ7;?3ZZGF["K^^'(Z;+T]PWW]:T\T6;==_,///^^WQ<#H\ MG$=@[J8)E-_S\F9Y`Y8^?;C?PQV(:K\Z[AX^7G^V5I4]N[[Y]*&NH/_N=S]/ MG7]?G1X//_WC_C[9O^R@MB%/(@-?#H=O0AK>"P2%;UAIK\Y`<;RZWSULOC^= MJ\//8+?_^GB&=,_@CL2-K>[_&SI^"%WJ?2"'Q*(\O1K35>VK?#SN%J?>?P*+ MV6PZ7[Q1E+`>?[_1H0;MHTD1U?-E=6EC'XA_2ZX79L;!F+;CA M=]VH=8OAPC_>Z10JM;G3"VOWIFG0=?]P-N?-IP_'P\\K&'2@S9Y>-V((LU86 M&,.>T;3'MJ^8N@JT;V'ELS#S\1KN`[K!"?KWCT_V[/;#S0_HDUNIN>,:2U6L M42&ZC3#KZ,#5@:<#7P>!#D(=1#J(=9#H(-5!IH-$&KH7&!OH'(W(AH^.:*&EHQ6U^6#$9<1CQ&E%PT\X"1F.,-IT445-/2D&8Z7S_&UXPXC+B,>(SXC`2, MA(Q$C,2,)(RDC&2,Y(P4C)2,5%VBY`"F3TH.ABM>J-6*EZ19=HCYTYH1AQ&7 M$8\1GY&`D9"1B)&8D821E)&,D9R1@I&2D:I+E(J'>>\[*EZHU8IOB%VO09L6 MWQ)Z3-QJ\V%':F#6USY*+'W2[+8B'+X\1GQ&`D9"1B))*.BX)120'G32VB'- MQ-+N+&U%&'3&2,Y(P4C)2"5)L]KOSI%AM:BDL#-^G1_WVV]W!ZADJ.J>/F7# M>J59Q0@C:F8;TLTL(XXDW?F=-=.F;FXKPBKQ&/$9"1@)&8DDZ>21D:0M15EC M(::M"$/,&,D9*1@I&:DDX5D3*_9_GK;:BIHW1--VM;,F1)6@-V]'BNQYO8:= MC"U;G4ZX),!:\L@P(I^0V5=`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`^BH;B M":1(>0"S>$(T)>.93/C42M[\4$0QFAF**+DHHE2JY&Q_,IDM1M;0,'1!>/DE MX147A5=JX5G+F3X;K-";H<;49@PU-MB,_SB\PBRJ=\^QNV,AS("NVXX;I`Q9 M+3)W3$>L?45C[VY/,.2ABKJ]3\AL/4`160\YBA"1]9B0V7J"(K*>2H0M0S9,'0H.3ZC<>0D&LY;=",(E^+_@VJ#G(X1SY M'`4(Q&M"->PZU6K M"#D1(J="<,3[/(O.TR:_8WN MN@,1S2C6A,P-WY$B\ZDY";"J/#*,R"=D]A60J?[3Y9`$:#@BPXAB0F9?"9DR MG)J3``UG9!A13LCLJR!3_?=5D@`-5V08D#J"BZ5UMXF\\325&R"=-2@L(NM! M'0;R]E3(8J?F?2JVO2)%G2-RER./3.']^80H!MUZP$V%'$5D"JW'A,S6$VXJ MY2@C4V@])V2V7G!3)4<5F6)I%JO[=Z2YV0Q0NKQ$\-&FV9YK1X1KL7TF9ENP M8&U5>B* MB?YD>+9V?ECA=4,\ZD`E]D#>T8*;+1.E!3=(K"S:MFG/M2./->P)RY4`J?3; M=TB$W=B5".;*HKE:2]AF4`^0/2P$2XW6OV[91Y&A2NH\!B1"]Z'F?@$;JJK[ M"`L-N8]1-.0^(1&Z3U7WL]OI"%Y'=NK(AYGY\JP^V$18:6PY%OK->!AX*AVO4O\1Z0"%,0 MHG$<^'C[:R(6N\O&CA638;,H(1%Z3U7O<**A[?AG*!CRGI-AL_>"1.B]1.-R MI)OJ-5^AP.!=;7W01)76-[S^%.^]ZLVL0;"=A1&NI4KLLA1A(BLQX3,UA,4D?64HPP16<\)F:T7*"+K)4<5HMJZFE.Q MI_O/1Y1F9[@[@Q?G7)!]V,V@5$L5?`RD6HJZ#9*M5ERTWLS@^=^MH%&A\++4304 M7H&BP?!*+;R^KVV@(4-(:C-^:QO\LJ]MP/D>&[(:I`Q9+3(W+D>:@FT>;/\N M1QXBZO8^(;/U`$5D/>0H0D368T)FZPF*R'K*48:(K.>$S-8+%)'UDB/QRT'U M^-$9LII?`FI^Z>1Y=_RZ6^^>GDY7V\-W\2L_4_&^4(N;GR"ZFZVJ>F34^7Q5 MU0.3SJWE2GQ)`5*F7YG`KQG!#*'OR@2NU)NL6AEGY,KL1G)K\"^XDIL)/(K\$-+G_O\WT'(_1%#P'UV[-5GJ';NX,Z&7W+JX]-5 M5>='NW$X-(-0^Z_,X$J?#SCC@JCZKL!)!%1C7[K@W`"JL>\*[/)#-?9=@3UY MB*#OBF-9*_'F%[]_>(EK)=[:XE?@!:R5>..*7X&7IU;B;2E^Y0[N]*[W3M=P M9=U[!=*G(WQ"&*X$O=>21:KK%:]W%G ML8*WIGF-.,L5O(7+>;18P;NXG,>+55SSF_;VX*?%7C=?=^GF^'7__`0``__\#`%!+`P04``8`"````"$`[[D?B>,%```T%P``&0```'AL M+W=OPS^8%FT[7"=NLFNA^Q"KV3M_B"U^W7S\T^K.ZV> MZS,AC0,,UWKMGIOF%OM^G9])F=4>O9$KO#G2JLP:^%F=_/I6D>S`!Y47/YQ, MYGZ9%5=7,,35&`YZ/!8YV=/\I2371I!4Y)(UX']]+FZU9"OS,71E5CV_W+[D MM+P!Q5-Q*9H?G-1URCS^=KK2*GNZ@.ZW8)KEDIO_L.C+(J]H38^-!W2^<-36 MO/27/C!M5H<"%+"P.Q4YKMW'($[#P/4W*QZ@OPMRKY7_G?I,[[]4Q>&WXDH@ MVI`GEH$G2I^9Z;<#@V"P;XU.>0;^J)P#.68OE^9/>O^5%*=S`^F>@2(F+#[\ MV),ZAX@"C1?.&%-.+^``_'7*@I4&1"1[X\][<6C.:S>:>[/%)`K`W'DB=9,6 MC-)U\I>ZH>4_PH@K:DE")(%G#\G`P`@'PA,'AMXBF"RC!4P^,&Z*X^`I)_3" MAUDPFS.O!P;"6RX7GC@0%L*`_1SMX3G&05]$ER=KGS799E71NP,K`.)7WS*V MGH(8N&26Q,QMWMY+&^2+D3PREK6[Y-(#&!5`%\4-3*@H3_#[(8"Y,E'=I*H-,9ZBIWTD(.V9M`8@*I`F@: MH/9,#>',:\MH='(8#Z07IE&R8_B]%481U&UK%$P7AKC6J%5G(8F%I"JB"83) M3('!S&,KK+])R&ICX[@@Z<96()'H(ZQT=A:RMY#$0E(5T5P%GU17A_UCQKI_ MB(CFQ/VSD+V%)!:2JHCF'RS=\?XQ8]T_@430Y)7L/QC9[S%:&!6R1QM8E@K1 M4B=*6B.9O[2E!D33!2U%U27:$R^1YESDSUL*T\!D/?F(H`V)YL0X=+D"`;G2 M@9V%[!$)>3<+)T%DB&C?2XY4Y=!$L".-TF-[G(7-07K+C'5O$8%'&].9V3K1 M9JG86+GIL0EF$T.6,`HG7'8P]:;Z^Q3?JPE6)M)D@S/C93-C7;9`0K5MS8PD M['#4.]Z(3:2UD8E*D)E5R.MF8DG$`="VVGB_)S&`%3->([?614H(PMI.-C,7 MGC0"QUHCQ2/<*YDK0+YLBSK!<9C,T)L;N93OWPF?ELP`C%2EGUJ)G,0(`.,% M2`W`W*QN.6XX`,BD!D!`&`"C5Z7(&H)17UAU^6R3'KV&V5YK5#-"X;1-SZZ# M>N?'M`HJ/"*SK2.1X[K=+I409]<=9[NOXOCG\B:V<)A%KJ%M(*!PWD([A`+8 M1/OBB7J02@VZW84DNUBBH=V&Y%S`UC>7'@*VJP^$X#N]00'V;B)*7V:RS)P* M2,MI"_7ZA3%`H^Y@F2![V$&IA'IRRHX!BJ#A#85]=)F.(Z0M.JOK"*-0-;*[ M#C*I*[,GG4B%NXIG3)6BB^-6(CLK*.(_5]#BP*$5M("T_69NG%QV`8Z#!/:5 M':87C;K37H+C0KGE6`'`(:/*F9TSE`!\D'UQ*M&4"D@KVQ8:TH5&7=])`@M* M)=13ME!)JN.?RQPC,;80`85=X]^Q[02L/JA=I/J@=I%*U&[/)HKOU8:F+!.] M$\%40Q$8V8D8BQ$"`6DI;:&AE*)1UW82.$#PT'50*B$[I;"S#@H:=3[G)+H> MA-3=15H-+CUII";#;D>2'7>7P.I'DF;,_!%G/39I_,8OK9L>[C3?.1G%&/> M+=QU\FYLXB'<@?;Q1,#3.R"*X3H#)O9;)KBSO&4G\GM6G8IK[5S($8(UX9^H ME;CU%#\:/&4\T09N*R&><-D&M],$3G03=JESI+21/]@$[7WWYE\```#__P,` M4$L#!!0`!@`(````(0`G'@P+^P4``&$7```9````>&PO=V]R:W-H965T?:>(DJ$,< M`=T]\_=3QA>P35!ZM/,P=`[EXZI35;;QP]?OU=EX1W53XLNCZ5@STT"7`N_+ MR_'1_.=;]&5M&DV;7_;Y&5_0H_D#->;7I]]_>_C`]6MS0J@U@.'2/)JGMKWZ MMMT4)U3EC86OZ`)O#KBN\A9^UD>[N=8HWW>#JK/MSF9+N\K+BTD9_/H>#GPX ME`4*O[Y=OQ2XN@+%2WDNVQ\=J6E4 MA9\>+[C.7\X0]W=GGA>,&'UH+Z&SJJ![SQM[8P/3TL"\A`B*[ M4:/#H_GL^)DS-^VGATZ@?TOTT0S^-IH3_HCK4&@-N2)9.`%XU=BFNX) M!(-M;7349>"OVMBC0_YV;O_&'PDJCZ<6TKV`B$A@_OY'@)H"%`4:RUT0I@*? MP0'XWZA*4AJ@2/Z]>WZ4^_8$?VU,XP4U;502*M,HWIH65_^QEXR"#G;98'CR MP3#UG8,]-AB>?+"U7BSFR_7J?I(Y(X$G(W$')!.NPQ1=W/!D`]?6W%VLU@[( M-!7SD@U,6I+8);:`"H0I$*A"K0*("J0ID M`\`&680VT`O_AS:$AFC#H]IRH!?+583@%GQ(H`*A"D0J$*M`H@*I"F0#0!(" M^EH28GQ%XK5`K*&<@$P4PT+)]);:>-#KPL:=;Q05A)&004-"#8DT)-:01$-2 M#1*#Y@-+$2B'1RU'4)AQ,LG$M0D#3F;#[?7 M$0W@D,)%(-:R"`R!OAP4QEK.U6[$2$UZ0&V\?A<*-202/#RN6"#]]"ISHO&D M&I()'K5VX/3S"7V(M:P/0X!?Z.,N9HH^S`@>PDB-(ABQ<52BD!JYLZ[B->B"%G)PL&]*32YQ$?`7OVS13'W&AJ[J0WXG.G\MS.QG)F MPW_*T2;C##=\D64'7R39?VGM=`B+D@T&R8VA+&0[/A`*Y:9L06_$%0D9Q!MA MMK&4#2WB%E-:QSWS[>F3WHA/GW)RUH?.W%)6Q(Q;W)A>S@$Y]=Z_1I-SK2HV MA=SN;H!N^LP*H-NA!=RH/_Z%.A1QJ&>/>^@V>\*->O94AS(.=>RR+N0`/-3E MUVJ3'J-A&IZ^K4,A=RF@'8/@=N5V0`$W&B956Q5#SDY7"L]S+:5!(\YSHT&[ M!,;<:,JCA!M->I0J'KEK:Z$LU)SGAD=R6L"CR;1\PU=8"T:/6X.C!I%:+6,* M264LH*F\,*/!V8*QNST4<6A8QG>P)WQ<3Y7J$+F7(^%0WZE>])Z-7G94J#ZB M'3J?&Z/`;^0.S5G!3B)@>L&WG?OP!01UJN#)TH?S\`B^\N$LJ./9TH<3H8X' M:Q].73J>K'TX,^DX7#@^=WVC^+,E%Y$C]EO7AT_X$1[/?P:!]!=;SX?/W!%\ MZ6_'`M@M_=T8'BQ]^#K1>8*5#T=P'8^6/AS$=3Q>^G`&N.,#I"\6?>Q7=,K4OJC957_@ENXXNP:X`17V0B^J6<6?.T=,&[Y#S*! MN!Q_^@D``/__`P!02P,$%``&``@````A`):+)>QC"@``BC$``!D```!X;"]W M;W)K&ULK)O;!^`(F34=B>:"-T M0!)(BMG=:QK+-M&`'$"WN]]^LB1EE2H3J7',SL78_OCKSU(=L@ZH[__\>=AW M?F2G\RX_/G2-WJ#;R8[;_'EW?'WH_N_E[=H1/7O+387.!/T^O M_?/[*=L\%X4.^[XY&$SZA\WNV"T=K-,M'OG+RVZ;V?GV^R$[7DJ34[;?7*#^ MY[?=^QG=#MM;[`Z;T[?O[W]L\\,[6'S=[7>77X5IMW/86O[K,3]MON[AN7\: MH\T6O8L_F/UAMSWEY_SET@.[?EE1_LRS_JP/3H_WSSMX`M'LG5/V\M#]8EBI M:73[C_=%`_UWEWV<:[]WSF_YAWO:/8>[8P:M#?TD>N!KGG\34O]9("C<9Z6= MH@?B4^]E\WU_2_,/+=J]O%^CN,3R1>##K^9>=G;?0HF#3,\?":9OOH0+P M_\YA)X8&M,CF9_'S8_=\>7OH#D<]8S28@+KS-3M?G)UP[':VW\^7_/"_4E,\ MD/0P*P_XB1Z3WG@Z&!J?,!E6)B-I8LIZM,2&6A;UAY]5[/$MQ295,9@&5;&; MHLVJ8O"S*C:Y)9H!W5JVLFJBF^(9V"KBE\\\GP'-6$:$)_W,$QI3+`B_?.H9 MH2G+B+>U:;\7S>/]*?_H0+*`L79^WXC48U@&>.&(+@>!'.--0QS& MMG#Y(FP>NO`0,'S/,"]_/`ZGP_O^#YA+VTKSQ#6&KIBC0DP<86M3L*#`H<"E MP*/`IV!)04!!2$%$P8J"-04Q!0D%:0WTH7MD'\$P_G_TD;`1?82M^X1`=9I) M.@056,2F8$&!0X%+@4>!3\&2@H""D(*(@A4%:PIB"A(*TAK0.@32`^L0<]R# MK/C):2.,8.9!G-J\&>F=\%2*AI!CI,@83W317(ID5S&R8,1AQ&7$8\1G9,E( MP$C(2,3(BI$U(S$C"2-IG6@]!XW(>LX8]Z;0==?7<$QPHF#14]B^3R49ELN\ MR%9S1FQ&%HPXC+B,>(SXC"P9"1@)&8D863&R9B1F)&$DK1.M#Z"MM3YH;WBA MUAN^(N6NJ&AX1FQ&%HPXC+B,>(SXC"P9"1@)&8D863&R9B1F)&$DK1.MX6%S M\HF&%VJ]X4LR++;(Q?H\ET2EINE4STQVI8'%K9:^B&@A13B]'$9<1CQ&?$:6 M%5&5#B11%:*5#J6/TACCF?YDD11AI5>,K!F)&4D822M2'D;J6P'886E=6&[7 MBOQU>=MMOSWET,C0U%?FU!"V9>5F39CH/5N2>L\R8E>DOE89XSN]2192A$WB M,.(RXC'B,[*L2*T?&0EEJ5JO309Z%2,IPBJN&%DS$C.2,))6A/<:[*O_>:\) M$[W7*C*2.[JY)*H!Z-"V2\UP4NS2S8%!MND+^3FVCR-=D;B2-,?QI(\X#4`< MLK?TY>?HNI2N2`))FN.$TJ>*0YXGDI^CZTJZ(EE+TAPGEC[7GR>1GZ-K*EV! M:(D8#K3:>+@R6^$LC]-5J/6.KPBLL"JE3NAAZHJ(C852,U1G@@4CCO3!YW(E M4>&IL\=\?$:6T@>=`TF:G4/F$S&RDC[HO):DV3EF/@DCJ?2A?2IN'3[1J85< M[U5$,&QJW4JFS1Q54!&IHJUO*Q$VP((CAR-7H69W3XG0W>=HR5&@4+-[J$3H M'G&TXFBM4+-[K$3HGG"4:DB;NH8XI-\\WZ0CHD9[XYEJOO MFG@OETY"*X>",2;KW:*R,L7Z_^-Q-NR1$>5@+#@T21L:RT51/185>==$K$*^ M7B'#G/6&@]I_)(\MT;2M>@&*VJH77A.QZD5Z]4RS1Q:4%=JT56B-HK8*Q==$ MK$*)7J'1P.B1C6B*/@TUT@>PN-2H#V"QA30GXKZZ<_L64EQ9D$4)D9Z^2./- M4=6>OBKWF=S9+*IRYJ`8Q4:/W'\X^'E;>[NW!/>4"#.$C^9E<+-'9NL2/V\+ M'BC?YFD6*A$&C]"\##[@P[%L++,M^%KY-@>/E0B#)WKP:8^&HC[S>I4\A)ZBR16=OQBJMZ4`%J?C`;1>JN9L&1@TBYNPHUNWLH4NX^1TM$ MRCU0J-D]1)%RCSA:(5+N:X6:W6,4*?>$HQ11X:[WJ;CE^>?9I+PK@L&$`^]) M?*4B^A4&MUR4C`F9>/-*)7Y(%5V5;!35QRC+L@L,6"V35S),54D8<(VQ7(S5 M5B$/1:T5\O4*&9"B2=I?HD];C0(4M=4H1%%KC2*]1B;91ZS0I*TZ:Q2U52=& M46MU$KTZP]F([FQ2]&FHD3Z2Q;49'2W9E9=9.9QPYB-3,=Q5J=O=0I-Q]CI:(E'N@4+-[B"+E'G&T0J3< MUPHUN\EIPKIFYVQ?M4T-TJ565?Q]%19 MU3<[##F5E:%4[BWN'B_G<[3D*+C%/>3E(HY6'*UO<8]YN82C5$/ZE!87MZW4RS3$%T??C#M^?#[]$E+N)!M<(7J M:<68D*WY7+S-(790=15//I652BL++(YSM$2DW`.%FMU#%"GWB*,5(N6^5JC9/4:162I$5CF2!.=8L"V[VBA2V76![N41ZXY<5#I8HB&WEFLRA2L7T2>T0OD)98IBUZ@**VZ"&*5/2(1#?H266%9=JBKU'4%CU&D8J>D.@C M>I!,L4Q#="V9B'LF+9G0KZ!O.R<5-F3P">?B*@=O`>:5JOUV!T7J-+#@R$&D M)JJK4/-$]5"DW'V.EHB4>Z!0LWN((N4><;1"I-S7"C6[QRA2[@E'XH5IU>YE M7Y;?Q[-+/CFC_-P M9L'W=IS',RNYQN'-[B_%@D3\G^"-[V*H4V["F^!7_+\,P>=J@:$%KXWQ"CV- MK+1H=Q(@G%C)Y(H^G%I)T=Y$GTXL>$&`^]MW%GSESKEW9\%7Y)R'=Q9\I;7N#VQX"T:[F]/+7@K@_/EQ()W,S@/)E90\+YL"'@3 M_GWSFD6;T^ON>.[LLQ<83(/BY953^2Y]^<>ENFGYFE_@)7A($O!:,OR;APS> ML1N(ERQ?\OR"?T#@OOQ7%(]_`P``__\#`%!+`P04``8`"````"$`S^)Q[Z4# M``#L"P``$``(`61O8U!R;W!S+V%P<"YX;6P@H@0!**```0`````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````"<5L%NVS@0O2_0?S!T;^1D@Z((9!5.G#0! MLANC=K-'@J'&,5&)U)*4D?3K^TC%ME336F1/IL4AY\U[,\/)OKQ4Y6A#QDJM M)LGIR3@9D1*ZD.IYDGQ?WGS\G(RLXZK@I58T25[))E_R#W]D$* M92?)VKGZ(DVM6%/%[0FV%796VE3(,O]+"J.M7KG1]8N@,DN[ MFQG0+4@T1KK7?)REW;_90O"2KG!QON*EI2S=?\ANB7O2YEP:FV<;=[$AX;09 M6?D3M)TEHR=NR<.9)!MN)%<.L+Q9^R>LR]HZD_^CS0^[)G(V2V'0?@S+KFUW M+<_S\\_!`JN^I;^A18*-/L:E="79A]6<&Q>!?`[E]Y@#BA9Q"VBK(D-NL&OE MP!>[4ZW:4G>1[V*XTA!:62H85E:7LN`.?Q8./Q78W!EZ7EHOPT=.WW/FDI=< MB7>Y>3OR+C=OT9Q%H5UR*RW3*S8W9%$"(2&CEE/Q;R.M]`EK`\4SN2$+EAL3 M#^$;=DTCL(\LC%YYS8W"GF6H6RA055JQQ9H?N>\.7:`BMN0OU,O#G30W4H%/ MR4O([EW[DHY;WJD-]K1!KX@"@\@.P-!WCED$F"`OI$Z%QF(#-WSF$# M[@)U#VZ-B.<:*,E)1>V&9&3+Z)&C M,D&+)W2KG0#[*HE*$[R2CA`_B.R0_R'S01FFT4"F MUJ(#A_RYE_Q)EJA%LNR6RH*MXOVM5X)L6A2A?$.!H"]&O>S$GB-#`P^^,NMF MH#-T"_/`217U$L^/+<#HD7O=OI:!@!L\:NR1EPWYWC6C>"R](]-*-^@'WOXK ME^AA_^WEX$@\6X;=Q/MNC`"V4S@*;2I$&\$W$B0W*#UB?Y/S`4W+>!EVJVI& MCLNX6:_='2@8!3-MG0"OWY6F$)\WKXEV26/NO&IARGO33",ND8A"FJ9HRC`YM9[^*'O'P%YC7+&L?C@?% M=JFC5]$C2^U0K?N#3Z]XJ'6!5Y5]-;V:[XU5OPU2]U+]L-_KI9X!XW92['_, M`@4%9JCM_OY#=HLAT93^DJL0=;&U.=SP<^UC.[SGI^6````J@```!````!X;"]C86QC M0VAA:6XN>&UL/([!"@(A%$7W0?\@;]\X,XN(4`<*^H+Z`'%>HZ!/\4G4WV>; M-A<.%\Z]:GFG*%Y8.632,`TC""27UT";AL?]=CB!X&9IM3$3:O@@PV+V.^5L M=%=O`XEN(-;@6RMG*=EY3):'7)!Z\\PUV=:Q;I)+1;NR1VPIRGD5HOT&B4^<"-YVQFHT0X\FK/SLTI8*CH'#ZZSX(("GT22\538&C4A6(JQ M%PUH[K/8,#%<=T[S$(]N@RT7[WP#N,CS2ZPA<,D#QWM@:BT+%\K?&R-]]D$U*/`OXBS$^(1 MP`;OGW_.O@```/__`P!02P$"+0`4``8`"````"$`X?R_7!8"```O'@``$P`` M````````````````````6T-O;G1E;G1?5'EP97-=+GAM;%!+`0(M`!0`!@`( M````(0"U53`C]0```$P"```+`````````````````$\$``!?10(``'0=```:`````````````````'4' M``!X;"]?K*54&``"-&P``&`````````````````"G#P`` M>&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`#X$;QLL M`P``>0D``!D`````````````````,A8``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`(ZS,OSQ%0``GXD``!D````` M````````````*B```'AL+W=O&PO=V]R M:W-H965T&UL M4$L!`BT`%``&``@````A`!_RD5ME!```&PO=V]R:W-H965T&UL4$L!`BT`%``&``@` M```A`+,RU?V=`P``BPL``!D`````````````````#TP``'AL+W=O&UL4$L!`BT`%``&``@````A`(BIGU"#`P`` MS@H``!D`````````````````&UD``'AL+W=O&POT@``>&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`/TTUTWE M"0``@C(``!D`````````````````2=T``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`+IQ8=]*`P``*@H``!@````` M````````````Z^P``'AL+W=O&UL4$L!`BT`%``&``@````A`.GQ'J@``P``4@D` M`!D`````````````````7?0``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`,VKQF$L!@``AA@``!D````````````` M````MBH!`'AL+W=O&PO=V]R:W-H965T M.9J`H``$LS```9```` M`````````````%\U`0!X;"]W;W)K&UL4$L!`BT` M%``&``@````A`.9GY(%7`@``4`4``!@`````````````````/D`!`'AL+W=O M&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`%48U9KS M!@``@1\``!@`````````````````?TP!`'AL+W=O&PO=V]R:W-H965T#T@D``#,O```9```````` M`````````*Q9`0!X;"]W;W)K&UL4$L!`BT`%``& M``@````A`*X7-,-:$P``@&(``!D`````````````````M6,!`'AL+W=OI_-<&``!F'P``&0`````````````` M```RH@$`>&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`)\\[*:`"```BB8``!D````` M````````````@+$!`'AL+W=O&PO=V]R M:W-H965T&UL M4$L!`BT`%``&``@````A`.^Y'XGC!0``-!<``!D`````````````````)O0! M`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@` M```A`,_B<>^E`P``[`L``!``````````````````#`L"`&1O8U!R;W!S+V%P M<"YX;6Q02P$"+0`4``8`"````"$`9%'/QY8```"J````$``````````````` M``#G#P(`>&PO8V%L8T-H86EN+GAM;%!+`0(M`!0`!@`(````(0#J&5H8-0$` M`$`"```1`````````````````*L0`@!D;V-0 XML 17 R4.htm IDEA: XBRL DOCUMENT v2.4.0.8
Condensed Consolidated Balance Sheets (USD $)
In Thousands, unless otherwise specified
Sep. 30, 2013
Dec. 31, 2012
Current assets    
Cash and cash equivalents $ 781,700 $ 896,300
Restricted cash 19,000 25,000
Accounts receivable, less allowances of $13,500 and $12,400, respectively 456,500 480,900
Inventories 332,100 328,500
Short-term deferred tax assets 33,800 42,600
Other current assets 103,800 73,900
Assets held for sale 24,400 0
Total current assets 1,751,300 1,847,200
Property, plant and equipment, at cost 655,600 631,900
Less accumulated depreciation and amortization 295,100 272,600
Net property, plant and equipment 360,500 359,300
Goodwill 971,000 961,600
Core technologies, net 482,400 506,500
Other intangible assets, net 358,600 368,100
Deferred tax assets 10,100 10,000
Other assets 231,100 98,600
Total assets 4,165,000 4,151,300
Current liabilities    
Short-term borrowings 97,500 0
Accounts payable 72,800 56,200
Accrued expenses 208,200 242,900
Accrued compensation and benefits 114,500 137,800
Income taxes payable 8,800 10,700
Liabilities held for sale 2,600 0
Total current liabilities 504,400 447,600
Long-term debt 1,406,500 1,409,600
Other long-term liabilities 731,700 342,400
Deferred income taxes 18,300 26,000
Commitments and contingencies      
Shareholders' investment:    
Preferred stock, $1 par value, authorized 5,000,000 shares; none issued 0 0
Common stock, $0.25 par value, authorized 600,000,000 shares; issued and outstanding 77,890,296 shares at September 30, 2013 and 81,697,409 shares at December 31, 2012 19,500 20,400
Capital in excess of par value 1,648,000 1,513,300
Accumulated deficit / retained earnings (89,700) 473,200
Accumulated other comprehensive loss (73,700) (81,200)
Total shareholders' investment 1,504,100 1,925,700
Total liabilities and shareholders' investment $ 4,165,000 $ 4,151,300

XML 18 R10.htm IDEA: XBRL DOCUMENT v2.4.0.8
Earnings per Common Share
9 Months Ended
Sep. 30, 2013
Earnings per Common Share

4. Earnings per Common Share

Earnings per share (“EPS”) is computed under the two-class method using the following common share information:

 

     Quarter Ended
September 30,
     Nine Months
Ended September 30,
 
     2013      2012      2013      2012  
(dollars and shares in millions)                            

EPS Numerator:

           

Net income

   $ 93.2       $ 129.3       $ 22.3       $ 401.9   

Less: Income allocated to participating securities

     1.6         2.4         0.3         7.7   
  

 

 

    

 

 

    

 

 

    

 

 

 

Net income available to common shareholders

   $ 91.6       $ 126.9       $ 22.0       $ 394.2   
  

 

 

    

 

 

    

 

 

    

 

 

 

EPS Denominator:

           

Weighted average common shares outstanding

     78.5         83.4         79.9         83.8   

Dilutive common share equivalents from share-based compensation plans

     1.5         1.2         1.3         1.1   
  

 

 

    

 

 

    

 

 

    

 

 

 

Weighted average common and common equivalent shares outstanding, assuming dilution

     80.0         84.6         81.2         84.9   
  

 

 

    

 

 

    

 

 

    

 

 

 
XML 19 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 20 R24.htm IDEA: XBRL DOCUMENT v2.4.0.8
Pension and Other Postretirement Benefit Plans (Tables)
9 Months Ended
Sep. 30, 2013
Components Of Net Periodic Pension Cost

The components of net periodic pension cost are as follows:

 

     Quarter Ended
September 30,
    Nine Months Ended
September 30,
 
     2013     2012     2013     2012  
(dollars in millions)                         

Service cost, net of employee contributions

   $ 7.5      $ 7.0      $ 22.6      $ 20.8   

Interest cost

     4.6        4.9        13.7        14.6   

Expected return on plan assets

     (6.5     (6.2     (19.5     (17.9

Amortization

     3.4        2.8        10.2        7.8   
  

 

 

   

 

 

   

 

 

   

 

 

 

Net periodic pension cost

   $ 9.0      $ 8.5      $ 27.0      $ 25.3   
  

 

 

   

 

 

   

 

 

   

 

 

 
XML 21 R18.htm IDEA: XBRL DOCUMENT v2.4.0.8
Segment Information
9 Months Ended
Sep. 30, 2013
Segment Information

12. Segment Information

The company’s management considers its business to be a single segment entity—the manufacture and sale of medical devices. The company’s products generally share similar distribution channels and customers. The company designs, develops, manufactures, packages, distributes and sells medical, surgical, diagnostic and patient care devices. The company sells a broad range of products to hospitals, individual healthcare professionals, extended care health facilities and alternate site facilities on a global basis. In general, the company’s products are intended to be used once and then discarded or either temporarily or permanently implanted. The company’s chief operating decision makers evaluate their various global product portfolios on a net sales basis and generally evaluate profitability and associated investment on an enterprise-wide basis due to shared geographic infrastructures.

Net sales based on the location of external customers by geographic region are:

 

     Quarter Ended
September 30,
     Nine Months Ended
September 30,
 
     2013      2012      2013      2012  
(dollars in millions)                            

United States

   $ 500.3       $ 483.4       $ 1,496.4       $ 1,469.6   

Europe(a)

     116.7         108.9         356.5         349.4   

Japan

     43.4         41.6         123.4         122.2   

Other(a)

     97.6         89.0         281.9         254.3   
  

 

 

    

 

 

    

 

 

    

 

 

 
   $ 758.0       $ 722.9       $ 2,258.2       $ 2,195.5   
  

 

 

    

 

 

    

 

 

    

 

 

 

 

(a) Beginning in 2013, certain emerging markets in Europe are included in the “other” geographic region. Prior year amounts have been reclassified to conform to the current year presentation.

Total net sales by product group category are:

 

     Quarter Ended
September 30,
     Nine Months Ended
September 30,
 
     2013      2012      2013      2012  
(dollars in millions)                            

Vascular

   $ 209.9       $ 202.5       $ 625.3       $ 633.0   

Urology

     193.7         188.1         574.2         562.0   

Oncology

     215.5         203.9         636.7         601.9   

Surgical Specialties

     118.1         107.7         358.4         333.8   

Other

     20.8         20.7         63.6         64.8   
  

 

 

    

 

 

    

 

 

    

 

 

 
   $ 758.0       $ 722.9       $ 2,258.2       $ 2,195.5   
  

 

 

    

 

 

    

 

 

    

 

 

 
XML 22 R48.htm IDEA: XBRL DOCUMENT v2.4.0.8
Total Net Sales by Product Group Category (Detail) (USD $)
In Thousands, unless otherwise specified
3 Months Ended 9 Months Ended
Sep. 30, 2013
Sep. 30, 2012
Sep. 30, 2013
Sep. 30, 2012
Segment Reporting Information [Line Items]        
Net sales $ 758,000 $ 722,900 $ 2,258,200 $ 2,195,500
Vascular
       
Segment Reporting Information [Line Items]        
Net sales 209,900 202,500 625,300 633,000
Urology
       
Segment Reporting Information [Line Items]        
Net sales 193,700 188,100 574,200 562,000
Oncology
       
Segment Reporting Information [Line Items]        
Net sales 215,500 203,900 636,700 601,900
Surgical Specialties
       
Segment Reporting Information [Line Items]        
Net sales 118,100 107,700 358,400 333,800
Other Product Group
       
Segment Reporting Information [Line Items]        
Net sales $ 20,800 $ 20,700 $ 63,600 $ 64,800
XML 23 R38.htm IDEA: XBRL DOCUMENT v2.4.0.8
Accounts Receivable, Net of Allowances (Detail) (USD $)
In Millions, unless otherwise specified
Sep. 30, 2013
Accounts, Notes, Loans and Financing Receivable [Line Items]  
Accounts receivable, net $ 60.6
Greater than 365 days past due 12.1
Spain
 
Accounts, Notes, Loans and Financing Receivable [Line Items]  
Accounts receivable, net 23.0
Greater than 365 days past due 4.8
Italy
 
Accounts, Notes, Loans and Financing Receivable [Line Items]  
Accounts receivable, net 23.1
Greater than 365 days past due 2.4
Greece
 
Accounts, Notes, Loans and Financing Receivable [Line Items]  
Accounts receivable, net 10.5
Greater than 365 days past due 3.2
Portugal
 
Accounts, Notes, Loans and Financing Receivable [Line Items]  
Accounts receivable, net 4.0
Greater than 365 days past due $ 1.7
XML 24 R27.htm IDEA: XBRL DOCUMENT v2.4.0.8
Acquisitions and Divestiture - Additional Information (Detail) (USD $)
1 Months Ended 9 Months Ended 1 Months Ended 1 Months Ended
Jun. 27, 2013
Sep. 30, 2013
Sep. 30, 2012
Sep. 30, 2013
Maximum
Aug. 29, 2013
Technology
Oct. 01, 2013
Medafor, Inc.
Subsequent Event
Oct. 01, 2013
Medafor, Inc.
Subsequent Event
Up Front Payment
Sep. 04, 2013
Rochester Medical, Inc.
Jul. 29, 2013
Loma Vista Medical, Inc.
Jul. 29, 2013
Loma Vista Medical, Inc.
In-Process Research And Development
Jul. 29, 2013
Loma Vista Medical, Inc.
Core Technologies
Significant Acquisitions and Disposals [Line Items]                      
Business acquisition purchase price             $ 203,700,000 $ 262,000,000 $ 39,400,000    
Business acquisition, maximum contingent consideration           80,000,000     8,000,000    
Business acquisition purchase price per share               $ 20      
Payments made for intangibles   33,500,000 14,100,000   29,500,000            
Contingent payments for intangibles         5,000,000            
Business acquisition, purchase consideration cash payment                 32,500,000    
Purchase price allocation at fair value, recognition of finite-lived intangible asset                     20,600,000
Purchase price allocation at fair value, goodwill                 8,600,000    
Purchase price allocation at fair value, recognition of indefinite-lived intangible asset                   20,000,000  
Purchase price allocation at fair value, other asset                 4,900,000    
Purchase price allocation at fair value, recognition of deferred tax liabilities                 14,700,000    
Risk-adjusted discount rate                 25.00%    
Divestiture of business in cash $ 275,000,000                    
Manufacturing and other transition services contract term       5 years              
XML 25 R26.htm IDEA: XBRL DOCUMENT v2.4.0.8
Segment Information (Tables)
9 Months Ended
Sep. 30, 2013
Net Sales Based on Location of External Customers by Geographic Region

Net sales based on the location of external customers by geographic region are:

 

     Quarter Ended
September 30,
     Nine Months Ended
September 30,
 
     2013      2012      2013      2012  
(dollars in millions)                            

United States

   $ 500.3       $ 483.4       $ 1,496.4       $ 1,469.6   

Europe(a)

     116.7         108.9         356.5         349.4   

Japan

     43.4         41.6         123.4         122.2   

Other(a)

     97.6         89.0         281.9         254.3   
  

 

 

    

 

 

    

 

 

    

 

 

 
   $ 758.0       $ 722.9       $ 2,258.2       $ 2,195.5   
  

 

 

    

 

 

    

 

 

    

 

 

 

 

(a) Beginning in 2013, certain emerging markets in Europe are included in the “other” geographic region. Prior year amounts have been reclassified to conform to the current year presentation.
Total Net Sales by Product Group Category

Total net sales by product group category are:

 

     Quarter Ended
September 30,
     Nine Months Ended
September 30,
 
     2013      2012      2013      2012  
(dollars in millions)                            

Vascular

   $ 209.9       $ 202.5       $ 625.3       $ 633.0   

Urology

     193.7         188.1         574.2         562.0   

Oncology

     215.5         203.9         636.7         601.9   

Surgical Specialties

     118.1         107.7         358.4         333.8   

Other

     20.8         20.7         63.6         64.8   
  

 

 

    

 

 

    

 

 

    

 

 

 
   $ 758.0       $ 722.9       $ 2,258.2       $ 2,195.5   
  

 

 

    

 

 

    

 

 

    

 

 

 
XML 26 R46.htm IDEA: XBRL DOCUMENT v2.4.0.8
Changes in Accumulated Other Comprehensive Income (Loss) By Component (Detail) (USD $)
3 Months Ended 9 Months Ended
Sep. 30, 2013
Sep. 30, 2012
Sep. 30, 2013
Sep. 30, 2012
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Beginning balance     $ (81,200,000) $ (66,600,000)
Other comprehensive income (loss) before reclassifications     1,600,000 (19,100,000)
Tax (provision) benefit related to other comprehensive income (loss) before reclassifications     (400,000) [1] (2,200,000) [1]
Other comprehensive income (loss) before reclassifications, net of taxes     1,200,000 (21,300,000)
Amounts reclassified from accumulated other comprehensive income (loss)     9,700,000 6,900,000
Tax provision (benefit) related to amounts reclassified from accumulated other comprehensive income (loss)     (3,400,000) (2,600,000)
Reclassifications, net of tax     6,300,000 4,300,000
Other comprehensive income (loss) 9,000,000 16,800,000 7,500,000 (17,000,000)
Ending balance (73,700,000) (83,600,000) (73,700,000) (83,600,000)
Derivative Instruments Designated as Cash Flow Hedges
       
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Beginning balance     (700,000) (1,400,000)
Other comprehensive income (loss) before reclassifications     2,300,000 5,200,000
Tax (provision) benefit related to other comprehensive income (loss) before reclassifications     (400,000) [1] (2,200,000) [1]
Other comprehensive income (loss) before reclassifications, net of taxes     1,900,000 3,000,000
Amounts reclassified from accumulated other comprehensive income (loss)     (600,000) [2] (1,100,000) [2]
Tax provision (benefit) related to amounts reclassified from accumulated other comprehensive income (loss)     300,000 200,000
Reclassifications, net of tax     (300,000) (900,000)
Other comprehensive income (loss)     1,600,000 2,100,000
Ending balance 900,000 700,000 900,000 700,000
Foreign Currency Translation
       
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Beginning balance     32,600,000 41,100,000
Other comprehensive income (loss) before reclassifications     (700,000) (24,300,000)
Tax (provision) benefit related to other comprehensive income (loss) before reclassifications     0 [1] 0 [1]
Other comprehensive income (loss) before reclassifications, net of taxes     (700,000) (24,300,000)
Amounts reclassified from accumulated other comprehensive income (loss)     0 0
Tax provision (benefit) related to amounts reclassified from accumulated other comprehensive income (loss)     0 0
Reclassifications, net of tax     0 0
Other comprehensive income (loss)     (700,000) (24,300,000)
Ending balance 31,900,000 16,800,000 31,900,000 16,800,000
Benefit Plans
       
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Beginning balance     (113,100,000) (106,300,000)
Other comprehensive income (loss) before reclassifications     0 0
Tax (provision) benefit related to other comprehensive income (loss) before reclassifications     0 [1] 0 [1]
Other comprehensive income (loss) before reclassifications, net of taxes     0 0
Amounts reclassified from accumulated other comprehensive income (loss)     10,300,000 [3] 8,000,000 [3]
Tax provision (benefit) related to amounts reclassified from accumulated other comprehensive income (loss)     (3,700,000) (2,800,000)
Reclassifications, net of tax     6,600,000 5,200,000
Other comprehensive income (loss)     6,600,000 5,200,000
Ending balance $ (106,500,000) $ (101,100,000) $ (106,500,000) $ (101,100,000)
[1] Income taxes are not provided for foreign currency translation adjustment.
[2] See Note 6 of the notes to condensed consolidated financial statements.
[3] These components are included in the computation of net periodic pension cost. See Note 10 of the notes to condensed consolidated financial statements.
XML 27 R34.htm IDEA: XBRL DOCUMENT v2.4.0.8
Location and Amounts of Gains and Losses on Derivative Instruments Designated as Cash Flow Hedges (Detail) (Cash flow hedges, USD $)
In Millions, unless otherwise specified
3 Months Ended 9 Months Ended
Sep. 30, 2013
Sep. 30, 2012
Sep. 30, 2013
Sep. 30, 2012
Derivative Instruments, Gain (Loss) [Line Items]        
Gain/(Loss) Recognized in Other Comprehensive Income (Loss) $ 0.4 $ 0.9 $ 5.1 $ 5.0
Gain/(Loss) Reclassified from Accumulated Other Comprehensive Loss into Income 1.1 0.2 0.6 1.1
Forward currency contracts
       
Derivative Instruments, Gain (Loss) [Line Items]        
Gain/(Loss) Recognized in Other Comprehensive Income (Loss) (0.5) 1.5 4.1 4.0
Forward currency contracts | Cost of Goods Sold
       
Derivative Instruments, Gain (Loss) [Line Items]        
Gain/(Loss) Reclassified from Accumulated Other Comprehensive Loss into Income 1.7 (0.4) 1.7 (0.4)
Option currency contracts
       
Derivative Instruments, Gain (Loss) [Line Items]        
Gain/(Loss) Recognized in Other Comprehensive Income (Loss) 0.9 (0.6) 1.0 1.0
Option currency contracts | Cost of Goods Sold
       
Derivative Instruments, Gain (Loss) [Line Items]        
Gain/(Loss) Reclassified from Accumulated Other Comprehensive Loss into Income $ (0.6) $ 0.6 $ (1.1) $ 1.5
XML 28 R40.htm IDEA: XBRL DOCUMENT v2.4.0.8
Contingencies - Additional Information (Detail) (USD $)
In Millions, unless otherwise specified
3 Months Ended 1 Months Ended 9 Months Ended 21 Months Ended 1 Months Ended 1 Months Ended 1 Months Ended 9 Months Ended 1 Months Ended 3 Months Ended 1 Months Ended 3 Months Ended 1 Months Ended 3 Months Ended 1 Months Ended
Jun. 30, 2013
Sep. 30, 2013
Dec. 31, 2012
Jul. 31, 2013
W. L. Gore
Jul. 31, 2010
W. L. Gore
Mar. 31, 2009
W. L. Gore
Dec. 31, 2007
W. L. Gore
Mar. 31, 2009
W. L. Gore
Attorney Fees
Mar. 31, 2009
W. L. Gore
Prejudgment Interest
Jul. 31, 2010
W. L. Gore
Minimum
Jul. 31, 2010
W. L. Gore
Maximum
Sep. 30, 2013
Total Receivables Related to Product Liability Matters
Dec. 31, 2012
Total Receivables Related to Product Liability Matters
Jun. 30, 2007
Hernia Product Claims
LegalMatter
Sep. 30, 2013
Hernia Product Claims
Sep. 30, 2013
Hernia Product Claims
Mar. 27, 2013
Hernia Product Claims
Arbitration Proceedings
Carriers
Oct. 17, 2013
Hernia Product Claims
Subsequent Event
Plaintiff
Oct. 17, 2013
Hernia Product Claims
Subsequent Event
United States
LegalMatter
Oct. 17, 2013
Hernia Product Claims
Subsequent Event
Canada
LegalMatter
Oct. 17, 2013
Hernia Product Claims
Subsequent Event
Federal Law Claims
LegalMatter
Oct. 17, 2013
Hernia Product Claims
Subsequent Event
State Law Claims
LegalMatter
Oct. 17, 2013
Hernia Product Claims
Subsequent Event
Superior Court of State of Rhode Island
Plaintiff
Oct. 17, 2013
Hernia Product Claims
Subsequent Event
Superior Court of State of Rhode Island
State Law Claims
LegalMatter
Jul. 31, 2012
Women's Health Product Claims
Sep. 30, 2013
Women's Health Product Claims
Carriers
Jul. 31, 2013
Women's Health Product Claims
Multi District Litigation
Sep. 30, 2013
Women's Health Product Claims
Multi District Litigation
Claim
Sep. 30, 2013
Women's Health Product Claims
New Jersey state case
Claim
Oct. 17, 2013
Women's Health Product Claims
Subsequent Event
Plaintiff
Oct. 17, 2013
Women's Health Product Claims
Subsequent Event
United States
LegalMatter
Oct. 17, 2013
Women's Health Product Claims
Subsequent Event
Canada
LegalMatter
Dec. 31, 2011
Brachytherapy Matter
Jul. 31, 2013
Filter Product Claims
State Law Claims
LegalMatter
Jun. 30, 2013
Filter Product Claims
State Law Claims
LegalMatter
Oct. 17, 2013
Filter Product Claims
Subsequent Event
Plaintiff
Oct. 17, 2013
Filter Product Claims
Subsequent Event
State Law Claims
LegalMatter
Oct. 17, 2013
Filter Product Claims
Subsequent Event
Minimum
State Law Claims
LegalMatter
Commitments and Contingencies [Line Items]                                                                            
Number of lawsuits                                     1   745 720   685                            
Number of individual plaintiffs                                   1,575         785             9,635           40    
Number of putative class actions                                     2                       5 3         3  
Number of previously filed class action lawsuits                                     10                                      
Number of Putative Class Actions Settled                                       3                                    
Number of Multidistrict Litigations                           1                                                
Expected trial date scheduled by Court                                                           2013-12                
U. S. District Court award for plaintiff's damages                                                 $ 3.6   $ 2.0                      
Loss contingency claims settled number                                                       1 1                  
Loss contingency claims dismissed number                                                       1                    
Number of putative class actions dismissed                                                                     2      
Number of putative class actions with class certification denied                                                                   1        
Period for additional Filter Product Claims trials                                                                         12 months  
Number of claims in settlement agreement                                                                           30
Non-cash charge write off related to insurance receivable                                 25.0                                          
Non-cash charge write off related to insurance receivable after tax                                 24.5                                          
Number of insurance carriers                                 1                 1                        
Insurance coverage no longer disputed                                                   50                        
Legal settlement costs, gross                                                                 51.0          
Legal settlement costs, net of tax                                                                 40.8          
U. S. District Court award for damages         109 371 185 19 20                                                          
Court-assessed royalty rate                   12.50% 20.00%                                                      
Escrow deposit representing an estimation of liability       542                                                                    
Product Claims, charges incurred before taxes 293.0                                                                          
Product Claims, charges incurred after tax 276.0                                                                          
Accruals for product liability and other legal matters   520.3 158.1                                                                      
Payments to qualified settlement fund                             19.5 177.1                                            
Payments to qualified claimants from qualified settlement funds                             25.6 158.2                                            
Other payments to qualified claimants from qualified settlement funds                             15.6 26.2                                            
Receivables related to product liability matters                       $ 186.2 $ 45.6                                                  
XML 29 R31.htm IDEA: XBRL DOCUMENT v2.4.0.8
Income Taxes - Additional Information (Detail) (USD $)
In Millions, unless otherwise specified
3 Months Ended 9 Months Ended
Sep. 30, 2013
Sep. 30, 2012
Sep. 30, 2013
Dec. 31, 2012
Income Tax [Line Items]        
Effective income tax rate 22.00% 27.00%    
Reduction in income tax provision     $ 3.7  
Unrecognized tax benefits related to federal, state and foreign taxes 48.5   48.5 43.4
Unrecognized tax benefits that would impact effective tax rate 40.4   40.4  
Accrued interest 6.3   6.3 4.8
Decrease in unrecognized tax benefits $ 18.4   $ 18.4  
Number of months unrecognized tax benefits may decrease     12 months  
XML 30 R43.htm IDEA: XBRL DOCUMENT v2.4.0.8
Components of Net Periodic Pension Cost (Detail) (Pension Plans, Defined Benefit, USD $)
In Millions, unless otherwise specified
3 Months Ended 9 Months Ended
Sep. 30, 2013
Sep. 30, 2012
Sep. 30, 2013
Sep. 30, 2012
Pension Plans, Defined Benefit
       
Pension and Other Postretirement Benefits Disclosure [Line Items]        
Service cost, net of employee contributions $ 7.5 $ 7.0 $ 22.6 $ 20.8
Interest cost 4.6 4.9 13.7 14.6
Expected return on plan assets (6.5) (6.2) (19.5) (17.9)
Amortization 3.4 2.8 10.2 7.8
Net periodic pension cost $ 9.0 $ 8.5 $ 27.0 $ 25.3
XML 31 R25.htm IDEA: XBRL DOCUMENT v2.4.0.8
Shareholders' Investment (Tables)
9 Months Ended
Sep. 30, 2013
Changes in Accumulated Other Comprehensive Income (Loss) By Component

The changes in accumulated other comprehensive income (loss) by component are as follows:

 

    Derivative
Instruments
Designated as
Cash Flow Hedges
    Foreign Currency
Translation
    Benefit
Plans
    Total  
(dollars in millions)                        

Balance at December 31, 2011

  $ (1.4   $ 41.1      $ (106.3   $ (66.6

Other comprehensive income (loss) before reclassifications

    5.2        (24.3     —          (19.1

Tax (provision) benefit related to other comprehensive income (loss) before reclassifications(a)

    (2.2     —          —          (2.2
 

 

 

   

 

 

   

 

 

   

 

 

 

Other comprehensive income (loss) before reclassifications, net of taxes

    3.0        (24.3     —          (21.3
 

 

 

   

 

 

   

 

 

   

 

 

 

Amounts reclassified from accumulated other comprehensive income (loss)

    (1.1 )(b)      —          8.0 (c)      6.9   

Tax provision (benefit) related to amounts reclassified from accumulated other comprehensive income (loss)

    0.2        —          (2.8     (2.6
 

 

 

   

 

 

   

 

 

   

 

 

 

Reclassifications, net of tax

    (0.9     —          5.2        4.3   
 

 

 

   

 

 

   

 

 

   

 

 

 

Other comprehensive income (loss)

    2.1        (24.3     5.2        (17.0
 

 

 

   

 

 

   

 

 

   

 

 

 

Balance at September 30, 2012

  $ 0.7      $ 16.8      $ (101.1   $ (83.6
 

 

 

   

 

 

   

 

 

   

 

 

 

Balance at December 31, 2012

  $ (0.7   $ 32.6      $ (113.1   $ (81.2

Other comprehensive income (loss) before reclassifications

    2.3        (0.7     —          1.6   

Tax (provision) benefit related to other comprehensive income (loss) before reclassifications(a)

    (0.4     —          —          (0.4
 

 

 

   

 

 

   

 

 

   

 

 

 

Other comprehensive income (loss) before reclassifications, net of taxes

    1.9        (0.7     —          1.2   
 

 

 

   

 

 

   

 

 

   

 

 

 

Amounts reclassified from accumulated other comprehensive income (loss)

    (0.6 )(b)      —          10.3 (c)      9.7   

Tax provision (benefit) related to amounts reclassified from accumulated other comprehensive income (loss)

    0.3        —          (3.7     (3.4
 

 

 

   

 

 

   

 

 

   

 

 

 

Reclassifications, net of tax

    (0.3     —          6.6        6.3   
 

 

 

   

 

 

   

 

 

   

 

 

 

Other comprehensive income (loss)

    1.6        (0.7     6.6        7.5   
 

 

 

   

 

 

   

 

 

   

 

 

 

Balance at September 30, 2013

  $ 0.9      $ 31.9      $ (106.5   $ (73.7
 

 

 

   

 

 

   

 

 

   

 

 

 

 

(a) Income taxes are not provided for foreign currency translation adjustment.
(b) See Note 6 of the notes to condensed consolidated financial statements.
(c) These components are included in the computation of net periodic pension cost. See Note 10 of the notes to condensed consolidated financial statements.
XML 32 R6.htm IDEA: XBRL DOCUMENT v2.4.0.8
Condensed Consolidated Statements Of Cash Flows (USD $)
In Thousands, unless otherwise specified
9 Months Ended
Sep. 30, 2013
Sep. 30, 2012
Cash flows from operating activities:    
Net income $ 22,300 $ 401,900
Adjustments to reconcile net income to net cash provided by operating activities, net of acquired business:    
Depreciation and amortization 106,000 101,400
Litigation charges, net 318,200 0
Acquired in-process research and development 30,000 2,000
Asset impairments 12,300 22,200
Restructuring (1,400) (1,600)
Deferred income taxes (16,800) 12,600
Share-based compensation 44,700 39,000
Inventory reserves and provision for doubtful accounts 17,100 15,000
Other items 1,600 (5,800)
Changes in assets and liabilities:    
Accounts receivable 10,200 31,600
Inventories (34,400) (34,000)
Current liabilities (96,700) (153,900)
Taxes 6,000 (2,500)
Other, net (2,100) (700)
Net cash provided by operating activities 417,000 427,200
Cash flows from investing activities:    
Capital expenditures (47,300) (55,500)
Change in restricted cash 6,000 119,600
Payments made for purchase of business, net of cash acquired (35,000) 0
Payments made for intangibles (33,500) (14,100)
Proceeds from sale of financial instruments 0 10,000
Other 1,900 0
Net cash (used in) provided by investing activities (107,900) 60,000
Cash flows from financing activities:    
Change in short-term borrowings, net 97,500 77,000
Proceeds from exercises under share-based compensation plans, net 74,400 70,200
Excess tax benefit relating to share-based compensation plans 9,500 10,300
Purchases of common stock (546,900) (372,500)
Dividends paid (49,800) (49,900)
Other (500) (4,900)
Net cash used in financing activities (415,800) (269,800)
Effect of exchange rate changes on cash and cash equivalents (7,900) (4,700)
(Decrease) increase in cash and cash equivalents during the period (114,600) 212,700
Balance at January 1 896,300 596,400
Balance at September 30 781,700 809,100
Cash paid for:    
Interest 36,200 31,600
Income taxes 89,700 132,800
Non-cash transactions:    
Purchase of common stock not settled 6,500 9,100
Purchase of business and related costs $ 8,200 $ 0
XML 33 R8.htm IDEA: XBRL DOCUMENT v2.4.0.8
Acquisitions and Divestiture
9 Months Ended
Sep. 30, 2013
Acquisitions and Divestiture

2. Acquisitions and Divestiture

On October 1, 2013, the company acquired all of the outstanding shares of Medafor, Inc. (“Medafor”), a privately-held developer and supplier of plant-based hemostatic agents. The purchase consideration included an up-front cash payment of $203.7 million and future contingent payments of up to an additional $80 million based on specific revenue-based milestones through June 30, 2015. The company has not yet completed the initial purchase accounting due to the timing of this acquisition.

On September 4, 2013, the company entered into a definitive agreement to acquire Rochester Medical, Inc. (“Rochester Medical”), a publicly-held developer and supplier of silicone urinary incontinence and urine drainage products, for a purchase price of $20 per share, or approximately $262 million in the aggregate to be paid at closing. The transaction is expected to close in 2013, and is subject to customary closing conditions, including approval by the shareholders of Rochester Medical as well as regulatory approvals.

On August 29, 2013, the company acquired early stage technology from 3DT Holdings LLC (“3DT”), providing the company with rights to develop and commercialize a novel technology related to peripherally inserted central catheters (“PICCs”). 3DT received an up-front cash payment of $29.5 million and is eligible for milestone payments of up to $5 million based upon regulatory product approval. The company recorded the up-front payment as a research and development expense.

On July 29, 2013, the company acquired all of the outstanding shares of Loma Vista Medical, Inc., a privately-held company specializing in the development and commercialization of aortic valvuloplasty products, which use noncompliant fiber-based balloon technology. The total purchase consideration of $39.4 million included an up-front cash payment of $32.5 million and the fair value of contingent consideration of up to $8.0 million. The fair value of the assets acquired resulted in the recognition of core technologies of $20.6 million, deferred tax liabilities of $14.7 million, primarily consisting of intangible assets, goodwill of $8.6 million, and other net assets of $4.9 million. The goodwill is not deductible for tax purposes. An in process research and development (“IPR&D”) asset of $20.0 million was recorded for the development of a next generation valvuloplasty product. The fair value of the IPR&D asset was determined based upon the present value of expected future cash flows adjusted for the probability of technological and commercial risk, utilizing a risk-adjusted discount rate of 25%. The company has not yet finalized the purchase accounting, which may be adjusted as further information about conditions existing at the acquisition date become available.

On June 27, 2013, the company reached a definitive agreement to sell certain assets and liabilities of its electrophysiology division (“BEP”) to Boston Scientific Corporation (“Boston Scientific”) for $275 million in cash. The transaction is expected to be completed in 2013, subject to certain regulatory and customary closing conditions. The company expects to record a gain on the sale when the transaction is completed, which will include, among other things, assets and liabilities held for sale, and the de-recognition of a portion of goodwill.

Assets and liabilities held for sale associated with BEP include the following:

 

(dollars in millions)    September 30,
2013
 

Inventories

   $ 14.4   

Other current assets

     0.4   

Net property, plant and equipment

     2.6   

Other intangible assets, net

     7.0   
  

 

 

 
   $ 24.4   
  

 

 

 

Accrued expenses

   $ 1.8   

Accrued compensation and benefits

     0.8   
  

 

 

 
   $ 2.6   
  

 

 

 
   $ 21.8   
  

 

 

 

The company has agreed to provide contract manufacturing and other transition services to Boston Scientific for up to five years following the closing date. Due to the company’s continuing involvement in the operations of BEP, the criteria for reporting the results of BEP as a discontinued operation were not met.

XML 34 R11.htm IDEA: XBRL DOCUMENT v2.4.0.8
Income Taxes
9 Months Ended
Sep. 30, 2013
Income Taxes

5. Income Taxes

The effective tax rate for the quarter ended September 30, 2013 was approximately 22%, compared to approximately 27% for the prior year quarter. The effective tax rate for the quarter and nine months ended September 30, 2013 reflected the discrete tax effects of an IPR&D charge related to the acquisition of 3DT, which was incurred in a high tax jurisdiction, and a benefit associated with the remeasurement of an uncertain tax position as a result of the settlement of the Brachytherapy Matter. In addition, the effective tax rate for the nine months ended September 30, 2013 reflected the discrete tax effects of litigation charges, primarily related to product liability claims, which were substantially incurred in a low tax jurisdiction, and the write-down of an insurance receivable, which also was incurred in low tax jurisdiction. See Note 8 of the notes to condensed consolidated financial statements. The effective tax rate was also impacted by the American Taxpayer Relief Act of 2012, which was signed into law on January 2, 2013 and retroactively reinstated the research tax credit. Although the reinstatement of this tax credit is retroactive to January 1, 2012, the enactment of this legislation in 2013 precluded the company from recording the benefit in 2012. As a result, the company’s income tax provision was reduced by approximately $3.7 million during the nine months ended September 30, 2013 to recognize the 2012 benefit of this tax credit that would have been recorded in 2012. At September 30, 2013, the total amount of liability for unrecognized tax benefits related to federal, state and foreign taxes was $48.5 million (of which $40.4 million would impact the effective tax rate, if recognized) plus $6.3 million of accrued interest. At December 31, 2012, the liability for unrecognized tax benefits was $43.4 million plus $4.8 million of accrued interest. Depending upon the result of open tax examinations and/or the expiration of applicable statutes of limitation, the company believes it is reasonably possible that the total amount of unrecognized tax benefits may decrease by up to $18.4 million within the next 12 months.

XML 35 R9.htm IDEA: XBRL DOCUMENT v2.4.0.8
Restructuring
9 Months Ended
Sep. 30, 2013
Restructuring

3. Restructuring

During the fourth quarter of 2012, the company committed to a plan (the “2012 Restructuring Plan”) to improve its overall cost structure and enhance operational effectiveness. At September 30, 2013, the remaining liability related to the 2012 Restructuring Plan was $2.3 million. Cash payments of $14.1 million and a reversal of $1.4 million of previously accrued restructuring costs were made during the nine months ended September 30, 2013. The company expects activities under this plan to be substantially complete by the end of 2013.

XML 36 R41.htm IDEA: XBRL DOCUMENT v2.4.0.8
Share-Based Compensation Plans - Additional Information (Detail) (USD $)
In Millions, except Share data, unless otherwise specified
3 Months Ended 1 Months Ended 1 Months Ended 3 Months Ended
Sep. 30, 2013
CompensationPlan
Apr. 17, 2013
2012 Long Term Incentive Plan
Sep. 30, 2013
2012 Long Term Incentive Plan
Sep. 30, 2013
Directors Plan
Jul. 31, 2013
Management Stock Purchase Program
Jul. 31, 2012
Management Stock Purchase Program
Mar. 31, 2013
Performance Restricted Stock Units
Mar. 31, 2012
Performance Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Additional shares authorized   2,000,000            
Number of remaining shares that may be issued     5,710,855 39,843        
Number of employee stock purchase programs 2              
Awards requisite service period             3 years  
Fair value assumptions, risk-free interest rate         0.10% 0.16% 0.42% 0.41%
Fair value assumptions, dividend yield         0.80% 0.90% 0.81% 0.85%
Fair value assumptions, expected life in years         7 months 6 days 7 months 6 days 2 years 10 months 17 days 2 years 9 months 29 days
Number of shares granted in period         200,000 200,000    
Fair value per share of shares granted in period         $ 37.20 $ 38.33    
Fair value assumptions, expected volatility         15.00% 20.00%    
Unrecognized compensation expenses related to share-based payment arrangements $ 79.3              
Weighted-average period of recognizing unrecognized compensation expenses related to share-based compensation, in years 2 years              
XML 37 R28.htm IDEA: XBRL DOCUMENT v2.4.0.8
Assets and Liabilities Held for Sale Associated with Electrophysiology Division (Detail) (USD $)
Sep. 30, 2013
Dec. 31, 2012
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]    
Inventories $ 14,400,000  
Other current assets 400,000  
Net property, plant and equipment 2,600,000  
Other intangible assets, net 7,000,000  
Assets held for sale 24,400,000 0
Accrued expenses 1,800,000  
Accrued compensation and benefits 800,000  
Liabilities held for sale 2,600,000 0
Disposal Group, Including Discontinued Operation, Assets (Liabilities) Net, Total $ 21,800,000  
XML 38 R32.htm IDEA: XBRL DOCUMENT v2.4.0.8
Financial Instruments - Additional Information (Detail) (USD $)
1 Months Ended 9 Months Ended 9 Months Ended
Sep. 30, 2013
Dec. 31, 2012
Sep. 30, 2013
Fair Value, Inputs, Level 2
Dec. 31, 2012
Fair Value, Inputs, Level 2
Sep. 26, 2013
Five-Year Credit Facility Expiring In October 2016
Sep. 30, 2013
Five-Year Credit Facility Expiring In September 2018
Sep. 30, 2013
Fair Value, Measurements, Recurring
Fair Value, Inputs, Level 3
Dec. 31, 2012
Fair Value, Measurements, Recurring
Fair Value, Inputs, Level 3
Sep. 30, 2013
Interest rate swap contract
Sep. 30, 2013
Option currency contracts
Dec. 31, 2012
Option currency contracts
Derivative [Line Items]                      
Notional value of derivative contracts                 $ 250,000,000 $ 150,000,000 $ 128,100,000
Fixed-rate notes interest percentage                 2.875%    
Fixed-rate notes due date                 2016    
Fair value of contingent consideration             86,800,000 77,100,000      
Fair value of commercial paper borrowings 97,500,000 0                  
Line of credit facility, borrowing capacity         600,000,000 750,000,000          
Line of credit facility, term, in years         5 years            
Line of credit facility, expiration date         2016-10            
Line of credit facility, expiration date           Sep. 26, 2018          
Fair value of long-term debt     $ 1,454,200,000 $ 1,532,200,000              
ZIP 39 0001193125-13-409536-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-13-409536-xbrl.zip M4$L#!!0````(`*%I6$/)7\9+*-8``'%K"P`0`!P`8F-R+3(P,3,P.3,P+GAM M;%54"0`#'E5I4AY5:5)U>`L``00E#@``!#D!``#<75MSHTB6?M^(_0]:/VSL M1FS:Y!72T5437'L<4=WVNJIG>O;%@25L$RV#!Y`O\^OW).@*R$9((-S]T&4; MD/B^/'ENF7G.3W]Y?9R.GH,D#>/HRPD^U4Y&032.)V%T_^5DEB(_'8?AR2C- M_&CB3^,H^'+R%J0G?_GZ[__VTW\@-+J^'CEQ%`73:?`V^GT<3(/$SX+11:2> M&`=P<3Q[#*+L?T:W?AI,1G$T^MVZ_C8BIW@T>LBRI_.SLY>7E]-@G:\C^<_0] MCE*X^_')C]Y&YG0ZNE9/I:/K(`V2YV!R.O_0U]MD.@)2H_3+R1H^]>?3.+D_ M@Z^@9^&^_?/L^?@@>?51&`*)R[_M/RR?O_/0V?VY^X2P?!PTC MBA>/3(+5%^5OE`;CT_OX^0PNU-Q^.TXVWFN;SU2M,LLTWF@/G9\7%C5O#VEM%<6NXN#7-GI)ZE.J*>@V\^1ICD.@L M>:M_9GZQYNW'LR2!B;OMN?E5]2#9?#!X'3_4/Z2NU'Q3&#T':5;_2'&MYJ%H M]E@O@9,L.5,C<@9W!$DX7CX`4^_C9^((E9Z;9?J: M3EK,W>9JX:Q`!=]Y?AV_^=/L[5JIX7$<9<%K=JW>)XBG-U8:>85_L)#P&Y',>-6YU"4Y&3+23BYH9AHE),;(1PL*;60S9F.F&E92.I<(&%9U&.& MHV&/W%``,YS_[860# M(C"Y:H[^%B7!.$XFP<1\5-.]-=IZ?'-M?_/;=V<=)A+M<'*%4SOYBC6IY?_] M=-80UVIHW11FV(L3/,6I>LFG!$QJ_IB;9O!ZRIA?WGT+_=MP&F9O._)!>^># MW?"3KYR1!1^[0UQ1L^0O@Y_2<**\*^7;[,J!063.`9,4.-`DYJ(5!YHE*1$2 MD!-L(^8YKOI)0YJ-#;%_TP8A"#;E>%!V:$*$;(R=?YQ!@8([VI!Z+4)=7Q7B18 MLQ0"I32%@.0VC/*9M&6"F4GBPU]5#)9>JY\N[RYG&7C-0?HW?SH+_@IAS.XJ M=:Y.B.#TU1`:9[(!9[S"F31=)N%C$,-"0TQX.C*(HR&A@YIAS*24LT*=@-P8 M9<8.2\*'!%_#>-Q'X;^"R<5$*>\[4-?3P$S3($O-\3]G80)C%4T66CP,4K@& MWNG$">X"\+\G/_S7M8N_QE'AEN]JX8]!OPZ*C.D?\]\91]V-SF7V$"2K+RJ> M^`1#(DZ^,MGAB-3RLO),G##-HU'ESWIQH#/=(+G8!H_ MJ5FG9ED[S^5]8C_VUIL3:N3>^CP&:0FO.S&]B";!70BX@V_AL_HU`ST6+I\] M!*_*/]1U#!$2UU@3(]A2?*EBF]%@Z)EQ#.%9FH=TS=(5 M&0:RA+019JYN6`YGADV+V(<:RF63N,1&(T!'$`T5$PD.,9&FPPAV*BA8"4K9 MF=I+2OIE"&L4&YTR1/.IA#5!HJ7?_] MP4^"JR0<[ZIG*$37;-.\,%6G"3Q M"Z@IVW^"*RVRD9*((A-'=>-5IQKC391--=W`'5<'0DB\=_Y,*27LZR?"DO M"AIKA!J&C0P7K"YCX+M9TL;(E=C4J,Y!6NP;HMQI73>D1J3XZ:P9@)*C4;[S M`ARV8-(32LW5I$T8^*6N#BK/EB;\9'*DVQ+KG.M<.M8-OF%X'>8'K[Z)[RJ9 M9QCR^Z[\Y#+YGBD=F3L<5T&2/[HWW(]UVA[P*8PR7N%N!ND]&CH9Z=3+)D%K:'JRT7-K<-LSK*'.%%!R,"D5*O5N.^\_U:@GU1.Y2*5L@.DC^5T MJ.--Q=I:5S,`'TAV_V:FJ6B31@IXJY4I5C6*S`'XGE80!7=AEOYX\+._Q[/I MY.(1/([,O;L+QAEXJW!+BP7_=Z7]`]^;FF!P78\@BUH2,?`TD*0613JWA6MI MS-*P>Y/G29C&2D/>#EQ5%,(L7ZA04?)R/2ALD4QZEX7#:&E2T=)K*1^[Y?)& M^^Q$P].W(+@.BHO4WC,%\D@)^G0*UCM5Y'\G33D7H`W:73"]"E._>G/23Q[6DI> MOA*IW`"(T2Z?YAL:"CU=C,7:+.Y1ZVJ&E(10$V'#MA&S=!U9KN,AS2/4QE*Z MGN7=Y*O4Y?SD_C!+6@I\ZDR)Z#)OU1T/[:<7")+4RY.KYM5+,VLRR5.5_O3* M#R<7D>T_A9D_'1X^1E4JFE7VZ&P!4-$?:JT]O?+?E&(=KE4%D#JIR;?7O/TF MPER0#[/YIW.45`.4%)>]Q.T0M@8`EW<[S/7A$4%T4/[EU=RV\#9)N@XR/XR" MB>LGD9KU&P;E+AR'`Y0+QM3RMBS+Q<=0WLOLM%F_[F,.J*W[VY(Y]4O4$$9_ MCM"`J<41@U2U6#V"$M#I-'Y1![^\.''BV6UV-YLN%.!U,`["YT%K"=,[P\")C$`A!FP7&[P';FM,;T?,3]Z7[;D/:1;%UXIFT0C+`E M-<2X9B/3(QZBNJ9[%F:.I]&;?`\`APFX41Q/7L+I`$-NS%1*H7J.:/["K66\O%/ZUV"`TDT7.RC;27<- MQOJ4Q,K_@UL&J_U`$ABOI&[?P[")]B)ZAK_%R5N78]T:':AV2DEY[JZ_\Q8T M7AB%Z4,P45.B6+Z:5^OH,U'J6$P7ILN11D&,X6>&I&YP)(5T'.QR;$BW<%5` MNLM+D@V@E*/K+:EFF!3I`/.B6.U.Y+R<97D?QE;?;#F9!SM3=27+%;.\'<$6 MR;[V7W[Q(10+X74&+M@D+PY0SAI]C*2U_=HJ.X,T9*0FQW@@L`TUPR!U/@8# M3X56-FG-X>:N79^N3'NHRKYQHRP$VP"4_)3\SY\\T2YA#E1VX[1`5LZQIUD2 MCK-@4G_F:'@\T+IR$1_!^-@8#CHP4R?+M;)O]SZ*@ZR:MSPVV[D]P&IGX4$6 MS.O.N7:,NKT8R/HL91V&+HY$]I&A@HC5J*RJMC@.^3V\C\*[<`P6T'Y0Q2PN MHFW9>@C]_#2.(/1[NP*_6=F1><&A8#*O@U%\Q&]/($&6*J8XO.6)/)%5GA/= MDK`UQS78N$*M96B5P*+ZY@VR'+V&$,)V&#.09C#0B9K&D&53CC#`Y+;NV$RG M\P6JRJGTVG??$B[]/4[^6)9P&'B\A%6FLJP'&R"IW[/Z':Z%XR#?EF^I"JQJ M)T]T65[KZ(R"/3*K\U$)#H!P156M=KZ\ M6VZU2']699J#Y`=8WA\/21#\%_B:O7GA<^#X;^F5GV;.++"+PK?? MGP`T6/WK,/VC1S8-G;JNQPU$L0V:VS(DDO"H.I6/-6Z9F!N\,%-XF:;NAX05 MX;FI][;7NQEFZH.K0QF$K7'6`,<13N7T51U$STMGPK0L5_8:<.&+,D4=EP?1 M57D011'"U=,*GXFF;NN#Z'GI!Z")XH/*4IZ.FHU5[83H?NY[MF4"`P?D53<, M0S8I1UNGF"4V#*[T"JACIDL/2+!-9$J#>F#GF,?$JAI(VOD2@H3//#Y,],@VJ*`IG0A79IGF-+]")NE(O@`9^$X(Q58>- M2=J*&,ZEK0O.D$?!"6`:^,]2"`BM5?$O)E1XY12NLSJ74`X;F\`>&%%<;U=O ML1%1"PG"977S"8D"O=`=471>^1F7(XG=B6I>W+5]9?#W>(-_9#LK9E@.89*9 MB%(/PE:FNRK)BU3T$4 MJ)V^B*)S^U\^"G)PG@ZJY+L/1M[N7N@E6_&K#6)\!Z6]URY;^I M/^5+!+_.'F^#Y/)N7M'IV0^G*K'GQY$(L^PJ>)ZC\G8LW$:#+I<1! M'-L:A,&$(`.L'_R/FIX4F@%WK;JRZ%B#D&#]$'HW5'P*P@4U,.Z&\(5YI=)@ MM&^ZNZUA.J=^=84 MY:]Q49:A59.Q-=@K_[Y=L(RE="2,ONY@5<^7"B2)J2/B:`+^,[!F\F4'&+(2 M@0_PE*WB;;9*/"S.L*KB:T4=PJL@&<,%_WZ/X:_EH=R>8A_\FJJIJ!%#Y^MV MKRFP7J1`<-JN08%F.5Q2J2-;"H$8*%\+>.N/M>@NY4W\#6Z MD[>%9TPJJ;7/+W!MB6LD<$OBV)]0X-JM)S42.+JY(ODG$[AVQ#42N`5QS/CS M"1S#W0DGZ50^BK("YG; M4S]\3(LDS.X<`B=JZX].5'L3($W@"J.@U'35@!9OI)N_!??^]!<_`WGZ*"ME MFA*$ET`$:1I`*78-9)F@"ER+.+;K"<%=NDRGX*VI@QJ\*X6P2$)=)<%S&,_2 M*4CS-)C`S:JU3KXJ[;^DLQ85H(?&D3IV,I_PS4'W)4CER:AZ%QLX;\:^0=*- M0330:J^ZVF2E=TB9F"_7"X/O+EB]\W4,AA:+%SK9GK4;-$,&:'9#=,B0L3C* MP?:0H<.V!X>IU7-[\'E^MW(2C M93/-8CL+J%8N17G="-XF:..]\OC?+]\L5V^ M-,W!-OX!C-XUK#KYE M[1F:-XVC#?L\=MLTK@\)S[LCZ.5C$Y^A:5P?\T!MTI:$ES>U#[9I7!\24S2- MDQ6E.-RF<3VPDC>-TRM5/;MI&K=_][,^Y(1LM-/IJ>U9'TI!;;?BF%82*[VU M/>MC]``DKVPX[K7M60\H5=LSRDC9V`^L[5D?PZUO3-:!-CSK8W*KLOHZ+0M^ M_PW/^I#^(S4\ZT.>5<,S1FJJH!R[X5D/X)5+7]%I@VYXUD-4Q]9V$.X![*`- MS_J8XZK%:MZ7?\AF?[2':CAF>D.!YCE)>PCM_PK`_I MQLM."D=O>-:'53$0T[GAVB:UH!G6K208SR]OD^FU#M8SX:U9XNS(=D9>$\;A.J M/B:E:D)5K9-XG"94/>!5'E*UZ=#1FE#U(-CJ[`NN^/R[-J$Z8`NE/J1:M5#B ME;+HO;=0Z@.JTLZBXO<.I852#PS(C?3-T'HG]>'^K\I##*)W4A]2KR_*1K7M MG=2J'5`?R&1]#-]7.Z`^XK>3KZJ0UOX;NO?N3M,#6(CC=%IVKSYJ3G/X[BT] M.!JJ.IDLVZ&=N[<,?#CSMAD&TRM+@O5M,P[?FJ`/C%QM/UP6F!]@:P+2[UF+ M_&R2&GE4DW0:ZBF",D<=G[7(#V#F'.%JG=[/1%.WARUX?MA"K;>_MTEF=Y(Z M**Z^9&80Y?J+0+:RVV009>AW8ZKK>OU%+JOL&W]"HKJNUY^[+.59.,1R_>_3 MUGVY_ERB=+VLU8=:KG]%5U_EZBS2O8:ZI_+,A2HARW6X(Y1G M7@/=4WGF^:8[2G8JS[Q15FR6Y>RLU1/;(;--\,[ETS@5ZT6,=JCC1.&K7.(P M1!TI$<1&!%FJ^"1CNF4;FN?H'EM69>&EZFDU,`=`1L>UY!9%F@I..!23G1#3B9(ZV2DU1#NTB*F[(.X;<)T&PV_'( M$C4E,L!T*AN"L9!+:@3#6!ZB@!YE3+H.YLAP/`]$QM:05`LS5'@N=5UB"3&? M27D+KDVFW@'_KCNQ9!J>AS_>W;6?6DW+,:ZQL_S6@PA17AA9K;*^4WZQBO=( M]-3KFL:$--(T_\_>M38GCC/KOZ)BSVQEJL89W_`EV=DJ8V`F[\DDLPF[>][S M):78`GQ>8U.VR23[ZX\D`^8>,/B*YLL$@Z3N1U*KN]7=GE72PUKPR1#IO(X1 MB27ID3@QDC:!'YYTCRT!DYIK;J%LPX.6P9[G.--E%/[`:KZ?_BC>#L#J"9.&5VE:]OB'('Z? M5O'>2'[&.MC^3&9VC$J'ZF"[;SJ2^XU>`+TPCCT3#@!(W;/*./VDZ?'KXM.Y M+_:J.2[,7L[`2ZN!#H<@$&-G(^<*/R51EX]OHV?_@(P4D;Z99%;P?OU^3^!% M2=-,3NOP9*Z[*M?238'KZ(*!*<CKX(T=O3V@@8-M M5>A%=W!T@-5]&C*QM=@R'MK`!`_@YLX$G^_^]3DF>A-U">T&/K1L:EZ[\("B M7N\0W5&[';'35KEFQU`Y63%%3I-;/->5#+/5%"59-ULQT7V\U%!,Z!(IJ^B2 M>N&!"2,T\(,#/*"G`1>+O5L8#!`P+`NY9*UBBXE2M`CQ$HD)_6W?BOT73FA! M]]\(!EW\Y!`)>!*LITI-3/`6FM:)[KV-3[>4]Z24QAUP?RQ32@A9)R\^ MW<:PYTVG.%43>9TC%M56NE:7LHE_$)#(`!N]_C?*?3&3^R_Z3]=T<7']KM"5 MD#V-1TP6RZD!WY-RO(1QSR(G"3'9V^C:MO?B62ED]V$)\L?&O;=`TTI9(FN( M[(F+[ONS,AFSBI1MQYU@`=1ZBQ//J;[1P[RT7-\ZX&TP[S$F2YIBB#IGME1: M;KW-M7B^R34-M:UU%4/NFF*\67]UHVO;>?EU$%UC#LBG,0BC-Q=]:7PW'K[> MW'&]^Q]70!E'UZ#7^9\>=W/7[MSUKH#\X1IT[^]Z7-?X?G/[[RO0[_[[%>!)%[3%X\W_=JZ`@!\TIN/.4`)C%`!:7!)<_`I' MX^M?7C&7YG7GQV/RL7W]$3AD$8S&!$JL"F$-!$1#A#N*?OJ<13`%(Q0-L3Y. M=)8!^1+T?5+W(:Y^2:"?CN-X?3\8407FBK#_>?P>%I21]Y@3$^:FE!O\]5K_ MM"C:;(S6_4.[\\"9][>WQH]'W(F%*8;C$+T']"JHX)F4Q@^^-/#"P$>>&Y)W MP'J#^>S&&L)X?^*MA1\HF_8.Z?V9_/''!`;X M(<`''++ITP!\GI+PB,81HB\ND?A/E+KG?2>XXJC<85L2?,?GW3!_028+0R6D^_CZ:&T0!3Z6/+Z!?3['2ZW2U;*_+' MB]_,K<`E`Y@3T&A/$_BVT\4-DM]O,(!_/(*[R8AX)_U@W0[-888->WZ$5IY(,Q#"+' MOCP8?@P_AE]5\*NK M[0O@"W1<&MZ`5>/2&94ZBO<'`_C(G_'>&0\%DU[GR0$HOY@ZUC6N73;K;E<=BY$F%71+5"&,5+W^KHL3K",M M6XSJKD72[$#G95E@`[3PYJ%^X(_BQ]PS#&GMI]$8>2%-8,,]C%WHE=^W>OQ- M/A/J[T)43$Q7I2`J)E*@4A`)!4KT"GI>ZW,SR?!C^#'\JHO?>;@T2,;;],]$ M3=[@Z/B$^X!A.!F1&%:;JMF^5WL]6>/K?ZM\-$9R_0,VCL:(61/[K*,B4Q`J MJ"O7Z7Z3(<@09`A6'<%E"?N9EN=:?#"ME);41$U9Z&U;M;@[%+60A_I.9/IA M%/;(^*>O#B>H1J?=[BB34CM`U=5W6#+%S4'4X4NTLR_)P MO2'5]\>^1WW@?A]X*"*UXAS?=BQ`_-]8F\<_"2-`'.8PG%9["UE)-[K!,BWI MMJ/)J9ZSH7,=FM6^JFA)MR*P((7<$A*F%=WFGW-&B*W<\M7T*HC-O&NUL=FL MT&SF7)?MC(JQ,0IK0&'=XZP>4?#B6(A:C)^H,8EM2C0:N_X;BBOC!\XSO2+* MO\I)RBPYM:"0J/SX*^8F*R_^1+'PZC09,\A7(SJT+#+JANA!*(RHD,I="AU[ M&U;4I6H!C!83%YX[HX*4=96ATG":^>*MNWXU>\,F"%`T"3S@>S0PG43@H*AZ MA>,NE/3*U<2P7FJ5,?*#R/D'IH__*U`0 M%96HESNC8M:V0ED8%?C":R_GQ*E:J/E7P?"X^H2BGVH),M08:@RU\B:+E-<@ MO=L6+Y9.!71+7S1/KT+B1XYX5*(,2(YXB$7=IY06D&;6V>!UTT_K%/B=I];` M<&.X,=Q.H:<>E*"Q,[=B.2%C-9>C!4.L-J9.OYAX3MS*"7U9%-2G/Q_;3U@; M?8K3E!O`1I8S@FY(X^!6DS7:74UJJBJGF9K)R7I3X5JRHG)JJZMWNEI;DI7V MD_0D"(W?^4M12SC?R,2VQ)/[:(B"-E:07R"I/Q3>^5$;A7CNR4N`C/`;L@>X MKQLOC(+)B"1A/$;X&_K7?;_K>-"S'.CBH?I^@#5S"QF>G3SV0X>X6V_).X7P M_QFEM714S3";JL(I9J?-R0HO<2U1D;F.*+=:JB)TVI)8NK06=XH)362'(W\R M37`90,<+R;V9/9\4X"3P8RTDPCW8\SDB.2_#>):6?E>[=!@M73:,P/,ITF$4 MX?!T&'%'D]E/3MOMJ9ZSH7,=^GQS%0(LBFCLJK1C2VZ73$<)8"H_U@QZK+,@[&?J*#[V$A@=D M^0//^0&*VUI[7N M<09=/_@)`QM8DR!`GO46YQ)"*PYZ#R?C3?>>S0_7X*_.0^_&-&XYX_;FZ]T5 MF)%^8<0R!C?-WL#;P]U_6@MW$3KJ@DX(O(C?([H0F8Q>2>`&^I0\\5"^B5&; M[G[WNVY>:;A^_9QX4?'Y*)^4PEP488840RH'<93V%:)9![M4*;:CB&.C[O?2 M#$&&($.PZ@B^$UVR2M6Z;V0:G7T-;F_N.MRWSLW7;SWJ7IAKPHGB_/=-N_>- MJ,`?UM3DBE6:I'?K2\??=G-LH8;A[)AV43^:'TPG,)'V6^:4F%4*>D,4HL60 MB[GY!D9.Y`Q@A'!/UA!Z`T0=0=AF(3U.$(G9"-`(P7`2(!OT_0#AKA,[T)Z] M&Q;9N`>'N,5(15/HO0'7AUX(8!37G*&3&OF+@ZQVACM`K_'W(,`]AI<'+^5= M@5(%Q@)M"T]Z0"_(FZ"P&_BCSBO&SH.N.0FQU$!!B+N_];W!+:85DT<2S%MO M7Y$_P!KP_,P)%(':0HP7F]3A,'S&QC,$<6]!&A`8Y8"5(.( MHEP+["K:X:$_4G%!,&QH%OJSJ>VY%MBM1$P`*[5;EHM.=K-;=X;9#%=!BIQC M(5Y&:^UIK?MM^I^>0U);J'^A,H5XFSQ?T'NE\^=5UHJO2)47K\(G65?.B5M% MKT89S+)(J\XD\,>(#);&B0V+C?,Y\%A;7R^"4GAYV/R9YK7"J__FSK34/*(: M:F69EO6L17_=E;E_0:P'5TZNR154<([F62B\>'O^HEP\PXD61#'KZJ/U4O'B M&.7SU/!T]?RD@E94&;T">18UX?R46K$IL_)OAX7AU:?X*<./X\^C6_IBP6I3JT(UV&*PP392,>I0^;$1/XEXY13S_HHJH"/HS:Q=I773*NN4 M3L(09`@R!*N.($L**S0I;.8VW;9.-N9QM=#`\;RX%BX@49J?,)E!!/$G-$(! MR5_"/8U@\!\4T:#`^.Z>5LMU/,N=V+3H($V-F8*->S&O_84:%?A!F]"3),9, MTV(NP8_`\0/PAF`P+^D[A"\(/"/DX1]9+@Q#I^_@,2(?]V#Y'DF5(EE?9,`X MS2N*VX\#%.(/-#GGM&E>I\ZIVEU"N^VX$Q++5>XBVB(MHJUN+Z(]96-;GIIA M69/1Q"6)`*'Y'TS+RBN+'KKAYDEHZD=U3":$B>T59F335W@#+TI MC:UR#KK("'BS$X`^Y[?@3=T_)9K3RC?0Z%8K-@&(4UH+#N(:4EP@70OJPQ(]YK.>TF4/"I9"6K_P"A8Z: M.%Y)'U)4YJF[4)3TD8`[&:M>L*CT7K#H;A<&(J6=%CR"<1&>HU,=LSF*UA9" MLZ"KW]P9O1"/B`[,92L?RV'BTY93STT-YEG0TY]*.4BV8C6M7;*N!U_!Q3CP M7QSR9G4BV:C]BD5;[,Z-_!T>7=Q^#X%8?,A];M(FO5QEPJ8RPH:AD.EB+S`P M:L\6J]*YWD&Z##6&&D.MS*A5S_I^-U4SE?7]"7@H`GX?=Q+!U[2%A]Q#XI-) MIX=&)1][\F;^3HRJ`I.[M5]Z1$JIJI8>M0M1R&@=,=VV7"#R?N"/]@RJG;M@:ZKL7AQQW4PQ2>-]?D[S7II*P*FE5U'J"4@!86;,?<),VE(,R%!CJ)4%M3JX3W9=%CYLNP,D-X`U M55\O^/064RWU#::VID&MJ"#PT@-3YX*R93BS2G=(,M08:@RU,J-6/1?N41%N M-55%6_(B'JJ3+Y`X1$=Y?&MIVZ9C\)*E@*%?AY_5R$>]3`+%FFO?%$:IW MG=0JZ8CHR9IJW(+$-.Y8XQ:**+I3$5=&F4HZ9KZ"CK^+RSC(I:K`U.X88M%U M1:`F9'V(5T_?/=,RE*5?JECBY5JIO/2`,(G'4*O\YJN'#[T^E\4,-88:0ZW, MJ-7!!\(*:QYELV5.."-AT63%-I@V>4!ODC[B"3KD6ZU]-4\\Z?Z$.7A)67S/3-7C,QJZU MR&,'12JM16+>IU5`V)WA.5AG##6&&D.MS*A5SW_"JFFN^418Z1VFI!Z+FE+7 MI)WC@6'5-,_J2&2H,=08:F5&K0XN7%9?LX"BF>=:O4QW!AN#+?B1SQ,`?T<03S&#JI:][W>_?<-BO$UN+VYZW#? M.C=?O_7H03/7&RDG/'GP]TV[]XVHC!_F7\XZ%!?4V.W<4?)62#+O;V^-'X]8 MQ%N^Z\)QB-[39]>=O7Y@H^!+@V\`"[FD%J?E>(/YYS&T[=GGGXX=#;\T!)[_ ML'2C@LS;RA_F9Z*+^]$B<%N'9MDYH^]5&-[&[EV8K`Q@@?%Q&<5BO M36)U_0#W0W*=<2M@38(`>=8;B`+HA2Z-?`#0_K])&(V0%UT>O"+J-P7/*:;@ M$2%PYT<(*#2`9$CG`+,8^1@"ST9>B&S<%?Z;[@X:,=UW/&P=.=#%Z.$'!/Z0 MX3_/6S@(_]X0A8C>@O@>P9%N`\>SW`G9`HY'IH3B/QI/HGC1XWDB\3YC%#B^ M[5CX#X]&P5M^&%V"^80*_-*,XDX6YS2+&?UL.R_DXV^?)R$W@'!\]6@-D3UQ MT7W?2"+NZ<6/N7CO$\N!6S\,>Z3+'GJ-6JYO_>=WW#'X;=;9W[3.,+*-%Q3` M`;J;$*O\OM]VW`E^^CC$R(7WDPASX)$I)AQ&N*<'U/_20+[[]*,CJI+,X7^" M)/#<'SPO-)\>>^TG_/B)V/.\+O%/>%U,/"=N%=(^&\!&EC.";OBEP34;P+&_ M-!S[21)$7FJ*3[+)M[565^4$H2-SLB&W.%W1.IS>;K8U25!,L\4_24_-QN\: M;D'^)?@_L=2\\;"\'-%U\H!>D#=!W<`?=5XC%'C0-;&P MQ$`'8>OM1^#;$RL*#<]^1,&+8Z%P#GMZY%:@:8MM76LU14X5-963A9;":;)A M`V1WA=#%O3R_D>.(``4&@3\9`PLOX($?O)%M>K5VJF^DF5_0(+;24#&M M01<3^6=A88&"70)TVDC1/NQMF\[:2-N;G.HY&SK7H8]V%&M;_<1'V4M[N^S> MLR.BJ8-]#>%Y<7QET]XAO3^3/_Z8P``_!!U\4MOT:0`^3TF8.Z.!Q'^BU#WO M.\$51^7.\5!"PG=\0`W#Y'/.6+$UW!!WSM;\=J0^R_-=AL5S8YC-=T8KH_7TFZ?DT;%_P=":X'V[9@-F.67D MRY17HB*O%W1=7@2O8M8!B*7A51&;!=6)*(!724K_UO83!)96+DSJSP`+S\%; M[C+JZ!!\_8CXC:(6]=%,:UKZ]W-5E>FF*F==SK2$3"MB->18>=6O>\^JIF@3 MA6;U=).CF>:EZBF?QS*M2,KY'6(*GWE4;KU4M,=),'`LZ(+',2(7_)&3]L4` M1:HNPAFJ+@*OGM_^EII:^JIIE64:VYU:%81:B?4U$E-4.;DF\EG/>REY/CNI MID@%97(7R;-NO`9\=UR%W)=P3#28#L>SPP24%V MO$$+ALY*HN+),N9D0U8Z[9;&"2;?Y635E#A-T#5.DY2V*G8U7C<[Y*AR?="3O:G.IY<6.SY)UW,ATV M5SRC7R?956>7_]%&UBHHP@906([(WE<&+)?AI.ZV\E[.=OW@)PSLI(0+T98" MB-6T5/KL,=IW2E^$4+V8NM2<5B)RM"Q+^WY,2[*48&4?'6YT?G$W1[QGFT7= MD&%NB)J$P@@$,,(FTD\XGF^`RJU__?Q"<00IW[<^'>3\.8%79H_R4=LJ+1GS MPG(E*R,E-W['(^Q11>I]SK;YPVZ\%_RM'[R9]%2+,G)U"5U#;NM:E]/T)BD. M938)PTVNI70Z+5/3=5GDWW5UC6`P<#P.B[XKA;AWII_CA7M%/3Z$6,XA9<^B M*^+Z(M=77.C\@ZX$^CW]W(?8[GF[6A&%B9R+$7&(1PO;1DY(7QS>W^&,6AB% M>.`6Z.23CPF9>_NA#O$5+;B8MKBO9G_L1&$5LGR<4'IQ/JC,A]ZF%^PY"44[ MH/;WH,P8BU?B;+UC&X.?^6-F'IHZN*"RQZ5<3JA3+M=\7%"+,W+JM5%I6M>F M>,WF.'#24UCITT.1E$:E6X$8'O_/WK7VN&TK[>\%\A^((`=(@;7C^]K)Z0$V M7F^S>-,V9Y.W_1AH)=KF&UER16DO_?7O#*F;;L4]2LECS,[&:^;([[1'6.3!'(K! M0KIR-M]NC5*RG^IL].VT5*!\/+LTL.73AQT633G`N=Y;_#4`;@V(!9[[+J/#',?NZRL][,5>KXYD(O5;-YW=S6[60]S%86FLXP)92M?/%J MI^[*3BU)L3DYDI/462IO7%L4CXAL;8^OK$9E;@+>[&U(F^77C.NFC?&OTP=E M^IW^36_T<=#HML;#1N_C]:AQ==WM-CKC_L=1Y^/UL#,<[<<_'H:LVU/0C;$> ML:\Y:)(0&Q(#1X`?[7R^2!0>G%P\AC_?^+=639[TN6;-*+F&%-.09CT3L5&-V[&N31RJ&3#!P.C:#RKC4%.?TZ59!K$%">;53Q'[ MA3PR=[Y&^F:NAZ^)JZ7FU%Q"J8:G4\+@=?JT%`;]2EQ2M''E%PU0%#R#J>GI MKB>2`7B3!!J%_2`O1Q+7-,VH11W-!&#LZ913%Z^+"=^`0N3M3<2#5:]C M/B.%'5S`#*]U8AX*%X&?P$`B MCQH*\:;=;S5;P9ZZ^.1-&V8![>C1UDN.\0LH)C'R(&(-%Z!(OJ0ZVK;YW$2V M'YEZ#A[(0@QP51[GTCH<.@/I19I`9&>K+40M`09&U%FB=`%^03A%;/!VJTB, M=M*]9=MOMH)"7^$=SXZQ6CNVAEQ9E@=OW]&E[;B8@@#M64`O:?Q/<[<^FH'' M$QXB)-O63"O M#ZZK2[\X\-Z_5IW/*?5]J,;]]*%SSNP9]@[([.FW]R=57&[YQ'^E6-7GFR[D0*=,3XQYL8\>Y<.&R32C-K!TZ7RB3X@E3/7B0_`G?PC>;B!/!\B=P`.SIRLW+FV![TZZN<_[R[=\F.U"VB4];[Z'B%7QF.WM]W?KQ/?\GKV/`RRG3HADFW MH.OK*@!-YM>+J_%H?_=6IP.H%8+E&)/*LF`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`FU?,<37L3S!\WI478]6[/=<<<440SP[C!57 M'']37''%%:]>W]W1%'YG%B6_P1I_SDO'%U>H*HNO!6>X\`;GS2.O-%B*45Y> MOW..C/+:RGI6R!0NH6*9[[4+>HQ1'Q@#ZQ44$RRBI:TJM50QT$M!V%4,=,5` MW\V@*^5=SK#)]6&G'\'CJ00[/?,,L;KQ@MX5,OC'!\+_I M%$=]5U6KJE755:WZ?%FD\9R'[60ZO[)[_-GGKH#_CQ:S?5BYFO:;WPGQ7-T].!G_E74RQQK/3T?61%&$6PO;\ MJ#`Q(?JR;'D?>>1N1"+()`Z%XYF9H#(\Y;FSL@*5@#(K85*2TJO2:T7T6GB# MRW`MC=)KZ?6J4@)+,;TY]\0WA:9"LP:REE_"$LE:]V376QR_:3S_T-'P>VM1RWSM5J72U8S38 MK>?-89W";P[+JZ5'=,&*M?3M$=VRS+9Z1!>LF@:/Z):'I[J7C'=>V'M'R+P^ M MZ2@'+/S'%A;%UD20&+5B-R>ZEZCM/45-R47)+#Z456I)V*"TA!(8T4"*B>98 MX-7Y6G.+#C06W0N+U6B-*>3%0J?(Y.?1@12)<;W!BGY<]P8KFNHY4KJ4K$K6 MNM/ZMM]AP;WE2H-][]/_UP?RY^3NV^WXZG/CZO/MK[^_)X'H;Z^DCX%/LU_@ M[;!K>]H5[LKQ]:MW#[YE8B$>(S7XS,&+Z(E%\V5$)K$N=B-ZI)P2$!$_HEU4 M&!][)Y6P"`J,0DHA52):53=KNFHMZ54JO+AS>%$AJ!!4"%8=P5U)`JE[(_YQ M_1_(Y]O?)XU/D]M?/WT3VPOA3#B:./]U>_WM$TZ!_[4Q32XHM.ZOK0Z+K:\, M?^G+L?`PS"@:;]*I&PY,)U@B[6;F0IAU";[-*8^?CQHMW\B"N6RFN7ADJC[7 MK!D5&T%XG.J#."'5GA*'+JC&/8<:9&H[%(J.UH$&M>P%$U2-5^*Z=.K`\@;6 MV<_$M#4\IM5U'7;O2:6Z=KR2]<*@`/HD_TXP:XPW#S?E%;[+\.CHZOJ%:`Q_ MOH%V6SK33'(;8Z;\%F"EN>0&3YK]4^)H$8W<46PKF!D4\U'C3,;\6.(*.+$I M@VR9.S?1R;B,@VZGS)(4'+0'^L1;<\TR#WHBNH4C,H`]4(9 M'#H3T:"UG%.7V`Y9:@S_1,#@+#ZE#N!@,NV>F0MP2Q\5+82%0M^,RG8$]@F:DP!Y'QI%H MB/@V)FE,+.@Q4$KLI."9QPS0-L#`T>@8ARX%+7'G#J4-DSY0D\P9=31'GS^3 MQSG3YT**)[9@_U`)(-8,W28I82BG/Y!X"S`&@:Q.'5=#QQ-VW-@IT<(*."HMUH%C!B`Z ML!-T8'*/W;<&O+-#!\?+P0&\L\MM)+(4OE*[0*Y4]G57/LJ<=5@M/=0?(P:< M7;#Q&H;<-5#:":"H@&0YPD-5DO6\0UE5N(X]\ZM/2]32(O>WU4W9.7$[DA1_ M\,WH19GXL4W._,JZNCOVX$P>L7=$\*`A4MGSA4;-X;G9?[N;]7DF9RFV(S05`H>[A@(] M=#F@--Q1@A\Y@V:)9!;XW*&F2&D$Z#3];X]Q)C%^!"3>#`?-8;#<$:B_N;QL MMJ,GN*F9O!86JU_Q2>*J4*P#+U"KH#K<_#>?FYMM01FVF%W"EA^:#=3)>+)2 MNR=2Z7#YE*"CIU4=Q2@(Z5MG&25>[1$:L&PW)3P@A"U/'T'5[L:".:-%2 M6X)>[VW'$=NL(JWWS>BRV=_#6)=+QWYB"]D=YN@7'.<9C2[:Q`9O@QK7Y]3P3.D+ MZ-.2.2(F\8?NVB`7BC*0&_E"!+$]S2S=]`R,.5C"YT+I&@]]D#:;.13#>!C7 ML##@8?I9UT)Y4A+M08-A0`X:4>=\46P;7%&_%?=-(E#G@F0\P`L@D"$:$9B1 MF=\&B@,2,#,%`E]NB]2B49>F);X'F/5 M-46`"W@DQB+^@Q]-IS#JR5@:_AZ,P2Q]L2"0B7DH$P/3;]H7O7ZOV8E071FK MVQ?];J?9B7G`%$7XF]7[#=<)@S5VP1`/.5X;5#/!]O_V;)=R8>K^O,]\;CCB M/1^?<$""0D#-C@_,0F.8AQKBX('!"5A]'Y/2^>Q[$PD$POX^KZDB96[069L; M0"D'SPXR&;['MH6[[G+F1NX8_U&R`?I*U^61&C+V+J9E]YJ)G9@'7H9PL`<1 MP9VAEBU4><-WIX*M,0>#<>Q5-EG8\"K:&]8C*!V^^KE'Y1*"PA?V`I8-\'_#G_;"@#?Q''M)_9DD M11O`NF!VO-DZ>#L(WXH_.DP:.7IO,'B01_ATTZ1BY4(<4!I(/4FH.%K3@*<' MN;D84!.*#R7$R#=V$>Z9TGE#J>?"!)7`.,IL8TWQ<^C#F*\`\("I&2MK!`-Q.B68)\`Y->EAO#>PKCW?$%^=2B4)]#X`G;MS303A\'M M\\^+5'^6)";Z;(N*45A#:H'H9!>2/Q&7.$5>@;)036!6\2-QEAJ,00;R2\!2 M7.$3P7"Z@SY,GYZ#8VY0*;4YZ"97PL%@>`#AH%L@X2#SNA7AX(70>C"TB@=1 M-#WF#S83M0)::9K:RSHB5R\J@IB>5R[L"O;I-2XYGS%T6:-HE.PI@O8LD MI=N&6:U)\&>1WWMPA?DNW\X/OV(F*#OK$?XRM2TW*7W8=]6IJL;O]JGKP+71 M('/N:F6A:7>R7E'4S2_7Z>`%A>!I??,&9_>=P1[PUW^_\WACIFG+]R'S+D:\ MNV9<-VVDW7VC3^Y'T]9__`<*(/\./OKJPJ,[NO0YYF`6,7@.*.:.3G]Y36WS^Y=)Y[+;:\!_[6Z[U?AOJ]7N?__Z[?H[ M//Z.X<;6J-OZWGI-/(O)K[@HZ#4QJ,X6FLE_>=WHOR;,^.4U,[YWVYU6M]^! MKR]O)L/Q=:/;N_[8Z`U:UXWA:-QM=,:3T>ARW.T.>C??VU#N?_H=H84(@WV: MLP:$3TS[8SK6^/S&M!\_46-&^:VD%!BWUI6N>PM/D&C$R79C>[%TZ)Q:G#U0 M>U3ZO?W#R_WBHLO5JKH> MK=CON8K.OW!]`%ZE\>XMCC`BYAJ+.T?7:D0BQJ_=D.>PKGZS,GBM_4V.922J M*\KI"J@UB#MP(>>V\/=%<_9)9KGP)6Y17W M-07_/AH27I\2TTK(@R3Y7S6C<%3V7='+1`IJ9MZ7Q"A+.!-+4.3(`KM0^27, MV"U4#@]%8CWO,[;>'L&.^CD/6;;1FRI#T.O M46+3RIRI4[")0=O4BUQ7G\/:6LU1-0SZV(:^/8+GDOF@D.`TT6.* M0"/Z1Y*76ZPURJ?I+T6>]%=!2E!]J(:G,D&%VD%?*'LNJ6;."S5%.#YRB7'$ M"B,_OG&N>!0S`\\5=>C%?L]5UPQQ1#/#F/%%?/(*PV68I27U^^<(Z.\MK*>%3*%2ZA8YGOM M@AYCU`"K! M3L\\0ZQNO)SZ\%(5?F7#3^DH=QV5H1&E0TTQUH]:,V-6`Y8#[]M#/%_>?R`5_%X<.8_C?(.S?^C[=O3[5%LP\_G]VH(D;A'W M^/-EDP1@,"IWO>]#'Y)X"GY,HD&*0`A?@UD&%/L>KQ(X0,"84*@0SC@>^V]/ MMQS/'ZL%;S2(R=F*?HW$#*%(-W:9=['/Y>RQG(J4=(W@AZTHK$.V?]+%96?_ MI(M1<3D#F5>=-H?<40E%\P-W9SP%#9.6&-A[N]EJ!?RIP.N'B(L.'[(S(TE\ MFF:,PEDZ&F'VN%Q3?1V6=@(L.1'+3FFN^=#*XAHI(+A37EDW5+RQ,[BGT@\( MK/N#HDFGKN@*&"F/#]Z-X.$!(_@-LQB'N9P,;AXT=2V"%S(:I1`GUK8O,@S* MYM?67LI6ULG:>J0?*YE)_V4[/]!;+AU;I[QZ')%.-V6CN<2V?70L?Y2R/9F= MC=?,D=]IC[#(@SD4T\SJV7R[-4JA^M79Z-N]YK!`SRX-;/GTH9R;\OX:0&RJ MX`+@*6D!<-I=MQ-7F>^RZCPQS'[NLK/>S-70W^9"K^B8:+>;=LESUEZV_-!T MABET0N6+5SMU5W9J&8C(R9&>/:HKAW*&E;E&=P4VC-^I=-D:3RT[CNM.[N>FW M1^/)Z.4+G;..$W6;9`4D@7@I(D7R/F]Q\_/4]AQW3O[VK["SIV)G]D+\3;<7 M2\W"#(_%@KD83')MHI&EJ>$]T6_Q%=_XX)NQR!5>;3'Y`J]&KUQ_^!E+8(NE M8S]0PO`^ZP?J:*8)Q>G(ZP^^I>)F:FK--4NGQ%["2YATHIF$3J<438Q:E/,F MN7)?Q4Y)6-F'%SOOLB$.76C,0H%,IMTSD[G/\$S8*PH$K_@[T@GBDT>-DS>= M9C?8\&T2C+*2I?8LK]@&R-[`VJ$-1?AOR!N[H09H'`>9Q1O-7OAG^'T)?V2V MQ\UGHNFZXU$#/G=6*D=`.'FD`,9",R@Q(J59>&S$0AX;0?'8B.T@-,5]XH$V MZ=,2$.10;]!3B0=E.%`RXU`0JA=1N:>$>_?VYRA704'$V5T_7SO>CCZ>'4];EQ?M:X;O4ZOW1B.N_U&IW_= M'D\&@_%XE9?0J[ODCSHIL+?EZ+BTR/&6 M./>IGJNJ5=6JZKI5?;YG1L5/.-Q^=$Y\!>"?5!?*%,Y-Q!L1&2*8?ZRM$%Y2 M>TRHLN(68M7NO026/&?P'9XY&$F3=/BF'?O[UT=MN1]JE4!J?9MK$[D0-OPA MOIOWUZ?;_V?O6G_;QI7]]P/T?Q""+9`%(J_U\*L]7<"O[.;>GC:GR=[]&#`2 M'7./+'E%*:W/7W]G*,F2XSAQY,AZA`L4&\L6.?/C<#@DYW$]5:\NAV.8;YFX M@5VY')^$][/GWJG7U,]D=9S06R&^FV>!A7OQU$;%E"L\>Q6J3ZE8YQQ,!_"Q M;*B['=T:-.^>S]28DA"E;)0XOC$1E((G-7=14B#33=Y5,`6I'%>II;B:9$LP&T5I_""M':]-36%[A^TVRV89\$F=,# MCJ?EZT])XE:!3)WB$[;91)\6E].]FJM(:E/\,G^B8B,OJT=))IH[*U*MDM,> M,H)&_G2I51Y!O>@LL)49P0.F8,TX/3U@6E995@^8@G4;P0.F9?[$]A7+,E?: M[PZ@^:'EV/3,5Z^E$21N4O*DY%4"-XF@1+!L!"O!10UQDP@^@^`!F3J/$L&T M&3[UA088N7;I>_?,IO9H]0?'W*!?H^@Z]RZ-Q,H?^12Z+'J+<<_4M=[-'U>3 M$\6F%EL0AW\Z48VMZ*C)J-\]'[7/U5Y[U%--7>^KH^Y@K&KFM-;?8:#;LE^'?$R#1I79*;,Q52K3XF:)N MQ$O."5=`X\RAI8#\4/\.00O-&(:SN9B/P%T_.,-/XE"=W8880PUR'W5X&W4( M+2SC+C'(DF-P*@F4P+NC`E,+HV$5B_H!82ZH+&`Y8);H!^8^!=T'+=#%TO%6 ME'(1UU=^<]DB>[LG;!SCA>K_VM%>FDGG%2/PY" M4G*KY\18$IO2);5);$I'U&JX437`*4U26/STJ+BSW%6TO14[QC.QF80]9;*[ M5M;[>)RO6QN\BE[T]TIW:2B:O[(=Q(KE3]=+JI-X-`;;.W(LOQJ#KZ.UJJ*C M$D]7H:2.KH4.]=/=52JA5^-9#(9S3H'Y%$4Z[%7?9?@4&]68SJ`V:/H1:+_]*E-_3MW9FU7#A^0'[ M;YISK4Z*R-A1;*MQ2[!>]%ZA*HQJ[?R:MUZ<]DK=_E4L(N&AOGO,=TU+*K8\ M!G\1SG*Y.SR&0$G4)&H2M:)0:_J&],LN?[%\)J"SF7?UD7O!G8O#D*AU[6?4IE`>D4'=7=-/NT2=$.39Z!A!\V-Q)K8'O;N>B!*)@SFP_A:S,3V_LMQL<4Z)$\PM#'18 M1WR(FDQL%M=?"GU1.TW$E)`[JM`?%ET&&$BB$/C9@N'5C!L*%UQOAL\7\%<: M78+'I%S4!(NN;1B6"9MAI3#[;-,[1H1;B!)E&"FSIL:/"+%"WZ=V5()L(V(C M_F44L2&*K+5;VD8)-7B@OTNKJB'I6&DJKE47ESY[JO"9:$74LWLGJJLMH])Q MSFI/YJP=_]X0-HF8=NS8RN(,&_HVF8`W)3X6!&/ M7U+_:DZ*B'#K#N?#8;=O]L?5B'`S6TJ" M!@ZA,O86,)Z*@$4,P>W:Y"H[EFV#3HX$*J>Q>(D:C-/+J_0CUEMD4817B+,] M*?.'$S/X[JF60SA7%C28>_`E3TM"8MA45()0`!'UPUP1@(I37D94B16QT(@J MH[S8(MEU(5W+N)2:1E25BPK&5BEQ2-4&WX\5^HB@6Q,LZWX<90`K%Z!3.L.R MVD/3&:YW,!;NOH19^Z;BLB2MC:>UZ9>XL,%5OH0+S.[C^=O[T,*=]\KZG:19 MTOQ*D[LJ4QG],5A4(?G8TSBO0X51NJ/FL5C5],&;R7"NZV^&5;.M%1VKUG0+ MY#/E_(,2E78'@!W,O$AM)?#2'&N8>%#AU`I]D7GP^%;*H0[II0=N'IUEO?2H MBJ.S7,,2%H>RW"LZ?+5I_EW-\6Z6^$G\)'[UQ:^I>U^%W!/F"/<&,"&S'A=S MS[&IG]-Z=*H?G5"6E5E]:#2]6U)&D>IC`YOU&@0ME`*-,3"+/I]JFGW;)+]H MB:!$4")8=P2;?GR*%[@3ZGH+YAYPA7O$Q;C,WTD>)8]ET][D;?B?%(UGK.43 M1TEE]]]<\<*`!\3%&(#JJZE#C\9K$1U?+D;]LG)OU0BCWJ#Y1Q>O($>U2(-< M72MRPIP0(R8W0]3HWR$#FD2!L)GO+:+':E0*+5OH#%I8KHN^-5FK:U*I/P]1 M.3Y=M8*H'$^!6D&DE:C1:WCRVIR;28F?Q$_B5U_\WL:1!D:\Q7^F9O(C!QV8 MH(1P'B[0A]469G;>)-DU6K[[[>;?*A^,45GU7.J$D=Q-["-'988@U-!6;M+] MID10(B@1K#N"S^1@W$Y:MS/=W&96NBMK3NW0H5]G$\:7'B?.;[X7+OF%:SDA MFJ>8UP[6*^:&U/ZZQ#!P3-P016-=!22(DN`1!Y,?7LTI#8:N/;1MAC\C3IH5 MC[]^OKM.VQ@-VJ.AJ@][7=7LM#OJ2!M-U([>'4['[;XV..^\+-]=P4DKAZ(2 M5YPWDMPR1T2K*7/JV"*[(:"/.1VY9S$1XO:=!7-E-+U$SV48#9%&+ILO[@VG MA>OV/V%0TR_\+MQ[P-_SRPBG MS>O%;Q;M+="LDZLH=;+(%PP;V9J6B6S78\RK.]%%E1;?`],N6)V)6_I`6"AX M:+E$XZYV(E%X4>^FBT2D&)@;$/>.W48V*>B&,TS@73MI*+SF2M,.O^1%TTN6 MZ[U'S:E\.)M>KOU4PZG2W!.FYBUJ0\OR0PIVS0_T2LR[JZG^+-;JX>I:-;'( M>JL*^S^WSP70\-;2>>CXR M.JHY'HS5X;`[4D>F-NX;IF'V],F+[K7;Q91QT[26D@4I'G[@;/!1W!_Q8'U^ MG-Z[E5W1+5L"TJ?+T+?F(ER-+)>^]X,M0'"?]3QS`R!0R9^Z!885RE\-T_GBR@&)6,PWJ.2Y_>,R_D0`QQ72\$*8Y+ M:+S[1X9PA83!W//9?R/QWZYG>*S*?IEJG&.`%Z0"RR;>TR1S[^EGC\)N!#;6XHJGM#7.7-!L3#B1'M(&!^1A/@* MO;J);W-EY,'_E+N0V:(N:#`G`0P;Z!$4H6RK@?<.*Y!2CK=PF:)_"KGU0GQ' ME`UD,V;%C^V_PFAF14&7\#:QK'`1.L)IQ(MN]3:&`!0=;RE_Q.4(&5^3=197 M)TQHBH04Z$@&?E%CS^'W/10;PUWM0HT0QHCA1`@X- M<`_DF>XKO07[Z0@5,2?N752MYCE^XKR"I\C7S\KM:@,/#),E//;9X6_88R=7 M(_H@[J(KW](60%PSSV?PI0)S7Y;->SI_[+`KE5H:3 M%#:`PJ9?1<>'4@KL""?4>G@4H(FC`&W+DB]FW',>YIYJ^7U%?CZ&/.>MUU1X M7I'2!Z[=S9]=ILI#=]KMYK^->Y*Q^GD\&,^[?3]UA$%G8/UNG3P=[!Q>S%*T M)0B=THL&'HG14]VL^%0^E,/T2L',/38-&&=MD']5.H)F*]?2>DK779,?RNG2 M]^X9!P7V<^+4!:K-28H([C[1A??W4(@\7#YVZ=YY_U'YO^FWZXOQ\+,Z_'SQ MVYA]9?;5ZJN?7JU+9U$;92!0*%?82?53V?..A=FZV"Z1$ M3:(F4:LR:O7;?>\1=)UC]RW"+R/GHX#\.$H`"S9Z['`$HPZ)`H'I!>7MFV-5DZ)FD1-HE9EU)I^_CKU_@$[KYRB:#5>%`LO+%^_XY'G+NS6]W7*:7Q? M]W/VPFYG,,J[YP-A-DY:&KJFM.N0$5^N"G5![53/'[;=R%.GTP.2/LCCDQIM MSB1J$C6)6I51:\+QR5.7A=]VW0'B#6!#S=?3=OX=4R/M#6FVYD&M+"?PR@-S MP"7R*QQ(2#-6FA:5Z%"B)E&K"FKU.\(]R,.MH8:K7E+D:.6!D8YKTCC=5U2T M`\IUR,/5&JUY$C6)FD2MRJ@U_7`UDX5E=T96O:+&:LX<&>U6KYF&1]YB*=VB M7]Z:2_6SNF M/TDS&)IU^'FSCHCW28#8,,O[]`#3NTEFE5%XR:R:`7*J:8:TN".+6RLCZ4Y- MCC*JE-*Q<`DZ_"ZN8">7N@+3N&5(>M>5@9I6:MW+2MJ[;S0-9>5%%33>43.5 M5QX0J?$D:K6??,TX0V_.9;%$3:(F4:LR:DTX`Y&)-0_:LQ6:HKL!(_S5IK>X'3*_5D=;J6UH+)6H2-8E:E5%KUA'K7CDUC8H: MJ+ES:C8TKB)OAI_&!IKDSZG9S6]X5=)"SXM$KRAGAV88GDW*U2=QD[A)W,KO M\64&Z"\!@3Z>H&KT]?KZZ[\>,8P_*I\OODS5WZ<7O_U^+1::M=TH.&GC@S\O M)M>_H\GX?OUETJ">,6-WT#2^.OGS\/+*U#QEN?OS`[FGTZT=OO]QG+B/S[.:(,G[YCOUVNB M0V?QDA@GX=DE)^+]AR]=1,>](EI9(3Z%Y3*(W'IM]-7U?&@'8YWA+<4*?9^Z MUDH)?.)R1W@^*,3^*^3!@KI!Z\42T;PAN,TQ!%>4*E^\@"I=X4`R%V,`+`8> M0.#:U.74AJ;@;S$[A,?TC+FP.V+$`?3@`<+/)?[KN(47X7\]IYR*6Q#/11S% M-&"NY80X!9B+0R+P7RS#(!)Z&"?T]UE2GWDVL^`/5WC!6QX/6LIZ0+7VQHA" M(]DQ+6)$?['9/7[\YR\A5^\(67ZXF@,[<\^!$>'3OT,6K(:N+1Z."!!Q25:B MJVOZ(Q@YGO6?7Z$EY9_KMZTYM4.'?IU-%TO'6U%Z1?U[9M&TA3'@`OP(8(8. M-"'^^CK[1BWOSF7_A3X$3&/`)NT&F0_@PS?FUSLW5]>0&'M_@5K\],-HW(#+,_G3"[!M#T]M&1[\Q^YW)H#?NJ,/!9**: M/=-4A]/SB=II:[U!>SC2]4GG1H,7?T5\8G@>KDA;J\O&N8;Y?L]3C60!$DT\ M'WH7PX/Z5>&(IWI+(KE($17"2#C\!J#]SC]L+6.[>7B.J)HMDP,]G?`6B"SU MG](8\4N][ON]-V/).\;N5U[KN>SZJ%T??#+:WWDP>M`&8>\SJN<,YR`^4=Y" M>)T-OOO8W,'6;_&/?X?$AX?*%)8F6SSUE5]B$M:GKXK1/A/4W>X[P(5LM(K& MX@MS:4K"OV"9FO/T\Y$1DI)[HC\Y6NM+@+H+Y;-LZF^#33F:U=43IS::>S[' M3=&".0Y&/CR]X."P M.@T'W*;F+ZB8NW[S09>_1V-0*]J'KF0&3;,D[\EC,6@,BA;19OGT)&=?%EDR M4%CB\`M,">;>@Y'D^2N%N'@0^@,>$\YI<'Q=]0H.U$<-DBR#P:/60#@^@UKS M&92EL0[17IF3>Z&\Q`4JGN$GZ8Z6/KUG7LB=U0--!XTT2->UZV*^',YH;HU0 M+T9K8Y`>SFAS$RQ++_G*.'=)U"1J$K7#W`@;L^>=$_\.C;T[PEP>Q'9C/J// M>8E3?BGN^5JWZ!7V-:`Y)B!EV595!<0TBT[`6S-`2CY,K*%1VB3?^6.:"A(W MB9O$[36,TWW\KXORH-YTU/[JWQ'XJ7ASO/8KQP9=^]*GG+I!W.IYXFA^M?8S MGS!N.1X/??KZ_MG]R:`S;!L3M6>.==74]9XZ--I#=3+L3]1O^L,;=T=I"&0*D.W_^`#.I/G(/5Z3C%E/D@*<5?, MO5-"EX0V"Z(P@B<#"N#M-*0`.1RWE&_(L&^?*1>NU1)'T0R^X^$M9S8C/@,2 M3J.PAW@RP`B//\;=IX\F'Q7/W_@)MIK]_F>%S[W0L95;+)=(XE-P(/2OT+6$ M4\)W%LQ%C$2&GZ?#(I!>:"2.DIE3GP;>1L#&)A&#CQQS!>C*T'5#:.@;77I^ MH$#7YYZ/I0A`G/^WI41A((_V-R?W%!B@+A[M+V':VO@V46Z%S`1S$N#)?H1? M0-P`7L>S?^"#\0!:R/`(0PC;01S`I0\DLZ6#<5?+I<-$D$\4;?(X%?LS!@TA M:REC,=WKX)5@-Z\^_3MD?A2L,H_"8F#(,7!E0?Y#%NF'<&OV!:C#^$$E? M4DS"7FLH;`IU$T"(R$:MBC90A:B8-P'@VQ>6K<8YD"6]T1\N8O MX'OLRJ<8"X>CF(:_<<6E%N6<^*OH-DB9$>8C\FMUTLI,Y`26!3KM)!%V&Q,0 M(S\VY@+A46E1<7,$/2!/?\>>V_C,92Z%]M!A6:'HIZP,PSN@+EW/#"U*FQ'/ MH!U?ZZ(UT9ORQ;M_//6&WH+O%!R^`&7%LT1TH)TM_Q%+V6.\V:%`#SF("1:< MI9[42.59VNG&%SHJG0F`O4F8^":>C"BB?C0-(Z&D]@,16'J<1=/!!YIYZ$3# MX2UI-$UX*C?Q'(AF4O+;9``8NG>R11P+QI/QQN'R::2EUH(!^AU^;XNDT?1NO@$FKE-QQ"ET5O"?\U?J+8U`)=X_!/)VIG.^YKW)[T1^<]5=.F MIFH.S9$ZZ/:GZF#2F?0-K3L>C]HWQHUQ\FMO,!!680K7BQC:Q"**E[TF/XJT MF:;G4Z/;;O=4W1P9J@DFE#J:#ONJ:1C#7K\[GDQ&O1?93/T";*9.2XF#AZ_7 MI8XK8RI1,>EQD@7DAP(SFFYIS$A#/IY;"%H1:O([$8NS[_T0BQY,7UU_?Q8I M!#^N<;3Y=>]]9OK"$@]_XR1.>FWM2UVBSU&7937Z$[F00)',G%35X9()EI'H M`UJ)^HQ68E>YN/PF&L!_D_AL^H'JAE4*+(%$2(CB34!W%!()U M2/V`H#V$=:8298WC(-]WC$DDH-]]L+A5V_ONQK`S%\9!Y-T"$X>R M>]S>)OV!)O8>#CRT\5@?F1CH_H%![;LFC)B:0!$:S3`;!?"W*]'3<`%KL07< M@&):DA7,IF\4[.N9,K2$A*"A<)8*,F((!HK@!\ASR'>T[O^'@$WMKS+F16HZ M`3B![Q%!D;,2\HAW.B09?%QQB6]%\P'$`&2NE38T=`+8$MTELA^_B=PF)@=N M*M9OXL8BTQ\BN$5;;+>=Q<-*7?AM.A^@`8?>L21C`TB&8&2)9=G$EBEKZ,?E MV=#)R;<3&RV>O_&K>I89&(5X.B:];^T2<9_"UGDF,D7C<`R!Q]"*QFY#E4)# M/QFM7A)GDK48]YV9@LUW(NA^[;,E&A"68L+3(XB+SSW^JLL3N%OB)Q_\ELMTQ<4^)O(B:C";1#(9XI;);Q>?M9 M63HASIF?NBUCW0YJ#\ORPV@2@6+"/`@`RK:5;CR0U7TQB+C"@E[KII+.$X+, M5G_[RT.6R18J%PJM\HE\#-6 M.'-#P`E@>L=]!$O#9_X`8OI'KAO`5/=2;YK<]QFODW?B%6OU0/2]]YCA?9$[ M8]#S6I/YC*PX%J6I8N3W=J&<'LZX.UB$A,;!OT*-7R M$$)Z69SU/B>U/%N,[NQ&C>/VMOB:X7'DQ5LP)6+0#P_H],,)+]0F+3F%@:-! MI'%Y0++Y?0!'\ZL;WJ.+`8^@/$*`6?0RY=(OF7^G\4RP<"*2LTPY,(7-U3-& M-7,!R_=?WWW.!RRY>00[D7189NS!<8N#,,HJM-Y5C!PY^`8O/=;.JE^,+\OO MEXZXL);GXD<7L*,;#S[FL35^^1"16,X(HYR:QI@0BR5^<%V*4@)8V0XR:!D- MP%I=9&P/,Z/DT);*/NZLP-8)25(YJ?4-ZRL7X)'C_V?/LWB*%T4K-#YAE80E M>D@@9@4R0>B3MXX;`XN_0RV%;^1=P>U"],6;JP M=)UPESZRGB2DGU3[P@(5Q=@B*D&1O)D'>3%$BT>"6"E8\D%B]")3\5M?S-VEO_F1=&CGE1!L@'T3 M7&S%"[$7`2>&W=8"<9F3).1WW!%=XF]!PLG\Y\L5&-JH[\!V!'ES7Z&SJF6V MLGRL$&Z/>>&628=8?X?8M1':CJ.NC5#QDOD`GW>O;O3573.6KHU0UT;H3#FW M:SQSV[41>G%@=FV$:A!+-[*Z-D)Y1NK:"+TT0,_&('T^H%T;H5?:I*1K[=)A MK<-:F['V0GW>KHU0$Z;$3JAI$B%=&Z%2<+!K(]2B8.(9&J4OJ3U)U]:EPUN' MM]._<3?C=/VH[$+&\E%3BM^)WB,AV)6B#CFXZ;G.[(Z73;+JQZ1\*TG1ID(/ M2CA?NB'F?_,2TD+..5;XLQ)07JT@2A1$%PYZ`%:AABO4B23R8BSPI8Y)28\% M*MD+79=*JUE]`_W"#WIS#R=74W>+;"ZY,XNQJF'I/`4K424LWM=[8#TIV$UW MX&\J8\R"%SSPS'C:2Y_*O-D.DZ40(:';QQ*/ZX47W5'!%MCO6`LL?LU_P@JE M[YWP+S>F$EFJE'B#Y=]S[\:#A]/]T35]ILX"ZT-7H=_[(=WLZ.>O5U_2/\<_ M_UV`).K6,>8\7P&%GF`+L,9M&*R65=A*2@`B1`O+YZ>4?_=QYK+"#D['/*X8 MI'R5GWMWP3<78+[@^TBR"2C=P`-"L`+F3%C)Y MU7*&X'U>ADD`<&$G[2R M$4_SNBHL36$TZ6%^J=L;.>$BZ$7>_8J7^@+O`()$13MP1#KF.MTY+)#;>_ZY MY-/<\6=;B$0-NN@*-,_#RJH-J$T.DI)5?OP$!S/ZJW^#YU=49.)IY?!)EYKR M-WH/_$O^&]6S+%U>:OUS$,;^+=>^HEH+43D77@W]!KE MTK(8-)>6RN0(''WLQ;$G9%L4NF9*[WP?&=6];]@!6E?185 M,9]910RL4:HM^W#UN5CUA@4BN5X6TF6V'I37C+)**UA2,!6Q!7'#9?+FW/;@ M3<0FI?+N#>MG5U?$ZOF3QMGRS7>",5G9&KXMQ1(5#:OFI2+A06:+$]7QBX1I MWU#?K7^ML'\'K+7F36POE2^P+E65Z3[VBJ2I5+K&S%G,^*F,\-2R$L/APIG] MU;^:@1@GI++S6O<,]7)GB$[0F^_8D9`E<89DHW0@DL/P$.".J/@:?B7KXA@I M4KUS)]YA%Q]_\UWUJ9,N#:ZSDAA:VG+>2.)MJ^8'/B*F_MZT+]4R M&U,9>:Y0.Z?SDDYGF78?%96QB,8P1#V5ZU6&&I-IE@3!\'MJL)>\CLP+;)7R MC?N:X8VT=T29??<<*[Z(5:G@/A0P_H;AC`":Z>4IWL1T$ MT7RB3F'Y,\O%\[7G'UPP'<)HD/:TB0;^'%XA6LMDVF`=H>3<&D_&LFT,^^K4 MEON:*2E]6]?5_MB4=5T:VM.QOKVC4Q,EY\IE+XLC.L9C.-0@*\'$9('FZR1Z M<^J"\T]^[],L#G+'5,[VW$AJ2&?4U7".K?Q2S1&DK;X$6\-W']RY`^*)]\;, MV=3\JYSFO*!C!M;<`YVC_AW*QSE:IMA+CA`8K:C!(WE3F#P;\S-RYV+W/V#J M&1Z3V[3?35+42CTDY[PE7=KC$ALD+<&$P@#DS(GNF$DL.KY\#SR7Z9Q"&2(K MI%ZV<6)2?(\=)7B?B'R)]O>6E*R1J"04\N".S$3G1@;)&^HH`DP")B/:ZR'U MM_G7*EL"Q<6G7A(OU"+OB6QB_'3ABC8ZW"E(L9'IGCE?N:)/%6AQ7JF.?5P0 MC)2!6Z)3@$\K%(I6Q:E4YR%Z$3G`2#>$!NI"X]R"PB,I6$W,]`*Z*L# M=WHS[`Q39MSD(5B%/U9D8D`S^*BS[1P<@<4`C$15^J'G8[]+O(5"NKCH%Y-? M$F*/GGD(3C[I'-;**KK@G3$%1;-NT/=9(^T"Z\/S^NE[Q5`2?O2$E^[<`DYN MT7=@*G#I>'/L_HFB'+B"-PX`!10YK-VL%V6U)O(/HE%4_>/?`9V*LE"PPV#02,:4>5:(0"()5)A2?8WE[J+4BND6S01 M*:N+K]06HP@8N-@L5+$W"EJP)(!H(-UND4RQ.[OS@T5PRQI,83.YWF^`&,!: MU'O_?I3G5OBVP)W4,TJTHTJ#,ZR''`OT(*DXTQ(1X9%[-\1V8MCVR0$I@\&" M="-OOLM:7V@5+;%?'&NB%KDAM2*&LQ9B280#KP6ZH73)[?3SN]$HRNWUDF!C MW=,J)'5&3L-:WRMVIDT39SUWX=U2#R`\*XE8+0OLWO?ZF^\*$IK:&67X2/20 M$_R4$[YOODM;6B$-DXV*/3J\N1=K9H;;XPCFEATW8]O#H^C#U>;0U!3(&@)O MOLN8`N]A$[U_>_!=7KB2N,QK_!2GI"*1ZY!=>7@I@[<2('W",SLDZ[T,!!TXX%:X2;%-4`54-PPY?1L]Y0UE@7*7]6^ MU`0[)6)M,PO#CY0"`\>%J%*A7W/IM9R5K M7N3_B*6!M7.RQV-$!44#;BA_V05J6)>Z&6(KK6P/:7Q4UB[-])!=9!HU\N[> MW/(`;0T^#IU:T>?Z-@CF%)ID)]W*OC-MON*[20]K?)]V:>?1D*Q"E@U:2G-L MF!Q-82^U!UB8G MD1XB7)-]`S(TZRL&A!<$SW$V:7_B[74AEWR;4K87#+G,41B#U2<"CFB*B$9N MO`%SNE#:5YD;P?O,=_WEP+3K2X2X2YIGQWM_IT:4@S$5OA2$4 M.NS4FA2#F\FZV`:4^K:)\*:B_VV3`8PM,%F:=YQU`U+#5PB!8GP;>[NL0F0I M.KH4LV:-7ZXQ4IY:+(`.SK8\J)YM\\K[I5^[%`)W'AQO@3=3;1+P69=",:L$ M?(@75HB2C/&?<4><)PP&@8=;#, M':/AI!!3A1<-`]3>O2N*G9#C-`K@L++C4+0F2@_GE\-3]KUBZEDK&)F9&`KA M6FOF(JNDOE5BZV:-7(8+.M2I%8KLOL'ZS7,R>U_$K&HF&H`&MW3/QXYFY(#0 M^G;GLK\*VTWVQUD<8UNL"Z"!2V)#:Q<>%M=+&.=*21V9G&=R8M;X$C M^@4E`8H17W/;)L/9H^V1IN[=] MDI67T8:HF28-QVZ141W&ST\(LUSSZW]FQA'+L M_A(OG2688*B(@?CN^7&#V>7/=R5CQU/7M:FV:'UUEG):^^D,C\K+36%_>4IM MP*>&B%RM_119^T^Q?&F=@_73-K;(=U?WY\D4EM;SR?,]J%,RS!E*_I[, M;^,AVM=D.JFK>89GI[.87J][<5K+I#LL+3HL[:B0+>9M4%*!F-6*]3&4Z13B M+$58>G6#=91L2KS(]WG#;^G9]3.O:XVJ$P5H'B)E1]U@!@/59KSY+E,01$D/ M_%(>,S^,T*[JRHI`E8JU8FIOG/P2+!Y9/S!.HTNGG>!L^G'SFF14X)C;T M'-I2Z-*%.2V1#DX4/V`Y@Y3V0J_"K'&Q**N8P627>S>N4P&R7]%&OO#CRKU% M"+^(71]S;K<\&6H3S9;[`V6@][6!/.P/!_*H;XW&(TTSAV-+5G:J\I".4^0A M*SB@E_#2>Y?F"A$1VE/<\74=%]^G%8\BG3"B5)WK%9P%3'QC&2^8CH6'`S,0 M.+1XMN+,6:S\,W2F?WE MX!3I='67K8DI3I$``7-]0LIANZ"-.+<^R!L0,OCD$JA/R,3M5D'*UW)ZUV'@ M4&D]%G11-8N`&C!^%T34I13VXOE4+X@5F7>NLXCO<.DWE.YW`_2A^A)X#,X< M&X1(;V9/]@`VD>A"-?$+$#T^9L]A*P"4?^GWZ'GW;A?!M4-%DUY$,[XY`2[6 MBL$WWZ7[QA=C!25M@['-BI6Z\$J&&-.54)XYE.D(`M#UA"1W[S&3B])!`ZK] M!]H`(C&#_)XNQMSY!H[!:380]9B,^1AI# M'*PT91EZD=O_ALJ.%D=V8EJ'V!U?A%7'RSM@+L^_"1W@RA7CUI9D57W,8BT-IIN M)-F9#M,[+5:ZL7KMHE;K!K&='."F!^R='.".PN<@15[CT+UNKR]^KR\]"^5W MWT-?_"H&E_QL$NMUZ1GSJPZ4^]D4K)JEGGRN2V,%$Q>:;;PF:`W[/%+#VR*M M)BLL#,"71:MEU=6R_K>?>_^>?/GZ;C1XWQ^\?_?KQY]Z8IL_.,P>@9\FIM4Y M)8[+LG&B7O2G!%JR+NW7!K2J&R5&NO$)"RXIRTB%^9V?B4:W?*[7P;//U207KZ/.$V@>S8LFOSZA5 M=.W809N7EF_[<@H[.OQU^.OP=[[XZPJSGAGL-77K1';.&>`&?*33F$/MQXUR MH0#GG,&0VA-A1[;U8X=*7YI5^9*JN#H,=ACL,'CN&*Q;B[DVZ8Y;O3_WWK_[ M..G_-GGWZV]?24LE@<>T1.*/=^.OOZ%!^K=2N<2954?(DO2WG-H)J^F,YK3X MC9865"S,L*.-DT2DH*9'?W MO""*M_[G9:$S;O,*Y%32B]=IU M<4#%;.%$$8XU%4-8`BI#3(I7>8])-E.5-71WTGD^>S%GHX7"-&LA4X:53N*@ M,:LX4,2]I1;;7?T0Y]RN?JA[]0Z?=[477?W0'ECIZH?:1:VNNJ0(<%<_]-(! M[NJ':M]2=W4NW5Z[^J%GI&O]VXEP[GQ8\@&/'2/;]\9`LL\O]69O6)7S2R/? M$U9#T5]-29BAJB>=(7!V.:6_AS18KW$9]=R4.=E67V'%CV5=RJ\-:-W43G3) M?TJ@#>4\Y%A[S:]/_NP\19LB'SUOHX5`2^KY&9_/!=I07V'9JB$=//3S'G\=FFB_P*31=9,E_?^59UZ_75,JK@=Y[%+)\6VVNBNO&L MY)IR])$\K83YU4DU0WU]]:>&UDT!V2T/].54-77XZ_#7X>]\\=<-O-I)U74U MB!MPT]4@KC>%NQK$C=CI:A!W5@DOJ7JIPV"'P0Z#YX[!+65>Y>&!-0;_Y2<% MCH+[>X_F7>&4P1'-+[QU_9GG1L<<&C@>3R:#J63W!\I4ZVNF)O6'BJ[U!^.1 M-%!EV1CIXZU#`^\=K.CK@U'\DTQEE?P#1KZ?J$X,]6T_\O[7_4E._[YQ[KW% MTT\%(SQ+[VO\MW79RR&$4'Z=:*S*XK7,GHS#;LG#?__*!IK1^[UG[P1)V??\ M.5#_)RP%W&-G[_@,S7#N^4[X!`RR"B.:DB?F$N9&TO6\J!>MKO_CSF)6`RG& MNRW<6S;=;>:Z6#!'\_1P%)MWRV=STLC`A>/=TU=8JPF/X6`_G,_I/L(I6K@7 M/==_\,+`1X:&]>Z=.'9#'+H'WP9/--9M[D5+G!=XD?P+UL"A9CC7E`Y".KD4 MMWWOAGCWESQ-X_:PJ@^W1<"]^2X!CXVU[$[[$H%IZ^IKI)?#1TG2CPX<\G M_C+XXK+WGFTPB&)$9&:4'KT?T!.Y@@ZTI/NX='T<0><@EJCH=7[9&\3PBB=8 MX-9[<(&G@-LND@&M]9GK33+AE=9G4PM[3F\)4.*$V1N<63AW;UQ_[K`)L$[/ M7U&A$PYV))33&C91=*3QYCS/RM_QJ;_B1\N/-`&?"*@3^-%!4O2:NM<#'DX5S3L-;V.*W.P_.$[#M M8D[XS]#,P^/&JL0O>Q](=MRL?_VFLTOB!]]`M>8.'C:<6[P`(?7@XGEQ;VZ0 MZIR@Z=%)AQB_^2XS!?FB=P/'S2>A-T.`B!W@?3\2W0"_\-'3AKF61]3+I/,^ M\ZKR]XF\_,#D2WO4XH!&0W^:Q<%UTC@`+#S9O.!M"9PE$/.1!#:(4U/3>S?N M'%4[$=94)!3&./^DMW"^12N/VA6@8&/-#9))LUQ\PZ'*KRA?Z*8.:R2"#\@* M`O&;NUC@?^-O00^T&1#\`<=IPP$08DX(73:#!59@4UA(=/,.!;`\B'!B]`H1 M5M0[*$YA]V!HX@#K1R1&IHMNBEMJH@L,&V/&39\L\9^2>"?'X(01EK?2[?W? MU:V[..2"=*BX?!"CR^%_?<_!">".%XH9M^DLW1^P7.?9,3@,)/9\"^&1L@(K!GAD/ M:$PNGOHW'F)M_<\OW]"H[?1D5A^&BYX?L-TP27[G1*R9!]*#.GF@`1JY[E\_ M]7[P_IXNQR=0@SZ$8Q2@0?`S/)!]`LD-&M")L2'&W+G'>=8H.>"I[&/+%2R` M^Q*/P`,/F>^=WG_`$"99?>.Q,PF[10N'3$IB:&<5D63_60CQ'W(K@.`+??"&,F`1\LP=F=,/$R)B;2++X#.SH1$`*O\.N1XSMS#PR/ MO+S!-=`.XPU34B)RY0JO`>F6,[-A8SEA9UBZX)B\S+Q(A2:QVE:Q:<)*.9$9 MIJ#0\<-W7*U`5V*GEQ'8H[%X,\E)_./+73!W>^\BD!/SB\0*!FCN'50J(6-Z MX?@PN^L_J]"+@([7$^LBW1TDAT<"+G-8GHC9/R:H[1A#F`/@\LZ],)I@GDS)D('3^Z<=%Y0DLV(`/\`Q*: M&>5T^M][PGWN_9!52A_&[W,*B/AF%C`_"Z4I',)^C#;DF^]R1F?.-A"6P9B_ MD!\'7`L?2CXF;LL>BM-SVZ'/!4G.0$+)`=)'8(1YI,)"9GZ>WWSG]`8\3D$"!' MN8^`2>2+2HEPV9O`=K*;R<=8$GLF,>6S\1/A+Q$0/):"OBUHE"5C'$YRX`(X MA(")5"$P\9FL#SZM=[^ZAT4R#G4">SEJDF!Y1C&VE8N8Z+G^+4@R)B*!DV>K M*$JTA'!NMR$T!&<)61EE_C)`YQ/5(\A!L*S$L/N5SP"95V/U@KMX\"(XE+2S M!^\V")EB8@&$-1*:6&4>@.40)W3-8AST8["ZO0-/2AS.O/TW0ZZ+*0["0R*@ M+5
I]\<:9-LM#$:_4%_H`T-ZR&RW*HLQM"[S?$\XS&PLI/_N0Z$C]EVK?2 M1LK(KV\>.!?XDC6.*`:I$E=TO:==X9]FO5/DTL/YIT<4,EM]P$0#)'YLV=>K M9[;8%X::-5PR;>?($D;_/LP0NL)KRY@D64^4["GX>,_ M,9.8H9**L1L\#77\Z,2+9H$C9B*O_1U9RDZ1B%FR94+./P`Q,H=PLSOZ!V(N MAV]8Z3?760"EMGJHY1\7?HI&/N/0O>U3#/-%B?^71A+Q_;5]-(IVYKRTFCX: M\[^V>6E;?31:IJZ75NVCX1)UO;0_"EY8_I21W!47)]D3?^TN//=!*!6.0SQ) MP/Y+^"J,R.%ST!H-KA?"DH07>][-T_9I4G9<\&'LDZZX/[&5@X2 M_)/&ND#-`2>C.#WX^6;&+1,LJ>V]J^5-7G8/3.J=K..K8(7&#.(V8RCW_G#A M?/_;0W7D.8Q(*]'\S0?]Y/NHO//.4[E]SH@FO>G`I(3#A774Y`'>REB3L;B!+"!Y[X%1` M+,("*1[+3KB0,#O(-!$3K'+6P?!$P4S6#F<#W`M='Z(#P0S:?ZU`(*+NY]=I M*/A8PUD2$+?LNJE".9/RS*O\[Q71D2IO/F8L5O@!@,+5A5B?/>V#>4,[Y%L& M;D"?9K5@N`QFLU68#!GWO7`Y M&@2"E`T((E>G"D5%!*F71C6*F(9@V"'?#L"?NS,OHB?'JY"9Z2Z_Z_LOZRF9 M$YZ)93]GCC?2VHG8-2E^@,;@O]#F?1(`P[=L%R+0E01ALAX5GK>L[Q;X-]Z< M.3!H'V:]-12R"$9BC,S7;IS+)]HAXCP38H85X#S?>U$D##;P_4E9N1?"],]> MSJ57`*A1Z7TH?3!4]X`WK6O5%)=\N$2""K'N/(#OF;_$E1*7/A@.=T,\:G25 MF<44=9ECW(H18,0<[2-MG/S`;+?$`02)"R]TR2I'D;CVZ)>B]7RWB#[FVT:X M%80(#\-U@*J?'#XAA46$SILQ_D:[/"N1*Z3Q'9,ZB?C]!I+&Y1R2=PTO>M=. M1(Q'7Y(M[B2V(]W@IR]%S9M<.>.B[$*<'1CVK!.Y8F_N6K-<6-T;-PVFR)VW MMY!KN<>1VZ2Z0`B`8,4Z_W4G;Q48KHJ/[7S M4I]ZFI1U2C=>(198?9,[NL89)9.AOCNZB=4?7-\!/GMPT/-"6RN3TI`/8Y4= M.93)XFH#[<62[U8%8T8K8AX""<([9W&3#Z+!^0T(BP0R$WX\LB,:Q@NO"KU" M3"FJZ1=.&9B;7$"\,?L6I,=IC?M*,*)HVV-@:5M:VRED<56,AH=-HKK`\0D5NL#[&A[&545I55F+S<1`+$ MY;>36I9HO6).#U!Z!JR)BC061AKLYIX:-NZ#**[2$EZ: MNTE(],B7!B_R(B/24%J2,`-4DH^-$M%EEQ\B:!%BGI:XO\R:.V1"1RX3H5SP M820E=4Q3;S9`L@3<>PRN>39%$M]![`)5D5=!%OMS<=".&>4[/._T9H4A.1>SX5#?T%Y3"[?"\=W$*/_"NFC<`*6%"V)5XZ M@O@'I&)$PR/!6D8JV!U,Q($OM/`PD9U[\2S;$]9,+^S29V=.&&(,D+N9R2VB M%\Y6]WA$9BY=)!:?1X'FALR3`#:EDK0J34/P.)@D27?/(.=!BE!R+ET)BB\= M%H2D@$1(<92BJDEVQAGYCSO,'T9I0S^*BGY[M4H1.Q!9WJ77L)RC#+Q\B^Q( MXL4EI:82%3C0C"QDO;AX+\G"JY4485H5,[KIT.#!%4<.\TO9R<-37(5*H57G M*S=]9Y1='+.[A8_.TZ1%9O=E;\!_SK]WYYF-5RJOJHSU"B;CC`M[CIA)D>3G MS!/LT1KW/&^"?H'R$GX%]L5_F8SBK)+<(7`=*!+.LZ=)L$#QJAFG.Z$D[MV" MM>0`H5VA[&G;R+6$;3!HA)HG*P^.>T)F>H#B?]^\"*]E\(0_.-Z"D-@F@94G M5@7'5F5MK`M31]TY!U/CL8? M?*_HEY*(T?5^^%[1+G7Q)Z+W!A>.G<>_D\ZFR,4/GH]!G+^+,H(+'#AUD;@) MWT(0:/UY\,UG&CMWV-)3Q+B&.5"../,\QR"]!W$?0<853KV09_Y$I M=>`\>'*&>%>YP1UB+7E"?J-JC2VHJD!4X80Z6&=SB\8!RY7[7D_IGU<_G%FY M^A&N6<'!$;8$"^%F]P:''?C,OW4Y@[\1R?;"\Z\X%YR'!&^D['+"7'?JS<5K M;%J7Y9YQ2)DP$"&+,J42\S=:72\#UT>=CK<*(^_!6P"-DU(OL!S&8"VBAF;V M?L8Z82F6`Q%CAI_S>K@D&)TW09,S3IJ'AM(Q-8/S_]@E;,VDA/*M&"W)(_7L MEW237IFSN6.<\[)@@&+,/.#.(0:/4V&#]P&`.%!Y5YY/Q@=3=*C:;EPG$O5F MX&]CN(QVP9K(PVN2(C'=CS4%QDJ,"-(U6V31HRFL?NVC[4T@'$,$9"5GMMQ6\K'<%1KA'-OJG MFQN/>;#O?-+YA!!Q_9H+^EUD3$%G%=\E>8ETY%E<]LUW_!I@AL?B M)G16S,>]<19IU`3-/E9T*4[J/``_@D>/"B>U.F(2.K.[)Y2&SO(I88;>#PPC M62"&N2>9T"QDLV"VL>.OL*80XWU%MA?I[0X>'+1/J?HP3;!,M.F,I!Q80`(;[RX'$BI='%CWBY!.(DEQ[PJQL`1SJL\BRB"YM,D*U@ MT\$B5:C@[GMBEZ7F6.'^5)L M\L%Y2B\7E(MMNIQYP2RTF@J8-,TA*H8Q::E;U.14^\O$4UH,F",O"D2GF$*7 MAB?9;]'@J0I3KAKT&8R;.F?^'_[PW$Q4P$[YU= M%J5]3BQEUN`)Z^[GK]-)[X'/^>G=AL".$;\A`@STV0=OTDK>#:J=E:=R*\.X MT%3C0E;U*LF"'[/'*[+C""NKY9V[8/Q&A:NIN$27F[V)//UO#AV_[`'X7K82 M[X>%=C`>P;Q>$9^CEV`-2`;IA&)2LBR\)T!FJ[.7,I\XO8)9WCGI)1A=4+## M6*!TR!)"Q$O0JG`\GB,"AT?'&3)DN!24P?.+C6:0&%N15^&COT*X^ M..'L#OG-KMP":ZS!8&'0(^K8*2XF?)AR@C\4I")B(#*NN1,AF0*;A5<17JLH MLR&K@2S([V4[E8O^G*=0L/LBC_(4HKA"P"J)[U-*+*U"!+L0RY\%9.#L%,?TQ8`8,:#CZ[`N.Q*TQF`&-Q[B:Y0F'AD/`L#*8Y^4V;5+G-#/XR M[F,!N2S+9HKR4X/Q_3ES!OBK)3.A:#Y ME=`"L*Y[&U!]$NV1!X0=ZG%:3)/E$>R/0"T,DM+[D#NTUV[\#<,ELG*I M_XWPJTA_8TD8XL([2"HJ\`Q<<'6#-O(UW4T326;.`D5;G"25OF'%&67R\^-. MN9+DXA"F!LL0+!/$2X(JAD[W<>F%3K9P0$B(!'UTN9>E"4-G$GJLH'J%]:`I MF51;1NN+-#^'L6L9&@$WWQ]#K\<9@N4E.>;S#"4#=X5#\4+\O+ORT8S2Q3$R"8NM"H!'(G8RX5U$O:$7V?!P6(S,,Y#GG!,<5;Z^K)<`B5K MR*:I.5Q:$*QBL6=<:#UL&7#RA2_8)H(=ONRQP20-$D&)?Y,'/I.^B6&F999W MR3.BY%BF_L@G*$?(UYX:5_A/N%BJWB_29%M:Z%XDVE;2YI-?D3_#;%SX7Z$X MB[1C],&`)=UU8@)$$`*IQ%O(\KI:+3'=C[V)MD(./\DO<0*N_,ZU:HH%:EW#C(LDO+3I3F"V8I&U2 M0([N,US_SJ'J0*&TF*W#(QZ<&XNY\&JEUKRE:PDT:X:`F1UW?+&)2/S7.<81 M"8$\H5^8=^M/"(+$[[(Y:*3:UIHD_*4%`S4A:`M M,:(H7/B>OG_*N"R=U]8E*'4ZVZS"S*3SP?6QT)0A7$EOYC9`/CQ9V MSS70HJP_LCO%S8B]@3YA[*91="MQ_12N#)Z2)\^7.*T!_DRVJ9E67J=LX MRQ;`L/O^"N3Q"'&,02=2[93J58K%PH;2-!SN*.#NL:B9W'01.,YZ.Y@_`KY` M&/%@;I*1T+L523.B*=X3%E\EHC&M5TNB);T)=O/RN`3(F`#[HSS*3)7K`K]HO>(I@Q#X]Y#JYWZQ>ZXP$3QFY: MQ,O#9]A5#TF*?!6S%CB8OR(`BS^,)E]&[P=_OV#>,.`5./XO'V^H0:-2*Y$;!)/>":N"-IKARWW, MHDD7_<*3-U"\,Z<1'EJX(/G^H&*PPH<#CSYB$3$0$A@D8SG&Y!$+?D"P":'Y M.QM6M$E!9@J@,M/]FX]2@'[/KEV"D)0`B@-'2#MTNY%3!".X[)F$"=Y\EV$# M<3/G\=)8P5Q!X4?I3RB\'K%.!"B>X\P"E`""P*^6F4^#D`'BW5]3\T#F860B MQ=3[`G\'/Z.DDLLDJ3%-Z0NIP"0Y$$E1":E(X@2Z:J/6"4(JB?P7C^)@^!HT MJ^>>T`'IR^)B`F%F>RP[,G/?EG0OI-Q)V-1_P*/"A'JBM?O`ZVXSKV5J)0/A MS[V[X!L^R>LR"]1G]S@BA5#<-,#B0;H+>$S(X:<1)6%V=N3!*QRTJ! MHZ09`^:%DKY,FT)>PK&=@5^]$`&?4EM/VFY>D&?X*E.IBRND==A(5%3+MSXE MA(/:9E6DY,GP--2,4_COI+-I'6!I0XA45"5HCR3^NAFLR?A0(9==HD6@B^8VE'U+N(U[E+F/&([CH MFVS:75:-Y5-,>72PNM7CW(UF<$;PG51X1A;,POL+S]6UFQY65HZ'>5N8[HCY MMBR.RC*6P+^FK]R32O.O6X;K09N&Y^3TI3I2O6%Y0JW**4I>RI#]Q9O%^%@ M\181W'#EZ?-,NE-F0Y3I$O*FV,B9=]:E%*ZD(35/=[U@XAS/(T#6I[;')/&P M"Q*5*'9[\1`I,^&\Y&9QTJ:*HBO#H1!&-%_TE>I,DKB$) M.?"SR`K'Y0L-BR(WMP?B_S>B&#*_=9:J4SI!:7J(([H_DV!JE;QS42+DDK?@JQ,JRB3%.1,\/,G8:&YF=[I MJ#IXR@U;`[M\L"$!/1)`H'_),\;*KY*"ZLS`O?GA+U)4,]7+-H, MO@/9&;R:E&6^9%E[F"FNCG@1/-L&-L$`(2":F53D.(N^S[Y+4:_4=@M3>T.D M,F.20W4R<\5-L:WF$Z5-(Y>;4T[&R9=:ICF9[%XC-00Y+.E.N<6#]EJAC?ZALAB0/_KW=>W&WJ1-:E@14\1*M9PY&M=1S(]2ENR9M#%\Q9NT M?HB=8);8Y#Z*C"&*;9%[4B@*QB@?>!THHMYL:7.V3Z\V[)TB6N3W1,O[JHPM M8<^L$3%)'B5>@R61188#'H/#':#_@(Y$L2U0>>%9IF,=-Y^9!& M:+=?54E#)BIK#\1+GC.UH#7ZX&62!G;//DU*\BIKH5+MN[7Y7<*-J1#9K?E= M)LZQ5UN!1IJS'[.M`/=B6SGP2K# M>\S!VX2()4T=-V0`?!::', M+`D-9L%1C,ND35-YT^NVC/<2G!&V;;J\9?CQIDV?7#!\K;*5O2];&4Q38)"`]R5.8ER5+>(C!T$QN`-:_4<.RPPF*\QRA2<;1%47E2^ M,RT4ICE)7SYJ`W)'W2NH:!7/&QG'KA-1$@3%J"Y(">[6N.\B8;V\@7O#!A\- MR,P4_F52^A,L%L$W*M!G!C+*.B=B-NPR1#OK[\PE8>7_^6MDJH<&)XL)H3B$ M)7A3'?XI4Q!T"\SCL*!/T:O(%EZ3@[F**8>1?L`B,F!3+[(6_!)O?DDB"5L^ M!V@^#$?-AJ([BNOP[BE4*<8:4JT< MND+TX07>V=(\(B?THJ3Y@E`+24OJ*L\L&UVHT/&7O=_),:94BB0^S0Q7/"%S M,=B*K<][:I-;`,XXSS'.JM(4-.;>$7`Y+QI@R?X@9LX!;^M`+,QCS[0\!MT? MN'9C=><47(DRS5%"]SX`Q*+/D)8WLR!L[L44TT15NV;CN,H^.TU63/::WVFT MP`KT[,IE=X`U"-ILUF[N59!*X]*,MPHN=%(>JZ18CPKM6RDA M).=9TN:$=O2A6%-?MW9%N_ M>L4]\@O([`2I&^Y7,M'(FV(*YZW4'3`69?!I@.\I2:QS&?-Z=T'`[E635E;7 M+LVS$HUT18VLR-Z@<309@1Y5",3RE,K=AD[F!U9>\4Z3GV[&H((>B'G?@9L9 MLFJR=SZ56>&_/]U,A:OT&?.7`0U3QPO_C3=`AY]HJ1B*:6NVWK=41>]KNJSU M[:$U[4\T963)0PN>T;=.M/PP^/+KNX]LNBC3&5\G_]_7_KN/X\G'KS_U4$-L M'B//%QA^^OKUTX>?>J1#UHR61[V1W.&R@CTO3`:E]>8)=K%46J`WF^(U=Y$; M'7[_!U2Y94'H].',?:,GG%[4=1%SL+/S>W+SU=C!Q4M%D@'13^N5;!9C!.TV M#"@I!C;#SU>P"%H#SC)RMU&CB/G>-9J[X3_?`OO,W,4B M6CHSP%GR]Q*/*__[FS>/[_[YUM+^EHSWGE'/R]P\[=P`[KGXD2[_K?9@;?$; M<\-/^".*S_R]P\G4_A!^GS93YL&(994\YR/V5,:)FUR=&F2=: M/U%SH.B;LTR._$L_\2>WU)][#NQ+Z[4=?5F]5$]XO#DG94J5UD/:!#9/<"AY ML(]N(M)(WR./]%70>-<3==07[LZ#'?YVP=]I[.-=S@MFJU6<:1&S74MJ_-VN M[VK;GO8-F*B7\DD4S1F@1N_T4?OTD0KBC?5D;4J@[O_&=FJDEX3!E^6P'3I" MTZ",;0Y)`U9?F.Z7%Z^V'T=[ZB'IV&KHC#%S%K<]KR?!"![,[*@0B%H$_FT?VRQE/N*5#!X77CD"_?45M.RPTRG>]H086E?3*?#X&'USX]43)C] MH%00>^"BUGS%+/E!N6[6[ZCMV/L@BH8T/>.+2Z6[K"<^)LNSC[\ZC_N7QZY\ MC_W*BP)-D*J$=F/)0GXR'?5W1U+ZF*%K?UG2] M;T\LRO9XH/]I2Y+VIRR__44VB(PI$I\#9Z'&&+O#?\'"^I7[T8V/B`2U MA`1Y/+54W33[UL@:]35;-_I#S3#[YG!J3Z;66-6,\9\JUA$KBFXI!1P4=IX' M2W3M^1H,9M37^W.(C:7BI\\+QX\'_GP"GRY%/Z#&(!X/+6,ZE*9]4QJ:2':K M/S3L45_6)J8U'.N:-5+_E.$M;W_13+4`<'V8JG$!)\Y[\.;4QZR%0*L*`&U; M:X#.;#X/W9"W$8/3<,V[9(^R74&_8GOV&Q?[T+U/8R#O1&NZ%B)"T]_^4N+V MYX%98(@PN/%BE!5M!%_&XU[B_63+U;P]#<+/K!E&-`V#>Y*/?-*V?XO#7AX( M'VV$5P%R]V5[#=_7!"R/%:8,0-:[T6?'FS#>$:XMZDZ("S>"=3_=C)SHCG_32I&G`$I4O8B2 M7:"JL`,_!GXR29ZA=L*N[]IHY!@@!%35JC3TU@)2//4L!Q>/31N)K(%D5XVB M8LONNDJ*X7%`R<=:YZP`!9^2#J',ILU(C`^>3W/;Q:)@%.5701,I?OK@QG?! MG(E1UKZEA1QA@=TO2]7BL1&DU'>MIFS&SHA?[9$MPMIKP;OH+S;F=$!#-'!Q M.K_'=;K*B(?#-1ZHLMV7U('VEE%RW#3!4:VMLEGLZ15V7S#)R^SH]70)A MBYT&,MGQ;[$GX(#-U&DAQ`J<;Y5;9QN,LR(HV\[VEZ1+,MEQ_LGT<5TT(.&- MHHVZ&US/CE8V(`2>%:P$5I&+BN`98*YU]K^XRU4XNP.$@QN0>DAMY!L5^$;7 MC`T._AI@ZC-+ID_2_Z,^VT\8'(BP29+;!,OLK3>4'6/;M0!=$PO!.6C^S%NP MH4+PP0CG?J$U$KE.B',;&CQ2ZD"7I9L!H_Z):;LA'(+ M(&5:8E=F_DPKHT#D5&HE65#<>NF")[DQR-@9Q/;\3KWMMR(J!A5*/L=N<)4N M#M`@AS7P'G$^?/H]0CXY%WR`-NQKLEYD^/I0%>[][YS0I?EON:'>+83'(KDVOSJ#G[Q MU0WOQ^YU*P6Y`I+<+@FX6N`4Q#ESM_$_&-%^]FO+6"]+:72S@FU_9"!F4`WQ49$C.<(OO-4&J&?!_1?%="YXUCOP);=.: M0-MH@5=XKMM-T@G-3?QT,WED0^._@+ORR:^6`&WD;A636_N#%>^(_IK#`Y0"FAC3JHBFE.)]9HW%%=0#EGE]EWCVA/+KG.90$^MO?T$K5WC M5F`M3(7S?[]^6&./BMVLP=+,0PFT\W7Y*Y,XQK2'GP6T7\=,"F]#5Z M-@:3P=2VI+ZF:W9?TRS@%-72^D/9MD?68&+"_P&G8%YS\60<"?SUEC(=1=:: M-IH\NN',BUJ:(04ZQ2Q%0[>"DH><+N;>W2\=+T1S>D13HUNI1PR\1RI&]:JW MGP?Q=W^.9H1WO8K=^<0)?1R.QCG&G7\-/CO@/\V\)=V^7[DS$+A'=OGW3A/$ MX'\!`WM"MY[_JVHPSB5O%MR%-4>A)E0E]X&N34`;C]T'=Q$LV<]HX7:F2NN" M0PJ^Q"8X"OKF$3\#?<2M41(DE5+W7.)DTMM?[&(PX5E0%D2H.&S5OS^^9;:W MOL6:DE)LH1XXM=*T^.5)IOJ@C?PAHX-B&Q67JO5@JA53/A<)2@$GJ>2NU8>J M_H7K9_R`0ICTU&>PTT+R>5`X\6.)=4S1>>2(8C2^%-4X$OQUU%2+/4(-JQVT MXKW%1C`.?XO=^BI/9*A2+R1DI4P9M1B'6$#(,7@(,%.$'8(. M+<8;JD0UB[D#P9LB\.,*YZ]]NOD`"+B+?O?3:;FI419]<)X^!S$LX.&4].?? MU.R7<@4Z\;.L?&"(>,:^4^!%@M(3RKP0="C(/-*MJ!"F03@.5M?QS6HATN/; M:"K(8#W*IISAD5VA*HB?CP'%?S/%$JV$6P.Y;.A%H5*Q^12\M,%!N=YA$$4! M7N:ZJ!UO2*,N+7F:N?=K* MS/XYZCF<`+!&F-#@HN>[,4U^QX';.#\WNNC=@(2C=7Q.D]Y=0I1>Q*@"J[#1 MWB248%W*G,1QXLX].[A+)XI[\Y7;NP41$+LX/][Q>ZJA]^;.4\1GB7>SOG%@ MM;''K&_#VGTHMZR>;BKW\=_]>L=RUQS]*D0P?9!.>\U(@W2#?FF&]L%[+[8* M-[\R(97N`J55`5$@N]+O48BE?Z&PRWS'AF)WXW/KR(=NH.VAB-SRIL=72\?S M]^KJ]9P>9'MVVU/42^DDC0B;!U4[]LBKES4LX%WL+)X:9^/GMC563C5OYI0P M=VWJG\?J8!2!;7AVO"Y+E_IKXW7UV"-+7Y80_QR$\>K669P=;VOG9Y8\^SA? MFB=D[98U/BX>D9?=T+W#7QL:XK^$T9%[^D:&=&F<1-ZV'S6R]1\US/9O%$Q9EZW]6+<6F"J"B>5PIK93(_^#@VGI MYA'!U!!,[)>GE^H_&P43D"PKQP-31S`U.IN[0'F*\1R($D.7'DW)A,T>-96. M-8RLL&UE29>NH6%3)LGEQ M-DTCB%.?B[@36C.-(,C$%D$ORYII!&]&50WB:[%G&L&P1O6QQS`9VVC2-()2 MA:3AR[1F&D$@%>N9+]N>,60`\YAX5-@8CUVF_)R15=,$^G8=DM1"VZ8)-)D[ MHND<;)LF\&;DC.978]0T@5KMX*AMI3'3!"I?M#'3!`+U!($';SGPP?%7-PYO MJ2LNQ*EBFR;)\PZ#U%DXA,>PI?3^.`-420K#F5+"ASF5U*&DZ'U5UP=]S3!' M_:%N&?V1+H\E:V1;VE3#VVZJN/ZL_P]#R![[+\UT\'QWGNDM@]U5<"[5%Q=6 M]3_Y^-GSQHX1Y`8&\FS5EO?B%DNS!H8N#_KRP)CV-1US'@QETI\8BCR>C'7= MF(R37`"YU-IK%RBWX2?;7/W3S:^.YT=X?O=OWM0H>JJG,.X`Y3;T<);#%IMG M@1`)&P\5XR,;P=J&`;`AF*3Q9OS3LT$&=F%BANA&9%1#N`TOHK_OV6`#>\^6 MNA1OANM$O"'#KO=3P_9(-B:2,>FK$T7%3F9V?S@V0`$-E:FLR=)DHH^2@U), M5MF/,W(S[3(=[9^#!4,&Q6I9EFWLQQ.F+5L66!_F2)'[FFE/P0X9#?H#VU*G M(]D&W6LPY4O]B(OS6]=!M&'R`.^'0PV?G45JYIT%$I2*ILRUH"L>CW(#U@A5 M#6J:U-1SYT4S;_0.SES`)ZA2UWA8`RN70%D]*R\*,&'A<5(,VX*_5,/0,6"G MP.-PQ@Q5H:-FVOM9O!-I:@YM%5S]*>9,3:6^K1I*7[7&`W.`WTQ'F.C'F*PL M=XZ#K!=!$D#644E",Q;[.%U/C_TXU0/C@L(?D8)UW"*.Q&WJV/ MAX$-9LU3",_0LU%J:I(I'4!NZX8YU,R!`@;C$$PD30.5.)T:_E@8J48UW=5=/L@XUS0?0`)4A?Y9/F5O(L.^<^R M\>HBGVP\N1S\.#;RWX,+_>F&3>6>.CBI.WZ:/"Z]D&)O8Y!OE[KZ`QU6(#35'3AAZ;OB:CJ>N@.S*\(1;.,D:YOZDY'.B3 MD6SV)_;$[&OR:`R6$IA+$VUB3B?&4![#VQ*?/]_IMP1#MH^O^"IX<$/GUOT8 MO`_\6S<<>]$2![(<'-QU1\%X!LA@R3#;,&WDNP6LPJV>"(E\#?[?REF0.AXM M'-C:,UH7IQBP97N_%!K3F`Y&EB+WY:&-5932"&PY98JY,N9T*&OCJ:0F@7*, MK17RJC>!E6*`/Y5YZ,J-XP5U\9^N_/EY8$#.WJ34`FL3!A(TH55VUGA10!CF M.&-/8%-L3;U'=XZN%'@';C1>N2@ZGX&+G!-95(>R;8]MD/?F6)[T-=".V-;9 M["MC"4=P6K(TT!.Q!ZL:#,;*+1ZI.E$V-,-^-"5=-_8+\8\53=&&YJ0_G-K3 MOC:9C/K#L23U)?@0E+YFR+:1>&RR9ANGJ<),X#24_9S]6G`JXE94*8^8;!1, M2U?W\UUJ@2E*AU7=*$8U&@436Z,?$4Q1.JQ8I1+(C6"*,7"?W5!T`_!FNP"K M(;#*IMX%?R[=\,\(%\]97N54AUHC831*OM0NS>R$KBH@-L,Y]A:[&ETG@!1+ MN"X-;3VD'(P\K'^XV'/&G0^X1<:-4_XL_2[ZM(JCV/'G.]ZOK<%!&>9]!Q=J MZ%-86I&'=P2I!C[6_72_*[<&\**!J"Z&`/:$K-88LD_`S,[^8\BVGY9#S-B` MHV3!&5',8N9*?:!JG9T2,@\E)P_)(2#^+;4X*FLG@$Z3QK\CJ^R9,ZCAM"(% MK^OLXC$Z7.;^,ZR&9Q^8FDH%$YO`?]O)&$K=V\'LORLO=#]C8Z0P?L+,"M0_*EAW=TZ:`5M%VL(MZM&+S>>B&J\CS MW2B"TW#ML7$V(V!W>)0%[RB'],8-0W>>F6L)QP53:0]L3AT&$9J>NWU['H"E M6<@W7HQ2HHV`HYDLE;R!=,]KLZ^RPY!)-#YS(FECYSQ/Z1TA*EW^@P(`^>Y& MGQUOWK0LK\O;Z+^K2E'GES=?LOA2!3=X<+P%M;@+X$SQ=0!PU2XU`]L1L"U*3H@*EQ56H3W)OVFEH%.42O:O`TZ%W?%[:2%P-0UBEMDW975?)+SP&*/.PSL/S M5X`"[@`E%FQ&5'SP_"#TXB>Q*)A`^570((J?/KCQ73!G`I08K(T,89'%5[3S M&T1*?4\*U!.X:#ZK19H]9<9"PKOHKT6AY&N?8LQG([[6:&OR0?O@A.W@8.T/ M_[9TO7+GUS:>;"J&KCK:V\'9A@!">Q+R&#E++W86+35EL-BYF-M<'Z(\)BHX MK&X"H5MWM8FX39"=ID]%@>!);!BGR M`5K`5DN*7#W2[1+-K`;I-]HCA[2T-`V&/"I[2L%'09,`X;@.9!@6(A5*V M5*E[/CUC&D05-M.E M2F8*E2<>,S?<>)%O&\6#A2E/%87]F^`HDS+""R+V3"L#(-3D6Y.*F5W%K9?N M,Y(P>4:]$M=//=_Q9ZV_`U#1FR[Y4CL"5BL_XEP00C:E81=]KOI0%6ZX*V?& MM!%R&Z\(BJJP>OM%H0;R'0<$L1A4MN5)&^%$!U,JU=UO`&+]H0=#.KD@OKJ# M7V!CH+%[W4I!KH`D-TNV3BUP"O*<^9GX'XSF/C@+_`E3YD6SL8V(4`WT`I22 MXMX!K$+I41!%+#I^BR%9_/.=SW[81OCS/>DV;'Y#WPU2C&T$#LW44G"XO/6" MD'87"_CF5[!>0F>!QW]^[_D>_(A\OQ;?Y*E8UULRR^O!L^8&_X0F:4V@;:PI M4HN7V;5L459&^.EF\CB['"Z_E2_&X'H`HL?[]VW9Z=FCU*45HJ[>?!_%W M?XZJT[O&,@%14<(YQIU_#3X[X"K,O"7=L5ZY,[`RCNS=[IT&)B<3/0"UQ.XSD2:7P/9?($!:YEN:3/`O,@B@59Z[Z]\ M.+5RBF&[G/^$$Z MAOLSF&NA&WLA=0C(]%2-SB,C$.//>M%,.1+\=;14BSU#C>:S%QVEC6"T9"!% M@_>V*)2,HDAZ`8,H&D0A]@D0)_+LYT\TB#>*8V0[O!Q\[H3(27GBG9+QKI:4 M"TK$:1".@]5U?+-:B%S@-FI*62(QED'3KE`5#N#'@$)_F MF#K/EC:TG:`\14>+IL:5:WP"PTZ^5BOG4IX,>YJ8]7X.8RE/AB5KQYSS]F88 M-XHV$ZS#(WBM+9M,>3+TZA7ML5Y85*!1?+[8&$&C6#3$K=,+F+9=B<0C3RW7 M>)/2%V?.-($W[;EX.Z$ATP1^K!V-Y3,P9)I`FUEUH?-:3)DF$(PW'%8Y5^%E MVC)-(%1]&9.V3X8_NO>P7K8=<]R!Y1K.D5%V[HUS1O9,`_C3#H6_4]HU#>#) MVAE/YV#9-(`X,V`(O0@Y>/\LT$;1 M@^T&S.(=Y`Y`;L,.K_+!FIVSP`=VEY>VXR,#UC8,@`IE9\V;\4_/!AD:3@0K MVF%U(=R&%U$Q>#;8P&(VK:+QR@:X3L0;,NQZ/SUDCV1C(AF3OCI15,R)MOO# ML3'H:T-EBET`)Q-]E!R48J+OOIQQ^C'0!2SRT>78=>3@,W-KC8B6>2Y$O]P5 MHPTSHEM*DGTGZ=8E"45`Y#+7-T&2C1/LUTZMSX]@WVG>;C7^-:!`<1#C'A@W M5%T=#U4)Q(PF`\:E:7\P'JC]J:7+TZDV4.3AE$WH)16TM7YG#USL@%[J+CA_ M%[OW[_RUR^\VS;@EV+7J%;;OCHL:\N1C$(_=R+OU\3"P%HYY$N$9>C9.34TR MI0.(;=TPAYHY4,!,&()BU+1!?S"=&OW)<&R-)5M6M(F<*,92$M;^"&B]8,Z( MXJ,*7S;KLY@ATPY]>.PY\@=&>:W)\0+E>BU>/NCD^/:B^P""I"[RR?XK=8'M MD/\L2Z\N\IFEUSSR#Y;%WMBH:8V-FC9*C=&;R=9O;-0TKQPJ]2MI%LRCCYJF M*(>JV4U-U*X$\_BCIED)J5[NTU8%)L;:Q=A1./BKT/%G[L@)0\\-=PGR6FRL MMJJ8[,K`M!!64S/0H]4LR7PT=5NVL\D0XBU9L*6R;3HR)=4>W6B[![@[F..U009^ M5C3AXJP#:P/0G\(K-XX7[JZ3*5H"OI3XS^O`SP%8M`6NXU358?/1W1%@@TN+ M1UM33>O15"6@11F<\<349#3ZI^JXKRF6TA](X+J.#-G2]8$LC14C4$SX![F7AJX^6H8$7OI^D=;!1`.30^D#X%)?,Z9F MWU+&$IHBJ@+NI:KJ6L+!ZMKI$>L`VWLJZBYAC).AA/K;%'74+D#FT8/-X;]Y MBX48)SBFOJ0[-XP]&3JTM[]81?MK$TQEO?9AM8@]UG9L%JOK0U3EBCSM#[2A@C&MZ6BD M:I8Z2IFAH-360%/=^C]7]QV&V*X33]8?7GSWSI_CE.&5LV#CQM]%T6J7UH&J MS,P;$_Y!SHQE@A)0=#M7]EUKA+HJZV-+EX=]V0#S1C.,4=^6IC+X,(.QKDPU M<)\'!`:QZS]H7?O&BOZ:AZV:# MB(?&['(5NEF\:L]`*Q9Q7,+[C6V]V`^(CR.B7^0[_#O`Z80++WYJ@@#*,PB` MB4.7RM96^`?%1P4!KK>_\'J7%Z+-LH/.W8CWO7&K@UEE?C#&!>0>!=8&F%K, MAF^"I;0H75)@IX MB^K8MON:#2[74-.LO@8H&EG2=&Q.->Q-01)!+9J4VR$[-B;4!!.*K8$["8BP MM)WQ8NR'%U&36.J_LBM>&K,\U28M3_DU69[;,'LXRU-.+,]CF3YG:7GN2H#] ME8;,+$]9[RS/]7C?&[>=Y;DW2^]O>D^6Y#;_'M#Q9%-EX@O^2^M)(MJ31V!J9HT%J M>]E;+PDV3VG?6P0(.@SF(I M!=R#B:J,^[H,[*29BM*WL$6H9:N#J6U(%CS%$IVD"K/^B.C8,*O#H\[K,_FTHJ)--#S":>@_P"N09;W>D^VE#Y[92]\8*FOF@R MC>E@9"ER7Q[:V'17&O4'4V7:5TW)G`YE;3R%8R5*S`1&,H6?F\!*,<"?RCR4 M7E9/5_[\/#"`E4.FF6VMO!6N32A(\(2'[*P10_44EK(1,;6@;6VXP)9X'H@P M/6496R);LKI;N$`:JH9IR^.^:JEF7U,Q37IB`4ZG^F@RG(R-H6TG`@A->TTY MOW`!_<\7%TR5R(O%@#AV9;V#[-^(\KW1"NKNL_H_!\#I)B#;Y_4?!YF@$CXK M_R-+'V3S=7O^S8L''DVTY,9=_S9*9WZ_TA3ZE40Z'PO]-:7SJ:7*)KSOC5LF M5>P/BOW*A4KC7"V$RK%CY.N%"OB=\]4L&=[V1+-XG073JSN/S+*%$[WW.)*) M--&F`WW8MS13[VO*:-2W[9'<']GV0#-E>ZK;4^Y$VZ5RP3K`9!R$&D\/;D`< M[-3BIC$4H,-L&MD4Y5T`JA:T9L9[J81A,YAC;X'#<]L-J$*`2NL! MY5#D0?W#]6[OL&#XP0V=6U?P!'^6!1H_K>(H=OPY+/9\%-1*$J@U[IBR2JQ2 M"Y4=(:J!CG4_3?N'M0LM6L68]#T!*YP+47"8S*1'S=*%TJ9N9]`0O&0'`&FK*46"QQV@N=`)7HU!.,A9H=2VKJI*#L-*@,[X<:+W^]4 MQM,8/#1%4-AV.=..[[DT7#CM?CAX<+R%<[UPOP9@/-\'_E4%=]->BT+-T]U;"S\=[K1G7I&YD MK7ATCP-]'L,5R[<830:U.BCVH-D`0WUV2GM+1.R.ZPG-.FH*Y.[1O;LQE"1] M,NKQ32TPC]G6O#'$X#POH]A(=/<>YM@O\=,-%G-&5Z`G6RBS%8S?*$6=5]AW M&2B#VH)/!_S%N2!W3ESE9@GWO'E/U[>[+4,J:`PCVARZ,H>;Z:`D<_;GOSE%2E,.I! M4]^8^XP?D`/!$@2!YT(W]D)V6Y@VE8[.PJ7"83_R+O;?,\`O3F>)7">7P;@$@O_=:(,H[#%IXD)97.V_=_C!BNF'!OJJJZ MKOSE$!/N15X`_&2GH.YAH;0DS=RSBW(M*)6DXTJI0U.34,HZB)KC0:GR>VC9 MLHK.?J-06KIY1"C%>")9,HNF99-0:OC9\:#4>>,)1=H)R./,!2I@H+%A'B29 MC(IB]39-!3H=V#Q9H-R9*(=& MN#'0[.%XJ/75X5C!\FRY/]#-(?Z/.K:5X6`LNF(`PLL&[LL>0+,!V0>0'G51 M+^\U:?!UX'Y?RZXN[LFRZ^]JVIUP]D\1;4V-_B$5IY73U!L)EC8V^(==VXSQ@J/[/VYC4$1:'UI:HS[VF@D]0>R;8).T"9C79H.1^J0U9U_5C(-?9H%ML%* MQ>,>/5"I9NE*Z'25BALUT"'RE:AG@ZE;.UD1^UV9EB@U@"V4KY83YT]4I M-@"SC2.JB]FF3=0I-@`;5H&7],XY%"HV<+IQ(DH!,R^I4+$!3Q8C_44GKL6% MB@WPE)1@Y&44*C9@_V&A8LE9.+]"Q0:$.6#*+DV=KUFH*$*@B83#B)*8XX38 M>CZ\69[&%0\S'8=,DGS_T;4P'*LNLP'!`=Z!"&(W7)>9S-UHK"Z3^4*RWF3% M8@'*!NHR^3Q2N\F?RZ3)G5 M919=H9/59:83@9HJJB+)9&PO,&M!7>8ID(-UF:5TNW;499X"'701NQ4;C==E MG@(56D40MPUUF:?`!=9EEM-W3U^76<3%\>LRF3]\(+9H1]U)BL23UV4JPOHJ MVE[M*$II)T6.6I>I\$SFG;/WS[@PLX3^)FL'A0/2+P9R7TAAYNF1JY>#Y.=< MEEE$:--EF?*1RC)1CK"$GUM,-*&9I1&;4#N.U:CD%QG=MF_(RRF@KD=U4";-PC?JOLX1Y&^Z/6L(LG*#F*_?0*9A:)D8V3W(,U5L%,5P"V M6:L8':^Q:2`IL\7PN%-VU+ZI*+*L\'G"9&1:X,)*^]V'V;HA#=3)L&_HN@30 M&FK?MB2M/U`->VBJMC56[324F]R';0-H,]B_AGM47YT"9A1)22NFC=`P@#E( M],*]0:*E8#%8WXN?^%_P-TY;CM'Z#'O1[`[>_\^W=W&\_.G''[]]^W89N;/+ MV^#AQ]&[_PM>-?V?;=G*/WY,?Y8N%;FW5%_[C\?K<#'W?G(?EPMOYL4?7'*` MYMX]RROZY]MJS\)SH^'31R=>A>ZGFXS#,7CTHK>_(**&H3.[>T+MY2R?V!A> MMO@_?JQ\YR__^%%LBH/_8P[^?RPI*IX!(7;">(RSIQ&1?<"N!(Y0^FGRH.O/ M,X\I?57&I>>9A_[Q8V;Q?_S(B;@71:O%4"LI>A4#!O`WO[K!+5#ISILYBY2` M9'F\Y\F=1R2=VI?,&J2#Q^R^*C5(.J8GSXUT2?;N*@R6[JND&QEQYT:W&>9& MAT\__>OS:Z,6.A;G2JW?KUX+M=8[SZVD796#_<6+_LH+R4_+&LKM6>],G/KA M$[^Z^.*R,M?HSEOF=S-RHKOI(OC&'WQ=LGM]8.R,^6L:A-B:!`UD,(?CJ..T M=G':^?!61]UG7\&UDM;OO=B[9=V*G,A-O:\/JT7LC:EX;!:G#QU*@.SJS?\1 MP!)7O[G.(K[['`;SU2QF=XNOD;FJ;O_/AKFB>!G^]/%?'0N=BH76IMJTDH5. M:^>PNZ[$#Q/1J$*0*M<9Z:,;OT:&JDJ&.V.&RF;+77USEHTPU)J6`*^2G;;F M#9\Q;I8"(59O+-%$(%'$55\ M6Q#IFYM?Y'__&DG/:OU>(NEY!Y373N=<87PKZ''\ZU_#8+7- MW'^1E&.-&\Z,K\!9O1:^6[LQS%MB\ZE72CEJ+G!GM?@^#17#[]!KIQ1K> MG!F]_NU$L]7".68:75L)QOLPG1G!/H%+\LI.V-%)=)[8J1ZOU4IV;DE6J%*/ M=$KCI.NR0L^4;EU6Z%E1J\L*/0=J=?=#+8N7OPK^ZFYF.DX[(J>=#V]UU*U) MW2[KZIRSKEK+4%W6U3EF7;67G;JLJW9JPW/,0CE3+N]T5^H8FR_:?%B!-4QY-T[(LLUW,30TFJ\KJ[]U/-V!J>[CV3<8.0+_[ MO?.M5AW]T0K[I]XB3@S))DKZM7HY?48CW-6NL]<:["B2RCN;JN`+@^ZW9+6E MJF2``;NO3\N,#OGLAC=!>._X,_>+RWJPN'.:L/N[[VT-ZCU3MC:##[[\J+O'S^P)<`]A-11^@YQC'> M^;/CGDBK+ODD[3CD$Q:#8K;08M#[BE7+8E#,HV)'DTVF<"S3!G%EVGI;8ZHX MIQ.,\I2COWX+OMX%J\CQYU^_N8L']WW@WWYUPWM@;7SC@XN_.2Z3JWVY#AFU MOGQ<,EJ*S;2.K6*S-%O6C7:2<>J!+>"^!^+,W_FQX]]ZUPN73:X>/GUP_A.$ M(YSWE+_X^.K.[GP*,`R=J/S#8]=ZH7[92F*KK]A');&9G5K0^=4OQ*^N62MG M'LMN+7(7TP.*;K^Q( MD2:%QPY-[L4ED2;M'"--[X-[Y]^@NYVF(DVU]>21/#3%XH%"Q6`'4C7!"%,E M36]II@P&2L#-N1^[UW$^AC\%Q_Q_7"<.K,O`5L>_*X]$*:`/]I%@>P M:";T=_-7C$`PRCUHK#JL:*PBJEUK6KV-,-J7MD>[7IH M#>VZ7C7G2KBN6U8[9BL=C[,U9&W+GF[ MCC5GWK&FI1S5M:PYTY8U;>6GKF=-.Q7BF?;P.$LV[]1RQ_`OAN&[KC6-=3-I M*>V[MC4OG="2;>AXR`VYK=#Q/_KN"78V"^V7@H_[($W0PFZWN5Z!`W/G7 M$(C*5,E@_I]5%..O7R=9)55NZ?7_[F2M.M.OF[R2J1HM=:MV)^]'-Q86X30, M[L=NY-WZ^,6G\/^MG(5W\P267]80?&WV6-=B[-Q)U_48.V?B=4W&SHM@79>Q M,Z-8UV;L7"C6KLX%K4"/FN^TTN7,'KI+3M.TZW)FSY5P7<[L>9&KRYD]"W*] MSD21ET;%]M>%M;T^JZTD[5H@O#C"8LVN9:A`C;82=M^:W2MW&=.RF:K=B7=[ M=_RRW=91N4N8:UG^T.M@L"Y5K6.U8[+:^3!71]ZZY.UJ4I+VT[PJ+7@&A)845%K7T5NJ+X]^Z>>)]1^]\5 M.BH/\#_I*]<\<-Q3;O6S7G]6QY'$?7 MU.#Q(PVHKLWC[>+JCJ]>`%^]ZLJKCJ^.QU==^5?'74?@+AK>;8\6T&6#;MS<\[6 MS:E*Z?#\&BD=W9DZQ)F"(X5#AB5,/>[,W^=PF;@Z%W&X*P9-E&\^,AIT#'UR MAN[L[HZMSY:M#;F3T\=GZ`U-HCJ&;HJA.SG=L77;V5JB'JNRHK(K9-W434SQ MM/26)F9/'2_\M[-8N<.GY)^_P9I..+M[>N\^N(6NE,E#[_SE*H[H">6P)/5\ M(!\\30U?X?^I,@#+/SLBI5C-I:&K+0L1[%QSZ7JW_N1Q=H>>=*U*X_.@CZ29 MCY8.'[0T?V\P(ZD:?0QB-WH?8&*[/Y]ZO@,*`:M19RZ0[WH!!RW]=SXYXFL0 M.XOTRX@J6-WYUX"KB/>>R&!\[@/`U951V/G639AIJO[\>_;)N* M#"VCI7;LT%D`==VK.]==4^Y+*=.C51C"PH,H@3=/] M!Q%_-MW1BK\] M8IDOAH];V_NSX^-G\O&.SLN+X>C6M@3O./J9''W<@6PGX>BNI=[YT:KKDW=V M-.N:WYTY)4_>1*9)F.5..QR*/^7&:=5IA[.C6:<=SIR2;=(.QX99,E-O&"ON M3=TV[;;6*ZRIL?_C_:]!>."!4RD))//8;%>C<8NH!K]VG0PZSCT#SEW;>*;CXWT5=-<$YU4N+Q!&K2U_6T-&DS62^0SHT%+9R'4H,&[KR^#!H;:LCC/ M#C3X?.8TZ!I@G`VEN@88YT"?]J;1':42YCQ(T_4F::PW28-DU533`G]6!5JT MDZSO`_\6D'T_=J_C/+FF<`K_QW7"4>C.O7CJS(@VD\>E%U*!T96[C&G9S&3[ MB7=[%[ONBQ"6JF6"Z6>HEMQ2-Q1S-C"FG))L[(7N+`[""+]Z.33035MOZ2UX MF0:9T_#UF[MXN[U+55>#'\VTG; MCF_/D6^[ODL=WYXAWW9M;#J&;3W#=GV7&HXV=PR[!\.VDRE?/86ZODOGT(3A M;%FIZ[O4;L8ZF[Y++>/CKN_22^7CQOHNM8RC6YLPTG'TN?1=:I"C94,&Q\*R MP+-H)]=^<9$8LWB%I,;KX`W7QZ5G7P"%NMXGYT>KKO?)V=&LZWURYI1L4^^3 M)F!6C#1ITE0EK:U%@/LG37Z:Q4$^9?+*>SQ^QJ1B')5NDL8\"5&\:;34_]U8 MO/DE@/U$0-8/0+H96LS;JCB?211).V)KO<[4.A2ME&,+OA*M.E/K[&C6F5IG M3LDVF5I'AUF53,7.JVP*_FFV:CU:J@'LW$Y>WJC`WP?WSK\]P%AM!;Y+&,V+ MW?=@W,W?^4"26^]ZX;)DA.'3!^<_03A:.%&4[F44A.Y7=W;G!XO@=GM2V+,L M";.OV"?@%=.4'ZENK:6E&:?BE7?^''5>?7Y)?_@Y#&:PXR]NY&(`>^"#^GQP M%\'RV'&)$[#0JV":]A(%G#:U:S6ZL=4H>&CJ4;N])B20;/CKT;042U7.@2!H M'59VYTII\SET_[.:T\+BBNE0`O:UL(-N*ZK]0MAA$,=!Z+M/4_=P"?(OE`]` M75I<79(]#NP@ZRV]R-S)+A8_2NSBIR'0K?3#8ZI4Z]AV3J=2MULUQSP[4D>" M+220FB,!.(<*"SV?A57S+(+4S_W`ED)Y@?C!>?3N5__?N[?.@C51*BU"<8ST^QJK)0W+ M*]=*OJVQTL@)0SBP9<@H8LJ_K+-.<+^$,T;G%F^4JMP;7;T8?K-^ M!3R^BY]N@B#V`S2'_;]ZCPOXWY_"8)&79_CD91#>_@B.A/HC?OTC/OB6/Q\_ M+>%Y.)*N/W?GR5;8^HM@QA^["]V;?[[]/][\3U56)%57_M0-M7"NW069,MJPUL^`&.H33*& M=A`L:X?`\EC1%&UH3OK#J3WM:Y/)J#\<2^`APX>V;6N&;!M_JG1PUN]XCT6. MOF'E$!M6&MRP>H@-JPUN6#O$AK6F-KS--MYCD:-O>*.IN<BVS_+JW#`.,NLU[-T&(_Q\[_/=8M\S9 M4R].4\I[3I*??,DBLRE8>P%K'A78H7OK^;[GW_8\OX=7;!>]F1O&#OSEWKLA M-J7IW3OA7VXMN[32:)]$)8//`O M>Y]Q8&#OR77"GG-/;>![=\Z#V[MV71\>FN$E+P;CY[TXZ,T"'_![C__$97E' M4O;K)4`"?Q"B#X)=Y;BL]/4.]MN;)XVB$#A6^M^[9W<'\!%-B8@$&A^PJ+L7 MW/2PIIOBA?,RO\U%6)C0'[LA<.S2\9]Z"^RLWW/B./2N5S'VR2>4IJ\H+>7R M,16]$%:+#H/4X[+LE>OV<(Q`ST`T(<[PYQ'G'4!-!%B!?T7!PIL3BFY$&7LO M$MGLAX%4;8)]9DG*?>6YPZ]7[$@@/GP7A!7=TL`!7+*[)'@FBB][">)DJ0', M#4*A?&["X/[9D>)@T^%UPMD6`O`G?KR!P]=/"1&$<#C_^5:^+,0?X?%UNND` M<"DO%"[UA<*EG1E<^T2Q*^"2SQ)Y"L7C9<`X4V^=.H@JNMLF.?:XN7A)< MZ@N%2WN)<-7PPLX5KFW>RKG"MXMEGU3&UL550)``,>56E2'E5I4G5X"P`!!"4.```$.0$``.U=ZV_CN!'_7J#_@YL" M10O4>6U[[0:W+9S77H#LVG5RO4._%(I$V^S)I$M*2=R_OD-*UL,6]:1",7=? M-FN;C_D-A\/A<(;\]N^O:W_TC!C'E'PZ.CL^/1HAXE(/D^6GH^\?QI.'J[N[ MH[__[=>_^O8WX_%H/A]=4T*0[Z/MZ$<7^8@Y`1H].J^4T/5V=.7X;N@[`;0V MNL?DIR>'HS^.Q+_>"+[Z\7)^/SH_/AN-5D&PN3@Y>7EY.4;>TF%C2GQ,T+%+ MUR>C\7C7WS\CRBY&WQR?`W&97^8T)-[%Z&/FJRN&HIX]H.EB='YZ]F%\=CH^ M/W\\/[TX_W!Q]M=_94O3S9;AY2H8_=[]`Q0^_?-8U!C-C^?'&9"_&SU0PJ'T M>N.0[6CB^Z.YJ,5'<\01>T;><=RH'^,=`4L)_W24@?CZQ/QCRI8GT,V'DUW! MHU__:A05OGCE.%?AY<.N^-G)CU_N']P56CMC3'C@$#=743165/7LX\>/)_+7 MJ#3'%URVT=]$A]\RZJ,Y6HPD M#1?!=H,^'7&\WOCH*/YNQ=#BT]&3RR3C3S]^.!75?WM-W7"-""#U;DB`@^T= M65"VED0?C42SW\_OO;GWZPN^( MAQER@_88#IOJ2NPUYJY/>8^=)^Q#7XA_AWSOEK('QQ<_4Y"/`'D_X&!UXP-[&=VLMK#(^G2Y M!4(Q[P1<3_?Z^`&+=,!"%U@/%HW>0:[1M#X<-PXCT`V?(?:P@JDL%&T8=`-0 MUJ8^RJ-5`"Q$Q/7RO[)A?1@2O7I'Q)@+1:493/T>]*':68(P76\=S/[I^"&: M+JX1P\_2Z,B0@W/B65%.X6,4$ITL(?;;28YU26N&38)75OSJ@24MZ`3XK!^TJ#_N>;)DIZ MU;%%UL07Y(C2WB1(-0:9(S=D8AF^=#ANSQZ-).BT65TY4M`!@A%Z\M%7!&;R MQ(%6MZS3"G@&;E*&.]";;4,?95>4!#!L"`9>MX52HVE].*0)=RD\ M;<*.@QVX[&#F.T0SJL8=:9P+ZYW`TB7!_T-R7U%(3OM)4;\+G3*XWE""I#Z& M.0@&.:8>=F?"CP*;>,J;[J<;-:T/1]PJJ$OI#9I!ZPP%L(L7JO02$;3`00\2 MV;%;S7-P17T/,2ZT%0_D&J)_^M7L0Z.$KAQ09-`A+!KA6KCXD:?R^`F#ZW*; M"%Y[T>W0IS[D,&F$ZX++^3\E.Q-JNKAYE>Y9_RKD`5#`H/_/B"Z9LUEA=XZ6 M70:Y4Z?ZL#_2P/$36K8S1KW0#3XS&FZN8#26E&U;0ZS3MA8W)1BQB#_2Q+A+ M?(U\RI8.Z'C)6EBK.?6QM[./9PQQ<7(0L;V@<@8)>@TN?>K^U)`7;TA8SXS\ M@M@29/'`[<],V3?(:L?M;H'4]`TRWM5/SW#3'S2?8IN:2<]`RSR4_>)M6Y_ MPX"M69B;]=J[:$?>EVV_HEW2B4&`F@>V1E<]@X6=TAH'T3$3\7*.JC['MV&W M/3,A[7*ZR'IV8EM`.$=XZON9.5M92S]7NM(Q;#9IGCMZJ.F9974\4KU.M-8$ M#)0QFH6H(QD],RGKXKN!C5NP!4+?0A$U[GA@C-`L)2V[[YLI:"G^SM&&,K%\ M]JE&ZO1E'J[N8:_=8PS=3:/>1=![C@50`Q%/A*9&WXJ^-00O1QV?[/7<)SFE MX)/KSA>.:\KR$A#W)B/*%PY_DF'E(1\O'6=S(D3C!/D!WWTCA65\ M>A9'E_\V_OK?8J&?+CY3ZO$'F**[+GSG"?F?CE2E3@Q1*LS=FU=AK`A!59*: M*V:"UO0TY9;1=62@AS`'IAN1Z2'\A9<(I#`;?/<%$\JD>((\(!X`A'PKD>K\ M@H(5]=(3*Q4;WI("<3>F!0EQ?E2)BB51MU74%Z1 MS(B0)<'&Y*W&D@)Z13S=B7I6SN;R. M"13R!'(.M)!0'+PJZ-XO9812Y$.;R\^@!)CCBR@^;XT)ALV+7(;+&5^SCO:/2"1'Z>_`R?-@S+M>'3T?G1*.1`*-U$@1+#1UIWN%,&?'A?#*C0 M+RGN/[TOW`96E5X.S>[M"X<0LZ!B_)5<@8 M(N[VD3F$.VX<\B@_Q=/>^T\8Z9,.+.K0V=#XUH$+@\74()Q?@S!TZ8>R;/*1Z\H;&*9+DRNKD=]815#&%B(O,S> MOQ*`HKQ!ZC.)^[6H+RAOB/I=SN,U`MTDKDV"R0C_]U%ZA0,+XBPQL)XVB`5; MH8V$1T;X8*2S7`U63_.&>=-A;]2T%2-(D[3>F8-A8ETY&QS`$J%`I"AMA')Y M<8:*T.A'+8S[Q1RB79\>720+!E<.8,/7E-2LJMU^MNF9"O]9K2AX"ZOY4"F"_F`E: MK]$"@<1[H.LBH:DT6,IJ#`7!5TKD6H3@] MH[8U5EW/!!H1=?*"?=4"G/QL)CPO3BI3QS#EBIB@,3.,(I1>*+Q_2LY_N,"N,H&E1D4CD?0KR@*QR%]2QNB+H$P5-E]0T@C% M!U9O8F?-A*.6DDD``>8]C]HAO MSX"R,@Q1C:Y<529@SRP*I5"#33?@*3"+3OH/@=4V6%.\%AW*JP=2;=:F0"W* MZE`#K7)*IG`MBO"I&-?#'6"*\AO;4.YMO',Y`O4.+:P,9ZL$7VW>6AF,58F[ M/++#RMBI2LQYW[*5>7>5&$O/OZR,PZR$7.1>5&3<68ZTU8&Z(N%KV*RH>\22 MY4[1448"_MPB1=8*O.)L(&6`15JN#0/*O+0I$RS2>VV84'WFGK+"(L78AA6Z M/$T)PSY89/ZI3W5S+"IR'Z9['#N7BQHV[WX4=@K9(E=:;&I$RQ2,/7.5JLY5^/CU05F?[OBPGZTA%2 MY9E3'P._14/OZ5M>O`IB#-*)99$IT1^/#L.H4P999'CTQR!EGDC*)XN44W]\ MJA/&D&Y;++)O>A2MILE6*?_:6$H#3'N=.<)R6L$Z!U28O7EY]Y8WOR,>AE4X M,)*2*WRI=^N-@YF@ZFKEL*7R5F-%X>&D&$4OHH(@,^1P=(VBOPHTC9HPF3K2 M[);AJEIFD*1FYIYUJ42AKF$D]66Q@!DJWNQTY4NF"P5:7CL+R1-*7X"3#05\!@%R%/WH`< M!S?7%<&FK1A&.D>;D,%^A$<M]L:>-"MC(72X_XU#YH5*1FV2E,):?= M[^H)N6[P2R-FK;R+IQL_2H-WK+RGIQL_*MWQ5M[KTXTGJEP&*^_[Z2P>!V<< M5EX&U%6+5F106'DK4#>>J(Z3K+Q)M1TKVD6]6ID;WDU62@+Z[$S][L:.>JDA MBEMZ?V:5UP#U,)55&DI6W"/+-X*?\ZIV$K?6GF&]?8<*]+65AYW MO3WK:KX=9=,9F8D96_:*D0UG:1HW"!H?7;#@Y*TGQFFXD??4IN"SKJ9&RXE; MYXIOFPX^#;&QVD?=ZJ34D-\N=PP^/+?B[N;2&6+R5%8NEP["KV!DU;^279]I"^[XF'>73%:^9^6U_VB+Q'.G-8 M@%V\D40=[D&132$GT-UT^(76-?D"[G")^&`0<; MS9,S^C]A%*JM0-ZVM<$@%ZJ_F-HFB$M:&1#2`^+*M$RS-DP?!+91J^\M&+8K M#UKK1(7[8.!F=$MUD.58PWEFI8>@+S;567*ZN04,V9R9^(KA&<3)Q>UITL@` MJ;P7*@?+N/Q;!S/YB@6(7$'&"[]&'"^)4%`3_AWREO)^_N37H:"8K&40VW3Q MV<$R&$-H:1![4HEI=X>]P(;LQ).%DPRGQ#-,.(I1^4J#`0M;P<0NBJGY@AQ1 MVIL$Z<0B<[&6LWB=,@NC\+GHZ4)8(2^`S_`,R(9<&KG^.#[L@L'&?(6\SY1Z M4-H&LW/[51EXVZ%8>`]=&7C)]NVW,#"U&:;(F'N). MHS@+2AR=#Y#8V``$JX,N"?X?DG''Q6E<)D*,=SZ88I+*KP"O6=G(V3L^8E]/Y+=2Q2,W:,'0\X5[]`G5(V[: MFJ,@9&0JS:WRD/PF30P#X^[Y52E7=5'E*@T#1V:FQ-\V0J2H/@QL\9+0"%"V MCE%-WG2H]N[#*&.%E1:!7G[DIZ^52[U>AI3I;(4Y,/"3=;W\*5FU%>?#`\_+ MCNVBG=$W`TXP%&`F7ZW.`!^@GT2:KW$<27J-Y_#HO))WK'-YYT&=]]@OMXD- MV\Q4+=P6E_:$@$,(=D+Q@^GQ&602],#EJ_`'&^?.31I[K:X1T?'7ASS0TJ0E M/)#.::TL2%H<&@0Q,']9@I=FY/FBQ(':4M;NG-*K M^!6)<0.7LCX6/]T\+E2&%B02]\UCK2NY(CEVX$X*8(NX>(W+LZHIN4\.\6Z@ M<0;D7<%*`'@9[)T_([IDSF:%W3E:FM[Z/]+HUKZ(^NV,42]T`YF8>P4#MQ1W MA;P]?5]I@/@C3:)T'P*@)7IUB"T=$KNWKF#)H#[V=H>",X8XE(DY7U`Y`QMH MN_3%&TY#`O<%L26(R,%-A");.OJ8(N#O"<*C"%TV$:RL!I)/U2;>'$E%EMZ2 M.71AVD_FMHS*`8I$DJHT]*$O2EMZ)S0/4BSBD-FAL[B,T`'R5>3BXFC[+!Y] MS<;O#IW3*7WRP<@D1&0D5QK;E#S?]1ZQ#%"PZIPH#E[$VH(8X'ADCTG% M)7'!%E#9,CV:$C]$_J.E^#M'&Q$Z$%W$-&31KT%O%9>_/1'4/,$(P8?_`U!+ M`P04````"`"A:5A#4L$71*`^```2L@0`%``<`&)C&UL550)``,>56E2'E5I4G5X"P`!!"4.```$.0$``.U];7/C.)+F]XW8_^"K MC;BXB[AZGYZ=[IC>#?FM6GLNRVN[IG?O2P=-0A*G*5(-D+8UO_X`D!))"0`! M$B0`%O?#3K4%@/DD@,Q$9B+QUW]_W41GSP"B,(E_?O/QW8/OV[/[^[#*)8Q!%8'?V7SZ(`/12O_^ MY>7E'0A6'GR;Q%$8@W=^LGE_]O;M_G-_RPG[Z>S/[SYAVBJ_W"=9'/QT]F/E M3Q<0>/3+`2;II[-/'SY^?OOQP]M/GQX_??CIT^>?/O[E_U5;)]L=#%?K].Q_ M^?\;-_[PPUO2X^S^W?V["L;_>?:0Q`BWWFR]>'](+G=T#!.`S"-X5 M@T8%WC/,T1C]_*8"\?4)1N\2N'J//_/Y_;[AFW_^I[.\\4^O**QU>/F\;_[Q M_7]]O7GPUV#CO0UCE'JQ7^M(!F-U_?CCCS^^I[]66V,Z@O30O$K6#^_S'_/6 M*/P)T6_>)#[EJ02<,VX+\E]O]\W>DC^]_?CI[>>/[UY1\.;?R`?_"I,(W(/E M&:7XIW2W!3^_0>%F&X$WQ=_6$"Q_?O/D0SI-'W[\_(%T_Y?+Q,\V(,9\":[B M-$QW\WB9P`TE^LT9&?;;_;Q&O0^?/!C0E986R_8]:?=>.-3[CG3>XXZ_/:1X M99)/+)9SO,DV8!:E`,;X"\]`D5CA4+J)7:1K`,D6@&`-8H0_D7^S/,N$7G27("J7+B(/H7`9@J`]]:)!!P1PYT&@NL@51L93E(:^%VF'=.&A M]764O*!Y'(00^&E[#*=#=27V,D1^E*`,@IG_1Q;FG$&S.+C$BQ1AL4!^"0+Z M9R_J(&U:?T3G!*^/%`2_ANGZ*L+L MAC/%GT!V` M#VN\E8F@S=)N`$1CZJ,\UP+8G`1(+_\;!]:'X2!7YS&9']'*SPLJG\VAJU/@IZX0W"99O:!$W4KA78H12H(4_VF@QSZDJ<8=II]0-SB@!*0/P MB3-YMTG:_W[31$FO,I9E37P%'FD=S-)28L3WP,\@4%UW[I=OBF/N1XTQ#7!:+[?Q'O3:C%\NJ5NF>C MBPREF`*(O_\%)"OH;=>A?P]672:YTT?U87],4B\ZT+*[@TF0^>D7F&3;"SP; MJP3N6D.4&5N+FQ(;L0`])@?C[N!K1`NX\K",IZS%NAHE41CL[>,["!")'.1L M9W2N(`&OZ7F4^+\K\F)`PGIFY%<`5W@MGK@]T;;P0U>(0OK9U?+S5C+ED=CA MJC9R3T3TS*"Z`S4.[@$5\3,?GT+I0:O/+=;JXSTSY-@AJQ\U_PNFH&E>[TW? MZ1GFP2?=Y](5?J1G@"P_=9]89;]G!VS-BUGMJ[TO[=S[LNMW:0L^8A"@YHF5 M^%3/8/%):1.F>9@I#FJ.JC[G5_&S/3.A_.1B6?7L%+8`<8Z@TO=SY^UH+_U< MZ4J'W6S2O'?T4-,SRV0\4KUNM-8$6,H8S8NH(QD],ZGJXKO"![=TAPD=0A`I M?]@R1FA>)2T_WS=3P(K\[SW8)I"HSS[%B,RWS,/5/>W27RR@>]"71<_)J-[G M:I-4ZA\H5[PH>G-6#%S%=.@5QNG[(-R\+]J\)QUZI`=_*I>9;P.P]+(H5:/N MM/LPM"8;+XQ;DYKW[I-2^H6W&[!Y`E"1S%K7'FER"_R#RK(WG[X6-Q\^!?\I]]F^-,!^?QUY*WVPT7>$XA^?G/Z^_O> MZ;G((,G\OL9"S(O^&WCP*@XNL:ACD,9MVC^5^SG+OYU'J:_QWQ"#3'[;H>DD M/)*CLFPY'(V598]W%YAC]28BE-E\.&KS>>0O3G:[X>A[Q,,*R*(_]T\-%6@A M-ER(`<(@I_[[0/3L+C`#('%3!N#U_X(=CZZ3=H/1EVPV2?R08LN-FN]HD:7D MXAVY$\DG5M1I*,HO"P.&0^-EU4+IGYKK,`*PC/QSB*JW&HHVDOR`3_%>G-YZ M&^[6.&[6/W4W8.5%^;=GKR%+`!^WZ)^F1^B15?RPVSPE$8.B^N\'>DIK;0;K ME&%3;S],8?7)'5B*/DN8;"24T?Z3"4O6G240G]-_?O/QPX=W'_#_X=;4D/V) MG-U`\/.;%&:@_&,2I]C"O(KHD0];R/F9[\W9%FL7B&?BYS>?WIQE".-(MGEB M55]\.#H#=.%(75?M&?+NPT?"#J>1'5G5);1/SD/C&$`EQ,^C@7AB-9<@_S0R MD+4C3`GS!^=A'NF.$MJ?G8?&-B1*A/\Z$H0GYGH)\2_.0^3[.TJ4/SJ/DFF/ M'P!^_#`2@.*#6XG7D('#=(T>HV8>V?5.*I1(T7QH M;H+VXVQ6)W'6)(!E.*%7!\E3V/X"M)U$I2WQW@;>$@*S'$8 MTUWL]B+S1\B-T]9F*,_96Y#"I;C>:ES>SO;T:QV:G2!J#L%K+9U](&=X.H-NYJT0SWQ'XJ M`=H746H#L,G$*?':%UYJ*YCJ+HD2H:G8DEE/6O\!^V;U7).L1TIQA/%Z188< MVY4V1[75H/%WKLUA;36,@[IG;`Z4MV$;P^=B'B\,Y:9,!Q9U^)AM?.O`!>LQY8F/^.\0>`A<@OQ_&Z+N&@:VC1\* M14DU;(XN7YLB5U/$87)[=3E?Z).+)R[<;G:("V?JX9G7Q6QQX3P_/$<[*3L7 M/`C#LY3%'T/NA\GQ/X1_T'6?OXXM,I[H@-!19-R;_WT[%$6/?1JPW??O\-QY M.\+DX@(3QX;G-#9QYF"^'R1'/;.+(0Q8VP25&%TC`$Y[@]17WJ:2HI[1WA#U M^V<]+@$6EN1E4+P9\;\C4!CCLPTIP98_A("U)A9:Z8[8D21R2F*EVXT0K)[A M#?.F@R-1=10C2`\OU]QY(=Y8%]XV3+WCJA1-K8U03M^&XQ&:_VB.K@:/ZU$C MY%;,)T?;^;V,(6@ MN,(MG(+C9B9HO01+@/=N@'5AONP;#5I1#UL0W":QKPRBTLDPCHJUJH*$W9^8\D?:<];@\!_R`>^)B$` M0)A\D(HXV4],EI.*:4]IY0.2N?QJ>A@O]Z1 M\%X2SU*\'Y^RE)#XF!"5A(U:F-!"#_NKF%Q\6@9WER\-1R3-'S&7U<,.FE4S M>CB!H$/*RV=[$[B:P369'25*>Q.S)*906\9!R0][[V-WF/5Z.8+/]B:/-V,L M/<0E'GM3M_EXI`_&)4Q[TZF;IXU_:B[QV5>L7!Y?4Z"N1&EO72W)63QU)QW` M_.SVR!D$5C;VUL819++6\9;DTBK*XDNU"1@)S\SF_A&N[S)&`*\[;+:': M+G@DH-9#L`=HGVP7.Q+0A+DJ)=(1B"16#*4$:/NI2V9#MDG6*SE@^XE,F@., MV9U*]PTU5ZJ9"M7I$T76R[FT]Q39"3LG,EWBMO>TV06W*#188K?7.NR"O3D[ ML>2`O09C%PX(\Y)+\/::D%W`Z_:LEV?]T:L'3D)?R0%[[=7F]+':&F'%)XW? MY-<.DW=WU86R\,I(>7KP:F#;)Y.Z4#F^ M-2\8,V[H"#H57=%;D./8GU].L+WG4CED\J99B=G0F=26NB-F)K./?)QZ.)^1 M[>I&@:&^67-Z"]6-4D-]\X5;?<%XB2(KV".3->M"C<4!%I)JP1(7"BGVSS9= MR:NJ-12M*[QUYQ&[>PW2T,=$FJB8$47)"Z8.7"?P,LF>TF46G4;*&ZJ5*(UA MN!H#YO@"TLD)J$KD:+_Y_<%^<%O6P`L$^J*U M%90OLA2E7DS$ERSYU2YCJ6?0`S6_?9KJ`S"/.8IB3+*S>5R2PJRADRTXA")- MT&&ZJ.5J[7^P]+(HK=O5#B;.Z$P$PC+\FOEI^)P'E1N*'O?Q*6,UD^>;K1="@N8"[ZP5 MM\PNI[$)NL\SA(4%0E@J/(4QS=*Y2/"N"XJ4'?JB5:[.*ZD"\SQ9F7%>T\ MK(9:=E3P>6%PF4$2TZ,\QR=%#N4R/4R68S[D1EZ];K%B!\73;AS^-_4R@Z2L M^W%4[H.+@M_#2#GIY1(;%8OEU:N_]N(5N,>6QR)6JE"F-(1581`S''_UL2;$ MZ[=8N-?8B*5V]SD6F`')=,"KFBX(AECA34&G,^DPHHN:V\$=@0BH.8P9FGQQ$M MQ$51::+!W#\4',',`/"99N13OP=Q@C$B1`S[7WF(*2\DGTOB:2IO(N_(?\[C M_/S$F7U1#Q,(2`D7AJ-,WJI4&,!N?`WJL<5`%N$M'1$MYY,U@-WXVLVG:""+ M\#(*`XO?7M>K%WAPPCCJ7<=;Q^``!%G1E'`4U;2J8YB&.D]V&;07V.[=[&L1&.; MP?$ZFL1#+H"3?1H'3;-3;6F2XL=DYO^1A1#LPU0@OUE$#Q[Y+]QD4Y4AK,!X M7`57%MA)/RO0J#[CK3"`H7=.#L+J$I\L%;+"%$*$K#%2*815P3; MOC:UY$E%=1332+'!AA8\%U25X!E&RS?QEY#ROR4AJ4O$B1^ M_ZC>T,P+0:QH&H=F3N/I^LF(W@G*MMO\XH$7[3-#YO$R@9L\M-_PT(UD;X/% M=GM,^:L7OQ1D4+B0+3T4HX3^:!?RK8=B5*..="%S>RAF\;)4C6=]6\0CEJGB M0I'&X41X0SJ?"\4=AV(6SXYTH29DWSQJ%_)VH8+D4*M+$((P7H+2(C:I)%2Y M4-E15\9[[64X9O#(A?<7=')C/V;76S$VO]^@<+&@OHFJ^5#ELV4C`GB:HES" MM/>@I9XN*I:-K$1G%UXLU]@5O%1Y%]Y,[65M M,'.:S;^P^OT]O]4^-?+H06>9B*4+C\OJ9P@GV.G"8[1ZF-'Q'IL+[]QJ6C42 MB5XE-^QU_^CE1BU-K(1OKP]'OPB1RG'E1$W,:)-GZL*SBGK7 MBO0EA)(USIEOBJQ1N816U/V$ZURH>ZJ'?RH7`(W7 M29TJ/>NMNMEF"1E_<:]O]$)E5**W]W33";WPO%RBM_<$(X=>K>18B=O>$XID MG5VEVHOERPT@7W">5-$O`]AXO)'6=[-V`$K*]IJ+\''?+N2EY84TA'L'0Y]W^4[K#]PAE&_HH,YWQ1^^U\B,Q<83OM@Y* M@NL\GL>%=@01"V-O.?`IN5\]XB_+#"TFOM9A(;0)#1^F_N-"HVR*<]9\!`\`G\=)U&R MPAOL:^T,7%OOS(8:2"#G3')]@G@Y\=GX<`^=?4V=&$^\/=EVI.G)A6N^>C_? M??7^GL"+R,,G&KXL41G!,H0E=;?>1KPK54?Y;I`:?ZB@6(E58G6U&^NX0&]J3#6J7:6&H]76_`C_3$+K!L_:W M$*7>5Q"$/G&I^UQSC-]6`R%?O3A;>D4]%SP#]+A%'7RY,Q/`YQ!/$C%1212# M7'1BD-AF%!/K]:OW&FZRC7!=UMOH8#$(O"4Q4?E3?-+$BGJR9;+T%RBH`MG4 MS0HL;E?ZK68HEQ&YQ;)D-0^/1$\C%2^)FUQ@XI2_&Z-.*"2J+:RG4(_[X#[Q MUWC]`"BALOAMC92GQ,0$6817_4.XBL,EIBA.3P+=:)L@+T+"4IOJ`QG!VTS< M35,!5)4AS)0=YG9KS+N1B*\,4 MJ/LR.]'>"U[*>`4G\RG:@I+U?0!&DMWJV"+ M)ELZ$%S+3&Z.4-J$7S#M_<"W8P%(5'64C33OI1M;-YN_1B.WUEN$+*O3KAPE M,[\$I/;`L&QQ96^TC(E6.2-I;KMP&ZL#-T0Y(^8OZ\A)CI8!UWIUE19Q/?,; M14J"F&&/*Y*D0T2WSB&I(*GY.XYC*PTI)R).0A&UYRZJ?G:;$`DVM2P@5[8A M(]911704TS5^E[88324:!@SN?OA3G,:YC^]":;RN+%"ITVJJ%EZ/;!!>TW3A M/5SM\W^2DNO"8[<]"$\]%\!=>/RV*_/$UZ9<>-K6KN734*'!A;=P;6(HIZR` M"Z_DVL3&YNHL+KRIV\5.:'VUW(4GB7XVIZP*TIXDJ\,I%$#Z:9=MY[$=9 M@"4-54SD#)MA:V?+KC+49203]Q$4Z"N>!JU,ZH6P8)R6H?64JI&F@\Y:U>X" MQ^ATC&CY1!^?A4Z9H&E0Z_F0OXR\TX%^/Y3EF*N/(0OO5W<;TR$NU)Z$ULF* MZL"6\X/[.)\6T2`/I1=*W#P;VCMA[)<[PM5HC ML=Q[@/!Y>9]JH??A0+LL-U/4B$2D0RF(B(D2PTW#R"AER7QY?D<9UDR(N#QQ<0 M/8.3E)GE5;CQ>TJ*0A;0] M9:\[J&_4#?M"M3"2$??1E0=C3#6Z`Y#>^+](-MLL[>@W:F_/'Y-S[J'0;_(I M-'0:2X+BN/Q?MR#-_=8W"4*S9R^,R/9Z3/`"W"3Q0YKXOZ^3".\@1*>3,_6J MHQAZ4FH9IC>"9[W*!F;/T,R-=+[+F4EK5DSL/IJ$?;CU2"N,!^%BH"S++VXYF`OFO(%RM,56S9P"]%;C-B'%R M&4:$=#I-:)&E*,7F#(TD-/B$VHYF#7(2;F53JX)8,(I%2$^($\E4M3&&=L[( M60ALMXRT?!NQ'443S6:'-H&7'HY)+[T7L%2',V4`>OSG() M_#1\+HDCI8/R0(`7XZ%$%&>>Y?OK9"S+J<%HX+[GCLF&O0[[BG?3&GV+X:$P&D9^ M#F(LKL@#++N[)"5UTO#!;'<)?`@\Q.)9E]$,/^!\L28U@.PM+T M*<+4(T3NQ%RA--R0,T)1/C@?XML6BZ/S)(L#SC+O^:-FW&I,^KEN,W9KBRB? MXT,]-N;215S5J/F5$C54PI$L0ORX]M)?DRP*YINMYZ<'G5MH6S7038,-Y382 M:]!]*/=8%8S0_]/,B#;6FLW^('G$"F:+S1X?>QA14L\4R1W MBB;!6N.NDG]!9G]GE%>`L,U(1BK-@:>TG(EK+X3T`1P.*EYK\Y3O=1Q1Y_0^ M;'"'Y07^P5O)@1$.8!Y?7BA;`@=M:(9>&#Y[Q*HZ%/<^*:-\0KF@RP@P&+JD M5I)4+HO[$/TNN-MB!"IYM9&1M_#&M0WI,4.'+916X)BKIJ"&!>8Z7TW\"#N:_VVO/I.>KJ M=1N2[\SCA9\F^%.5ZUH/(3["`OY-ZZXC#@#J`6Q3^K$*$5P05UH(C7OJ"'F<2,RKGVQ=L* MB>%O_"]0LI#6$+1BHGJ+.*;,2/ M"M".>VH0(JS/?/7(%4S\O\2W/8L#(NH8<7""YNJ6(5& MANJS29$FC?]CF#"KE M:9>/Q=F<1R4)6W"6M3F-2G%26P7#;4ZD4L3/-+5LSI92Q*=VFK4Y`:J3M#IZ M@MKB@O424DG^<.Q"$?D."_G$96&\J'M?Z[>2LU-B_&AIEEY#Z-G>5#T=R.1. M#:K%PZR&*A52+A!_'@5BMANO@/BG44"4S7\H0/]@^2%>+9V#R0BY0+!Q(:;, MCZ8TD"9FG,3YS;.@60LK)"PT+H:3>'FIHNT]_;;*;V"R@I5V4W+`WA-B+QSX M?,J!J3+(D"YJ481-I,)MQ"F0W]U@6N&&EMBBXA!>Z:7KF"%4[E5[_7EZ6"&3 M5U1R0\Y+8N2&T0V)OA+NQ\%!#"^6K$,7N@0H7,7$0SU#OX!@11EQ^-7$#:33 MIRN%"3O_-=W-"1Y+.<_]ZM5'@]T)E7/&RM!3JS01H$3=FFUUX:'T=)2]D M:H&13+,J!4T%W=AM3?C0+Q*4+I8/7M3@-#]M-^4T33DRM>U(]BS9KP?+XAY$ M=&.C=;A51"&L[$$ MI-T#G[R<&BY#$%QC/3_S_6R3142O+2[F\SA-\AD\O+)SET`R@;<2N8^:/V,]DY3;RQOBJFV M!(:$J(=%"(2S(.XSY8%US`.S/N+8'#]VH4Y2I_BQL2C0]QA3[5"-4O[`Q_`Y MLM2236&%`[9%B9.A3L4C"!.:85K7->Q.6-$^_KH89C3+1>$1P'CD M42(=2<:+U6U;MF?W=Y&GI'4"6CN;7,C6[H]G[9V;+B2`-[I9JJSBQ`C-)W]+ M&;X2'AD)Z6V/M=\\N5(>G-H$GX93S6>Y3SD%TCD%U92"LCX9R2DPD5(PA;M= M#7=/8=_QA'W'$H:;`BHZ`RH6H3`7H(/`0^`2Y/\[CRLW':C.#,C6F\?56U1U MI*Z9(CVVR!,;5ZQ9;HD"J`D:][52XHX>`K?4!PL;K MEW8>J48:*K3<:3S%@_J.5TQ1'PWQ"G-!GRE>,;YXA29[<]P!"CT'%?/!"+E4 MG;%YZ0BL2MG(C\A:P M7Q-H:FW#.5+7C1PKS>;)"3TYH1UAVN2$GIS0DQ/:M#M)\P1('B/,>YZGU.=N MWL5&N]`FQ_EWXU^\#F,O]D,O*G=<7ER?)$!72['3]YB#65J&1.+#(]OG'@H[ M.!9'TZ?,Q?X M2R0[&\95>=O]&H(_,A#[+->$2D^CB"I/S7\2^^($/8PB8/%5Z-22Z3DZ1(;2 MIUF4H=/MK8R./\9W@=*FV3SH(CGQ(>IJ!!/#AA3(X9N?*PSCM M.H6'IC1ZI^J>#4CC(_1BM`206.@/`#Z'/I9BBR5K7Y'(`F+_)%0(6C\Q\:CQ M$U6=.I`[N)"9U0QJ.$EK"+=_XQ7GI,\BJ`FM.1N5+DCNW&99%<%&\@?MAQ@4!YB33Y M;YOX<>*0LXD'[5Q4YSXO,R'?]LQH-%+R60%*VA@4XZ# M4!:(_7U5O'H/L.;WB)R@,,,?.Z2(V1P*$T*A#R>-6F*QJ>H6YGG#>QK`WLZ)NDQ3D M=2'Q#)84GKBMCARLTMU-.)B9#&\`4F^KX;9(XZQ_@0"O9OBX]N)'/`[X)8L# MDHR&=U#XFNZNPV=PZ>W0G8?2RPQ.QYV[ M+MQI+QH?_#4(L@A@F5"5X%1\8R%0:&5R86`O0$19B6U',X(\#S5]`MMU MZ'N1,(3(;^\T]88RA`ZI]%6*!/DT_/9#QV)5#:6JV=IZMXTXJ-J%GQS#SKR+ MJ1_80YF1YIV4(_.O2$?P.JKC$83'-7!`0L<8#X%+2(A&%4^P5D\BQO-"=(,B M1PD7_']*H,A)S047GA*HNT=UWYNIP$ZCZ5F3(7PN&)>IW-4HU5O8APN;`ER0)$#5S[P$" M\!GP2RDU]S2*J,F-SFAHE%Z^G[S6Q"B-]][+5W+B";U(;9'P.QK%\VL"?Y_' M=S#!ASDU0(*>5GM>#1TUA-+1WJ,4US/%ES+UT"D3]8@]3(I\$6D=%SQ+BG!% MXL:\(T@[7(&V<.'\K(CVR!UJY0,QXRPY0Q*9PG@%8A^?1&9!$.8DS>-E`C>T M>)#Q+`^!3^U\5_&O8:($D9E.0^K(JSCP]I%NZCN\MY/@B%A!0QTDP*M&-]W(1 M>>&&+P8X#760$$9X1V,!%V1^VD0%MZV)DSBIQ5A;V^>[6R\EB9M\+2CN8QY% M08TP1T34PWD$AO).=$#L=)+PW;\Q<`X]"3VY[\MAH(FR*$'JS+&WP46%'->^$AD6!G-#1/[VF-?B'5E>8. MTZXLP=D+MQQ][<$50*S\TEBRQF2VCV5IC;0++D" M:XT=I5O3OL&*X\3`W8#%\@[;`_C/RR5C&2AT'(1$)O>4NKI!IB%CETD>,<$7 MRXHU*Q(7\@.8Q[>;^3[,O&B67G@0[O`?1944Y?I:@"JW[[$AO0D1`L%M)BBO M)]75&DRYWFR!J-[1`CR7W@8?>M",W)@&@<*R8W6T``]Y)L''QS;JF"=.1OQ' MD$>495#QNUN`3<)M(>KA/`(K=-$NW[L512FG@EC]+$!S!V(2,\JEDXH\8W6T M`$\9&92#46EO@OJOWFNXR3;"RK/U-D:H#.-F*FMM-!BW7[,H#;$%D,+03\OS M"->U*&[?W8N'TBTD+/M(_T7H_5AA%?G;;[?_<437_J\:V+$7'_F&F\?ET7VV M@H"EXF1[:22N]*9B6S0$D'6*X[?52`A=#,')8A"0P^NAD:@[")[#)$/1[CK$ M1B">$X1F/LT;\5Y0%C*]-@J==9*:I?E;E>5GA,2QFO=,SN%PH$A7V:]G`@M; M7Y&\?:^>B?LU3-?TOR\`3,E]S?P5,A"'RA0+A](`@SZ"=N?M\AH_R7_BPR[^ M"MT"X<9C^SJ;^V@@K!B?-?PU3#:'OY9"]SJ+`Q:Y;4?J!40;]B\%[@'R]^-42>TIJLMC%!82[`4'MB931VD64]PXS[9>5&Z(]7D&/NF M^JO!6B\R]5W,5Z21IU+/U-'KKA9$\-1#XFJ1>5&@/1%\]!\)@<6T%YYCE?`M>Y:+D.QJ8?9BA,Z;MU4KW>Q;2;C M%U/EZE$,P0PKBH0WWD-6N!UB[VUDW2C;Y)(8K^;4%Q.X!HO];Q*U1-Q-.AA_ MBJBWW>?B@/VC?76WM6,_N4-3HO\X"O0*R7XE]'%8<]TR]4INC,?` MX]7A*K&.S[03IG67P,=CTS5=7R\QC\><8U<,*)&.PX9KN!!0PAV'P299>::$ M/0Y;K:&&S`'NIW&89\V5:DK$XS#)V#YG1MVI$OAX#+):&F<)<#PVEFHEPI(' MX["]U'+U2_3C,<#4K@"4'!B'.:98B*.$/QX;3>+F3PE[/+9:ZUM;)3/&8\%) MW*T[P/X\#DM.HG!`"=F4*2>7#2I57E9@R]7+<1A/`)3+^M0)VHKL3HFW&B3J MUQZ<9XR2[>5ZMD]RM8`HN!EZ0/JG[_.!"E.2B%\$E9][Z&#&>3>8KDB;IBJK M^WU8O\M1"AG[;$559-+WDDIY8Y]K0!5T0\&=$JI]1R`5J(=*/24@4UI15;:> M%LD5)3L[*UO;P'1/MK*J\!Z,..$S0*6DM?-Y9)54[2,/NW1!6_-S+5S4_;/` M]@6O-IUU'O#>G"D7OIU.Z+9XV94'2OUDMQ="O5:S*(G919=$;QRP?9,KE'G= MKW7!:S'E]K;8F)9'VGCWO-S@]HFS%G@%+_:52"T^&\HC%3Q(=D#Z@]42ZZ0^ MULDUPA-`%HL?1CVM*IZC\K6EF+$OE"F+J%XVN-Q>%B,25.?:[ZNVE59*_/:N M4691*P*\6GBE7)KVY1E(`R&OH)8S8BHG2,YVE:JA5;N)6D=O7CI*B?MN,.VP M0N6`BNMR-53$L&=6);9A4QTO`=9332BW2XT\?_ZP]B`X]Q`(+I(-R4K*W6(1 M*>AAS6/HY%I60Q&X>AL-M:TNP1)`6&?+#$)B.9"]2^Z-S.,@?`Z#S(NNO1#2 M7*;%DC(4W6707WOL\MFZ1C91WTZ)]IS@.4+9"1^ZCZ=CBD,(?-P4D>7.+5G& M:F6"]5>;;93L`'@`\#GT.1OW-HF?`<)6'=T/B)I\U=])5O5MDOXW2+$AF*SB M\!_GO>Z/B7I[1>9W`XD^DW<>A6_&,SU0KZ+$?=9'NIO&5@L/2JWT-2S0&;%0-'*'3T/ME#_X:!%FTM\].Q'G% MFD'GN[)-D1:GZI"%*9[A9FK.9YV[>=;3G'M M<%J882-Y0X^7:%_=XY)8T?B\R"B>/]QWC7'SJ1G5DPJJ1P`WPH78SP='LQK_ MED1X&.)M'GH]'GW9>8[>A^CW:PC`/EE[*'XRO^L4-V^.+[#H8E,O][C,LG2=0(&KH,\O.LG!`L6S%T;$],('\R^X+^^5Y-X^9R7ON%9JZ<*- M`RG[OY=/33Q3_I2>!X(>7Y+'=9(A+PX>7T#T#$B-#V+US/%1/R9UFX1N6J7N MAI^98,4S:@&E7M:#^;B;W+L3)KCC0!!VM+?;6'ZS6A$)-]>Q&BP[%F!S8)RM M9`XI1DHRW.:*55!OT.E9K;I8^T(7VGHF?=]NH1L?@#"=38/C5PXB^C@F+M,D@Z%RYD1=LG.UEZ" M*>@/28GZX[U)'V6X\+8AWLWDK_M'"IB,Z.MK[G+N1*SVPK$;#=EGTP6@(6X, MZ)EON=L#.K]E3XZ44I:3CBPE#M_B@-9Z9^0E-708.K;3DR!C!WJTKN\1!WT& MF!19D\:%8,X`[.K-4G(AL-,C?V5$J`LAGB'$*$?AF0_8C"Q-L45R2`^&F[:4 M(B/G>8([B8F?8[&\!6D.,O3O14#DQNY/D+GM"ZF2IIK-CM&^V=%_41KLP>T?UZ(/!CF MG9\F.2/P7MF<:=X_8WB.%.,IXHV^Y:Y'"8=OHNJ`WM%X5;V8:L2W+L,CNPJV M?V>>SN:9J:Q%4;:.GK&=X0HE]Q%OD7-,V>\\1T\OG["$1Y./?!`?^>2=[6]^ MFZ23O*NPS4BF4P*T:@.';;G>^#&P@3=<(F8?&K.!86UF8H2.+7,ST'Q,M=)# M_'T%2S3'!UKI1_/.4+,A`W-/H:V3").*YO3V(KVDI_=0/9FB:ER&&%]'GM31R:8;<#KT'V_U5>ZS?[JD8"BXS&,:K7!OE]_$Y5KG2 M$/9BI'?E.T',1QBGO!TF1"NQH6MW!%C;;83VJ`)KVNUK\^:E`?#%AC=N24F% M01JTB^-W`]:D"`(VJ6:^GVTR^N@XM8K)I0$,FS#E&$V@9'+ M_R65K"--\/AC%8J2B MR)S2$(8Q/D(L8J+\"IJRM!)U'DL`ID,9$*J;#^I)&,ABMW62ZDX7/*SV,0CM M$+!,(+@'?N0A%"Y#_VA7H%.IJ&5(8U$\):*+/_,U0Z%!@W+L,J)M'.@` MU2BF8PX3*U1"FU]D$.(-F9\EFY:ZWF^XRJ6&%:+U$QI$OPYZV!I`U\AFO*F8 M1***C@P!43*2N,_0@?6V9[A:M1RE$\,(?9(&F%F*#YN3_'4RIIO197/&OPXN MZ3'/C=\`L'"ZP*-Y7[KS"@T-,W`7>AEA]072^^P+(.\C;=>C?@]6(LH$[1!@SF&R!,,9< M:](]FNB3>&U,N)T)COO'CR# M.",;D>=F/FIE]NV&A]QO>P^VI"9'O*K<#CC?%3_*OI9O#TYC[*!B+L:#=%4>2P3GCEI/ZP8_O;`$B47(3K-7-Z8(O00H4VRQUP6N@-&?$KC7O#=`$BFNU&H\&Z>I-_00Q>2^LMY]98D#B%U:(H,KHM8?ML`/ MO2@-.;; MH`H,[LY(77FYHE&3[D_:QSO/!=>/-+@C.>:"WT<:V[$9[X+_1QJ<0!,:]P)I MG43>P.QAP-LD!>@QN0YC+R;"_.#T M1`NX\N+B%9.+)$9)%`;[)\#O($"X39%[Q>A<<2SNB[!.[D.][D--=\EUSS+[ MD*[],T8S.AI=$J<-C=(K]!#5&TUG]XZZE[M&F"D+WX$2E6*(?C%D_*@L;Z4R MMZF+Q03YQL17`%<`HIG_1Q8B^EER_,(3MTV*_ZS6M)],!IM-AI9SR58_+0>; MU/^D_B?U/QKUWU:D3$K>?25/&8(F56^CJB\]@ODL>A'U@Z-Y[$=9$,8K,J%8 M'H5Q!H(%W@IYR9+\"OEA89Q[$5XJX&$-0(H71/E4AX*=8(*2R)G[*7V`@CY(00LZS/PT?`Y)''N*6SABF;2:2;9V:C74 M9!M,ML%D&XS&-F@G3B;E;I-RO_)@C&)>=+%`=$X*UPF%.[GT+59'MY+.0.6SH+NTP6 MR:27)[T\Z>4>];)89$W*UR;E>_C3/":QB+%?HVLO?V49Q1;,LKTG[3QIYTD[ M3]JY1^TL+<@F1>V@HIZ#='OM\Q&`^KOEN4YL2"8QRIOQ4P(-`F,<'@5&YLWQ77(2Y]D+X-R_*%#BFYRMF.74@"&\4 M0`LPW83>4QB%>0DIC\C/8!'C#95!DHAU[J%0=67I^(8E7"*;@Y:=.KX*8HU-Z6C[U289;35,24&PMAG5\^ZCA#1OEODK;IG#F= M,Z=SYFC.F=I-%>/GT1Y8H]G^=:&:J2J+!C),7*B5JLHZHY:&"T596Z_%+D<) MXW5<.S.F9^^':N'*R?'8;WK.,_Z?!.ZFL"`S/4?`';9Y+NSBOJ]T.IA-![/I M8&:AUI836<9/69/RE52^4ZC/8O5UL(X/,WB!CP3[Q2KOD&WH/JGF235/JGDT MJEE>;$QJVB8U3:X9A2G]YRP.+F@YKQ7`C337=FHO!!4I9`M)Q4&F&A)6FB:3 M^I[4]Z2^^U#?JD)V4N(V*?%RBA9+$F_%_*"1BZ(JUT6"4D1O%Y][>#G?>3O: MRZA6[THR6YAV'772^Y/>G_3^I/>_&[W?60Q/AL"(#(')+V^Q$BQ+QFRV4;(# MH'A=MYS/ZHS/HJC(;EHL[X&?K.+P'WC&`5[&^3)0J%2E^7N3"3&9$),),1H3 MHD?!-!D7-AD7=SD#9G&>V'V')PN"-(3Y,Q\@QM2,N@+'N.R)UK/)UD6MAYNL M@U+HDT*?%/IH M%+JTT)CTMTWZFSI?UDF$24=7?V0$3!STD@,P:>P>]83J+'(TB>HPDPZ?=/BD MP\>CPY7%R*3,75;FTR'<8I5>K3[10Z5(ARI"3@I_4OB3PN_WT-ZY'->D_RW0 M__F2O`?;!)*+&5.0W15E+S%Q'#TBT7-2VI/2GI3V>)2VC+"8%+-CBGDZBUNL MGLO454K(KV&`;6):,C2_-?$,X@QW>#S1I`7'SW??0')"GK;=>A[T0P"3]7) MH?V#DRDUF5*3*34>4ZI'T63<`NOCYH9N]6>\G+O%9NI?WY-//'D(X/_X_U!+ M`P04````"`"A:5A#0%TAH%5]```'J08`%``<`&)C&UL550)``,>56E2'E5I4G5X"P`!!"4.```$.0$``.1=^V_C1I+^?8']'^J\ MP2$!))NDWG.9+/P83[QPQCY;VD);FS+PJ:)=_"+CDWL(`_#'+W9EKW>P3UZP:8+]\3Z M[06YN`?L7P-L"WZY>KH'[5P%6'G>YMW%Q9:<- MWJG3_TV6MC<[ARQ7'GRK?T<+*Z,^>P*>SI_.$_C^$YYMRZ6EUQMD[>#2-.&) M/>7"$W:Q\XJ-\T"H&>`%:DW+?7^6@/CVXICGMK.\H-4,+L*"9W_^$_B%W[VY M)/7`ET%87+WXY:?[9WV%UZA/+-=#EIYZD`G+>U2=S687_%>_M$O>N5S*O:US M*PDH"(4EV%_]L%B??=57M?Y`/7]SC;,?6(7?.[:)G_`"N`[OO-T&OS]SR7IC MXK/@NY6#%_E:F(YSP9Z_L/"2ODN#U3!C-:AC5L-?@J^YHYT!*_GSTUTAH%E* MEO_016M*SFT/F0=IFG@R4-=D?S!>I13&;QZV#&R$*C,9)6^75\$=@PME8FT] M)=!D+F([N2;@LA;(?>$"MVY_B=#F@C'G`IN>&W[#N=17U,`G_A)\_?E2UREQ M/1I9'FV3Z`2[ER^NYR#="VOC&-^?"3QP$>G/'DDA<+!K;QT=US*)_XYJ:O'9 M?&$/K4WZ"`N7V.K__'P&Q'A_1HS/`U53!B/M\T0=**/!9_6S>O9#+`M"8?!K M*.[_OO?U:!::1\,HOC\]/NTP?)=.VO^0HX=ZTH\5`(,2%[I-(^/&ZZ=>X\*Q MUT*^%-9O"]OD0AY[W$^V1[6QC'L;6>X3UC%Y12\FII$!WWEX[9:_Y>K'VV=6 MI4ZB?J@.1],4SUS@HH'*!BX<8NGP*Y,/O`*YS&L6?Y*';L\W0"]`CZ@=;HE% M^Q&,H35LT3)+A9T\A[-BUI3.8*X=U3)Z';&F5[OX\YPJ=?E&A%A=5Z0LIM?4 M4]3[1\IPDLM^W_"PBE-Q0.%.'(I(>!`EA2&A4/L M*3-4/*(=T^=ZZSC8JN@F9PM+H'=:`U%OG&K#;+,="()`DEPF'H$JU1C#QA?4 M!7;E.U8>;W+0RV1$3-)/N(H0Z;(2^)!20-!QM,%8&6?HD(C25)!<-AR.*4T& M)Y+3`RL?5-NDR/6M/$[LVZ`SE!!K*G(?D4V0>@%64Z>S82E/NM%Z'`VQF#8F M=NF8SC3M+VQFV`5[`=^H@]Y(4?A([QM5ZPT5I4>?<3=8]\@K-G>=XYE`$U1H MPGJL>]$=3B5E-E`XD>@7^74\+"XCJWYD*PO8F:^0-:=R\(];RW"P03N1S^3- MV]U2J]Z@'6TF7>]FBZ^9,&?W3.U-%D1_(NYO&?]HJ=*&R6S8^G9-SK#T50./ZD;_H.T\AE^L&"*@@&U9#VXEP/ MC"V5I?M:@ANH"0[5\_PDX28OF';0[J7A^&$!L5X0*`9,,^"J0:`;'ZIS[8"I M!TP_8`H"U1`"%2'4$9B2[8;X#AJ>-Q(?DXX\&(_2_BHC\K<;85G;T>*[D=3G M<[;8N+-T>XWGZ`V[E1V^@O+M]O;RE1#M!RD3=13%%B8*?%G`A4GOYS4`CO,W M`.5Q4-V8+"AWMDQGK<0.$KER3]`+,8E'!+F24[Y]KNPK(3KO-!M,)FFN)&1U M@BI'8M.2V/#;!ELN=CM`DV(_RZ%)@0VZ09.?\/H%.\(O,2@NE22^#N(+I;-I M,4=^]87)6_\Y'EN*(Q\ZR9&TDY53)&$!20S9KKNQP;'5;RI(Z1=-M703-0/E8$:%E\/T)G4?>?S$9:7B2(JX:H;C[WDZP=PNHY9SS^>Z1! M!X)$6_;CX>.>3_@GC&@DC<@F*U&BXL[$EP9H5QAYCK6_Y)CT"7L?$;'N;=>] MI0:\P2Y96NR'!^>_M\@DBQVQEM?(7=V:]I*9/! M6-F/0VQFFM4+K&)@-4-<-3PX$%<.K'9@U8-??W=Z*^T8CP>A&^R05\16$^'. MC!6V&''7)R\(H.%.F+]2?Q&)K[ MZFWE]<3(B2U"NHE28:I,9_MQA%63JQW?QT]M!JV.-;5LUW7=IT M?A`5"F*!N&T[S'N^8#9';\>Y4B2E>ZP/51/NA(]F:GW2!\O>M)Z34)[V:XEM M?+",!FA_D$&&S""T?M8Y>D$F6UP](=!G#SF>+*@C?_YF22SKU&B;BN0'X=P+ MY#;W<3WEXR:5_A6$[&P4.R!BIVS8X8`]9XO%Q[F++Z)[H9KK)3S72O]W0.>, MU]'M?EE],QS2)RLV1,>XG7+X`X@=FU,RJ^<.LER33U757THJ>U@.DTLT$G7> ML9K8[A,Y;T)P)Q>,F@+.67MK.Y@LK6"_AKY+HN\(.07\MH"659:20DC#($PA M9#XB8MQ9UVA#/%3XV@M*MTFY?!6$CZ>IL_"4420(F"3:($`@2Q*E&@#&.10\ M",0"_*:SI1-[`1ODP"LRY6R'%72V%&U*K-'$\8=(_-PAR'0?^4`K\V9*"K9] MS"!7"T'7&"GCV2PX&A#[O"\(?$GM[MT_'DR6P*<'4[XI_GA$G+G^<["P'4`Q MN%MBLMWMCXYM;'4/KDU$UBYXO"9IF]M+^1-M2"^VBYRV+FQTW;G]A!E$PO?( M)WK'-ENMH*9^)08VKG8_NVQK[\.&I7LCUO*2G2;C6[.J4CB=HJI66]GF]1?. MTJ!%W>!8"YC;$.G!YQ>3XUCZ(U]Y"[5AR2V8/JQ1CS2"6"7YR:=DVU?+VM>S MV7FQP+[LM!@)=N7;_"^=F7<3FO=E!W9D5A1I$A\ST_^U)>Q(T\O6)1;M@KR3 MV^TX'>_3?983O50IP=+DPK'QO$(.OF+I+-F,`K9>C@B1I!MUW.=Y<)[_LY3_4D]HWT M#9^UW#C%9G'+R>(G/]5W:SLW]O;%6VS-_0.`%2=_:LEHF:W"B@F?HID,U)BT M7#Q0^1!6`'D'>.4>'#J9&8J3*\0GQ&73MK9W9]E;SW2'D]C%^OG2?KTP,/'Y M2S]D:4N_^GQ)NP8&ZQ[>7[O[=`M[U*1;>^C&:S<&MS^#BPY]NER7'J M:V+JG]KC"QV#>7,^PB;FOYP7XCGA/F$=8[:5(7^+;67QMN?"2G01=(#I9#B> M!C-BL31(B#OM\DKAS%A3T%1IT,KGR9K"IY7@DS8E)D"I:&*LRA!2>I2N2X>J MZPTB#N/?->WV+G'A!MC\PFWV$7,U$![)#";A.A"3`[$@""1)ZO(=CTJ+49%( MD-S>7*EGI;IMQ?"E4:*4`NV[O+`S:./I-.'B)W+HQ%4/3>D\CB<84*'FK?IN ML:_*]LVJ=8ATH=9]M>[DZT[BK6V)X.[K@.W';CTD$$WX]:]6W7Q+RX M1\M9>'>+"Q).%!1J>PY\3P/1S88S;1#N!0UD`!,B:;[[.!AJRS#*Y[:/PZ+M M89$VCUU(@6CV.A^JE"[%%^08V6N0LJ$X5:;-;D"R8N%+)>-#0.SQ#ES,=3`* M31A%:PU4GKNDFIX]L#*\^LH_9/V\PM@+[RXNI$.PIM29[.@7QM( M`BX*0EE2*=`(..T@<&TQH\KEDB0I-4=7^')CKQ$I&C^6/""9,[X6PDEOI]J@ MG#6^O`[QY@"`I?4^%8YGB MLBT/:0H5$;P/9#`:*,$%."E1X,N2,\!I!I0J!U3I<*<99%H1,EF#GTKJA&.@ M%E8^UV:36*6,>#KX87!+7B@2$C(A%"J[ M@6P4KE8$MR>&M[7V4M134\VFD*FZ0KR2P5I!:D^.<'N<3. MD.=`D&D*H03(#=5ZA5P,&R84-K0/R\\.=HQ4^YY90:V,H602[-I>OQ"+#[.N M;T\Q@H;K^,$3MP1=6?Q+7G9W$4-">TFR7,T%<[U&FV*KTG[Y$UI M8:6=CP3'&LK/2A2&`7L1Y?/@EZXXV,]0R+(`2-T/UPQS#@P813;N3@AAF478 M89HD@$N'(EAB?C3HB7UZ6#QL/9:FQ/T[2Q/W(UFN:OG?P95(#S&':B[,)'6H ME(><0(-,]$GJ`%P)MMDO5`.X'L`4Z5(8:L68A5V6'JS1&UEOUZ#'5M63NG0O M3!W+SNJP==0[Z788"X/O[F@GC25U,B!%ZHFG^3@LZD05=3VJ'&81/\LP(D$V M5-:G^;I#Q1X##HL':6MVA/0LA]K2(K]CX\Z@"I,%84E;@N-J08JY2RO9`Z._ M;=?\9D[>-YNCM\2/GVQ++SU=UJH*3+(+=,GX%.L'204AV/(> MJLCOQ4P.S0(M(523W4&3*A!KVID`UXUWD1[K^?.SR,^!QEX(\F`1ASQ5) M=>8_T1AJA.;VJ+G-6)>.Q="3!Y2*X'O:-_VU1^T[RV`W*A,/WY-7]J='O99$ MS[9`J"H-OM*870%+^"SP<)I=^&TR9,=:`E<38CWAE!DLVHS83;Z)HP(VB13I MF]S8)#8V/^#Z1XG<@D'E5(%;Y(5__7$[!-5.C(YK^VKC<01!E/'J4!F?-/9& M&OT1@NQAYCTJH/X_":9[3#]=X$R_Q*\]2/([V>(.>VM=VOQZO]+`F0M&_-R\ M5K;T>VP(]2\9C)7[P_19CS=ZO<#J7[SZAXJ;I>0_500M?F\=B:55R>M*'Y$; MP6IGA%.F2LETI_P\=XUAU`[%*)'7I=GQ*BUS?.)XGI;>V?ED"O[(\BCX^O/U M9>8-)GYH@1-Q;<+)UD>3(%7'-5RVZ]P'*AOM?(<7;$6O*-`P7Q1>S9%H.ZD$+"O9S)-$C:P:\A M8UU$_B$A&2X]"&7[>W=.PH4-OV+O`^T/M(I]F#RB3?MSS]2W^7%(&"@GQ/GL M(<=K%^DH@_1OR-HB9R=K6WCS`+7(C=D>3W[O&XXERVRY:\6?9!,N;J3NA%7_ MKLP[2WESDW&4EVV9LWL*"`\!H[M;.2>9'`@$24I6T1RLN&%<,%@K*DCN!I=2 MM\J2)!^[3#:PJ2GZ\QDI$RS=`SJA*A2WH1&U29O28XKECX_U:K%.--I37UN*(^=]6&7'-N6 MW'N,FR).7F@XRJX-Y*SBUR(C8MSPSHG??M_:3@'G19YH.7]5A3J"_C=1AK,@ MBY5_H3F5"+[(L%/+KBP],1OS0E?3&%7)&$NS6S4)-.XV;!C0A>U("2(U2!;F MN!*Q0A/4M]=KPJ]-9QWY\'B"3L/-G*UTY;V>BB?:IGZY.H(9T=3!:#P.J!\) M](>W29'P*Q?:,O$;1*A*15A.^P9A:L?`;"48B-$N"@8"MI$RFHCT?!]JA`ZP5'#;7-F=GF3W';]X5 M5>*W8SPG%M(U;D>:"3OU;"S2J*:\\O,[V5X4?DS;<+=9)T,/&0W5_S)O7@OS*)`,7+6ODVQ!8@KF;H_J"XPE:R6G_;>O9H%'M$SH/S[+%L;7RORR-V M>,;2DM:DZLF6V_D*=41;M.%456,*LJR[3"I0L?#@@"\XR*Q%1?LY>>6UZ$V" MUA*@72:U!QL4G+F0W:`+>FFV%1\](8=H636$ M+WZ;#,^Y<=RO.G*"T3-;X M*@CO.)B,)\6,\65UA"T'`,MA"BF$)(TE:1@C/2(S&2C%9$@([PIA#(>;0QBX')XT[.0Y82J"L222SJ/304K:8 M'+;4.L.AC)19#D-.=^*H#BGJ(\DAPC?*N3:*!R_)KA>,%:6G^/_W+Q9Q_RMH M;_BL0X)#,)GTIC.EI\W&0,._ASTW5WG@VZ0V56:+L#=:#HBHOJG6$ MEL7'8/)>A"3Z;;#E^HF(+>,)>\3AJ8CKK#<*2VB7M*)J"=\=/)K$W<-(.)\U MC,5W;*7Q)#;0]FR`#K1!BYRLZ^89NM8RI"PF.WA%U22O^,[2[37^A+V'Q1R] ME;A'T1,M,[5`#>%\TF,EP[=P%EOR2K2_CY:HAZ!NCZ4!3_96[^0H#6K/T!"P/VL;V6)8: M9/H'#S=HYR_Z>"O$\JMO379OC+LU/6!OE)]"+$K`#BB^I(#MFT[>]!`(-&RP M;`_6[$YP)BI(MACD9$/1?37G+2\:'F]:-;7LGLG2+V-5\'A(6@92Y!OLW9+R M#(3MK`"64CA>]"LVA9PV.%>?J]VN=L"D M2KVIMEF\66:E\;Y4XFVOV19TU73C+6*J#C&/Z55ZY7KU<_*9%RLC.M\_3>R* M+?!$WPVE7KG>+-QRXE7"E%H*'@P;C"1U3!3O>'`Q)0:?-D%#<63T:CBH!3D5O]6A,6BXF>5W3,HK$ M/=-"V'*:1Y>.L3_:MN$^VV;Q"GZZ5*M-7ZIJX=P[RBSR>9=/\G`1P&3(:M0. M!Z)%0.B(>)RL4'%[-IVM.Y M$-FI?(Z"D_+W[7?^\,;6)TK.V6:*M>SQR;J%(Z(V M',0.[V_.#V7(FL8_`@F?NY^S*OQ+NOF2&2[!TZ;'Y[E0UN'WD'?!WRO7I@N* M2_3_NBNNFC94BWC0@17F!L!I,;@D*>0F>*IPM#)V-)R2W,#$)PC]D.4%_>KS MM7^IP"UQ=63^#T;.!\NX05YV)U5IT1;X4%:_Z$3/6!F&,\K!S1Z^*&"R@`H# M)JU=*C2&2SL$UZGY(.)@C`N55I#16MS@%^_.HF3DDTCLJNFR+89%I5ML*PI4 M$+]6.SQ2Q01!+`GX-=L2-QXV`2SGOG#3MI9]6OD:#%J!S/:BPM62S469+>2S MY,ZB]L2N]T2)ZY_D>L34&RP/+<6(4RI`&I?*M!)>9A@.AOGT"J4#$Q^>78PK MZ`+G&C.`3T/RAHV^P]!:MD<[HB2TP*84M1PZBOAT,4,K+2>?M',:`H6\@!>4 M1D)6N_B:WJ2@+6-2NL"HVF@X<^[9\7K:=.D.-@B[;4UG5X7M>L":L1Y+%[^C M/2>I,P+%OE5,DL@8#2Q"AC>LIW;=QOO/_D&\U9UED%=B;)$9M9\/"_]02WBY M77:1HTG)+2]S-J2V:-+$Z3C,!!)6#.D-[XF]@%]HW1!7WDOT-)F7!Z?!(A5: M74Z58395S&S_2)LM:;6'EJQ6NFHKPW39_CWM2?A'?)@C!6=]EE0%C]_J*_'" MC!/$J'#9N$F[R^F6U-!?X$SYX?):[>0W9>'1H9.G`X?5V[./?%+#E MQP`[%C`:8T>Z_W6,564&!__4QQR]!1/F5]C""U*TAE/UE`2B%Z@BO!ZHCH89 M.@<'E:C(<&T'`J%R*=L$4BV%U#^P!!YZD[OL*>B,>8PK,XI,7E&-_)NE/V$O MF(NO>+UY3TC@4XX:POR=(%.)!^81J<@J72%1?&-[C=>;>$@RE6)-A'UM'$^ZY;,IEMD=0AV( M,]TN=9=(^UY8Q:6,0233Z9Z@%S;'2;!;AU#YC\FA5*XNPLE3QH.\)BHALTNL M.AYJM_M[50Y9P*UBLTAB%[&P$70\'^E+N5S3O@'YG8\"'Q8?$;'<>]LMWA%: M1T*[G!-52WCOP"S,4Q8(#T=6P,1#4CX_/\!J`+^*9LDX\^%;>,G6$"OH>!HK M\+OAD[(D,[*N$V?(6`I&S+J_^[NW98CQXUUX5?!Q8[P3(1Z7,4ZKWTE MJ;O'\E:W]*LU=JR8"P=5A9)HE\@:DJ7N\M/_./!,``1/2&A6Q/*T)#*1F3S/^#X%/IW/N.;S=O:MJ`@`8I4.5_:38:FL[4"JND`B(^`[OP$PM*P M#0:L0RF"H343.N1"$R]UI$);$:NV-FXU@!L49P>"TW00FO6K;1*EET!16N1$ M-ZR;.;.-`I=9]A.E"1;`#B4G"U\SD;82D>!`)K(_-:QJJK`#2&2ARAN9>MOD MMZT@)7D=%%QBGK1W)=:;A0)F=/LEI9[]Q2;(#2`]/\3#<7)81P1]2@25`;&_ MH$W7OD81=%D3E!XET#6(?1Y'#52U[U&HR@XO1"_NW,4O.+PG?(598(U>>.ZCRX#Q- M#S"JW5#7;_-N?!1C.6N5=ROI8S?*$+9[+`G?^DT`!G%W:5-_,$@]7\+XB$>6E,[O1@O59S0SJPFFZ4!UNE&=\\1.0 ME3?'5TU_3P-?J;,76AI\AZ:Z;7$2JDJ>\N>!P=ZFE.5T,E%'&[`5.X<13PI* M/4Q:4<:ST3J;@->U;.=8X/J&PS=OBUMMP1;?`059@1'M7;C)>J[8;$TH6K6_ MVE5*GCR:"$2W%R^0CUG--?QZ/`1GS.O^A][3B=7SMPM7`L-48ZNJ)AA\'4.\ M]=*&,<7,!.GGEK]A%%M2-K23_E>++-\M)\;6R4VI)R90-8Q\3DT^.G>YUJ36 M-)I?&4-JI<`@*/3>"`MOF!:_IN6T&FNY*U\QBB$Y']H[OK/\+#"EAE)R-A1O M'TQ(1R:D'6%>LQ66D=2@%5@H%6X,Y[]D&3:-7UGQ*@BTY/SH^O'Y>C6O0:Q\ M$;_P!T8:&FH#"2VHI+7+);4ALTS?8,7H:U"4A2A,$\S/W8P@?]T>-&8\::<] MSB=K?41FY*U$93?AU<@\J"2V!)PU.VX!T++.8$&:ES9Z\*+_*`\@%*^`@+'. MAW9WU\)5IE,/70NCL0!L*C8Y`3Y'OPP=< MG7FM'E:VESY^2[EC'4ME,9,ZP]L8`U;[FJY2:4_U9!],'O#VX4>3M/;S[ M3/1QN=V>7D\'6NS@[OKFQH\#[I0^[?>8K@?Q/;`"P:_N]OM_/1D\9//O>?VG= M5V8%)2,8VDMV&LHB#]F%?^T:5JV\8\()>4`(WO?G%D=7K<@EIEKTE%KDS]OL M__I`N(WOZ_R1K/%[7X/X(XZ\9Y^Z[,LH6;!6I&UCPGH$H7V8%I?Z=3"GJG-T M6O`S1OEPZ#+*=K&J_LPB7S2\BC*/4W$UG]S0)Z0M24+K"HY&OZ&O4%COH+^G M`[R!TW;+8KHL=)G+@&K3ODPWB:J;,/;MM6ANK`RUBY+VTO;\-QS%'`/\WU7K MY[\ML$!`2J9I]W#Y&IQJ=:N;GC:`@@86M'OH3)SZF7!*"G%:9L$PI&"\KE@J MC2BW0$P`R"5E7-9HX@W=^2T_?V@M1B M+IM.PC6.JZ'/E!7KH"^8=O63?K/F-XUBH9$=[3I*6V(AMI>B+?DT8B61Q""2?:4Z4;7=18T#6/?-<_H9[-/V(FIQ,>W&JG_&]7J6(RVY^ MW.W+/9:3(5E!H`CE@Z)T5/@;->:4Y524%:B4=<&U]:&5NHQ-WH,`K#2O]_\, M5GN:JR+;65'1OC8IH6JCKQ&SJKT_G_C M3HC2AHIA/]&"->U=U=FB$(2D`Z!\!':G-QT#\4&LB#G&4H:C4H;;6ADF?4$' M`%2QWU:K@VP3D&%/?OQ`',SG(+SQ[\-@BVE:4X2)`EXH`_@-'X(C]35T;G\D'37$$=U//G*I8<,9OWGFY`OAZG[7Q>">!F@(Q M'4,TF6:M=QUO)"H*0FF=YRZD;'43"7_:QE%IEB.YO"?[D8CH?-`D. MK/<#/155B`NVB>`6]&T8`B0=781$G^_(5Q260<.:5Y&P_5ZCP*UV09_)>CJ$ MZR@,_:[\1U>5E79^M\6,&GK`^,1;ZKU'CR*`T@!NI:IFRWW+?1B0?\9GFAT5 M7_J[3W^@L6RUFQ]09`^]B*V,P]?'+ MV#A&QX3B!3HRG5"O@U.J[\3MZ*"LH^]I5/@0YU#),0TE3\:/SS?^/@A?^>ZL M.$=/^S73)TH:/&G:Z6RSG"6I.RE59IR<+BH0-GL6-+2$TY*$ET()P7(,1Y'8 MZ2^QD2.9%K#,SEUT==6_C,H.>SQD(?^H1BKD5QDKGXE;2 MND"-CQO&@8@'7;M9;)95,)1"C%NH6D"#"NAT%M`D/E2F5P6)5"7FD,)GJ$_^ M[J,;5ZO]R)\SC(W2X/K.=%:-E))(XA/-VI>DJYO!0G>!G+8"F;1]H3%5C;XN MNSEK?R1D%9^%_=FP;=,Q]2W`J?IY^CJ<';=FWM%BWJ3-%DVB:JJ9>!"[[VE= M8H(7=O>VX1:K]'&#^^,R'K2[):_624Y.2HEZN.1..O3UTT&$PWA5+0C M$2UBHKEOKG>@E0/I%=9M\/I*0G_VEY?@L"/,V02=DO6I<),KR1K0R);,FB]! MPZCMZG(Z62NF'6Z-\.5T!Q15,@E=<%DOT-.9ECRAZ+JF[96*MTT>OP?\E^@+ MCE_(T@-ZZ=W.D!N!.-0R?#A$?O0.IQCO-*TB?1H0@PD+VD4XYZN-%'P)+3L0 MUT6PI*X(>_&]3VD52U1AJ:@J&T#45#I,_CP@D%I7KYJMTFJ>HA4&>`VO8>0K M3UY'WB6,PH;1M`DORI);:F6`8"9M%L9[ASVZ/V@=C&N>*418S8L#R;ZO/@&3 MJ-+F2KM@U-Q)ZC_D#?V2WG2$.B\8D],O%)("@MTX"G#*"O"X`F*B`*A*,-T- MN03,=NJ"0^K=_M./[0OY4)@R>.=?NQ&M4$/_0Y/WWMP#+=*G-`I-$L;1JL>7 M=A[H?+$HXI56P$SI<[3>D94.H$ MR&RZI6J@:8CL'UBM#[/(;F?X=6RWT"H(NE^/A^",<5)\4[MD4_-[)G'_+K`T2A?"#=>MCY\9!&Q7\9QY(O9B1.*`7#>>C[ST MECSS2GOO!VN7`WTI>&0HB_S9&%_H_7K!QJ.C@4=Y=UZO]8G-=)H6,1K:VUEP MI@6H4D>NTJ1[2)&)BZ).@^XZ?5^.4'U^-L+'L];Q?0U8*USBI;^[X2YB)?2* M?Z>R?`WB_\5Q+F4?H^\TGFW.L(L0VA'*:KUHZQ8S?A!GB%="+#]#>:*MJ!'A MJH!RB_WCZ%IFGO(W/\Q=7FE5FE;Q16&R+H\#?H29N-$C;Q>"W#"D>R[@+11' MQWMK)]GY"_ZIW&5Z5RY,?D6?FYH&AIB)/X-C%4JFG;NZ2.]2&/&V^97/$!78 M1=,_F1ON_TV8;_XG]IY?R,@?W#<':Y48Q_3X;=Y?=P).K]7O^[H9LRI4'U;PQNDI(3Z>LPW=[[ M">#H"F#BQHS0.-(K,W49#5GK^9H$E*%[N/%W^,?_P]52M_+G3%IO=7#].U-S MIV#%9Y3008P0(I2`K+F70$Y;@8Q9M\R82E8NE-V8M;-DMV]QL/T/FW*BNU,< MQ:Y/L[/E'TOUDED<*#C1MZ&TA7)J0TD"(*7*X]$(%>B"060H61V)K!>:PAJ$ MCX9U5K#4I"13P/H8O+I>M=17[<]&P<+';%$\9%&"Q>_\?:B`IPO[CB;[YBRZ M;!9EVRT(:,I*/WL''%Z3-=ISO:J_["FC-EL:6O_;3R8ETV544$H&RH"[R^*T MDL6<-0O-IVS4=:%-V?8#?O;H'6(__NJ^2E>?U<>,6G=Y;/VEW+H=D$*4# M9=\]I'':26/.PL5&5#9Q@=P@.^E_G'@`=`Q\LJ(0!B#J9TWN2XL8T#69S6R= M)G$R,BBC`Q2D#">5TUHJ8UND*O,J[61*E=#?\[-^NN&9@R+YH8J'Y-?_^O2M M\I4*?S!@Z?EHVIYPE=8@_(2^F37@CLPR:_UV)-\7PC+K'YJ:8464`>I,?XH( M*]\_XF,0>?$#/M)6YO3ZSO.G*/9>DVR4-`&Y&D5W(&"X]G0[[C3M8S&;K.>\ M"C6GCW9\`!061D"NCW`V"CU@.J3CF.T#/Z(.I@4=)`.@X@@H'X)FUV6#F"]8 M/:(2G.Z&`%7&NAOJTX+6'70)$C.>:)W^+_CU"8>RF*;XB,D(L3"N=HV$Q2S= MLV)OH]_Y^U#A8%<1G%P$T)!/8!VE2*\J'X@)_]CB*'IT?USQJTR?B0CBT_// MGN_Z6X+!2WHA5]6LJA]-DR#IPZAVUMXRK1'/AV/7TI,!$1U1GK23C8KR88&P M:$Q33D%3]/YZR>652VH@,";74VM*O\K]-:?`64<7+)!.<` MGP$,)61M9N/T+E(QK0"5W`*%8)*HQ!80S5J#:&8'B&:M[(M$3INU&D0S"T'4 M1<@&$,UL`]&L'8AFMH!(-$!TJB(]#`^;(^"Q8'$&^CV`?:8311 MW4/5DQ@2L8WFW81=M>*L07&V.ZL7GJI>A<9LA1_M@GNBLY(25/,]?DL"UZ&D M5LVJQ;,-Z\`IL=I&3(J4!0K%Z",.O3>7MG2(KESRR6BQ%HSCVZ0PX=4Y?X"V M>:!-+!\)=U?GO^'=,Q'D(XZ\9Y\]JW5L.OR`$+`?7`KMW9--/6\D0@5N4,(. M8OR@E"&Z69L_A5*>6)-A^K>$+53@RY*S5EA5.PI57TATS7H$2I5MTZGL:.@7 M.L)QON0`5V(^XQV)D`ZW[O?K@^N]1L)01/&@X2LN8B[TS'H]=Z;K);_*DM!! MA!#BE,:-+T2>=2!YIA#R**^?#""4(Q8*Z@J)&B7I51&%W$,@U3L0K=^'P>ZT MC9O`*GW6-%YEC&C.1,OYE,Q$'+*,%$IHP:)V$*FF0%*IL3N(:(Y4-#`$-Z$G M`[%2`2`+%IY-3^N*17'(X*9*Q)`\;7*I(&9!=WF\7,[G*3@20BBG!)MA,8!D M3@?)C$7':E,KA;8*55B"DNBC%VT/`=V!:.KSJ_LV+(I$+&EO.DW2&Y4BVR.+ MNXRT!1V!QY!=BCO06UHMS;8!@5(EV8+(N^\^WEW&V;JXQ?>OO0J,Q2H_VE<+ M-UENKQ"(C"ZZC`NG5/:`L)?0%01Z^5?CKDB>P_H]?T@H0;HSW5QYM, M'Y"`E5EU$UJ%V@2"JA?C6^\-[V[(8LY_]IX.R=6"J_,7]]]!2"+A*%*'G=H4 MS`)7ERW=R62^F:TS_!+BB%%'.?GTL@_-$:8C(#8$=-PZBAJ<7`T?9&IXTE6# M002W-?8*D%OITC(\YQS2&G?JM)&65.S`M8@U[9H=:\?1PG;1HNDPT-DC(ZI# M`^,7[?1A`=!5*-`$NU2Q@^SUON'_Q6YX34(?C\0'6U93^6*2[BZ_841'1'Q( ME(Z)TD&)V:-D6$3&1>G`*!D9:BO:G**F[T%1#;O;YK3EI-KZH*TMX@>6ZTF6/-T]OE;#+9M/&HV-D?>/?@ MQOAK$./HXPE_)/\6VHCH.>.^4,"$INU-YIO-(G5OA`P*R;O(IX30[H31COQH MV%/U%6::"T/I($8($4KHXUC"-/B1OA(YF40?-#^/&?PK,))#6B8\R"Y2$&+O MV?_T8_M"&S3?'2FBU'<5%&^8W!V2LZ%]5+^8I:C#9;7VFGID$A0`"B[5W3A%YQOE[#PV9A(^!`O^WP:I,A MAM+)DK^A\MD&E,LIRF4=3A1&5H&(3`\0Z/C5]7S*"PE6B38]'%V=O[KQ*<2* M8T;U.P:QHF1$^WJUD[8WH^10B1X]/N0404\.AY/3$)HZHYPDXC2M@%4O01FT M?OL%??N%YL3&H4?O+A"68^2RZ&\?A&CGOKK/X@8(0/B2&:<"8T(M@>`L"';? MO8/TXZ9_-HF<9$Q=RYDZ:79U^B80$+KP[33Q;KG]X^2% M>/?Q1+?9[W'H!;N&KR%\!<":17SH6TIZ92VEAE)RB--#G""LX?<6D8'AGO#W MXD88'8G[Q\@]'-):`J4\Y`OT;!%J5(8I0I)456:[>_[Z4/FDA3\8[.[YZX-^ MP\SY-$$">H#I[MF26>[@0XRW(,!^$F#_WZ/[`T1?/#T(O/M_XY&/C*+[T=V4JG_XX MD3]_P?%+0/[R1AYAEZ8ESMXD!P9G:(-BZVC<_Y0SB#B M'*+D:<8C2IE$*9>LZV&-(&<5<5Y1@=EQO$X0T_)M[^]K+`M?@_H3%.3:?^+: M]_A?8\H39,`"X"F*(9#I+PCGC+^1@(=57KY\BEB^E]*FZT\;=W(U%K33BS:3 M=Y)[EM:!MOD@,X-(\IEGX[P_5& MXB'*=:QI$))S6"B*QO(Q4R81YQ)E;*(BG\70![XEO:U?0^C5JF7%7?GG>*I] MCHL!O@>0WS3A?!2^>'2C^'/Z=U73!U.C_ZG\>KL&\:OY!,:G0_:&L/$C`+ER M^&82AEV,60_>M4D`WMH&\Q*^^W$FJE^O%6;+KV%]'I*J)9+"F- ML(XDN5XLP5%3KP;E*[!(:MV98+&:.THH@;=B&$S*"IIL.(54FUT#=.`;+!3. M*.]=;_<5-TX]^8,0.,E&U[6;]60VK:(#1XA2080,,""ZB5.$@26'\2(+$AI_ M66)0D__TXXC]"%]A'^^]1KNO/`UA_&46=*^D.?.T%U9A?DA(H806,`QZ"%;! M`CJ&P9L7D>#>"DR(34P(#($.!LBFSL> M_S3]XN=;H M`4>8"/[2Y%X;WX>8S)J8TBZX,9LN:\`I$V>_2LBCE#[PE#>H^`QJ#YBFUF?*$0^B&R?)]NS7 M)DB(<_2>,M3F1;A#:+FMUZ9#\*/<$+L1_HCY?V_\RRV[_$^@O\7>FSJ+IOE5 MLQ-@(S_ZB?OS_!H%HX92LK1J?4H8Y92'1>,*[TI[.N2T$)12@D2AF2[M':=:+0P9(2K]\C2D9 M`BP>'44';)*S88N^K>DVPE*A'#O0F;6"O=O3R]J$6[**O?'3JT>T-4#V"'M@ MJFT;'4B#XKD]O]K+KJ42Z'G?972W1WQLMO5!_YA=5V3-,@J/LN?0U!9/,++V MLOJS?V5W->G:[MGW_DL419:PMX'__.$1AZ]$K4_"[6DX'](=8&KGTE'?UGD= M*<.LI5#6N;J3V]&F;8O?T658^P!PLUYJ.QZEI^&MK?*F\3;ZG5&TQQS/3]3I M_/Q75HVX['J^?7>/UCJFM-/=0F` M8DO&E7;/\J6S4``M(X\2^C9DJXZA`C917K->6!$]5')YXWIZ#>O@N4^T5R2Q MY_^Q"YI--JW&J5)OEH`V?L'A->L?%=_FGT'?-"3OPT)6S)3VGM-FO58AEE)' M"7E4H&\-7`<0GZ,UD?&@EA$0GFKK;4"G0DT6@;/J1)19M;H$X.$IX$K[R,8I M'-[*\%F?5P=/T.T3R@ZC`Q;7,E(7R!>+!PQ.A?5JH%.F(#O@^8!Y-QZ\NW:C M%U:%2Z,H8!LBH#!5<:;?P,A13:7Y$(B.D93<&ZFF7A^X#J>+>1X&TR@XS#6P M)93M0K".@:M1W*@W&"3O\-[SO1C?>F_T_"TF7\-[.N!+MB2Y.G]Q_QV$UP>R M0E%>[V]'Q2B66[&F?:-WE5]<3@=`;`24#X'X&+22"1L%L6&`RP.,IPZGK(X/ M!XDZ;*@=T,GJR_ANKT@+`9YS^=5]53G?^-MC.(`[?@(Z+L7OY!U8?H2NVZSP^$OAN]4#*F' M:5D/*4WT-4"<*DK)0MR\&%)2I_&+[Q22FKF?H0G3_,J&CH)@YG2>8Y)<=9;. M&>6GC,[3I:&U+Z(7.4DB5.O8=@9:\>4L$B*A@M6DWSNVS`@MC,1*@0*`(&'SRI]9RDY*B; M&8B>-8H.`0.Z>\BKS3R+=Q(R63H9<"W_OE(Y):DN=,0R!PR%?95Q(=,"*"Q: MU/65OP$!D>Y%;V?350TH5I7U'49"IZ.$QI&C6]57K19+4-1[ M=2:+N0I(%A3U'4A(QZJ;/LU&UP`<&VKZ)DQ]]GPO>L&[7X-@%WW%\=V>GBN% M;XK+`LUO0N!(SH[VWN9D6IN74JJ(D:7)QO3.;$H9&%4#B/T[&LZTT`8ZM0W`*O$=!=")J/JSW]SHOB/[R\J.A(_C M"\2&LP*:TOLP%7%!X?C@?O_B$@OSW$.[R$_^(@1TI=QH!T'3E5,%-"&*,JJ6 MA7W#",SK`1,Q7U-:5B"GT2B%>%*K9)!$N'2DA/"EO[M/BR9_#L*/P>DIWI\. M:4W&RC?L1,)XFEP[_C1SJ*;S59XUE\(K3(9@=0*RXM-H'X1HEPR#W&0Y="VUN,&EI2\;8=>P_ZS]ND4P;%WH?KZ::,,1 M?!=Z%.GYY'=S>75S>_-X\^D;NOSZ$7W[V^7#I[_=W7[\]/#M+^CFZS\^?7O\ M\NFK<-?1%FRJ-J%;:0X8J\DMMF8;2!^$P5\RNNZ9QVJQW-21EA`!G^BZ"%.8 MVK9VU=V7&Y,$$T7Q[;!^_;FI^@(H&MJ>!"Y6Z3TO`2ILFF_ZR&=C:XIFBU-# MQ:8)XVY/:WL%D7OX-0Q.QQM_>SCM//^9WDH+_-CS3WB7%.:O;8+T)@<#MU8\ M:M=(6:\$:[.[/4K'0FPPE(V&BL.A;#QPL(ZG':>JG1=\V+%D/C+82/7.6DSC MXPF^;"TX@"?KY`@D?JZ]*F&\H(_O]M4^K0%P%81A\YZU(R%\4 MNTPM2!CU=OI\:3>A6:^SY:[/>L1R^B@=(`L]LB%0.@:45QM)"TZFA6"/MEP+ M^V2`"_24B;]5B&\.XNVMO`SKEDJT!6F8U.G$N](Z0M@V:$JMM0J1(7T.7CBQUWQ"TX;+$3(\]D1XJZ8;H:>L(_W'LU! M>SKSQWF^^/<7;TMBT!"CG1?B;7R@MZP/M$'M`_0*T3REQHV])&PWOLDV`DCJ7KF[D MU8TI)NSR(MWU)O,G=V$AO1GBPL)P(O9S,M:X%B&TI4ZFKB[8R/X;<0(G54-J MX:,@$7T^OG9;U?S63XXD3L:2]6U'F:I!?*-,YH/XNF&)`_B*!FQ`@^8JM_0P M("):+@(7\X44$Y8L;SO+)<.%5X7O/.V[N'&WPI[ M!JF?-1V0RAC1##B6D\4\/3PAI!"CA1)B-%5JW.Y!TGAQ$+&F4&*I`\5!9'/$ MLEU0X82QO9$0L`E"6?2GU`'(5!?XSX\X?/V(GV(2>F_56?SBATU.=4(.M!/@ MU^MT,Y?00900HI103@IHINLOEI.*]2&F8NT()=#936E7I=E-+CL4(.*$';J/ MK%H)B1XU#(;J^-IM0V>K`A3B#`G\5`-R*=17J`H0*)V+)K%,HD)F7%5,")5@ M`R+4JR'QPX"H:+5JF*PV6:ZI`!>PRZ'^@BFP8<.*2&EH*GP,O2**HFN6+?Z, M_:V'HZOS5_<5W^WO#V24V-OO!9-"BQ>-KY5TN-*,PIW)9NZD"Z MDJ9'@1GQ,6<3^3IJ<)&G$I&O$I'O#(GZX%C? MVW2.98:*]@4,QJ>0YN5FOQ:5Y^Q`P.BJ0)K)2XY629PGJ^0#`2^M1 M="#";2:^#6ONM@9=7FFTTAD\8L^7VVUX<@^7\;4;AF?RRW^XAY.LP[W>NV`X ME3"D7\O+F0LA>D8)8709HY0T8K1M@.808C-4)G0B=N7[&`:[TS:O97%F%X(" M5KK_P,H()BE3]J"UP9CE0%5IT`*,7I/)_C7ZZ$6O7A3AW=>3X+RUU:MP"!7R MHUW*:S,5SZ%GQ.FBC##BE*V`9W^9\SES6Y!YRV7>93+[4IF!\*@T7`45W-]SA78M@5?0B'/H$W&C':YL\+:&"OH0J2LA:%*+VE9>A[[=? MT+=?Z!P?A]Z6%N<^A3%R*4D>L:9[(G\ADR(?SR(D*@Q7@429WBQ`XJZ1MJV]#EY?R2]97KJ>1 MF[>CQRA'I9Q0&),:J`II8A59@+=[[--2MGPKI\TVI>A%.,0)N-%>D"S6LMDL MH9IN5UJT3=E7W@KH#N[WZ.2);_H#X4QAF`J@R?1B`=(>LJ(">I^X\#P\_E$-H,]*,LJ&,=01]D8=/)WHV()B?IIN'VGWW4[5."IHJ,!_*57]P(WX?!<^B^2B\):[UF.$=5AR==TUILEG.>GYI3Y8VW4$H7 M)81A;A$/+NS4`F&5^:B#2^QH20R5?-H&F&GBJ;:*AG$=+?W=' M0]>//%;%`(=OWA8SYT6[T=#;G^*/VIJ*>;?2ED7-E.C%=#-;95XF'X3E M;+%A4#X.2@="Z4CL;K-IIS.J*J9U55P"JZ+))8VJ#T=L&CR=+\[U$:7ZV*;Z MB"7Z,.2YNGJ&@B/KI%B(=<47]X?W>A*'2N)G#*X?2@/K[[9.G12+['6@6;^_ M$$Y!",B87V@CQ3B_+N(04S3>N?L@5!7[J3UB>G*MC*]?)V8Q269.3N$"KJ!/ M+QFF!1F`B_?TDL.I?@NP0CTRJ\_F%I&8(!,'#I_)][C<_G'R^+Q&.P#SWF;\ M1]K1[!!$)_*I'_&/^(HP\Q^9C^Q&S.14U(E#;7>_G"Y3,+%Q4'$@%D86AT*% ML=#O=#3$AH.:X<;737)7I*`3E^F$]K;WZ,$CZ/S8"PJEB;2[)D%\@.1UZ."QLQ!.00A0<(ALI&3S-1&'"!Y/A]A+LW;SI"5Y M)*E\WG18J6)&TP@6L^4ZW0.FY/(4YD(*%TS`.9AT4T#IU+'H8"(Z2A'!@E0= M=&41:Z,R(*:NKSB^=J.7^S!X\W9X=W7^+<*[&_^SY[O^EF[;;&/OC37LE7CF M%@0,3GKZ7.D>-DP7:1$!0INVWGE!*75:0X#2IQFNV0@H'P*F;?5(*EBF*F"E M_T]4;,]'^TQL5RFVJ=FVO5D7I^*6JK,;MY=/$=M>[6TF&2$K<9QRIWVY=[EV M.N(9_9X.!A0-CZP5-MDRC>P/P?<(46@)$?X_[P/B501T@WI)E19!_L9GB__N M4[6(`#S$!5QI9Q1-%QL-:&:K^*9FK?Z8)55P93V?R+60$`WJ-LZ M<=\=,6T`WGWB%A&`A[B`*_T6T.D5;B6TLQ%LG;C[JJ`\<1>GZR`3W>KI6F': M&AB6J<]N[':;KE6$K,1RRXEI.MNL=()Q$:9MG:Z'THIPNA8AW,;I6@,!W:!N MPW1]XV^#5TRO;5R^N=Z!7M5X#&B!"=K8+=C^YR4X[(CQ7+F1MY7;3BLJ9L'> MAC5=FUZ3T7.D\Q%XY8=L#/08(#X**@Z#V#A@4_AHRLCF<8\KP\WT$`=HR_40 MO;@A3D8`AGD7JZ]@O+4JNP,\PMM?GH.WOT;Q,:3@GK)_45!/"Z"FO_O7U[]7 M/G[Z6P.@2X;2;OXRG24=I+^BOYN=];IPRJ^\XN_H[Y3J&44Q+3A$PE:01*3* MQZ:V611J@'R*],XYOPM[X^<=H2^?0RPJP:7[EN'<"@V6-`UA-MTLD_LO>36% MY'+WC5]H>8XRRD;S+(:6=`HNJ3+G8FAQ*Y?:DZ*;GI_4W63BNBIQ321BM(!E MFHZAJZ@E;OSH%+I$"%H/WR,?4/'IZL\">84:(YK73N;3Y6)9#1XR8BBE!N(" M^LDT!9%)"_#]!*N5EDH%VRH$,PEM*8"JD!;K84`H?PG\^"7ZS0_Q-GCVO?_B MW:/[XPK[>._%T1?W?!_$!%N>>SBB2)@(`.9P`A';VO"!X>-4"NYB04JAG0$=R'^,T+3M'A M_-D[X-WUP8TB>B88^+=)&47%Y]-X&<@]-'.F.W%-5M/:+FM._0,CCQA]Q`=` MMXKZDZ.[C8$%G\H$1Z8%U_(G`TM?<2W'7/H]DW[+I'>Y])!E1[LANNIR-+4W MI/AS*PPAXT;U:N5A,EM7HXYC0*QE5!!-[]):MZC92V8KN M`M)-])6OZAB$WP[<$2C`58.^3",C@SWK=]CR:^7O603_C"G=,G7.=%H[DA'; M4M[QTAZ/T$U<+=>0-S6URTET$UG+6^1?V$:_4<.IC@,I:VMD3Y)T;FSY0=.W M+/(B"4NZ]<-FDZFCZ4.2CIWV>)`NHNKYCX2R7=ZCB[@5W]%>7&C/4<&ECM\H MZFEDK_%/+WYA/U_C,/;VWI8A]B/VO=:N1$G*(O^BXK.%:CXOD9-#^`0 M[_QM<`B>S])J9)4'##NO\NBZ29.S6=IS(GT?IKQ8#^ZGYKA7>H(>(CA%$:!P M*K;O%'T"Z2!N.]T=I04!A8\8O*=4'%>[$5>6`<'?!JY;V5D$IR#"]A2&K-=3 MVA@`]**0R&"*MX!J(H-8=?CL^MY_F6N_)M-9;!AS&)KH%YUS7O^<99)P@M<(!*++!*ST4F:`";L8%R M/@H5H"TH``VJ4N8QZ,6ZB"W0"\.!>HN1@%CR.&.H'<1KT08IEU&$X^B:^7Q9 M,0'!@R8]1VUTW;)4LT5:5IIW`^)$4$(%"+3]I'%R:?@\'2.7$0-%G=202K@1 M2PYL^>I0M/88C>/$K\.7H\A?L%^ MY+WAO!C$%=X'(7[`;"\UVTV\W/W[%,4L"GMT?X@V@/J2-+UCV)-?[9+XSCS= M8V0F6!HRK;SR$QWUYPOTQ`9&U9%186AZ'\3LYJ1)14T;%,5*U%Q!:&G#M>3C M9]KK6KH-:E19C_H)U9W+B+D?DYOPA2[L M%R"94%-Q]?Q.7,F0**H%9WUT_DY_DQ+AT9_P[MGW,>QZ-&UQ+UH,:L-'V>IN4(J#(OR<=%EA/C(HSN; M/D'+\#KCQ7M?R(/4RZ!=-@"MB!*')[YDW.'(>_;9FLF->#EO6NL7O;"!BW[' M5J_3"G*ZOD?_<]CF@3X3GTF^Z'62DO$8NG[$TP4O_1W[Z5!9ZO5P2ST&L\17 M=9=`=QFQF6\()29E"!&Y9P4."GL.]CM5\SI%_F[%+]9>E(<4%?;KZU M8:LGZP]=7??6\ZO8YO-Z>##;_%'KJ7XYG^IY%YN76IVDUEM3V0KVKM!]%T"\ M)^%3L"._9S69TMI,#0U(!B!L&8C5W&JG,\PFB[801WQHE(Z=U4P#;UEB6&]Z M^[>@_4N&`U1;'Z*A9]L\S#W]!0M3V%/W`>$5QU[((NCW\M3=!TZ888L9_FR9'Y0PQ`I.1R;6.,TGW%8IF1U^ITJBQ<>+ZYKW ML%LS`'YUO5S?CP+G^GC>DVZVJ>AQX\ZGSH/V;:+ULNP]DB1E>W)0^PKGR(2# M!ZGMH;X^V+3V_:>LF!"VC^F1X,2REF&EH9RDGPV?W3CR.9VS$A+K^9KW@: MPBF(6=$MLCF?K"9%9Y#$U`DY%AS#W.$?2+0IG&C-H!]`OD($\!/?>/@984X0 M'O%J3)60KE`%6+3<'"PT/FXZ6NX\=ZP<9[Z9EN$"/CL.*EH!*>(@!SQF;I@5 MM;0!!I9;SWWR#JR-L=[-+O$+I@$CY$*[T^UROBQ"ID#,CHM>_:4KH.80^,\? MR+BO9*F0D04'C=+N:K"1*V2H./(VX-F$ZOBQ\A1$W%AF0=,HUHOY:E&,%U,J M@%%B#T&FI@5IC@E[2)-C%33J$R.@%.T)A`2;N*@?<*.74@"J\JG"YTU/6R(F MM-.:EN5`+Z%561^!'H;T%V]>B/9B#--T4]O,:M.45/ZA9BDRP#49H)">)6KZ M('T48KX2\*&Y+>;0"U?%2CN44."]X-GI(NT;G:8^`^RB]E5: MV4T@2JN8.PK00&(0L=A,F?4@IM\H>'TE\O&.O=00(MARSDT@+Q1!2Z&9H6+=>_?,ZTX$_,*5Q_JJ>:^N+^RLV/P.1/2K8DC3CN9K9^84P^!C M0I-&K7^D5&G1=T[6?+0ZF)`%KY#21(\!RJBBZU&%;`Y@!Y/4T?Z MX;)%RO[D[V!KT^A@M!3S-BH0;%J69P-^Y$O*Y%?-\7!+2J8G\';L:>>U+9:E M?5EE&F\R4/9;"V+I$;7BZ&GEHJH6\,B@&R1JX4('U0X60X3![K2-?PV#TU%] MLB-X$B1>J+&AFT/F9-W,$E/CE!`C!7C,TU.B*8A$&I%`/[$4Y M7"PZQ,R=AA.?`\K5%N-=])G(E*1:O.&(+E%H?Z`WMOR73`!MJ1B)QHLP$)5PTZ)*SU2`RIPJO?#&Z2)&V`(<#B+RO'BN$U4/ M=BR!8X.-2A"HT@\XZ&C5IVU\"HD_T/G2Q<>A`%;@0;MLYW0Q%\*J0`MFY3F( M9/S>"#WAS7:2"D6/PR)=1`PQ?(8]T&DR0"F.JOJ!1,_=_J-'LPK\75-,67P2 M`#.%X;6-*LNPR^!"IIV,#/2"!I`AJF)()`56Q(ZW\,+K=_ MG+P07YTBS\<1F;/)8C!J@H+T-0!A$@MP+#5]34R+U6H%OJL7QG1MIO8>))*KS&CGA&>YK"+X MUFXZ6C+-]I+6$4,TO_H('H`/]%4EOJA!4#!G(\.ATL,(-62%6[D/:097?*;' ML/&EO_M$?GM\E5_];$$`TM%(N=)>*CH+15R?DF<']C$K6I:-8`TL!]+!G&\K M'3UZ5X(E+.Z\F%Z6L`J6C7:LQ*=:50,D(20CBK*=Z)%,]MMO65+7YU-]3ZD/ M)<-)#!W9U#P[G\YG:9)#,M"`27.CI4&8T$G194E2)OFA;OZ'?#CT>32=*!,I M3"BF'$^]KQ3+GMXC3=KHH^91?&`7;V>=7^MDE*O%=+9>*#Q8U?3,WCT<5DJY M3[+1]?215.%D*A_4'E?2VFF,Y1XTBK)&'[.[NK>>CV_HS7#11^U*RK0SZ-+4MN(C)B?APKC: MP>)ZE=ZKI:W8Z.OH=TH`:FKM*H.C*X.QB5-@**5)LBHII#5_#%Y=KSHK21X" ML&@^LJX]S.>+9*T&3-BY($`-+SH3EET=G'[`AV)[&^4)BC`6MEM"7CZ>H(').,ENCS%+T'H M_5=^_4?]$A@`JYSHE]B:K,3`XQ113M(&L/424PPR5RD@#,IDQBA'EU`QMJ#J M)HI.K1"5O`",)LZ%KHE-IXN)$DF&$&>5#!(])2-K@DY!67`HX;- MCUI?DC\)AA,VO/;%I5E6-:L"D'_(8AS3P&@OCQ@1_V>:QV[%&08M+B:3"?U_ MVF&#"/1_:5<.;!V"2@8HATZNKB'VST/\[]/NF>Y*W_CDN^%(WHU6_JSI?7(9 M([HMK)QU6IVZ0`JEM(!VPP<1:@HCE'K/>Q#)')ED8#O;3=#)=K.5\L-,?'F) MO8\X]-X(TM[PC4_+%7$VM_YKK_UW`/RLN%@_$U)PFHBW0.:S,3E%F5L"%0"ZIYTZF2];K=H>>\#X@J\_8_0%V0ZW),O_>C^$&[%MWC=^*F./F^:&?++Z2:]!/'X@I%+WZ9V MAMS7X.2S4K$N.@01[3YP)"$-,<8=;SI`EA_HR"%)JZVYGL]^&Z!C8LV'E$W# MU6[&4E(K]X38$(B,`7&:-)(&])Q59D-PQT[M/4!^$M52=X!!Q%WX#8=OWE9Y MS4+TJ/D@H32^]LT_9[(HHXXFW'(ZL/U M``B)Z-+?I:I47]>0/F\>''4F=%-]ENO)IH20B-WSSXT)]D+'(.*IL&+#/8\F MPQ-`1J(1(-SLO?A6T>8E?\`L,I)1M0[> M"-W0.$J=:_-37(BC007OR!I@PHMK;ROQOTS]F@VO?3%I,D]X.]"KIOU8UY M1X=Y4PZU9A1%[UF6#\QFE07IBD^8MMM6=TJFL_5Z7;)\Q=X;K0C[2(92[J(*'S5IU8+Q]:_>I]E`.15$R0#OFO:6R:G( M9(79*VRJ9/\RX8&`<'"CR-M[6W8B3[.)+K?;T^OI0*N%L`3AFU_7]!C4C_F1X17+W*BG&HPSAEGH#<>X[JIO/EMN,LR6AN>9?`4&DESW M$@N(\X`2)M(C>\[&\&?U^MW^`)7)&@)>LF0/FN.1\D$4R+(%W8)&`Z;1;4FC M?+\7_4131'X&]C##@[7BF@;^1N_5I[&^RN.ZM&R(=^;14KYU,3C99*O#`1U: MTO9\9(?VV+3/!Z?0C4BC>?-SH-RD,3$XM*!(G;`Y%V7`NYT!L M:^)BZ2R<*4_S'-+1C)7>*'+34$H;W#N#Y(1":(XM1,E+]'CFS6.E^W]ZXB7N M?R:A)M=;'"2IQN\R^AS!M:69J$-^,9A(,\)$@R^7_NXC?L.'@)UCJ:^XJ-\Q M&@LJ&-%>8#FK>>H^.#EV`EL@"'N993@AG9*0]/1U5Q`2RX4T%W)I&&,YAFK2 MC3V8NO'9?3=I[E#36^"XREAI449GTX"L&Q\E1&T"5S=)&;PNMW^*TS:F70.LM@JM1*Y^G]9.I&S"--? M=TU7&QFZ()>4W86Q>"8K&9`2`Y98/+T2H[H-('P6RNY3!K27.LNI(S)]UM,0 M],I`;ZD$\T:#5"!XJ)J7%!(E)5B!BH84;?'3D,AH605B+IX6N!4!YVKWETR* M#RO2MI6FIL0(>/)V@9\DAM/YBNFC4/A(QM$V* MRF65Y(I9(V%)7EZ%S!JL5`Q."I2BZ3&U*G%Q5RO3[BO;?UY#AL?-$H")NXT3;&:3ZU<9HH)5K*O$S(0L%O4'&3 M3(]X@\N[6U&.UV$B22A1!(S&*M9=HZJLJ@0`>DW M]X`CN@[P3UA>.*WZE,%0LS*T=L%*9YX4?F`$4$)AO'IH33%D'SFRHJ&T@RAH M2"@QEV+\)Q(4Q++)E+4['?#=GD2@[.[1UR#&T6W@^K0T;]94K5"-@OZ/[/-U MI&82*=U8U-['GJV3>W+I0/3Z<3H48F,A-AA+DLC[#Q:KE+`1@?;Q3>C'*>DG MR/5SP15TD6C([:`A8QCO!YR2+^BA\@&BROKP^4"7411L/;HJ_:<7OWQE\9][ M^!LF,_++U@WQMW-$$T%N_$\G6JZ1\25+=AQW+,,1[VB":"Z79IO9/%G@DO=/ M!S=$NSPSDD"*#!2>68HP[U[C1NRZ_PM&3RZAO,4H>L%DLMP1/K-J`.[A$'QG M?]P'A&!P>HKWIP.]>YK`DS[#?Z!75!-Y([0C,0.[I;KE[6\0KYGHL5XHB(MI MMO6-'=]'/A$4G%G.#J+\H)0AE'.$$I;H52[.%'I,'"%4"JP]2DXW"JN*O6#% M/^CLDEHU2%!HQ,6FBZ5QOPAX@-ITXYL6LU?.04-1A0I8V[.JG=BZGDV$_DJG MK`,=%MPC02BLT-&7376:^OJ)#OLSNCJS/P<^\#W5@3`FC6D[?@18=T,O"'XF M$\??\(Y\7,+HX;3#NQM_'#$&<&I=S0`.I] M^S0X+3-?=QLD57_HVCRME4ABK%])U,\7['04HG'RR$<[@/ M(H_5\W&]\!_NX=3"7PXS"HB?'(1U[9WQR=*I^T<),HESS+B@CV5\H)011#E! MC!6KO*)YG=:]84$U@53%9>=',4_W:`I/V.'_!@6QV.\-]\F`_9T7'8/(/?P: M!J=CXK_)-Z576`,_]OP3\=]''/*ZF]QO9S)>\:VX;W0G[M+?7>YV'E^5YQ=@ MHQ8^T1@G,'[3E'C:3156"Y%O3=A$G$^4,8J*G**A]]>W!!?N9&WO3J3R/PU M\*]IB4J]PW%=.B!N5I,Y[:6CLYS7G626O4Q&06P8Q,9)ML3(2(@-9Y3]X5W]"-A/V)?B1Y0\XV$N_T#W@;/OO=? MO.-UJUG9"[SV[ MS+9[*_/UVHC;M"B,`U2T4VQ,5U`6V[MBGK.NXC^5*]2,#4?X1,`NT8^]^/Q/ M;X=O?/*Q7QG?R:T1V@3ETP]BP;Y[N#Y%48GVW6-IOOS^VE.F-7[Z@J[=&#\'X=D2;S@.G"7><(2/`^L-L^-??IY# MN"RGD-8UH=N$;?/PAA@#Q.L-P+@^_I:"JPV%](?DO.VR M<9-GA2!"L>7/Q5X^#E7J!N7LD]JZK7# M_0V(7['+&^J36>+FDNR@0GI,=G(:%;-C<,C\._D2^6W!/&DFS5'JZ@A'Y0+6 M58XIFG:9_^5LH72F@ARQ/%4DJJ3IY9P6KQ<7$_BRE#6+/:XUWV68E.=*TE_E MVX)6:@3R.@WN>_3O#^O@;WP2A)-1SDF#TI:>N>%U$)>JYDD[#EI.!;N*&>VL M>[!]KFM`^9G/2>EYMER(T+-9,:XUE`,+R*\XON+-F/,#$7T\JM\&@:.2)>VC MN_E&D-Y*-UL2VLDNO7UH'$[\I%Y6SI]TS?5>/J/&2DQ^X[3R@6V^>&6!CQ-/#M"&`COUE.JEYQT+6R3G-5,` M<>.-;.GO8<\$T6*Y84"QI:=5B7'#:J&6[E;6@MM&"^8]D+:IB_V$GBJAT5/F!)A#2.6FJ1DE(M[!JDAE[,NY?6 MZ!#[C79*!G8(XNS:,*2U\-BRC["B:)265K;0W.#1)@3CF32YT\;.?"I8DQ5& M0<5AV%HL&\@:-S.&3NK^1*835U70BG($1D10=PH;64++\F+*!1%[<4=`Q<\+QY8Z\S MH9^M,7?*AE_:Y;,"!3VE8XC0ELHP*N3F)D"(1!&`:,F6W)=/41RZ6VF+-]GC MYK%2XZ'%SLNT#)5\M^7WE!@L4OK)YG21S3!>I`8G@(M8&S:@):_3UW@6IO$F M((8$[&AW--LL'!F<S2_N/!50-2)^-'V](O-0@:[XE'*[Y0R8J0MP5UOJ27S6QNIH?"H,EX5(*4Z M@T'D@=!\_A7[.'0/K'#MJ^=[=&ZFJ7&??M"-4.F&H=[+1E&IPY%NFVEGGN6! M<;HH(9S4L2Z21@EM*%P.+C=#YA&XQ[>][9)?3+M#W%V_[@KY[ MAP-ZPK1=;UHVSO,3,R./NS'Z[D;H&.(W+SA%AS/:ND>/@(`]2?_BAKPUL$]^ MBG!LN(WO<%I4ND@6G#":`%UTAY.Q5"A0^,5IR4`W>4#RT=G#Z95K&KGLO1_, M%FBN(E@'72UOD+7!;5:I/7%)(5M"EBS!_NKFSHM2HKTJU$R7:X;.8 M?8'00&AMCJ.&^!3ORLD5JW>=7H\L5X2N)+N\_FL MX"O5*>29JQ0ED#=Y2LH6:.`(KV>E;\2IH@[>'M,%[1F[(6R%A]%!77..XWVC M/TU8^8_@0,@0\NR.-K+P&G)88X:7.8<_MG"RQZZUW.B;]D` MX![4C`,8/^Y-^C->E]6`]\@SNH6 M/D.U*^M?3Z]/.+S;7^YV[+*N>V#/19>G^"4(:7K`T`:L,>)[\%_-8FC?K9AE M]8)Z.S;.%;V9G_/%'X]0SMD[Q.5I?I-W MZ0L32=Y<[T"K%7P.PE_)N](;HF,-]YZ\H$0&75Q.G-ER>!>8^KV4*T380HRO M=^H`A]`RK_3(=13L48CI;6R:29JX098A^NJ>:0JI1]9>[]P=-F!Y4%^H^CQ6 M.D)IK29>L(GP=^GO[HE1?75?L;JFQ!A#V>0`._"OWWAL-=%W?@T%W?C_4GY8 MAC/E"%&6H`MB0.O7R5/JT[6L#;4T1D1H*]?65?U@;NTE..R(T?$O2ML75[EO M;H+>EHQI=]2"-^V"9>MI\<0@&0&EN*!MQ^N>Q8H6Y&,JQ*DJY"^L!5T44YK@ M[J&#I=>@WU9S0]WF*HTKV_AN>AKB'I>8%A(P1 MJYSJ8[J]0'(\0Y1M'4HJ.8SA"J]J8$:.7N#2J2]!&-.,T*L@#(/OGO\L/\"N M/VDT=JX-KQL-KJ?3#`V$",^ZSLE`A;[]Y*GFJ01[>IO\%8>L9>'1/>(0/8TK MXQL.GX)QI9PZV6?[$-//IA;)7`0O14TY2!=+#P+TYB+.LDB^$PF3KJ$%7]II MM?-U&A%KUD('"Y)'5X.C5(/;2@W&$-K!W$O0;:M,8$Q?O]`]OQO_-S\O%_'H M_DCZ0$Z4]_1[HJW=[3N*W(YDYKH*3+\T0 M&7=0&+\Q@B2ZM81F8Z+GIX052]S8B`B7.+ZQ/M$0.Q2T M*?&M^_WZX'JOT1=,3VI%"T[18Z;W)@0\:%KJ:KU>KY*-"4H%$3*(TT&_CEK(*GV/`2*JDQH9]#/EYLJ@LHMBFP`3R_I!&V7[,&,S-B$ M>!&J`10KC3O']0EQ7+#FK]=_MK M-WKY?`B^1TUMQU2O0"!"P(?VM8/-RJEB@VXU$GJ($81O0C:4E!7$!"VD-(X> MA3$*<233#3"B/GN^Z].C[/N`'[WH(TO^*@S"I/QHUZ58K6JS$$%:1A>EA&U" MW#!2UY'76FH`!#8:KP2):IT!(_*&%9Z_]-E=@Q"_8#_RWG#R6VUP:E&!P:D. M:]K3QF)9V]8CD.7$6.9`:9#T#Q;A=W!M"";1]BH``',;NY?@6EN7P!#_%@?; M_Y0O%6@#6_$N#)SE#&FOEF:+N0#$1<)9\JD]P!U([CI0@";&VRN*?3=584(-^#@,A('T",ZE8*7`JZVF2$)@^<>%Z# M&YD/#Z>=YS_?TUZA)/B-X]![.L64SU7J5M<023638R2H9&Q;'18X#*HV=%)(%:^9E7'6O]]T@9X_4ULEG1 ML^."Z:#8*CN/P73]?IU.8U`\Z"#OS@FU#3<79($X@C.R("8'TZ;@ZGONF?[G M_;LF=4@_N-K!7-4#/A*S?*$W^B_]W0..O1#O/K(6H;P]&*]-I#)`71*FW8PF M7_HGF_-YP8F@`GFVW98,@/@(:<\^/@:@>QA#"Y528$D!L.1^(/&?$5-0-BZX M-VAIY#6LM]&AO4AF5;%[F0JG8!V.&5NZ5S..V';,F:VR,VUQ<(8$]/$?[C1#,3:?MDX>T2];,F02AB0'>^F.=PR\@@1@?H M3L9P4CDBJ4"!H[*J$D2DLEL`!E8S3I$-*WD:#A`I"]IGE2MG(H$$*[\(F@@[ M@&A"7#2)!H21JK$I4%+2A24X49=6E3X/BY5V13@7Z[D:+;#E20<13X48&XJ- M-AE>`VHZE_T47\P]L8;OX37YFNQ0U8WQW?[A)=CAFX@H>R>_JZOYINGKNWIL M:9:BFR[(P,F-WH0P8I1IB!^_8,2ODI(?V`B(#P%TV7<$R:<"R5E*!97ZSJ34 MZFO!(XCNB#^Z\(.#72!NA][L3G$+=<',SRX?*D MKZ^Q04*`\)E>3?MVQ#27.?:PHD"']%GCT[R$$5T?OUZL)NG$SDFA`BVH&7P( MH:8P0C5,T$-(YL@D@YM_&Z"3S[@J^2'FV$>\??�_!\9@7(;PC4_&=:$N@R MBG`L]@#MWC4XOVHQI-^A>Y$D/.9DDU+\.6'$*0-ONPXOMU.6&W(&;66AQ?E3 M7RL#S)XLJ^P!;['W1O,3H@=\H/6T'H/[,-B=MO&MYSZQCN-?W)A^3^G4VI&0 MX7FW&Y>:7G[AD'_Q29DGZQ4&0LE(*`Y0,A;*!D/):##3M@&=3-4Z>033B7+6 M-Z`8I[NQ0`4-_3Q&&E'TT&WW<"/"VU^>@[>_[K#'(PWRCVJ`07[UK\?0I?E; MW\ZO3T'5,.I_-Q`HU`;5G107V:WYY'7$WS<+IG[L.WKLCVW[4L.@)BV6$"0P M#ET_VI,O01OTX/#-VQ*>"G=];WRR_#[Q;CV$ETC\)^59TJ!#F`RS!^1;/SD@ MO4R?C_#X$IPBU]\]?L>'-WP;^,^T#\$-49V^8]OR3KQS:O&YZO=""-TTS7JPV MBZ2O%Z&.4O*(TT=T`-XR)!N"]]^$61N,)?_4+OG5ZX"QE,!\&8&3(Y4:+,CO M`.DLM&^KKC%6`C MLKT--XQ)P'8DD"?K1+PE?-.C%$F(W96:P1551Q:U.V?,-DE9H])`*!T)94.Q M+<3B8"@?#6:!9$(U#-RW.(K^)RUGY&8*B0-T+"DD4BK$U/JH)T2*2Z$^&H;Q M#L*^)E+[$3]M%-U"%O1+%Z35;*4]A:"@V5\NIR97L8X=`]7*"( MI=[1Z&,?A-A[]NDKT&A4FF09;7*E682F]$+UG<\]XB-5\>5V&YZPK,-8%TKP M*%2QISN)$,VN&A":US>X\]-)A@V%DK&L@O!@2F'P3EY$GJ+>##!2=K,(X8\O;OS/X'38W;P>W6W\:;_'6[JI0!YY(`ZVG<$T$8/'>0.'VI.6LW&: MH$Z'0FPLQ`=#V6CL03J>57`?4C<-$WI,=?.=Z<;CNL&9;NB#H40WP/Y!$RP: M+D)'UP-LY/UV_!P&?GSOGE]E=Z&ECQG>H!/QT&)O9LTWXWX[(D8&)71@MMUZ MRS(U+XMR,ZVW0(Y((*@=,Q4JTMTQJ<1#H#)D^8AR.);^;AJ'Q<&U[TA-UTFJ M7O(Z$.XZ\SXUQKL:9YT%<`H"@.%*9-<9H&JB]<\\VP8G/P[//`A.?JC&O\FO M_T555])WX0\&XM)\-.ULK<4RN=?U&_IFUA0[,IL$?1[=JF'7"$%V8^H?G)I@ M1:0!O/@_W&A[.KBAU(U7'C#LQ\NC:_J2R7RU26XXI^_#>/(>W$_-<:_TY3U$ M<(HB0'ESL7VG[EP@'<2NQC^Q]_Q"_,WE&P[=9\P+YWWT#O00@U>.NSO%4>SZ M-)?T?*(_8C?PCZ2 M@4!/*GK"IKC!T4?IUGB,N[V,XS:FIJ`"[2'DK&EW]%JO5VK/<+=7.`>8ZO)C MZF)9TH6;Z"+Q"/1<,OEG[A:R:J[YB!?(C:+3*_6>.^948.L4=`1'HS]H4+E% M?J#&X)4;>=MVYB6A`>\#Q(SI%R=/,Q`4'D`0%K!!+(H(!M&#HT)_'><6@EIM MZ1J05FAQ@.7U/V]_#4(L75R7_FQX:5T<6S=#?;/:)-<4_HEN$7T?9F'=F?>I M.=Z5R^K.`G#$_H)N?V$B0"VK17:=+JIKL@V!HX"8\K>_8?<0OR2W@:\/KOYC+8:RB%@RX1Z):\37XF/Y%_T/T%\L/_#U!+`P04````"`"A:5A# MHS6BA^-````R8@4`%``<`&)C&UL550)``,>56E2 M'E5I4G5X"P`!!"4.```$.0$``.U]6Y/C-I;F^T3,?\BMB=C8C=ARN:JZ>]J. M]DSDM:S9K%1V9E:[9U\<3!*2T*9(&2`S4_WK%P!%D90`$"!!@8+0#VT[!8#G M?+@=G.M?_O-M&9^]`(1AFOST[N-WW[\[`TF81C"9__3NV^/[\\?+R>3=?_[' MO_[+7_['^_=G#P]G5VF2@#@&Z[._AR`&*,C`V5/PEB;IQ/WWTBU-5^>4CS)/KQ[(?:GRX1*+X<$:)^//OT M_Z"]\-D#X16]@.B[S:#QAM\S@FF"?WI7 M8_'M&<7?I6C^@7SF\X>RX;M__9>SHO&/;Q@V.KQ^+IM__/#WK[>/X0(L@_

UX\__/##!_9KT1K#'S$;Y38-&4H*!)X)6]#_>E\V>T__]/[C MI_>?/W[WAJ-W_T$_^!>4QN`!S,X8#3]FZQ7XZ1V&RU4,WFW^MD!@]M.[YQ`Q MX+__X?/WM/N_7:5AOJ2K*(FNDPQFZTDR2]&2$?WNC`[[[6'2H#Y$SP&*V-K) M-DOQ`VWW03K4AYYT/I".OSZ2Q0[H)Z:S"=DX2W`>9P`EY`LO0)-8Z5"FB9UF M"X#HHD9@`1),/E%\LSO-PA%-DWX#$[()8!#?IQC2F;R,`XSA#(*H._6R00_( MP'V`@.XBUQB93%$&PR`VSM)E@!\Y+)#!YTET118I)L<"_26*V)^#N,=IT_D[!CG$&&3TF[

EXCEL 41 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\Y.#)A,SAA,U\W8C(X7S0T9C!?.65C95\W,#=F M9&4Y,60T93(B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-O;F1E;G-E9%]#;VYS;VQI9&%T961?0F%L86YC M93$\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/E)E#I7 M;W)K#I%>&-E;%=O&5S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O M#I%>&-E;%=O#I7 M;W)K#I%>&-E;%=O#I7;W)K#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE M/E-E9VUE;G1?26YF;W)M871I;VX\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I7;W)K#I7;W)K M#I%>&-E;%=O#I% M>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/E-H87)E:&]L9&5R#I. M86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O&5S7T%D9&ET:6]N86Q?26YF;W)M M/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I.86UE M/DQO8V%T:6]N7V%N9%]!;6]U;G1S7V]F7T=A:6YS7S(\+W@Z3F%M93X-"B`@ M("`\>#I7;W)K#I7;W)K#I7;W)K#I7;W)K#I7 M;W)K#I%>&-E;%=O MF5D7V9O#I%>&-E;%=O#I%>&-E M;%=O#I% M>&-E;%=O#I.86UE/E-H87)E:&]L9&5R#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-H86YG97-?:6Y?06-C=6UU;&%T961?3W1H97)?0SPO>#I.86UE M/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DYE=%]386QE#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E1O=&%L7TYE=%]386QE5]0#I. M86UE/@T*("`@(#QX.E=O6QE#I!8W1I=F53:&5E=#X-"B`@/'@Z4')O=&5C=%-T#I0#I0#I0&UL/CPA6V5N9&EF72TM/@T*/"]H96%D/@T*("`\8F]D>3X-"B`@(#QP M/E1H:7,@<&%G92!S:&]U;&0@8F4@;W!E;F5D('=I=&@@36EC'1087)T7SDX,F$S.&$S7S=B,CA?-#1F,%\Y96-E7S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA6UB;VP\+W1D/@T*("`@("`@("`\=&0@ M8VQA'0^0D%21"!#(%(@24Y#("].2B\\ M2!#96YT3PO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^,#`P,#`P.3@Y,CQS<&%N/CPO'0^+2TQ,BTS M,3QS<&%N/CPO3X-"CPO:'1M M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Y.#)A,SAA,U\W8C(X7S0T9C!?.65C M95\W,#=F9&4Y,60T93(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO M.3@R83,X83-?-V(R.%\T-&8P7SEE8V5?-S`W9F1E.3%D-&4R+U=O'0O:'1M;#L@8VAA M'!E;G-E'!E;G-E3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Y M.#)A,SAA,U\W8C(X7S0T9C!?.65C95\W,#=F9&4Y,60T93(-"D-O;G1E;G0M M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.3@R83,X83-?-V(R.%\T-&8P7SEE8V5? M-S`W9F1E.3%D-&4R+U=O'0O:'1M;#L@8VAA#PO=&0^#0H@("`@("`@(#QT9"!C M;&%S2!T'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQA'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ MF%T M:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR.34L,3`P/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S2P@<&QA;G0@86YD(&5Q=6EP;65N=#PO=&0^ M#0H@("`@("`@(#QT9"!C;&%SF5D(#4L,#`P M+#`P,"!S:&%R97,[(&YO;F4@:7-S=65D/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S&-E'0O:F%V87-C3X-"B`@ M("`\=&%B;&4@8VQAF5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV,#`L,#`P+#`P M,#QS<&%N/CPO3X-"CPO M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Y.#)A,SAA,U\W8C(X7S0T9C!? M.65C95\W,#=F9&4Y,60T93(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O M0SHO.3@R83,X83-?-V(R.%\T-&8P7SEE8V5?-S`W9F1E.3%D-&4R+U=O'0O:'1M;#L@ M8VAA'!E;F1I='5R97,\+W1D/@T*("`@("`@("`\=&0@8VQA6UE;G1S(&UA9&4@9F]R('!U6UE;G1S(&UA9&4@9F]R(&EN=&%N9VEB;&5S/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S,RPU,#`I/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S2!I;G9E'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$&5R8VES97,@=6YD97(@"!B96YE9FET(')E;&%T:6YG('1O M('-H87)E+6)A'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Y.#)A,SAA M,U\W8C(X7S0T9C!?.65C95\W,#=F9&4Y,60T93(-"D-O;G1E;G0M3&]C871I M;VXZ(&9I;&4Z+R\O0SHO.3@R83,X83-?-V(R.%\T-&8P7SEE8V5?-S`W9F1E M.3%D-&4R+U=O'0O:'1M;#L@8VAA'0M:6YD96YT.C0E.R!F;VYT+7-I>F4Z,3!P=#L@9F]N M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B!4:&4@86-C;VUP86YY:6YG M('5N875D:71E9"!C;VYD96YS960@8V]N2!F;W(@82!F86ER('!R97-E;G1A=&EO;BX-"B!4:&4@86-C;W5N=',@;V8@ M;6]S="!F;W)E:6=N('-U8G-I9&EA$$P.S(P,3(@ M=&AA=`T*(&UA=&5R:6%L;'D@869F96-T960@=&AE(&9I;F%N8VEA;"!P;W-I M=&EO;B!O2X@5&AE(')E2!I;F1I8V%T:79E(&]F('1H92!R M97-U;'1S(&5X<&5C=&5D(&9O'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA6QE/3-$)TU!4D=)3BU4 M3U`Z(#$X<'0[($9/3E0M1D%-24Q9.B!4:6UE2!A8W%U:7)E9"!A;&P@;V8@=&AE#0H@;W5T#(P,4,[365D869O#(P,40[ M*2P@80T*('!R:79A=&5L>2UH96QD(&1E=F5L;W!E6UE;G0@;V8@)#(P,RXW(&UI;&QI;VX@86YD(&9U='5R92!C;VYT:6YG M96YT('!A>6UE;G1S(&]F('5P('1O#0H@86X@861D:71I;VYA;"`D.#`@;6EL M;&EO;B!B87-E9"!O;B!S<&5C:69I8R!R979E;G5E+6)A6QE/3-$)TU!4D=)3BU43U`Z(#$R<'0[(%1% M6%0M24Y$14Y4.B`T)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@ M34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($]N(%-E M<'1E;6)E$$P.S0L(#(P,3,L('1H92!C;VUP86YY(&5N=&5R960@:6YT M;R!A(&1E9FEN:71I=F4-"B!A9W)E96UE;G0@=&\@86-Q=6ER92!2;V-H97-T M97(@365D:6-A;"P@26YC+B`H)B-X,C`Q0SM2;V-H97-T97(-"B!-961I8V%L M)B-X,C`Q1#LI+"!A('!U8FQI8VQY+6AE;&0@9&5V96QO<&5R(&%N9"!S=7!P M;&EE2!T:&4@#(P,4,[,T14)B-X,C`Q1#LI+"!P2!W:71H(')I9VAT0T*(')E;&%T960@=&\@<&5R:7!H97)A M;&QY(&EN#(P,4,[4$E# M0W,F(W@R,#%$.RDN(#-$5"!R96-E:79E9"!A;B!U<"UF6UE;G0@;V8-"B`D,CDN-2!M:6QL:6]N(&%N9"!I6UE;G1S(&]F('5P('1O("0U#0H@;6EL;&EO;B!B87-E M9"!U<&]N(')E9W5L871O6QE M/3-$)TU!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T)3L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4)/5%1/33H@,'!T.R!& M3TY4+5-)6D4Z(#$P<'0G/@T*($]N($IU;'DF(WA!,#LR.2P@,C`Q,RP@=&AE M(&-O;7!A;GD@86-Q=6ER960@86QL(&]F('1H92!O=71S=&%N9&EN9PT*('-H M87)E0T*('-P96-I86QI>FEN9R!I;B!T:&4@9&5V96QO<&UE M;G0@86YD(&-O;6UEF%T:6]N(&]F(&%O#(P,4,[25!2)F%M<#M$)B-X,C`Q1#LI M(&%S2!H87,@;F]T('EE M=`T*(&9I;F%L:7IE9"!T:&4@<'5R8VAA2!R M96%C:&5D(&$@9&5F:6YI=&EV92!A9W)E96UE;G0-"B!T;R!S96QL(&-E7-I M;VQO9WD-"B!D:79I#(P,40[*2!F;W(@)#(W-2!M:6QL:6]N(&EN(&-A2!E M>'!E8W1S('1O#0H@6QE/3-$)TU!4D=)3BU43U`Z(#!P=#L@34%21TE. M+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$R<'0G/@T*("8C>$$P.SPO<#X- M"B`\=&%B;&4@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE M/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z(#$P<'0G/@T* M($YE="!P2P@<&QA;G0@86YD(&5Q=6EP;65N=#PO<#X-"B`\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/C(N-CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\ M+W1R/@T*(#QT$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P M,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T M9#X-"B`\+W1R/@T*(#QT6QE/3-$ M)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#XR-"XT/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^ M#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z M(#$P<'0G/@T*($%C8W)U960@97AP96YS97,\+W`^#0H@/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T M)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#XQ+C@\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)U1%6%0M24Y$ M14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)' M24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($%C8W)U960@8V]M M<&5N$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$ M)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA! M,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UE$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(N-CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X M03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P M>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D M/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/C(Q+C@\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X- M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%\Y.#)A,SAA,U\W8C(X7S0T9C!?.65C95\W,#=F9&4Y,60T93(-"D-O M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.3@R83,X83-?-V(R.%\T-&8P M7SEE8V5?-S`W9F1E.3%D-&4R+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^/&1I M=CX-"B`\<"!S='EL93TS1"=M87)G:6XM=&]P.C$X<'0[(&UAF4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W M(%)O;6%N)SX-"B`\8CXS+B!297-T'0M:6YD96YT.C0E.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM M97,@3F5W(%)O;6%N)SX-"B!$=7)I;F<@=&AE(&9O=7)T:"!Q=6%R=&5R(&]F M(#(P,3(L('1H92!C;VUP86YY(&-O;6UI='1E9"!T;R!A('!L86X-"B`H=&AE M("8C>#(P,4,[,C`Q,B!297-T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA M6QE/3-$)TU!4D=)3BU43U`Z(#$X<'0[($9/3E0M1D%-24Q9.B!4:6UE M$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/ M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T M;VT@8V]L$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]- M.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X] M,T0V(&%L:6=N/3-$8V5N=&5R/CQB/DYI;F4@36]N=&AS/"]B/CQB6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@ M=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB M/C(P,3,\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI M9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R M/CQB/C(P,3(\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S M;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N M=&5R/CQB/C(P,3,\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P M="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$ M8V5N=&5R/CQB/C(P,3(\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.SPO=&0^#0H@/"]T$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&-O;'-P86X],T0R/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P M86X],T0R/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^ M#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P M.SPO=&0^#0H@/"]T6QE/3-$)U1%6%0M M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!- M05)'24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($QE$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(N-#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#XP+C,\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D M/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\ M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^ M#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO M='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T9/3E0M M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#XQ,C8N.3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA! M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR,BXP M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C,Y-"XR/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D M/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P M,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU4 M3U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE M/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z(#$P<'0G/@T* M($504R!$96YO;6EN871O6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE M/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T M)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T M9#X-"B`\+W1R/@T*(#QT$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/C$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^ M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#XX,RXX/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS M1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$ M$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M$$P M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O M;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA! M,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UE$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/ M3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/C@Q+C(\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP M="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#XX-"XY/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T M>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU4 M3U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@ M/"]T7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA&5S/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\9&EV/@T*(#QP('-T>6QE/3-$)VUA3I4:6UE2`R,B4L(&-O;7!A&EM871E;'D@,C$$P.S,P+"`R,#$S M(')E9FQE8W1E9"!T:&4@9&ES8W)E=&4@=&%X#0H@969F96-T"!J=7)I M"!P;W-I=&EO;B!A M$$P.S,P+`T*(#(P,3,@2!I;F-U"!R871E('=A'!A>65R(%)E;&EE9B!!8W0@;V8@,C`Q,BP@=VAI M8V@@=V%S#0H@&EM871E;'D-"B`D,RXW(&UI;&QI M;VX@9'5R:6YG('1H92!N:6YE(&UO;G1H&5S('=A$$P.VUI;&QI;VX@<&QU"!E>&%M:6YA=&EO;G,@86YD+V]R('1H M92!E>'!I2!B96QI979E$$P.VUO;G1H M3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%\Y.#)A,SAA,U\W8C(X7S0T9C!?.65C95\W,#=F9&4Y,60T M93(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.3@R83,X83-?-V(R M.%\T-&8P7SEE8V5?-S`W9F1E.3%D-&4R+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'!O2!O9F9S970@8GD@;6]V96UE;G1S M#0H@:6X@=&AE('5N9&5R;'EI;F<@:&5D9V5D(&ET96TN(%1H92!N;W1I;VYA M;"!V86QU92!O9B!T:&4-"B!C;VUP86YY)B-X,C`Q.3MS(&9O2!C;VYT$$P.S,P+"`R,#$S(&%N9`T*($1E8V5M8F5R)B-X03`[,S$L(#(P,3(L(')E M2X@1F]R(&9U28C>#(P,3D[$$P.S$@;V8@=&AE(&YO=&5S('1O(&-O M;G-O;&ED871E9"!F:6YA;F-I86P@6QE/3-$)TU!4D=)3BU43U`Z M(#$R<'0[(%1%6%0M24Y$14Y4.B`T)3L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CL@34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0G M/@T*(%1H92!L;V-A=&EO;B!A;F0@9F%I$$P.R8C>$$P.SPO M=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T M('-O;&ED)R!V86QI9VX],T1B;W1T;VT@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P M,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L M:6=N/3-$8V5N=&5R/CQB/E-E<'1E;6)E$$P.S,P+#QB$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@ M=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB M/D1E8V5M8F5R)B-X03`[,S$L/&)R("\^#0H@,C`Q,CPO8CX\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$ M)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($9O M6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!& M3TY4+5-)6D4Z(#$P<'0G/@T*($]T:&5R(&%S$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/C`N,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#XF(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[ M/"]T9#X-"B`\+W1R/@T*(#QT$$P.SPO M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X- M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA! M,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT M6QE M/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE M/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#XQ-2XS/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO M='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P M,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@2!C M;VYT6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$ M)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($%C M8W)U960F(WA!,#ME>'!E;G-E$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C`N,SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T M>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XP+C0\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@ M/"]T6QE/3-$)U1%6%0M24Y$14Y4.B`M M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5& M5#H@,65M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($9O6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C`N,3PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/ M3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/B8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@ M,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X- M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#XP+C0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W M$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE: M13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X- M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M#(P,3D[ M(&EN=F5S=&UE;G0@87)E(&%S(&9O;&QO=W,Z/"]P/@T*(#QP('-T>6QE/3-$ M)TU!4D=)3BU43U`Z(#!P=#L@34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-) M6D4Z(#$R<'0G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S M='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L M:6=N/3-$8F]T=&]M(&-O;'-P86X],T0V(&%L:6=N/3-$8V5N=&5R/CQB/D=A M:6XO*$QO$$P.VEN)B-X03`[3W1H M97(\8G(@+SX-"B!#;VUP$$P.SPO=&0^#0H@/'1D('-T>6QE M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX] M,T1B;W1T;VT@$$P.T%C8W5M=6QA=&5D/"]B M/CQB$$P.TQO M$$P.U)E8VQA$$P.TQO M6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P M,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L M:6=N/3-$8V5N=&5R/CQB/C(P,3,\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P M(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N M/3-$8V5N=&5R/CQB/C(P,3(\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M2!C;VYT$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1&-E M;G1E$$P.W-O;&0\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`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`\=&0@=F%L:6=N/3-$8F]T M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T* M(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1% M4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X- M"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O M;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@ M/"]T$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/C`N.3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^ M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/C`N,CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\ M+W1R/@T*(#QT"<^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO M<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU4 M3U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D/B8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO M=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T M('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]LF5D)B-X03`[ M:6XF(WA!,#M/=&AE$$P.U)E8VQA$$P.W1O/&)R("\^#0H@26YC;VUE/"]B M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S M;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0V(&%L:6=N/3-$8V5N M=&5R/CQB/D=A:6XO*$QO$$P.T%C8W5M=6QA=&5D/&)R("\^#0H@3W1H97(F(WA!,#M#;VUP M6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S M;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0V(&%L:6=N/3-$8V5N M=&5R/CQB/DYI;F4@36]N=&AS($5N9&5D/&)R("\^#0H@4V5P=&5M8F5R(#,P M+#PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N M/3-$8F]T=&]M(&-O;'-P86X],T0V(&%L:6=N/3-$8V5N=&5R/CQB/DYI;F4@ M36]N=&AS($5N9&5D/&)R("\^#0H@4V5P=&5M8F5R(#,P+#PO8CX\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT M6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED M)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.SPO=&0^#0H@/'1D M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V M86QI9VX],T1B;W1T;VT@8V]L$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@8V]L$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L$$P.SPO=&0^#0H@/"]T M6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@ M,65M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($9O$$P.V=O;V1S)B-X03`[$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z M(#$P<'0G/@T*($]P=&EO;B!C=7)R96YC>2!C;VYT$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+C`\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT M9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T M9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P M,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C M,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P M,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P M.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/C4N,#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@ M.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL M93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$N M,3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P M,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P M(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT M9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO M=&0^#0H@/"]T6QE/3-$)TU!4D=)3BU4 M3U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T)3L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CL@34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P M<'0G/@T*(%1H92!L;V-A=&EO;B!A;F0@86UO=6YT$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N M/3-$8F]T=&]M(&-O;'-P86X],T0Q-"!A;&EG;CTS1&-E;G1E$$P.U)E8V]G;FEZ960F(WA!,#MO;B8C>$$P.U-W87`\ M+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S M='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L M:6=N/3-$8F]T=&]M(&-O;'-P86X],T0Q-"!N;W=R87`],T1N;W=R87`@86QI M9VX],T1C96YT97(^/&(^/&9O;G0@F5D)B-X03`[;VXF(WA! M,#M,;VYG+51E6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B M;W1T;VT@8V]L$$P.T5N9&5D/"]B/CQB$$P.S,P+#PO M8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI M9VX],T1B;W1T;VT@8V]L$$P.TUO;G1H$$P.T5N9&5D/"]B/CQB$$P.S,P+#PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P M.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@ M,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.T5N9&5D/"]B/CQB$$P.S,P+#PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@ M,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.TUO;G1H$$P.T5N9&5D/"]B/CQB M$$P.S,P+#PO8CX\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B M;W1T;VT@8V]L$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/ M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T M;VT@8V]L$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B M;W1T;VT@8V]L$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/ M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T M;VT@8V]L$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B M;W1T;VT@8V]L$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX] M,T1B;W1T;VT@8V]L$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B M;W1T;VT@8V]L$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX] M,T1B;W1T;VT@8V]L$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R/B8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&-O;'-P86X],T0R/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X] M,T0R/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R/B8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&-O;'-P86X],T0R/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&-O;'-P86X],T0R/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[)B-X03`[/"]T9#X-"B`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`N,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$ M$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU4 M3U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$ M)TU!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T)3L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4)/5%1/33H@,'!T.R!&3TY4 M+5-)6D4Z(#$P<'0G/@T*(%1H92!L;V-A=&EO;B!A;F0@86UO=6YT$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@6QE/3-$ M)TU!4D=)3BU43U`Z(#!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CL@34%21TE.+4)/5%1/33H@,7!T.R!&3TY4+5-)6D4Z(#AP="<@86QI9VX] M,T1C96YT97(^/&(^3&]C871I;VX\+V(^/"]P/@T*(#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$ M8F]T=&]M(&-O;'-P86X],T0Q-"!A;&EG;CTS1&-E;G1E6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,CXF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!C;VQS<&%N/3-$,CXF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,CXF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,CXF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT2!C;VYT6QE/3-$)T9/3E0M4TE:13H@.#4E.R!615)424-!3"U!3$E'3CH@=&]P M)SXH02D\+W-U<#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"=-05)'24XM5$]0.B`P<'0[($9/3E0M1D%-24Q9.B!4:6UE M$$P.RAI;F-O;64I)B-X03`[97AP96YS92PF(WA! M,#MN970\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@ M86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C M,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P M6QE/3-$)T9/3E0M4TE: M13H@.#4E.R!615)424-!3"U!3$E'3CH@=&]P)SXH02D\+W-U<#XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1T;W`@86QI9VX],T1L969T/E1H97-E(&1E M&-H86YG92!R871E2X@1F%IF5S('1H92!U2!R86YG M92!F$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,CXF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!C M;VQS<&%N/3-$,CXF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT2!C;VYT$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$ M$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)U1%6%0M24Y$14Y4.B`M M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5& M5#H@,65M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($]P=&EO;B!C=7)R96YC>2!C M;VYT$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+C0\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#XY+C@\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W M$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$ M$$P.S,P+"`R,#$S(&%N9"!$96-E;6)E$$P.S,Q+"`R,#$R+"!R M97-P96-T:79E;'DN#0H@5&AE(&9A:7(@=F%L=64@=V%S(&UE87-U6QE/3-$)TU!4D=)3BU43U`Z(#$X<'@[ M($U!4D=)3BU"3U143TTZ(#!P>#L@1D].5"U325I%.B`Q<'@G/@T*("8C>$$P M.SPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`P<'0[($9/3E0M1D%- M24Q9.B!4:6UE6QE/3-$ M)TU!4D=)3BU43U`Z(#9P=#L@5$585"U)3D1%3E0Z(#0E.R!&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M M4TE:13H@,3!P="<^#0H@5&AE(&9A:7(@=F%L=64@;V8@8V]M;65R8VEA;"!P M87!E65A'!I$$P.S(V+`T*(#(P,3@N(%1H92!A;65N M9&5D(&-R961I="!F86-I;&ET>2!S=7!P;W)T28C>#(P M,3D[2!I;F-L=61E$$P.S,P+"`R,#$S+"!T:&4@8V]M<&%N>2!W87,@:6X- M"B!C;VUP;&EA;F-E('=I=&@@=&AI$$P.S,P+`T*(#(P,3,@86YD M($1E8V5M8F5R)B-X03`[,S$L(#(P,3(L(')E2X@5&AE(&9A M:7(@=F%L=64@=V%S#0H@97-T:6UA=&5D('5S:6YG(&1E86QE2UR871E9"!D96)T(&EN2!C;VYT:6YU97,-"B!T;R!M M;VYI=&]R('-O=F5R96EG;B!D96)T(&ES2!C;VYT:6YU90T*('1O(')E2!T;R!R M92UE=F%L=6%T92!T:&4@8V]L;&5C=&%B:6QI='D@;V8@=&AE7,@87)E(&%S M#0H@9F]L;&]W$$P.V1A>7,F(WA!,#MP M87-T)B-X03`[9'5E/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE6QE/3-$)U1% M6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(%-P86EN M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(S+C`\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/C0N.#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R M/@T*(#QT$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR M,RXQ/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(N-#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X M03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XS+C(\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C M>$$P.SPO=&0^#0H@/"]T6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(%!O$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/C$N-SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT M"<^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1% M4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X- M"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA! M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ,BXQ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF M(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M/B8C>$$P.SPO=&0^#0H@/"]T7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/&1I=CX-"B`\<"!S='EL93TS1"=M M87)G:6XM=&]P.C$X<'0[(&UAF4Z M,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B`\8CXW+B!) M;G9E;G1O$$P.SPO<#X-"B`\=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP861D M:6YG/3-$,"!W:61T:#TS1#6QE/3-$)T)/4D1% M4BU#3TQ,05!313I#3TQ,05!313L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O M;6%N.R!F;VYT+7-I>F4Z,3!P="<@86QI9VX],T1C96YT97(^#0H@/'1R/@T* M(#QT9"!W:61T:#TS1#6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@ M9F]N="US:7IE.CAP="<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N M=&5R('-T>6QE/3-$)V)O$$P.S,P+#QB$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@8V]L6QE/3-$ M)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.CAP="<^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XH9&]L;&%R$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@8V]L$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C M0T-%149&('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@ M9F]N="US:7IE.C$P<'0G/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N M)SX-"B!&:6YI$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/"]TF4Z,3!P="<^#0H@/'1D M('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HQ+C`P M96T[('1E>'0M:6YD96YT.BTQ+C`P96T[(&9O;G0M3I4:6UE$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(S+C`\+W1D/@T*(#QT M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)VUA$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$P.2XW/"]T9#X- M"B`\=&0@;F]W6QE/3-$9F]N="US:7IE.C%P>#L^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)V)O$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@"!S M;VQI9"`C,#`P,#`P)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[ M/"]T9#X-"B`\+W1R/@T*(#QT3I4:6UE M$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1&9O;G0M$$P.R8C>$$P.SPO=&0^#0H@/"]TF4Z,7!X.SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)V)O6QE/3-$)V)O3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Y M.#)A,SAA,U\W8C(X7S0T9C!?.65C95\W,#=F9&4Y,60T93(-"D-O;G1E;G0M M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.3@R83,X83-?-V(R.%\T-&8P7SEE8V5? M-S`W9F1E.3%D-&4R+U=O'0O:'1M;#L@8VAA'0^/&1I=CX-"B`\ M<"!S='EL93TS1"=M87)G:6XM=&]P.C$X<'0[(&UAF4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N M)SX-"B`\8CXX+B!#;VYT:6YG96YC:65S/"]B/CPO<#X-"B`\<"!S='EL93TS M1"=M87)G:6XM=&]P.C9P=#L@;6%R9VEN+6)O='1O;3HP<'0[(&9O;G0M3I4:6UE6QE/3-$)VUA3I4:6UE2!C;W5R2!O<&5R871E M2!S=7-C97!T:6)L92!T;R!S:6=N:69I8V%N="!P M2!A8V-O=6YT'!E;G-E9"!A2P@=&AE(&-O;7!A;GD@;6EG:'0- M"B!B92!R97%U:7)E9"!T;R!M86ME('-I9VYI9FEC86YT(')O>6%L='D@;W(@ M;W1H97(@<&%Y;65N=',@;W(@;6EG:'0-"B!B92!S=6)J96-T('1O(&%N(&EN M:G5N8W1I;VX@;W(@;W1H97(@;&EM:71A=&EO;B!O;B!I=',@86)I;&ET>2!T M;PT*(&UA;G5F86-T=7)E(&]R(&1IF4Z M,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B`\:3Y02!-871T97)S/"]I/CPO<#X-"B`\<"!S='EL93TS1"=M M87)G:6XM=&]P.C9P=#L@;6%R9VEN+6)O='1O;3HP<'0[('1E>'0M:6YD96YT M.C0E.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O M;6%N)SX-"B!!&EM M871E;'D@-S0U(&9E9&5R86P@86YD(#2!A<'!R;WAI;6%T96QY(#$L M-3#QS=7`@6QE/3-$)V9O;G0M2!V M;VQU;G1A2!R96-A;&QE9"!C97)T86EN#0H@F4Z.#4E.R!V M97)T:6-A;"UA;&EG;CIT;W`G/B8C>$%%.SPO2UF:6QE9"!5+E,N(&-L87-S(&%C M=&EO;B!L87=S=6ET$$P.W!U;FET:79E(&1A;6%G M97,[("AI=BDF(WA!,#MA(&IU9&EC:6%L(&9I;F1I;F<@;V8@9&5F96-T#0H@ M86YD(&-A=7-A=&EO;CL@86YD+V]R("AV*28C>$$P.V%T=&]R;F5Y#(P M,3D[(&9E97,N($$@&EM871E;'D@-C@U M(&]F('1H92!S=&%T92!L87=S=6ET2`W.#4@<&QA:6YT:69F$$P M.S(P,##QS=7`@6QE/3-$)V9O;G0M6QE/3-$)VUA'0M:6YD96YT.C0E.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UF86UI;'DZ M5&EM97,@3F5W(%)O;6%N)SX-"B!/;B!*=6YE)B-X03`[,S`L(#(P,3$L('1H M92!C;VUP86YY(&%N;F]U;F-E9"!T:&%T(&ET(&AA9"!R96%C:&5D#0H@86=R M965M96YT&ES=&EN9R!(97)N:6$@4')O9'5C="!#;&%I;7,N($5A8V@-"B!A M9W)E96UE;G0@:7,@$$P.S$W+"`R,#$S+"!P2!L87=S M=6ET2!A<'!R;WAI M;6%T96QY(#DL-C,U('!L86EN=&EF9G,@:&%V92!B965N(&9I;&5D#0H@;W(@ M87-S97)T960@86=A:6YS="!T:&4@8V]M<&%N>2!I;B!V87)I;W5S(&9E9&5R M86P@86YD('-T871E#0H@:G5R:7-D:6-T:6]N2`H86QL(&QA=W-U:71S+"!C;VQL96-T:79E;'DL('1H92`F(W@R,#%#.U=O M;65N)B-X,C`Q.3MS#0H@2&5A;'1H(%!R;V1U8W0@0VQA:6US)B-X,C`Q1#LI M+B!4:&4@5V]M96XF(W@R,#$Y.W,@2&5A;'1H(%!R;V1U8W0-"B!#;&%I;7,@ M9V5N97)A;&QY('-E96L@9&%M86=E$$P.VUE9&EC86P@;6]N:71O2`R,#$S(&%N M9"!R97-U;'1E9"!I;B!A(&IU9&=M96YT(&%G86EN2`D,RXV(&UI M;&QI;VXN(%1H92!C;VUP86YY(&AA2!I2!D;V5S(&YO=`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`T*(&EN9F]R;6%T M:6]N(')E9V%R9&EN9R!A;GD@0T*(&UA='1E6QE/3-$)VUA'0M:6YD96YT.C0E M.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N M)SX-"B!4:&4@8V]M<&%N>2!B96QI979E2!I;G-U2!C;&%I;7,@;W(@=&AA="!C M;W9E3I4:6UE#(P,3D[6QE/3-$)VUA'0M:6YD96YT.C0E.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UF86UI M;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B!);B!.;W9E;6)E2!R96-E:79E9"!A('-U8G!O96YA(&ES2!T:&4-"B!5 M+E,N($1E<&%R=&UE;G0@;V8@2&5A;'1H(&%N9"!(=6UA;B!397)V:6-E#(P,4,[3TE')B-X M,C`Q1#LI+"!U;F1E2!B=7-I;F5S2!A9W)E96UE M;G0@=VET:"!T:&4@8VEV:6P@86YD(&-R:6UI;F%L#0H@9&EV:7-I;VYS(&]F M('1H92!5;FET960@4W1A=&5S($%T=&]R;F5Y)B-X,C`Q.3MS($]F9FEC92!F M;W(@=&AE#0H@3F]R=&AE2!-871T97(@86YD(')E8V]R9&5D(&$@8VAA&EM871E M;'D@)#4Q+C`-"B!M:6QL:6]N("@D-#`N."!M:6QL:6]N(&%F=&5R('1A>"D@ M:6X@=&AE(&9O=7)T:"!Q=6%R=&5R(&]F(#(P,3$N($]N#0H@36%Y)B-X03`[ M,BP@,C`Q,RP@=&AE(&-O;7!A;GD@0T*('1O('!A>2!A M<'!R;WAI;6%T96QY('1H92!A;6]U;G0@=&AA="!W87,@<')E=FEO=7-L>2!R M96-OF4Z,7!X.VUA#MM87)G:6XM8F]T=&]M.C!P>#X-"B`F(WA!,#L\+W`^#0H@ M/'`@F]N82!F;W5N9"!T:&%T#0H@ M8V5R=&%I;B!O9B!7+DPN($=O#(P,4,[,3,U('!A=&5N="8C>#(P,40[*2X@5&AE(&IU2!O9B!T:&4-"B!P871E;G0@86YD(&%W87)D960@ M=&AE(&-O;7!A;GD@)#$X-2!M:6QL:6]N(&EN('!A2!A;'-O(&9O=6YD('1H870@1V]R92!W:6QL9G5L;'D@:6YF2`D,S2!A='1O7,F(W@R,#$Y.R!F965S(&]F#0H@ M)#$Y(&UI;&QI;VX@86YD('!R96IU9&=M96YT(&EN=&5R97-T(&]F(&%P<')O M>&EM871E;'D@)#(P(&UI;&QI;VXN#0H@26X@861D:71I;VXL('1H92!$:7-T M#(P,3D[28C>#(P,3D[2`D,3`Y(&UI;&QI;VX@:6X@861D M:71I;VYA;"!D86UA9V5S(&9O6%L='D@6%L=&EE#(P,3D[28C>$$P M.S$T+"`R,#$S+B!4:&4@1&ES=')I8W0@0V]U&5C=71E(&]N('1H92!J=61G;65N="P@9&5N:65D M($=O28C>$$P.S(X+"`R,#$S+"!';W)E(&9I;&5D('=I=&@@ M=&AE(%4N4RX@1&ES=')I8W0-"B!#;W5R="!A(%)E<75E#(P,3D[&%M:6YA=&EO;B!O9B!T:&4@,3,U('!A=&5N="X@3VX-"B!!<')I;"8C M>$$P.S$L(#(P,3,L('1H92!54U!43R!I&%M:6YA=&EO;BX@3VX@2G5L>28C>$$P.S$P+"`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`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`[;6EL;&EO;B!T;R!Q=6%L:69I960@6UE;G1S(&]F("0Q-3@N,B8C>$$P.VUI;&QI;VX@ M9G)O;2!T:&5S92!14T9S(&AA=F4@8F5E;B!M861E('1O#0H@<75A;&EF:65D M(&-L86EM86YT$$P M.S,P+"`R,#$S+B!);B!A9&1I=&EO;BP@;W1H97(-"B!P87EM96YT$$P.S,P M+"`R,#$S+CPO<#X-"B`\<"!S='EL93TS1"=M87)G:6XM=&]P.C$R<'0[(&UA M0T*(&UA='1E$$P.VUI;&QI;VX@870-"B!397!T96UB97(F(WA!,#LS M,"P@,C`Q,R!A;F0@1&5C96UB97(F(WA!,#LS,2P@,C`Q,BP@$$P.S,P+"`R,#$S(&ES#0H@=&AE('-U8FIE8W0@ M;V8@82!D:7-P=71E('=I=&@@82!S=7!P;&EE2!T:&4@8V]M<&%N>2P-"B!W:&EC:"!T:&4@8V]M M<&%N>2!R969U=&5S+B!!9G1E3I4:6UE2!P;W-S:6)L92!L;W-S97,@;W(-"B!R86YG92!O9B!L;W-S97,L M(&EF(&%N>2P@87)I2!M871T97)S(&%N9"!O=&AE0T*(&%C8V5P=&5D(&%C8V]U;G1I;F<@ M<')I;F-I<&QE28C>#(P,40[(&%N9"!A M;@T*(&5V96YT(&ES("8C>#(P,4,[#(P,40[+B!7:71H(')E0T* M('!O$$P.W1H97)E(&%R92!S:6=N:69I8V%N="!F86-T=6%L(&ES7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A6QE/3-$)TU!4D=)3BU43U`Z(#$X<'0[($9/3E0M1D%-24Q9.B!4 M:6UE6QE/3-$)TU!4D=)3BU43U`Z(#9P=#L@5$58 M5"U)3D1%3E0Z(#0E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!- M05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P="<^#0H@5&AE(&-O M;7!A;GD@;6%Y(&=R86YT(&$@=F%R:65T>2!O9B!S:&%R92UB87-E9"!P87EM M96YT$$P.U(N)B-X03`[0F%R9"P@26YC+BP@87,-"B!A;65N9&5D M(&%N9"!R97-T871E9"`H=&AE("8C>#(P,4,[3%1)4"8C>#(P,40[*2!A;F0@ M=&AE(#(P,#4-"B!$:7)E8W1OF5D(&%N(&%D9&ET M:6]N86P@,BPP,#`L,#`P('-H87)E#(P,3D[(%!L86X@=V%S(#,Y+#@T,RX@07=A6QE/3-$)TU!4D=)3BU43U`Z(#$R M<'@[($U!4D=)3BU"3U143TTZ(#!P>#L@1D].5"U325I%.B`Q<'@G/@T*("8C M>$$P.SPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`P<'0[(%1%6%0M M24Y$14Y4.B`T)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%2 M1TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($%M;W5N=',@ M6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L M;&%P6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED M)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.TUO;G1H$$P.T5N9&5D/&)R("\^#0H@4V5P=&5M M8F5R(#,P+#PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE6QE/3-$)U1% M6%0M24Y$14Y4.B`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`\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@ M/"]T6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z M(#$P<'0G/@T*($%M;W5N=',@8V%P:71A;&EZ960@:6X@:6YV96YT;W)Y(&%N M9"!F:7AE9"!A$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#XH,"XS/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<#XI)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,"XT/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#XH,2XT/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#XH,2XR/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<#XI)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QTF5D(&EN(&EN8V]M92!F;W(@86UO=6YTF5D(&EN#0H@:6YV96YT;W)Y(&%N9"!F:7AE M9"!A$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XP+C4\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/C$N-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#XQ+C(\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT M9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1% M4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\ M=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)U1%6%0M24Y$14Y4.B`M M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5& M5#H@,65M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($%M;W5N=',@8VAA$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$V+C(\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS M1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L M:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XT-"XW/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/C,Y+C`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W$$P.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X- M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P M.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@2!G65A2!P965R(&=R;W5P+B!4 M:&4@86-T=6%L('!A>6]U="!U;F1E6]U=#L@:&]W979E M6]U="!L979E;"!W:6QL(&)E M(&%C:&EE=F5D(&%N9"!M87D@8F4@861J=7-T960@9F]R('-U8G-E<75E;G0- M"B!C:&%N9V5S(&EN('1H92!E>'!E8W1E9"!O=71C;VUE(&]F('1H92!P97)F M;W)M86YC92UR96QA=&5D#0H@8V]N9&ET:6]N+B!4:&4@9F%I28C>#(P,3D[2X\+W`^#0H@/'`@#(P,4,[35-04"8C>#(P,40[*2!A M2`P+C(F(WA!,#MM:6QL:6]N('-H87)E'!E8W1E9"!V;VQA M=&EL:71Y(&]F(#$U)2!A;F0-"B`R,"4L(')E3L@9&EV:61E M;F0@>6EE;&0@;V8@,"XX)2!A;F0@,"XY)2P@'!E8W1E9"!L:69E(&]F(#`N-B!Y96%R$$P M.VUI;&QI;VX@;V8-"B!U;G)E8V]G;FEZ960@8V]M<&5N2!T=V\@>65A'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA6QE/3-$)TU!4D=)3BU43U`Z(#$X<'0[($9/ M3E0M1D%-24Q9.B!4:6UE2!H87,@8F]T:`T*('1A>"UQ M=6%L:69I960@86YD(&YO;G%U86QI9FEE9"P@;F]N8V]N=')I8G5T;W)Y(&1E M9FEN960@8F5N969I=`T*('!E;G-I;VX@<&QA;G,L('1H870@=&]G971H97(@ M8V]V97(@8V5R=&%I;B!D;VUE65E M6QE/3-$)TU!4D=)3BU43U`Z(#$R M<'0[(%1%6%0M24Y$14Y4.B`T)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CL@34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0G/@T* M(%1H92!C;VUP;VYE;G1S(&]F(&YE="!P97)I;V1I8R!P96YS:6]N(&-O6QE/3-$)TU!4D=)3BU43U`Z M(#!P=#L@34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$R<'0G/@T* M("8C>$$P.SPO<#X-"B`\=&%B;&4@6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]4 M5$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P M86X],T0V(&%L:6=N/3-$8V5N=&5R/CQB/E%U87)T97(@16YD960\8G(@+SX- M"B!397!T96UB97(@,S`L/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T M9#X-"B`\=&0@6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]4 M5$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P M86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P,3,\+V(^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]- M.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X] M,T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P,3(\+V(^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C M,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R M(&%L:6=N/3-$8V5N=&5R/CQB/C(P,3,\+V(^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P M,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L M:6=N/3-$8V5N=&5R/CQB/C(P,3(\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,CXF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!C M;VQS<&%N/3-$,CXF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,CXF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!C;VQS<&%N/3-$,CXF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/C$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/C0N-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#XT+CD\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE'!E8W1E9"!R971U M$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#XH-BXU/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS M1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH-BXR/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#XH,3DN-3PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$ M6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XS+C0\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/C$P+C(\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$ M)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C M,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/C@N-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR-RXP M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/C(U+C,\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/"]T M$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P M.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@F5D('!O$$P.S,P+"`R,#$S(&%N9"`R,#$R+`T*(')E2X@5&AE(&YE="!P97)I;V1I8R!B96YE9FET(&-O'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA'0^/&1I M=CX-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`P<'0[($9/3E0M1D%-24Q9 M.B!4:6UE2!R97!U$$P M.VUI;&QI;VX@2!A;FYO=6YC960@ M2!A9&]P=&5D(&YE M=R!&:6YA;F-I86P-"B!!8V-O=6YT:6YG(%-T86YD87)D6QE/3-$)T)/4D1%4BU#3TQ, M05!313H@8V]L;&%P6QE/3-$)T)/4D1%4BU"3U143TTZ(",P M,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.T-U$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D M/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S M;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N M=&5R/CQB/D)E;F5F:70\8G(@+SX-"B!0;&%N$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.SPO=&0^#0H@/"]T$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,CXF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!C M;VQS<&%N/3-$,CXF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,CXF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!C;VQS<&%N/3-$,CXF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.SPO=&0^#0H@/"]T6QE/3-$)U1%6%0M24Y$14Y4 M.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM M3$5&5#H@,V5M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($]T:&5R(&-O;7!R96AE M;G-I=F4@:6YC;VUE("AL;W-S*2!B969O$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XU+C(\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/B8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/B@Q.2XQ/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)T9/3E0M4TE:13H@.#4E.R!6 M15)424-!3"U!3$E'3CH@=&]P)SXH82D\+W-U<#X\+W`^#0H@/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#XH,BXR/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XF(W@R M,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#XF(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#XH,BXR/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P M,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P M,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P M,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[ M/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/C,N,#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@ M.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/B@R-"XS/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS M1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B8C>#(P,30[)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X- M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^ M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@ M/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X- M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T9/3E0M4TE: M13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/B8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$ M6QE/3-$)T9/3E0M4TE:13H@.#4E.R!615)424-! M3"U!3$E'3CH@=&]P)SXH8RD\+W-U<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/C`N,CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@ M.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/B8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,BXV/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\ M+W1R/@T*(#QT"<^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T M9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X- M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^ M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@ M/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)T9/ M3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/B@P+CD\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XU+C(\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS M1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#XT+C,\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/"]T$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T* M(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1% M4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X- M"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)U1%6%0M24Y$14Y4 M.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM M3$5&5#H@,65M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($]T:&5R(&-O;7!R96AE M;G-I=F4@:6YC;VUE("AL;W-S*3PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X- M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^ M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@ M/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X- M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE$$P.S,P+"`R,#$R M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL M93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$V+C@\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL M93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH.#,N-CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P M.SPO=&0^#0H@/"]T$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B M;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D M;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@.'!T M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,3$S M+C$\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/B@X,2XR/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT M$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$ M$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/C$N-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)T9/3E0M4TE:13H@.#4E.R!615)424-!3"U!3$E' M3CH@=&]P)SXH82D\+W-U<#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@P+C0\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=& M3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#XF(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/ M3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/B@P+C0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C M,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@ M.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/C$N,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P M,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P M,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P M,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[ M/"]T9#X-"B`\+W1R/@T*(#QT$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/ M3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/C$P+C,\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z M(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#XY+C<\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,V5M.R!&3TY4+5-)6D4Z M(#$P<'0G/@T*(%1A>"!P$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,RXW/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE: M13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/B@S+C0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$ M)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P M,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P M,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\ M+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M#PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C8N M-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C8N,SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X- M"B`\+W1R/@T*(#QT"<^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^ M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@ M/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X- M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\ M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^ M#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C8N-CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE: M13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/C"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P M,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C M,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P M,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X M03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C`N.3PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE: M13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#XS,2XY/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@Q,#8N-3PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z M(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P M,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P M.SPO=&0^#0H@/"]T6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!,24Y%+4A%24=(5#H@.'!T M.R!-05)'24XM5$]0.B`P<'0[(%=)1%1(.B`Q,"4[($U!4D=)3BU"3U143TTZ M(#)P="<^#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL93TS1"="3U)$15(M M0T],3$%04T4Z(&-O;&QA<'-E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&)O6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P'1087)T7SDX M,F$S.&$S7S=B,CA?-#1F,%\Y96-E7S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA6QE/3-$)TU!4D=)3BU43U`Z(#!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4)/5%1/33H@,'!T.R!& M3TY4+5-)6D4Z(#$P<'0G/@T*(#QB/C$R+B!396=M96YT($EN9F]R;6%T:6]N M/"]B/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`V<'0[(%1%6%0M M24Y$14Y4.B`T)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%2 M1TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(%1H92!C;VUP M86YY)B-X,C`Q.3MS(&UA;F%G96UE;G0@8V]N2!S:&%R92!S M:6UI;&%R#0H@9&ES=')I8G5T:6]N(&-H86YN96QS(&%N9"!C=7-T;VUE28C>#(P,3D[6QE M/3-$)TU!4D=)3BU43U`Z(#!P=#L@34%21TE.+4)/5%1/33H@,'!T.R!&3TY4 M+5-)6D4Z(#$R<'0G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N M/3-$8F]T=&]M(&-O;'-P86X],T0V(&%L:6=N/3-$8V5N=&5R/CQB/E%U87)T M97(@16YD960\8G(@+SX-"B!397!T96UB97(@,S`L/"]B/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@ M=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB M/C(P,3,\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI M9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R M/CQB/C(P,3(\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S M;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N M=&5R/CQB/C(P,3,\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P M="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$ M8V5N=&5R/CQB/C(P,3(\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,CXF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!C M;VQS<&%N/3-$,CXF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,CXF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,CXF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XD/"]T9#X-"B`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`M,65M.R!& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($5U$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$Q-BXW/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$P."XY/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C,U-BXU/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/C,T.2XT/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T* M(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/C0S+C0\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@.#4E.R!615)424-!3"U! M3$E'3CH@=&]P)SXH82D\+W-U<#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#XY-RXV/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/C@Y+C`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P M,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1% M4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X- M"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/ M3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#XR+#$Y-2XU/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^ M#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P M,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P M.SPO=&0^#0H@/"]T6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!,24Y%+4A%24=(5#H@.'!T M.R!-05)'24XM5$]0.B`P<'0[(%=)1%1(.B`Q,"4[($U!4D=)3BU"3U143TTZ M(#)P="<^#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL93TS1"="3U)$15(M M0T],3$%04T4Z(&-O;&QA<'-E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&)O#(P,40[#0H@ M9V5O9W)A<&AI8R!R96=I;VXN(%!R:6]R('EE87(@86UO=6YT2!A6QE/3-$ M)TU!4D=)3BU43U`Z(#!P=#L@34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-) M6D4Z(#$R<'0G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$ M8F]T=&]M(&-O;'-P86X],T0V(&%L:6=N/3-$8V5N=&5R/CQB/E%U87)T97(@ M16YD960\8G(@+SX-"B!397!T96UB97(@,S`L/"]B/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S M='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L M:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P M,3,\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@ M=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB M/C(P,3(\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI M9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R M/CQB/C(P,3,\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S M;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N M=&5R/CQB/C(P,3(\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!C;VQS<&%N/3-$,CXF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS M<&%N/3-$,CXF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,CXF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!C;VQS<&%N/3-$,CXF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(P,BXU/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XV,C4N,SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@ M/"]T6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z M(#$P<'0G/@T*(%5R;VQO9WD\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#XQ.3,N-SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#XQ.#@N,3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XU M-S0N,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XU-C(N M,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR M,34N-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR,#,N M.3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XV,S8N-SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XV,#$N.3PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[ M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ,3@N,3PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ,#$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XR,"XX/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/C(P+C<\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T* M(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^ M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@ M/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^ M#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/C$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/C(L,C4X+C(\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-) M6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$"<^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D M/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO M<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L M92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P M>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D M/@T*(#PO='(^#0H@/"]T86)L93X-"B`\+V1I=CX\'0O:F%V M87-C3X-"B`@("`\=&%B M;&4@8VQA6QE/3-$)TU!4D=)3BU4 M3U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T)3L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CL@34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P M<'0G/@T*($%S6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.SPO=&0^#0H@/"]T6QE M/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z(#$P<'0G/@T* M($EN=F5N=&]R:65S/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$T+C0\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)U1%6%0M24Y$14Y4.B`M M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5& M5#H@,65M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($]T:&5R(&-U6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#XR+C8\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($]T:&5R(&EN=&%N9VEB;&4@87-S971S M+"!N970\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XW+C`\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P M.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@ M/"]T6QE/3-$)T)/ M4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D M/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C`N M.#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P M,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T M9#X-"B`\+W1R/@T*(#QT6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR+C8\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C M>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D M;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@6QE/3-$)T9/3E0M M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#XR,2XX/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R M('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1% M4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X- M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/&1I=CX-"B`\<"!S='EL93TS M1"=-05)'24XM5$]0.B`V<'0[(%1%6%0M24Y$14Y4.B`T)3L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4)/5%1/33H@,'!T.R!&3TY4 M+5-)6D4Z(#$P<'0G/@T*($5A$$P M.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P M,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S M;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0V(&%L:6=N/3-$8V5N M=&5R/CQB/DYI;F4@36]N=&AS/"]B/CQB6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$ M15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P,3,\+V(^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"=" M3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T M=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P,3(\+V(^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$ M8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P,3,\+V(^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N M/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P,3(\ M+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@ M/"]T$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P M86X],T0R/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&-O;'-P86X],T0R/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T* M(#QT$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($QE$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/C(N-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#XP+C,\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/ M3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X- M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA! M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ,C8N M.3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR,BXP/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/C,Y-"XR/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R M('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1% M4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^ M#0H@/"]T6QE/3-$)U1%6%0M24Y$14Y4 M.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM M3$5&5#H@,65M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($504R!$96YO;6EN871O M6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@ M.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/ M3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT M$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L M:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA! M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/C$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XX,RXX/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L M:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T* M(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^ M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@ M/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^ M#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/C@Q+C(\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XX-"XY/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA! M,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE: M13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1% M4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T* M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/&1I M=CX-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5. M5#H@-"4[($9/3E0M1D%-24Q9.B!4:6UEF5D(&EN('1H92!C;VYD96YS960-"B!C;VYS;VQI9&%T960@8F%L86YC M92!S:&5E=',@87)E(&%S(&9O;&QO=W,Z/"]P/@T*(#QP('-T>6QE/3-$)TU! M4D=)3BU43U`Z(#!P=#L@34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z M(#$R<'0G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$ M8F]T=&]M(')O=W-P86X],T0R(&%L:6=N/3-$8V5N=&5R/@T*(#QP('-T>6QE M/3-$)TU!4D=)3BU43U`Z(#!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CL@34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#AP="<@86QI M9VX],T1C96YT97(^/&(^0F%L86YC92!3:&5E=#PO8CX\+W`^#0H@/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI M9VX],T1B;W1T;VT@8V]L$$P.SPO=&0^#0H@/"]T6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@ M,7!T('-O;&ED.R!724142#H@,38R<'0[($9/3E0M1D%-24Q9.B!4:6UE$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O M;'-P86X],T0R/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R/B8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO M='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z(#$P<'0G M/@T*($]T:&5R)B-X03`[8W5R$$P.V%S$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/C$N-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4 M+5-)6D4Z(#$P<'0G/@T*($]T:&5R(&-U$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/C`N-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R M/@T*(#QT2!C;VYT M$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"=415A4+4E.1$5.5#H@+3%E;3L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@1D].5"U325I%.B`Q,'!T)SX- M"B!/=&AE$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#XP+C(\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE M/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z(#$P<'0G/@T* M($EN=&5R97-T(')A=&4@6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@ M,65M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($]T:&5R)B-X03`[87-S971S/"]P M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$S+C,\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^ M#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D/B8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/C$S+C$\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP M="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@ M/"]T6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z M(#$P<'0G/@T*($9O6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XP+C,\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z M(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$ M6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W6QE/3-$ M)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(#QF M;VYT('-T>6QE/3-$)U=(251%+5-004-%.B!N;W=R87`G/D]T:&5R)B-X03`[ M;&]N9RUT97)M)B-X03`[;&EA8FEL:71I97,\+V9O;G0^/"]P/@T*(#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-) M6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#XP+C$\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#XF(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R M/@T*(#QT"<^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X M03`[/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/C`N-#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\ M+W1R/@T*(#QT"<^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P M,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU4 M3U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D/B8C>$$P.SPO=&0^#0H@/"]T'0^/&1I=CX- M"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@ M-"4[($9/3E0M1D%-24Q9.B!4:6UE$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B M;W1T;VT@8V]LF5D)B-X03`[:6XF(WA!,#M/=&AE$$P.U)E8VQA$$P M.W1O/&)R("\^#0H@26YC;VUE/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O M;'-P86X],T0V(&%L:6=N/3-$8V5N=&5R/CQB/D=A:6XO*$QO$$P.T%C8W5M=6QA=&5D/&)R M("\^#0H@3W1H97(F(WA!,#M#;VUP6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O M;'-P86X],T0V(&%L:6=N/3-$8V5N=&5R/CQB/E%U87)T97(@16YD960\8G(@ M+SX-"B!397!T96UB97(@,S`L/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O M;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.SPO=&0^#0H@/"]T M$$P.R8C>$$P.SPO M=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T M('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.SPO=&0^ M#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O M;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S M='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L M:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P M,3,\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!S='EL M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N M/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P,3(\ M+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@ M/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!C M;VQS<&%N/3-$,CXF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,CXF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&-O;'-P86X],T0R/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.V=O;V1S)B-X03`[$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/"]T6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($]P=&EO;B!C=7)R96YC>2!C;VYT$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C M,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T* M(#QT6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XP+C0\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z M(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+C$\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL M93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/ M4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P M,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C M,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$ M)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P$$P M.T]T:&5R/&)R("\^#0H@0V]M<')E:&5N$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI M9"<@=F%L:6=N/3-$8F]T=&]M(')O=W-P86X],T0S(&%L:6=N/3-$8V5N=&5R M/CQB/DQO8V%T:6]N(&]F/"]B/CQB$$P.T-O;7!R96AE;G-I M=F4F(WA!,#M,;W-S)B-X03`[=&\\8G(@+SX-"B!);F-O;64\+V(^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V M86QI9VX],T1B;W1T;VT@8V]L$$P.T-O;7!R96AE;G-I M=F4F(WA!,#M,;W-S/&)R("\^#0H@:6YT;R!);F-O;64\+V(^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V M86QI9VX],T1B;W1T;VT@8V]L$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/ M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T M;VT@8V]L6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N M/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P,3,\ M+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S M='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L M:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P M,3(\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS M<&%N/3-$,CXF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,CXF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT M2!C;VYT$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1C96YT97(^#0H@0V]S="8C>$$P.V]F)B-X03`[ M9V]O9',F(WA!,#MS;VQD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/C$N,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#XQ+C`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W M$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1C96YT97(^0V]S="!O9B!G;V]D$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#XH,2XQ/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#XQ+C4\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C M,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P M,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT M9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X- M"B`\+W1R/@T*(#QT6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XU+C$\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=& M3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/ M3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#XP+C8\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@ M,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P M,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B M;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D M;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI M9VX],T1B;W1T;VT@8V]L$$P.V]N)B-X03`[4W=A M<#PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V M86QI9VX],T1B;W1T;VT@8V]L$$P.U)E8V]G;FEZ960F(WA!,#MO;B8C M>$$P.TQO;F$$P.T1E8G0\+V9O;G0^/"]B/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1% M6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($EN=&5R M97-T)B-X03`[$$P.W-W87`F(WA!,#MC;VYT$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/DEN=&5R97-T)B-X03`[97AP96YS M93PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(N-3PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO<#X-"B`\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P M.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B M;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P M(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P M,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P$$P.U-T871E;65N=#PO8CX\+W`^#0H@/'`@ M$$P.R8C>$$P.SPO=&0^#0H@/'1D M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V M86QI9VX],T1B;W1T;VT@8V]LF5D(&EN#0H@16%R;FEN9W,\+V(^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S M='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L M:6=N/3-$8F]T=&]M(&-O;'-P86X],T0V(&%L:6=N/3-$8V5N=&5R/CQB/E%U M87)T97(F(WA!,#M%;F1E9#PO8CX\8G(@+SX-"B`\8CY397!T96UB97(F(WA! M,#LS,"P\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI M9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0V(&%L:6=N/3-$8V5N=&5R M/CQB/DYI;F4F(WA!,#M-;VYT:',F(WA!,#M%;F1E9#PO8CX\8G(@+SX-"B`\ M8CY397!T96UB97(F(WA!,#LS,"P\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O M;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P,3,\+V(^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$ M15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P,3(\+V(^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"=" M3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T M=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P,3,\+V(^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$ M8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P,3(\+V(^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T M$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&-O;'-P86X],T0R/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P M86X],T0R/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^ M#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)TU!4D=)3BU43U`Z(#!P=#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4)/5%1/33H@,7!T.R!&3TY4 M+5-)6D4Z(#$P<'0G/@T*($]T:&5R)B-X03`[*&EN8V]M92DF(WA!,#ME>'!E M;G-E+"8C>$$P.VYE=#PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<#XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS M1&YO=W)A<#XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS M1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XS+C`\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P M.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1% M4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T* M(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X- M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D M;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T* M(#PO='(^#0H@/"]T86)L93X-"B`\<"!S='EL93TS1"="3U)$15(M0D]45$]- M.B`C,#`P,#`P(#%P>"!S;VQI9#L@3$E.12U(14E'2%0Z(#AP=#L@34%21TE. M+51/4#H@,'!T.R!724142#H@,3`E.R!-05)'24XM0D]45$]-.B`R<'0G/@T* M("8C>$$P.SPO<#X-"B`\=&%B;&4@$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1'1O<"!A;&EG;CTS1&QE9G0^ M5&AE0T*(&5X8VAA;F=E(')A M=&5S+CPO=&0^#0H@/"]T6QE/3-$)TU! M4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T)3L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-) M6D4Z(#$P<'0G/@T*(%1H92!F;VQL;W=I;F<@=&%B;&4@6QE/3-$)TU!4D=)3BU43U`Z(#!P=#L@34%21TE.+4)/5%1/33H@,'!T M.R!&3TY4+5-)6D4Z(#$R<'0G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/ M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T M;VT@8V]L$$P M.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P M,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M24Y$14Y4 M.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM M3$5&5#H@,65M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($9O$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C`N-CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X- M"B`\+W1R/@T*(#QT$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$S+C,\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/"]T7-T96US#0H@:6X@=&AE6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N M/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/D%C8V]U M;G1S/&)R("\^#0H@$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$ M15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/D=R96%T97(F(WA!,#MT M:&%N/&)R("\^#0H@,S8U)B-X03`[9&%Y$$P.W!A$$P.SPO=&0^#0H@ M/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!C M;VQS<&%N/3-$,CXF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,CXF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\ M+W1R/@T*(#QT$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE3PO M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(S+C$\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ,"XU/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/C,N,CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\ M+W1R/@T*(#QT$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#XT+C`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/ M3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^ M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XV M,"XV/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$R+C$\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO M=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P M>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@3X-"CPO:'1M M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Y.#)A,SAA,U\W8C(X7S0T9C!?.65C M95\W,#=F9&4Y,60T93(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO M.3@R83,X83-?-V(R.%\T-&8P7SEE8V5?-S`W9F1E.3%D-&4R+U=O'0O:'1M;#L@8VAA M6QE/3-$)VUA3I4:6UEF4Z,3)P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM8F]T=&]M M.C!P=#X-"B`F(WA!,#L\+W`^#0H@/'1A8FQE(&-E;&QS<&%C:6YG/3-$,"!C M96QL<&%D9&EN9STS1#`@=VED=&@],T0W-B4@8F]R9&5R/3-$,"!S='EL93TS M1"="3U)$15(M0T],3$%04T4Z0T],3$%04T4[(&9O;G0M9F%M:6QY.E1I;65S M($YE=R!2;VUA;CL@9F]N="US:7IE.C$P<'0G(&%L:6=N/3-$8V5N=&5R/@T* M(#QT$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG M;CTS1&-E;G1E6QE/3-$)V)O$$P.R8C>$$P M.SPO=&0^#0H@/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;3XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D(&-O M;'-P86X],T0R('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)VUA$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/C$Y-"XV/"]T9#X-"B`\=&0@;F]W6QE/3-$ M)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.C$P<'0G M/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@F4Z,3!P M=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B!7;W)K(&EN('!R M;V-E$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR,RXP/"]T M9#X-"B`\=&0@;F]W$$P.R8C M>$$P.SPO=&0^#0H@/"]T'0M:6YD96YT.BTQ+C`P96T[(&9O;G0M3I4:6UE$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ,#DN M-SPO=&0^#0H@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ,30N.#PO M=&0^#0H@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^)B-X M03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"=B;W)D97(M=&]P.C$N,#!P>"!S;VQI M9"`C,#`P,#`P)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*(#QP('-T>6QE/3-$)V)O$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)V)O$$P.SPO<#X-"B`\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO=&0^#0H@/"]TF4Z,3!P="<^#0H@/'1D('9A M;&EG;CTS1'1O<#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ MF4Z.'!T/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/C,S,BXQ/"]T9#X-"B`\=&0@;F]W$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/C,R."XU/"]T9#X-"B`\=&0@;F]W6QE M/3-$9F]N="US:7IE.C%P>#L^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)V)O6QE/3-$)V)O$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"=B;W)D97(M=&]P.C,N,#!P>"!D;W5B;&4@(S`P,#`P,"<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"=B;W)D97(M=&]P.C,N,#!P>"!D;W5B;&4@(S`P,#`P,"<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T* M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAAF5D(&9O M$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@ M8V]L$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P M(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0V(&%L:6=N M/3-$8V5N=&5R/CQB/DYI;F4F(WA!,#M-;VYT:',F(WA!,#M%;F1E9#QB$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@ M8V]L$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L M$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&-O;'-P86X],T0R/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R/B8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&-O;'-P86X],T0R/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF5D(&EN(&EN M=F5N=&]R>2!A;F0@9FEX960@87-S971S/"]P/@T*(#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L M:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/"]T6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-) M6D4Z(#$P<'0G/@T*($%M;W5N=',@2!C87!I=&%L:7IE9"!I;@T*(&EN=F5N=&]R M>2!A;F0@9FEX960@87-S971S/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$ M$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C`N-#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+C4\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X- M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^ M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@ M/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X- M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ M-BXR/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/C$Q+C4\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z M(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XS.2XP/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T* M(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L M92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T M7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA'0^/&1I=CX-"B`\<"!S M='EL93TS1"=-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4[($9/ M3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@ M8V]L$$P.TUO;G1H M$$P.T5N9&5D/&)R("\^#0H@4V5P=&5M8F5R(#,P+#PO8CX\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT M6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M8V]L$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L$$P.SPO=&0^#0H@/"]T6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(%-E65E(&-O;G1R:6)U=&EO;G,\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/C(R+C8\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/C(P+C@\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)U1%6%0M24Y$ M14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)' M24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($EN=&5R97-T(&-O M$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XT+C8\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/C$S+C<\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@Q-RXY/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X- M"B`\+W1R/@T*(#QT$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/C(N.#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ,"XR/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C"<^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA! M,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\ M+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M$$P M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA! M,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT M$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/CDN,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XX+C4\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@.'!T M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR-2XS M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF M(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P M,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M/B8C>$$P.SPO=&0^#0H@/"]T7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAA6QE/3-$)TU!4D=)3BU43U`Z M(#$R<'0[(%1%6%0M24Y$14Y4.B`T)3L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CL@34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0G M/@T*(%1H92!C:&%N9V5S(&EN(&%C8W5M=6QA=&5D(&]T:&5R(&-O;7!R96AE M;G-I=F4@:6YC;VUE("AL;W-S*2!B>0T*(&-O;7!O;F5N="!A$$P.SPO M=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T M('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.V%S/&)R("\^#0H@0V%S:"8C>$$P.T9L;W$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T* M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI M9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R M/CQB/D9O3QB6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE6QE/3-$)U1%6%0M24Y$14Y4 M.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM M3$5&5#H@,65M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($)A;&%N8V4@870@1&5C M96UB97(F(WA!,#LS,2P@,C`Q,3PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,2XT M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/B@R-"XS/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<#XI)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XF(W@R,#$T.R8C>$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,3DN,3PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C M>$$P.SPO=&0^#0H@/"]T6QE/3-$)U1% M6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M.R!-05)'24XM3$5&5#H@,V5M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(%1A>"`H M<')O=FES:6]N*2!B96YE9FET(')E;&%T960@=&\@;W1H97(@8V]M<')E:&5N M$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/"]T$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI M9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z(#$P<'0G M/@T*($]T:&5R(&-O;7!R96AE;G-I=F4@:6YC;VUE("AL;W-S*2!B969O&5S/"]P/@T*(#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-) M6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#XS+C`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,C0N,SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=& M3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#XF(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/ M3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/B@R,2XS/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C M,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^ M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XF(W@R,#$T M.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C@N,#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/'-U<"!S M='EL93TS1"=&3TY4+5-)6D4Z(#@U)3L@5D525$E#04PM04Q)1TXZ('1O<"<^ M*&,I/"]S=7`^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C8N.3PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T M9#X-"B`\+W1R/@T*(#QT$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@R+C@\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L M:6=N/3-$$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C M,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P M,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C M,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C M>$$P.SPO=&0^#0H@/"]T6QE/3-$)U1% M6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(%)E8VQA M6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/B8C>#(P,30[)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$ M)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P M,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P M,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\ M+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(N,3PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE: M13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/B@R-"XS/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C4N,CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/ M3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/B@Q-RXP/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C M,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^ M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/C`N-SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ-BXX/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/B@Q,#$N,3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1% M4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/ M4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)U1%6%0M24Y$14Y4.B`M M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5& M5#H@,65M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($)A;&%N8V4@870@1&5C96UB M97(F(WA!,#LS,2P@,C`Q,CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@P+C<\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/C,R+C8\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE: M13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#XH.#$N,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^*28C>$$P.SPO=&0^#0H@/"]T6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,V5M.R!&3TY4+5-)6D4Z(#$P<'0G M/@T*($]T:&5R(&-O;7!R96AE;G-I=F4@:6YC;VUE("AL;W-S*2!B969O6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(N,SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE M/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/B@P+C<\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+C8\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)U1%6%0M24Y$14Y4.B`M M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5& M5#H@,V5M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(%1A>"`H<')O=FES:6]N*2!B M96YE9FET(')E;&%T960@=&\@;W1H97(@8V]M<')E:&5N6QE/3-$)T9/3E0M4TE:13H@.'!T M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/B8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH M,"XT/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<#XI)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O M;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI M9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O M;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\ M+W1R/@T*(#QT6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$N.3PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/ M3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/B@P+C<\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+C(\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C M>$$P.SPO=&0^#0H@/"]T$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI M9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,V5M.R!&3TY4+5-)6D4Z(#$P<'0G M/@T*($%M;W5N=',@6QE/3-$)T9/3E0M4TE: M13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/B@P+C8\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M4TE:13H@.#4E.R!615)4 M24-!3"U!3$E'3CH@=&]P)SXH8BD\+W-U<#XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ M,"XS/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<#X\6QE/3-$)T9/3E0M4TE:13H@.#4E.R!615)424-!3"U!3$E' M3CH@=&]P)SXH8RD\+W-U<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C`N,SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$ M)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/B8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA! M,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T* M(#QT6QE/3-$)T9/3E0M4TE: M13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/B@P+C,\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XV+C8\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4 M+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#XV+C,\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W M$$P.R8C>$$P.SPO=&0^#0H@/"]T$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C M,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$ M)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($]T M:&5R(&-O;7!R96AE;G-I=F4@:6YC;VUE("AL;W-S*3PO<#X-"B`\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$ M$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P M.R8C>$$P.SPO=&0^#0H@/"]T$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI M9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O M;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI M9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T M6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z(#$P M<'0G/@T*($)A;&%N8V4@870@4V5P=&5M8F5R)B-X03`[,S`L(#(P,3,\+W`^ M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$ M)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#XP+CD\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W M$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$ M)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#XH,3`V+C4\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@W,RXW/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T M9#X-"B`\+W1R/@T*(#QT"<^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO M<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L M92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^ M#0H@/"]T86)L93X-"B`\<"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P M,#`P(#%P>"!S;VQI9#L@3$E.12U(14E'2%0Z(#AP=#L@34%21TE.+51/4#H@ M,'!T.R!724142#H@,3`E.R!-05)'24XM0D]45$]-.B`R<'0G/@T*("8C>$$P M.SPO<#X-"B`\=&%B;&4@&5S(&%R92!N;W0@<')O M=FED960@9F]R#0H@9F]R96EG;B!C=7)R96YC>2!T6QE/3-$)T)/4D1%4BU#3TQ,05!313H@ M8V]L;&%P3X- M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Y.#)A,SAA,U\W8C(X7S0T M9C!?.65C95\W,#=F9&4Y,60T93(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z M+R\O0SHO.3@R83,X83-?-V(R.%\T-&8P7SEE8V5?-S`W9F1E.3%D-&4R+U=O M'0O:'1M M;#L@8VAA2!' M96]G'0^/&1I=CX-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`Q,G!T.R!415A4 M+4E.1$5.5#H@-"4[($9/3E0M1D%-24Q9.B!4:6UE2!G96]G$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX] M,T1B;W1T;VT@8V]L$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O M;'-P86X],T0V(&%L:6=N/3-$8V5N=&5R/CQB/DYI;F4F(WA!,#M-;VYT:',F M(WA!,#M%;F1E9#QB$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V M86QI9VX],T1B;W1T;VT@8V]L$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED M)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O M;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.R8C>$$P.SPO M=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T M('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O M;'-P86X],T0R/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R/B8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R/B8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@ M/"]T6QE/3-$)U1%6%0M24Y$14Y4.B`M M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5& M5#H@,65M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($IA<&%N/"]P/@T*(#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/C$R,BXR/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/CDW+C8\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR M.#$N.3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR-30N M,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P M,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C M,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T* M(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^ M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@ M/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)T9/3E0M M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#XW-3@N,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA! M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XW,C(N M.3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR+#(U."XR/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/C(L,3DU+C4\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X- M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D M;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P M,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU# M3TQ,05!313H@8V]L;&%P65A6QE/3-$)T)/4D1% M4BU#3TQ,05!313H@8V]L;&%P6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.TUO;G1H$$P M.T5N9&5D/&)R("\^#0H@4V5P=&5M8F5R(#,P+#PO8CX\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UE6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z(#$P M<'0G/@T*(%9A$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/C8S,RXP/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO M='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE M/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z(#$P<'0G/@T* M($]N8V]L;V=Y/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C M>$$P.SPO=&0^#0H@/"]T6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(%-U$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@ M/"]T6QE/3-$)U1%6%0M24Y$14Y4.B`M M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5& M5#H@,65M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($]T:&5R/"]P/@T*(#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$"<^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1% M4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\ M=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M$$P M.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO M<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T* M(#QT6QE/3-$)T9/3E0M4TE:13H@ M.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#XW-3@N,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XW,C(N.3PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE M/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#XR+#(U."XR/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/C(L,3DU+C4\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W M$$P.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P M>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@3X-"CPO:'1M M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Y.#)A,SAA,U\W8C(X7S0T9C!?.65C M95\W,#=F9&4Y,60T93(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO M.3@R83,X83-?-V(R.%\T-&8P7SEE8V5?-S`W9F1E.3%D-&4R+U=O'0O:'1M;#L@8VAA M&EM=6T\8G(^/"]T:#X- M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^075G+B`R.2P@,C`Q,SQB6UE;G0\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$ M=&@^4V5P+B`P-"P@,C`Q,SQB'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO M=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%\Y.#)A,SAA,U\W8C(X7S0T9C!?.65C95\W,#=F9&4Y,60T93(-"D-O;G1E M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.3@R83,X83-?-V(R.%\T-&8P7SEE M8V5?-S`W9F1E.3%D-&4R+U=O'0O:'1M;#L@8VAA'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'!E;G-E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$2!R96QA=&5D('1O(')E'1087)T7SDX,F$S.&$S7S=B,CA?-#1F,%\Y96-E7S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2!#;VUM;VX@0VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA"!;3&EN92!)=&5M M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$"!P'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$F5D M('1A>"!B96YE9FET'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$2!D96-R96%S93PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^,3(@;6]N=&AS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%\Y.#)A,SAA,U\W8C(X7S0T9C!?.65C95\W,#=F9&4Y,60T M93(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.3@R83,X83-?-V(R M.%\T-&8P7SEE8V5?-S`W9F1E.3%D-&4R+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R2!C;VYT&5D M+7)A=&4@;F]T97,@:6YT97)E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S&5D+7)A=&4@;F]T97,@9'5E M(&1A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$65A'!I'!I'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Y.#)A,SAA,U\W8C(X7S0T9C!? M.65C95\W,#=F9&4Y,60T93(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O M0SHO.3@R83,X83-?-V(R.%\T-&8P7SEE8V5?-S`W9F1E.3%D-&4R+U=O'0O:'1M;#L@ M8VAA'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$3PO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0O:F%V87-C3X-"B`@ M("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$F5D(&EN($]T:&5R($-O;7!R96AE;G-I=F4@26YC;VUE("A,;W-S*3PO M=&0^#0H@("`@("`@(#QT9"!C;&%S2!C;VYT'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!C;VYT3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%\Y.#)A,SAA,U\W8C(X7S0T9C!?.65C95\W,#=F9&4Y,60T93(-"D-O M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.3@R83,X83-?-V(R.%\T-&8P M7SEE8V5?-S`W9F1E.3%D-&4R+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%\Y.#)A,SAA,U\W8C(X7S0T9C!?.65C95\W,#=F9&4Y,60T M93(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.3@R83,X83-?-V(R M.%\T-&8P7SEE8V5?-S`W9F1E.3%D-&4R+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S2!L;V%N3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Y.#)A,SAA,U\W M8C(X7S0T9C!?.65C95\W,#=F9&4Y,60T93(-"D-O;G1E;G0M3&]C871I;VXZ M(&9I;&4Z+R\O0SHO.3@R83,X83-?-V(R.%\T-&8P7SEE8V5?-S`W9F1E.3%D M-&4R+U=O'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2P@ M;F5T+"!T;W1A;#PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA M2!S=&%T M92!C87-E/&)R/D-L86EM/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S71H97)A<'D@ M36%T=&5R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S2!C;&%I;7,@9&ES;6ES'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^,3(@;6]N=&AS/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M#PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$6UE;G1S('1O('%U86QI9FEE9"!C;&%I;6%N=',@9G)O;2!Q M=6%L:69I960@'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'1087)T7SDX M,F$S.&$S7S=B,CA?-#1F,%\Y96-E7S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ MF5D/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$65A6EE;&0\ M+W1D/@T*("`@("`@("`\=&0@8VQA'!E8W1E9"!L:69E M(&EN('EE87)S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\7,\7,\'0^,B!Y96%R'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'!E8W1E9"!V;VQA=&EL:71Y/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$FEN9R!U;G)E8V]G;FEZ960@8V]M<&5N'0^,B!Y96%R7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA65E(%-E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$F5D(&EN(&EN=F5N=&]R>2!A;F0@9FEX960@ M87-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S,#`L,#`P M*3QS<&%N/CPO2!C87!I=&%L M:7IE9"!I;B!I;G9E;G1O&5D(&%S7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2!;3&EN92!)=&5M7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M"`H<')O=FES:6]N*2!B96YE9FET(')E;&%T960@=&\@;W1H97(@8V]M M<')E:&5N'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S"!P'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S"`H<')O=FES:6]N*2!B96YE9FET(')E;&%T960@=&\@ M;W1H97(@8V]M<')E:&5N'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S#PO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S2!4'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S#PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'1087)T7SDX,F$S M.&$S7S=B,CA?-#1F,%\Y96-E7S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S65A M'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2`H1&5T86EL*2`H55-$("0I/&)R M/DEN(%1H;W5S86YD'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S M+6%S8VEI(@T*#0H\>&UL('AM;&YS.F\],T0B=7)N.G-C:&5M87,M;6EC&UL/@T*+2TM M+2TM/5].97AT4&%R=%\Y.#)A,SAA,U\W8C(X7S0T9C!?.65C95\W,#=F9&4Y ),60T93(M+0T* ` end XML 42 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.8 Html 192 247 1 true 70 0 false 9 false false R1.htm 101 - Document - Document and Entity Information Sheet http://www.crbard.com/taxonomy/role/DocumentandEntityInformation Document and Entity Information false false R2.htm 103 - Statement - Condensed Consolidated Statements Of Income Sheet http://www.crbard.com/taxonomy/role/StatementOfIncomeAlternative Condensed Consolidated Statements Of Income false false R3.htm 104 - Statement - Condensed Consolidated Statements of Comprehensive Income Sheet http://www.crbard.com/taxonomy/role/StatementOfOtherComprehensiveIncome Condensed Consolidated Statements of Comprehensive Income true false R4.htm 105 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.crbard.com/taxonomy/role/StatementOfFinancialPositionClassified Condensed Consolidated Balance Sheets false false R5.htm 106 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.crbard.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical Condensed Consolidated Balance Sheets (Parenthetical) false false R6.htm 107 - Statement - Condensed Consolidated Statements Of Cash Flows Sheet http://www.crbard.com/taxonomy/role/StatementOfCashFlowsIndirect Condensed Consolidated Statements Of Cash Flows false false R7.htm 108 - Disclosure - Basis of Presentation Sheet http://www.crbard.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock Basis of Presentation false false R8.htm 109 - Disclosure - Acquisitions and Divestiture Sheet http://www.crbard.com/taxonomy/role/NotesToFinancialStatementsMergersAcquisitionsAndDispositionsDisclosuresTextBlock Acquisitions and Divestiture false false R9.htm 110 - Disclosure - Restructuring Sheet http://www.crbard.com/taxonomy/role/NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlock Restructuring false false R10.htm 111 - Disclosure - Earnings per Common Share Sheet http://www.crbard.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock Earnings per Common Share false false R11.htm 112 - Disclosure - Income Taxes Sheet http://www.crbard.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock Income Taxes false false R12.htm 113 - Disclosure - Financial Instruments Sheet http://www.crbard.com/taxonomy/role/NotesToFinancialStatementsFinancialInstrumentsDisclosureTextBlock Financial Instruments false false R13.htm 114 - Disclosure - Inventories Sheet http://www.crbard.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlock Inventories false false R14.htm 115 - Disclosure - Contingencies Sheet http://www.crbard.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock Contingencies false false R15.htm 116 - Disclosure - Share-Based Compensation Plans Sheet http://www.crbard.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Share-Based Compensation Plans false false R16.htm 117 - Disclosure - Pension and Other Postretirement Benefit Plans Sheet http://www.crbard.com/taxonomy/role/NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock Pension and Other Postretirement Benefit Plans false false R17.htm 118 - Disclosure - Shareholders' Investment Sheet http://www.crbard.com/taxonomy/role/NotesToFinancialStatementsShareholdersEquityAndShareBasedPaymentsTextBlock Shareholders' Investment false false R18.htm 119 - Disclosure - Segment Information Sheet http://www.crbard.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlock Segment Information false false R19.htm 120 - Disclosure - Acquisitions and Divestiture (Tables) Sheet http://www.crbard.com/taxonomy/role/NotesToFinancialStatementsMergersAcquisitionsAndDispositionsDisclosuresTextBlockTables Acquisitions and Divestiture (Tables) false false R20.htm 121 - Disclosure - Earnings per Common Share (Tables) Sheet http://www.crbard.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables Earnings per Common Share (Tables) false false R21.htm 122 - Disclosure - Financial Instruments (Tables) Sheet http://www.crbard.com/taxonomy/role/NotesToFinancialStatementsFinancialInstrumentsDisclosureTextBlockTables Financial Instruments (Tables) false false R22.htm 123 - Disclosure - Inventories (Tables) Sheet http://www.crbard.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlockTables Inventories (Tables) false false R23.htm 124 - Disclosure - Share-Based Compensation Plans (Tables) Sheet http://www.crbard.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables Share-Based Compensation Plans (Tables) false false R24.htm 125 - Disclosure - Pension and Other Postretirement Benefit Plans (Tables) Sheet http://www.crbard.com/taxonomy/role/NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlockTables Pension and Other Postretirement Benefit Plans (Tables) false false R25.htm 126 - Disclosure - Shareholders' Investment (Tables) Sheet http://www.crbard.com/taxonomy/role/NotesToFinancialStatementsShareholdersEquityAndShareBasedPaymentsTextBlockTables Shareholders' Investment (Tables) false false R26.htm 127 - Disclosure - Segment Information (Tables) Sheet http://www.crbard.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlockTables Segment Information (Tables) false false R27.htm 128 - Disclosure - Acquisitions and Divestiture - Additional Information (Detail) Sheet http://www.crbard.com/taxonomy/role/DisclosureAcquisitionsAndDivestitureAdditionalInformation Acquisitions and Divestiture - Additional Information (Detail) false false R28.htm 129 - Disclosure - Assets and Liabilities Held for Sale Associated with Electrophysiology Division (Detail) Sheet http://www.crbard.com/taxonomy/role/DisclosureAssetsAndLiabilitiesHeldForSaleAssociatedWithElectrophysiologyDivision Assets and Liabilities Held for Sale Associated with Electrophysiology Division (Detail) false false R29.htm 130 - Disclosure - Restructuring - Additional Information (Detail) Sheet http://www.crbard.com/taxonomy/role/DisclosureRestructuringAdditionalInformation Restructuring - Additional Information (Detail) false false R30.htm 131 - Disclosure - Earnings Per Share Computation (Detail) Sheet http://www.crbard.com/taxonomy/role/DisclosureEarningsPerShareComputation Earnings Per Share Computation (Detail) false false R31.htm 132 - Disclosure - Income Taxes - Additional Information (Detail) Sheet http://www.crbard.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation Income Taxes - Additional Information (Detail) false false R32.htm 133 - Disclosure - Financial Instruments - Additional Information (Detail) Sheet http://www.crbard.com/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformation Financial Instruments - Additional Information (Detail) false false R33.htm 134 - Disclosure - Location and Fair Value of Derivative Instruments Designated as Hedging Instruments (Detail) Sheet http://www.crbard.com/taxonomy/role/DisclosureLocationAndFairValueOfDerivativeInstrumentsDesignatedAsHedgingInstruments Location and Fair Value of Derivative Instruments Designated as Hedging Instruments (Detail) false false R34.htm 135 - Disclosure - Location and Amounts of Gains and Losses on Derivative Instruments Designated as Cash Flow Hedges (Detail) Sheet http://www.crbard.com/taxonomy/role/DisclosureLocationAndAmountsOfGainsAndLossesOnDerivativeInstrumentsDesignatedAsCashFlowHedges Location and Amounts of Gains and Losses on Derivative Instruments Designated as Cash Flow Hedges (Detail) false false R35.htm 136 - Disclosure - Location and Amounts of Gains and Losses on Derivative Instrument Designated as Fair Value Hedge (Detail) Sheet http://www.crbard.com/taxonomy/role/DisclosureLocationAndAmountsOfGainsAndLossesOnDerivativeInstrumentDesignatedAsFairValueHedge Location and Amounts of Gains and Losses on Derivative Instrument Designated as Fair Value Hedge (Detail) false false R36.htm 137 - Disclosure - Location and Amounts of Gains on Derivative Instruments Not Designated as Hedging Instruments (Detail) Sheet http://www.crbard.com/taxonomy/role/DisclosureLocationAndAmountsOfGainsOnDerivativeInstrumentsNotDesignatedAsHedgingInstruments Location and Amounts of Gains on Derivative Instruments Not Designated as Hedging Instruments (Detail) false false R37.htm 138 - Disclosure - Financial Instrument Assets and (Liabilities) Measured at Fair Value on Recurring Basis (Detail) Sheet http://www.crbard.com/taxonomy/role/DisclosureFinancialInstrumentAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasis Financial Instrument Assets and (Liabilities) Measured at Fair Value on Recurring Basis (Detail) false false R38.htm 139 - Disclosure - Accounts Receivable, Net of Allowances (Detail) Sheet http://www.crbard.com/taxonomy/role/DisclosureAccountsReceivableNetOfAllowances Accounts Receivable, Net of Allowances (Detail) false false R39.htm 140 - Disclosure - Inventories (Detail) Sheet http://www.crbard.com/taxonomy/role/DisclosureInventories Inventories (Detail) false false R40.htm 141 - Disclosure - Contingencies - Additional Information (Detail) Sheet http://www.crbard.com/taxonomy/role/DisclosureContingenciesAdditionalInformation Contingencies - Additional Information (Detail) false false R41.htm 142 - Disclosure - Share-Based Compensation Plans - Additional Information (Detail) Sheet http://www.crbard.com/taxonomy/role/DisclosureShareBasedCompensationPlansAdditionalInformation Share-Based Compensation Plans - Additional Information (Detail) false false R42.htm 143 - Disclosure - Amounts Recognized for Share-Based Compensation (Detail) Sheet http://www.crbard.com/taxonomy/role/DisclosureAmountsRecognizedForShareBasedCompensation Amounts Recognized for Share-Based Compensation (Detail) false false R43.htm 144 - Disclosure - Components of Net Periodic Pension Cost (Detail) Sheet http://www.crbard.com/taxonomy/role/DisclosureComponentsOfNetPeriodicPensionCost Components of Net Periodic Pension Cost (Detail) false false R44.htm 145 - Disclosure - Pension and Other Postretirement Benefit Plans - Additional Information (Detail) Sheet http://www.crbard.com/taxonomy/role/DisclosurePensionAndOtherPostretirementBenefitPlansAdditionalInformation Pension and Other Postretirement Benefit Plans - Additional Information (Detail) false false R45.htm 146 - Disclosure - Shareholders' Investment - Additional Information (Detail) Sheet http://www.crbard.com/taxonomy/role/DisclosureShareholdersInvestmentAdditionalInformation Shareholders' Investment - Additional Information (Detail) false false R46.htm 147 - Disclosure - Changes in Accumulated Other Comprehensive Income (Loss) By Component (Detail) Sheet http://www.crbard.com/taxonomy/role/DisclosureChangesInAccumulatedOtherComprehensiveIncomeLossByComponent Changes in Accumulated Other Comprehensive Income (Loss) By Component (Detail) false false R47.htm 148 - Disclosure - Net Sales Based On Location of External Customers by Geographic Region (Detail) Sheet http://www.crbard.com/taxonomy/role/DisclosureNetSalesBasedOnLocationOfExternalCustomersByGeographicRegion Net Sales Based On Location of External Customers by Geographic Region (Detail) false false R48.htm 149 - Disclosure - Total Net Sales by Product Group Category (Detail) Sheet http://www.crbard.com/taxonomy/role/DisclosureTotalNetSalesByProductGroupCategory Total Net Sales by Product Group Category (Detail) false false All Reports Book All Reports Element bcr_RoyaltyRate had a mix of decimals attribute values: 2 3. Element us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax had a mix of decimals attribute values: -5 -3. Element us-gaap_OtherComprehensiveIncomeLossNetOfTax had a mix of decimals attribute values: -5 -3. Element us-gaap_PaymentsToAcquireIntangibleAssets had a mix of decimals attribute values: -5 -3. Element us-gaap_SalesRevenueNet had a mix of decimals attribute values: -5 -3. 'Monetary' elements on report '128 - Disclosure - Acquisitions and Divestiture - Additional Information (Detail)' had a mix of different decimal attribute values. 'Monetary' elements on report '129 - Disclosure - Assets and Liabilities Held for Sale Associated with Electrophysiology Division (Detail)' had a mix of different decimal attribute values. 'Monetary' elements on report '131 - Disclosure - Earnings Per Share Computation (Detail)' had a mix of different decimal attribute values. 'Monetary' elements on report '133 - Disclosure - Financial Instruments - Additional Information (Detail)' had a mix of different decimal attribute values. 'Monetary' elements on report '140 - Disclosure - Inventories (Detail)' had a mix of different decimal attribute values. 'Monetary' elements on report '143 - Disclosure - Amounts Recognized for Share-Based Compensation (Detail)' had a mix of different decimal attribute values. 'Monetary' elements on report '147 - Disclosure - Changes in Accumulated Other Comprehensive Income (Loss) By Component (Detail)' had a mix of different decimal attribute values. Process Flow-Through: 103 - Statement - Condensed Consolidated Statements Of Income Process Flow-Through: 104 - Statement - Condensed Consolidated Statements of Comprehensive Income Process Flow-Through: 105 - Statement - Condensed Consolidated Balance Sheets Process Flow-Through: Removing column 'Sep. 30, 2012' Process Flow-Through: Removing column 'Dec. 31, 2011' Process Flow-Through: 106 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Process Flow-Through: 107 - Statement - Condensed Consolidated Statements Of Cash Flows bcr-20130930.xml bcr-20130930.xsd bcr-20130930_cal.xml bcr-20130930_def.xml bcr-20130930_lab.xml bcr-20130930_pre.xml true true XML 43 R45.htm IDEA: XBRL DOCUMENT v2.4.0.8
Shareholders' Investment - Additional Information (Detail) (USD $)
In Millions, unless otherwise specified
9 Months Ended
Sep. 30, 2013
Shareholders Equity [Line Items]  
Number of shares of common stock purchased 5.2
Purchase of common stock $ 533.4
XML 44 R3.htm IDEA: XBRL DOCUMENT v2.4.0.8
Condensed Consolidated Statements of Comprehensive Income (USD $)
In Thousands, unless otherwise specified
3 Months Ended 9 Months Ended
Sep. 30, 2013
Sep. 30, 2012
Sep. 30, 2013
Sep. 30, 2012
Net income $ 93,200 $ 129,300 $ 22,300 $ 401,900
Other comprehensive income (loss):        
Change in derivative instruments designated as cash flow hedges, net of tax (1,200) 100 1,600 2,100
Foreign currency translation adjustments 8,000 14,900 (700) (24,300)
Benefit plan adjustments, net of tax 2,200 1,800 6,600 5,200
Other comprehensive income (loss) 9,000 16,800 7,500 (17,000)
Comprehensive income $ 102,200 $ 146,100 $ 29,800 $ 384,900
XML 45 R14.htm IDEA: XBRL DOCUMENT v2.4.0.8
Contingencies
9 Months Ended
Sep. 30, 2013
Contingencies

8. Contingencies

General

In the ordinary course of business, the company is subject to various legal proceedings, investigations and claims, including, for example, environmental matters, employment disputes, disputes on agreements and other commercial disputes. In addition, the company operates in an industry susceptible to significant product liability and patent legal claims. The company accounts for estimated losses with respect to legal proceedings and claims when such losses are probable and reasonably estimable. Legal costs associated with these matters are expensed as incurred. At any given time, in the ordinary course of business, the company is involved as either a plaintiff or defendant in a number of patent infringement actions. If a third party’s patent infringement claim were to be determined against the company, the company might be required to make significant royalty or other payments or might be subject to an injunction or other limitation on its ability to manufacture or distribute one or more products. If a patent owned by or licensed to the company is found to be invalid or unenforceable, the company might be required to reduce the value of certain intangible assets on the company’s balance sheet and to record a corresponding charge, which could be significant in amount. Many of the company’s legal proceedings and claims could have a material adverse effect on its business, results of operations, financial condition and/or liquidity.

Product Liability Matters

As of October 17, 2013, approximately 745 federal and 720 state lawsuits involving individual claims by approximately 1,575 plaintiffs, as well as two putative class actions in the United States are currently pending against the company with respect to its Composix® Kugel® and certain other hernia repair implant products (collectively, the “Hernia Product Claims”). The company voluntarily recalled certain sizes and lots of the Composix® Kugel® products beginning in December 2005. One of the U.S. class action lawsuits consolidated ten previously-filed U.S. class action lawsuits. The putative class actions, none of which has been certified, seek: (i) medical monitoring; (ii) compensatory damages; (iii) punitive damages; (iv) a judicial finding of defect and causation; and/or (v) attorneys’ fees. A settlement has been reached with respect to the three pending putative Canadian class actions within amounts previously recorded by the company. Approximately 685 of the state lawsuits, involving individual claims by approximately 785 plaintiffs, are pending in the Superior Court of the State of Rhode Island, with the remainder in various other jurisdictions. The Hernia Product Claims also generally seek damages for personal injury resulting from use of the products.

In June 2007, the Composix® Kugel® lawsuits and, subsequently, other hernia repair product lawsuits, pending in federal courts nationwide were transferred into one Multidistrict Litigation (“MDL”) for coordinated pre-trial proceedings in the United States District Court for the District of Rhode Island.

On June 30, 2011, the company announced that it had reached agreements in principle with various plaintiffs’ law firms to settle the majority of its existing Hernia Product Claims. Each agreement is subject to certain conditions, including requirements for participation in the proposed settlements by a certain minimum number of plaintiffs. In addition, the company continues to engage in discussions with other plaintiffs’ law firms regarding potential resolution of unsettled Hernia Product Claims, and intends to vigorously defend Hernia Product Claims that do not settle, including through litigation. The company cannot give any assurances that the resolution of the Hernia Product Claims that have not settled, including asserted and unasserted claims and the putative class action lawsuits, will not have a material adverse effect on the company’s business, results of operations, financial condition and/or liquidity.

As of October 17, 2013, product liability lawsuits involving individual claims by approximately 9,635 plaintiffs have been filed or asserted against the company in various federal and state jurisdictions alleging personal injuries associated with the use of certain of the company’s surgical continence products for women, including its Avaulta® line of products. In addition, five putative class actions in the United States and three putative class actions in Canada have been filed against the company (all lawsuits, collectively, the “Women’s Health Product Claims”). The Women’s Health Product Claims generally seek damages for personal injury resulting from use of the products. The putative class actions, none of which has been certified, seek: (i) medical monitoring; (ii) compensatory damages; (iii) punitive damages; (iv) a judicial finding of defect and causation; and/or (v) attorneys’ fees. With respect to certain of these claims, the company believes that one of its suppliers has an obligation to defend and indemnify the company. In October 2010, the Women’s Health Product Claims involving solely Avaulta® products pending in federal courts nationwide were transferred into an MDL in the United States District Court for the Southern District of West Virginia, the scope of which was later expanded to include lawsuits involving all women’s surgical continence products that are manufactured or distributed by the company. The company expects additional Women’s Health Product Claims pending in federal courts to be transferred to the MDL in West Virginia, with the remainder of the Women’s Health Product Claims in other jurisdictions. The first trial in the MDL commenced in July 2013 and resulted in a judgment against the company of approximately $2 million. The company intends to appeal the judgment. The next MDL trial is scheduled to occur in December 2013, with additional trials scheduled in 2014. The first trial in a state court was completed in July 2012 and resulted in a judgment against the company of approximately $3.6 million. The company has appealed this decision. During the third quarter, the company settled one MDL case and one New Jersey state case. The amounts of the settlements are subject to confidentiality requirements. In addition, during the third quarter, an MDL case was voluntarily dismissed with prejudice, and the company is currently seeking to recover attorneys’ fees for this case. The company does not believe that any verdicts or settlements entered to date are representative of potential outcomes of all Women’s Health Product Claims. The case numbers set forth above do not include generic complaints involving women’s health products where the company cannot, based on the allegations in such complaints, determine whether any of such cases involve the company’s women’s health products. While the company intends to vigorously defend the Women’s Health Product Claims, it cannot give any assurances that the resolution of these claims will not have a material adverse effect on the company’s business, results of operations, financial condition and/or liquidity.

As of October 17, 2013, product liability lawsuits involving individual claims by 40 plaintiffs are currently pending against the company in various federal and state jurisdictions alleging personal injuries associated with the use of the company’s vena cava filter products. In addition, three putative class actions were filed against the company in various state courts on behalf of plaintiffs who are alleged to have no present injury (all lawsuits, collectively, the “Filter Product Claims”). Two of these putative class actions were dismissed during the second quarter, and class certification was denied for the third putative class action in July 2013. The first Filter Product Claim trial was completed in June 2012 and resulted in a judgment for the company. The company expects additional trials of Filter Product Claims to take place over the next 12 months. During the second quarter of 2013, the company finalized settlement agreements with respect to more than 30 Filter Product Claims, and made payments with respect to such claims within the amounts previously recorded. While the company intends to vigorously defend the remaining unsettled Filter Product Claims, it cannot give any assurances that the resolution of these claims will not have a material adverse effect on the company’s business, results of operations, financial condition and/or liquidity.

In most product liability litigations of this nature, plaintiffs allege a wide variety of claims, ranging from allegations of serious injury caused by the products to efforts to obtain compensation notwithstanding the absence of any injury. In many of these cases, the company has not yet received and reviewed complete information regarding the plaintiffs and their medical conditions, and consequently, is unable to fully evaluate the claims. The company expects that it will receive and review additional information regarding any remaining unsettled product liability matters.

The company believes that some settlements and judgments, as well as legal defense costs, relating to product liability matters are or may be covered in whole or in part under its product liability insurance policies with a limited number of insurance carriers. In certain circumstances, insurance carriers reserve their rights with respect to coverage, or contest or deny coverage, as has occurred with respect to certain claims. When this occurs, the company intends to vigorously contest disputes with respect to its insurance coverage and to enforce its rights under the terms of its insurance policies, and accordingly, will record receivables with respect to amounts due under these policies, when recovery is probable. Amounts recovered under the company’s product liability insurance policies may be less than the stated coverage limits and may not be adequate to cover damages and/or costs relating to claims. In addition, there is no guarantee that insurers will pay claims or that coverage will otherwise be available.

The company’s insurance coverage with respect to the Hernia Product Claims has been exhausted. In the first quarter of 2013 the company recorded a non-cash charge of $25.0 million ($24.5 million after tax) to other (income) expense, net, for the write-down of an insurance receivable related to a dispute with one of its excess insurance carriers in connection with these claims.

In connection with the Women’s Health Product Claims, the company was in dispute with one of its excess insurance carriers relating to an aggregate of $50 million of insurance coverage. In June 2013, the company settled this dispute with no change to the amount of the insurance coverage or the related receivable.

Other Legal Matters

During the first half of 2013, the company received subpoenas or Civil Investigative Demands from a number of State Attorneys General seeking information related to the sales and marketing of certain of the company’s products that are the subject of the Hernia Product Claims and the Women’s Health Product Claims. The company is cooperating with these requests. Since it is not feasible to predict the outcome of these proceedings, the company cannot give any assurances that the resolution of these proceedings will not have a material adverse effect on the company’s business, results of operations, financial condition and/or liquidity.

In November 2006, the company received a subpoena issued by the U.S. Department of Health and Human Services, Office of Inspector General (“OIG”), under the authority of the federal healthcare fraud and false claims statutes, seeking documents related to the company’s brachytherapy business (the “Brachytherapy Matter”). In January 2012, the company reached a preliminary agreement with the civil and criminal divisions of the United States Attorney’s Office for the Northern District of Georgia to resolve claims with respect to the Brachytherapy Matter and recorded a charge of approximately $51.0 million ($40.8 million after tax) in the fourth quarter of 2011. On May 2, 2013, the company settled this matter. The resolution includes agreements with the government that required the company to pay approximately the amount that was previously recorded.

 

In December 2007, a U.S. District Court jury in Arizona found that certain of W.L. Gore & Associates Inc.’s (“Gore”) ePTFE vascular grafts and stent-grafts infringe the company’s patent number 6,436,135 (the “135 patent”). The jury upheld the validity of the patent and awarded the company $185 million in past damages. The jury also found that Gore willfully infringed the patent. In a second phase of the trial, the District Court ruled that Gore failed to prove that the patent is unenforceable due to inequitable conduct. In March 2009, the District Court doubled the jury award to approximately $371 million for damages through June 2007. The District Court also awarded the company attorneys’ fees of $19 million and prejudgment interest of approximately $20 million. In addition, the District Court denied Gore’s remaining motions, including its motions for a new trial and to set aside the jury’s verdict. In July 2010, the District Court awarded the company approximately $109 million in additional damages for the period from July 2007 through March 2009. Gore has deposited or secured the foregoing amounts with the District Court. The District Court also assessed a royalty rate of between 12.5% and 20%, depending on the product, that will be used to calculate damages for Gore’s infringing sales from April 2009 through the expiration of the patent. Gore has made additional deposits with the District Court of approximately $542 million, representing Gore’s calculation of royalties for its infringing sales through July 2013. Gore appealed this matter to the Court of Appeals for the Federal Circuit (the “Court of Appeals”), which on February 10, 2012 affirmed the decision of the District Court. Gore filed a petition with the Court of Appeals for a rehearing of its appeal. On June 14, 2012, the Court of Appeals reaffirmed its February 10, 2012 decision, including the ongoing royalty rates as set by the District Court, with the exception of the issue of willfulness with respect to Gore’s infringement of the 135 patent, which was remanded to the District Court. On October 12, 2012, Gore filed a petition for a writ of certiorari to the U.S. Supreme Court requesting a review of the portion of the decision that the Court of Appeals reaffirmed. The U.S. Supreme Court denied Gore’s petition on January 14, 2013. The District Court heard oral argument on June 5, 2013 as to three pending motions before it, including the company’s motion to execute on the judgment with respect to all amounts other than enhanced damages due to willfulness. In October 2013, the District Court granted Bard’s motion to execute on the judgment, denied Gore’s motion requesting a determination that Gore’s infringement was not willful and denied Gore’s motion for a new trial. The District Court’s rulings on the motions are subject to appeal. On January 28, 2013, Gore filed with the U.S. District Court a Request for Judicial Notice that the U.S. Patent and Trademark Office (“USPTO”) granted Gore’s previously filed request for a re-examination of the 135 patent. On April 1, 2013, the USPTO issued a First Office Action initially rejecting all of the claims of the 135 patent that are the subject of the re-examination. On July 10, 2013, the USPTO issued a Notice of Intent to Issue an Ex Parte Reexamination Certificate upholding the patentability of all re-examined claims of the 135 patent. This action terminated the re-examination proceeding and upheld the claims involved in the re-examination. The timing of final resolution of this litigation remains uncertain. Since the company considers these matters a gain contingency, no amounts have been recorded. Even if the company is ultimately successful in this lawsuit, it cannot give any assurances that royalties for Gore’s future infringing sales will remain at or near historic levels.

The company is subject to numerous federal, state, local and foreign environmental protection laws governing, among other things, the generation, storage, use and transportation of hazardous materials and emissions or discharges into the ground, air or water. The company is or may become a party to proceedings brought under various federal laws including the Comprehensive Environmental Response, Compensation and Liability Act (CERCLA), commonly known as Superfund, the Resource Conservation and Recovery Act, the Clean Water Act, the Clean Air Act and similar state or foreign laws. These proceedings seek to require the owners or operators of contaminated sites, transporters of hazardous materials to the sites and generators of hazardous materials disposed of at the sites to clean up the sites or to reimburse the government for cleanup costs. In most cases, there are other potentially responsible parties that may be liable for remediation costs. In these cases, the government alleges that the defendants are jointly and severally liable for the cleanup costs; however, these proceedings are frequently resolved so that the allocation of cleanup costs among the parties more closely reflects the relative contributions of the parties to the site contamination. The company’s potential liability varies greatly from site to site. For some sites, the potential liability is de minimis and for others the costs of cleanup have not yet been determined. Accruals for estimated losses from environmental remediation obligations generally are recognized no later than completion of the remedial feasibility study and are adjusted as further information develops or circumstances change. Costs of future expenditures for environmental remediation obligations are not discounted to their present value. Recoveries of environmental remediation costs from other parties are recorded as assets when their receipt is deemed probable. The company believes that the proceedings and claims described above will likely be resolved over an extended period of time. While it is not feasible to predict the outcome of these proceedings, based upon the company’s experience, current information and applicable law, the company does not expect these proceedings to have a material adverse effect on its financial condition and/or liquidity. However, one or more of the proceedings could be material to the company’s business and/or results of operations.

 

Litigation Reserves

The company regularly monitors and evaluates the status of product liability and other legal matters, and may, from time-to-time, engage in settlement and mediation discussions taking into consideration developments in the matters and the risks and uncertainties surrounding litigation. These discussions could result in settlements of one or more of these claims at any time.

The company evaluated the product liability matters discussed above under the heading “Product Liability Matters” based on information currently available, including: the allegations and documentation supporting or refuting such allegations; publicly available information regarding similar medical device mass tort settlements; historical information regarding other product liability settlements involving the company; and the procedural posture and stage of litigation. Based on these, and other factors, the company recorded a charge, net of estimated recoveries to other (income) expense, net, of approximately $293.0 million ($276.0 million after tax) in the second quarter of 2013, which recognized the estimated costs for certain of these product liability matters, including (with respect to such matters) asserted and unasserted claims, and costs to administer the settlements related to such matters. The charge excludes any costs associated with all but one putative class action lawsuit. The company cannot give any assurances that the actual costs incurred with respect to these product liability matters will not exceed the related amounts accrued. With respect to product liability claims that are not resolved through settlement, the company intends to vigorously defend against such claims, including through litigation. The company cannot give any assurances that the resolution of any of its product liability matters, including asserted and unasserted claims and the putative class action lawsuits, will not have a material adverse effect on the company’s business, results of operations, financial condition and/or liquidity.

Accruals for product liability and other legal matters amounted to $520.3 million and $158.1 million at September 30, 2013 and December 31, 2012, respectively. The company made total payments of $177.1 million to qualified settlement funds (“QSFs”), of which $19.5 million were made during the nine months ended September 30, 2013 subject to certain settlement conditions, for certain Hernia Product Claims. Payments to QSFs were recorded as a component of restricted cash. Total payments of $158.2 million from these QSFs have been made to qualified claimants, of which $25.6 million were made during the nine months ended September 30, 2013. In addition, other payments of $26.2 million have been made to qualified claimants, of which $15.6 million were made during the nine months ended September 30, 2013.

The company recorded receivables related to product liability matters amounting to $186.2 million and $45.6 million at September 30, 2013 and December 31, 2012, respectively. A substantial amount of the receivable at September 30, 2013 is the subject of a dispute with a supplier who has contested at least, in part, its obligation to defend and indemnify the company, which the company refutes. After considering the following factors (as appropriate): the nature of the claims, relevant contracts, relevant legal issues, the advice and judgment of outside legal counsel, and other pertinent factors, the company believes that it should collect these receivables.

The company is unable to estimate the reasonably possible losses or range of losses, if any, arising from certain existing product liability matters and other legal matters. Under U.S. generally accepted accounting principles, an event is “reasonably possible” if “the chance of the future event or events occurring is more than remote but less than likely” and an event is “remote” if “the chance of the future event or events occurring is slight”. With respect to all putative class action lawsuits relating to product liability matters, the company is unable to estimate a range of reasonably possible losses for the following reasons: (i) all or certain of the proceedings are in early stages; (ii) the company has not received and reviewed complete information regarding all or certain of the plaintiffs and their medical conditions; and/or (iii) there are significant factual issues to be resolved. In addition, there is uncertainty as to the likelihood of a class being certified or the ultimate size of the class.

XML 46 R5.htm IDEA: XBRL DOCUMENT v2.4.0.8
Condensed Consolidated Balance Sheets (Parenthetical) (USD $)
In Thousands, except Share data, unless otherwise specified
Sep. 30, 2013
Dec. 31, 2012
Accounts receivable, allowances $ 13,500 $ 12,400
Preferred stock, par value $ 1 $ 1
Preferred stock, authorized 5,000,000 5,000,000
Preferred stock, issued      
Common stock, par value $ 0.25 $ 0.25
Common stock, authorized 600,000,000 600,000,000
Common stock, issued 77,890,296 81,697,409
Common stock, outstanding 77,890,296 81,697,409
XML 47 R2.htm IDEA: XBRL DOCUMENT v2.4.0.8
Condensed Consolidated Statements Of Income (USD $)
In Thousands, except Per Share data, unless otherwise specified
3 Months Ended 9 Months Ended
Sep. 30, 2013
Sep. 30, 2012
Sep. 30, 2013
Sep. 30, 2012
Net sales $ 758,000 $ 722,900 $ 2,258,200 $ 2,195,500
Costs and expenses:        
Cost of goods sold 291,900 272,600 883,800 837,700
Marketing, selling and administrative expense 223,900 196,600 666,600 604,300
Research and development expense 99,400 52,200 224,800 150,500
Interest expense 11,200 9,700 33,700 28,900
Other (income) expense, net 12,600 13,600 338,600 19,000
Total costs and expenses 639,000 544,700 2,147,500 1,640,400
Income from operations before income taxes 119,000 178,200 110,700 555,100
Income tax provision 25,800 48,900 88,400 153,200
Net income $ 93,200 $ 129,300 $ 22,300 $ 401,900
Basic earnings per share available to common shareholders $ 1.17 $ 1.52 $ 0.28 $ 4.70
Diluted earnings per share available to common shareholders $ 1.15 $ 1.50 $ 0.27 $ 4.64
XML 48 R29.htm IDEA: XBRL DOCUMENT v2.4.0.8
Restructuring - Additional Information (Detail) (2012 Restructuring Plan, USD $)
In Millions, unless otherwise specified
9 Months Ended
Sep. 30, 2013
2012 Restructuring Plan
 
Restructuring Cost and Reserve [Line Items]  
Remaining liability related to restructuring charge $ 2.3
Cash payments related to restructuring charges 14.1
Reversal of restructuring costs $ 1.4
XML 49 R23.htm IDEA: XBRL DOCUMENT v2.4.0.8
Share-Based Compensation Plans (Tables)
9 Months Ended
Sep. 30, 2013
Amounts Recognized for Share-Based Compensation

Amounts recognized for share-based compensation are as follows:

 

     Quarter Ended
September 30,
    Nine Months Ended
September 30,
 
     2013     2012     2013     2012  
(dollars in millions)                         

Total cost of share-based compensation plans

   $ 16.0      $ 11.5      $ 44.6      $ 39.0   

Amounts capitalized in inventory and fixed assets

     (0.3     (0.4     (1.4     (1.2

Amounts recognized in income for amounts previously capitalized in inventory and fixed assets

     0.5        0.4        1.5        1.2   
  

 

 

   

 

 

   

 

 

   

 

 

 

Amounts charged against income

   $ 16.2      $ 11.5      $ 44.7      $ 39.0   
  

 

 

   

 

 

   

 

 

   

 

 

 
XML 50 R44.htm IDEA: XBRL DOCUMENT v2.4.0.8
Pension and Other Postretirement Benefit Plans - Additional Information (Detail) (Other Postretirement Benefit Plans, Defined Benefit, USD $)
In Millions, unless otherwise specified
3 Months Ended 9 Months Ended
Sep. 30, 2013
Sep. 30, 2012
Sep. 30, 2013
Sep. 30, 2012
Other Postretirement Benefit Plans, Defined Benefit
       
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]        
Net periodic benefit cost $ 0.1 $ 0.2 $ 0.4 $ 0.5
XML 51 R39.htm IDEA: XBRL DOCUMENT v2.4.0.8
Inventories (Detail) (USD $)
Sep. 30, 2013
Dec. 31, 2012
Inventory [Line Items]    
Finished goods $ 199,400,000 $ 194,600,000
Work in process 23,000,000 19,100,000
Raw materials 109,700,000 114,800,000
Inventory, net, total $ 332,100,000 $ 328,500,000
XML 52 R35.htm IDEA: XBRL DOCUMENT v2.4.0.8
Location and Amounts of Gains and Losses on Derivative Instrument Designated as Fair Value Hedge (Detail) (Interest rate swap contract, Interest Expense, USD $)
In Millions, unless otherwise specified
3 Months Ended 9 Months Ended
Sep. 30, 2013
Sep. 30, 2012
Sep. 30, 2013
Sep. 30, 2012
Interest rate swap contract | Interest Expense
       
Derivative Instruments, Gain (Loss) [Line Items]        
(Loss)/Gain Recognized on Swap $ (0.3) $ 1.0 $ (3.5) $ 2.5
Gain/Loss Recognized on Long-Term Debt $ 0.3 $ (1.0) $ 3.5 $ (2.5)
XML 53 R36.htm IDEA: XBRL DOCUMENT v2.4.0.8
Location and Amounts of Gains on Derivative Instruments Not Designated as Hedging Instruments (Detail) (Forward currency contracts, Other (income) expense, net, USD $)
In Millions, unless otherwise specified
3 Months Ended 9 Months Ended
Sep. 30, 2013
Sep. 30, 2012
Sep. 30, 2013
Sep. 30, 2012
Forward currency contracts | Other (income) expense, net
       
Derivative Instruments, Gain (Loss) [Line Items]        
Gain Recognized in Earnings $ 0 [1] $ 0 [1] $ 0 [1] $ 3.0 [1]
[1] These derivative contracts mitigate changes in the value of remeasured foreign currency denominated intercompany loans attributable to changes in foreign currency exchange rates.
XML 54 R13.htm IDEA: XBRL DOCUMENT v2.4.0.8
Inventories
9 Months Ended
Sep. 30, 2013
Inventories

7. Inventories

Inventories consisted of:

 

     September 30,
2013
     December 31,
2012
 
(dollars in millions)              

Finished goods

   $ 199.4       $ 194.6   

Work in process

     23.0         19.1   

Raw materials

     109.7         114.8   
  

 

 

    

 

 

 
   $ 332.1       $ 328.5   
  

 

 

    

 

 

 
XML 55 R30.htm IDEA: XBRL DOCUMENT v2.4.0.8
Earnings Per Share Computation (Detail) (USD $)
Share data in Millions, unless otherwise specified
3 Months Ended 9 Months Ended
Sep. 30, 2013
Sep. 30, 2012
Sep. 30, 2013
Sep. 30, 2012
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]        
Net income $ 93,200,000 $ 129,300,000 $ 22,300,000 $ 401,900,000
Less: Income allocated to participating securities 1,600,000 2,400,000 300,000 7,700,000
Net income available to common shareholders $ 91,600,000 $ 126,900,000 $ 22,000,000 $ 394,200,000
Weighted average common shares outstanding 78.5 83.4 79.9 83.8
Dilutive common share equivalents from share-based compensation plans 1.5 1.2 1.3 1.1
Weighted average common and common equivalent shares outstanding, assuming dilution 80.0 84.6 81.2 84.9
XML 56 R42.htm IDEA: XBRL DOCUMENT v2.4.0.8
Amounts Recognized for Share-Based Compensation (Detail) (USD $)
3 Months Ended 9 Months Ended
Sep. 30, 2013
Sep. 30, 2012
Sep. 30, 2013
Sep. 30, 2012
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]        
Total cost of share-based compensation plans $ 16,000,000 $ 11,500,000 $ 44,600,000 $ 39,000,000
Amounts capitalized in inventory and fixed assets (300,000) (400,000) (1,400,000) (1,200,000)
Amounts recognized in income for amounts previously capitalized in inventory and fixed assets 500,000 400,000 1,500,000 1,200,000
Amounts charged against income $ 16,200,000 $ 11,500,000 $ 44,700,000 $ 39,000,000
XML 57 R16.htm IDEA: XBRL DOCUMENT v2.4.0.8
Pension and Other Postretirement Benefit Plans
9 Months Ended
Sep. 30, 2013
Pension and Other Postretirement Benefit Plans

10. Pension and Other Postretirement Benefit Plans

Defined Benefit Pension Plans - The company has both tax-qualified and nonqualified, noncontributory defined benefit pension plans, that together cover certain domestic and foreign employees. These plans provide benefits based upon a participant’s compensation and years of service.

The components of net periodic pension cost are as follows:

 

     Quarter Ended
September 30,
    Nine Months Ended
September 30,
 
     2013     2012     2013     2012  
(dollars in millions)                         

Service cost, net of employee contributions

   $ 7.5      $ 7.0      $ 22.6      $ 20.8   

Interest cost

     4.6        4.9        13.7        14.6   

Expected return on plan assets

     (6.5     (6.2     (19.5     (17.9

Amortization

     3.4        2.8        10.2        7.8   
  

 

 

   

 

 

   

 

 

   

 

 

 

Net periodic pension cost

   $ 9.0      $ 8.5      $ 27.0      $ 25.3   
  

 

 

   

 

 

   

 

 

   

 

 

 

Other Postretirement Benefit Plan - The company does not provide subsidized postretirement healthcare benefits and life insurance coverage except for a limited number of former employees. As this plan is unfunded, contributions are made as benefits are incurred. The net periodic benefit cost was $0.1 million and $0.2 million for the quarters ended September 30, 2013 and 2012, respectively. The net periodic benefit cost was $0.4 million and $0.5 million for the nine month periods ended September 30, 2013 and 2012, respectively.

XML 58 R12.htm IDEA: XBRL DOCUMENT v2.4.0.8
Financial Instruments
9 Months Ended
Sep. 30, 2013
Financial Instruments

6. Financial Instruments

Foreign Exchange Derivative Instruments

The company enters into readily marketable forward and option contracts with financial institutions to help reduce its exposure to foreign currency exchange rate fluctuations. These contracts limit volatility because gains and losses associated with foreign currency exchange rate movements are generally offset by movements in the underlying hedged item. The notional value of the company’s forward currency and option currency contracts was $150.0 million and $128.1 million at September 30, 2013 and December 31, 2012, respectively. For further discussion regarding the company’s use of derivative instruments, see Note 1 of the notes to consolidated financial statements in Bard’s 2012 Annual Report on Form 10-K.

Interest Rate Derivative Instrument

The company’s outstanding interest rate swap contract effectively converts its 2.875% fixed-rate notes due 2016 to a floating-rate instrument. The notional value of the company’s interest rate swap contract is $250.0 million.

The location and fair value of derivative instruments that are designated as hedging instruments recognized in the condensed consolidated balance sheets are as follows:

 

    

Balance Sheet

Location

   Fair Value
of Derivatives
 

Derivatives Designated as Hedging Instruments

      September 30,
2013
     December 31,
2012
 
(dollars in millions)                   

Forward currency contracts

  

Other current assets

   $ 1.7       $ 1.4   

Option currency contracts

  

Other current assets

     1.4         0.6   

Forward currency contracts

  

Other assets

     0.2         —     

Interest rate swap contract

  

Other assets

     9.8         13.3   
     

 

 

    

 

 

 
      $ 13.1       $ 15.3   
     

 

 

    

 

 

 

Forward currency contracts

  

Accrued expenses

   $ 0.3       $ 0.4   

Forward currency contracts

  

Other long-term liabilities

     0.1         —     
     

 

 

    

 

 

 
      $ 0.4       $ 0.4   
     

 

 

    

 

 

 

The location and amounts of gains and losses on derivative instruments designated as cash flow hedges and the impact on shareholders’ investment are as follows:

 

     Gain/(Loss)
Recognized in Other
Comprehensive
Income (Loss)
    Location of
Gain/(Loss) Reclassified
from Accumulated
Other Comprehensive Loss to
Income
   Gain/(Loss) Reclassified
from Accumulated
Other Comprehensive Loss
into Income
 
     Quarter Ended
September 30,
       Quarter Ended
September 30,
 
     2013     2012        2013     2012  
(dollars in millions)                              

Forward currency contracts

   $ (0.5   $ 1.5      Cost of goods sold    $ 1.7      $ (0.4

Option currency contracts

     0.9        (0.6   Cost of goods sold      (0.6     0.6   
  

 

 

   

 

 

      

 

 

   

 

 

 
   $ 0.4      $ 0.9         $ 1.1      $ 0.2   
  

 

 

   

 

 

      

 

 

   

 

 

 
     Gain/(Loss)
Recognized in Other
Comprehensive
Income (Loss)
     Location of
Gain/(Loss) Reclassified
from Accumulated
Other Comprehensive Loss to
Income
   Gain/(Loss) Reclassified
from Accumulated
Other Comprehensive Loss
into Income
 
     Nine Months Ended
September 30,
        Nine Months Ended
September 30,
 
     2013      2012         2013     2012  
(dollars in millions)                                

Forward currency contracts

   $ 4.1       $ 4.0       Cost of goods sold    $ 1.7      $ (0.4

Option currency contracts

     1.0         1.0       Cost of goods sold      (1.1     1.5   
  

 

 

    

 

 

       

 

 

   

 

 

 
   $ 5.1       $ 5.0          $ 0.6      $ 1.1   
  

 

 

    

 

 

       

 

 

   

 

 

 

The location and amounts of gains and losses on the derivative instrument designated as a fair value hedge are as follows:

 

     Income Statement
Location
     (Loss)/Gain Recognized on Swap      Gain/(Loss) Recognized on Long-Term Debt  
        Quarter Ended
September 30,
     Nine Months Ended
September 30,
     Quarter Ended
September 30,
    Nine Months Ended
September 30,
 
        2013     2012      2013     2012      2013      2012     2013      2012  
(dollars in millions)                                                            

Interest rate swap contract

     Interest expense       $ (0.3   $ 1.0       $ (3.5   $ 2.5       $ 0.3       $ (1.0   $ 3.5       $ (2.5
     

 

 

   

 

 

    

 

 

   

 

 

    

 

 

    

 

 

   

 

 

    

 

 

 

The location and amounts of gains on derivative instruments not designated as hedging instruments are as follows:

 

    

Income Statement

Location

   Gain Recognized in Earnings  
        Quarter Ended
September 30,
     Nine Months Ended
September 30,
 
        2013      2012      2013      2012  
(dollars in millions)                                 

Forward currency contracts(A)

  

Other (income) expense, net

   $ —         $ —         $ —         $ 3.0   
     

 

 

    

 

 

    

 

 

    

 

 

 

 

(A)  These derivative contracts mitigate changes in the value of remeasured foreign currency denominated intercompany loans attributable to changes in foreign currency exchange rates.

Financial Instruments Measured at Fair Value on a Recurring Basis

Fair value is defined as the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement that is determined using assumptions that market participants would use in pricing an asset or liability. The fair value guidance establishes a three-level hierarchy which maximizes the use of observable inputs and minimizes the use of unobservable inputs used in measuring fair value. The levels within the hierarchy range from Level 1 having observable inputs to Level 3 having unobservable inputs.

The following table summarizes certain financial instrument assets measured at fair value on a recurring basis:

 

     September 30,
2013
     December 31,
2012
 
(dollars in millions)              

Forward currency contracts

   $ 1.5       $ 1.0   

Option currency contracts

     1.4         0.6   

Interest rate swap contract

     9.8         13.3   

The fair values were measured using significant other observable inputs and valued by reference to similar financial instruments, adjusted for restrictions and other terms specific to each instrument. These financial instruments are categorized as Level 2 under the fair value hierarchy.

The fair value of the liability for contingent consideration related to acquisitions was $86.8 million and $77.1 million at September 30, 2013 and December 31, 2012, respectively. The fair value was measured using significant unobservable inputs and is categorized as Level 3 under the fair value hierarchy.

 

Financial Instruments not Measured at Fair Value

The fair value of commercial paper borrowings of $97.5 million at September 30, 2013 approximated the carrying value. There were no commercial paper borrowings outstanding at December 31, 2012. On September 26, 2013, the company amended its $600 million five-year committed syndicated bank credit facility that was scheduled to expire in October 2016. The amendment includes an increase of the aggregate principal amount of credit available under the syndicated bank credit facility to $750 million and extends the commitment termination date until September 26, 2018. The amended credit facility supports the company’s commercial paper program and can be used for general corporate purposes. The facility includes pricing based on the company’s long-term credit rating and includes a financial covenant that limits the amount of total debt to total capitalization. At September 30, 2013, the company was in compliance with this covenant.

The estimated fair value of long-term debt including the effect of the related interest rate swap contract was approximately $1,454.2 million and $1,532.2 million at September 30, 2013 and December 31, 2012, respectively. The fair value was estimated using dealer quotes for similarly-rated debt instruments over the remaining contractual term of the company’s obligation. Long-term debt is categorized as Level 2 under the fair value hierarchy.

Concentration Risk

Accounts receivable balances include sales to government-supported healthcare systems outside the United States. The company continues to monitor sovereign debt issues and economic conditions in Europe and evaluates accounts receivable in certain countries for potential collection risks. Economic conditions and other factors in certain countries in Europe have resulted in, and may continue to result in, an increase in the average length of time that it takes to collect these accounts receivable and may require the company to re-evaluate the collectability of these receivables in future periods. The company has experienced significant delays in the collection of accounts receivable associated with the national healthcare systems in Spain, Italy, Greece and Portugal. At September 30, 2013, the company’s accounts receivable, net of allowances, from the national healthcare systems in these countries and amounts past due greater than 365 days are as follows:

 

     Accounts
receivable, net
     Greater than
365 days past due
 
(dollars in millions)              

Spain

   $ 23.0       $ 4.8   

Italy

     23.1         2.4   

Greece

     10.5         3.2   

Portugal

     4.0         1.7   
  

 

 

    

 

 

 
   $ 60.6       $ 12.1   
  

 

 

    

 

 

 
XML 59 R7.htm IDEA: XBRL DOCUMENT v2.4.0.8
Basis of Presentation
9 Months Ended
Sep. 30, 2013
Basis of Presentation

1. Basis of Presentation

The accompanying unaudited condensed consolidated financial statements of C. R. Bard, Inc. and its subsidiaries (the “company” or “Bard”) should be read in conjunction with the audited consolidated financial statements and notes thereto included in Bard’s 2012 Annual Report on Form 10-K. These financial statements have been prepared on a basis that is substantially consistent with the accounting principles applied in the financial statements in Bard’s 2012 Annual Report on Form 10-K. The preparation of these financial statements requires the company to make estimates and judgments that affect reported amounts of assets, liabilities, revenues and expenses and the related disclosure of contingent assets and liabilities at the date of the financial statements. These financial statements include all normal and recurring adjustments necessary for a fair presentation. The accounts of most foreign subsidiaries are consolidated as of and for the quarter and nine months ended August 31, 2013 and August 31, 2012 and as of November 30, 2012. No events occurred related to these foreign subsidiaries during the months of September 2013, September 2012 or December 2012 that materially affected the financial position or results of operations of the company. The results for the interim periods presented are not necessarily indicative of the results expected for the year.

XML 60 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 61 R47.htm IDEA: XBRL DOCUMENT v2.4.0.8
Net Sales Based On Location of External Customers by Geographic Region (Detail) (USD $)
In Thousands, unless otherwise specified
3 Months Ended 9 Months Ended
Sep. 30, 2013
Sep. 30, 2012
Sep. 30, 2013
Sep. 30, 2012
Segment Reporting Information [Line Items]        
Net sales $ 758,000 $ 722,900 $ 2,258,200 $ 2,195,500
United States
       
Segment Reporting Information [Line Items]        
Net sales 500,300 483,400 1,496,400 1,469,600
Europe
       
Segment Reporting Information [Line Items]        
Net sales 116,700 [1] 108,900 [1] 356,500 [1] 349,400 [1]
Japan
       
Segment Reporting Information [Line Items]        
Net sales 43,400 41,600 123,400 122,200
Other
       
Segment Reporting Information [Line Items]        
Net sales $ 97,600 [1] $ 89,000 [1] $ 281,900 [1] $ 254,300 [1]
[1] Beginning in 2013, certain emerging markets in Europe are included in the "other" geographic region. Prior year amounts have been reclassified to conform to the current year presentation.
XML 62 R33.htm IDEA: XBRL DOCUMENT v2.4.0.8
Location and Fair Value of Derivative Instruments Designated as Hedging Instruments (Detail) (Derivatives Designated as Hedging Instruments, USD $)
In Millions, unless otherwise specified
Sep. 30, 2013
Dec. 31, 2012
Derivatives, Fair Value [Line Items]    
Fair value of derivative assets $ 13.1 $ 15.3
Fair value of derivative liability 0.4 0.4
Forward currency contracts | Other Current Assets
   
Derivatives, Fair Value [Line Items]    
Fair value of derivative assets 1.7 1.4
Forward currency contracts | Other Assets
   
Derivatives, Fair Value [Line Items]    
Fair value of derivative assets 0.2 0
Forward currency contracts | Accrued Expenses
   
Derivatives, Fair Value [Line Items]    
Fair value of derivative liability 0.3 0.4
Forward currency contracts | Other Long-term Liabilities
   
Derivatives, Fair Value [Line Items]    
Fair value of derivative liability 0.1 0
Option currency contracts | Other Current Assets
   
Derivatives, Fair Value [Line Items]    
Fair value of derivative assets 1.4 0.6
Interest rate swap contract | Other Assets
   
Derivatives, Fair Value [Line Items]    
Fair value of derivative assets $ 9.8 $ 13.3
XML 63 R19.htm IDEA: XBRL DOCUMENT v2.4.0.8
Acquisitions and Divestiture (Tables)
9 Months Ended
Sep. 30, 2013
Assets and Liabilities Held for Sale Associated with Electrophysiology Division

Assets and liabilities held for sale associated with BEP include the following:

 

(dollars in millions)    September 30,
2013
 

Inventories

   $ 14.4   

Other current assets

     0.4   

Net property, plant and equipment

     2.6   

Other intangible assets, net

     7.0   
  

 

 

 
   $ 24.4   
  

 

 

 

Accrued expenses

   $ 1.8   

Accrued compensation and benefits

     0.8   
  

 

 

 
   $ 2.6   
  

 

 

 
   $ 21.8   
  

 

 

 
XML 64 R15.htm IDEA: XBRL DOCUMENT v2.4.0.8
Share-Based Compensation Plans
9 Months Ended
Sep. 30, 2013
Share-Based Compensation Plans

9. Share-Based Compensation Plans

The company may grant a variety of share-based payments under the 2012 Long Term Incentive Plan of C. R. Bard, Inc., as amended and restated (the “LTIP”) and the 2005 Directors’ Stock Award Plan of C. R. Bard, Inc., as amended and restated (the “Directors’ Plan”) to certain directors, officers and employees. At the company’s Annual Meeting of Shareholders on April 17, 2013, the shareholders authorized an additional 2,000,000 shares for issuance under the LTIP. The total number of remaining shares at September 30, 2013 that may be issued under the LTIP was 5,710,855 and under the Directors’ Plan was 39,843. Awards under the LTIP may be in the form of stock options, stock appreciation rights, limited stock appreciation rights, restricted stock, unrestricted stock and other stock-based awards. Awards under the Directors’ Plan may be in the form of stock awards, stock options or stock appreciation rights. The company also has two employee stock purchase programs.

 

Amounts recognized for share-based compensation are as follows:

 

     Quarter Ended
September 30,
    Nine Months Ended
September 30,
 
     2013     2012     2013     2012  
(dollars in millions)                         

Total cost of share-based compensation plans

   $ 16.0      $ 11.5      $ 44.6      $ 39.0   

Amounts capitalized in inventory and fixed assets

     (0.3     (0.4     (1.4     (1.2

Amounts recognized in income for amounts previously capitalized in inventory and fixed assets

     0.5        0.4        1.5        1.2   
  

 

 

   

 

 

   

 

 

   

 

 

 

Amounts charged against income

   $ 16.2      $ 11.5      $ 44.7      $ 39.0   
  

 

 

   

 

 

   

 

 

   

 

 

 

In the first quarter of each of 2013 and 2012, the company granted performance restricted stock units to certain officers. These units have requisite service periods of three years and have no dividend rights. The actual payout of these units varies based on the company’s performance over the three-year period based on pre-established targets over the period and a market condition modifier based on total shareholder return (“TSR”) compared to an industry peer group. The actual payout under these awards may exceed an officer’s target payout; however, compensation cost initially recognized assumes that the target payout level will be achieved and may be adjusted for subsequent changes in the expected outcome of the performance-related condition. The fair values of these units are based on the market price of the company’s stock on the date of the grant and use a Monte Carlo simulation model for the TSR component. The fair values of the TSR components of the 2013 and 2012 grants were estimated based on the following assumptions: risk-free interest rate of 0.42% and 0.41%, respectively; dividend yield of 0.81% and 0.85%, respectively; and expected life of 2.88 and 2.83 years, respectively.

Anticipated purchases under the Management Stock Purchase Program (the “MSPP”) are approximately 0.2 million shares for the 2013 grant. Purchases under the MSPP were approximately 0.2 million shares for the 2012 grant. The fair value of the 2013 annual MSPP purchases was $37.20 per share and was estimated in July 2013. The fair value of the 2012 MSPP purchases was $38.33 per share. These fair value calculations used the Black-Scholes model based on the following assumptions: risk free interest rate of 0.10% and 0.16%, respectively; expected volatility of 15% and 20%, respectively; dividend yield of 0.8% and 0.9%, respectively; and expected life of 0.6 years for both valuations.

As of September 30, 2013, there were $79.3 million of unrecognized compensation expenses related to share-based payment arrangements. These costs are expected to be recognized over a weighted-average period of approximately two years. The company has sufficient shares to satisfy expected share-based payment arrangements in 2013.

XML 65 R22.htm IDEA: XBRL DOCUMENT v2.4.0.8
Inventories (Tables)
9 Months Ended
Sep. 30, 2013
Inventories

Inventories consisted of:

 

     September 30,
2013
     December 31,
2012
 
(dollars in millions)              

Finished goods

   $ 199.4       $ 194.6   

Work in process

     23.0         19.1   

Raw materials

     109.7         114.8   
  

 

 

    

 

 

 
   $ 332.1       $ 328.5   
  

 

 

    

 

 

 
XML 66 R20.htm IDEA: XBRL DOCUMENT v2.4.0.8
Earnings per Common Share (Tables)
9 Months Ended
Sep. 30, 2013
Earnings Per Share Computation

Earnings per share (“EPS”) is computed under the two-class method using the following common share information:

 

     Quarter Ended
September 30,
     Nine Months
Ended September 30,
 
     2013      2012      2013      2012  
(dollars and shares in millions)                            

EPS Numerator:

           

Net income

   $ 93.2       $ 129.3       $ 22.3       $ 401.9   

Less: Income allocated to participating securities

     1.6         2.4         0.3         7.7   
  

 

 

    

 

 

    

 

 

    

 

 

 

Net income available to common shareholders

   $ 91.6       $ 126.9       $ 22.0       $ 394.2   
  

 

 

    

 

 

    

 

 

    

 

 

 

EPS Denominator:

           

Weighted average common shares outstanding

     78.5         83.4         79.9         83.8   

Dilutive common share equivalents from share-based compensation plans

     1.5         1.2         1.3         1.1   
  

 

 

    

 

 

    

 

 

    

 

 

 

Weighted average common and common equivalent shares outstanding, assuming dilution

     80.0         84.6         81.2         84.9   
  

 

 

    

 

 

    

 

 

    

 

 

 
XML 67 R1.htm IDEA: XBRL DOCUMENT v2.4.0.8
Document and Entity Information
9 Months Ended
Sep. 30, 2013
Document Information [Line Items]  
Document Type 10-Q
Amendment Flag false
Document Period End Date Sep. 30, 2013
Document Fiscal Year Focus 2013
Document Fiscal Period Focus Q3
Trading Symbol BCR
Entity Registrant Name BARD C R INC /NJ/
Entity Central Index Key 0000009892
Current Fiscal Year End Date --12-31
Entity Filer Category Large Accelerated Filer
Entity Common Stock, Shares Outstanding 77,890,296
XML 68 R21.htm IDEA: XBRL DOCUMENT v2.4.0.8
Financial Instruments (Tables)
9 Months Ended
Sep. 30, 2013
Location and Fair Value of Derivative Instruments Designated as Hedging Instruments

The location and fair value of derivative instruments that are designated as hedging instruments recognized in the condensed consolidated balance sheets are as follows:

 

    

Balance Sheet

Location

   Fair Value
of Derivatives
 

Derivatives Designated as Hedging Instruments

      September 30,
2013
     December 31,
2012
 
(dollars in millions)                   

Forward currency contracts

  

Other current assets

   $ 1.7       $ 1.4   

Option currency contracts

  

Other current assets

     1.4         0.6   

Forward currency contracts

  

Other assets

     0.2         —     

Interest rate swap contract

  

Other assets

     9.8         13.3   
     

 

 

    

 

 

 
      $ 13.1       $ 15.3   
     

 

 

    

 

 

 

Forward currency contracts

  

Accrued expenses

   $ 0.3       $ 0.4   

Forward currency contracts

  

Other long-term liabilities

     0.1         —     
     

 

 

    

 

 

 
      $ 0.4       $ 0.4   
     

 

 

    

 

 

 
Location and Amounts of Gains and Losses on Derivative Instruments Designated as Cash Flow Hedges

The location and amounts of gains and losses on derivative instruments designated as cash flow hedges and the impact on shareholders’ investment are as follows:

 

     Gain/(Loss)
Recognized in Other
Comprehensive
Income (Loss)
    Location of
Gain/(Loss) Reclassified
from Accumulated
Other Comprehensive Loss to
Income
   Gain/(Loss) Reclassified
from Accumulated
Other Comprehensive Loss
into Income
 
     Quarter Ended
September 30,
       Quarter Ended
September 30,
 
     2013     2012        2013     2012  
(dollars in millions)                              

Forward currency contracts

   $ (0.5   $ 1.5      Cost of goods sold    $ 1.7      $ (0.4

Option currency contracts

     0.9        (0.6   Cost of goods sold      (0.6     0.6   
  

 

 

   

 

 

      

 

 

   

 

 

 
   $ 0.4      $ 0.9         $ 1.1      $ 0.2   
  

 

 

   

 

 

      

 

 

   

 

 

 
     Gain/(Loss)
Recognized in Other
Comprehensive
Income (Loss)
     Location of
Gain/(Loss) Reclassified
from Accumulated
Other Comprehensive Loss to
Income
   Gain/(Loss) Reclassified
from Accumulated
Other Comprehensive Loss
into Income
 
     Nine Months Ended
September 30,
        Nine Months Ended
September 30,
 
     2013      2012         2013     2012  
(dollars in millions)                                

Forward currency contracts

   $ 4.1       $ 4.0       Cost of goods sold    $ 1.7      $ (0.4

Option currency contracts

     1.0         1.0       Cost of goods sold      (1.1     1.5   
  

 

 

    

 

 

       

 

 

   

 

 

 
   $ 5.1       $ 5.0          $ 0.6      $ 1.1   
  

 

 

    

 

 

       

 

 

   

 

 

 
Location and Amounts of Gains and Losses on Derivative Instrument Designated as Fair Value Hedge

The location and amounts of gains and losses on the derivative instrument designated as a fair value hedge are as follows:

 

     Income Statement
Location
     (Loss)/Gain Recognized on Swap      Gain/(Loss) Recognized on Long-Term Debt  
        Quarter Ended
September 30,
     Nine Months Ended
September 30,
     Quarter Ended
September 30,
    Nine Months Ended
September 30,
 
        2013     2012      2013     2012      2013      2012     2013      2012  
(dollars in millions)                                                            

Interest rate swap contract

     Interest expense       $ (0.3   $ 1.0       $ (3.5   $ 2.5       $ 0.3       $ (1.0   $ 3.5       $ (2.5
     

 

 

   

 

 

    

 

 

   

 

 

    

 

 

    

 

 

   

 

 

    

 

 

 
Location and Amounts of Gains on Derivative Instruments Not Designated as Hedging Instruments

The location and amounts of gains on derivative instruments not designated as hedging instruments are as follows:

 

    

Income Statement

Location

   Gain Recognized in Earnings  
        Quarter Ended
September 30,
     Nine Months Ended
September 30,
 
        2013      2012      2013      2012  
(dollars in millions)                                 

Forward currency contracts(A)

  

Other (income) expense, net

   $ —         $ —         $ —         $ 3.0   
     

 

 

    

 

 

    

 

 

    

 

 

 

 

(A)  These derivative contracts mitigate changes in the value of remeasured foreign currency denominated intercompany loans attributable to changes in foreign currency exchange rates.
Financial Instrument Assets and (Liabilities) Measured at Fair Value on Recurring Basis

The following table summarizes certain financial instrument assets measured at fair value on a recurring basis:

 

     September 30,
2013
     December 31,
2012
 
(dollars in millions)              

Forward currency contracts

   $ 1.5       $ 1.0   

Option currency contracts

     1.4         0.6   

Interest rate swap contract

     9.8         13.3   
Accounts Receivable, Net of Allowances

At September 30, 2013, the company’s accounts receivable, net of allowances, from the national healthcare systems in these countries and amounts past due greater than 365 days are as follows:

 

     Accounts
receivable, net
     Greater than
365 days past due
 
(dollars in millions)              

Spain

   $ 23.0       $ 4.8   

Italy

     23.1         2.4   

Greece

     10.5         3.2   

Portugal

     4.0         1.7   
  

 

 

    

 

 

 
   $ 60.6       $ 12.1   
  

 

 

    

 

 

 

(8Q^1;`/X,X MNDG18Q#3GU.R/C(0_0*SQ75,X$7I:K$FEVR$4(A[,6[F\^;P()=TAO*0 M0$]$&K.3K#"T.3ZN`Y20S^![@!X79"O3@S;/^C$@&],M(2B,+0Y/I@(=T$U;52.(R]P]H'[.$@, MP'\"]J[@DM-]4ZA_PN0:7*[2!+#SF.Q!(I##-(+A/=6C MD$=\BG7?TUI#F^-C,RHY+IDVZ)Z,CD!&7O'T*+T`"9C!;(`5V?.SAO?@(HTC M@#`]K7#&[A#SVT_Q&P97Z"(@!QGY(+DT\F4>4X%`I/&C`M?%>KOPNB_='M\T MQSG9-%1U@=G^GR:E"#6=7;\Q]6Q\F>.,4(#(][^`=(Z"U0*&#V#>9Y)[?=0< M[T]I%L1;6M;W*(WR,/N"TGQU269CGJ)U9Q95QC:BIB1"+,!/Z5:XV^H:\13- M`W+&,VC)78W3&$:E?%PW9=44JU7G&B?@+;N(T_`W32P.2-C`0'X%:$[6XI[: M$Z\V>N@:4=@\7!T_/TI0GJ@DEV@-N<4Z M?7Q@0'85LN:Y%G_!%FN&UWO;=P9FE\=?&D7VI?UL$M;\A&+#!J>6(5/#2DM85:8F9*HH:@:HB#2/O#(P/"\"KI^/FA00%S^L\'L$H1O3Z'/$94 MOF6?7=/3KOS%#>NKFDJ.>KTW,"!=0!)1W]3BK_3C!KR7V9?)MPDUC<_%5%6< MHB;FFZ\Q'VX,PN_FZ?_]QXT'][^1/_UZ3CX=T<_?Q,&\ M'"X.GD'\T[O]WS\,3L]ECJ@'ZPV9C"#^;Q"@ZR2Z(E/&(4W85(_*O95*_O!K M.2GGG$DY?R;72$"=7QLD*7<;'L22C`*:PAAX0_Z&.2B*VQZ:3CJ%:E16+0]' M8VTFR>8'$W**R`CE-C\5`Y%_W M9,EFE-ZFQ8<5B_UY'RY@O!5#9RA=:H@F)1$I[_P[2Q%Y(K'X4?*_=V>$@1D@ M(EAT6_`J))!1EY'7%6`M:4^8(D+"3^\^O3O+,6$N715N+5;@4;WF2UB:EUB% MRL>31F7G)5'!\NFD81%(9!4\GST\O"=`!=`?/$#\MUP%T1]/&J*="[B"Y4\G M#0M?DJO0^7>/SOY;JX+GSR<-CU@/5R'TPTDCQ'W$;<'Y>-HBLHJFH,+*/<&9 MJUDJP=E[Q+K\L)(B(5]2)2S??^\B,`)51G,'E1JKPZV0OWS8M7,-:OV2IL/I MK+J9!?B9@9#C]_,@6!7Z&Q!GN/S+KB)G\^=?J6/)=/8E32/\F%;3ME'GB%IU M5S+UHY2Z5UV_4><8L*L+$S8;`ZT"$UIK:<[>LR9\(X(,<4.I*DRZ-3*P6SI9(./>Y22!4C/!`'- MM08VZ*.I-XDLO:"A;.`%Q.F*;GDYS/(^-KA@D:\/A)8DIP&_`KIW6UFA%,1D MS/D7IHE9-SHM#Q3&\?XSOWMLGI_I%IL.VM$ M+&@VEL?N@\!55RD]6,3'CZN^4GKX'%03V<_[:ORGN0[D'`6?JYY7>O#4]4?] MG*Y<63`"6Y&K/E?]P-F:I%SUN9+K+`@,M*Z'_N&-#XX:( MUG">%'ZQX?H)!0DFKY,BO0C[K[@X1*-_Y(48W0.B'A\;&VX]4!@]3T4T!OD[ M`@$&5Z#X9XL'@X&!QX:'1F9N`YNCS]>\F=TA\^C6932).$NE91OJCN(-P5X1 MK/S$,7=Y[)FH^@EKKBNN#@]\'[G0U4A%>[/12Q+IIJ8[)A/OX2>$AVX7+9\K M&F*^SOR4[7XFUJ2W$+8J[$[&HJ?W*CA%OPUOE_!V"4V[A*3DO`W31%G3\CY8 MT[G:)"L0/)`%C6T\Z+FU.-6HYW:QQ`/*051S,VEE0-#>(O6U.J]*U'/:6Z*^ M+)%W!0N4>+F34S MO&5L>M@C=$>QPNFV"N1]`,G&N@Q6D,AG(HX$K:U0SNHLBP@M?K1'5XO&>*>1 M/3I;3JQ&&^M4*H&ZV]8>U=-9434OB%F-2K+CXSS:9(G2_!#%U_CS/+@.$J/J8U3P7N7HH];63:T)8?$CLMB+L88N# M3=HDZ13L-K-!Z]7FL4/NPF+9MPJTLAYCX>`N34)M)FJ=+/-1DU9U..%WLY*] M9+F*TS4`FVI/RM)Z>S]7W-"Z8TMC;U]A+!(7MS_;R4NQJ9@G#I1O-/%N?`4H MM85.:Q?1*Z%1T$B`96NW,?+2(E`J=[?,F_P@&XF^89\,=?3'(-/7R#$AV'<> MS@KO:3)_`FAY!9[;Y1E!8VN.ABH/74Y#R_2VPLQO:Z!>%1OX!B8P`[?PA6I; MLR"9P^<8;,73'9)4>UF#M)V%UN;6:-<1P"4=['BK;AX$K>]/7DM+_K5\-30Y MF64^M[).H^)#O/*E72RE[,H0#&F%7JZ"2,!':S<[O&3DC0:B,FZQ81V9P5"8 MZ4^AHQ5OXD6*,GK)7Z0(I:^4,I%+,:>E]TS7\DS?,YBKNZ.+NQZ=#_I!Z=Q] MZ6UE\GMJLB0P9N2,>HU^Q*87 M$-\46/<"$IBWMNY1G]WTYFP'IDT0JQ!RTTM38>D8\]^HL'2K/):!U=;,J?2Y M2Z#+^-U=V_&I]/P5%FZ&F8BQ4%:-5!"YF:&E?;F(=2X5-FZF9VG'ILU$7"'D M9@Y;Q=6SKP3=`O,'-UW&587%.A)=\M`>RWTD,!(U@E34G(ZJ=*(N'\@*>+5K MU"JH7#Z?%:"2>]=7,+E\2"O`U'2RV,+RR>4C6@$6J2=;A9*;:<254>)99RMP M7-9\J!Q`75R(*_1E MY//7L.0:%OB?5^BYJ?]J]Y1NK$V>*TZO!$DO`#VG1[3$--0YNTD>7*\8IXV2 M**&!ZV7B](!2B"ESO5AN$X/:"Z1YET*RIW`CAR5II;6J!V%]=] MU1A'%OWHIFI##15UB;7"RTVUAH[CL<]XM^O,[#/>C3;CG2UFC5(LQ?*OGU+JYD+',KXU;S`:=Y;"AVML^7XN'1TFDL?$B/$$D' MG_K`IS[PY?>.ZH&C9%31$V[=U\ZIU:]2N_?:F'W9'>!H/>->]#[TK@7THII?%XRLJ2;_99Y4,W*0*R1`JRGH/Z`D='P]6OGT;$ M%[_TLQ9[@B%L\4BO`FKP)O]*4W%@=N`ET4;:JA]^U&L\3G&.]LH6<_CN-:R! M%/3L0`]@=)4C:N9GF-^D2$"Y2@^;592V40_7;RN08'`!$C`39GQNZV6'DRK! MY$Y>22$7XAY6JD#-9D18FLZNW\)%D,S!`Y&HIHE68G&M(5RQM/9`_"TD-SQ9 MOYN%>T-D?/8&OB`')BNG3E8U6Q"<8T4T!;W&M%.%:AOQ1(\G62VJO8:6Z&W< M;)-DWXPAYJ"]ZVAXV@E'VP2&ZK`F&&$<'):)N<1[2=YG'%QL'W$;1^$6T45C M@)'PQWQ("ZM@[:&CSIZ@_XBXVYT!Z0FH.L`X^-M+IUC(RDN)#*$YB!T^"X]9 M>@L)N:@U,2#N;[,($C``>F$A>$R?@^E-OF]1Y\C_VD-XY[-B+JD&K\0@`A39<:F;_-#T+'2?)E';[-1;VJ3X*3T/?\\A`J7Y#12!BNSA4?PB]&C7 M&6(4/.Z6'U%E;*_?*+B15&]28TL\@*7RI-O#ZHJ\'%[(_4;C9\FMEE.B-$[` M#B/9YKAVL)4%A11?*KJCV.:4G-O;,W";IY#F"5;@3]S7-E?L[IDRCR!\_090 M"+$D%*BMGR5N9C"[E98T+AM8*OT+`G+ADX/J"KR`.%T5>YFA*22ZK9>U(L9Y MF#&S]&6*Y66+FPWM%/;E6=,$-`L:^Q@WK1BWK4N?>FS;?I>CBVD[))WY:A4S M&H*X1&Z2S%*T#%1""A5[6ZV+,:!#9C/]NL0/Q/68D4.!+-7(NQYUG@FD2S' M[!M)YVH]/8V`G^;&K_LI5C71/3B"L(,*(C=5!_KNX_)[A!?X4)4><_7>-HUB M(Q"A@D_GVCAE^(01`A64;AUX`^YF4NHT)21VEZ#/O;YT7< M653=O=*;Z=J4G$6J=>6FLM@\F`(?E4H&]*M24MZQ7^AR!;*;6F%#JU7!+[A" M4D?_>PSWR3!8-GR2*_!TU+@G")ZN:V8%K)N95LW`JA.65R':19TX_LJ+MXNO;"&7BM2F-.*E1UY'N/*B?*I7HJZ4CX M)PAEEQ"4"MR3DNP[KE+EV,8*UA,3\S6!U8F,KS#MXL1QM"*5IO=`/1#&]3(3 M9A`;QJ_#]>(59K#7R:30K]C%^/>_6O[]+KA77D)N6M9Z(2>]L2KDW#2D]4). MJCZID',SVD`-.;TDK15F;AJ%%"N,:&6ZKA[:7>P_KMP*BEG/*[`ZO/96;`8( M/2@[&.^ MC!+P993:X)!MS$.64;*$BUXZ@#(8HM4+^W!%70]R!JGG"-%G.5/^/M!_F\ZF>4;5OIC)_S_# M^4(+A.W#8T MO-AK!UN1_.^:J-C&/\QW6)*UM%)"CT_+Q?J)?%DB:+7W&Q$WE":IZ-O>S\@" M0>`)A(LDC=,Y69!?P?(9(.[ZX#:T4O:./'P8-CG9.:L-+,7#!Z]2',1?4)JO MVO+VZ8YB`&SVR3S)J`&%O%&W::WX6:^H6"7:K5U'\O7O;L07_\7Z:_"/%%W& M`7GKB$\9G1%&QF%%W5VPE)\^NJ/8X/1+FD:O,([+N[6N`Q*P)>UBIZZ35!A5 M7).ZHXR04XVUV64D.QQ+CV7N7:O7]_C+97$ORELR9W^#.`N^@@B&5'D9"@43 M<5L#A'P-DGP6;-+XD1E@@CI3#15J,(!>()DD*JI1(8&&QG)([#**C?7Z-7B# MRWPI79?--B8@!E$PHR*,>(KWFHRB^$,5.D$D17'*]K9NH^#EN,MRU&,&*MO' M=%9!+>)'H:>5]/14P2JY[JO?K5$G/23J+0P<$0]IN"!S`Y#"=2!N:R7'.2$F MRF.RHA[A/($S0E&2[9GKBOMKX(#]MB(W M8))MKG?AV.UX9( MAE4)K*X[_2E;M!JNM^V&HQ/%;5\&*' MD+4^^K?A:1X_&7Y:#XH24[\FI9@*#1LE?I\\?C+\M&7B$M?/'E<9K@HJOQ+) M/W@D94C6Q,`2L3]ZQ*1GHI89_@1BRSNX)72L$??QD!'G+J'9/;+5]0R1IO`6 MQ'R[GN2Q+WPZV9T[975T%T)I"&(%FJ,)'4VONSV'XPI!-WU7!KAHS`155\"[ M:4_N"[P\,*M"STWCW+B6;4NVA M>K0`)H9V M2K/Z&1G:3-8@93K8^JP+MF"7.Q,CCGRB=Q^Y^R`8&G3T.-`K*D5K$]R70XV< M9R;W72JD[^LWYA&A4-N[9J&H#SQR/(05>8T<#=+1?<:UH@+=-JG]14!@"L'C M`@`*5I6AO!(U\<6Z*6+(\6]-*7!("MQ$6)::XE!?/_Y<5V9FNW;NFGC3=![N MR`,>#[9I7->?6#C?Z_/832!VW4?K>":%)[&[[M%U/+,CEYQ==QT[GGGBZCQ< M=TNS/#V=],K]O-[&7^KS>+:,1!_LNF/=\4R24)/EN@N>Y2GJ_LCLY]WG#SC! MQ!BQ!/5S]O-SD_AH`,Y27/F1F*Z>.RYCCED*\ M#)2Y25%C"@4*;V%S*[G4&VLNB1Y`3'VHJHKJ+3XZZOVM9XHQ1B`%Z`6TV M.Z6NUGFB:C%9GGYNVU%0+4VA+6IMG?+-"E`ANVPZ%IJ9NB&(SZ-_Y#A;BMW. MU/K:+68@.'7H-E6L8M`^@@'/N:?7]&F1YCA(HJ=7$+^`O74M3'6NW-4+;R-X MCVC?HOS,MPK+^J20;+FQ&SE:N*>TZU;6KFB))5;7+9\FUQ?G1G7=("D5/H5X MU>6]DSK`]@7=4I6J+AJX;D3M(-6=K-ZS(U8MN_>$DF?VATUX9QQ25VM-17D= MH(2`@.\!8BF<+M/E*L]ZZB:[OPAWR6E15@F;VWC-[A)S$6`8MFFE6CJYXNSO MEG[X#F2%U>@VQ?C\)8`Q/6F>4K)YEFGRF*7A;XLT)J<'9M,IF'K=42Q50IW! M[%92C;9J8%>#Q-U(%^L"3)9L5DV/I#J.#6Z_)1$D!QQ\SLD55Q)Z'K,O@N@I MO0]0!D.X"FA^M$<0DOM-$J75=30;G/\"X'Q!%3`O``5S<)=34?H*QI1T-DUX MFFJWA@V1=@V28>O4%0^ MY5Q_.*D)6SL9<;97F>MJ1'UT.E\MKNL7]:'4E@[[Z1C'[T2G#Z'F5>"Z1LT0 M@"KRDNLY=(VM1;$`UL_7?[S;V1N)A5I(S<>G5W=W04QU"Y^$WK:0,)Z"-X`- M.Y;V4(#.9H`Z2%3$T;2>1;KVG,Q8Y1$M4H:J#^"*8K1OC@Z"42VCGEQ;+NMA MP#EJ.[Q(YRUH9!4\FO+FCEFDDB('I"%E^`R7WP'!/J,:8QW-18)D/_%$[.G0N_4(=.;_UB"B?)$1B`3B;)G69H`A%UN-*.M*(.'Y:!-DO M:1Y'D^6*W%U;J6$C+^@QW3:8_:@XZ15?NA_MWA&NOB3D@D;CF:`AC;JJ#U9' M2T,@R,FO=U?5M>JP#2T7NYJYI1WAWF\N M5S.JB-_D)Z?8E4,A6F,^"\(I94&X@4E`)$JJGJ9NURQ.:30Z:TXI,$%]T3+U MC2CY?9>1K&0Y!\]9-1,W`42L\K&`*U%K^Y27@A&5'UGVEN@>H)"NY+D:,](! M[/-75)12X(,UM$,O@B\!%>.W5;#V2AWM42[I8I>'"M`'B'^3Y&"0=AD+#S1U M]<\@FE/WCFW0LK*EJ,^(=A$0V9YD+?O;2V!"*^P5]!;_ODMI\=?:Y^_2XOX[ M7]+ZASO4MK6VB[',D7ZWE;?3;N_,B_7V7W^&1!1`X6)]2XM;2LX:Q75"GIU6.)LDJSS"#]Q,WH8=*C[%P\%F;@\]CX("W,J2B MA4K/L7"$]S>S-F_B,4;#Y0/U$ZX-= MOZT@_`"F'L$J8Q^K$7'-'%I[\*4PJ!'6 MWJA>-J/"#Y$T!@X1WF>^!C3S`_DG-6J05RT]ZCCGBG)7*\"GR9SLOB55!5$5BD3< MYC8=`\U2D4?0V(KKW2)%3,NVW7,BJ'DMK58U4]#0-;U`^,=_E>;=+?^8KCA) M+_K#E6ZW#9989=HHSB$%UU7+J$'E+!],QQW]%%2[%)=6O:JKKGV*^'2QG;GJ MX*<(F>3MZ:I_G^9BZF0T=]7#3Q,[KC#IJAN?)C9Z+V97/?-ZG>R%UX"KGG<: M)[CZP[]??;&C!TM+E=.OWI<3QHI[Q[GKDM_-#XN[N-0\.%R_\S0AYZ9^:A#T/N^CYY8R9L0! M77:6D6I(./3NS+`W??GF,,VD/X)%U'R%-;F+5R][%$8OIHTN.-)JW> M1WOF("&/O#YVN)#NZ MJK+]A5]'2KS*77>Q[X"3""`W#7-Z`(D5>JZ[UW=82-*C^71?"XSB&U2:H.Z'5,A- M8?)S]E3>"6UFM^:"4C#9NYHK8,2>UF-PW"SRV>#I[`MAGCXT;U/R3,'3I-6- M\S+`BYLX?:4K"EAQX:Q3T)8-EM_6AFGL,L79=/88Q"VVL/UVWMW1N\]Y][D& MO?34HB?65L!Z`#$[VO`"KC3G5V&PX^#[8EU4QV(IN&ASGGC:7-=JM1<&)V!T M^.XIKG2PN;7LJ"DA[0&$<8`QG$$0W1`YZ3P,\V4>TYM]>CF9)%E:S."VHN9] MBN@$WBDXAAO^W!BQVQ0KG"2%]T*Z)"+;`B1X6Q;8'&Z=/N7=:(_<#;1^FJKX M4W+:VW&HY![[DHM8UF-$'$CG0-['.XCV=!`]`MM^NX>(6TH5PQXBSEM"O>># MQ8S6PS^;3G)JE)_>'(4]3[SQ()I^QY^LL=\.U'UWB_/.`>.;EA-R%K`+OO1A MZ+S_P/@6/D_!Z;YC@9ZJ5QG#S@I!UR.U[.+@:4N:]B\QY%]6=BZH$HM2[R(9SD7=\\8XOQ^KX MXAU`W'$`<<4@[TW#)DW#O;A`(,#@"A3_G"2UJ#MVVT9TR4Z2>KQR\SH6U=XV M,O3H,!$2V\QAVPD4Y;%M9L>Z?EN!!`.EY%C-MCZGUP`N&T=@YF]-=>#8*]`; M_+W!W_VI\;9J=Z#6,XJ>ID%H'$91O_"]472D1CI#SR9O!>T$L/);W76+I[?F M#6K-$Z@!7+41>XN>AD5/D";@+LW&5_#)&_2\0<\;]+Q!S[9!SS!?K6?M%Y7S M37M`;]`\U@AC;X@U:8@=2XSN^N2M3^Y/C;<^N0.UMSZ-`'QO?1K7PO?6)P,A8HJO8==- M3MXD,HA)I/5-Y:JIS1M%]HTB-S`)DA`&<76Z%.7Y:)A3O:A:0%M'YUEENTT> M`*V^1DZFBP!#R]:0X];".Z--+!>';`W5%@YI<)5CF: M)*L\PPS>3W(#@J2'50YXN$HU\2H]Q\(1WM\*VKR)QQ@-E]OS3&T)RKI:X8DC MB4G.!$'KD5".IZ])0UI49V._J[>+^L"QH\KU>T`:GU"08/(JI5+>(T`O,"2G MV'3&VU?4+H;Y/TFO`Z.?&)V6SD!5VOYBO.NZJ4'>A8VY4+J"7+>=&W]8GJQ% M<1`DM5Z"SML-#P6Q5(G@O(5P6)1%3Q;G9O&:N2W=-[_JJ0RY4*NI2T[F MVFO74;:AN*=&.QGLVG6)K2MP3Y7EJDFVE]J2"R-/%^VZHT2+ZK".DUE]@:M[ M>L2>`G96V!!J)CUO=S=S+0V-JZA4E9N%O(9&LSTCV-`EP*SY"9V'(0N9)I() M@"_TY7('LNGL/([35X*@G=+I)5%W:0:*O,QD_BL*VSQ)E+O;4.QS`6]AI-G6 M0.A5ZZQ_08#L!?2T")(G,@[X.4\BZB9&]A]\R]8W\`57=#"T M?ER!$,Y@2)V+.1%O:^:H/._34?C@L M)5\>!)20'PY+R>1)0`GYP2U[SPCF8TV/N"TCG*%@M8!C$4N.UN+T5ZDOO_#H]$B\? M<7N;8K:NV%47H05BC>L:FBZ0'4H`T^K'+49QS@-K=(K MMGXUFEBE\2%X_4JU,3"(]1:)N*-5?GY)T6^3Y!ZE(HPM7*!:F)YLDL(JE)0NF2=]U`H0F5[&9PW9Z@"95$*'!= M0Z2)U(XEL(N2*,V">)R8C-A*8NV-3]U]83('24A>^>=1!`NR)LDL14OV6>M> MA1*M^<6ZID$G1$GL^+V&-.''M\7VB9U#]^0X2J,=8B4-39"`GB&13^C@[-H` M$>&Q5(07BMH=U M@+H\%SA`D1\,0'*9+I-M[-%4UXERAE#9C>&$:AW_N@ M2$6DW.V8G4RY8%UCPN+&FLS)8=\V!37,``R3? M`")&4*'H]3(.X%)\V`D:FB`!QN3<(L=XE(=9&Q7"MC9V-,VSW%C;%^N[(*,[ M4'S7R_O8YV)#C=1K4M9C!!Q\H\'N5#[>%/)3XV*OEX&E_3-`"0S4EK:XK0%" M)@FY&*A'X&7Z0K;Q'-REMRGA&Y%;8Y5G@"?LM?<9M:ZV.UALR$>093$SQEZF M.,-?4(IY%YVX[4"$,!W!4_"F2,NVN8U]>4L>"W-V:UT&6'8H_`).4 MZEIS$U-?C;T(T!S@?0.7L-D0GY^B:F%Q]X&\@]W9I'X5.59:?[6F8Z!9708(KE@U?J.@*M"?"-RTA)B#**[7)(C5*GK:'@J M#O4.'#4[CH"?JV!)9%I\3A-+@$ACV?$ZCH`?6J@E)%(YT\Q2_0OY([M]U;@2 M=Q\!;PIO4EF/,7#`UGWMBE$[OGG]1L#-/4BHPKW8V3IG`:_C"/BIS"IJ;-3: MVZ#^:_`&E_E2FGJZV<8*E3!II[+1QH!8^#6/,TANSPS!,*L$9*'61=Z^OX(# M9RM$(?O(_HW2^[$&%?W;KW?_M4-7^5<#<)3'1['A)DGU)CN?(\"['E1[&22N M4C01.0X"Q'M8B-L:)(0MAFAO,4C($?4P2-0]`B\PS7&\OH%$@")S@C$-2DV3 MV^`5YY#['-?H;)+4/"M*+5>?D1+':SXP.5O!6I.NJM_`!&[D9$WRREX#$_<+ MS!;LOR\!RFB(>%%#$"10FV+I4`;88"4,[X-UD MQP!AF_%YP]^@=+G]:W7HWN1)Q".WZTB#,-&%W"$(0^`?><0BH\IT;,*[7]S6 MAKBTL?QLK;L;[4;A8K.IPBF0HI2Z&@&W_3OG,YIO@FN?T.IN8PH>`B+>2U1K MU>_6J)-*T_465BAL>*=)G^O+Z8E44A*9@X1% ME;8[>'";6F^Y;<=`=4M?JNB MUB.A7+[-A.U-;+E\12\U=)GF*)O.V.JL-7 MYS!^`#$M*/^4[M[3A6.I^.3H.-!A752_B;(Z?M/-ZL@%\Y?;+RGBW\Y[/YOX M7$I.M\>?`;G-%FKN16T]1I/^K*-+?3UDA"^'N!K.IN$A?7+QHIK8=#'".YLP MJB-V0A'"V6):'8'J=^HY6T.KZY;E^!J6&'WV&$D\XDJ4_N!1VM4"E=#\\<2A MT?$)+#'[TXECIA@D4L+U[QXN%>U/"=>?3QPN]=@\][.==`JLW`=1@/EI/(W: MHSO%[R.^.YBK*5$,XL9S"G0U/4H7V-I]2UQ-D=(;+06G(5?S[0ZQTK9>.:[F MY.T+FM!USM6GSUZ&G$<%6X_>-PTXGFVN'WTPJY>;%>%W,>3 M1T[#";>"S;\2^GG?5DCZA\.S)*E9A9-_,BB'B%2@^;>"2GZ$"B__3!"GLZA0 M\F^#EH"H"BK_$%!,:%1!YM\`+6F-ME!]\F)_>^*E"BTOZBNG8*M`\X+^7J!" M!8Z7W9\[)-*L\/,RO5X\686<%^SU0]PJ]+R8KYG@J8+.R_Z*$;459/X-T"N2 MN@+2OPP48^6WD'WV+P2%)$(57&X]$12=&EO?!\V$7JZZ6"DQOZ.UYA2>J!:3 M6\=5!W@DZ1VV*/W!+4EVQ)6!["P7<59I<3S(*<0!JF:Q+O=2,V2U.F3<$BYU M45$.W:[.&[=T-KJ`M637'@I-]$05H*IUYIY.O2M6_%1*U:GNYF-? MOR2!+.;EI%[^"GG,R[4EJ155;45'14UUE%H3WU2;T:UCJP-6DDJB%4J.OO;4 M49*4']RB]$]?)=[:1#VD'#TG.;DUJQCL9/*OCJ/W3+[JJ+1+#]0G26. MHB'):EH>(EUSZ578N;FON`E/*6CUM'S5=G)+@I[V(7H.4#1=V&Z_)`%;VF2+M<%;56RD\<%0?(BP""Z3)?49ZU0)L8TQ]PV M+&J2S%)4.%.^LY"PEP7LMB08;K8QD#?U:C/7=5C.$:+R#CUL:(3=)(G@"XSR M(+X)(&+>:M,9`Q3?YRA#OW',S'%$(&0-,5T MN0O3X?):68%^NV>I,JV":R-`LL@#AM`S71VEC]9N,J-=_/L-:@.'Z^4J3M<` M/`+T`D/!`7:7)B\`$P[8N8"9T%W_G3)VEV;_#3(BBJ?S!/Y3N$2'^YY3Z!5^ MSS>_GX:D1^`#5"-IM8:*<7I`$Q:'] MF*7A;^4U15ZU=1E9J580+$.5Q*?WM'9(U M60E?K*LVFYNZD(HEU4K-C6\%G3::122S_WL@+SZ(859>0\7E(;JSAOG64:&V M?8N<$Q%\R1ZPN,Q(=45E=/(:Y913.MQWK:'YW,[5LPY73P`MI0MQF`\ZLQK_ MEI+G"].B'WH][GSYZ!%]@/BW&P1`Z4-_*#RYWSTJ-&]W`X),P54-?%1XE-)T MI58L]#GG>;9(D>0!/N07CQ+!#1NU](7Y&*9[#/C1([H91:*8B3 M2$GZ'^13)HJQO:9/BS3'01(]O8+X!=!L-O3^GI"G8$(SP4G5F5K=K9;ZXFG] M&T:;0=:"ZW8Q,VKDQCR8>Z.Z"KZ/S-M9A3P=42,ER8GM2OZ-M/49TCKR74U; MJ885UZCG:I)%-4C45/.NIE@<3)5Z!$L3 MBB#W*VR94Y<9P5Y%Z>1J^:F13XE0B^5J7:MAYD/1N<'5\E1R`[.K];1& M.AGJ=BU7:W8=T<3P'0I"[N>/:X64QMV:@:,H7"U3-N13H@@+,/5$G"'\!/99IA5\]P_7$$T:T&D M1>467*TZLM[X,V`E?#1F@Y.YX9*T+7#!]0)2[.P#`D<>$+B91TC+P>R>CHRI MRV`%R7E*_UH6(N("--37CA>YO8MM$,1N#7B]^G"^0T0JF9EOM:@ED]\:CS^K MED>J"9]2`6Y)Q.I]<+Q(6SJXZN!H=&F[[B8RT.W2`.K!I*QN MYMX?BKE)R,V7;=J>XNRH'-ZNFWX/L/A%UW0_0R[5WXP36N^O+O0L&T"Z]8ZD M0Z$ZV!%Q2$<^:VH]"DZ:4.EX.KL#68$$#.\)8!MMLPUUWLXE]P`RB)A*MZ:/ ME.NX=$:PE&2-K+3H`B3D7S*JA":R$LK@/S>+DU9!PS1O-1"I7'1&&`>'I7V/ M3$:.DBG+0'A.Z,O4690,,0X>2U\CMG-4N6IT&@ZUB*L]_$*9;,*94&>,R8UE,_2>P(\VEZ\ MFXFI;1B14:'74(=G@Z?%[CR,E41I!:'%IF_L(FZ&`>5N-I\='23(RN;?9?I= M?\?UND9WW"-%-],I8BC,5]Z^*UW5>'O-5*TX7=\[5;[U&F*5JT%9P\/8?/6Y MJHP?'D>9AJ";'OX8;$C#XRK1+74+A_*PRI0D_2*9QFLRZOLX.CDCB`G`>@K@ MSB;7,(%MOR/B)`Q$*O",JY30*1J/G%;7MZ^]VD$H\RDU,_;1H,+(?2*'P`6A M[#>1MG603XP$(V_H.8BAQYM(AIO?MM-)75_?9:0C5.$;ODAW`-O M,!3]JV\\@/>0M-Q/!CB$9-I7Z^:6.\Y&5FD]&AK/0@Q(DK%8 MC."O(,NF+X6SKA'=J+4#7!6E!P-NLZU<%?X4[K.34_TH8M*ZY-Q7$6C)%&+, M#JZ0M1>4N:`I[,B3XCP,\V7.!A)K1.:@]B0L&HDWH&,>M%1\&_(6K\"&,X3-DWHKWD0P]F: M7`V7`5[A+6,B6Z%MQF?M84;,*YG`Z>PI>.O'ZG:4D^'T MUT]CYE7F5Z(UA&4>GQ`Y3N/B^M<^F66=77$?Z)%JD8DIVZM8ZH;!;^NH7DXJ MNX!9BL`#".,`8SB#X<[JPOOGBY$AK?ER:!&]^;/XC.TUY)%@T'+-]!EQ;`CT M8-4J3[L(4\E5X5:\S!%]/!8ZE+:E;O8;QXI2RPHQ^@D#1[\)>O@W@*F1K5I9 M=L0`F4NJO(]E6U&![7D2<1!7MQHIC6)3D]7UM=O(9ZK[MNJ5@'!5Z/6S`&7C M5A*:@+:??.5Z8;@^")N1XKO%11Y#K*GE5I&TLJYMSGFC57FLN[J?3.%8TI;E.M=-.`TE]PT&_8F>%D'R=N'$, MG[9;1E^P%)_HS@?8],5/_QQPWQ%&:B`2@-?#T\!5+[X^<$K-GZZZ[_4!3,FC MQ]6,9][C6.3*)U-<-ZHR\)?"DIQKO<(&>CECBGY"A=`:FC3Z-)?U>4D-;^ M0NN"Q,U_[%*W^?.O_W6_0U/M!Y>=8LI%S)T742LKMCZZ\Q[`"TARNA%%MKR= M5G:+E#Z".3V"'\"*9K],YK5PS(OUYD>U$J3J(UGAN""@.O."6.I[)FYOD?HM MMFWF8E'S,=!>6Q=["JX6/KA=K5KUZ^M#Q2]AK_UAKY!OCX(KA/S@WPYCD(F[ M'\PGJ\7LB9G"GG9>D6D*0J6CWGT=9JNP04&KG\FN:R&5`.&_PES7-VJM%?H$ M=%6/J`6(\''8KQ+QT:`C?`DTCN,NI[KSTH+&=K>IU?8_2*`^S+RC-5Y<$Q'F*UJXH5\>M+DS"-$[G:[&FL-G`E(:R M/N%R+26GI95JA@494[2I;25177";6J299L[,*A#"(,RC(\R%O:X"0;TA^.S1_-_#!OP4XS.,`";^XT\"K8$<@ M]\KNQD;M4?%]="(0B:_B\HF^NP%"=UW9I0R,Y!)U M7>6EOGA$;S'G537>:FC+Y,67%KS!T!L,O5;_N+7Z7(KF0;(I?'V9)CB-8506%+NO$3.=<3K7E.!EJ1I+Z56IB93FFB;D MAT0Z:E'B2#JXDJ1O+*IZ0QG!3*]2_KHP_AFK[HFM*L#]AE;IE6J3FXTLQWVV MG#9_M"G07N28S!7&E^GRF?!1D"H7::5=O%`[1J&V MXWKDSW_'P;R`ZIZ`JG)Z>!'5BZB*(FK78\H+HEX0]8*H.4&4X8J]..K%T:%= M/XN5&,3,C(XG21CG$4SF=%&F5/&5@VBZ`JB8U2+1RG9Q7P0Q6>[@<0%`1A9U M5>I90Y:U08D7A+T@[`5A+PC+S,4V#D@O17LIVDO1/"GZ`9"3/`\S5F2:%9UF MJ>#.PPR^0.HB:=0[P4N>0U9]:IG)EL>&>O]1LEMY[[4 M/CI.4=[7$W.[G5=>3O5RJI=3>7+J=8`2LI/P/4"/B\"RJ^PN,2V2E;"YE02] M0B#5B#8&ZDXPH.8J](.@%02\(:@F"]BS[]L5! M+U`=PJ*_.W%7,,[)F_Z"UIU9ILDEK8>I;I77&\V+DEZ4]**D%R5;K>J:AY07 M-+V@Z05-GJ!9>)P\!6\.6\"[W[4<=%K$7EF/D7#0)KQ)NWAYV4N-ASC"%7:> M%QR]X*@H.,I/02\=>NG02X<\Z7#[ITE"'3W,)W)R15!4!8I_[ZKVMB-`OH"B M/CD^CV.6.;/^IS9I6*FS%RJ]4'D8H5)G+7OYTLN7BO*E\O'O14TO:GI1LX>H MV=?^[8K`Z<6R[F5FME:D37I&_`!"`%_HRCK'."6+,`/1+S!;W`7%7OD9!'&V M",EV?UQCNDO/X-H#C91K2":)(3+?)FS M(`"VK"[3)3E)%B#!\`446IC;%&,I;D-_S7+"!(#(]&>,P.U!-TFV!V$M>^/] M)L7'30#1WX(XUT#,S%?L(K4EB&P4P*HZW,+@&<:PJ&D1T'LAFB9D0^6(QI]< M!!CJKBP3WQ@)2G1SL(3FV_FN9>ZN33=`+.-Y$@+"[=XJN-V4R>V*XZ!4V$6: M'3'5QL)$EKD"&,X3%O*$K>)ODS:O*?&:$J\I\9H2W<0H9@2AD]&H*,)J6#)W MO>"<+KP'$K=<+V>G"[M5V3^SB_D'RE:>S<6@55A!QT%4X*HQT@X:/=WEG0Y?AN(5[@=Y+8O7 MLBC[.\M.P9-1F7CIT$N'QJ1#[WDR+AG1,?EJJPS8HG69(U3N6G5+8$MW+SMZ MV='+CEYV5-'SMIU$7H[T^$DETR0I]S$$2FJXTT/V.4Z*P M1:[3&\/&3:XY#SW8]`EC1RY?>QETT,NATWGBI5(OE2I*I;HGN9=-O6SJ95.> M;%IME^F,.@&"!+./;VIW7*8XPRRGWD6`070?K%DOJ\*J,LG/=9);I->>@]H0 M"OI.74\@!*-Z@=<+O*`"1V%Y-!K<$ M8R\.'J2^PW(5IVL`'@%Z@;2X>+FNZW-]'L>;8)CI[`&$Z3R!_R1S#0Y4NY\6MB[IU/&.4![!R\QCE)D[KU?^@N@\G)=XW9-X M.YPO7KSUXJVB>-O]Y/+2JY=>O?1J4GJUIQWV,JR782M%QQTH5VFAL=`+*Y/W M]A*JEU"]A.HEU"X*V)9SR0ND7B#U`BE/(&6FBD4:$];Q]>\Y72))Y#UWO8/" M<0JJNJM9($#I#N-%5_=$5^].X*79PTJSVH>7%VN]6.O%6A-BK?>^]<+MZ(7; M>JKO`0JD'5$A-"_Z>M%WE%>U%WU[*G)[5YCQDK"7A+TD7).$P9S^\P&L4D33 MG3A56E2=7@+``$$ M)0X```0Y`0``[5U;<^.XL7Y/5?X#CAZ2V:J5Y3:; M\[(%D9"$+`5H`="V\NM/`[Q?!)&2/*;J\&5&)KH;W?B:0*.)R^=_O"X\]$R$ MI)Q==$Z.CCN(,(>[E,TN.E_'W?[XZO:V\X^?_ORGS__3[:+1"`TX8\3SR`K] MZA"/"*P(>L*OG/'%"HV=.5G@[]$$2^(BSM"OEZ,[='IT@M!5YK_?R\G)$ MW!D67"SN8*?7"^`^+CCUW-@49'HZ.4 M67]!8\XD4"^6F*U0W_/02'-)-"*2B&?B'H5"I;$601,R>=%)&?AR=L3%K`=5 MG/1^O;\+6J7SYS^A@/;\=2(\FN'03R*>LQYE4F'FD!0+M-7O%@Y=K!L]74F! M)53KY-.G3SU3FJ+V97>&\3*FGV(Y,=1A0<\T[O%)]^PDRZ562R)+V4Q).=_$ M$1G-'#'!PC6^H.F//YT=IZ@98.,ORJUWE>CIBGI`U`4J(JB39MW,5^#1-*Z* MV=(-_;$7%*:H'7!+)5998Y2?$H+&9$/>`%D4OLD$J. M`3W/@C!UP\5B0*;8]T#+/WSLT2DE;@=AI02=^(ID"'R6D/RDI7S&C'%ENA#S MMWZR7%(VY>&?\$"_)^>">^0)O`7I'U]'M^MT5&%'V--TO0%W?*TE9NXU4U2M M;D&R6)CZ.HBZ%QTK1:Q#I(5+II11H^W)\0GJHH@]_1-$H4`62@G[W,M+R`OW MH<<>LI_,;P=[CN\9QCOX.V0.*6R,2P%=)%-;<"::K><+GT9@[`6C,2AK7&DX MO86!;T'ZGB*"@07/),!H!&2_6O!R$Q*) MAE,45-*BMAFUH9H3H0=K0>;0K(!'T';EX*VEMF/X0VT,^11EJFD1K8SH#640 M_%#L/7)I-+GRL)1ASUX&JHW!CNO':KA>8D^'8V@\)T3)%L.=,'S$$-?`:Z@H M-$UM0`WW!E1_W`95]"&CV'&//G,?4W:F7LV$>4"EXW'I M"_)$7M6EQYW?4W[P#2NU>]7?=90<<\$?EUA2,U"G*VN=I[;SW!.8OPG9=_[P M:=!=2T`0FGH9]MXIL&0]%]E2M-T1/N4=(2W>S)\&5,]MJ8+BUA]J^\,(VD[X M#K0>93.`:T0\W5_W'9@L@:)DZPYC*\%67S@YSOM"IHX6_-K@7V/!H.7D(Q'C M.:Z+\'IN.XPG>1@C06A)A)Z(+3A#1F(+:6U(@YGK$W[=]KVU"K`#>YH'-I"E MOSB0-M"KCV7\Z);I?FZG^*VJ+#O"9WF$8[$H);>%>HO7]AG^XV*U_6MK$6`' M]8?B:QO(HNU;NP64>@"CROR$L`?F2@K&-@)$V\=2-47:X?Z8ASLCKP6\-N!) M8PZG.HU,F#1VA1'O%9=*FG#F4G]H?\0KPU7/`W:MP^X2/^9=PHCJ&EDH71UZ M]#!K?:2^CSSJ#PLF66(^:CP"7H(H*DSI)6&@\/9C^];"[5[QM[Q7A/686;>I M"66K0F%=K9=LZ27FM9MSSR5"7O_A4[4"3'?M.FH+M7M%(3.7EO]7$SM(,U2U M^-?'G\ST_R.RY$(/R=MV"%7DV%$NI-U"D>TRA7?(OC[AB4?D&^9@PPJL+G%: MR+[9,K'H0R"S_3*WQZQ<#3_8),,.=?4,78OSFZ=W:J!>3Z+=!PK)O-)43XO_ MV^1\:H!>08P=Z4)2+Y7_:?%]M[Q`#1?83TUV+RED">TY@M9QOGVRH(;'[%B% MW54*&<9ZB8/6=;Y=!J&&RVPIVNXJY9G'DFQ"ZQ1OFE:HXP>5I=FA+Z072U(, M+>H;MZW$+5B8\\>3\;[KFL=Z7I#?T[(UNQW<0I;0FBR`XKB.+/P#HC!MU_=6 M@5]*8CX/WE$\H9Y98O4S\=P;+L;8T\4CJ1U(5_[0NX!T+),;25DJS/:(:ZVDJ_%>@]8WW$GVBES@ZGX M!7L^&4X'1-!GLR4YG:PGDLZ862(^RC3_/OR.$L-=HS:A]2U7^'(@405IEHCJ%8BW#_=>M6-=+QYCPQ"4U(X#V>>.2! MJ.&T[T$`HD^R*'C+9@:[$Y3LE`X$HD3B]PADZEXFD=IB6B<-$R^,*69T`U65"07E-DUH54PK@V MOQWQ0B9TPZJGU@7V,'(NHG&0SQC]+S$?&TMA+0RAU3GML!>RHU&`GH@./D2N M\X86[AK]^&+)&3$S,(A.'F':PUWJA&O&]-K%8C^^D<,.;R&AF4C4P9&.D2*A M\=HU+;:%M3JL55885N_6=Y1F=X==URNVG?Z>QOUPW5^RZJ_ZD%^1U>X(U5.?8PB=`3*8J/H+WRQ57W?DJ\Z\7J[B;KHP(NP@RNX2A;Q=6!6B#*4J M"[N)LE-DT0==XW?HB]IHJPAB_*FP^GUJSG5V;ORI8)V M%H#J%\)G`B_GU!F164E7L9,LNZ,44)ZZP%T.\>A3<]1WU17!_>04OZ8R+5=XAJK#8<2^DW8S(%/J` M:B@6&;DH$OS_"5K]C[[R8D2FR-QF<:[O<[CH2+I8>J03/L/"T?SV>S!Z2\&7 M1.C4=2\2&PDH<&U^DUU_`LBIOM!OH2NP>QE`,QV\,3XE6S&$A+++[3`@[$V/P[ MOMEFX"BQ.7W*;IGIGWOINS?@K^S=')_!733,E M<>@4II-4ALH*PA'S$5VYPO.8-8A5K>*+'2@WD%X(I7`CKKH3+%G MP@U#N#09\"?#&HRU*BJ:!)=Q7'1<,J'PE%'/TYI?=)3P]3#J3\S6/@V*F?-$ ME5.H=$V3Q^FT)T%!C2#_GFJF->5ITUQ?&#^H95K$M!\K!+1'(`_F?`XA^FY& M>4\6$R)2MEBI`HN":_3.7;[`M-2@0,>WMD(?R)EA(FF2)7KC\B*D[,!OB`L^_X:(?:I'8LY$P_;;`,[V"\=V, MBL^TS1]I:[9\IXS:1/B-C7+5^1PXA>-/R&T%\PI']L)TRC#*,AMMU(U"+U11 MZ;"QR8%#.3>TJT%9#!TH&R[5W@_;;#D$GN&_)8YGN^&AY*8'L@G[G`9=C[!`NC4TF>( MM#-ML9N@`XBRHXMG^R57V!;#B6K4#1J5KJ4C^,N`F,-.1R1,AH)&UR!I$7[J MBV!;)8;6Y3L`I&^('G*]._QRY6&Z*`QAZ\J;U+W=4'UO;_CQ;(T9ZTF:9\+&\(P`TH_O?"G.?"TF3H(@/TRB9N)65-6A`C-7+S:GSSQLYA;YE$@3#N'C%GV&LFH&OWW&8 M;0@=J?DJ/3>I0+KSF)U8^6:#=GR4KXZ_Q3.1YG)5'IQB!?'Y@/L3-?6]*&>< M;H"ZG(?0'G=DAKTQ42IX:LZQ!5:9,MQ">EA0)C3 M?"@2EY06"W-T!V$K1!R_4/")>W`_1R\A=_+!BX6D2<&+7GN:1J\B_;>/&%RZ"+9EK(\8-BL_,&C4,3?B:!*H]YCA(.LZ5MSY M/:L! M<00Q2UOS1F\EI%G=9&R*[D_<0G]28O,ZPD9Z[J,@SY3[TEO=4(^XT*M(V7?, MRF[\(GVJ2ERY"L^NQNYSLA3K;0X%?B8IA14-C(D/QCR]R,'\?:7W:$QIL.YT0!BM:K-=0J,:8L@<Z`U=Y`Y,="'&P6Q& M)UYX\T,F=U6)^`"^C1L[`C2O7_5:)KWDNN#E-J+&N7RT!+[4BGQAX[1_X$PO M7363=)P?_-=3',P+%M^-Q?_I8P\Z#!.9T07.)$XKD!Z.Q:F-U*4^64;0)+\, M<2B#X4;P1?PTF>/?^,Q-H;FU@$/`N&APD-6E!0]][( M[+*#[;@;N3CAD0BS%A+Q/X=JVWQUTA(^[,PAMHV8'W_&%K4]3TRG!9WRF:O'WPP#82]GPG8,7>P(..5U"/H+;OV];$: M9CR)+RE-+'_#*C*HJ^CY^^5TRD]#C0;D5)-LH#N$[JYX87%)5&8E:E#@5=0S M%UNM)6AD^&2N$UZ[.:&\M$D]Z-@WHF%T\X4:3HW"P^EHSEUR*\&3W8))51F: M9:68Z6',G"8`/5[)5D@+29,L,8>R);TZ=/`F0GGB^2@OV`5>,'-;_D:U0;+S MX>F%>,]$+Y'6RU\@2M&?>I])V2;(>ER-MC=SKVPE6]=R-,G.KTN(NR&<#A(M M>9O*2QNEORC]S)1[W"2-?\%2G_U7.$\B_[Q).O_K[@L7)*]Q]FFC](6)(AL' M@;9U%]%&PG>TZG,O.*$(?OX?4$L!`AX#%`````@`H6E80\E?QDLHU@``<6L+ M`!``&````````0```*2!`````&)C`L``00E#@``!#D!``!02P$"'@,4````"`"A:5A#/32L,'`4``"I)`$`%``8 M```````!````I(%RU@``8F-R+3(P,3,P.3,P7V-A;"YX;6Q55`4``QY5:5)U M>`L``00E#@``!#D!``!02P$"'@,4````"`"A:5A#4L$71*`^```2L@0`%``8 M```````!````I($PZP``8F-R+3(P,3,P.3,P7V1E9BYX;6Q55`4``QY5:5)U M>`L``00E#@``!#D!``!02P$"'@,4````"`"A:5A#0%TAH%5]```'J08`%``8 M```````!````I($>*@$`8F-R+3(P,3,P.3,P7VQA8BYX;6Q55`4``QY5:5)U M>`L``00E#@``!#D!``!02P$"'@,4````"`"A:5A#HS6BA^-````R8@4`%``8 M```````!````I('!IP$`8F-R+3(P,3,P.3,P7W!R92YX;6Q55`4``QY5:5)U M>`L``00E#@``!#D!``!02P$"'@,4````"`"A:5A#L.P4'R02``"^MP``$``8 M```````!````I('RZ`$`8F-R+3(P,3,P.3,P+GAS9%54!0`#'E5I4G5X"P`! @!"4.```$.0$``%!+!08`````!@`&`!0"``!@^P$````` ` end XML 40 R37.htm IDEA: XBRL DOCUMENT v2.4.0.8
Financial Instrument Assets and (Liabilities) Measured at Fair Value on Recurring Basis (Detail) (Fair Value, Measurements, Recurring, Fair Value, Inputs, Level 2, USD $)
In Millions, unless otherwise specified
Sep. 30, 2013
Dec. 31, 2012
Forward currency contracts
   
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Financial instrument assets and (liabilities) measured at fair value $ 1.5 $ 1.0
Option currency contracts
   
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Financial instrument assets and (liabilities) measured at fair value 1.4 0.6
Interest rate swap contract
   
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Financial instrument assets and (liabilities) measured at fair value $ 9.8 $ 13.3